IDF 2013
melbourne
world diabetes congress
2 - 6 December 2013

PROGRAMME BOOK

FOR YOUR ADULT PATIENTS WITH TYPE 2 DIABETES*

*Trajenta®: as monotherapy, add-on to metformin and/or sulfonylurea or insulin.[4]

Control and care matter[1–5]

TrajentaDuo® is not available in Australia.

Before prescribing Trajenta®/TrajentaDuo®, please review the full Product Information, available from the Boehringer Ingelheim and Eli Lilly and Company exhibition booths.

Trajenta® (linagliptin) 5mg tablets

TrajentaDuo® (linagliptin/metformin HCl)

PBS Information for Trajenta®: Streamlined authority code 3540 –
Type 2 diabetes, in combination with either metformin or a sulphonylurea – criteria apply.

Before prescribing TRAJENTA®, please review the full Product Information, which is available on request from Boehringer Ingelheim or from www.boehringer-ingelheim.com.au/pi

TRAJENTA® (linagliptin) 5mg film-coated tablets. INDICATION: TRAJENTA® is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise. *Monotherapy when metformin and sulfonylureas are not tolerated, or are contraindicated. Add on to metformin, sulfonylureas or metformin plus sulfonylureas, *or to insulin (with or without metformin). **CONTRAINDICATIONS:** Hypersensitivity to linagliptin or to any of the excipients. **PRECAUTIONS:** Not for use in type 1 diabetes, diabetic ketoacidosis. *Discontinue if pancreatitis is suspected. Risk of hypoglycaemia when used in combination with sulfonylureas and *insulin; pregnancy; lactation; children < 18 years. **INTERACTIONS:** Antagonized by strong P-gp or CYP3A4 inducers. Others, see full PI. **ADVERSE REACTIONS:** *Very common:* combination with metformin and a sulfonylurea and *combination with insulin – hypoglycaemia; *Common:* *increase in uric acid; combination with metformin – arthralgia, back pain, headache; combination with a sulfonylurea – nasopharyngitis, hypertriglyceridaemia, urinary tract infections; combination with metformin and a sulfonylurea – cough. Others, see full PI. **DOSAGE AND ADMINISTRATION:** 5mg once daily taken with or without food. No dose adjustment is necessary for the elderly, or patients with renal or hepatic impairment. 9 May 2013.

*Please note changes in Product Information.

References: 1. Two of a KinD (Kidneys in Diabetes). The burden of diabetic kidney disease and the cost effectiveness of screening people with type 2 diabetes for chronic kidney disease. Deloitte Access Economics, www.deloitte.com/au/economics, June 2011. **2.** NKF/KDOQI. *Am J Kidney Dis* 2007;49 (suppl 2):S13–S179. **3.** Morris AD. *Diabetes Educ* 2003;29:440–6. **4.** TRAJENTA® Product Information. Date of approval: 9 May 2013. **5.** Gallwitz B *et al. Lancet* 2012;380:475–83. BOEHRINGER INGELHEIM PTY LIMITED, ABN 52 000 452 308, 78 WATERLOO ROAD, NORTH RYDE NSW 2113, AUSTRALIA COPYRIGHT © 2013. ELI LILLY AUSTRALIA PTY LIMITED, ABN 39 000 233 992 112 WHARF ROAD, WEST RYDE, NSW 2114 AUSTRALIA COPYRIGHT © 2013. AUTRJ00177 PREPARED SEPTEMBER 2013.

Boehringer Ingelheim

Lilly

TABLE OF CONTENTS

IDF 2013
melbourne
world diabetes congress
2 - 6 December 2013

Stay up-to-date with @IntDiabetesFed #WDC2013

- Welcome address 4
- Patronage 5
- International Diabetes Federation (IDF) 12
- IDF Board 2013-2015 12
- Congress committees 13
- Abstract reviewers 14
- Grant Programme 17
- Previous and future congresses 18
- Acknowledgement of sponsors 19
- Exhibitors profiles 20
- Congress overview 39
- Programme overview by day 40
- Member Associations programme overview 48
- Floor plans 49
  - Venue map 49
  - Convention centre 50
  - Exhibition 54
  - Posters 56
- General information A-Z 61
- Congress application 68
- WDC TV 69
- List of hotels & map 70
- IDF initiatives 72
- Programme Tuesday 77
- Programme Wednesday 133
- Programme Thursday 185
- Programme Friday 243
- Poster discussions Tuesday 279
- Poster discussions Wednesday 307
- Poster discussions Thursday 331
- Poster display Tuesday – Friday 355
- Abstracts accepted by title 463
- Member Association programme 485
- Satellite symposia 517
- Author index 547
- Keyword index 587

The content of this publication reflects the situation at the time of print and may be subject to change. The organizer cannot be held liable for any inconvenience resulting from these changes.

WELCOME ADDRESS

Premier of Victoria – The Hon Dr Denis Napthine MP

I am delighted to welcome you to Melbourne for the World Diabetes Congress and I am immensely proud to be able to support one of the world's largest health-related events focused on such an important topic.

The increasing rates of diabetes in countries throughout the world pose significant challenges that are too complex for any person, organisation, institution or government to tackle alone. Addressing diabetes needs a collaborative effort across many disciplines and sectors including health professionals, health agencies, scientists, individuals and carers.

Events such as this Congress present an enormous opportunity to come together and share the most recent evidence and best practice to support improvements in diabetes care, treatment and prevention. I am particularly pleased to see that this Congress will include a new stream on Diabetes in Indigenous Peoples.

Victoria is an ideal venue for the Congress, hosting many leading scientific research institutions and becoming increasingly recognised as a world biotechnology hub. I am proud that Melbourne researchers are making a major contribution to efforts globally to find a cure for type 1 diabetes. We also look forward to showcasing some of the activities supported by the Victorian government in diabetes prevention, in addition to learning what is happening in other countries and regions. I would like to thank the International Diabetes Federation for holding the Congress in Melbourne, and also thank the Congress committees and staff for their commitment and dedication to successfully delivering the World Diabetes Congress. I would also like to acknowledge the important role played by Diabetes Australia in supporting the event.

It is with enthusiasm and encouragement that I welcome you to the Congress. I hope that your attendance supports you to deliver practical solutions to the serious problems associated with diabetes.

I hope your visit to Melbourne is enjoyable and I encourage you to take the time to explore our wonderful city, and Victoria more broadly.

PATRONAGE

The World Diabetes Congress Melbourne 2013
is held under the high Patronage of

The Hon David Davis MLC, Minister for Health and
Minister for Ageing, Victoria, Commonwealth of Australia

It gives me great pleasure to welcome you to Victoria for the World Diabetes Congress 2013. We are very excited to be hosting this prestigious event in Melbourne and look forward to a week of exchanging research, ideas and best practice on the prevention, treatment and management of diabetes.

Diabetes is the fastest growing chronic disease epidemic in world history and Australia is not immune to this trend. The prevalence of type 2 diabetes has more than doubled over recent decades and diabetes is predicted to become the leading burden of disease in Australia in the next five years.

With the World Diabetes Congress bringing together thousands of national and international experts, including some of the most outstanding and well-regarded researchers and physicians in the field, it presents a significant opportunity to share the most recent evidence to improve the lives of people living with this disease across the world.

Melbourne itself is home to several world-leading scientific institutions and researchers who are making a major contribution to the global understanding of diabetes and I am sure that their involvement in the Congress will be highly valuable. I personally am looking forward to chairing a session as part of the scientific programme which will look at innovative health promotion programs in the community to tackle obesity.

It was recently announced that Melbourne had won the title of the world's most liveable city for the third year in a row, and I hope that you have the opportunity to experience why. The restaurants, shops and hidden laneway cafes that Melbourne is known for will give you a real flavour of our vibrant city. Melbourne's multiculturalism contributes greatly to this vibrancy, along with our many major sporting events and theatre shows and our culture and heritage.

I hope that you have a successful and productive week at the World Diabetes Congress and I look forward to hearing about the outcomes from this esteemed international meeting.

MELBOURNE EXHIBITION CENTRE

WELCOME TO THE WORLD DIABETES CONGRESS MELBOURNE

The International Diabetes Federation (IDF) is the global voice for people with diabetes and those at risk. Twenty years after the World Diabetes Congress in Japan, the Western Pacific Region is once again in the global health spotlight as we bring the World Diabetes Congress to Melbourne, Australia.

Today, more than a third of all people with diabetes are found in the Western Pacific Region. This Region also has the highest number of people with diabetes in the world.

In Australia, diabetes is the fastest growing Non-communicable Disease (NCD) and all types of diabetes are increasing in prevalence.

Indigenous communities in Australia are also a major concern as the prevalence within this population is three to four times higher than the rest of the Australia.

The World Diabetes Congress 2013 will raise awareness of the diabetes pandemic and its impact by convening the global diabetes community to exchange research and best practices on diabetes prevention, treatment and management.

Melbourne's location makes the Congress easily accessible to delegates from China and India, the two countries with the highest numbers of people with diabetes in the world.

We cordially welcome the global diabetes community to the World Diabetes Congress in Melbourne from 2-6 December 2013.

Join us in our mission to promote diabetes care, prevention and a cure worldwide.

Sir Michael Hirst
President
International Diabetes Federation

Dr Shaukat Sadikot
President-Elect
International Diabetes Federation

Welcome to Melbourne

On behalf of the Organising, Programme and Melbourne National Advisory Committees, we are delighted to welcome you to IDF's World Diabetes Congress in Melbourne, Australia.

The city of Melbourne will host more than 10,000 delegates over four days at the Melbourne Convention and Exhibition Centre.

The Programme Committee has put together a timely and exciting schedule including two new streams on *Diabetes in Indigenous Peoples and Diabetes Research in the 20th Century*. These new additions accompanied by the five existing streams will provide delegates with a varied and comprehensive experience.

Over 400 speakers and 70 exhibitors have been given the platform to showcase their diabetes expertise, research and breakthroughs in the field of diabetes.

The World Diabetes Congress will be held in partnership with Diabetes Australia. On the ground, Diabetes Australia has engaged political leaders and senior bureaucrats to emphasise the importance of this event. Their local support has been extremely helpful and appreciated in the organisation of the Congress.

We hope that the World Diabetes Congress in Melbourne will raise awareness of the diabetes pandemic in the region.

We also trust that it will shine a light on the existing work in prevention and care, which is on-going in Australia and in the Western Pacific.

We welcome you to an exceptional Congress.

Ms Anne-Marie Felton
Chair, Organising Committee

Prof. Paul Zimmet
Chair, Programme Committee

Prof. Trisha Dunning
Chair, Melbourne National Advisory Committee

ABBREVIATED PRESCRIBING INFORMATION

Tresiba® (insulin degludec) 100U and 200U (100 units/mL or 200 units/mL insulin solution for injection) in a prefilled pen (FlexTouch®) Tresiba® 100U solution for injection in a cartridge (Penfill®) Consult Summary of Product Characteristics before prescribing. Presentation: Tresiba® FlexTouch® Tresiba® Penfill®. All presentations contain insulin degludec. Tresiba® 100 units/mL – 1 mL of solution contains 100 units insulin degludec (equivalent to 3.66 mg). One pre-filled device or one cartridge contains 300 units of insulin degludec in 3 mL solution. Tresiba® 200 units/mL – 1 mL of solution contains 200 units insulin degludec (equivalent to 7.32 mg). One pre-filled device contains 600 units of insulin degludec in 3 mL solution. **Indications:** Treatment of diabetes mellitus in adults. **Posology and administration:** Tresiba® is a basal insulin for once-daily subcutaneous administration any time of the day, preferably at the same time of day. On occasions when administration at the same time of the day is not possible, Tresiba® allows for flexibility in the timing of insulin administration. A minimum of 8 hours between injections should be ensured. In patients with type 2 diabetes mellitus, Tresiba® can be administered alone, in combination with oral anti-diabetic medicinal products as well as in combination with bolus insulin. In type 1 diabetes mellitus, Tresiba® is to be used with short-/rapid-acting insulin. Administration by subcutaneous injection only. Tresiba® is available in 100 units/mL and 200 units/mL. For Tresiba® 100 units/mL a dose of 1–80 units per injection, in steps of 1 unit, can be administered. For Tresiba® 200 units/mL a dose of 2–160 units per injection, in steps of 2 units, can be administered. The dose counter shows the number of units regardless of strength. No dose conversion should be done when transferring a patient to a new strength. When initiating patients with type 2 diabetes mellitus the recommended daily starting dose is 10 units. Transferring from other insulins; in type 2 diabetes changing the basal insulin to Tresiba® can be done unit-to-unit, based on the previous basal insulin component; in type 1 diabetes the same applies apart from where transferring from twice-daily basal insulin or patients with an HbA_{1c} <8.0%, the Tresiba® dose needs to be determined on an individual basis with a dose reduction considered. Doses and timing of concomitant treatment may require adjustment. In all cases doses should be adjusted based on individual patients' needs; fasting plasma glucose is recommended to be used for optimising glycaemic control. In elderly patients and patients with renal/hepatic impairment glucose monitoring should be intensified and the dose adjusted on an individual basis. The safety/efficacy of Tresiba® has not been established in adolescents/children below 19 yrs. of age. Tresiba® comes in a pre-filled pen, FlexTouch® (2 concentrations) or cartridge, Penfill®, designed to be used with NovoFine®/NovoTwist® needles and for Penfill® Novo Nordisk insulin delivery systems. **Contraindications:** Hypersensitivity to the active substance or any of the excipients. **Special warnings and precautions:** Too high insulin dose, omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. Reduction of warning symptoms of hypoglycaemia may be seen upon tightening control and also in patients with long-standing diabetes. Administration of rapid-acting insulin

The abbreviated prescribing information is based on EU SmPC. Registration conditions vary internationally. Tresiba® is approved in EU, Norway, Iceland, Switzerland, Japan, Mexico, El Salvador and India. Always refer to the full Summary of Product Characteristics before prescribing. Full prescribing information is available upon request from the information desk/Novo Nordisk representative. For international delegates please visit www.novonordisk.com for full product information.

novo nordisk®

This product is not registered in Australia

INTRODUCING TRESIBA®

GET HbA1c DOWN[1,2]

1. Successful reductions in HbA_{1c}[1,2]
2. Lower risk of nocturnal hypoglycaemia versus glargine[1,2]
3. Flexibility in day-to-day dosing time when needed[3]

...delivered in a once-daily dose[3]

recommended in situations serve with severe hyperglycaemia. Inadequate dosing and/or discontinuation of treatment in patients requiring insulin may lead to hyperglycaemia and potentially to diabetic ketoacidosis. Concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased insulin requirement. Transferring to a new type, brand or manufacturer of insulin should be done under strict medical supervision. When using insulin in combination with pioglitazone, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs. Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between the two strengths of Tresiba® and other insulins. Hypoglycaemia may constitute a risk when driving or operating machinery. **Pregnancy and lactation:** There is no clinical experience with use of Tresiba® in pregnant women and during breastfeeding. Animal reproduction studies with insulin degludec have not revealed any adverse effects on fertility. **Undesirable effects:** Refer to SmPC for complete information on side effects. Very common (≥1/10); common (≥1/100 to < 1/10); uncommon (≥1/1.000 to < 1/100); rare (≥ 1/10.000 to < 1/1.000); very rare (< 1/10.000); not known (cannot be estimated from the available data). Very common: Hypoglycaemia. Common: Injection site reactions. Uncommon: Lipodystrophy and peripheral oedema. Rare: Hypersensitivity and urticaria. With insulin preparations, allergic reaction may occur; immediate-type allergic reactions may potentially be life threatening. Injection site reactions are usually mild, transitory and normally disappear during continued treatment. **Marketing authorisation numbers:** Tresiba® FlexTouch® 100 U/mL EMEA/H/C/002498/0000/004 (5 piece) and Tresiba® FlexTouch® 200 U/mL. EMEA/H/C/002498/0000/013 (3 piece); Tresiba® Penfill® (5 piece) EMEA/H/C/002498/0000/007. Legal category: Prescription-only medicine (POM). Marketing authorisation holder: Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark. **Date of Review of Prescribing Information:** January 2013. **Summary of Product Characteristics can be obtained from Novo Nordisk A/S.**

REFERENCES: 1. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN™ Once Long). *Diabetes Care*. 2012;35(12):2464-2471. **2.** Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Ocampo Francisco AM, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet*. 2012;379(9825):1489-1497. **3.** Tresiba® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; 2013.

Changing diabetes®, FlexTouch®, NovoFine®, NovoTwist®, Penfill®, and Tresiba® are registered trademarks of Novo Nordisk A/S. © Novo Nordisk A/S, Novo Álle, DK-2880 Bagsværd, Denmark, APROM ID #5485; approval date: October 2013

NEW

TRESIBA®

insulin degludec [rDNA origin] injection

International Diabetes Federation

THE INTERNATIONAL DIABETES FEDERATION

The International Diabetes Federation (IDF) is an umbrella organisation of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF's mission is to promote diabetes care, prevention and a cure worldwide.

IDF BOARD 2013-2015

President

- Michael Hirst

President-Elect

- Shaukat Sadikot

Vice-Presidents

- Anne Belton
- Gordon Bunyan
- Chris Delicata
- Trisha Dunning
- John Grumitt
- Akhtar Hussain
- Linong Ji

Regional Chairs

Evariste Bouenizabila	Africa (AFR)
João Nabais	Europe (EUR)
Adel El Sayed	Middle East and North Africa (MENA)
Serge Langlois	North America and Caribbean (NAC)
Edwin Jimenez	South and Central America (SACA)
Veenoo Basant Rai	South-East Asia (SEA)
Nam Cho	Western Pacific (WP)

CONGRESS COMMITTEES

Organising Committee

Anne-Marie Felton	United Kingdom	Chair
Pablo Aschner	Colombia	
Anne Belton	Canada	
Nam Cho	Korea	
Trisha Dunning	Australia	
John Grumitt	United Kingdom	
Mike Jones	Bermuda	
Sonia Kakar	India	
Kaushik Ramaiya	Tanzania	
Alex Silverstein	United Kingdom	
Paul Zimmet	Australia	

Melbourne National Advisory Committee

Trisha Dunning	Australia	Chair
Guy Barnett	Australia	
Gordon Bunyan	Australia	
Greg Johnson	Australia	
Michelle Robins	Australia	
Victoria Stevenson	Australia	
Paul Zimmet	Australia	

Programme Committee

Paul Zimmet	Australia	Chair

Clinical and Basic Science

Mark Cooper	Australia	Stream Lead
Marc Donath	Australia	Deputy Lead
Monira Al Arouj	Kuwait	Member
Sof Andrikopoulos	Australia	Member
Cliff Bailey	United Kingdom	Member
Takashi Kadowaki	Japan	Member
Steven Kahn	USA	Member
Mark McCarthy	United Kingdom	Member
Mark Sperling	USA	Member
Sophia Zoungas	Australia	Member

Diabetes in Indigenous Peoples

Alex Brown	Australia	Stream Lead
Ashim Sinha	Australia	Deputy Lead
Mick Adams	Australia	Member
Stewart Harris	Canada	Member
Jeff Reading	Australia	Member
Donald Warne	USA	Member

Diabetes Research in the 20th Century: A Historical Perspective

Pierre Lefèbvre	Belgium	Stream Lead
George Alberti	United Kingdom	Deputy Lead
Juan José Gagliardino	Argentina	Member
Anant Nigam	India	Member
Jesse Roth	USA	Member
Samad Shera	Pakistan	Member
John Turtle	Australia	Member

Education and Integrated Care

Angus Forbes	United Kingdom	Stream Lead
Trisha Dunning	Australia	Stream Deputy
Nuala Harkin	Australia	Member
Buyelwa Majikela-Dlangamandla	South Africa	Member
Rutu Mehta Dave	India	Member
Maria Ruiz	Argentina	Member

Global Challenges in Health

Linong Ji	China	Stream Lead
Kaushik Ramaiya	Tanzania	Stream Deputy
Pablo Aschner	Colombia	Member
William Herman	USA	Member
Viswanathan Mohan	India	Member
Itamar Raz	Israel	Member
Alexander Silverstein	United Kingdom	Member

Living with Diabetes

João Nabais	Portugal	Stream Lead
Guy Barnett	Australia	Stream Deputy
Khadija Al-Arayedh	Bahrain	Member
John Grumitt	United Kingdom	Member
Shirley Murray	Australia	Member
Phil Southerland	USA	Member
Nicola Stokes	Australia	Member
Bas van de Goor	The Netherlands	Member

Public Health and Epidemiology

Jonathan Shaw	Australia	Stream Lead
Edward J. Boyko	USA	Stream Deputy
Beverley Balkau	France	Member
Wendy Davis	Australia	Member
Ayesha Motala	South Africa	Member
Ambady Ramachandran	India	Member
Marian Rewers	USA	Member
Nigel Unwin	United Kingdom	Member

ABSTRACT REVIEWERS

IDF received 2,423 abstracts for inclusion in the World Diabetes Congress Melbourne. The abstracts were reviewed by 129 peers:

- Zulfiqarali Abbas Tanzania
- Terry Ackley USA
- Mick Adams Australia
- Monira Al Arouj Kuwait
- George Alberti United Kingdom
- Sof Andrikopoulos Australia
- Ranjit Mohan Anjana India
- Clifford Bailey United Kingdom
- Beverley Balkau France
- Peter H Bennett USA
- Edward J Boyko USA
- Alex Brown Australia
- Sven-Erik Bursell USA
- Nigel Calcutt USA
- Alan Chait USA
- Juliana Chan China
- Kelly Close USA
- Edward John Coetzee South Africa
- Ricardo Cohen Brazil
- Stephen Colagiuri Australia
- Mark Cooper Australia
- Melinda Coughlan Australia
- Donald Coustan USA
- Samuel Dagogo-Jack USA
- Ann Dapice USA
- Rutu Dave India
- Wendy Davis Australia
- Dick de Zeeuw The Netherlands
- Ralph DeFronzo USA
- Stefano Del Prato Italy
- Marc Donath Switzerland
- Daniel Drucker Canada
- Trisha Dunning Australia
- David Dunstan Australia
- Robert Eckel USA
- Steven Edelman USA
- Vivian Fonseca USA
- Angus Forbes United Kingdom
- Martha Funnell USA
- Juan José Gagliardino Argentina
- Stephen Greene United Kingdom
- Simon Griffin United Kingdom
- Per-Henrik Groop Finland
- Leonor Guariguata Belgium
- Anthony Hanley Canada
- Stewart Harris Canada
- Simon Heller United Kingdom
- William Herman USA
- Graham Hitman United Kingdom
- Philip Home USA
- Roman Hovorka United Kingdom
- Wendy Hoy Australia
- David E James Australia
- Philip James United Kingdom
- Takashi Kadowaki Japan
- Steven Kahn USA
- Phillip Kantharidis Australia
- Kamlesh Khunti United Kingdom
- Tim Kieffer Canada
- Shigeo Kono Japan
- Sari Koski Finland
- Karen Lam China
- Harold Lebovitz USA
- Pierre Lefèbvre Belgium
- Åke Lernmark Sweden
- Jaana Lindström Finland

- Ronald Ma China
- Dianna Magliano Australia
- Buyelwa Majikela-Dlangamandla South Africa
- Rayaz Malik United Kingdom
- Louise Maple-Brown Australia
- David Matthews United Kingdom
- Mark McCarthy United Kingdom
- Viswanathan Mohan India
- Greg Morton USA
- Ayesha A Motala South Africa
- Shirley Murray Australia
- Michael A Nauck Germany
- Robert Nelson USA
- Anant Nigam India
- Kerin O'Dea Australia
- Trevor Orchard USA
- Niti Pall United Kingdom
- Jerry Palmer USA
- Chris Patterson United Kingdom
- David J. Pettitt USA
- Mark Peyrot USA
- Ambady Ramachandran India
- Kaushik Ramaiya Tanzania
- Joao Filipe Raposo Portugal
- Eric Ravussin USA
- Itamar Raz Israel
- Jeff Reading Australia
- Anne Reutens Australia
- Marian Rewers USA
- Christopher J Rhodes USA
- Gojka Roglic Switzerland
- Peter Rossing Denmark
- Jesse Roth USA
- Maria Lidia Ruiz Argentina
- Naveed Sattar United Kingdom
- Susumu Seino Japan
- Jonathan Shaw Australia
- Samad Shera Pakistan
- Wayen H-H Sheu Taiwan
- Alexander Silverstein United Kingdom
- Mark Sperling USA
- Bart Staels France
- Nicola Stokes Australia
- Naoko Tajima Japan
- Ming Yeong Tan Singapore
- Caroline Thomas Australia
- Bernie Tuch Australia
- Jaakko Tuomilehto Finland
- Koujiro Ueki Japan
- Nigel Unwin Barbados
- João Nabais Portugal
- Bas van de Goor The Netherlands
- Kabayam M Venkat Narayan USA
- G. Vijayakumar India
- Wim Wientjens The Netherlands
- John Wilding United Kingdom
- Terence Wilkin United Kingdom
- Jennifer Wilkinson-Berka Australia
- Ingrid Willaing Denmark
- Philip Zeitler USA
- Paul Zimmet Australia
- Bernard Zinman Canada
- Sophia Zoungas Australia

Look out for these forthcoming titles in the book series *Frontiers in Diabetes*

Genetics in Diabetes
Edited by Anna Gloyn and Mark McCarthy

Diabetes Secondary to Endocrine Disorders
Edited by Ezio Ghigo and Massimo Porta

Technological Advancements in the Treatment of Type 1 Diabetes
Edited by Giorgio Grassi and Daniela Bruttomesso

Frontiers in Diabetes
Series Editors: Porta, M. (Turin); Matschinsky, F.M. (Philadelphia, Pa.)
ISSN 0251–5342, e-ISSN 1662–2995

More information available soon at
www.karger.com/fdiab

For further information or special pre-publication offers, please contact Stephanie Repka (s.repka@karger.com).

KARGER

KI13722

GRANT PROGRAMME

The International Diabetes Federation is the global voice for people with diabetes and is committed to assisting delegates with limited resources by providing a number of travel grants based on the following criteria:

- Professional profile: young scientists / diabetes healthcare professionals
- The applicant is under 40 years old at the time of the Congress
- The applicant submits an abstract which must be accepted
- The applicant must submit a strong letter of motivation of maximum one page clearly demonstrating the benefits / learning experience of attending the congress
- The applicant must submit a one-page curriculum vitae

Grant Committee

- Anne-Marie Felton Chair
- Anne Belton Member
- Michael Jones Member

Grantees

- Rehman Rabia Abdul Pakistan
- Khalid Abdul Basit Pakistan
- Dhruba Acharya Nepal
- Afsana Afroz Bangladesh
- Ritvik Agrawal India
- Vallim Elizabeth Aguiar USA
- Md Abdullah Al Mamun Bangladesh
- Syed Imran Ali Pakistan
- Altanzul Altaisaikhan Mongolia
- Faraz Alvi Pakistan
- Anthony Anyanwu Nigeria
- Jayaprakash Appajigol India
- Ferdous Ara Bangladesh
- Ardiansyah Ardiansyah Indonesia
- Asal Ataie-Jafari Iran
- A.S Mohammed Nurullah Awal Bangladesh
- Mendel Baba Australia
- Virtue Bajurny Canada
- Ghinwa Barakat Lebanon
- Battsetseg Batchuluun Japan
- Prerna Bhasin India
- Amrita Bhowmik Bangladesh
- Danielle Borg Australia
- Jennifer Browne Australia
- Soler Mónica Carreira Spain
- Marlon Cerf South Africa
- Parinya Chamnan Thailand
- Carina Chan Malaysia
- Ludivine Chateau-Degat Canada
- Shatdal Chaudhary Nepal
- Chien-Hsieh Chiang Taiwan
- Thanh Dang Vietnam
- Dinh Tung Do Vietnam
- Nancy Elbarbary Egypt
- Jorge Elgart Argentina
- Guy Fagherazzi France
- Maicon Falavigna Brazil
- Narayan Gautam Nepal
- Leylya Gaysina Russia
- Ibrahim Gosadi Saudi Arabia
- Kapil Gudala India
- Harshi Gunawardena Sri Lanka
- Yawei Guo Hong Kong, China
- Matthew Hare Australia
- Mohammad Akhtar Hussain India
- Nauman Arif Jadoon Pakistan
- Mehdi Javanbakht Iran
- Ranil Jayawardena Sri Lanka
- Ashwini K N India
- Muhammad Adnan Kanpurwala Pakistan
- Navchetan Kaur India
- Joseph Kibachio Kenya
- Vidula Krishnaswamy India
- Michael Laxy Germany
- Chien-Chiang Liao Taiwan
- Amy Liu New Zealand
- Radrigan Trinidad Lopez Chile
- Sadaf Mateen Pakistan
- Joseph Mboi Kenya
- Nasrin Milani Iran
- Ali Abdulnabi Mohammed Bahrain
- Margaret Morris USA
- Georgina Murphy United Kingdom
- Mwavua Shillah Mwaniga Kenya
- Pragalathan Naidoo South Africa
- Feng Ning Finland
- Kiran Kumar Niraula Nepal
- Jean Claude Njabou Katte Cameroon
- Moses Obimbo Kenya
- Maria Teresa Onetto Flores Chile
- Brenna Osborne Australia
- Natalia Palarie Moldova
- Neesha Patel United Kingdom
- Maksam Prystupiuk Ukraine
- Priyanga Ranasinghe Sri Lanka
- Abril Rebolledo Mexico
- Shuang Rong China
- Zahra Sabahi Iran
- Yempabou Sagna Burkina Faso
- Maria Elena Sáinz de la Maza Viadero Mexico
- Mark Anthony Sandoval The Philipines
- Salikou Dit Salif Sanogo Ivory Coast
- Arjun Shrestha Nepal
- Rebecca Simmons United Kingdom
- Leena Simon India
- Michael Smith United Kingdom
- David Soyoye Nigeria
- Lorena Ivona Stefan Romania
- Claudia H.T Tam Hong Kong, China
- Alice Tang Australia
- Noule François Stephan Tcheutchoua Cameroon
- Thomas Vallim USA
- Olga Vasilkova Belarus
- Indra Wijaya Indonesia
- Tongzhi Wu China
- Roseanne Yeung Hong Kong, China
- Junmei Yin China
- Jenny Zhang Hong Kong, China

PREVIOUS AND FUTURE CONGRESSES

From the first meeting in Leiden in 1952 to Montréal in 2009 the Congress was held every three years. As of 2011 in Dubai, the World Diabetes Congress became a biennial event to meet the demand of what has become one of the most urgent public health issues of the 21st century.

Congress Date	Location	Region	Chair of OC	Triennium	IDF Presidents
7-12 Jul 1952	Leiden, The Netherlands	EUR	Robin D. Lawrence	1950-1952	Robin D. Lawrence, UK
4-8 Jul 1955	Cambridge, UK	EUR	Robin D. Lawrence	1952-1955	Robin D. Lawrence, UK
21-25 Jul 1958	Düsseldorf, Germany	EUR	Karl Oberdisse	1955-1958	Robin D. Lawrence, UK
10-14 Jul 1961	Geneva, Switzerland	EUR	Eric Martin	1958-1961	Joseph P. Hoet, Belgium
20-24 Jul 1964	Toronto, Canada	NA	Charles H. Best	1961-1964	Howard F. Root, USA
30 Jul-4 Aug 1967	Stockholm, Sweden	EUR	Rolf Luft	1964-1967	Howard F. Root, USA
23-28 Aug 1970	Buenos Aires, Argentina	SACA	Virgilio G. Foglia	1967-1970	Rachmiel Levine, USA
15-20 Jul 1973	Brussels, Belgium	EUR	Paul A. Bastenie	1970-1973	Frank G. Young, UK
31 Oct-5 Nov 1976	New Delhi, India	SEA	Jasbir S. Bajaj	1973-1976	Rolf Luft, Sweden
9-14 Oct 1979	Vienna, Austria	EUR	Werner Waldhäusl	1976-1979	Rolf Luft, Sweden
10-17 Nov 1982	Nairobi, Kenya	AFR	Eric Mngola	1979-1982	Albert.E.Renold, Switzerland
23-28 Sept 1985	Madrid, Spain	EUR	Manuel Serrano Rios	1982-1985	Leo P. Krall, USA
20-25 Nov 1988	Sydney, Australia	WP	John R. Turtle	1985-1988	Jasbir S. Bajaj, India
23-28 Jun 1991	Washington DC, USA	NA	Harold Rifkin	1988-1991	Joseph P. Hoet, Belgium
6-11 Nov 1994	Kobe, Japan	WP	Shigeaki Baba	1991-1994	Wendell Mayes, Jr, USA
20-25 Jul 1997	Helsinki, Finland	EUR	Marja R. Taskinen	1994-1997	Jak Jervell, Norway
5-10 Nov 2000	Mexico City, Mexico	NA	Fernando Lavalle	1997-2000	Maria L. de Alva, Mexico
24-29 Aug 2003	Paris, France	EUR	Gérard Cathelineau	2000-2003	Sir George Alberti, UK
3-7 Dec 2006	Cape Town, South Africa	AFR	Sir George Alberti	2003-2006	Pierre Lefèbvre, Belgium
18-22 Oct 2009	Montréal, Canada	NA	Linda Siminerio	2006-2009	Martin Silink, Australia
4-8 Dec 2011	Dubai, UAE	MENA	Abdullah Ben-Nakhi	2009-2012	Jean-Claude Mbanya, Cameroun
2-6 Dec 2013	Melbourne, Australia	WP	Anne-Marie Felton	2012-2013	Sir Michael Hirst, UK
30 Nov – 4 Dec 2015	Vancouver, Canada	NAC	Anne-Marie Felton	2013-2015	Shaukat Sadikot, India

ACKNOWLEDGEMENT OF SPONSORS

The Organising Committee of the World Diabetes Congress Melbourne 2013 expresses its appreciation and recognition to the following companies and organisations for their support:

- Abbott
- ACON BIOTECH CO., LTD
- American Diabetes Association
- Ascent Footwear
- Asian Association for the Study of Diabetes (AASD)
- AstraZeneca
- Australian Diabetes Council
- Australian Diabetes Educators Association
- Australian Diabetes Society
- Becton Dickinson
- Bigpond
- Bioscientifica
- Boehringer Ingelheim
- BMJ Group
- Australian Institute of Health and Welfare
- Diabetes Australia (NDSS)
- Diabetes Counselling Online
- Diabetes WA
- Diploma MSC
- EASD
- EKF diagnostics
- Elsevier
- Eli Lilly and Company
- Endocrine
- FeelTech
- Gi Dynamics
- Glycemic Index Foundation
- Handicap International
- Impeto Medical
- Insulin for Life
- i-Sens
- Lifescan & Animus Corporation
- LKC Technologies
- Medtronic
- Merck Sharp & Dohme
- Mercodia
- Natural-Med International Ltd
- Nestlé
- Nipro Corporation
- Novartis Pharma AG
- Novel
- Novo Nordisk
- Nuts for Life
- Owen Mumford
- Pic Solution
- Predict BGL, Coach and Live Share
- Qiagen
- R3i Foundation and Diabetic Retinopathy
- Roche Diagnostics
- Sanofi
- SD Biosensor
- Servier
- Swissmedical Press
- Type 1 Diabetes Network
- Takeda
- The Fred Hollows Foundation
- Tonghua Dongbao Pharmaceutical Co. , Ltd
- Tourism Vancouver
- Victorian Department of Health
- Viforpharma
- Wiley
- World Diabetes Foundation
- World Heart Federation

Abbott # D5

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes.

Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.

ACON Laboratories, Inc. # A33

ACON Diabetes Care, a part of ACON Laboratories, Inc., is headquartered in San Diego, California, USA. For over 10 years, ACON Diabetes Care has been focused on providing accurate, painless, and easy to use blood glucose monitoring systems and other related test systems to diabetics all over the world. Our products are sold in more than 130 countries worldwide and are highly recommended by health care professionals and clinical institutes. ACON Diabetes Care is also committed to delivering diabetes care education to patients to help inform them of what they can do to live a healthier life.

Visit www.acondiabetescare.com for more information

American Diabetes Association # S25

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voices to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

Animas Corporation # K13

Animas Corporation, Part of the Johnson & Johnson Diabetes Solutions Companies. At Animas, we make insulin pumps. We've been committed to helping people with diabetes perform at their best since 1996. We've made it our job to listen hard to patients, then put the features that benefit them most into our insulin pumps. That's how we've led the way in insulin pump innovations for the last decade. Come by our booth for a demonstration of our latest insulin pump, the Animas® Vibe™.

To learn more about Animas and where our pumps are distributed around the world, please visit www.Animas.com.

Ascent Footwear # S33

Ascent is a footwear brand, engineered in Australia. Our aim is to provide the best quality footwear available at an affordable price. Ascent started as a running and cross training brand in 2001. However after working closely with medical professionals we have taken our sports shoes technology into the following footwear categories: formal school shoes – duty shoes and work boots.

Ascent provides a range of footwear that can be sold in different sizes between left and right feet at no extra cost nor waiting time in

programme called "IIFit". IIFit is ideal for anyone suffering from diabetes, polio, club foot, full or partial amputees. All Ascent shoes are constructed on sports shoe technology to provide all day comfort and support.

For further information or to review our range, visit www.ascentfootwear.com.au

Asian Association for the Study of Diabetes (AASD) # S31

The Asian Association for the Study of Diabetes (AASD) was launched in Osaka, Japan in 2009 with Professor Yutaka Seino as Founding Chairman. AASD now has 1700 members and 20 affiliated associations.

For detailed information, please visit our website at http://www.aa-sd.org/

AstraZeneca/Bristol-Myers Squibb Diabetes Alliance # H13

Dedicated to addressing the global burden of diabetes by advancing individualised patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialise a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control.

Find out more about the Alliance and our commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com or www.bms.com.

Australian Diabetes Council # M44

Australian Diabetes Council is Australia's oldest and largest charity directly serving the needs of people living with diabetes. 75 years ago, our founder, Sir Kempson Maddox, pioneered the collaboration between health professional and patient in the education, management and care of diabetes and in doing so established us as the shared voice for diabetes. We continue that proud tradition today, representing almost 200,000 Australians living with diabetes.

For more information please visit www.australiandiabetescouncil.com

Australian Diabetes Educators Association (ADEA) # F52

The ADEA is the leading Australian organisation for health professionals who provide diabetes education and care. There are more than 1000 Credentialled Diabetes Educators (CDEs) working across public and private practices and hospitals in Australia.The association actively promotes evidenced-based diabetes education to ensure optimal health and wellbeing for those affected by and/or at risk of diabetes and sets standards and develops guidelines for the practice of diabetes education.

For further information about the ADEA visit www.adea.com.au.

Australian Diabetes Society # G51

The Australian Diabetes Society (ADS) is the peak medical and scientific health professional organisation in Australia working towards improved care and outcomes for people with diabetes. It is a national body and was founded in 1973. The ADS currently has almost 1000 members, predominantly endocrinologists and basic and clinical science researchers. The aim of the ADS is to enhance the welfare of individuals who have diabetes mellitus through better knowledge and understanding, management guidelines, service to people with diabetes, and research into diabetes.

Australian Institute of Health and Welfare # N52

The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by the Australian Government to provide reliable, regular and relevant information and statistics on Australia's health and welfare. We are an independent statutory authority established in 1987, governed by a management Board, and accountable to the Australian Parliament through the Health and Ageing portfolio.Our aim is to improve the health and wellbeing of Australians through better health and welfare information and statistics.

Becton Dickinson (BD) # O6

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases.

For more information, please visit www.bd.com.

Bioscientifica # O52

Bioscientifica publishes leading titles on behalf of learned societies. Bioscientifica journals have an excellent reputation for high-quality publications in the diabetes field, including the *Journal of Endocrinology*, *Journal of Molecular Endocrinology*, *Endocrine-Related Cancer*, *European Journal of Endocrinology and Endocrine Connections*. *Endocrinology, Diabetes & Metabolism Case Reports* was recently launched and links together case reports in the field. Authors publishing in our journals will reach large international audiences and benefit from rapid publication.Visit the stand for free access to the *Themed Collection: Diabetes*, an exclusive offer for meeting attendees.

BMJ Group # Q51

The world renowned BMJ has partnered with the University of Leicester to offer unique Postgraduate Diabetes Qualifications that give healthcare professionals from around the world the opportunity to learn from key opinion leaders in an innovative online environment. Our internationally recognised qualifications are based on the International Diabetes Federation's (IDF) curriculum and will give you the knowledge, judgement and skills necessary to meet the healthcare needs of your patients living with diabetes.

Boehringer Ingelheim # K27

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Helping those who live with diabetes is one central area of focus for Boehringer Ingelheim's research and development activities.

For more information, please visit www.boehringer-ingelheim.com.

Britannia NutriChoice

Britannia NutriChoice is one of India's top health brands today, leading a change in the way Indians think, feel and behave about health and healthy living. NutriChoice has developed a unique range of healthy snacking choices that can meet in-between cravings and nutrition needs of a diverse set of consumers.

In 2010, NutriChoice introduced a 'first of its kind' range of snacks in India specially created for people with diabetes. NutriChoice Diabetic Friendly Essentials is the first ever range of snacks in India that is clinically proven to manage blood sugar levels, while providing sustenance and nutrition that keeps people with diabetes feeling fuller and active for longer.

Diabetes Counselling Online # G52

Diabetes Counselling Online (DCO) www.diabetescounselling.com.au is a unique virtual diabetes team that is online, personalised, professional and understanding. An Australian charity, we offer e-counselling and diabetes education to people living with all types of diabetes, their families and friends. Founded in 2001 by a person living with type 1 diabetes, and supported by the Australian Government, our aim is to connect people to a better quality of life. DCO is a major contributor to improved mental health and self management for people with diabetes; leaders in awareness raising about the experiences and psychosocial needs of people living with diabetes; and a contributor to research in diabetes.

Diabetes Research Group

The Diabetes & Cardiovascular Disease EASD Study Group became an official EASD study group as of September 2007. The group exists to promote advancement of knowledge on all aspects of cardiovascular disease on diabetes through active co-operation between interested diabetologists and other specialists. It works actively for the establishment of European collaborative studies and acts as a reference group for EASD in matters related cardiovascular disease and diabetes.

The Diabetes Research Group is a highly renowned institute for experimental and clinical research in diabetes. It focuses on Diabetes and Cardiovascular Disease together with research on new treatment strategies, diabetes technology and immunology.

Diabetes WA # F51

Founded in 1965, Diabetes WA is the peak body and voice of diabetes in Western Australia. Its vision, Freedom from Diabetes, captures the focus of what the organisation does to minimise the impact of diabetes in Western Australia.

Diploma MSc. # A43

Diploma MSc has been providing diabetes postgraduate qualifications since 2010 in partnership with the University of South Wales, the sixth largest university in the United Kingdom.
The diabetes diploma is based on the International Curriculum for Diabetes Health Professional Education and is designed to be relevant to all healthcare professionals in the multidisciplinary team who treat people with diabetes. The online nature of the course enables students to study whenever and wherever they want, with the support of our experienced tutors.

For further information see: www.diploma-msc.com

EKF Diagnostics # A15

EKF Diagnostics' range of blood analysers are simple to use and designed to quickly deliver accurate results to aid the diagnosis of anemia, diabetes and associated conditions. As manufacturer, distributor and supplier of hemoglobin analysers, hemoglobin photometers, lactate analysers, glucose testing and HbA1c analysers / hemoglobin A1c Analysers, EKF offers world class products and support.

Our analysers are used in more than 70 countries by healthcare professionals in blood banks, GP surgeries, diabetes clinics, pharmacies, hospitals, sports medicine and laboratories.

Elsevier # R25

Featuring *Diabetes Research and Clinical Practice*, the official journal of IDF, and new title *The Lancet Diabetes & Endocrinology*!

Diabetes Research and Clinical Practice
Official journal of the International Diabetes Federation. Claim a free 6-month online subscription if you register for the A1chieve.com newsletter! Free print copies on display.

The Lancet Diabetes & Endocrinology
Learn more about the latest Lancet journal dedicated to diabetes, endocrinology, and metabolism, and receive special 'Founding Subscriber' discounts and free sample copies!

Visit Stand R 25 for:

- Free six-month online subscription to *Diabetes Research and Clinical Practice* for new registrants to A1chieve.com
- Free samples of our diabetes and endocrinology research journals
- Latest book titles with 20% conference discount
- Discounts on personal journal subscriptions

www.diabetesresearchclinicalpractice.com
www.thelancet.com/diabetes-endocrinology
www.a1chieve.com

Endocrine Society # A5

Founded in 1916, the Endocrine Society is the world's oldest, largest, and most active organisation devoted to research on hormones and the clinical practice of endocrinology. The Society works to foster a greater understanding of endocrinology amongst the general public and practitioners of complementary medical disciplines, and to promote the interests of all endocrinologists at the national scientific research and health policy levels of government. More than 16,000 scientist and clinicians worldwide consider The Endocrine Society their professional home.

Learn more at endocrine.org.

Feel Tech # A19

Feel Tech has been in business since 2004.We focus on bringing the highest quality and most innovative diabetic products at cost-effective and competitive prices.

More information here www.feeltech.co.kr

GI Dynamics # D1

GI Dynamics' EndoBarrier Therapy is a device-based, adjunctive, 12-month treatment option for obese patients with type 2 diabetes. It represents a paradigm shift in the treatment of patients for whom lifestyle changes and oral diabetes medications are no longer effective and for those who want to avoid the progression to injectable therapies or consider surgery a step too far. Delivered endoscopically, the EndoBarrier device creates a barrier between food and the proximal intestine, which clinical data suggest affects hormones involved in insulin sensitivity, glucose metabolism, food intake and satiety. In clinical studies, 87% of patients reached healthy HbA1c levels by 9 months with 18% weight loss.

Glycemic Index Foundation # N51

The Glycemic Index Foundation (GIF) is a not-for-profit health promotion charity founded by the University of Sydney and JDRF (Australia). GIF's mission is to translate the science of GI into practice for the benefit of the community. Our goal is to educate consumers

and healthcare professionals about the benefits of a healthy low GI diet in the prevention and control of life-style related diseases. This includes facilitating the management of diabetes, weight loss and weight loss maintenance and reducing the risk of developing type2 diabetes, diabetes complications and cardiovascular disease.To make healthy choices easier we developed the GI Symbol Programme, a public health initiative based on over 30 years of scientific research. It is the only independent worldwide GI certification programme that is a powerful tool for quickly and reliably making healthy food choices when grocery shopping.

Visit www.gisymbol.com for more information.

Handicap International # M51

Handicap International is an international aid organisation acting in situations of poverty, exclusion, conflict and disaster. Working alongside persons with disabilities and vulnerable populations, we take action and raise awareness in order to respond to their essential needs and to promote respect for their dignity and fundamental rights.

Handicap International intervenes in difficult circumstances in order to prevent impairments and disabilities caused by chronic diseases, accidents or violence. The organisation also aims to ensure access for all to services in a range of sectors. Lastly, H.I. works on capacity-building, promotes greater social participation and encourages people to exercise their rights.

Impeto Medical # A1

Impeto Medical has developed a technology to assess the eccrine sweat glands activity Based on this technology.

More information please visit http://www.impeto-medical.com/

Insulin for Life # S19

Insulin for Life Global (IFL) collects and donates in date insulin, test strips and other diabetes supplies to countries in need. Many of these supplies would have otherwise been wasted. Instead they are saving many lives. They are sent following specific requests from recognised organisations and with an agreed protocol. IFL supplies countries on a continuous basis, and following emergencies and natural disasters. IFL also assists the International Diabetes Federation (IDF) Taskforce on *Insulin and other Essential Medicines and Technologies*, and the IDF Life for a Child programmes with supplies.

For more information visit www.insulinforlife.org and www.facebook.com/InsulinForLife

i-SENS # A17

i-SENS is a chemical and biosensor company which develops and manufactures self monitoring blood glucose test systems sold in more than 60 countries. POCT diagnostic devices such as blood gas & electrolyte analyser are also in the pipeline based on innovative and proprietary technology. Their "CareSens" product lines feature tiny sample size and fast testing times, and no coding with high accuracy. With manufacturing faculties in Korea producing 1.8 billion strips a year, it is one of the fastest growing SMBG sensor companies.

Janssen # K13

Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in metabolic diseases (including diabetes), cardiovascular, oncology, immunology, neuroscience, infectious diseases and vaccines and gastroenterology.

Janssen comprises companies with nearly 40,000 employees in more than 150 countries around the world. We work within and beyond

our communities, globally, to bring innovative products, services and solutions to people throughout the world.

Janssen is one of the Johnson & Johnson Pharmaceutical Companies. Please visit http://www.janssen.com/ for more information.

Juvenile Diabetes Research Foundation Australia – JDRF # S21

JDRF is the global not-for-profit leader in funding type 1 diabetes research. The organisation strategically influences and guides the best research into type 1 diabetes, supporting nearly every major advance in type 1 diabetes research in the past 40 years.

Through information, resources, and support, JDRF provides the help and community connections that people with type 1 diabetes need.

LifeScan # K13

LifeScan, Inc., Part of the Johnson & Johnson Diabetes Solutions Companies

"With a shared vision of "creating a world without limits" for people with diabetes, LifeScan is a part of Johnson & Johnson Diabetes Solutions Companies, a cross-company collaboration that reflects an ongoing commitment to better serve the diabetes community with integrated solutions that meet the needs of people with diabetes across the continuum of care.

LifeScan Inc., is a world leader in blood glucose monitoring. Globally, more than 10 million people depend on OneTouch® Brand products for simple testing and accurate results to help them manage their diabetes.

For more information visit: www.OneTouch.com.

Lilly Diabetes # M22

There is no group of people with whom Lilly has a longer and deeper history than those impacted by diabetes. Since 1923, we've made it our mission to understand the personal needs of people living with and treating this disease. It's through this understanding we will provide support that fits into everyday lives. We are committed to research and continued collaboration to bring forward innovative therapies and dynamic solutions to make lives better.

Lilly Diabetes is dedicated to helping healthcare professionals, caregivers, patients and their families address the challenges of this disease everyday...because it is personal. And, until there is a cure, our priority is to create solutions that will better the daily lives of everyone who is affected by diabetes.

LKC Technologies # A23

Accessible and affordable Diabetic Retinopathy screening is a worldwide challenge. The LKC RET*eval*® is a fast, easy, hand-held, and accurate way to assess the ischemic level of the retina which highly correlates to the level of diabetic retinopathy present.

RET*eval* is highly sensitive and specific to sight threatening retinopathy with immediate objective results in less than 3 minutes per patient regardless of pupil size or the presence of cataracts. There is no need to dilate and nothing touches the eye of the patient. It is battery powered and weighs only 240 grams.
RET*eval* has a multi-lingual interface for local language support and an EMR interface module. No matter where you are in the world, a remote area, a general practitioner's office, a clinic, or in a state of the art hospital, this device easily meets your needs. Visit the LKC Technologies stand today.

ManageBGL # A21

ManageBGL.com saves $8000 for people with diabetes (PWD) by giving them the dose calculation and insulin on board tracking of an insulin pump, but without the pump.It provides highly intelligent, patient-centred care:Unnecessary blood tests and insulin stacking are avoided, and correct dosage for the patient is ensured. Available for iPhone/iPod/iPad/Android Smart Phone/Tablet/PC/Mac.

Visit www.ManageBGL.com for more information

Marjorie's Fund # A47

Marjorie's Fund, founded by Dr. Jason C. Baker, an endocrinologist at Weill Cornell Medical College in New York City, envisions a world where all people with type 1 diabetes thrive, and the day when type 1 diabetes is cured.

The mission of Marjorie's Fund's Type 1 Diabetes Global Initiative is to empower adolescents and adults living with type 1 diabetes in resource poor settings to not only survive their diagnosis, but to effectively control their diabetes and to thrive. Marjorie's Fund fulfils this mission through education of patients and healthcare providers on prevention of diabetes complications, improving sustainable access to diabetes treatment and testing resources, and support of research of understudied populations aimed at improving the epidemiology of type 1 diabetes, and toward the prevention, treatment and cure of type 1 diabetes.

Medtronic # M13

As a global leader in medical technology, **Medtronic** is committed to Innovating for Life by pushing the boundaries of medical technology and actually changing the way the world treats chronic disease. Driven by our deep understanding of the human body and our close partnerships with physicians, we're transforming technology to treat patients across the entire care continuum.

Medtronic Diabetes offers advanced diabetes therapies including external pumps and infusion sets for insulin delivery and glucose sensing devices for both retrospective and continuous glucose monitoring. By combining insulin pump technology and glucose sensing technology, an important step in delivering the artificial pancreas, Medtronic Diabetes is well placed to distinguish itself as a global leader in diabetes care

For more information www.medtronic.com

Merck Sharp & Dohme # K1

Today's MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships.

For more information, visit www.msd.com or http://www.msd-australia.com.au and connect with us on Twitter, Facebook and YouTube.

Mercodia # A41

Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre- clinical and clinical phase trials.
The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.

Natural-med International Ltd. # L52

Natural-med International Ltd, was founded in 2003 in Memphis, Tennessee, USA. Nowadays Natural-Med is located in Seattle, Washington since 2010 and has established research institutions, manufacturing plants and marketing companies across Asia, Europe and America. Natural-Med becomes one of the leading companies focusing on the development and promotion of anti-oxidative stress drugs.

Nestlé # A7

With sales of CHF 92.2 billion in 2012, Nestlé is the world's leading nutrition, health and wellness company.

Nestlé has the world's largest food and nutrition research organisation. With 34 R&D facilities and about 5000 people involved in R&D, as well as corporate venture funds and research partnerships with business partners and universities, Nestlé aims to develop the scientific base for personalised health science nutrition for individual prevention and maintenance of a healthier life.

Nestlé Health Science, through its Healthcare Nutrition Business, provides nutritional products designed to help patients in many countries manage diabetes and minimise its common side effects.

Nipro Corporation # M36

Nipro Corporation is a leading global healthcare company dedicated to developing and delivering innovative and patient-oriented products for healthcare professionals, patients and the pharmaceutical industry. Nipro is a leading manufacturer and marketer of quality diabetes testing supplies and offers a portfolio of blood glucose management systems. Nipro is committed to delivering outstanding performance and value, and to improving the quality of life of people with diabetes around the world.

Novartis # H23

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world.

For more information, please visit http://www.novartis.com.

Novel # A13

The objective for diabetes healthcare professionals is to reduce ulceration and amputations caused by high local pressure on the plantar surface of the foot. With more than 35 years' experience, novel is the leader in accurate and reliable pressure distribution measurement systems for the pedographic analysis of the diabetic foot. Well-known major clinics, prominent universities and research institutions as well as healthcare suppliers worldwide rely on novel´s technology.

Novo Nordisk # H1

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 36,000 employees in 75 countries, and markets its products in more than 180 countries.

Changing Diabetes® is Novo Nordisk's commitment to answer the needs of people with diabetes in every decision and action. This means delivering targeted treatments based on a deep understanding of individual needs, and doing so with financial, social and environmental responsibility. By leading through collaboration with individuals, organisations and governments to drive prevention and provide holistic support, we will break the curve of the diabetes pandemic and empower people to live fuller, healthier lives until a cure is found.

Nuts for Life # A37

If you love nuts anywhere near as much as we do, then come along and visit our stand for a sample of delicious warmed nuts. Just a handful a day can help reduce the risk of diabetes and heart disease, as well as help manage weight. Plus studies have shown including nuts in a meal can improve postprandial blood-glucose levels – visit us to find out more.

Nuts for Life is a health education programme co-funded by the Australian Tree Nut Industry and through government-matched funding for R & D activities through Horticulture Australia.

Owen Mumford # A25

Owen Mumford designs and manufactures innovative medical devices for self-injection and capillary blood sampling, which help healthcare professionals and patients around the world to diagnose, manage and treat diabetes and other conditions. Our product range includes insulin pens, safety lancets, pen needles and autoinjectors, for use in hospitals, surgeries, clinics and in the home.

The company also offers a custom design and build service, providing bespoke devices for pharmaceutical and diagnostic partners, to meet individual requirements for a specific drug package or diagnostic test.

Come and visit us on Stand A25 to see our new, thinnest and shortest ever pen needles and the latest addition to the Unistik® family, Unistik® 3 Gentle with new, thinner 30G needle.

PiC Solution # S15

PiC Solution is a trademark of Artsana, a leading Italian company in healthcare and baby products. Its diabetes range includes innovative and specialised devices for insulin delivery and finger pricking: pen needles (a wide portfolio that meets everybody's needs), syringes (29G to 31G in 0,3-0,5-1 ml), lancing devices, blood lancets and a few innovative accessories.

More information www.picsolution.com or www.artsana.com

Qiagen # H51

QIAGEN® is the leading global provider of sample and assay technologies and offers a modern solution for infectious disease testing: QuantiFERON®. This whole blood method detects cell-mediated immune (CMI) responses in whole blood samples. QuantiFERON-TB Gold (QFT®) is a simple blood test that accurately assists the identification of people infected with mycobacterium tuberculosis, the causative agent of tuberculosis (TB). Testing for TB is important for those most at risk, such as patients taking immunosuppressive therapy, people living with HIV/AIDS, healthcare workers, people from and travellers to countries with high TB infection rates, and those who have been in close contact with active TB.

Visit www.QuantiFERON.com to learn more about QuantiFERON technology.

R3i Foundation and Diabetic Retinopathy # H32

The R3i, a worldwide, academic, multidisciplinary non-profit organisation, aims to successfully address the high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.

The R3i is led by a board of trustees and an International Steering Committee (ISC) of 44 officers and members from the disciplines of cardiology, diabetology, lipidology, endocrinology, epidemiology, nutrition, ophthalmology, nephrology and basic science. National organisations have being established in more than 40 countries worldwide. These beneficiaries of the R3i Foundation implement research and educational programmes in their respective countries and also initiate their own national initiatives, according to the mission of the R3i.

Roche Diabetes Care # C33

Roche Diabetes Care is a global market leader providing innovative solutions for personalised diabetes management and services. For more than 30 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals to effectively manage their patients' therapy. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals' innovative products and impactful solutions for efficient and effective diabetes management in everyday life. The Accu-Chek® portfolio encompasses smart blood glucose meters like the Accu-Chek® Mobile or the Accu-Chek® Aviva Expert system and interactive insulin delivery systems as the Accu-Chek® Combo system. Plus, diabetes management solutions like the Accu-Chek® 360° software as well as a range of education programmes help people with diabetes and caregivers alike to optimally manage the condition and facilitate informed therapy decisions - leading to an improved outcome.

Sanofi Diabetes # R13

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalised solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the company is forming partnerships to offer diagnostics, therapies, services and devices, including intelligent blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Saudi Society of Endocrinology & Metabolism (SSEM) # D52

SSEm aims to be the leading scientific society in Saudi Arabia. It promotes adequate healthcare delivery to communities and provides education and training to healthcare providers in the field of endocrinology, diabetes and metabolism.

SD Biosensor # E52

SD BIOSENSOR is the manufacturer of in vitro diagnostics such as blood glucose monitoring systems, lipid monitoring system and HbA1c POCT system. GlucoNavii NFC is the blood glucose meter connectable to smartphone by wireless which can provide the best customer satisfaction for the Healthcare management by NFC technology and its App. SD A1cCare is the new concept of HbA1c POCT system and its advanced Immunoassay technology provides high accuracy of less than CV 3%. SD BIOSENSOR aims to be the innovative global leader of in vitro diagnostics with the highest quality standard.

SERVIER # E14

SERVIER is the leading French independent pharmaceutical company and the second largest French pharmaceutical company worldwide. Currently established in 140 countries with 20,000 employees worldwide, it has one of the world's highest ratios of investment in research and development (25%). SERVIER's strong commitment to innovative research underlines its mission to improve the quality of people's lives by discovering and delivering therapeutic innovations to healthcare professionals and to enable patients to feel better and live longer.

SERVIER's leading partnership in diabetic research is re-known for supporting the largest ever prospective trial in type 2 diabetes, ADVANCE; with more than 11000 type 2 diabetic patients from 20 countries worldwide.

Swiss Medical Press # S35

Swiss Medical Press is a Swiss-based medical communications company that specialises in creating, developing and delivering medical, scientific and technical information to the healthcare, educational and professional domains. They also publish the *Journal of Comorbidity*, an international, open-access, peer-reviewed journal for original clinical and experimental research articles on the pathophysiology, diagnosis, prevention and management of comorbidity/multimorbidity.

Takeda # M1

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China.

Additional information about Takeda is available here www.takeda.com.

The European Association for the Study of Diabetes (EASD) # S23

The European Association for the Study of Diabetes (EASD) is an international academic association dedicated to diabetes research. The EASD Annual Meeting is attended by over 18.000 participants and provides an excellent forum to discuss the latest findings in all areas of diabetes research. The official journal of the Association is

Diabetologia. EASD awards four major prizes annually: the Albert Renold Prize, the Camillo Golgi Prize, the Claude Bernard and the Minkowski Prize. Each year the Association holds the EASD Scientists Training Course and the EASD Robert Turner Clinical Research Course. The EASD's Postgraduate Education Committee is active in organising workshops and courses for clinicians and educators worldwide. To stimulate diabetes research in Europe the European Foundation for the Study of Diabetes (EFSD) was created in 1999; since its inception nearly 100 million euro has been dedicated to diabetes research following competitive review.

The Fred Hollows Foundation # Q52

The Fred Hollows Foundation is an international development organisation, focusing on the elimination of avoidable blindness. We are inspired by the life and work of Professor Fred Hollows, an internationally acclaimed eye surgeon and social justice activist who championed the right of all people to high quality and affordable eye care and good health. Our vision is for a world in which no person is needlessly blind and Indigenous Australians exercise their right to good health. To date, we have worked in more than 30 countries in Africa, Asia and the Pacific.

In 2012 our work in partnership touched over 8 million people worldwide in the following ways: 1,989,410 screened for blindness causing eye conditions; 404,915 eye surgeries, treatments and procedures; 98 facilities upgraded; 40,719 eye health workers trained; and 7.6 million people treated for trachoma. We have identified tackling diabetic retinopathy as a priority and are seeking to work collaboratively with the diabetes sector to address this growing problem.

The National Diabetes Services Scheme (NDSS) # O14

The National Diabetes Services Scheme (NDSS) provides diabetes-related products at subsidised prices, as well as support services, to people with diabetes across Australia. The NDSS is an initiative of the Australian Government administered by Diabetes Australia.The NDSS provides education and support to help people manage diabetes.

Visit the NDSS website ndss.com.au or call 1300 136 588 for information on diabetes programmes and how to obtain NDSS products.

The World Diabetes Foundation # R51

The World Diabetes Foundation is dedicated to supporting prevention and treatment of diabetes in the developing world through funding of sustainable projects. The Foundation creates partnerships and acts as a catalyst to help others do more and strives to educate and advocate globally in an effort to create awareness, care and relief to those impacted by diabetes. The World Diabetes Foundation has to date funded 317 projects in 106 developing countries with a total project portfolio of USD 287 million, of which USD 94 million has been donated by the Foundation. The establishment of the World Diabetes Foundation was announced by its founding father, Novo Nordisk A/S, on World Diabetes Day 2001. The Foundation was legally established in February 2002 with an endowment to a maximum of DKK 1.1 billion in the period; 2001-2017, i.e. the equivalent of USD 195 million. The Foundation is registered as an independent trust and governed by a board of six experts in the field of diabetes care, access to health and development assistance.

For further information, please visit our website at www.worlddiabetesfoundation.org

Tonghua Dongbao Pharmaceutical Ltd. # E23

Founded in 1985, Tonghua Dongbao Pharmaceutical Ltd. is a conglomerate industrial group, actively engaged in the field of pharmaceutical production and is now one of the pioneering manufacturers of recombinant biopharmaceuticals, especially recombinant human insulin.

In Dongbao, innovative R&D programmes, state-of-art technology facilities, rigorous quality control systems, effectual marketing strategies as well as satisfactory after-sales services have been integrated into a well organised business operation system.

Since its establishment, Dongbao Group has demonstrated its commitment to improving people's life and adding good value to the society. Due to its achievements, Dongbao is enjoying a sound international recognition today and will endeavor to further its international collaboration.

Tourism Vancouver # M52

Visit us at the 2015 World Diabetes Congress booth and enter to win a one of four *Vancouver Experience Passes* valued at over $2,000 Cdn. These passes include complimentary admission for two to a variety of top Vancouver attractions, adventure activities, sightseeing tours and much more and are valid from July to December 2015. Vancouver, Canada is proud to be the next host city for the World Diabetes Congress in 2015.

Vancouver is Canada's Pacific gem, a clean, safe and vibrant cosmopolitan city nestled between the Pacific Ocean and the beautiful North Shore Mountains. Our culturally diverse population and unique neighbour hoods are reflected in a wide array of shopping, attractions and award-winning cuisine options all within walking distance of the Vancouver Convention Centre.

Victorian Department of Health, Australia # A49

The department is the lead Victorian government agency overseeing all health services, mental health, ageing and aged care, and preventive health. The department is responsible for planning, policy development, funding and regulation of health service providers and activities that promote and protect Victorians' health.

The department is undertaking a bold and different approach to prevention through Healthy Together Victoria (HTV), a government effort to build a robust prevention system to achieve sustained local and population health change. Through HTV, the government invests in a comprehensive suite of population level interventions aimed at addressing the risk factors of chronic disease, including type 2 diabetes: unhealthy eating, physical inactivity and obesity.

Vifor Pharma # E32

Vifor Pharma is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines and over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.

Wiley # P52

Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

For more information, visit http://www.wiley.com.

World Heart Federation # A43

The World Heart Federation is a non-governmental organisation that unites its members and leads the global fight against heart disease and stroke with a focus on low- and middle-income countries. In 2014, in collaboration with its members CSANZ and the National Heart Foundation of Australia, the World Heart Federation will hold its World Congress of Cardiology in Melbourne from 4 – 7 May 2014.

For more information visit www.worldheart.org

JAYROW HELICOPTERS INC

Visit the Elsevier exhibition booth!

ELSEVIER

THE LANCET Diabetes & Endocrinology

NEW LAUNCH!

The Lancet Diabetes & Endocrinology is the latest *Lancet* title and is dedicated to covering diabetes, endocrinology, and metabolism. Come meet our Editors and learn about this exciting new journal. Free sample copies and special subscription discounts are available.

An invitation to a unique symposium:

You are also cordially invited to attend an exclusive Symposium co-hosted by *The Lancet*, *The Lancet Diabetes & Endocrinology*, and the IDF on 'Managing Diabetes in the 21st Century'. This symposium, featuring presentations by leaders in their field, summing up the latest developments from basic science to clinical care, is here at the World Diabetes Congress, on Wednesday, 4th December.

Symposium Stream: Basic and Clinical Science

Plenary 2 Date: **4 December 2013** From: **14:30** To: **16:30**

Co-Chairs: George Alberti, United Kingdom
Justine Davies, United Kingdom

Diabetes: a 21st century challenge
Invited Speaker: P. Zimmet, Australia

Adiponectin in the development of type 2 diabetes
Invited Speaker: T. Kadowaki, Japan

Future perspectives and controversies in type 2 diabetes
Invited Speaker: S. Kahn, USA

The spectrum of diabetes: more than type 1 and type 2 diabetes
Invited Speaker: L Groop, Sweden

www.thelancet.com/diabetes-endocrinology

Come to The Lancet & Elsevier exhibition booth!

Visit the Elsevier stand for your free samples of the new *The Lancet Diabetes & Endocrinology* – and also available are:

- Information about the new Open Access title *Journal of Clinical and Translational Endocrinology*
- Register on the A1chieve.com resource center for a free 6-month online subscription to *Diabetes Research & Clinical Practice*
- Sample copies of our premier titles, *Canadian Journal of Diabetes*, *Journal of Diabetes and its Complications*, *Metabolism*, and others.

PROGRAMME OVERVIEW



PROGRAMME OVERVIEW - TUESDAY 3 DECEMBER

	Plenary 2	Plenary 1	Plenary 3	Melbourne Room 1	Melbourne Room 2	Room 203/204	
08:30	**IDF Award Lecture** Diabetes in the 20th century: a historical perspective - The mode of action of insulin: the tenth day of creation	**Symposium** Phenotyping the diabetic patient	**Symposium** GLP-1	**Symposium** Is globalisation driving diabetes?	**Symposium** Adipose biology	**Symposium** Novel complications of diabetes	08:30
09:30	**Teaching Lecture** Understanding the pathogenesis of type 1 diabetes			**Meet-the-Expert** Bridging the gaps from the ivory tower to local communities: a global initiative			09:30
10:30							10:30
10:45	**Oral Presentation** Obesity and bariatric surgery	**Oral Presentation** Insulin resistance - clinical	**Oral Presentation** Hypoglycaemia	**Oral Presentation** Late-breaking abstracts - Basic and Clinical Science	**Symposium** Estimates and surveillance of diabetes prevalence and incidence	**Oral Presentation** Experimental models of type 1 and type 2 diabetes	10:45
11.45							11.45
12:45							12:45
13:00				**President's Address** The diabetes pandemic: how is IDF responding to this growing threat to mankind?			13:00
14:00							14:00
14:30	**IDF Award Lecture** Basic Science - Beyond HbA1c: hyperglycemic variability and diabetic complications	**Symposium** Inflammation	**Meet-the-Expert** New targets for treatment and prevention of type 1 diabetes	**Symposium** Diabetic macrovascular disease	**Symposium** Public health challenges in treating diabetes	**Symposium** Approaches for diabetes prevention	14:30
15:30	**Debate** Is continued searching for type 2 diabetes genes valuable?		**Meet-the-Expert** Antibody testing in type 1 diabetes				15:30
16:30							16:30

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

	Room 210/211	Room 212/213	Room 219/220	Room 207	Room 208	Room 209	Room 106	
08:30	**Symposium** MicroRNA and diabetes	**Symposium** Overcoming the determinants of diabetes in Indigenous peoples	**Open Forum** Living your dreams	**Speaker's Corner** Living with diabetes in the family	**Symposium** Diabetic neuropathy: from basic to clinical	**Symposium** Implementing diabetes and clinical guidelines in the real world	**Symposium** The importance of safe and reliable blood glucose monitoring	08:30
09:30			**Open Forum** How to build effective relationships with a healthcare practitioner	**Meet-the-Expert** Diabetes and extreme sports			**Symposium** IDF Young Leaders in Diabetes	09:30
10:30								10:30
10:45	**Symposium** MicroRNA and diabetes	**Oral Presentation** Diabetic complications in Indigenous peoples	**Symposium** Modern technology and social media: how it is shaping diabetes care, education and research	**Oral Presentation** Psychological and other complications of diabetes	**Symposium** Inflammasomes	**Symposium** Innovative approaches to engaging people with diabetes	**Open Forum** Diabetes, drugs and alcohol	10:45
11.45							**Open Forum** Diabetes and natural disasters	11.45
12:45								12:45
13:00								13:00
14:00								14:00
14:30	**IDF Award Lecture** Living with Diabetes	**IDF Award Lecture** Diabetes in Indigenous Peoples - Understanding the burden of diabetes in Indigenous peoples	**Symposium** Famines, other natural disaster and diabetes	**Symposium** Meeting the challenge of diabetes in the ageing population	**Meet-the-Expert** Gastric emptying and incretins: relevance to diabetes management	**Symposium** Mental health: the key to physical health	**Teaching Lecture** Effective lifestyle modification strategies	14:30
15:30	**Interview** Diabetes and celebrity: professional sport and advocacy	**Symposium** Developing models of care for Indigenous people with diabetes: access, integration and equity			**Meet-the-Expert** A role for the gut and its bacteria in diabetes		**Teaching Lecture** How to get people with diabetes to be more active	15:30
16:30								16:30

Basic and Clinical Science	Diabetes in Indigenous Peoples	Diabetes Research in the 20th Century: a Historical Perspective	Education and Integrated Care	Global Challenges in Health	Living with Diabetes	Public Health and Epidemiology

PROGRAMME OVERVIEW - WEDNESDAY 4 DECEMBER

	Plenary 2	Plenary 1	Plenary 3	Melbourne Room 1	Melbourne Room 2	Room 203/204	
08:30	**Symposium** Diabetes and cardiovascular disease	**Symposium** Diabetes care at the coal face: manpower, multidisciplinary and primary healthcare	**Teaching Lecture** Childhood diabetes: from death sentence to a normal life expectancy	**Symposium** Strengthening the beta cell	**Symposium** Affordability of diabetes drugs	**Symposium** Brown fat in adult metabolism	08:30
09:30			**Meet-the-Expert** The adolescent with diabetes				09:30
10:30							10:30
10:45	**IDF Award Lecture** Basic Science - Beyond HbA1c: hyperglycemic variability and diabetic complications	**Oral Presentation** Physiology of insulin actions and obesity	**Oral Presentation** Screening and risk stratification of type 2 diabetes	**Symposium** Intersection of type 1 and 2 diabetes	**Symposium** Tackling obesity: innovative health promotion programmes in the community	**Oral Presentation** Genetics and epigenetics	10:45
11.45	**Teaching Lecture** Glucagon: a bystander or a key actor in the pathogenesis of diabetes mellitus?						11.45
12:45							12:45
13:00				**Named Lecture** ISPAD lecture			13:00
14:00							14:00
14:30	**Symposium** The IDF World Diabetes Congress presents The Lancet and The Lancet Diabetes & Endocrinology symposium: Managing diabetes in the 21st century	**Meet-the-Expert** The role of new insulins	**Symposium** Bariatric surgery: clinical controversies	**Symposium** Exercise	**Symposium** Diabetes prevention: real world examples	**Symposium** Circadian rhythm and metabolic control	14:30
15:30		**Meet-the-Expert** Insulin resistance: translating molecular findings to the clinical problems of diabetes and obesity					15:30
16:30							16:30

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

	Room 210/211	Room 212/213	Room 219/220	Room 207	Room 208	Room 209	Room 106	
08:30	**Symposium** Diabetes related syndromes	**Symposium** Diabetes in American Indians: the Pima story and beyond	**Symposium** Socio-economic and ethnic issues in diabetes	**Meet-the-Expert** Diabetes is what we eat	**Workshop** Patient empowerment through social media	**Symposium** Diabetes transitions and their psychosocial effects	**Workshop** Contemporary issues in diabetic foot care	08:30
09:30				**Meet-the-Expert** Conversation maps: well used tool or in the box gathering dust?	**Symposium** Technology in diabetes: how to remove the barriers			09:30
10:30								10:30
10:45	**Symposium** Advances in angiogenesis-relevance to diabetic complications	**Oral Presentation** Addressing the complications of diabetes in Indigenous peoples	**Oral Presentation** Diabetes management	**Oral Presentation** Enhancing patient care and self-management with e-health	**Oral Presentation** Internet, social media and community	**Oral Presentation** Self-management	**Workshop** The integrated care: rhetoric or reality? Sharing experiences and finding solutions	10:45
11.45					**Oral Presentation** Youth living with diabetes	**Oral Presentation** Insulin therapy		11.45
12:45								12:45
13:00								13:00
14:00								14:00
14:30	**Symposium** Preventing diabetes in children and adolescents	**Symposium** Community prevention: what works?	**Symposium** Novel type 2 diabetes risk factors	**Debate** Managing diabetes is harder in older people than in children and adolescents	**Symposium** Beta cell renewal and survival	**Symposium** WHO global targets for national action: hope or hype, are they achievable?	**Symposium** Role of the parliamentary diabetes groups	14:30
15:30				**Teaching Lecture** Managing diabetes in the presence of complex comorbidities			**Open Forum** Associations of people with diabetes: examples	15:30
16:30								16:30

Basic and Clinical Science	Diabetes in Indigenous Peoples	Diabetes Research in the 20th Century: a Historical Perspective	Education and Integrated Care	Global Challenges in Health	Living with Diabetes	Public Health and Epidemiology

PROGRAMME OVERVIEW - THURSDAY 5 DECEMBER

	Plenary 2	Plenary 1	Plenary 3	Melbourne Room 1	Melbourne Room 2	Room 203/204	
08:30	**Symposium** What is in the pipeline for type 2 diabetes	**Symposium** Neuronal regulation of glucose and body weight	**Teaching Lecture** Insulin therapy: 1921-2013	**Symposium** Diabetic nephropathy: from basic to clinical	**Meet-the-Expert** Type 2 diabetes and the metabolic syndrome: the ominous octet revisited	**Symposium** Non beta cells in the endocrine pancreas	08:30
09:30			**Teaching Lecture** Diabetes monitoring: from testing urine to HbA1c and continuous blood glucose determination		**Meet-the-Expert** Monogenic forms of diabetes: relevance to the global burden of diabetes mellitus		09:30
10:30							10:30
10:45	**Debate** Should controlled trials of bariatric surgery be mandatory?	**Symposium** Asia-Pacific	**Oral Presentation** Type 2 diabetes risk factors, prevention and prevalence	**Oral Presentation** Clinical - cardiorenal complications	**Oral Presentation** Treatment of type 2 diabetes	**Oral Presentation** Diabetes childhood and adolescence	10:45
11.45	**Meet-the-Expert** Systems analysis of insulin resistance						11.45
12:45							12:45
13:00							13:00
14:00							14:00
14:30	**Symposium** Pregnancy and diabetes	**IDF Award Lecture** Public Health and Epidemiology - Researching strategies for the prevention of diabetes	**Teaching Lecture** Gestational diabetes has a rich history	**Symposium** What after Metformin and lifestyle?	**Meet-the-Expert** Target blood glucose in ICU and the ward	**Symposium** Nuclear receptor targets	14:30
15:30		**Meet-the-Expert** New technology for prediction, prevention and treatment	Understanding the genetics of diabetes: from the "geneticist's nightmare" to today's reality		**Meet-the-Expert** Current management of diabetic nephropathy		15:30
16:30							16:30

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

	Room 210/211	Room 212/213	Room 219/220	Room 207	Room 208	Room 209	Room 106	
08:30	**IDF Award Lecture** Global Challenges in Health - Global health and governmental policies in diabetes: are we on the right track?	**Symposium** Maternal diabetes and dysglycaemia: current and future risks	**Symposium** Technical developments: type 1 diabetes	**Speaker's Corner** Living with diabetes complications	**Symposium** Diabetes at school	**Symposium** DAWN 2	**Workshop** How to assess physical activity and sedentary behaviour	08:30
09:30	**Debate** To screen or not to screen: should we screen when there are no resources to treat?			**Open Forum** Living with diabetes in a busy world	**Workshop** Summer camps		**Workshop** Developing eye care in vulnerable populations	09:30
10:30								10:30
10:45	**Symposium** Gestational diabetes update	**Oral Presentation** Micro and macrovascular complications	**Oral Presentation** Islets and incretin biology	**Oral Presentation** Discrimination and diabetes	**Symposium** Type 2 diabetes in children and adolescents	**Oral Presentation** Meeting the needs of older people	**Workshop** Accommodating different language, literacy and learning abilities in education	10:45
11.45				Living with diabetes	**Q&A** The primary prevention of type 2 diabetes: dream or reality?	**Oral Presentation** Peer to peer		11.45
12:45								12:45
13:00								13:00
14:00								14:00
14:30	**Symposium** Mitochondria	**Symposium** Diabetic kidney disease	**Symposium** Diabetic retinopathy	**Open Forum** Diabetes and public awareness	**Symposium** National diabetes plans on the ground: what works?	**Symposium** The independent choices people with diabetes make about their care	**Workshop** Traditional healers panel - Traditional therapy: from resilience to recovery	14:30
15:30				**Open Forum** Fighting discrimination against people with diabetes	**Open Forum** Implementing diabetes care in vulnerable populations			15:30
16:30								16:30

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

PROGRAMME OVERVIEW - FRIDAY 6 DECEMBER

	Plenary 2	Plenary 1	Plenary 3	Melbourne Room 1	Melbourne Room 2	Room 203/204	
08:30	**Symposium** Metabolic memory and epigenetics	**Symposium** Update: type 1 diabetes	**Teaching Lecture** Nutrition and diabetes: from starvation to "healthy lifestyle"	**Symposium** Diabetes and the brain	**Symposium** Cross talk between cells, fat, muscle and liver	**Symposium** Can we regulate unhealthy food? What lessons from tobacco can be applied to the food industry	08:30
09:30			**Teaching Lecture** Type 2 diabetes: past and future perspectives on therapy				09:30
10:30							10:30
10:45	**Symposium** Late-breaking clinical trials	**Oral Presentation** Insulin resistance and metabolic syndrome	**Oral Presentation** Insulin action and inflammation	**Oral Presentation** Insulin resistance - experimental	**Oral Presentation** Neuropathy, the foot and the brain	**Meet-the-Expert** Diabetes and cancer	10:45
11.45						**Meet-the-Expert** Application of modern genetics to human disease: what we can learn from the past	11.45
12:45							12:45

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

	Room 210/211	Room 212/213	Room 219/220	Room 207	Room 208	Room 209	Room 106	
08:30	**IDF Award Lecture** Education and Integrated Care - Power and fragility in health, illness and disease: the role of healthcare providers and patients	**Symposium** The diabetes cure: where are we?	**Symposium** Screening for type 2 diabetes	**Meet-the-Expert** Diabetes and pregnancy	**Symposium** Twinning of diabetes programmes between developed and developing nations	**Symposium** Innovative approaches to diabetes education	**Workshop** Strategies to reduce the burden of diabetes and related conditions in Indigenous peoples	08:30
09:30	**Debate** Peer educators are more effective than health professionals			**Open Forum** Living with diabetes for more than 50 years			**Workshop** Diabetes education in disadvantaged and culturally diverse populations: making it work	09:30
10:30								10:30
10:45	**Oral Presentation** Developing effective diabetes support	**Oral Presentation** Obesity and complications - experimental aspects	**Symposium** Type 1 diabetes epidemiology update	**Oral Presentation** Lipids	**Symposium** Contemporary issues in diabetes care in the developing world	**Symposium** Involving people in developing and using therapies	**Oral Presentation** Determinants of diabetes in indigenous populations	10:45
11.45	**Oral Presentation** Supportive care systems			**Oral Presentation** Late-breaking abstracts - Public Health and Epidemiology				11.45
12:45								12:45

	Basic and Clinical Science		Diabetes in Indigenous Peoples		Diabetes Research in the 20th Century: a Historical Perspective		Education and Integrated Care		Global Challenges in Health		Living with Diabetes		Public Health and Epidemiology

MEMBER ASSOCIATION PROGRAMME OVERVIEW

	Tuesday 03 December	Wednesday 04 December	Thursday 05 December	Friday 06 December	
10:00	AFR Region - Diabetic foot: prevention and management	NAC Region - Youth	AFR Region - Diabetes education: innovative approaches	MENA Region - Regional and national activities	10:00
10:15					10:15
10:30					10:30
10:45					10:45
11:00	SACA Region - Diabetic foot: centres to early attention		SACA Region - Educator programmes	EUR Region - Sharing experiences	11:00
11:15					11:15
11:30					11:30
11:45					11:45
12:00	EUR Region - How to put diabetes on the political agenda	MENA Region - Diabetes and youth	Life for a Child: education symposium	NAC Region - Prevention and management	12:00
12:15				EUR Region - Grand tour: engaging with the mHealth industry and access publishing	12:15
12:30					12:30
12:45					12:45
13:00					13:00
13:15					13:15
13:30					13:30
13:45					13:45
14:00	EUR Region - Prevention of blindness in people with diabetes	AFR Region - Empowerment of diabetes associations: how to share success stories	EUR Region - The IDF Europe leadership camp and related activities		14:00
14:15					14:15
14:30					14:30
14:45					14:45
15:00		SACA Region - Living with diabetes: different experiences in the region			15:00
15:15					15:15
15:30	WP Region - Targets and indicators for treatment, prevention and management of diabetes		SEA Region - Youth camps		15:30
15:45			WP Region - Youth camps		15:45
16:00		WP Region - Experience sharing	Young Leaders in Diabetes: symposium		16:00
16:15					16:15
16:30	SEA Region - Diabetes prevention				16:30
16:45		SEA Region - Experience sharing			16:45
17:00					17:00

AFR = Africa, SACA = South and Central America, EUR = Europe, MENA = Middle East and North Africa, NAC = North America and Caribbean, SEA = South East Asia, WP = Western Pacific

	AFR Region		EUR Region		MENA Region		NAC Region		Non-regional		SEA Region		WP Region

VENUE MAP

MCEC Venue Map
Wurundjeri Way
Siddeley Street
World Trade Centre
Southern Cross Station
Clarendon Street
Docklands
North Wharf
Melbourne CBD
Sealarers Bridge
Orrs Dock
Polly Woodside Maritime Precinct
Yarra River
South Wharf Promenade
Restaurant precinct opening August 2011
Dukes Walk
Hilton Melbourne South Wharf
Fiona Walk
Orrs Walk
CONVENTION CENTRE
The Plenary
Link
EXHIBITION CENTRE
LOADING DOCK
Normanby Road
Entry
Exit
Offices
Wright Walk
DFO
Convention Centre Place
Car Park Entrance
South Wharf Retail Car Park
Homemaker Hub
Montague Street
Freeway Ramp
Freeway Car Park
Munro Street
Car Park
Exhibition Centre Loading Dock
Convention Centre Loading Dock
South Melbourne
ATM
Business Centre
Disabled Access
Parking
Security
Ticket Office
Berthing Dock
Cafe
Door Numbers
Polly Woodside
Stairway
Tramline
Bike Racks
Cloak Room
Lift
Prayer Room
Taxi Rank
Tram Number
Bike Share Station
Customer Service
Parents Room
Public Access

FLOOR PLANS

Melbourne Convention Centre Ground Floor





Legend	
1	Link to Exhibition Centre
2	WDC 2013 Congress bag distribution area
3	Registration
4	IDF Info
5	Foyer
6	Cloakroom
7	Plenary
8	Prayer rooms
9	First Aid room
10	South Wharf

FLOOR PLANS

Melbourne Convention Centre Level 1



Legend	
106	Session hall (workshops)
101/102	Press interview rooms
103	Media centre
104	Press conference room

Legend	
105	IDF volunteers
107/108	Hospitality suites
109	IDF Young Leaders in Diabetes
110	Corporate meeting room

Melbourne Convention Centre Level 2



Legend	
201 202 203-204 207 208 209 210-211 212-213 219-220	Session halls

Legend	
205 206 214 215	Hospitality suites
216	Speaker preview room
218	IDF meeting room

FLOOR PLAN EXHIBITIONS



Children and members of the public are not permitted to enter the exhibition area

Legend	
Internet Zones	Exhibition Concourse
Congress bag distribution	Exhibition Concourse
Poster area	Door 4 & 5

Legend	
Exhibition area	Door 6,7 & 8
Global Village and Diabetes Café	Door 9

Company	Booth
Abbott	D5
ACON Laboratories	A33
American Diabetes Association	S25
Ascent Footwear	S33
Asian Association for the Study of Diabetes (AASD)	S31
AstraZeneca/Bristol-Myers Squibb Diabetes Alliance	H13
Australian Diabetes Council	M44
Australian Diabetes Educators Association	F52
Australian Diabetes Society	G51
Australian Institute of Health and Welfare	N52
Becton Dickinson	O6
Bioscientifica	O52
BMJ Group	Q51
Boehringer Ingelheim	K27
Diabetes Counselling Online	G52
Diabetes WA	F51
Diploma MSc	A45
EKF Diagnostics	A15
Elsevier	R25
Endocrine	A5
Feel Tech	A19
Gi Dynamics	D1
Glycemic Index Foundation	N51
Handicap International	M51
Impeto Medical	A 1
Insulin for Life	S19
i-SENS	A17
International Diabetes Federation	R1
Juvenile Diabetes Research Foundation	S21
LifeScan & Animas Corporation	K13
LKC Technologies	A23
Lilly Diabetes	M22
ManageBGL	A21

Company	Booth
Marjorie's Fund	A47
Medtronic	M13
Merck Sharp & Dohme	K1
Mercodia	A41
Natural-Med International Ltd	L52
Nestlé	A7
Nipro Corporation	M36
Novartis	H23
Novel	A13
Novo Nordisk	H1
Nuts for Life	A37
Owen Mumford	A25
Pic Solution	S15
Qiagen	H51
R3i Foundation and Diabetic Retinopathy	H32
Roche	C33
Sanofi Diabetes	R13
Saudi Society of Endocrinology & Metabolism (SSEM)	E51
SD Biosensor	E52
Servier	E14
Swiss Medical Press	S35
Type 1 Diabetes Network (T1DN)	D52
Takeda	M1
The European Association for the Study of Diabetes (EASD)	S23
The Fred Hollows Foundation	Q52
The National Diabetes Services Scheme (NDSS)	O14
The World Diabetes Foundation	R51
Tonghua Dongbao Pharmaceutical	E23
Tourism Vancouver	M52
Victorian Department of Health	A49-51
Vifor Pharma	E32
Wiley	P52
World Heart Federation	A43

FLOOR PLAN POSTERS



Basic and Clinical Science	Diabetes in Indigenous Peoples	Diabetes Research in the 20th Century: a Historical Perspective	Education and Integrated Care	Global Challenges in Health	Living with Diabetes	Public Health and Epidemiology

LIST OF MEMBER ASSOCIATIONS IN GLOBAL VILLAGE

	Association name
Africa	
Burkina Faso	Association Burkinabe d'Aide aux Diabétiques
Burundi	Burundian Diabetes Association
Cameroon	Cameroon Diabetes Association
Central African Republic	Association des Diabétiques en Centrafrique
Chad	Association Tchadienne de Lutte Contre le Diabète
Côte d'Ivoire	Association des Diabétiques de Côte d'Ivoire
Democratic Republic of Congo	Association Vaincre le Diabète au Congo
Eritrea	Eritrean National Diabetic Association
Ethiopia	Ethiopian Diabetes Association
Gambia	Gambian Diabetes Association
Ghana	National Diabetes Association
Guinea	Association Guinéenne d'Education et d'Aide aux Diabétiques
Kenya	Diabetes Kenya Association
Lesotho	Lesotho Diabetes Association
Madagascar	Association Malgache contre le Diabète
Malawi	Diabetes Association of Malawi
Mali	Association Malienne de Lutte contre le Diabète
Mauritania	Association Mauritanienne de Lutte contre le Diabète
Mozambique	Associacao Mocambicana dos Diabéticos
Nigeria	Diabetes Association of Nigeria
Republic of Congo	Diabaction-Congo
Rwanda	Association Rwandaise des Diabétiques
Senegal	Association Sénégalaise de Soutien aux Diabétiques
Seychelles	Diabetic Society of Seychelles
South Africa	Diabetes South Africa
South Africa	Society for Endocrinology, Metabolism and Diabetes of South Africa
Tanzania	Diabetes Association of Zanzibar
Tanzania	Tanzania Diabetes Association
Togo	Association Togolaise du Diabete
Uganda	Uganda Diabetes Association
Zambia	Diabetes Association of Zambia
Zimbabwe	Zimbabwe Diabetic Association

	Association name
Europe	
Albania	Shoqata E Diabetit Ne Shqiperi
Armenia	Armenian Association of Diabetes
Austria	Österreichische Diabetes Gesellschaft
Azerbaijan	Azerbaijan Diabetes Society
Belarus	Belarussian Humanitarian Organisation
Belgium	Association Belge du Diabète
Belgium	Vlaamse Diabetes Vereniging
Bulgaria	Bulgarian Diabetes Association
Croatia	Hrvatski savez dijabetickih udruga
Cyprus	Cyprus Diabetic Association
Czech Republic	Ceska Diabetologicka Spolecnost
Czech Republic	SVAZ Diabetikù Ceské Republiky
Denmark	Diabetesforeningen
Estonia	Estonian Diabetes Association
Finland	Finnish Diabetes Association
France	Association Française des Diabétiques
Georgia	Georgian Union of Diabetes and Endocrine Associations
Germany	DiabetesDE
Greece	Hellenic Diabetes Association
Greece	Hellenic Diabetes Federation
Hungary	Magyar Diabetes Tarsasag
Hungary	National Federation of Hungarian Diabetics
Iceland	Samtök Sykursjúkra
Ireland	Diabetes Federation of Ireland
Israel	Israel Diabetes Association
Italy	Associazione Medici Diabetologi
Italy	Associazione Nazionale Italiana Atleti Diabetici
Kazakhstan	Diabetes Association of the Republic of Kazakhstan
Kyrgyz Republic	Diabetes and Endocrinological Association of Kyrgyzstan
Latvia	Latvian Diabetes Association
Latvia	Latvian Diabetes Federation
Lithuania	Lithuanian Diabetes Association
Luxembourg	Association Luxembourgeoise du Diabète
Macedonia	Macedonian Diabetes Association
Malta	Ghaqda Kontra D-dijabete

LIST OF MEMBER ASSOCIATIONS IN GLOBAL VILLAGE

	Association name
Moldova	Prodiab
Norway	Norges Diabetesforbund
Poland	Polskie Stowarzyszenie Diabetyków
Poland	Polskie Towarzystwo Diabetologiczne
Portugal	Associação Protectora dos Diabéticos de Portugal
Portugal	Sociedade Portuguesa de Diabetologia
Romania	Federatia Romana de Diabet
Romania	Societatea Romana de Diabet, Nutritie si Boli Metabolice
Russia	Russian Diabetes Federation
Serbia	Diabetes Association of Serbia
Serbia	Serbian Association for the Study of Diabetes
Slovakia	Slovenska Diabetologicka Spolocnost
Slovakia	ZVAZ Diabetikov Slovenska
Slovenia	Zveza Drustev Diabetikov Slovenije
Spain	Sociedad Española de Diabetes
Sweden	Svenska Diabetesförbundet
Sweden	Swedish Society for Diabetology
The Netherlands	Diabetesvereniging Nederland
Turkey	Türk Diabet Cemiyeti
Turkey	Turkish Diabetes Foundation
Ukraine	Ukrainian Diabetic Federation
United Kingdom	Diabetes UK
Uzbekistan	Endocrinological & Diabetes Association of Uzbekistan
Middle East and North Africa	
Afghanistan	Afghanistan Diabetes Association
Algeria	Fédération Algérienne des Associations des Diabétiques
Bahrain	Bahrain Diabetes Society
Egypt	Egyptian Diabetes Association
Iran	Iranian Diabetes Society
Iraq	Iraqi Diabetes Association
Jordan	Jordanian Society for the Care of Diabetes
Kuwait	Kuwait Diabetes Society
Lebanon	Lebanese Diabetes Association
Libya	Libyan Diabetic Association
Morocco	Ligue Marocaine de Lutte contre le Diabète
Pakistan	Diabetic Association of Pakistan
Qatar	Qatar Diabetes Association

	Association name
Saudi Arabia	Saudi Diabetes and Endocrine Association
Sudan	Sudanese Diabetes Association
Sultanate of Oman	Oman Diabetes Society
Syria	Syrian Diabetes Association
Tunisia	Association Tunisienne des Diabétiques
United Arab Emirates	Emirates Diabetes Society
Yemen	Yemen Diabetes Association
North America and Caribbean	
Anguilla	Anguilla Diabetes Association
Antigua and Barbuda	Antigua and Barbuda Diabetes Association
Aruba	Aruba Diabetes Foundation
Barbados	Diabetes Association of Barbados
Belize	Belize Diabetes Association
Bermuda	Bermuda Diabetes Association
British Virgin Islands	British Virgin Islands Diabetes Association
Canada	Canadian Diabetes Association
Canada	Diabète Québec
Cayman Islands	Cayman Islands Diabetes Association
Curaçao	Sosiedat Kurasoleno di Diabetiko
Dominica	Dominica Diabetes Association
Grenada	Grenada Diabetes Association
Guyana	Guyana Diabetic Association
Haiti	Fondation Haïtienne du Diabète et des Maladies Cardiovasculaires
Jamaica	Diabetes Association of Jamaica
Mexico	Federación Mexicana de Diabetes
Mexico	Sociedad Mexicana de Nutrición y Endocrinología
Montserrat	Montserrat Diabetes Association
Sint-Maarten	Diabetes Foundation of Sint Maarten
St Kitts & Nevis	St Kitts Diabetes Association
St Lucia	St Lucia Diabetic and Hypertensive Association
Suriname	Diabetes Vereniging Suriname
The Bahamas	Bahamas Diabetic Association
Trinidad and Tobago	Diabetes Association of Trinidad and Tobago

LIST OF MEMBER ASSOCIATIONS IN GLOBAL VILLAGE

	Association name
USA	American Association of Diabetes Educators
USA	American Diabetes Association
South and Central America	
Argentina	Asociación Civil de Diabetes Argentina
Argentina	Federación Argentina de Diabetes
Argentina	Liga Argentina de Protección al Diabético
Argentina	Sociedad Argentina de Diabetes
Bolivia	Sociedad Boliviana de Endocrinología
Bolivia	Vivir con Diabetes
Brazil	Associação de Diabetes Juvenil
Brazil	Federação Nacional de Associações e Entitades de Diabetes
Brazil	Sociedade Brasileira de Diabetes
Chile	Fundación Diabetes Juvenil de Chile
Chile	Sociedad Chilena de Endocrinología y Diabetes
Colombia	Asociación Colombiana de Diabetes
Colombia	Federación Diabetológica Colombiana
Costa Rica	Asociación nacional pro estudio de la diabetes, endocrinologia y metabolismo
Cuba	Sociedad Cubana de Diabetes
Dominican Republic	Sociedad Dominicana de Diabetes
El Salvador	Asociación Salvadoreña de Diabéticos
Guatemala	Patronato de Pacientes Diabéticos de Guatemala
Nicaragua	Asociacion de Padres de Ninos y Jovenes Diabeticos de Nicaragua
Nicaragua	Fundación Nicaraguense para la Diabetes
Nicaragua	Fundación Pro Ayuda a Enfermos Crónicos
Paraguay	Fundación Paraguaya de Diabetes
Paraguay	Sociedad Paraguaya de Diabetología
Peru	Asociación de Diabetes del Peru
Peru	Asociación de Diabéticos Juveniles del Péru
Puerto Rico	Asociación Puertorriqueña de Diabetes
Puerto Rico	Asociación Puertorriqueña de Educadores en Diabetes
Puerto Rico	Sociedad Puertorriqueña de Endocrinología y Diabetología
Uruguay	Asociación de Diabéticos del Uruguay
Uruguay	Sociedad de Diabetología y Nutrición del Uruguay
Venezuela	Federación Nacional de Asociaciones y Unidades de Diabetes

	Association name
South East Asia	
Bangladesh	Diabetic Association of Bangladesh
Bangladesh	Faridpur Diabetic Association
India	Diabetic Association of India
Maldives	Diabetes Society of Maldives
Mauritius	Mauritius Diabetes Association
Nepal	Nepal Diabetes Association
Sri Lanka	Diabetes Association of Sri Lanka
Western Pacific	
Australia	Diabetes Australia
Cambodia	Cambodian Diabetes Association
China	Chinese Diabetes Society
Fiji	Diabetes Fiji
Hong Kong	Diabetes Hongkong
Hong Kong	Hong Kong Juvenile Diabetes Association
Hong Kong	Hong Kong Society of Endocrinology, Metabolism and Reproduction
Indonesia	Persatuan Diabetes Indonesia
Japan	Japan Association for Diabetes Education and Care
Japan	Japan Diabetes Society
Korea	Korean Diabetes Association
Malaysia	Persatuan Diabetes Malaysia
Mongolia	Mongolian Diabetes Association
Nauru	Nauru Diabetes Association
New Zealand	Diabetes New Zealand
Papua New Guinea	Diabetic Association of Papua New Guinea
Samoa	Diabetes Association of Samoa
Singapore	Association of Diabetes Educators
Singapore	Diabetic Society of Singapore
Taiwan	Chinese Taipei Diabetes Association
Taiwan	Taiwanese Association of Diabetes Educators
Thailand	Diabetes Association of Thailand
The Philippines	Diabetes Philippines
Tonga	Tonga Diabetes Association
Vietnam	Vietnamese Association of Diabetes & Endocrinology

Open Access from 2014!

Journal of Diabetes Investigation

We are pleased to announce that JDI will change to OPEN ACCESS in 2014. From January 1, 2014, all newly published articles will be open access and free to view, download and share. To cover the cost of publishing, authors or their funders will be required to pay an Article Publication Charge upon acceptance. Articles will be made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in PubMed Central.

Impact Factor 1.770*
*2012 Journal Citation Reports® (Thomson Reuters)

Submit your next paper to JDI

Author Guidelines: **wileyonlinelibrary.com/journal/jdi**

Receive free e-alerts!

Sign up to receive free E-mail alerts of the very latest articles. Registration takes only a few minutes. Alerts can be set to daily, weekly, monthly, or by issue.

Three simple steps

1. Register on Wiley Online Library (skip to step 2 if already registered)
2. Login (top right)
3. Go to the journal website and click on Get New Content Alerts



wileyonlinelibrary.com/user-registration

wileyonlinelibrary.com/journal/jdi

▶ Visit: **wileyonlinelibrary.com/journal/jdi**

WILEY

13-58773

Abstract Book and CD-Rom

Abstracts are available only on CD-ROM.

Accommodation, transfers and tours

arinex pty ltd is the official housing agency for the World Diabetes Congress 2013 Melbourne. They operate a desk in the registration hall of the Congress centre. The desk is open for enquiries and assistance on accommodation and tours.

Accommodation desk opening hours	
Sunday 1 December	08:00 – 18:00
Monday 2 December	07.00 – 18.00
Tuesday 3 – Thursday 5 December	07.30 – 18.00
Friday 6 December	07.30 – 13.00

Badges

Participants are requested to wear their badge at all times while in the Congress centre. Kindly note that an administrative fee of € 45/AUD$ 60 will be charged should a new badge be issued.

Colour code for badges	
Delegate	Blue
Invited Speaker	Green
Exhibitor	Red
Press	Orange
Organiser	Yellow
Crew	Black
Australian Consumer	Purple

Blue Circle

The Blue Circle is the universal symbol for diabetes. The purpose of the diabetes symbol is to give diabetes a common identity.

The icon was originally developed in 2006 for the campaign for a United Nations Resolution on Diabetes. The campaign was a response to the emerging diabetes pandemic.

The blue circle aims to:

- Support all existing efforts to raise awareness about diabetes
- Inspire new activities, bring diabetes to the attention of the general public
- Brand diabetes
- Provide a means to show support for the fight against diabetes

Blue Circle pins are available for free at the registration desks. Please wear the pin throughout the Congress and unite with us for diabetes.

Business Centre

Melbourne Exhibition Centre Business Centre

A business centre with reception, secretarial support and business equipment for sale and photocopying services is located off the Clarendon Street entrance to the Exhibition Centre.
Tel: +61 3 9235 8448
Opening hours 08.00-17.00

Cash Dispenser

ATMs are located adjacent to the Convention Centre entry and on the Exhibition Centre concourse.

Catering

Food outlets in the exhibition and convention areas will provide lunch during the congress days. Each delegate will be provided with one lunch voucher per day covering Tuesday 3 - Friday 6 December. Please note that lost or misplaced vouchers will not be replaced.

Continuing Medical Education (CME) Accreditation

CME accreditation for delegates

An application has been made to the EACCME for CME accreditation of the World Diabetes Congress Melbourne 2013.

EACCME is an institution of the European Union of Medical Specialists (UEMS), www.eaccme.eu. Each medical specialist should claim only those hours that he/she spent in a medical activity.

EACCME credits are recognised by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME credits to AMA PRA category 1 credit, contact the AMA.

CME certificates will be available to print onsite in the registration area as of Thursday 5 December 2013 and online through the IDF website, www.idf.org , as of 14 December 2013.

Australian physicians and healthcare professionals can self-record CPD points with their respective institutions by presenting their certificate of attendance.

All delegates will be asked to complete an evaluation form in return for a certificate of attendance.

CME accreditation for satellite symposia

Companies or institutions holding a satellite symposia lasting more than one hour at the Congress need to make a separate application for accreditation to the EACCME.

New criteria for the accreditation of Live Educational Events (UEMS 2012/30 documents) are found on the EACCME website.

To check whether these symposia are eligible for EACCME accreditation, click here www.eaccme.eu

Diabetes Café

Surrounded by the Global Village, bringing together IDF's Member Associations, the Diabetes Café provides the setting for the global diabetes community to present their initiatives, best practices and successful projects.

Scheduled opening hours	
Tuesday 3 - Thursday 5 December	10.00-17.00
Friday 6 December	10.00-14.00

Electricity

Electricity in Melbourne is 220/240 volts AC. Power sockets in Melbourne generally accept the 3 pin plug. If the plug of your appliance has a different shape, you will need an adapter. If your electrical appliance uses lower voltage (110 volts), you will need a converter.

Exhibition

Companies from all over the world can showcase their newest technologies and scientific research in the field of diabetes on the exhibition floor.

Scheduled opening hours	
Tuesday 3 - Thursday 5 December	10.00-17.00
Friday 6 December	10.00-14.00

Global Village

Over 200 national member associations will have the opportunity to interact with the diabetes community at large. The Village's main objective is to serve as an avenue of exchange between associations and for them to showcase their activities.

Scheduled opening hours	
Tuesday 3 - Thursday 5 December	10.00-17.00
Friday 6 December	10.00-14.00

Internet Zone

Several internet stations with printers are at the delegates' disposal on the exhibition concourse.

IDF Congress Secretariat

The IDF Congress Secretariat is located in the Convention Centre on level 1 (Congress Organisers' Office 101).

The secretariat's opening hours	
Monday 2 -Friday 6 December	07.00-18.00

Language

The official language of the Congress is English. All sessions will be in English only.

Liability and Insurance

The International Diabetes Federation (IDF), Moreton Hire (the official exhibition builder) or any other supplier active in the congress centre will not assume responsibility for injury and/or damage involving persons or property during the congress. Participants are advised to take out a personal insurance for the congress.

Lost and Found

The Lost and Found Office is located on the ground floor of convention centre. Items will be returned to the rightful owner upon presentation of reasonable proof of ownership. The Office operates during Congress hours. The Congress organisers and the congress centre (MCEC) assume no responsibility for the care and/or protection of any personal belongings left unattended on MCEC property or for the loss, under any circumstance, including theft, vandalism, or malicious mischief of any such belonging.

Media

The media centre will serve the needs of print, radio, and broadcast journalists covering the World Diabetes Congress 2013. Services provided to accredited journalists include: computer work stations,

internet connection, ISDN lines, printers, telephones, fax and photocopy machines. A multi-lingual communications team will be available to assist journalists with editorial, technical and logistical support. Rooms will also be available for interviews and for official daily briefings and third-party press conferences.

The media centre is located in room 103/104 on level 1 of the Melbourne Convention Centre.

Scheduled opening hours	
Monday 2 December	14.00-17.00
Tuesday 3 - Thursday 5 December	08.00-18.00
Friday 6 December	08.00-14.00

Only accredited journalists have access to the media centre.

Medicine and First Aid

The majority of medicines used worldwide are available in local pharmacies and hospitals in Melbourne. A first aid unit will operate in the congress centre during congress opening hours. The main first aid room is located off the Convention Centre foyer. A smaller first aid room is located off the Exhibition Centre foyer.
Tel: +61 3 9235 8333

Opening Hours

Activity	Day	Hours
Group registrations Collection of congress materials (badges, vouchers) at pre-arranged times	Sunday 1 December	08.00-18.00
Satellite symposia	Monday 2 December	08.00-16.00
	Tuesday 3 - Thursday 5 December	17.15-19.15
Individual registrations	Monday 2 - Thursday 5 December	07:00-18:00
	Friday 6 December	07.00-13.00
Exhibition	Tuesday 3 - Thursday 5 December	10.00-17.00
	Friday 6 December	10.00-14.00
Global Village	Tuesday 3 - Thursday 5 December	10.00-17.00
	Friday 6 December	10.00-14.00
Programme	Tuesday 3 - Thursday 5 December	08.30-16.30
	Friday 6 December	08.30-14.00
Diabetes Café	Tuesday 3 - Thursday 5 December	10.00-17.00
	Friday 6 December	10.00-14.00
CME certificates will be issued at the registration desk	Thursday 5 December	08.00-18.00
	Friday 6 December	08.00-14.00

Prayer Rooms

Separated male and female prayer rooms including washing facilities are located in the Convention Centre off the main foyer.

Programme Streams and Sessions

Programme-at-a-glance

The overall programme will consist of an array of sessions in different formats separated into seven major streams.

Programme Committee Chair: Paul Zimmet

Stream	Stream Lead
Basic and Clinical Science	Mark Cooper
Diabetes in Indigenous Peoples	Alex Brown
Diabetes Research in the 20th Century: a Historical Perspective	Pierre Lefèbvre
Education and Integrated Care	Angus Forbes
Global Challenges in Health	Linong Ji
Living with Diabetes	João Nabais
Public Health and Epidemiology	Jonathan Shaw

Invited speakers programme sessions

Debate (D)
These will include sessions on controversial topics in the format of a discussion in which two opposing teams will defend and refute a given proposition.

Meet-the-expert (ME)
These sessions will provide the opportunity for participants to interact with one or more experts on a specific topic.

Open Forum (OF)
A topic of common interest will be introduced for discussion between a speaker and participants. Participants may put forth new ideas and questions to the speaker at any time.

Speakers' Corner (SC)
These informal sessions will showcase critical evaluations and analyses of a topic by the speaker. Participants may question the speaker at the end of the lecture.

Symposium (S)
Symposia will include the latest findings in diabetes research and current issues in therapy and education as well as exploring subjects related to the organisational, economic and personal impact of diabetes.

Teaching Lecture (TL)
Recognised experts will give educational lectures on specific topics. This format will combine a lecture with an audience interaction.

Workshop (WS)
Workshops will include the discussion of specific topics accompanied by practical demonstrations, problem-solving or hands-on training sessions.

Abstract Programme

Oral Presentation
Some accepted abstracts will be chosen for oral presentations enabling authors to communicate their findings to a global audience.

Poster Discussion
An array of accepted abstracts will be chosen for poster presentation sessions. Authors will present their poster and discuss their findings with a small group. The sessions will take place from 13.00 – 14.00 on Tuesday 3 to Thursday 5 December.

Poster Display
A collection of accepted abstracts will be displayed as posters from Tuesday 3 to Friday 6 December in the Poster Area.

Session recording policy

No session may be recorded or broadcast in any format by any attendee. The Congress records some sessions itself with the presenter's consent for webcasting for up to one year after the Congress.

Use of digital cameras to record individual slides is not allowed. The use of photographs of slides in any subsequent publication or presentation or any other distribution is a breach of copyright and may result in prosecution by the owner of the data or ideas. The use of flash is also forbidden.

Please note that there is no need to sign up for individual sessions. Access is on a first-come, first-served basis.

Social Programme

Opening ceremony and welcome reception

We welcome you to the Congress opening ceremony

- Room: The Plenary
  Location: Melbourne Convention Centre
  Time and date: Monday 2 December 2013, 19:00
  Free entrance for all registered delegates
  Dress code: casual

The Coroboree

Join well-known Indigenous performers, The Black Arm Band, in their performance of the 'Murunduk'.
The Corroboree will take place at:

- The Federation Square
  Thursday 5 December 2013, 18.00-20.00
  Free entrance to registered delegates and the public

Social Responsibility

Where possible, IDF strives to promote social responsibility and ethical practices towards the environment and the global community. IDF makes every effort to take decisions that reflect these ethics to fulfill our role in society. IDF plans to support and encourage the environmental policy adopted by the Congress venue and follows an environmentally friendly approach.

Speaker Preview Room

The speaker preview room is located in room 216 on level 2 of the convention centre. All speakers need to report to the speaker preview room at least 4 hours prior to the start of their session, for their presentations to be uploaded to the appropriate session hall. Speakers with early morning presentations should be at the speaker preview room the day before. No laptop presentations will be allowed in the session halls for the scientific programme.

Opening hours	
Sunday 1 December	12.00-18.30
Monday 2 December	08.00-17.00
Tuesday 3 December	07.30-20.45
Wednesday 4 December	07.30-19.45
Thursday 5 December	07.30-19.15
Friday 6 December	07.30-13.00

Tax

A 10% Goods and Services Tax (GST) is incorporated into the price of all goods and services sold in Australia except some basic items. International tourists may be eligible for a GST refund on some goods bought in Australia. For more information visit www.customs.gov.au or phone +61 2 6275 6666.

Time Zone

Melbourne is 11 hours ahead of Coordinated Universal Time (UTC) and Greenwich Mean Time (UTC/GMT +11 hours) at the time of the Congress.

Transport

Airport

Melbourne International Airport (airport code MEL) is located 20km or 25 minutes from the city centre.

Airport transfers

Please note that IDF will not organise shuttle buses to/from the airport for the Congress. Taxis are available at the arrivals terminal at all times, a taxi fare is approximately AUD$40.
A shuttle bus service, SkyBus, operates 24 hours a day between the Airport and the city centre. The service runs approximately every 30 minutes at a cost of AUD$ 16 each way. Drop off points are located throughout the city centre close to hotels and facilities.

Public transport

A valid Myki card will allow delegates to travel on Melbourne's public transport system - trains, trams and buses. Myki vending machines dispense full fare cards and are located at the Clarendon Street tram stop (located outside the Melbourne Convention and Exhibition Centre). A visitor card can be bought at the Melbourne Exhibition Centre Café.

Taxis

Taxis can be hailed in the street if their sign is illuminated. An orange light indicates that the taxi is not for hire.

Emergency telephone number in Melbourne

Emergency: 000

Venue

The Melbourne Convention and Exhibition Centre (MCEC) is a 20-30 minute drive from Melbourne International Airport.

- Melbourne Convention and Exhibition Centre
  2 Clarendon Street
  South Wharf
  Victoria 3006
  www.mcec.com.au

Webcast

Congress sessions will be recorded and webcast on the IDF website free of charge as of January 2014 for 12 months.

Wheelchair

All exhibition halls, meeting rooms and public areas are accessible by wheelchair.

Wifi

Free wireless internet access will be provided throughout the Congress centre. Wifi network is WDC 2013 and the password is idfatlas06.

The World Diabetes Congress has gone mobile!

Download the congress app to:

- receive up-to-date programme information
- create your own schedule
- locate sessions and exhibitor booths with ease
- learn about speakers and exhibitors

Access the congress app by scanning the code or visiting eventmobi.com/wdc2013

To access the app offline please bookmark the site and save to your homescreen

#wdc2013

Kindly sponsored by

International Diabetes Federation

SANOFI DIABETES

WORLD DIABETES CONGRESS CONFERENCE TV

Premiere!

The International Diabetes Federation (IDF) is partnering with the international film and broadcasting company, WebsEdge, to bring World Diabetes Congress TV (WDC TV) to this year's World Diabetes Congress Melbourne, Australia from 2-6 December 2013.
WDC TV will be an onsite conference television channel featuring a new episode daily, screened around the venue, as well as online and on a dedicated television channel in selected guest hotel rooms.
This venture serves to raise the visibility of the hard work of the global diabetes community. It will also provide an opportunity to learn about new and on-going research and collaborations that are advancing the prevention, treatment and care of diabetes.

Be Featured!

Each daily programme has two features: "Thought Leadership" and "Conference News".

Thought Leadership pieces are five-minute sponsored film segments highlighting programmes, case studies and best practices in the field of diabetes.

Conference News is a daily programme of Congress highlights, featuring "behind the scenes" interviews, coverage of conference events, and reactions to the day from attending delegates.

LIST OF HOTELS

5 STAR ACCOMMODATION

1. Crown Metropol — I12
2. Crown Towers — J10
3. Grand Hotel Melbourne — H9
4. Hilton Melbourne South Wharf — E12
5. InterContinental Melbourne the Rialto — I7
6. Quay West Suites Melbourne — M8
7. The Langham Hotel Melbourne — L9

4.5 STAR ACCOMMODATION

1. Citigate Melbourne — M7
2. Clarion Suites Gateway — J8
3. Crown Promenade — J10
4. Crowne Plaza — H10
5. Holiday Inn on Flinders — H8
6. Mantra Southbank — M9
7. Adina Apartments Northbank — H9
8. Oaks on Collins — I7
9. Oaks on Market — J7
10. Radisson Flagstaff Gardens — H3
11. Rendezvous Hotel Melbourne — L7
12. Rydges Melbourne — O3
13. Vibe Savoy Hotel Melbourne — G7

APARTMENTS

1. Metro Apartments on Bank Place
2. Melbourne Short Stay Apartments – Southbank Deluxe
2. Melbourne Short Stay Apartments – Southbank ONE
2. Melbourne Short Stay Apartments – Southbank Central
4. Quest Southbank Melbourne

4 STAR ACCOMMODATION

1. Alto Hotel on Bourke
2. Novotel Melbourne on Collins
3. Quality Hotel Batman's Hill on Collins
4. Travelodge Southbank
5. Travelodge Docklands
6. Harbour View Apartment Hotel

3.5 STAR ACCOMMODATION

1. 8Hotels – Pensione Hotel Melbourne
2. Great Southern Hotel Melbourne
3. Ibis Styles Melbourne, The Victoria Hotel

3 STAR ACCOMMODATION

1. All Seasons Kingsgate Hotel
2. Ibis Hotel Melbourne




QUEEN VICTORIA MARKET
FLAGSTAFF GARDENS
FLAGSTAFF
MELBOURNE CENTRAL
PARliament
FLINDERS ST
FEDERATION SQUARE
ALEXANDRA GARDENS
QUEEN VICTORIA GARDENS
KING'S DOMAIN
ROYAL BOTANIC GARDENS
GOVERNMENT HOUSE
GOVERNMENT HOUSE DRIVE
MELBOURNE PARK
MELBOURNE CRICKET GROUND
East Melbourne
Jolimont
Southbank
Yarra River
To Station Pier
To Mornington Peninsula & Phillip Island via Nepean Hwy
To Mornington Peninsula & Phillip Island via Monash Fwy
To Bridge Rd & Dandenongs via Burwood Hwy
QUEEN ST
ELIZABETH ST
SWANSTON ST
RUSSELL ST
EXHIBITION ST
SPRING ST
NICHOLSON ST
LA TROBE ST
VICTORIA ST
VICTORIA PDE
WELLINGTON PDE
WELLINGTON PDE SOUTH
BOURKE ST
COLLINS ST
WILLIAM ST
KING ST
SPENCER ST
FLINDERS LANE
BATMAN AV
BRUNTON ST
JOLIMONT ST
JOLIMONT RD
ALEXANDRA AV
ST KILDA RD
BOATHOUSE DRIVE
RIVERSIDE AV
RIVERSIDE QUAY
SOUTHBANK
CITY RD
FANKNER ST
STURT ST
BOULEVARD
QUEENS BRIDGE ST
POWER ST
KAVANAGH ST
KINGS WAY
CLARENDON ST
NORMANBY RD
MORAY ST
HANCOCK ST
MILES ST
WELLS ST
GRANT ST
SOUTHERN LINK RD
SWAN ST
BATMAN AV
ALEXANDRA AV
BIRDWOOD AV
ANZAC AV
LANSDOWNE ST
CLARENDON ST
HOTHAM
GEORGE
GISBORNE ST
CATHEDRAL PL
ALBERT ST
EADES ST
MACKENZIE ST
FRANKLIN ST
THERRY ST
A'BECKETT ST
LT LATROBE ST
LITTLE LONSDALE ST
LONSDALE ST
LITTLE BOURKE ST
LITTLE COLLINS ST
TREASURY PL
ST ANDREWS PL
PRINCES ST
FITZROY GARDENS
TREASURY GARDENS
1
2
3
4
5
6
7
8
9
10
11
12
13

We are proud to present sessions spearheaded by IDF. These are related to the task forces and consultative sections of IDF and other activities where IDF played a leading role or published statements or guidelines.

IDF Award Lectures

As a fixture of the scientific programme, IDF is presenting Award Lectures in recognition of the contributions made by individuals to advancing diabetes care, prevention and a cure. Eight outstanding people representing the different programme streams will hold inspirational lectures about their achievements.

Basic Science – Professor Michael Brownlee

Professor Michael Brownlee holds the Anita and Jack Saltz Chair of Diabetes Research at the Albert Einstein College of Medicine in New York where he is Associate Director for Biomedical Sciences at Einstein's Diabetes Research Center. At Einstein Dr Brownlee discovered that most known mechanisms underlying diabetic complications share a common upstream link – hyperglycaemia-induced overproduction of superoxide by the mitochondrial electron transport chain.

Clinical Science – Professor Stephen O'Rahilly

Stephen O'Rahilly is Professor of Clinical Biochemistry and Medicine at the University of Cambridge and Honorary Consultant Physician at Addenbrooke's Hospital. He has sought to better understand the molecular mechanisms leading to diabetes, obesity and related metabolic and endocrine disorders. He remains active in clinical practice and in the teaching of medical students.

Diabetes in Indigenous Peoples – Dr Alex Brown

Professor Alex Brown is an Indigenous doctor who, in 2012, was appointed the Theme Leader for Indigenous Health at the South Australian Health and Medical Research Institute. He remains a part-time Senior Research Fellow at Baker IDI. He has more than 10 years of involvement in Aboriginal health, education, policy, communicable disease control, service delivery and public health, epidemiology, research and research ethics. He has been heavily involved in engaging government and lead agencies in setting the agenda in Aboriginal CVD control.

Diabetes Research in the 20th Century: A Historical Perspective – Professor Jesse Roth

Professor Jesse Roth, M.D, FACP, serves as Chief Geriatrician of Long Island Jewish Medical Center. He introduced the direct study of cell surface receptors for insulin and other hormones, leading to the recognition of the vital role of cell surface receptors in transforming the information provided by extra cellular hormonal signals into intracellular events. He also played an important role in uncovering the first few steps in insulin action and understanding the role of these events in genetic and acquired disorders of glucose metabolism.

Education and Integrated Care – Professor Jean-Philippe Assal

Professor Jean-Philippe Assal, former chief, Division of Therapeutic Education for Chronic Diseases, University Hospital, Geneva, and Director of a WHO collaborating centre for research and development of new educational strategies for patients, currently helps various medical centres to develop therapeutic patient education programmes. Currently President of the Foundation for Research and Training in Patient Education, he holds regular workshops for healthcare providers/patients where emphasis is put on coping with the burden of chronicity by creative approaches through theatre, painting and writing.

Global Challenges in Health – Professor Jean Claude Mbanya

Professor Jean Claude Mbanya is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, University of Yaoundé I and Director Biotechnology Centre, University of Yaoundé I. As IDF President 2010-2012 he was a driving force of the UN High-Level Summit on Non-Communicable Diseases (NCDs). Professor Mbanya also currently serves on several international scientific and WHO advisory groups, including the Expert Advisory Panel on Chronic Degenerative Diseases and Diabetes and the WHO African Advisory Committee on Health Research and Development.

Living with Diabetes – Mr Wasim Akram

Wasim Akram is an erstwhile Pakistani cricketer and pioneer of reverse swing bowling. He has headed the cricket team of Pakistan in test as well as one-day internationals. He holds world records for taking the most wickets in ODIs. He was diagnosed with diabetes in 1997 and, by carefully managing his condition through diet and exercise, he continued to play world class cricket. After his retirement in 2003, Wasim Akram has taken up commentary and can be seen as a sports caster.

Public Health and Epidemiology – Professor Nicholas Wareham

Professor Nick Wareham is Director of the MRC Epidemiology Unit in Cambridge and an Honorary Consultant at Addenbrooke's Hospital, Cambridge. He is also Director of the Centre for Diet and Activity at the University of Cambridge (CEDAR). He undertakes research into the aetiological determinants of diabetes, obesity and related metabolic disorders and the translation of that epidemiological understanding into preventive action. He is also Chair of the NICE Programme Development Group on the prevention of prediabetes.

IDF Member Association programme in the Diabetes Café

The Diabetes Café, part of the IDF Global Village, becomes the exclusive platform for IDF Member Associations to showcase their work, activities and projects. Sessions will take the format of best practice presentations and *open forum* discussions.

Diabetes film programme

For the first time the World Diabetes Congress will showcase international films giving a personal view of how people deal with diabetes. Take a seat in the Diabetes Café, stretch-out on one of our back-friendly gymnastic balls and be inspired.

Films are shown daily during lunch between 13:00-14:00.

IDF BRIDGES programme

BRIDGES is an IDF programme supported by an educational grant from Lilly Diabetes. It aims at supporting translational research in diabetes. The funding will support research to identify, test and publish new non-pharmaceutical strategies for combating diabetes and improving outcomes for people with diabetes. So far there are 38 BRIDGES projects running in 34 countries.

Join BRIDGES programme participants and coordinators at a dedicated symposium in Melbourne to discover the latest worldwide data on diabetes published by IDF as well as the solutions tested by IDF to prevent the condition and its complications

IDF Diabetes Atlas

The latest edition of the IDF Diabetes Atlas will be distributed to delegates in Melbourne. The Atlas is the authoritative source of evidence on the burden of diabetes for health professionals, scientists, economists, policy-makers, and national and international agencies. The new edition of the IDF Diabetes Atlas, shows that one in ten people will have diabetes by 2035 and that in some countries up to one person in three has the disease.

The evidence within the Diabetes Atlas has been used widely by news media, governments, and international organisations such as the World Bank, the World Health Organization and the World Economic Forum.

Life for a Child

The International Diabetes Federation "Life for a Child" Programme was established in 2000 with support from the Australian Diabetes Council and HOPE worldwide. It is an innovative and sustainable support programme in which individuals, families and organisations contribute monetary or in-kind donations to help children with diabetes in developing countries. The formula is simple: contributions from

donors go to established diabetes centres enabling them to provide the ongoing clinical care and diabetes education children need to stay alive.

Life for a Child is currently helping over 12,000 children and adolescents with diabetes in 43 countries.

The Young Leaders in Diabetes programme

In 2011, IDF launched the Young Leaders in Diabetes (YLD) Programme to identify talented young people with diabetes and provide them with training to improve the lives of people affected by diabetes worldwide. Since the first YLD Leadership Training in Dubai, the Young Leaders have conducted numerous successful projects strengthening their local diabetes communities. In Melbourne the second YLD Leadership 137 Young Leaders from over 70 countries will participate in training at the Congress.

Opportunities to meet the Young Leaders are in the Symposium session on Tuesday 09:30-10:30 (room 106) and the YLD Diabetes Café session on Thursday 16:00-17:00.

- More information: http://youngleaders.idf.org

WDC Melbourne 2013: a healthy Congress

Turn your words into action and make this Congress your healthiest yet!

Pedal powered smoothie bikes "Bike n' Blend"

Visit the amazing smoothie bike area in the Global Village. Use your own pedal power to blend a healthy smoothie as your reward.

The early delegate catches the worm

Join us every morning from Tuesday 3 to Friday 6 December at 6.30am at the Yarra River boardwalk opposite the Melbourne Exhibition Centre. After a 'warm-up' led by professional Australian fitness instructors we'll take you on a 30 min walk/run along the beautiful waterfront to get you in the mood for a day of sessions.

Walk the talk

Most of the hotels are within walking distance of the Congress centre. So get out your sneakers and walk the talk. You'll like it!

Food for thought

Tired of the same boring congress lunch bag sandwich? The World Diabetes Congress Melbourne will be different: a whole world of healthy food from steamed dumplings to quinoa burgers is available for you to enjoy.

Use your lunch vouchers included in the registration fee or choose from a large reasonably priced menu.

Topic	Session	Room	Chair	Speaker	Time
Tuesday 03 December 2013					
IDF Award Lecture - Diabetes in the 20th Century: A Historical Perspective	IDF Award Lecture	Plenary 2	P. Lefèbvre (Belgium)	J. Roth (USA)	08:30 - 09:30
Living your dreams	Open Forum	Room 219/220	P. Buchanan (United Kingdom)	J. Feijoo (Spain) B. Hauck (Germany)	08:30 - 09:30
The importance of safe and reliable blood glucose monitoring	Symposium	Room 106	K. Brownlee (USA)	D. Cavan (United Kingdom) N. Cohen (Australia) K. Ramaiya (Tanzania)	08:30 - 09:30
Bridging the gaps from the ivory tower to local communities: a global initiative	Meet-the-Expert	Melbourne Room 1	S. Sadikot (India)	L. Siminerio (USA)	09:30 - 10:30
Diabetes and extreme sports	Meet-the-Expert	Room 219/220	M. Saraheimo (Finland)	J. Morris (USA) C. Thomas (Australia) B. van de Goor (The Netherlands)	09:30 - 10:30
IDF Young Leaders in Diabetes	Symposium	Room 106	J. Valente Nabais (Portugal)	K. Boyea (Barbados) K. Hall (South Africa) A. Silverstein (United Kingdom)	09:30 - 10:30
Estimates and surveillance of diabetes prevalence and incidence	Symposium	Melbourne Room 2	N. Unwin (Barbados) N. Wareham (United Kingdom)	P. Bennett (USA) L. Guariguata (Belgium) A. Karter (USA) N. Tajima (Japan)	10:45 - 12:45
Diabetes and natural disasters	Open Forum	Room 106	R. Raab (Australia)	G. Ogle (Australia) J. Satoh (Japan) S. Seogondo (Indonesia)	11:45 - 12:45
President's address	President's Address	Melbourne Room 1	A. Felton (United Kingdom)	M. Hirst (United Kingdom)	13:00 - 14:00
IDF Award Lecture - Basic Science	IDF Award Lecture	Plenary 2	M. Cooper (Australia)	M. Brownlee (USA)	14:30 - 15:30
IDF Award Lecture - Diabetes in Indigenous Peoples	IDF Award Lecture	Room 212/213	D. Warne (USA)	A. Brown (Australia)	14:30 - 15:30
IDF Award Lecture - Living with Diabetes	IDF Award Lecture	Room 210/211	J. Valente Nabais (Portugal)	W. Akram (Pakistan)	14:30 - 15:30
Diabetes and celebrity: professional sport and advocacy	Interview	Room 210/211	S. Cockburn (Australia)	M. Foy (USA) C. Freeman (Australia)	15:30 - 16:30
Wednesday 04 December 2013					
Diabetes is what we eat	Meet-the-Expert	Room 207	J. Brand-Miller (Australia)	C. Mattocks (USA)	08:30 - 09:30
Contemporary issues in diabetic foot care	Workshop	Room 106	G. Sussman (Australia) Z. Xu (China)	M. Al Arouj (Kuwait) K. Bakker (The Netherlands) S. Kono (Japan) V. Viswanathan (India)	08:30 - 10:30
Conversation maps: well used tool or in the box gathering dust?	Meet-the-Expert	Room 207	D. Howarth (Belgium)	A. Jalang'o (Kenya) A. Yoshihito (Japan)	09:30 - 10:30

Topic	Session	Room	Chair	Speaker	Time
IDF Award Lecture - Clinical Science	IDF Award Lecture	Plenary 2	J. Prins (Australia)	S. O'Rahilly (United Kingdom)	10:45 - 11:45
Role of the parliamentary diabetes groups	Symposium	Room 106	G. Barnett (Australia)	M. Hirst (United Kingdom) J. Moylan (Australia) A. Sanders (United Kingdom)	14:30 - 15:30
Thursday 05 December 2013					
IDF Award Lecture - Global Challenges in Health	IDF Award Lecture	Room 210/211	L. Ji (China)	J.C. Mbanya (Cameroon)	08:30 - 09:30
Life for a Child: education symposium	Symposium	Diabetes Café		A. Middlehurst (Australia) G. Ogle (Australia)	12:00 - 13:00
IDF Award Lecture - Public Health and Epidemiology	IDF Award Lecture	Plenary 1	J. Shaw (Australia)	N. Wareham (United Kingdom)	14:30 - 15:30
Diabetes and public awareness	Open Forum	Room 207	S. Peresson (Belgium)	A. Al Hamaq (Qatar) B. Young (United Kingdom)	14:30 - 15:30
Fighting discrimination against people with diabetes	Open Forum	Room 207	S. Langlois (Canada)	S. Ajmal (Pakistan) D. Cairns (United Kingdom) W. Wientjens (The Netherlands)	15:30 - 16:30
Young Leaders in Diabetes	Symposium	Diabetes Café	D. Jones (Bermuda)	A. Abdul Rahman (Maldives) M. Al-Ostad (Kuwait) T. Froment (Belgium) M. Hillinger (Austria) J. Markovic (Serbia) K. Schudmann (Germany) S. Tembo (Zimbabwe)	16:00 - 17:00
International Diabetes Federation joint Diabetes Atlas and BRIDGES symposium: Translating the evidence into real solutions	Symposium	Room 212/213	M. Hirst (United Kingdom)	N. Cho (Korea) J.J. Gagliardino (Argentian) J. Shaw (USA) L. Siminerio (USA) J. Tuomilehto (Finland) D. Whiting (United Kingdom) X. Yang (China)	17:15 - 19:15
Friday 06 December 2013					
IDF Award Lecture - Education and Integrated Care	IDF Award Lecture	Room 210/211	A. Forbes (United Kingdom)	J-P. Assal (Switzerland)	08:30 - 09:30

PROGRAMME

TUESDAY 03 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:30 - 09:30 Plenary 2

IDF award lecture - Diabetes in the 20th century: a historical perspective

Chair: P. Lefèbvre

The mode of action of insulin: the tenth day of creation 0001

Invited Speaker: J. Roth (USA)

Jesse Roth

Professor Jesse Roth, M.D, FACP, serves as Chief Geriatrician of Long Island Jewish Medical Center. He serves as an Investigator in Lab of Biomedical Science, Institute for Medical Research at North Shore-LIJ. He is Professor of Medicine at Albert Einstein College of Medicine, Geriatrician-in-Chief of North Shore-Long Island Jewish Health System, and Associate Director at the General Clinical Research Center, Institute for Medical Research at North Shore-LIJ. Prof. Roth served as the Assistant Surgeon General in the U.S. Public Health Service from 1985 to 1991.

He held distinguished positions at Johns Hopkins University School of Medicine, Picower Institute, and National Institute of Diabetes and Digestive and Kidney disease. In 2005 he led the Diabetes Grand Rounds at the Naomi Diabetes Center at Columbia. Professor Roth has been member of scientific advisory board of N-Gene Research Laboratories, Inc. since February 2005. He served as member of scientific advisory board of Mannkind Corp. and Medingo Ltd. He is an internationally recognised diabetes researcher and served for almost four decades in a leadership capacity at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases and at Johns Hopkins University School of Medicine.

He introduced the direct study of cell surface receptors for insulin and other hormones, leading to the recognition of the vital role of cell surface receptors in transforming the information provided by extra cellular hormonal signals into intracellular events. He also played an important role in uncovering the first few steps in insulin action and understanding the role of these events in genetic and acquired disorders of glucose metabolism. Professor Roth is widely published with over 400 published articles during his distinguished career.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Plenary 1

Phenotyping the diabetic patient

Chair: G. Schernthaner (Austria)
Chair: S. Twigg (Australia)

08:30 **Role of fat** 0002
Invited Speaker: K. Ueki (Japan)

09:00 **Muscling in on insulin resistance through epigenetic modifications** 0003
Invited Speaker: J. Zierath (Sweden)

09:30 **New insights into non-alcoholic fatty liver disease** 0004
Invited Speaker: H. Yki-Järvinen (Finland)

10:00 **Role of the beta cell** 0005
Invited Speaker: S. Del Prato (Italy)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Plenary 3

GLP-1

Chair: B. Ahren (Sweden)
Chair: C. Deacon (Denmark)

08:30 **Overview of incretin** 0006
Invited Speaker: Y. Seino (Japan)

09:00 **GLP-1 controls the gut to brain to peripheral tissue axis** 0007
Invited Speaker: R. Burcelin (France)

09:30 **Clinical update on treatments targeting GLP-1** 0008
Invited Speaker: M.A. Nauck (Germany)

10:00 **Extra pancreatic effects of GLP-1** 0009
Invited Speaker: D. Drucker (Canada)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 09:30 Melbourne Room 1

Is globalisation driving diabetes?

Chair: D. Simon (France)

08:30 **Nutrition and lifestyle transition and diabetes** 0010
Invited Speaker: K.S. Chia (Singapore)

09:00 **Urbanisation, climate change and diabetes** 0011
Invited Speaker: T. McMichael (Australia)

08:30 - 10:30 Melbourne Room 2

Adipose biology

Chair: T. Kadowaki (Japan)
Chair: J. Stoeckli (Australia)

08:30 **The regulation of metabolism by insulin and nutrients** 0012
Invited Speaker: M. Birnbaum (USA)

09:00 **Epigenomics of insulin resistance** 0013
Invited Speaker: E. Rosen (USA)

09:30 **Adipocyte biology and in upper and lower adipose tissue: relationship to whole body phenotypes** 0014
Invited Speaker: F. Karpe (United Kingdom)

10:00 **Ceramides and adipocytes** 0015
Invited Speaker: S. Summers (Singapore)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 203/204

Novel complications of diabetes

Chair: T. Davis (Australia)
Chair: V. Mohan (India)

08:30 **Liver disease** 0016
Invited Speaker: J. George (Australia)

09:00 **Cognitive impairment and dementia in type 2 diabetes** 0017
Invited Speaker: D. Bruce (Australia)

09:30 **The double burden of diabetes and chronic infection: the public health relevance of tuberculosis and other infections in developing countries** 0018
Invited Speaker: A. Kapur (Denmark)

10:00 **Depression** 0019
Invited Speaker: T. Roy (Bangladesh)

08:30 - 10:30 Room 210/211

MicroRNA and diabetes

Chair: F. Danesh (USA)
Chair: A. Hardikar (Australia)

08:30 **MicroRNAs and insulin resistance** 0020
Invited Speaker: M. Stoffel (Germany)

09:00 **MicroRNAs and pancreatic failure in type 2 diabetes** 0021
Invited Speaker: E. Van Obberghen (France)

09:30 **MicroRNAs and renal fibrosis** 0022
Invited Speaker: P. Kantharidis (Australia)

10:00 **MicroRNAs in diabetic nephropathy** 0023
Invited Speaker: R. Natarajan (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 212/213

Overcoming the determinants of diabetes in Indigenous peoples

Chair: C. Hotu (New Zealand)
Chair: D. Simmons (United Kingdom)

08:30 **Understanding the socio-cultural determinants of diabetes in Indigenous peoples** 0024
Invited Speaker: T. Ehau (New Zealand)

09:00 **The growing epidemic of diabetes in Canadian First Nations** 0025
Invited Speaker: A. Hanley (Canada)

09:30 **Overcoming the obesity epidemic: lessons from the Pacific** 0026
Invited Speaker: B. Swinburn (New Zealand)

10:00 **International political advocacy: can it work for Indigenous peoples?** 0027
Invited Speaker: J.C. Mbanya (Cameroon)

08:30 - 09:30 Room 219/220

Living your dreams

Chair: P. Buchanan (United Kingdom)

And if dreams come true... 0028
Invited Speaker: J. Feijoo (Spain)

Adventure diabetes: living your dreams 0029
Invited Speaker: B. Hauck (Germany)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 09:30 Room 207

Living with diabetes in the family

Chair: K. Close (USA)

08:30 **Living with diabetes and its complications** 0030
Invited Speaker: K. Hirst (United Kingdom)

09:00 **My experience as a mother of three daughters with diabetes** 0031
Invited Speaker: F. Mata Mouros (Portugal)

08:30 - 10:30 Room 208

Diabetic neuropathy: from basic to clinical

Chair: C. Nierras (USA)
Chair: Z. Zhao (China)

08:30 **Cellular and molecular pathways** 0032
Invited Speaker: N. Calcutt (USA)

09:00 **Experimental studies** 0033
Invited Speaker: H. Kamiya (Japan)

09:30 **Diagnosis and treatment of diabetic neuropathy** 0034
Invited Speaker: R. Malik (United Kingdom)

10:00 **The diabetic foot** 0035
Invited Speaker: A.J. Boulton (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 209

Implementing diabetes and clinical guidelines in the real world

Chair: B. Balkau (France)
Chair: C. Pan (Israel)

08:30 **Guidelines to achieving realistic clinical outcomes: what is missing? (The GIANT study in Asia)** 0036
Invited Speaker: A. Reutens (Australia)

09:00 **Building guidelines into primary care practice: experience from the Australian Diabetes Care Project** 0037
Invited Speaker: T. Fountaine (Australia)

09:30 **How to implement guidelines in the real world: the China experience** 0038
Invited Speaker: L. Ji (China)

10:00 **National diabetes prevention and other aspects of the Mauritius Diabetes Programme** 0039
Invited Speaker: S. Kowlessur (Mauritius)

08:30 - 09:30 Room 106

The importance of safe and reliable blood glucose monitoring

Chair: K. Brownlee (USA)

08:30 **The impact of inaccurate blood glucose monitoring on people living with diabetes** 0040
Invited Speaker: N. Cohen (Australia)

08:50 **The impact of the financial crisis on access to blood glucose monitoring** 0041
Invited Speaker: D. Cavan (United Kingdom)

09:10 **Blood glucose monitoring in developing countries** 0042
Invited Speaker: K. Ramaiya (Tanzania)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Plenary 2

Understanding the pathogenesis of type 1 diabetes

Chair: L.C. Harrison (Australia)

Invited Speaker: *J. Nerup (Denmark)* 0043

09:30 - 10:30 Melbourne Room 1

Bridging the gaps from the ivory tower to local communities: a global initiative

Chair: S. Sadikot (India)

Invited Speaker: L. Siminerio (USA)

09:30 - 10:30 Room 207

How to build effective relationships with a healthcare practitioner

Chair: A. Felton (United Kingdom)

Perspective of a person living with diabetes 0045
Invited Speaker: A. Costa (Portugal)

Perspective of a diabetes educator 0046
Invited Speaker: D. Fornasier (Australia)

Perspective of a general practitioner 0047
Invited Speaker: N. Pall (United Kingdom)

09:30 - 10:30 Room 219/220

Diabetes and extreme sports

Chair: M. Saraheimo (Finland)

09:30 **Extreme activities done by people with diabetes: examples** 0048
Invited Speaker: B. van de Goor (The Netherlands)

09:50 **Changing diabetes in extreme sports** 0049
Invited Speaker: J. Morris (Australia)

10:10 **Diabetes need not hold you back: the Kokoda track adventure** 0050
Invited Speaker: C. Thomas (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Room 106

IDF Young Leaders in Diabetes

Chair: J. Valente Nabais (Portugal)

09:30 **The past, present and future of Young Leaders in Diabetes** 0051
Invited Speaker: A. Silverstein (United Kingdom)

09:50 **The road to alleviating the burden of living with diabetes** 0052
Invited Speaker: K.R. Hall (South Africa)

10:10 **A Young Leader living with diabetes in the Caribbean** 0053
Invited Speaker: K. Boyea (Barbados)

10:45 - 12:45 Plenary 2

Obesity and bariatric surgery

Chair: J. Dixon (Australia)
Chair: TBC

10:45 **Bariatric surgery, diabetes remission and diabetic complications over 15 years in Swedish Obese Subjects study (SOS)** OP-0054
M. Peltonen, L. Sjöström, L.M.S. Carlsson (Finland)

11:00 **Bariatric surgery reduces the incidence of albuminuria in the Swedish Obese Subjects (SOS) Study** OP-0055
L. Carlsson Ekander, M. Peltonen, L. Sjostrom (Sweden)

11:15 **Changes of serum bone morphogenic protein 4 and other inflammatory markers after bariatric surgery in obese type 2 diabetes mellitus** OP-0056
H.S. Kwon, M.K. Kim, O.K. Hong, K.H. Baek, S.J. Yoo, W. Kim, B.Y. Cha, E.K. Kim, K.H. Song (Korea)

11:30 **Bariatric surgery in obese patients with type 1 diabetes mellitus** OP-0057
A. Tang, K.L. Milner, L.V. Campbell, J.R. Greenfield (Australia)

11:45 **Very low carbohydrate, low saturated fat diet improves glycaemic control and cardiovascular risk in type 2 diabetes** OP-0058
J. Tay, M. Noakes, N.D. Luscombe-Marsh, C.H. Thompson, J.D. Buckley, G. Wittert, G. Brinkworth (Australia)

12:00 **Weight change in the year following diabetes diagnosis and cardiovascular risk factors at five-years: results from ADDITION-Cambridge** OP-0059
M.J.L. Hare, G.H. Long, R.K. Simmons, N.J. Wareham, S.J. Griffin (United Kingdom)

12:15 **Fibroblast growth factor 21 is an independent predictor for nonalcoholic fatty liver disease: a 3-year prospective study in China** OP-0060
H. Li, K. Dong, Q. Fang, Q. Song, X. Hou, M. Zhou, Y. Bao, K. Xiang, A. Xu, W. Jia (China)

12:30 **DPP4 as a marker of liver fibrosis in non alcoholic fatty liver disease (nafld) in subjects with type 2 diabetes and obesity** OP-0061
K.H. Williams, A. Zekry, S.V. McLennan, A.J.V. Ribeiro, E. Prakoso, E. Cavanagh, J. Raleigh, N.A. Shackel, B. Brooks, F.M. Keane, M.D. Gorrell, S.M. Twigg (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Plenary 1

Insulin resistance - clinical

Chair: J. Proietto (Australia)
Chair: TBC

10:45 **Circulating fibroblast growth factor 21 levels predict incident hyperglycaemia in Chinese subjects without the metabolic syndrome** OP-0062
W.S. Chow, M.M.A. Yuen, P.C.H. Lee, Y.C. Woo, A.W.K. Tso, A. Xu, C.H.Y. Fong, B.M.Y. Cheung, K.S.L. Lam (Hong Kong China)

11:00 **Hyperaminoacidemia overcomes the insulin resistance of protein anabolism in obese, glucose tolerant men** OP-0063
E.B. Marliss, S.A. Burgos, J.A. Morais, R. Gougeon, M. Bassil, M. Lamarche, S. Chevalier (Canada)

11:15 **Evidence and implications of metabolic syndrome, insulin resistance and impaired beta cell function in prediabetes: (project D-START)** OP-0064
D. Do, T. Van Binh, V. Bich Nga, N. Thanh Lam, M. Van Sam, N. Thi Thu Trang, N. Van Dong, T. Thanh Ha, P. Dinh (Vietnam)

11:30 **Role of carnosine in obesity related insulin resistance in humans** OP-0065
B. de Courten, J. Ukropec, M. de Courten, I. Everaert, W. Derave, B. Ukropcova (Denmark)

11:45 **Decreased insulin sensitivity, antioxidant status and increased thrombotic, inflammatory factors in obese children, adolescents, youth** OP-0066
V. Dimitrijevic-Sreckovic, B. Sreckovic, P. Djordjevic, H. Janeski, E. Colak, I. Soldatovic (Serbia)

12:00 **Dapgliflozin improves muscle glucose uptake and increase hepatic glucose production in T2DM individuals** OP-0067
M. Abdul-Ghani, A. Merovci, C. Solis, R. Eldor, D. Tripathy, D. Giuseppe, R.A. DeFronzo (USA)

12:15 **Phoenix of Malnutrition Related Diabetes Mellitus (MRDM): nutrient mediated teratogenesis** OP-0067
C.S. Yajnik, P.C. Yajnik, C. Joglekar, H. Lubree, D. Bhat, K. Kumaran, C. Fall (India)

10:45 - 12:45 Plenary 13

Hypoglycaemia

Chair: R.J. McCrimmon (United Kingdom)
Chair: TBC

10:45 **Rates of confirmed hypoglycaemia in type 1 and type 2 diabetes are correlated with within-subject variability in fasting blood glucose** OP-0068
B. Bode, T. Heise, T.R. Pieber, T. Johansen, S. Rasmussen, D. Russell-Jones (USA)

11:00 **Hypoglycemic episodes in patients with type 2 diabetes: risk factors and impact on quality of life and other PROs The PANORAMA study** OP-0069
D. Simon, P. de Pablos-Velasco, K.G. Parhofer, L. Gönder-Frederick, E. Eschwège, I. Duprat-Lomon, H. Vandenberghe, C. Bradley (France)

11:15 **Antecedent exercise of moderate intensity attenuates the glycaemia-increasing effect of sprinting** OP-0070
P.A. Fournier, T.D. Justice, G.L. Hammer, K.J. Guelfi, R.J. Davey, N. Paramalingam, E.A. Davis, T.W. Jones (Australia)

11:30 **High prevalence of hypoglycaemia in patients with dumping-like symptoms after RYGB revealed by continuous glucose monitoring (CGM)** OP-0071
K. Rett, D. Wagenknecht, C. Stier, R. Chandra, R. Weiner, E. Fischer, K. Krieger, E. Weitz (Germany)

11:45 **Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine in patients with T2D: a meta-analysis of 5 randomized trials** OP-0072
A. Garber, T. Hobbs, S. Rasmussen, H.W. Rodbard (USA)

12:00 **Effects of liraglutide adjunct to insulin on counterregulatory hormone responses to hypoglycaemia in type 1 diabetes: a randomised trial** OP-0073
T. Pieber, S. Deller, M. Brunner, L. Jensen, E. Christiansen, F. Kiyomi, S. Heller (Austria)

12:15 **Role of mobile technology to improve diabetes care in adults with type 1 diabetes: the REMOTE-T1D Study** OP-0074
S. Garg, K. Reed, E. Moser, J. Snell-Bergeon, M. Dhingra, F. Flacke (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

Hypoglycaemia

12:30 **An investigational new insulin U300: glucose control and hypoglycemia in people with type 2 diabetes on basal insulin and OADs (EDITION II)** OP-0075

H. Yki-Järvinen, R.M. Bergenstal, M. Ziemen, M. Wardecki, I. Muehlen-Bartmer, E. Boelle, M. Riddle (Finland)

10:45 - 12:45 Melbourne Room 1

Late-breaking abstracts - Basic and Clinical Science

Chair: R. Bergenstal (USA)
Chair: M. Evans (United Kingdom)

10:45 **FG-4592, an oral Hypoxia Inducible Factor (HIF) stabilizer, raises hemoglobin (Hb) in diabetics with anemia of Chronic Kidney Disease (CKD)** OP-0076
A. Besarab, B. Roberts, R. Leong, M. Franco, T. Lee, K. Saikali, T. Neff, K. Yu (USA)

11:00 **A randomized trial of gastric band surgery in people with type 2 diabetes who are overweight but not obese** OP-0077
J. Wentworth, P.E. O'Brien (Australia)

11:15 **Gastric electrical stimulation (GES)in T2DM improves long-term glycemic control through a plasma triglyceride-dependent mechanism** OP-0078
H. Lebovitz, M. Zalewski (USA)

11:30 **Combining the GPR40 Agonist Fasiglifam (TAK-875) with Sitagliptin Improves Glycemic Control in T2DM Patients with or without Metformin** OP-0079
X. Peng, M. Raanan, J. Marcinak, C. Cao, P. Viswanathan (USA)

11:45 **Primary endpoint results from the T1DAL study: targeting memory T cells with alefacept in newly diagnosed type 1 diabetes** OP-0080
M.R. Rigby, L.A. DiMeglio, M.S. Rendell, S.E. Gitelman, C.J. Greenbaum, S.M. Willi, A. Pinckney, M. Howell, G.T. Nepom, J. McNamara, M.R. Ehlers, A.N.D. The T1DAL Study Team (USA)

12:00 **Empagliflozin improves glycemic control in patients with type 1 diabetes: a single-arm clinical trial** OP-0081
B.A. Perkins, D.Z. Cherney, H. Partridge, N. Soleymanlou, H. Tschirhart, B. Zinman, N. Fagan, S. Kaspers, H.J. Woerle, U.C. Broedl, O.E. Johansen (Canada)

12:15 **Liraglutide contributes significantly to glycaemic control achieved in IDegLira: a double-blind phase 3 trial in type 2 diabetes** OP-0082
J. Buse, T. Vilsbøll, J. Thurman, T. Blevins, I.H. Langbakke, L.H. Damgaard, H.W. Rodbard (Denmark)

12:30 **Endoscopic, duodenal-jejunal bypass liner exerts robust metabolic effects: accumulating clinical experience across four studies** OP-0083
D. Maggs, E. Moura, A. Escalona, K. Malomo, A. Liao, J. Tetreault, J. Teare, R. Cohen (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Melbourne Room 2

Estimates and surveillance of diabetes prevalence and incidence

Chair: N. Unwin (Barbados)
Chair: N. Wareham (United Kingdom)

10:45 **Epidemiology of diabetes across the continents** 0084
Invited Speaker: L. Guariguata (Belgium)

11:15 **How accurate are national and global estimates?** 0085
Invited Speaker: P.H. Bennett (USA)

11:45 **Registries for diabetes** 0086
Invited Speaker: N. Tajima (Japan)

12:15 **Health system databases: strengths and limitations** 0087
Invited Speaker: A. Karter (USA)

10:45 - 12:45 Room 203/204

Experimental models of type 1 and type 2 diabetes

Chair: Å. Lernmark (Sweden)
Chair: K. Walder (Australia)

10:45 **Prevention and rescue of diabetes by all-trans retinoid acid and exendin-4 in NOD mice with and without islet transplantation** OP-0088
J.H. Juang, Y.H. Van, C.H. Kuo, Y.H. Liu, H.Y. Chang (Taiwan)

11:00 **Postnatal events in intestinal gene expression and splenic cell composition is altered in NOD mice** OP-0089
D.M. Damlund, S. Metzdorff, M.B. Kristensen, J.P. Hasselby, A.K. Hansen, K. Buschard, H. Frøkiær (Denmark)

11:15 **Lowering advanced glycation end products alters experimental autoimmune diabetes incidence in a time dependent manner** OP-0090
D.J. Borg, F.Y.T. Yap, A.K. Fotheringham, B.E. Harcourt, D. McCarthy, M. Ward, R. Slattery, M.T. Coughlan, P. Kantharidis, J.M. Forbes (Australia)

11:30 **Role of prothymocin-alpha in the development of insulin resistance** OP-0091
H.T. Wu, F.H. Lu, H.Y. Ou, Y.C. Su, H.C. Hung, J.S. Wu, Y.C. Yang, C.L. Wu, C.J. Chang (Taiwan)

11:45 **Amyloid beta42 administration impairs energy metabolism in vivo and in vitro** OP-0092
J.K. Czeczor, T. Connor, A.J. Genders, K. Walder, S. McGee (Australia)

12:00 **Astaxanthin ameliorates hepatic insulin resistance and inhibits the progression of lipotoxic model of nonalcoholic steatohepatitis** OP-0093
N. Nagata, Y. Ni, M. Nagashimada, F. Zhuge, S. Kaneko, T. Ota (Japan)

12:15 **Exercise improves vascular insulin sensitivity by downregulating GRK2 in spontaneously hypertensive rats** OP-0094
W. Xing, Y. Li, H. Zhang, F. Gao (China)

12:30 **Follistatin treatment of db/db mice ameliorates hyperglycemia by preserving pancreatic beta cells** OP-0095
J. Davey, E. Estevez, R. Thomson, M. Whitman, H. Qian, M. Coughlan, M. Febbraio, P. Gregorevic (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 210/211

Advanced glycation and oxidative stress

Chair: J. Forbes (Australia)
Chair: G. Sainani (India)

10:45 **Why beta cells are so susceptible to oxidative stress** 0096
Invited Speaker: C.J. Rhodes (USA)

11:15 **Advanced glycation end products and other markers of protein damage in early diabetic nephropathy in type 1 diabetes** 0097
Invited Speaker: B.A. Perkins (Canada)

11:45 **Clinical implications of oxidative stress in diabetic complications** 0098
Invited Speaker: A. Ceriello (Italy)

12:15 **Pathogenesis of diabetes associated atherosclerosis** 0099
Invited Speaker: K. Bornfeldt (USA)

10:45 - 12:45 Room 212/213

Diabetic complications in Indigenous peoples

Chair: A. Hanley (Canada)
Chair: A. Sinha (Australia)

10:45 **Improving diabetes outcomes in Indigenous health: findings from a multi-country review** OP-0100
S. Sinha (Australia)

11:00 **A Multiethnic study of diabetic retinopathy: poorer outcomes continue for Australian Aborigines and Pacific Islanders** OP-0101
M. Constantino, L. Molyneaux, T. Alharbi, T. Wu, S. Twigg, D. Yue, J. Wong (Australia)

11:15 **Effect of diabetes on lifetime risk for end stage renal disease in a remote Aboriginal community** OP-0102
Z. Wang, W. Hoy (Australia)

11:30 **PCOS, diabetes and metabolic syndrome in Indigenous Australian women** OP-0103
J. Boyle, R. Norman, J. Cunningham, K. O'Dea (Australia)

11:45 **Improving diabetes health, care and education on the Rosebud Sioux Tribe Reservation, Rosebud, South Dakota USA** OP-0104
J. Pearson, G. SImonson, C. Brushbreaker, S. Two Hawk, D. Warne (USA)

12:00 **Diabetic retinopathy observed at first presentation to eye services in Fiji** OP-0105
E. Damato, B. Sikivu, J. Szetu, N. Murray, C.M. McGhee, S. Emma (New Zealand)

12:15 **Dyslipidemia and diabetes mellitus in Xavante Brazilian Indians** OP-0106
A.L. Dal Fabbro, L.J. Franco, D.S. Sartorelli, L.P. Soares, A.S. Silva, L.F. Franco, P.C. Kuhn, R.S. Moisés, J.P. Vieira-Filho (Brazil)

12:30 **Post-pregnancy T2DM screening for Aboriginal and Torres Strait Islander women with GDM in remote and urban communities** OP-0107
C. Chamberlain, A. McLean, A. Sinha, B. Davis, C. Smith, B. Oldenburg, B. Fredericks, J. Mein, C. Dowey, K. Vickers, J. Oats, S. Eades (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 219/220

Modern technology and social media: how it is shaping diabetes care, education and research

Chair: B. Majikela-Dlangamandla (South Africa)
Chair: V. Mohan (India)

10:45 **Interactive technologies in diabetes** 0108
Invited Speaker: K. Harno (Finland)

11:15 **Electronic records and communication in diabetes** 0109
Invited Speaker: M. Georgeff (Australia)

11:45 **Social media old and new in diabetes** 0110
Invited Speaker: M. Al-Ostad (Kuwait)

12:15 **Use of SMS in diabetes care** 0111
Invited Speaker: W. Hussein (Bahrain)

10:45 - 12:45 Room 207

Psychological and other complications of diabetes

Chair: D. Bruce (Australia)
Chair: M. Kamp (Australia)

10:45 **Factors associated with acute complications among individuals with type 1 diabetes in China: the 3C Study** OP-0112
W. Liu, L. Ji, K. Kissimova-Skarbek, H. McGuire, D. Whiting, T.I.L.L. Seuring, Z. Puhong, Y. Wu, S. Lin, J. Weng, Z. Zhou, L. Jaacks (China)

11:00 **Risk of cancer in patients with type 1 diabetes mellitus: A population-based cohort analysis in Taiwan** OP-0113
C.L. Lu, P.C. Hsu, H.Y. Li, C.Y. Li (Taiwan)

11:15 **Cancer risk in people with type 1 diabetes** OP-0114
J. Harding, A. Peeters, J.E. Shaw, T. Guiver, D.J. Magliano (Australia)

11:30 **The association of clinical and psychosocial risk factors with depression in Chinese patients with type 2 diabetes** OP-0115
Y. Zhang, W. Yang, J. Weng, W. Jia, L. Ji, X. Guo, W. Li, H. Nan, R. Yeung, Y. Wing, N. Sartorius, J. Chan (Hong Kong China)

11:45 **Enhanced usual care is as effective as a collaborative primary care model for diabetes and depression in primary care** OP-0116
J. Johnson, F. Al Sayah, S. Rees, W. Qiu, C.L. Chik, P. Chue, P. Florence, J. Jacquier, P. Lysak, A. Opegenorth, W. Katon, S.R. Majumdar (Canada)

12:00 **Mid-life predictors of late-life cognitive impairment in type 2 diabetes: The Fremantle Diabetes Study** OP-0117
D.G. Bruce, W.A. Davis, J.L. Mace, M. Nelson, S.E. Starkstein, T.M. Davis (Australia)

12:15 **Diabetes mellitus and HIV in Botswana: a case control study** OP-0118
M. Reid, D. Moyo, G. Tanthuma, A. Steenhoff, O. Kwadiba, M. Cary (Botswana)

12:30 **Excess mortality in early adulthood in a population-based cohort of childhood onset type 1 diabetes** OP-0119
M.N. Cooper, N.H. de Klerk, T.W. Jones, E.A. Davis (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 208

Inflammasomes

Chair: S. Masters (Australia)
Chair: S. Zraika (USA)

10:45 **The IL-1 system in islets: physiology and pathology** 0120
Invited Speaker: M. Boni-Schnetzler (Switzerland)

11:15 **Amyloid-induced islet inflammation in type 2 diabetes and islet transplants** 0121
Invited Speaker: B. Verchere (Canada)

11:45 **ER stress and the inflammasome: role in beta cell destruction** 0122
Invited Speaker: F. Urano (USA)

12:15 **The inflammasome: role in IL-1beta processing and relation to insulin sensitivity** 0123
Invited Speaker: C.J. Tack (The Netherlands)

10:45 - 12:45 Room 209

Innovative approaches to engaging people with diabetes

Chair: N. Harkin (Australia)
Chair: C. Feste (USA)

10:45 **Narrative Medicine** 0124
Invited Speaker: N. Piana (Italy)

11:15 **The arts and disease** 0125
Invited Speaker: T. Assal (Switzerland)

11:45 **Storytelling and play** 0126
Invited Speaker: TBC

12:15 **Self-management support: empowerment and motivational interviewing** 0127
Invited Speaker: M. Funnell (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Room 106

Diabetes, drugs and alcohol

Chair: S. Murray (Australia)

Drug abuse and diabetes 0128
Invited Speaker: S. Edelman (USA)

Alcoholism and diabetes 0129
Invited Speaker: A. Dapice (USA)

11:45 - 12:45 Room 106

Diabetes and natural disasters

Chair: R. Raab (Australia)

Diabetes during natural disasters and political crises 0130
Invited Speaker: G. Ogle (Papua New Guinea)

Diabetes and natural disaster in low and middle income countries 0131
Invited Speaker: S. Soegondo (Indonesia)

Experience from the great East Japan earthquake and tsunami 0132
Invited Speaker: J. Satoh (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Melbourne Room 1

President's Address

Chair: A. Felton (United Kingdom)

The diabetes pandemic - how is IDF responding to this growing threat to mankind? 0133

Invited Speaker: M. Hirst (United Kingdom)

Sir Michael Hirst

Sir Michael Hirst from the United Kingdom is the President of the International Diabetes Federation (IDF) 2013-2015. He became interested in diabetes over twenty years ago when his youngest child was diagnosed with type 1 diabetes at a very young age. Then a Member of the British Parliament, Sir Michael championed the cause of diabetes in Parliament, as a result of which he was co-opted to the Board of Trustees of the British Diabetic Association, now Diabetes UK. There he served as a trustee in a variety of capacities for 17 years, most recently as the first non-medical Chairman of the Board of Trustees from 2001-2006. As Chairman, he oversaw major changes in the operations and governance of Diabetes UK, Europe's largest organisation for people with diabetes.

Sir Michael Hirst is a graduate in law of the University of Glasgow, and was an exchange student at the University of Iceland. He later qualified as a chartered accountant and became a partner in KPMG, the international accounting firm, until he entered the British Parliament. Sir Michael held a number of senior positions in frontline politics until 1997 and was knighted for political and public service in 1992. He has also served on the board of a number of leading charities and public bodies, and is currently Chairman of two companies in the UK.

14:30 - 15:30 Plenary 2

IDF award lecture - Basic science

Chair: M. Cooper (Australia)

Beyond HbA1c: hyperglycaemic variability and diabetic complications 0134

Invited Speaker: M. Brownlee (USA)

Michael Brownlee

Professor Michael Brownlee holds the Anita and Jack Saltz Chair of Diabetes Research at the Albert Einstein College of Medicine in New York, where he is Associate Director for Biomedical Sciences at Einstein's Diabetes Research Center. Dr Brownlee did his medical and research training at Duke, Stanford, and Harvard. He was Assistant and then Associate Professor of Medical Biochemistry at Rockefeller University prior to his current appointment.

At Einstein Dr Brownlee discovered that most known mechanisms underlying diabetic complications share a common upstream link – hyperglycaemia-induced overproduction of superoxide by the mitochondrial electron transport chain. In recognition of his research, Professor Brownlee has received both the American Diabetes Association's Banting Medal and its Outstanding Scientific Achievement Award, the European Association for the Study of Diabetes' Claude Bernard Medal, the Juvenile Diabetes Research Foundation's David Rumbough Award for Scientific Excellence, Columbia University's Naomi Berrie Award for Outstanding Achievement in Diabetes Research, the Barbara Davis Center for Childhood Diabetes' Davis Award, The Japan Society of Diabetic Complications' Outstanding Foreign Investigator Award, and Duke University Medical School's Distinguished Alumnus Award.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Plenary 1

Inflammation

Chair: M. Febbraio (Australia)
Chair: G. Steinberg (Canada)

14:30 **Targeting inflammation with salsalate in type 2 diabetes** 0135
Invited Speaker: S. Shoelson (USA)

15:00 **Contribution of beta-cell associated macrophages to type 2 diabetes** 0136
Invited Speaker: T. Biden (Australia)

15:30 **Inflammation and sirtuins** 0137
Invited Speaker: S. Imai (USA)

16:00 **Inflammation and insulin resistance/obesity** 0138
Invited Speaker: A. Ferrante Jr (USA)

14:30 - 15:30 Plenary 3

New targets for treatment and prevention of type 1 diabetes

Chair: P. Colman (Australia)

Invited Speaker: Å. Lernmark (Sweden) 0139

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Melbourne Room 1

Diabetic macrovascular disease

Chair: R. O'Brien (Australia)
Chair: E. Ur (Canada)

14:30 **Overview** 0140
Invited Speaker: A. Chait (USA)

15:00 **Glucose and lipids** 0141
Invited Speaker: R. Eckel (USA)

15:30 **Mechanisms of vascular disease in diabetes: implications for blood pressure treatment thresholds and targets** 0142
Invited Speaker: B. Williams (United Kingdom)

16:00 **Effects of renal denervation on metabolic control** 0143
Invited Speaker: M. Schlaich (Australia)

14:30 - 16:30 Melbourne Room 2

Public health challenges in treating diabetes

Chair: W. Cheung (Australia)
Chair: A.A. Motala (Saudi Arabia)

14:30 **Improving the quality of diabetes care** 0144
Invited Speaker: R. Gabbay (USA)

15:00 **Care delivery in low-resource settings: what are the successes and failures and the most cost-effective targets?** 0145
Invited Speaker: S. Mendis (Switzerland)

15:30 **Retinal screening programs** 0146
Invited Speaker: D. Owens (United Kingdom)

16:00 **Guidelines: do we have the best approach to guide practice?** 0147
Invited Speaker: P. Home (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 203/204

Approaches for diabetes prevention

Chair: P. Aschner (Colombia)
Chair: B. Oldenburg (Australia)

14:30 **WHO targets and their achievability** 0148
Invited Speaker: G. Roglic (Switzerland)

15:00 **Outcomes and results of diabetes prevention trials** 0149
Invited Speaker: K.M. Venkat Narayan (USA)

15:30 **The role of public policy** 0150
Invited Speaker: G. Rodgers (USA)

16:00 **Individual and group approaches** 0151
Invited Speaker: J. Lindström (Finland)

14:30 - 15:30 Room 210/211

IDF award lecture - Living with diabetes

Chair: J. Valente Nabais (Portugal)

0152

Invited Speaker: *W. Akram (Pakistan)*

Wasim Akram

Wasim Akram was born on June 3, 1966 in Lahore, Punjab, Pakistan. He is an erstwhile Pakistani cricketer and pioneer of reverse swing bowling. He has headed the cricket team of Pakistan in test as well as one-day internationals. He holds world records for taking the most wickets in ODIs.

Wasim Akram made his test cricket debut in 1985 and proved himself as a fine exponent of reverse swing in his second test match by achieving 10 wickets. During the renowned victory of Pakistan in the 1992 World Cup, his performance was instrumental. He was the top bowler of Pakistan in the 2003 World Cup as well.
He was diagnosed with diabetes in 1997 and, by carefully managing his condition through diet and exercise, he continued to play world class cricket, and went on to become a legend in his own lifetime. He was the first bowler to take more than 400 wickets both in test and one-day internationals.

After his retirement in 2003, Wasim Akram has taken up commentary and can be seen as a sports caster. He is also serving as a bowling coach for the Kolkata Knight Riders, one of the ten Indian Premier League Franchises.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 15:30 Room 212/213

IDF award lecture - Diabetes in Indigenous peoples

Chair: D. Warne (USA)

Understanding the burden of diabetes in Indigenous peoples 0153

Invited Speaker: A. Brown (Australia)

Alex Brown

Professor Alex Brown is an Indigenous doctor, completing his BMed in 1995. He undertook his MPH in Israel in 1998, and is a Fellow of the Cardiac Society of Australia and New Zealand. He undertook his PhD thesis on chronic disease and depression in Aboriginal men in Central Australia. Alex has more than 10 years of involvement in Aboriginal health, education, policy, communicable disease control, service delivery and public health, epidemiology, research and research ethics.

Alex has a national profile in Indigenous cardiovascular and metabolic disease research and policy development, through specific projects, and national advisory groups. He has presented extensively across the country and overseas. His publications include invited editorials discussing CVD in Aboriginal Australians and key evidence based guidelines for CVD in Aboriginal people.

Alex has been heavily involved in engaging government and lead agencies in setting the agenda in Aboriginal CVD control (particularly notable in relation to Indigenous health, acute rheumatic fever/rheumatic heart disease, quality use of medicines, and advisory roles within the NHF).

Between 1999-2003, Alex ran the Centre for Disease Control in Alice Springs, he was then employed as the Senior Research Fellow for Menzies School of Health Research. In 2007, he commenced as Head, Centre for Indigenous Vascular Research at Baker IDI. In 2012, he was appointed the Theme Leader for Indigenous Health at the South Australian Health and Medical Research Institute. He remains a part-time Senior Research Fellow at Baker IDI.

14:30 - 16:30 Room 219/220

Famines, other natural disaster and diabetes

Chair: P. Gluckman (New Zealand)
Chair: L. Ji (China)

14:30 **The Chinese famine and type 2 diabetes** 0154
Invited Speaker: X. Zhou (China)

15:00 **The Cambodian famine and type 2 diabetes** 0155
Invited Speaker: L. Keuky (Cambodia)

15:30 **Prenatal exposure to the Dutch famine** 0156
Invited Speaker: R. Painter (The Netherlands)

16:00 **Lessons from studies of kwashiorkor and marasmus** 0157
Invited Speaker: P. Gluckman (New Zealand)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 207

Meeting the challenge of diabetes in the ageing population

Chair: K.A. Kadir (Malaysia)
Chair: R. MacIsaac (Australia)

14:30 **The impact of ageing on diabetes and our future needs** 0158
Invited Speaker: K. Lam (China)

15:00 **Ageing and the life course perspective** 0159
Invited Speaker: N. Barzilai (USA)

15:30 **Managing CVD risk in the elderly with diabetes: is it important, particularly in LMICs?** 0160
Invited Speaker: E. Standl (Germany)

16:00 **Diabetes in an ageing population: example from Japan** 0161
Invited Speaker: N. Hotta (Japan)

14:30 - 15:30 Room 208

Gastric emptying and incretins: relevance to diabetes management

Chair: M.A. Nauck (Germany)

Invited Speaker: M. Horowitz (Australia) 0162

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 209

Mental health: the key to physical health

Chair: A. Forbes (United Kingdom)
Chair: V. Stevenson (Australia)

14:30 **Overview of mental health and diabetes** 0163
Invited Speaker: F. Snoek (The Netherlands)

15:00 **Managing metabolic health in severe mental illness** 0164
Invited Speaker: F. Gaughran (United Kingdom)

15:30 **Diabetes distress and depression: new approaches to clinical care** 0165
Invited Speaker: L. Fisher (USA)

16:00 **Cognitive impairment and dementia** 0166
Invited Speaker: K. Yokono (Japan)

14:30 - 15:30 Room 106

Effective lifestyle modification strategies

Chair: G. Johnson (Australia)

Invited Speaker: *S. Koski (Finland)* 0167

Invited Speaker: *M. Jacobs (The Netherlands)* 0168

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Plenary 2

Is continued searching for type 2 diabetes genes valuable?

Chair: T.E. Shyong (Singapore)

Yes 0169

Invited Speaker: M. McCarthy (United Kingdom)

No 0170

Invited Speaker: M. Lean (United Kingdom)

15:30 - 16:30 Plenary 3

Antibody testing in type 1 diabetes

Chair: R. Scott (New Zealand)

Invited Speaker: *C. Greenbaum (USA)* 0171

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Room 210/211

Diabetes and celebrity: professional sport and advocacy

Chair: S. Cockburn (Australia)
Invited Speaker: C. Freeman (Australia)
Invited Speaker: M. Foy (USA)

15:30 - 16:30 Room 212/213

Developing models of care for Indigenous people with diabetes: access, integration and equity

Chair: M. Adams (Australia)

15:30 **Striving towards a centre of excellence in Indigenous primary health care** 0174
Invited Speaker: N. Hayman (Australia)

15:50 **Diabetes prevention in American Indian populations** 0175
Invited Speaker: S. Manson (USA)

16:10 **Primary care as the vehicle for improved care of patients with diabetes** 0176
Invited Speaker: C. Hotu (New Zealand)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Room 208

A role for the gut and its bacteria in diabetes

Chair: B.K. Pedersen (Denmark)

Invited Speaker: C. Mathieu (Belgium) 0177

15:30 - 16:30 Room 106

How to get people with diabetes to be more active

Chair: B. van de Goor (The Netherlands)

15:30 **How to get people with diabetes to be more active** 0178
Invited Speaker: J. Grumitt (United Kingdom)

16:00 **Motivating people with diabetes to be more active** 0179
Invited Speaker: C. Feste (USA)

PROGRAMME

WEDNESDAY 04 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:30 - 10:30 Plenary 2

Diabetes and cardiovascular disease

Chair: S. Matthaei (Germany)
Chair: R. Ritchie (Australia)

08:30 **Calcium signalling in the cellular pathophysiology of atherosclerosis and type 2 diabetes** 0180
Invited Speaker: I. Tabas (USA)

09:00 **New pathways regulating platelet activation in diabetes** 0181
Invited Speaker: S. Jackson (Australia)

09:30 **Cardiac failure and diabetes** 0182
Invited Speaker: L. Burrell (Australia)

10:00 **Treatment update** 0183
Invited Speaker: R. Holman (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Plenary 1

Diabetes care at the coal face: manpower, multidisciplinary and primary healthcare

Chair: W. Nitiyanant (Thailand)
Chair: S. Sadikot (India)

08:30 **Global shortages and barriers to care** 0184
Invited Speaker: S. Sadikot (India)

09:00 **Diabetes care in Taiwan** 0185
Invited Speaker: W.H. Sheu (Taiwan)

09:30 **Diabetes care in Thailand** 0186
Invited Speaker: C. Deerochanawong (Thailand)

10:00 **Diabetes care in Russia** 0187
Invited Speaker: M. Shestakova (Russia)

08:30 - 09:30 Plenary 3

Childhood diabetes: from death sentence to a normal life expectancy

Chair: M. Sperling (USA)

Invited Speaker: *M. Silink (Australia)* 0188

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Melbourne Room 1

Strengthening the beta cell

Chair: M. Donath (Switzerland)
Chair: J. Gunton (Australia)

08:30 **Sleeping beta cells** 0189
Invited Speaker: D. Accili (USA)

09:00 **Novel insights into beta cell biology** 0190
Invited Speaker: R. Kulkarni (USA)

09:30 **The signals that strengthen beta cells: toward better understanding and treatment of diabetes** 0191
Invited Speaker: S. Seino (Japan)

10:00 **It is best to leave the beta cell alone** 0192
Invited Speaker: S. Andrikopoulos (Australia)

08:30 - 10:30 Melbourne Room 2

Affordability of diabetes drugs

Chair: A. Ametov (Russia)
Chair: M. Kamp (Australia)

08:30 **Affordability and cost-effective use of drugs for diabetes** 0193
Invited Speaker: E. Gale (United Kingdom)

09:00 **The payer's perspective** 0194
Invited Speaker: S. Hill (Australia)

09:30 **Drug cost and supply challenges for low-resource countries** 0195
Invited Speaker: J.J. Gagliardino (Argentina)

10:00 **The pharmaceutical industry's challenges and responsibilities** 0196
Invited Speaker: M. Cross (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 203/204

Brown fat in adult metabolism

Chair: A. Carey (Australia)
Chair: B. Oldfield (Australia)

08:30 **Cellular origins of fat: brown, white and beige** 0197
Invited Speaker: B. Cannon (Sweden)

09:00 **Regulation of brown fat** 0198
Invited Speaker: A. Chawla (USA)

09:30 **Physiological role of brown fat** 0199
Invited Speaker: E. Ravussin (USA)

10:00 **Targeting brown fat as a treatment strategy** 0200
Invited Speaker: B. Spiegelman (USA)

08:30 - 10:30 Room 210/211

Diabetes related syndromes

Chair: H. Teede (Australia)
Chair: TBC

08:30 **Cardio-metabolic dysfunction in PCOS: relationship to obstructive sleep apnoea** 0201
Invited Speaker: D. Ehrmann (USA)

09:00 **Diabetes and CV disease: role of new agents** 0202
Invited Speaker: M. Diamant (The Netherlands)

09:30 **Diabetes and end-stage kidney disease** 0203
Invited Speaker: S. Zoungas (Australia)

10:00 **Diabetes and dementia** 0204
Invited Speaker: G.J. Biessels (The Netherlands)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 212/213

Diabetes in American Indians: the Pima story and beyond

Chair: P.H. Bennett (USA)
Chair: B. Zinman (Canada)

08:30 **The history of type 2 diabetes in American Indian populations** 0205
Invited Speaker: D. Warne (USA)

09:10 **Chronic kidney disease in the Pima Indian population** 0206
Invited Speaker: R. Nelson (USA)

09:50 **Epidemiology and prevention of type 2 diabetes in American Indians** 0207
Invited Speaker: W.C. Knowler (USA)

08:30 - 10:30 Room 219/220

Socio-economic and ethnic issues in diabetes

Chair: A. Peeters (Australia)
Chair: E. Sobngwi (Cameroon)

08:30 **Social determinants of diabetes in developing countries** 0208
Invited Speaker: D. Levitt (South Africa)

09:00 **Ethnicity and diabetes risk** 0209
Invited Speaker: R. Ma (China)

09:30 **Ethnic differences in diabetes complications** 0210
Invited Speaker: A. Kanaya (USA)

10:00 **Social determinants of diabetes in developed countries** 0211
Invited Speaker: TBC

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 09:30 Room 207

Diabetes is what we eat

Chair: J. Brand-Miller (Australia)

Invited Speaker: C. Mattocks (USA) 0212

08:30 - 09:30 Room 208

Patient empowerment through social media

Chair: D. Cairns (United Kingdom)

Sugar in the cloud: connecting the diabetes world in likes and tweets 0213
Invited Speaker: A. Overbeeke (The Netherlands)

Patient empowerment through social media 0214
Invited Speaker: K. Close (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 209

Diabetes transitions and their psychosocial effects

Chair: G. Jerums (Australia)
Chair: J. Speight (Australia)

08:30 **Adjusting to the diagnosis** 0215
Invited Speaker: M.G. Ruiz Morosini (Argentina)

09:00 **Women's life transitions and diabetes** 0216
Invited Speaker: B. Rasmussen (Australia)

09:30 **Transitions in older age** 0217
Invited Speaker: M. Munshi (USA)

10:00 **Men's transition and diabetes** 0218
Invited Speaker: D. Villarroel (Bolivia)

08:30 - 10:30 Room 106

Contemporary issues in diabetic foot care

Chair: G. Sussman (Australia)
Chair: Z. Xu (China)

Diabetes foot problems in WPR and the IDF/WPR foot care project 0219
Invited Speaker: S. Kono (Japan)

IDF task force on foot care 0220
Invited Speaker: K. Bakker (The Netherlands)

Foot care in India 0221
Invited Speaker: V. Viswanathan (India)

Foot care in MENA 0222
Invited Speaker: M. Al Arouj (Kuwait)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Plenary 3

The adolescent with diabetes

Chair: K. Donaghue (Australia)

Invited Speaker: P. Zeitler (USA) 0223

09:30 - 10:30 Room 207

Conversation maps: well used tool or in the box gathering dust?

Chair: D. Howarth (Belgium)

09:30 **Africa** 0224
Invited Speaker: G.A. Jalang'o (Kenya)

10:00 **Diabetes education in Japan** 0225
Invited Speaker: A. Yoshihito (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Room 208

Technology in diabetes: how to remove the barriers

Chair: S. Garg (USA)

09:30 **Tools to assist day-to-date insulin management** 0226
Invited Speaker: M. Saraheimo (Finland)

10:00 **Insulin pumps** 0227
Invited Speaker: F. Kaufman (USA)

10:45 - 11:45 Plenary 2

IDF award lecture - Clinical science

Chair: J. Prins (Australia)

Human metabolic disease: lessons from genetics 0228

Invited Speaker: S. O'Rahilly (United Kingdom)

Stephen O'Rahilly

Stephen O'Rahilly is Professor of Clinical Biochemistry and Medicine at the University of Cambridge and Honorary Consultant Physician at Addenbrooke's Hospital. He led the establishment of the Institute of Metabolic Science, which he now co-directs. He is Scientific Director of the Cambridge NIHR Biomedical Research Centre. He qualified in Medicine from University College Dublin and undertook post-graduate training in London, Oxford and Boston before setting up his laboratory in Cambridge in 1991.

He has sought to better understand the molecular mechanisms leading to diabetes, obesity and related metabolic and endocrine disorders. He remains active in clinical practice and in the teaching of medical students. He has won many national and international awards including the Heinrich Wieland Prize and the Inbev Baillet Latour Prize. He was elected to the Royal Society in 2003, Foreign Associate of the National Academy of Sciences USA in 2011 and Knight Bachelor in 2013.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Plenary 1

Physiology of insulin actions and obesity

Chair: K. Walder (Australia)
Chair: J. Wilding (United Kingdom)

10:45 **The human INDY homolog is induced in obesity and insulin resistance** OP-0229
C. Löffelholz, S. Lieske, F. Neuschafer-Rube, D.M. Willmes, I.M. Sauer, S.L. Helfand, R. de Cabo, M. Bernier, J. Jordan, G.P. Püschel, A.F. Pfeiffer, A.L. Birkenfeld (Germany)

11:00 **Genetic variants of adiposity measures explain more variance in Indian population** OP-0230
D. Bharadwaj, I. Kaur, O.P. Dwivedi, A.K. Giri, N. Tandon (India)

11:15 **Liver and visceral fat in insulin-sensitive obesity** OP-0231
D. Chen, D. Samocha-Bonet, C. Liess, M. Trenell, B. Milner, D. Chisholm, J. Greenfield (Australia)

11:30 **Obesity decreases the expression of sirtuin proteins in adipose tissue in monozygotic twins, independent of genetic factors** OP-0232
J.S. Jukarainen, S. Heinonen, A. Hakkarainen, J. Lundbom, J. Kaprio, A. Rissanen, K.H. Pietiläinen (Finland)

11:45 **Pancreatic clamps alter postabsorptive metabolism, but reponses to a subsequent hyperinsulinemic clamp are physiological** OP-0233
E.B. Marliss, S. Chevalier, J.A. Morais, R. Gougeon, M. Lamarche, S.A. Burgos (Canada)

12:00 **Weight loss following laparoscopic adjustable gastric banding prevents progression from impaired fasting glucose to diabetes** OP-0234
J.M. Wentworth, P.E. O'Brien, J.E. Shaw (Australia)

12:15 **Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin** OP-0235
G. Steinberg, M.D. Fullerton, S. Galic, Z.-P. Chen, B.J. van Denderen, B.E. Kemp, K. Marcinko, R.J. Ford, J.D. Schertzer, R. Palanivel, T. Pulinikunnil, H.M. O'Neill (Canada)

10:45 - 12:45 Plenary 3

Screening and risk stratification of type 2 diabetes

Chair: S. Colagiuri (Australia)
Chair: D. Magliano (Australia)

10:45 **Shifting from glucose to the HbA1c reduces the screening capability of the FINDRISC within a real-life primary care preventive strategy** OP-0236
B. Costa, F. Barrio, J.L. Piñol, J.J. Cabré, R. Sagarra, D. Research Group (Spain)

11:00 **Receipt of glucose testing and ability to identify eligible US adults with prediabetes or diabetes for four screening guidelines, 2007-2010** OP-0237
K.M. Bullard, M.K. Ali, G. Imperatore, L.S. Geiss, S.H. Saydah, A. Albright, E.W. Gregg (USA)

11:15 **Correlates of HbA1c in a rural Ugandan population: the relevance of anaemia and sickle cell trait** OP-0238
G.A.V. Murphy, G. Asiki, E.H. Young, R.N. Nsubuga, D. Gurdasani, K. Ekoru, J. Seeley, M.S. Sandhu, A. Kamali (United Kingdom)

11:30 **Consumption of government subsidized foods and abdominal obesity among US adults** OP-0239
K. Siegel, M.K. Ali, K.M. Venkat Narayan (USA)

11:45 **Fasting glucose, two-hour glucose and HbA1C as predictors of all-cause mortality: the Ausdiab study 2012 follow-up** OP-0240
D. Sarink, E.L. Barr, D.J. Magliano, J.E. Shaw (Australia)

12:00 **Impact of HbA1c vs. fasting plasma glucose on screening and characteristics of newly diagnosed diabetes populations** OP-0241
G. Nichols (USA)

12:15 **Validation of the WHO-5 as a first step screening tool for depressive mood in English-speaking adults with type 1 or 2 diabetes** OP-0242
J.A. Halliday, C. Hendrieckx, J. Browne, G. Nefs, F. Pouwer, J. Speight (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Melbourne Room 1

Intersection of type 1 and 2 diabetes

Chair: D. Leslie (United Kingdom)
Chair: O. Rolandsson (Sweden)

10:45 **Insulin resistance in type 1 diabetes** 0243
Invited Speaker: S. Fourlanos (Australia)

11:15 **Insulitis in type 2 diabetes** 0244
Invited Speaker: J. Ehses (Switzerland)

11:45 **Clinical and genetic overlap between type 1 and type 2 diabetes** 0245
Invited Speaker: T. Tuomi (Finland)

12:15 **Autoimmunity in type 2 diabetes** 0246
Invited Speaker: J. Palmer (USA)

10:45 - 12:45 Melbourne Room 2

Tackling obesity: innovative health promotion programs in the community

Chair: D. Davis (Australia)
Chair: J. Shaw (Australia)

10:45 **Healthy together Victoria: a systems approach to prevention** 0247
Invited Speaker: S. Bowen (Australia)

11:25 **Partnership for a healthier America: urgency for private sector engagement to reduce childhood obesity** 0248
Invited Speaker: J.R. Gavin III (USA)

12:05 **Designing homes and communities for active lifestyle** 0249
Invited Speaker: A. Friedman (Canada)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 203/204

Genetics and epigenetics

Chair: A. El-Osta (Australia)
Chair: P. Hamet (Canada)

10:45 **Characterizing the spectrum of variation present in known Mendelian diabetes genes by exome sequencing 2,734 individuals in the GoT2D study** OP-0250
J. Perry, J. Flannick, A. Majithiaon, A. Gloyn, GoT2D Consortium (United Kingdom)

11:00 **Characterization of the transcriptional machinery bound across the widely presumed T2D causal variant within TCF7L2** OP-0251
S.F.A. Grant, S. Deliard, C.X. Yuan, M.E. Johnson, Q. Xia (USA)

11:15 **Fine-mapping of type 2 diabetes susceptibility loci via trans-ethnic meta-analysis** OP-0252
M. Horikoshi, A.P. Morris, J. Asimit, J.R. Huyghe, F. Takeuchi, A. Mahajan, N. Kato, Y.Y. Teo, E. Zeggini, M.I. McCarthy (United Kingdom)

11:30 **Fine-mapping type 2 diabetes susceptibility loci with the Metabochip (on behalf of the DIAGRAM Consortium)** OP-0253
A.P. Morris, T.M. Teslovich, T. Ferreira, A. Mahajan, Y. Lee, N.W. Rayner, C.N.A. Palmer, D. Altshuler, M. Boehnke, M.I. McCarthy (United Kingdom)

11:45 **Exploration of the impact of low-frequency and rare coding variation in the genetic architecture of type 2 diabetes susceptibility** OP-0254
A. Mahajan, C. Fuchsberger, D. Pasko, J. Flannick, N. Grarup, N. Robertson, X. Sim, N. Burtt, A. Morris (United Kingdom)

12:00 **Association of variants of genes involved in epigenetic mechanisms with type 2 diabetes** OP-0255
I. Kaur, O.P. Dwivedi, N. Tandon, D. Bharadwaj (India)

12:15 **MicroRNA-29a promotion of nephrin acetylation ameliorates diabetes-induced podocyte dysfunction** OP-0256
C.L. Lin, P.H. Lee, F.S. Wang (Taiwan)

12:30 **A genome-wide study identifies multiple copy number polymorphisms associated with diabetic complications** OP-0257
J. Tremblay, J. Raelson, F. Harvey, M. Ivanga, J. Chalmers, M. Woodward, S. Harrap, M. Marre, P. Hamet (Canada)

10:45 - 12:45 Room 210/211

Advances in angiogenesis-relevance to diabetic complications

Chair: R. Gilbert (Canada)
Chair: M. Thomas (Australia)

10:45 **Overview of angiogenic factors and their receptors** 0258
Invited Speaker: S. Stacker (Australia)

11:25 **VEGF and the kidney: implications for diabetic nephropathy** 0259
Invited Speaker: S. Quaggin (USA)

12:05 **VEGF and its receptors: implications for diabetes associated cardiovascular disease** 0260
Invited Speaker: M. Simons (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 212/213

Addressing the complications of diabetes in Indigenous peoples

Chair: S. Chadban (Australia)
Chair: H. Taylor (Australia)

10:45 **Microvascular and macrovascular complications of diabetes in Aboriginal and First Nations communities in Canada** 0261
Invited Speaker: S. Harris (Canada)

11:15 **Renal disease and diabetes in Aboriginal Indigenous peoples** 0262
Invited Speaker: W. Hoy (Australia)

11:45 **Mitigating cardiovascular disease among Indigenous people with diabetes** 0263
Invited Speaker: G. Jennings (Australia)

12:15 **Retinopathy and novel telemedicine solutions in Indigenous peoples** 0264
Invited Speaker: S. Bursell (USA)

10:45 - 12:45 Room 219/220

Diabetes management

Chair: P. Drury (New Zealand)
Chair: R. Gabriel (Spain)

10:45 **Attainment of treatment targets in young onset type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) Program: analysis of nine regions** OP-0265
J.C.N. Chan, L. Sobrepena, K. Jothydev, S.R. Aravind, J.P. Weng, R. Bian, Y.Y. Zhang, R.O. Yeung, N. Brown, T.K. Nguyen, S.Y. Goh, K.H. Yoon (Korea)

11:00 **Pooled analysis of quality of care indicators from diabetes registers of 19 European countries: results of the EUBIROD project** OP-0266
F. Carinci, M. Massi Benedetti, E.U. Eubirod (Italy)

11:15 **The frequency and impact of hypoglycemia among hospitalized patients with diabetes in the Spanish National Health System (1997-2010)** OP-0267
R. Gómez-Huelgas, R. Guijarro-Merino, R. Barba-Martín, M.D. López-Carmona, S. Santamaría-Fernández, R. Bernal-López, A. Zapatero-Gaviria (Spain)

11:30 **Determinants of glycaemic control over 4 years in people with type 2 diabetes starting insulin therapy across three continents** OP-0268
B. Balkau, F. Calvi-Gries, N. Freemantle, M. Vincent, V. Pilorget, P. Home (France)

11:45 **Trends in metabolic control and use of treatment in people with diabetes between 1999-2012** OP-0269
S.K. Tanamas, D.J. Magliano, P. Zimmet, J.E. Shaw (Australia)

12:00 **Longitudinal associations between depression, anxiety and initiation of insulin therapy in people with type 2 diabetes - the HUNT2 study** OP-0270
M.M. Iversen, G. Nefs, G.S. Tell, B. Espehaug, K. Midthjell, M. Graue, F. Pouwer (Norway)

12:15 **A cross-sectional study on the management and perceptions of South African school children regarding their type 1 diabetes diagnosis** OP-0271
K.L. Kalweit, N. Briers, S.A.S. Olorunju (South Africa)

12:30 **Why physicians do not follow AACE/ACE guidelines in treating qualified patients with t2dm: a survey study in the United States** OP-0272
Q. Li, Y. Qiu, J. Tang, C.P.S. Fan, Z. Li, M. Apecechea, R. Hegar, R. Shankar, S.S. Engel (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 207

Enhancing patient care and self-management with e-health

Chair: M. Cohen (Australia)
Chair: M. Georgeff (Australia)

10:45 **Does practice nurse-led telephone coaching improve HbA1c in type 2 diabetes? Results from the PEACH pragmatic cluster randomised trial** OP-0273
I. Blackberry, J. Furler, J. Best, P. Chondros, M. Vale, C. Walker, T. Dunning, L. Segal, J. Dunbar, R. Audehm, D. Liew, D. Young (Australia)

11:00 **Telemedicine vs. standard care in type 2 diabetes: a randomized trial** OP-0274
O.W. Rasmussen, M. Løkke, F.F. Lauszus (Denmark)

11:15 **A comparison of in-person, telephone, and secure messaging for type 2 diabetes self-management support** OP-0275
D. Greenwood, A. Hankins, C. Parise, V. Spier, J. Olveda, K. Buss, R. Spirakis, B. Schatzman, K. Reilly (USA)

11:30 **Telemedical coaching for weight loss: a randomized controlled trial** OP-0276
K. Kempf, M. Stichert, G. Fischer, E. Boschem, J. Könner, S. Martin (Germany)

11:45 **Social networks: diabetes connections** OP-0277
H. Edwards, H. Wilde, K. Philp, D. Mapletoft, K. Marsh (Australia)

12:00 **Sparsh impact: telephone counselling to improve diabetes self management and diabetes related outcomes** OP-0278
S. Mukherjee (India)

12:15 **Piloting diabetes communication in Kenya** OP-0279
C. Karekezi, E. Gitonga, E. Njenga, S. Sudhoff, P.B. Halberg (Kenya)

10:45 - 11:45 Room 208

Internet, social media and community

Chair: S. Murray (Australia)

10:45 **Searching for help online: understanding the experience of pregnancy and motherhood for women with type 1 diabetes** OP-0279b
H. Edwards, H. Bridgman, J. Speight, T.C. Skinner (Australia)

11:00 **Alone/Together: blogging diabetes** OP-0280
V. Bajurny (Canada)

11:15 **"It's like saying to a child 'be good'!": a qualitative study of the perceived impact of language among people with type 1 and type 2 diabetes** OP-0281
E. Holmes-Truscott, C. Hendrieckx, T. Dunning, T. Skinner, J. Speight (Australia)

11:30 **The power of community: creating a diabetes slipstream** OP-0282
C. Vance, J. Hanson (Canada)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Room 209

Self-management

Chair: M. Gill (Australia)

10:45 **Assessment of the peer to peer support programme of the Association Française des Diabétiques - 2010/2012** OP-0284
C. Avril, G. Raymond, A. Namur (France)

11:00 **Pictorial diabetes self-management guides: a simple solution for low health literacy** OP-0285
A. Mackie (Australia)

11:15 **A family based intervention to manage type 2 diabetes** OP-0286
N. Mshunqane, A.V. Stewart (South Africa)

11:30 **Professional continuous glucose monitoring in office practice improves diabetes self-management, glucose control, and hypoglycemia** OP-0287
A. Rizvi (USA)

10:45 - 12:45 Room 106

The integrated care: rhetoric or reality? Sharing experiences and finding solutions

Chair: M.L. Ruiz (Argentina)

Learning how to integrate diabetes care: experiences from a in inner-city London 0288
Invited Speaker: J. Stopher (United Kingdom)

Learning how to integrate diabetes care: experiences from a in inner-city London 0289
Invited Speaker: S. Thomas (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:45 - 12:45 Plenary 2

Glucagon: a bystander or a key actor in the pathogenesis of diabetes mellitus?

Chair: J. Turtle (Australia)

Invited Speaker: *P. Lefèbvre (Belgium)* 0290

11:45 - 12:45 Room 208

Youth living with diabetes

Chair: B. van de Goor (The Netherlands)

11:45 **To be a sibling to a child newly diagnosed with type 1 diabetes** OP-0291
K. Huus, A. Wennick (Sweden)

12:00 **The first African Diabetes Youth Leadership Programme (ADYLP)** OP-0292
M. Skjødt Sørensen, K. Ramayia, E. Majaliwa, D. McLarty (Denmark)

12:15 **Society's perception of young persons living with diabetes** OP-0293
J.M. Mboi, J.M. Mburu (Kenya)

12:30 **The young Indian female with type 1 diabetes: challenges with marriage** OP-0294
J. Kesavadev, A. Shankar, G. Sanal, J. Lally, G. Krishnan, S. Jothydev (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:45 - 12:45 Room 209

Insulin therapy

Chair: V.D. Basant Rai (Mauritius)

11:45 **Global perspectives on knowledge, treatment and care of type 2 diabetes: clinical awareness survey of 21,019 physicians** OP-0295
G. González-Gálvez, Z. Hussein, Z. Latif, J. Haddad, V. Prusty, P. Home (United Kingdom)

12:00 **Quality of life change for patients after moving to insulin pump therapy - Kazakhstan's experience** OP-0296
A. Demessinov, M.S. Naila Tokhtarova, M.S. Gulmira Abduakhassova, M.S. Leila Zhubandykova, M.S. Nicola Tara Dunne (Kazakhstan)

12:15 **Higher rates of diabetic kidney disease in males and role of gender bias within the family** OP-0297
A. Jhingan, D.R. Vikram Kalra, D.R. Ram Mohan Jhingan (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Melbourne Room 1

ISPAD lecture

Chair: F. Cameron (Australia)

Diabetes in the young: do we have the correct targets for the right outcomes? 0298

Invited Speaker: S. Greene (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Plenary 2

The IDF World Diabetes Congress presents The Lancet and The Lancet Diabetes & Endocrinology symposium: Managing diabetes in the 21st century

Chair: G. Alberti (United Kingdom)
Chair: J. Davies (USA)

14:30 **Diabetes: a 21st century challenge** 0299
Invited Speaker: P. Zimmet (Australia)

15:00 **Adiponectin in the development of type 2 diabetes** 0300
Invited Speaker: T. Kadowaki (Japan)

15:30 **Future perspectives and controversies in type 2 diabetes** 0301
Invited Speaker: S. Kahn (USA)

16:00 **The spectrum of diabetes: more than type 1 and type 2 diabetes** 0302
Invited Speaker: L. Groop (Sweden)

14:30 - 15:30 Plenary 1

The role of new insulins

Chair: T. Davis (Australia)

Invited Speaker: *S. Gough (United Kingdom)* 0303

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Plenary 3

Bariatric surgery: clinical controversies

Chair: G. Segal-Lieberman (Israel)
Chair: G. Wittert (Australia)

14:30 **Different surgical approaches** 0305
Invited Speaker: F. Rubino (USA)

15:00 **Surgical versus medical approaches** 0306
Invited Speaker: J. Dixon (Australia)

15:30 **Long-term sequalae: good and bad** 0307
Invited Speaker: P. Schauer (USA)

16:00 **Physiological lessons from bariatric surgery** 0308
Invited Speaker: C. Le Roux (United Kingdom)

14:30 - 16:30 Melbourne Room 1

Exercise

Chair: D. Marrero (USA)
Chair: N. Owen (Australia)

14:30 **Myokines and exercise** 0309
Invited Speaker: B.K. Pedersen (Denmark)

15:00 **Metabolic flux and exercise** 0310
Invited Speaker: D. Muoio (USA)

15:30 **Improving glycaemic control through exercise-nutrient interactions** 0311
Invited Speaker: J. Hawley (Australia)

16:00 **Role and impact of exercise in type 1 diabetes** 0312
Invited Speaker: E. Davis (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Melbourne Room 2

Diabetes prevention: real world examples

Chair: J. Dunbar (Australia)
Chair: R. Gabriel (Spain)

14:30 **The Americas** 0313
Invited Speaker: P. Aschner (Colombia)

15:00 **Europe** 0314
Invited Speaker: J. Tuomilehto (Finland)

15:30 **Middle-income countries** 0315
Invited Speaker: A. Nanditha (India)

16:00 **Low-income countries** 0316
Invited Speaker: E. Sobngwi (Cameroon)

14:30 - 16:30 Room 203/204

Circadian rhythm and metabolic control

Chair: B. Drew (Australia)
Chair: L. Van Gaal (Belgium)

14:30 **Clock genes** 0317
Invited Speaker: G. Asher (Israel)

15:00 **Circadian Rhythms and tissue energy metabolism** 0318
Invited Speaker: G. Cooney (Australia)

15:30 **REVERB alpha** 0319
Invited Speaker: B. Staels (France)

16:00 **Clinical relevance of nuclear receptors and circadian rhythm in type 2 diabetes** 0320
Invited Speaker: P. Grant (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 210/211

Preventing diabetes in children and adolescents

Chair: M.L. Ruiz (Argentina)
Chair: M. Wilson (Australia)

14:30 **Preventing type 2 diabetes in youth: can we move mountains?** 0321
Invited Speaker: S. Arslanian (USA)

15:00 **The health benefits of play and activity in children** 0322
Invited Speaker: A. Page (United Kingdom)

15:30 **Which children are at risk of insulin resistance and why: the Earlybird Study** 0323
Invited Speaker: T. Wilkin (United Kingdom)

16:00 **School- and family-based approaches to diabetes prevention** 0324
Invited Speaker: J. Salmon (Australia)

14:30 - 16:30 Room 212/213

Community prevention: what works?

Chair: L. Chuang (Taiwan)
Chair: I. Nicolaisen (Denmark)

14:30 **Enabled communities for primary prevention: lessons from Canada** 0325
Invited Speaker: T. Delormier (Canada)

14:55 **Poverty, food insecurity and political inertia: overcoming the barriers to nutritional interventions** 0326
Invited Speaker: K. O'Dea (Australia)

15:20 **Policy, politics and the rights to health: New Zealand approaches to the prevention of diabetes** 0327
Invited Speaker: M. Harwood (New Zealand)

15:45 **Research, leadership and national action: diabetes policy and prevention in Canada** 0328
Invited Speaker: J. Reading (Australia)

16:10 **Panel Discussion - Prevention of diabetes in Indigenous peoples: priorities for the road ahead**

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 219/220

Novel type 2 diabetes risk factors

Chair: W. Davis (Australia)
Chair: K.M. Venkat Narayan (USA)

14:30 **Sleep disturbance** 0329
Invited Speaker: N. Punjabi (USA)

15:00 **Environmental toxicants** 0330
Invited Speaker: D. Magliano (Australia)

15:30 **Biomarkers** 0331
Invited Speaker: E. Selvin (USA)

16:00 **Stress and psychological traits as risk factors for type 2 diabetes** 0332
Invited Speaker: E.J. Boyko (USA)

14:30 - 15:30 Room 207

Managing diabetes is harder in older people than in children and adolescents

Chair: T. Dunning (Australia)

Older people 0333

Invited Speaker: A. Sinclair (United Kingdom)

Children and adolescents 0334

Invited Speaker: P. Vardi (Israel)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 208

Beta cell renewal and survival

Chair: R. Laybutt (Australia)
Chair: S. Andrikopoulos (Australia)

14:30 **Physiology of beta-cell turnover** 0335
Invited Speaker: M. German (USA)

15:00 **Cytokine rescue** 0336
Invited Speaker: T. Mandrup-Poulsen (Denmark)

15:30 **Targeting the terminal unfolded protein response in diabetes mellitus** 0337
Invited Speaker: F. Papa (USA)

16:00 **Role of proteases in the islet** 0338
Invited Speaker: S. Zraika (USA)

14:30 - 16:30 Room 209

WHO global targets for national action: hope or hype, are they achievable?

Chair: J.C. Mbanya (Cameroon)
Chair: T. Van Binh (Vietnam)

14:30 **PEN perspective on the ground: integrating diabetes care into the primary health system in LMICs in Africa** 0341
Invited Speaker: K. Ramaiya (Tanzania)

15:00 **The challenges of LMICs: challenges on the ground, Western Samoa** 0339
Invited Speaker: L. Talalelei Tuitama (Samoa)

15:30 **The challenges of LMICs: challenges on the ground, Pakistan** 0340
Invited Speaker: M. Daud Khan (Pakistan)

16:00 **WHO global targets for national action: can we rely on governments to act?** 0342
Invited Speaker: A. Misra (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 15:30 Room 106

Role of the parliamentary diabetes groups

Chair: G. Barnett (Australia)

14:30 **Parliamentary diabetes support groups** 0343
Invited Speaker: J. Moylan (Australia)

14:50 **Raising the profile of diabetes among decision makers: the ExPAND Initiative** 0344
Invited Speaker: A. Sanders (United Kingdom)

15:10 **Global initiatives** 0345
Invited Speaker: M. Hirst (United Kingdom)

15:30 - 16:30 Plenary 1

Insulin resistance: translating molecular findings to the clinical problems of diabetes and obesity

Chair: J. Roth (USA)

Invited Speaker: *R. Kahn (USA)* 0346

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Room 207

Managing diabetes in the presence of complex comorbidities

Chair: M. Cohen (Australia)

Invited Speaker: *F. Schellevis (The Netherlands)* 0347

15:30 - 16:30 Room 106

Associations of people with diabetes: examples

Chair: TBC

The case of the oldest association in the world 0348

Invited Speaker: J.F. Raposo (Portugal)

Qatar Diabetes Association 0349

Invited Speaker: S. Al-Jundi Matthis (Qatar)

PROGRAMME

THURSDAY 05 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:30 - 10:30 Plenary 2

What is in the pipeline for type 2 diabetes?

Chair: C. Bailey (United Kingdom)
Chair: J. Buse (USA)

08:30 **GLP-1 analogs and gastrointestinal peptide drug development** 0350
Invited Speaker: M. Meier (Switzerland)

09:00 **Role of chaperokines in health and disease** 0351
Invited Speaker: M. Febbraio (Australia)

09:30 **The fatty-acid receptor GPR40 as a new drug target for type 2 diabetes** 0352
Invited Speaker: V. Poitout (Canada)

10:00 **New directions in treatment of type 2 diabetes** 0353
Invited Speaker: K. Kaku (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Plenary 1

Neuronal regulation of glucose and body weight

Chair: M. Cowley (Australia)
Chair: J. Proietto (Australia)

08:30 **Brain lipids** 0354
Invited Speaker: J.C. Brüning (Germany)

09:00 **Hypothalamic injury and obesity pathogenesis** 0355
Invited Speaker: J. Thaler (USA)

09:30 **Central pathways** 0356
Invited Speaker: M. Sleeman (Australia)

10:00 **Leptin signalling** 0357
Invited Speaker: G. Morton (USA)

08:30 - 09:30 Plenary 3

Insulin therapy: 1921-2013

Chair: A. Nigam (India)

Invited Speaker: J. Skyler (USA) 0358

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Melbourne Room 1

Diabetic nephropathy: from basic to clinical

Chair: K. Jandeleit-Dahm (Australia)
Chair: J. Vora (United Kingdom)

08:30 **Molecular mediators** 0359
Invited Speaker: F. Danesh (USA)

09:00 **Novel pathways** 0360
Invited Speaker: D. Koya (Japan)

09:30 **Genetics** 0361
Invited Speaker: P. Groop (Finland)

10:00 **Treatment update** 0362
Invited Speaker: V. Perkovic (Australia)

08:30 - 09:30 Melbourne Room 2

Type 2 diabetes and the metabolic syndrome: the ominous octet revisited

Chair: S. Del Prato (Italy)

Invited Speaker: R. DeFronzo (USA) 0363

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 203/204

Non beta cells in the endocrine pancreas

Chair: K. Al-Hasani (Australia)
Chair: S. Kahn (USA)

08:30 **Alpha cell mediated beta cell regeneration** 0365
Invited Speaker: P. Collombat (France)

09:00 **Glucagon antagonism** 0364
Invited Speaker: P. Rorsman (United Kingdom)

09:30 **Eye reports on the status of the endocrine pancreas** 0366
Invited Speaker: TBC

10:00 **Cell interactions in the endocrine pancreas** 0367
Invited Speaker: T. Kieffer (Canada)

08:30 - 09:30 Room 210/211

IDF award lecture: Global challenges in health

Chair: L. Ji (China)

Global health and governmental policies in diabetes: are we on the right track? 0368

Invited Speaker: J.C. Mbanya (Cameroon)

Jean Claude Mbanya

Jean Claude Mbanya is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Director Biotechnology Centre, University of Yaoundé 1 and Adjunct Professor of Medicine, Endocrinology & Diabetes, at the University of Technology, Jamaica. He is also Consultant Physician and Director of the National Obesity Centre at the University Teaching Hospital in Yaoundé. He is immediate Past President of the International Diabetes Federation. He initially studied in Cameroon where he obtained his MD and trained at the University of Newcastle-upon-Tyne, England where he obtained a PhD. He is a Fellow of the Royal College of Physicians, London and Doctor philosophiae honoris causa, University of Oslo, Norway.

Professor Mbanya also currently serves on several international scientific and WHO advisory groups, including the Expert Advisory Panel on Chronic Degenerative Diseases and Diabetes and the WHO African Advisory Committee on Health Research and Development. He is a recipient of several international awards. His major interests include diabetes and other non-communicable diseases epidemiology and prevention, integration of diabetes care in the health care system of developing countries, diabetes complications, obesity and physical activity as risk factors of non-communicable diseases.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 212/213

Maternal diabetes and dysglycaemia: current and future risks

Chair: C. Connors (Australia)
Chair: M. Okihiro (USA)

08:30 **From HAPO to health: building better systems to improve maternal and foetal outcomes** 0369
Invited Speaker: J. Oats (Australia)

09:00 **Outcomes for children born to mothers with gestational diabetes** 0370
Invited Speaker: D.J. Pettitt (USA)

09:30 **Diabetes in pregnancy in the Northern Territory** 0371
Invited Speaker: L. Maple-Brown (Australia)

10:00 **Diabetes in pregnancy in South American populations** 0372
Invited Speaker: M.I. Schmidt (Brazil)

08:30 - 10:30 Room 219/220

Technical developments: type 1 diabetes

Chair: L. Guo (China)
Chair: K. Kumareswaran (Australia)

08:30 **Continuous glucose monitoring update** 0373
Invited Speaker: T. Battelino (Slovenia)

09:00 **Future pumps automatically regulated** 0374
Invited Speaker: M. Phillip (Israel)

09:30 **Artificial pancreas** 0375
Invited Speaker: R. Hovorka (United Kingdom)

10:00 **Approaches to assess beta cell or islet cell mass: current status and future directions** 0376
Invited Speaker: A. Powers (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 09:30 Room 207

Living with diabetes complications

Chair: W. Wientjens (The Netherlands)

08:30 **Kidney failure: a devastating but preventable complication of diabetes** 0377
Invited Speaker: S. Chadban (Australia)

09:00 **Living with diabetic foot complications** 0378
Invited Speaker: Z. Abbas (Tanzania)

08:30 - 09:30 Room 208

Diabetes at school

Chair: S. Gerlach (Germany)

08:30 **Taking diabetes to school** 0379
Invited Speaker: J. Double (United Kingdom)

09:00 **The kNOw diabetes project** 0380
Invited Speaker: L. Simon (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 209

DAWN 2

Chair: M. Massi-Benedetti (Italy)
Chair: M. Robins (Australia)

08:30 **DAWN 2: study objectives and methodology** 0381
Invited Speaker: M. Peyrot (USA)

09:00 **Psychosocial impact of diabetes: DAWN 2 multi-national results** 0382
Invited Speaker: A. Nicolucci (Italy)

09:30 **Family burden and support: DAWN 2 multi-national results** 0383
Invited Speaker: F. Pouwer (The Netherlands)

10:00 **Active involvement of people with diabetes and support for self-management** 0384
Invited Speaker: I. Willaing (Denmark)

08:30 - 09:30 Room 106

How to assess physical activity and sedentary behaviour

Chair: E.J. Boyko (USA)

Invited Speaker: *F. Assah (Cameroon)* 0385

Invited Speaker: *D. Dunstan (Australia)* 0386

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Plenary 3

Diabetes monitoring: from testing urine to HbA1c and continuous blood glucose determination

Chair: H. Breidahl (Australia)

Invited Speaker: *G. Alberti (United Kingdom)* 0387

09:30 - 10:30 Melbourne Room 2

Monogenic forms of diabetes: relevance to the global burden of diabetes mellitus

Chair: K. Samaras (Australia)

Invited Speaker: *M. Sperling (USA)* 0388

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Room 210/211

To screen or not to screen: should we screen when there are no resources to treat?

Chair: A. Palmer (Australia)

Ethical issues: screening versus treatment in resource-limited settings 0389
Invited Speaker: S. Colagiuri (Australia)

Population-wide versus targeted interventions: when you decide you will screen, what will you do afterwards? 0390
Invited Speaker: V. Mohan (India)

09:30 - 10:30 Room 207

Living with diabetes in a busy world

Chair: G. Bunyan (Australia)

Invited Speaker: *U. Ranjit (India)* 0391

Invited Speaker: *K. Sparling (USA)* 0392

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Room 208

Summer camps

Chair: N. Piana (Italy)

Diabetes camping programs: encouraging, motivating and teaching children how to live well with diabetes 0393

Invited Speaker: T. Ackley (USA)

Camps/retreats: empowering young people and families to master the challenges of a life with diabetes 0394

Invited Speaker: P. Madden (USA)

09:30 - 10:30 Room 106

Developing eye care in vulnerable populations

Chair: B. Doolan (Australia)

Developing eye care in vulnerable population 0395
Invited Speaker: M. Daud Khan (Pakistan)

Developing eye care in vulnerable populations 0396
Invited Speaker: W. Mathenge (Rwanda)

The Fiji National Diabetes Eye Care Project 0397
Invited Speaker: B. Sikivou (Fiji)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Plenary 2

Should controlled trials of bariatric surgery be mandatory?

Chair: F. Rubino (USA)

Yes 0398

Invited Speaker: R.E. Ratner (USA)

No 0399

Invited Speaker: R. Cohen (Brazil)

10:45 - 12:45 Plenary 1

Asia-Pacific

Chair: L. Ho (Taiwan)
Chair: M.A. Lim-Abrahan (Philippines)

10:45 **Prevalence and incidence of diabetes across the region** 0400
Invited Speaker: R.M. Anjana (India)

11:15 **Da Qing: long-term outcomes of diabetes prevention** 0401
Invited Speaker: G. Li (China)

11:45 **The Asian phenotype: does it really exist?** 0402
Invited Speaker: L. Ji (China)

12:15 **Linking large clinical data sources to improve care** 0403
Invited Speaker: J. Chan (China)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Plenary 3

Type 2 diabetes risk factors, prevention and prevalence

Chair: L. Guariguata (Belgium)
Chair: R. Ma (China)

10:45 **Community Interventions for Health (CIH) reduce the risk factors for type 2 diabetes in selected populations in China, India and Mexico** OP-0404
P.A. Dyson, D. Anthony, B. Fenton, D.E. Stevens, B. Champagne, L. Li, J. Lv, J.R. Hernandez, K.R. Thankappan, D.R. Matthews (United Kingdom)

11:00 **DE-PLAN project: a multicentre European community program of screening and prevention of diabetes with lifestyle intervention** OP-0405
R. Gabriel, T. Acosta, J. Lindstrom, P. Schwarz, K. Makrilakis, A. Januszewska, K. Midthjell, X. Cos, J. Tuomilehto, on behalf of DE-PLAN Consortium(9) (Spain)

11:15 **The role of ethnicity of the development cohort in the performance of diabetes risk prediction models in new populations** OP-0406
S.K. Tanamas, D.J. Magliano, B. Balkau, P. Zimmet, J.E. Shaw (Australia)

11:30 **Fasting and 2-h plasma glucose within a normoglycemic range did not increase mortality risk: a cohort study of 65,597 men and women from the VIP** OP-0407
E. Fhärm, W.C. Knowler, M. Norberg, L. Nyström, H. Stenlund, P.W. Franks, O. Rolandsson (Sweden)

11:45 **Dietary acid load and risk of type 2 diabetes in the French E3N cohort** OP-0408
G. Fagherazzi, A. Vilier, M. Lajous, D.J. Magliano, J.L. Harding, B. Balkau, F. Clavel-Chapelon (France)

12:00 **Long working hours is associated with increased risk of diabetes in urban male Chinese workers: The Rosai Karoshi Study** OP-0409
J. Tayama, J. Li, M. Munakata (Japan)

12:15 **Waist-to-height ratio has the best anthropometric association with diabetes in Sri Lankan adults** OP-0410
P. Ranasinghe, R. Jayawardena, P. Katulanda (Sri Lanka)

12:30 **Population level change in the prevalence of diabetes in urban and rural Delhi, India-Results from repeat cross sectional survey** OP-0411
P. Pradeep, R. Amarchand, K. Pesala, R. Gupta, L. Ramakrishnan, A. Roy, N. Tandon, K.S. Reddy, A. Krishnan, P. Dorairaj (India)

10:45 - 12:45 Melbourne Room 1

Clinical - cardiorenal complications

Chair: P. Groop (Finland)
Chair: C. Johnston (Australia)

10:45 **Age and diabetes duration: impact on risks of macrovascular and microvascular complications and death in type 2 diabetes** OP-0412
S. Zoungas, Q. Li, M.E. Cooper, S. Heller, M. Woodward, J. Chalmers (Australia)

11:00 **Postprandial blunting of vascular function within the first hour after a high fat meal, and is independent of glycemic excursion** OP-0413
H. Steinberg, N.K. Shankar, C.A. Dehn (USA)

11:15 **Relationship between birth weight and cardio-metabolic risk factors in Chinese adolescents and adults** OP-0414
C. Tam, V. Lam, Y. Wang, J. Luan, H. Lee, A. Luk, P. Tong, C. Chow, A. Kong, W. So, J. Chan, R. Ma (Hong Kong China)

11:30 **Prospective study on incidences of cardio-renal complications in Chinese patients with young-onset type 1 and type 2 diabetes** OP-0415
A. Luk, E. Lau, W.Y. So, R. Ma, R. Ozaki, C.C. Chow, J. Chan (Hong Kong China)

11:45 **Heterogeneity of Chronic Kidney Disease (CKD) phenotypes in patients with type 1 diabetes mellitus** OP-0416
E. Russo, G. Penno, D. Lucchesi, L. Pucci, M. Garofolo, V. Sancho Bornez, R. Russo, L. Giusti, R. Miccoli, S. Del Prato (Italy)

12:00 **Is asymmetric dimethylarginine (ADMA) a predictor for the development of diabetic microangiopathy?** OP-0417
M. Miuchi, H. Konya, T. Ikawa, T. Matsuo, F. Ochi, M. Tokuda, Y. Kusunoki, K. Murai, T. Katsuno, T. Hamaguchi, J. Miyagawa, M. Namba (Japan)

12:15 **Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong Diabetes Registry** OP-0418
A. Kong, X. Yang, R. Ma, W.Y. So, A. Luk, C.C. Chow, J.C. Chan (Hong Kong China)

12:30 **Plasma macrophage inhibitory cytokine-1 (MIC -1) is associated with diabetic retinopathy** OP-0419
O. Ebisui, H. Tokunaga, T. Ueda, Y. Hara, K. Akesaka (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Melbourne Room 2

Treatment of type 2 diabetes

Chair: R. DeFronzo (USA)
Chair: A. Garber (USA)

10:45 **Initial triple combination therapy is more effective and safer than stepwise add on conventional therapy in newly diagnosed T2DM** OP-0420
M. Abdul-Ghani, C. Puckett, J. Adams, E. Cersosimo, C. Triplitt, R.A. DeFronzo (USA)

11:00 **Postprandial glycaemic control with a combination of insulin degludec and liraglutide vs. each component individually in T2D** OP-0421
J.B. Buse, S.C.L. Gough, H.W. Rodbard, V.C. Woo, S. Linjawi, P. Poulsen, L.H. Damgaard, B.W. Bode (United Kingdom)

11:15 **IDegLira, a novel combination of insulin degludec and liraglutide, is efficacious and safe in subjects with T2D: a randomised phase 3 trial** OP-0422
S.C.L. Gough, J.B. Buse, H.W. Rodbard, V.C. Woo, S. Linjawi, P. Poulsen, L.H. Damgaard, B.W. Bode (United Kingdom)

11:30 **Liraglutide improved glycemic control but failed to preserve beta-cell function in type 1 diabetes with residual insulin secretion** OP-0423
Y. Hamamoto, S. Honjo, Y. Kawasaki-Ogita, K. Mori, H. Tatsuoka, K. Fujimoto, A. Matsuoka, H. Ikeda, Y. Wada, H. Koshiyama (Japan)

11:45 **Effects of sitagliptin on glycaemic and incretin responses to intraduodenal glucose infusion in health, obesity and type 2 diabetes** OP-0424
T. Wu, M.J. Bound, J. Ma, C.F. Deacon, K.L. Jones, M. Horowitz, C.K. Rayner (Australia)

12:00 **Effects of vildagliptin on glycaemic, gut hormone, triglyceride, energy expenditure and energy intake responses to fat in healthy men** OP-0425
T. Little, G. Heruc, N. Luscombe-Marsh, B. Bartlett, C. Feinle-Bisset, C.K. Rayner, M. Horowitz (Australia)

12:15 **Oxyntomodulin has significant acute glucoregulatory effects in diabetic and non-diabetic subjects** OP-0426

S. Shankar, R. Shankar, L. Mixson, D. Miller, B. Pramanik, C.R. Beals, S.A. Stoch, H.O. Steinberg, D.E. Kelley (USA)

12:30 **Prospects for targeting protein kinase C in diabetes treatments: additive effect of metformin and liraglutide** OP-0427

B. Batchuluun, T. Inoguchi, N. Sonoda, S. Sasaki, T. Inoue, Y. Fujimura, D. Miura, R. Takayanagi (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 203/204

Diabetes childhood and adolescence

Chair: S. Greene (United Kingdom)
Chair: M. Sperling (USA)

10:45 **Prevention of ketoacidosis at the onset of diabetes in high-risk children** OP-0428
A. Rewers, G. Klingensmith, M. Rewers (USA)

11:00 **Effects of a vitamin D analog on pro-inflammatory cytokine interferon-gamma in type 1 diabetic children from Iran** OP-0429
A. Ataie-Jafari, A. Rahmat, B. Larijani (Iran)

11:15 **Immune dysregulation is more pronounced in autoimmune polyendocrine syndrome - 4 patients compared to patients with type 1 diabetes** OP-0430
N. Kaur, R.W. Minz, S.K. Bhadada, D. Dayal, N. Pasricha, S. Anand, B. Saikia, E. Kawasaki (India)

11:30 **Plasminogen activator inhibitor 1 in children and adolescents with type 1 diabetes: relation to micro- and macrovascular complications** OP-0431
N. Elbarbary, A. Adly, E. Ismail, S. Hassan (Egypt)

11:45 **Complications present early in youth with T2D in Western Australia: a 22 year retrospective audit** OP-0432
R. Kalic, J.A. Curran, M. Shah, E.A. Davis (Australia)

12:00 **Clinic attendance rates pre and post transition in type 1 diabetes mellitus** OP-0433
M. White, M. O'Connell, P. Colman, F. Cameron (Australia)

12:15 **The effect of a structured transition process from paediatric clinic to adolescens clinic on adherence and Hba1c** OP-0434
E. Hommel, B. Olsen, J. Svensson, A. Sinding-Olsen, M. Wittrup (Denmark)

10:45 - 12:45 Room 210/211

Gestational diabetes update

Chair: J. Flack (Australia)
Chair: M.I. Schmidt (Brazil)

10:45 **New diagnostic criteria** 0435
Invited Speaker: D. Coustan (USA)

11:15 **Implications of new criteria for diagnosis and management** 0436
Invited Speaker: D. Simmons (United Kingdom)

11:45 **Outcomes of gestational diabetes for the mother** 0437
Invited Speaker: N.H. Cho (Korea)

12:15 **Outcomes of gestational diabetes for the offspring** 0438
Invited Speaker: U. Elchalal (Israel)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 212/213

Micro and macrovascular complications

Chair: L. Rydén (Sweden)
Chair: K. Tuttle (USA)

10:45 **Cardiovascular risk factors in newly diagnosed type 2 diabetics in China** OP-0439
L.N. Ji, C.Y. Pan, J.P. Weng, Q.H. Ji, G.W. Li, J.M. Lu, B.L. Su, H.M. Tian, D.J. Zhou, Y. Liu, T. Hung, D.Y. Zhang (China)

11:00 **Change in HbA1c over 3 years slightly improves the prediction of cardiovascular disease over and above HbA1c measured at a single time point** OP-0440
P. Chamnan, R.K. Simmons, K.T. Khaw, N.J. Wareham, S.J. Griffin (Thailand)

11:15 **Racial/ethnic minorities with or without diabetes have better survival on dialysis than Whites, United States, 1995-2010** OP-0441
M.E. Pavkov, N. Rios-Burrows, P. Cho, K. McKeever Bullard, A.S. Narva, P.W. Eggers (USA)

11:30 **Racial differences in progression of nephropathy in patients with diabetes mellitus in Singapore** OP-0442
A.M. Saw, M. Munisamy, J. Khoo, D.M. Roy, J.M. Ng (Singapore)

11:45 **Increasing prevalence of nonalbuminuric renal impairment in patients with type 1 diabetes mellitus** OP-0443
G. Penno, E. Russo, D. Lucchesi, L. Pucci, M. Garofolo, V. Sancho Bornez, R. Russo, L. Giusti, N. Chaturvedi, J.H. Fuller, R. Miccoli, S. Del Prato (Italy)

12:00 **The changing character of diabetes-related complications in the United States** OP-0444
E.W. Gregg, Y. Li, J. Wang, M.K. Ali, N.R. Burrows, D.E. Williams, L. Geiss (USA)

12:15 **Retinopathy and risk factors in young onset type 2 diabetes in the Hong Kong Joint Asia Diabetes Evaluation Program (JADE)** OP-0445
R.O. Yeung, Y.Y. Zhang, A. Luk, E. Wu, W. Lau, R. Ting, D. Chan, R. Wong, H. Chung, K. Cheung, J.C.N. Chan, W.Y. So (Hong Kong China)

12:30 **Risk models for progression to sight threatening diabetic retinopathy - how do they perform?** OP-0446
I.M. Stratton, S.J. Aldington, M. Histed, P.H. Scanlon (United Kingdom)

10:45 - 12:45 Room219/220

Islets and incretin biology

Chair: R. Burcelin (France)
Chair: S. Zraika (USA)

10:45 **The full insulinotropic effects of GIP are impaired following PI3Kgamma inhibition or knockdown in rodent and human beta cells** OP-0447
J. Kolic, A.F. Spigelman, A.M. Smith, J.E. Manning Fox, P.E. MacDonald (Canada)

11:00 **Differential regulation of zinc transporter and metal binding protein in human type 1 and type 2 diabetes** OP-0448
D. Mohanasundaram, D. Mariea Bosco, P. Peter Zalewski, T. Loudovaris, T. Key, P.T.H. Toby Coates (Australia)

11:15 **The hepatokine fetuin-A induces proinflammatory cytokine expression and hypersecretion of insulin in human islets** OP-0449
S. Ullrich, F. Gerst, G. Kaiser, N. Stefan, H.U. Häring (Germany)

11:30 **The long-acting analogue of short-from GIP suppresses the progression to hyperglycaemia in a streptozotocin-induced diabetic model** OP-0450
T. Yanagimachi, Y. Fujita, J. Honjo, H. Kitsunai, H. Sakagami, Y. Takiyama, A. Abiko, Y. Makino, M. Haneda (Japan)

11:45 **Effect of glutamine on GLP-1 secretion and Wnt/beta-catenin signal pathway of NCI-H716 cells** OP-0451
Q. Wu, Y. Long, T. Chen, Z. Zhao, H. Tian (China)

12:00 **The effects of truncal vagotomy in energy homeostasis and acute response to GLP-1** OP-0452
T. Morais, S.S. Pereira, S. Andrade, M. Costa, D. Monteiro, M.P. Monteiro (Portugal)

12:15 **Activation of the p75 neurotrophin receptor causes the loss of sympathetic nerves from islets under autoimmune attack** OP-0453
G. Taborsky, Q. Mei, D. Hackney, T. Mundinger, K. Bornfeldt (USA)

12:30 **Flexibility in timing of lixisenatide administration prior to either the main meal of the day or the breakfast in T2DM patients** OP-0454
B. Ahren, N. Vorokhobina, E. Souhami, N. Demil, J. Ye, R. Aronson (Sweden)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Room 207

Discrimination and diabetes

Chair: K.S. Al-Aryedh (Bahrain)

10:45 **2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study: Discrimination and self-efficacy among people with diabetes and family members** OP-0455
J. Wens, S. Kalra, A. Kokoszka, M. Massi-Benedetti, N. Munro, M. Peyrot, DAWN2 Study Group (Belgium)

11:00 **Living in the shadow and light: Iranian youths' response to diabetes-related stigma** OP-0456
S. Abdoli, M. Doosti Irani, S. Parvizy, N. Seied Fatemi, M. Amini, B. Iraj (Iran)

11:15 **Diabetes-related stigma: perspectives from adults with type 1 diabetes** OP-0457
J.L. Browne, A. Ventura, K. Mosely, J. Speight (Australia)

11:30 **Type-1 diabetes, is it a social stigma? "A journey from childhood to parenthood"** OP-0458
A. Jhingan, M.D. Ram Mohan Jhingan (India)

10:45 - 11:45 Room 208

Type 2 diabetes in children and adolescents

Chair: A. Hanley (Canada)

10:45 **From the cradle to the grave: early life determinants of diabetes in Indigenous peoples** 0459
Invited Speaker: D. Dabelea (USA)

11:15 **Type 2 diabetes in the Australian youth** 0460
Invited Speaker: A. Sinha (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Room 209

Meeting the needs of older people

Chair: K. De Backer (Belgium)

10:45 **Expectations and aspirations of elderly patients and physicians with type 2 diabetes** OP-0461
W. David Strain, M. Blüher, P.M. Paldánius (United Kingdom)

11:00 **Factors associated with functional balance and falling among elderly diabetic patients** OP-0462
B. Tander, A. Atmaca, Y. Ulus, C.T. Bahadir, G.C. Ecemis, Y. Akyol, O. Kuru (Turkey)

11:15 **Preventing hypoglycaemia within the elderly population in a district general hospital** OP-0463
S. Raj, J. Williams (United Kingdom)

11:30 **Managing diabetes at the end of life: a guideline development process** OP-0464
T. Dunning, S. Savage, N. Duggan, P. Martin (Australia)

10:45 - 12:45 Room 106

Accommodating different language, literacy and learning abilities in education

Chair: TBC

Developed countries 0465

Invited Speaker: K. Cavanaugh (USA)

Developing communities 0466

Invited Speaker: G. Dent (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:45 - 12:45 Plenary 2

Systems analysis of insulin resistance

Chair: M. Birnbaum (USA)

Invited Speaker: *D.E. James (Australia)* 0467

11:45 - 12:45 Room 207

Living with diabetes

Chair: C. Thomas

11:45 **"I have diabetes and I fast during Ramadan" - beliefs and the experiences of fasting in Muslim people with diabetes: a qualitative study** OP-0468
N.R. Patel, A.P. Kennedy, D. Reeves, C. Blickem, C.A. Chew-Graham (United Kingdom)

12:00 **Diabetes and blindness – how to face the darkness** OP-0470
M. Franquet, M. Falabella, S. Brunoldi (Argentina)

12:15 **My Voice - a patient's perspective and means for advocacy** OP-0471
J.L. Colquhoun ()

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:45 - 12:45 Room 208

The primary prevention of type 2 diabetes: dream or reality?

Chair: N. Swan (Australia)

11:45 **The primary prevention of type 2 diabetes: dream or reality** 0472
Invited Speaker: M. Wenitong (Australia)

12:05 **The primary prevention of type 2 diabetes: dream or reality** 0473
Invited Speaker: A. Ramachandran (India)

12:25 **The primary prevention of type 2 diabetes: dream or reality** 0474
Invited Speaker: K. Wyatt (Australia)

11:45 - 12:45 Room 209

Peer to peer

Chair: J. Speight (Australia)

11:45 **Use of different types of diabetes education in 17 countries in the Second Diabetes Attitudes, Wishes and Needs study** OP-0475
N. Hermanns, H. Stuckey, M. Comaschi, M. Davies, M. Peyrot, B. Kulzer, R. Malek, A. Mayorov, N. Munro, N. Piana, I. Willaing, M. Peyrot (Germany)

12:00 **Peer-to-peer, multidisciplinary, process-focussed education increases GP confidence in using insulin therapy in type 2 diabetes** OP-0476
G. Deed, G. Kilov, P. Phillips, A. Sharma, S. Leow, I. Arthur, J. Barlow, M. Kennedy (Australia)

12:15 **Peer educators structured educational intervention in type 2 diabetes: a randomised controlled trial in Mali** OP-0477
S. Besançon, A.T. Sidibe, X. Debussche, I. Nientao, M. Balcou-Debussche, D. Sissoko, S. Halimi (Mali)

12:30 **Feasibility, reach, effectiveness, and sustainability of peer support in diabetes management: results from peers for progress** OP-0478
E. Fisher (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Plenary 2

Pregnancy and diabetes

Chair: D. McIntyre (Australia)
Chair: C. Nolan (Australia)

14:30 **Developmental pathways to metabolic compromise: maternal factors** 0479
Invited Speaker: P. Gluckman (New Zealand)

15:00 **Predictors of gestational diabetes and post-gestational type 2 diabetes** 0480
Invited Speaker: P. Catalano (USA)

15:30 **MiG TOFU study** 0481
Invited Speaker: J. Rowan (New Zealand)

16:00 **Embryonic malformations and diabetes** 0482
Invited Speaker: M. Loeken (USA)

14:30 - 15:30 Plenary 1

IDF award lecture - Public health and epidemiology

Chair: J. Shaw (Australia)

Researching strategies for the prevention of diabetes 0483

Invited Speaker: N. Wareham (United Kingdom)

Nicholas Wareham

Professor Nick Wareham is the Director of the MRC Epidemiology Unit, Co-Director of the Institute of Metabolic Science, Honorary Consultant at Addenbrooke's Hospital and Professor of Epidemiology at the University of Cambridge, England.

He studied Medicine at St Thomas' Hospital Medical School and Epidemiology at both the London School of Hygiene and Tropical Medicine and Cambridge University, England. After research fellowships at Harvard and Cambridge University, he took up the Directorship of the MRC Epidemiology Unit when it was founded in 2003.

His principle research interests are in understanding the aetiology of type 2 diabetes and in developing strategies for prevention and early detection. These preventive approaches include individual and societal level interventions and he is the Director of the UKCRC Centre for Diet and Activity Research (CEDAR).

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 15:30 Plenary 3

Gestational diabetes has a rich history

Chair: J. Oats (Australia)

Invited Speaker: B.E. Metzger (USA) 0484

14:30 - 16:30 Melbourne Room 1

What after Metformin and lifestyle?

Chair: G. Fulcher (Australia)
Chair: S. Sadikot (India)

14:30 **Sulphonylureas** 0485
Invited Speaker: T. Davis (Australia)

15:00 **Agents targeting the incretin axis** 0486
Invited Speaker: J. Rosenstock (USA)

15:30 **Insulin** 0487
Invited Speaker: H. Gerstein (Canada)

16:00 **SGLT2 inhibitors** 0488
Invited Speaker: J. Wilding (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 15:30 Melbourne Room 2

Target blood glucose in ICU and the ward

Chair: A. Deane (Australia)

Invited Speaker: M. Egi (Japan) 0489

14:30 - 16:30 Room 203/204

Nuclear receptor targets

Chair: A. Calkin (Australia)
Chair: A. Chawla (USA)

14:30 **Control of lipid metabolism by PPAR and LXR** 0490
Invited Speaker: P. Tontonoz (USA)

15:00 **Nor-1 controls endurance, and glucose utilisation: implications for metabolic disease** 0491
Invited Speaker: G. Muscat (Australia)

15:30 **Impaired ER action promotes metabolic dysfunction, obesity and type 2 diabetes susceptibility** 0492
Invited Speaker: A. Hevener (USA)

16:00 **Physiologic and pharmacologic actions of FGF21** 0493
Invited Speaker: S. Kliewer (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 210/211

Mitochondria

Chair: H.K. Lee (Korea)
Chair: N. Turner (Australia)

14:30 **Update in our understanding of mitochondria in human disease** 0494
Invited Speaker: M. Ryan (Australia)

15:00 **Mitochondrial function and regulation of insulin sensitivity** 0495
Invited Speaker: D. Neufer (USA)

15:30 **Beta cell and mitochondrial dysfunction** 0496
Invited Speaker: C. Mathews (USA)

16:00 **Mitochondrial dysfunction and diabetic complications** 0497
Invited Speaker: M. Coughlan (Australia)

14:30 - 16:30 Room 212/213

Diabetic kidney disease

Chair: R. Ma (China)
Chair: M. Thomas (Australia)

14:30 **Epidemiology of diabetic kidney disease: update for 2013** 0498
Invited Speaker: K. Tuttle (USA)

15:00 **Predictors of kidney disease in diabetes** 0499
Invited Speaker: R. Nelson (USA)

15:30 **Renal and cardiovascular outcomes in diabetic kidney disease** 0500
Invited Speaker: P. Rossing (Denmark)

16:00 **Has treatment of diabetic kidney disease delivered population-level benefits?** 0501
Invited Speaker: D. de Zeeuw (The Netherlands)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 219/220

Diabetic retinopathy

Chair: P. Drury (New Zealand)
Chair: H. Taylor (Australia)

14:30 **Haemodynamic factors implicated in diabetic retinopathy: basic mechanisms** 0502
Invited Speaker: J. Wilkinson-Berka (Australia)

15:00 **Metabolic pathways implicated in diabetic retinopathy: basic mechanisms** 0503
Invited Speaker: A. Stitt (United Kingdom)

15:30 **Natural history and modern diagnosis of diabetic retinopathy** 0504
Invited Speaker: H. Hammes (Germany)

16:00 **Pathogenesis and treatment of diabetic retinopathy** 0505
Invited Speaker: T. Gardner (USA)

14:30 - 15:30 Room 207

Diabetes and public awareness

Chair: S. Peresson (Belgium)

Best practices and innovative ways 0506

Invited Speaker: B. Young (United Kingdom)

How the WDC in Dubai has contributed to raise awareness of diabetes 0507

Invited Speaker: A.O. Al Hamaq (Qatar)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 15:30 Room 208

National diabetes plans on the ground: what works?

Chair: J. Carter (Australia)

14:30 **Creating and implementing a national diabetes strategy in Australia** 0508
Invited Speaker: M. Wooldridge (Australia)

15:00 **Diabetes strategies: a global perspective** 0509
Invited Speaker: R. Colagiuri (Australia)

14:30 - 16:30 Room 209

The independent choices people with diabetes make about their care

Chair: S. Kakar (Canada)
Chair: TBC

14:30 **Complementary and alternative therapies: an overview** 0510
Invited Speaker: C. Yuan (USA)

15:00 **Sifting useful dietary advice from the fads** 0511
Invited Speaker: T. Sanders (United Kingdom)

15:30 **Managing glucose before, during and after exercise in type 1 diabetes** 0512
Invited Speaker: R. Andrews (United Kingdom)

16:00 **Mind and body therapies** 0513
Invited Speaker: T. Dunning (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:30 - 16:30 Room 106

Traditional healers panel - Traditional therapy: from resilience to recovery

Chair: A. Brown (Australia)
Chair: D. Warne (USA)
Invited Speakers: Nganakari Traditional Healers (Australia)

15:30 - 16:30 Plenary 1

Look AHEAD update

Chair: M. d'Emden (Australia)

Look AHEAD update 0518

Invited Speaker: S. Kahn (USA)

Discussion

Invited Speaker: R. Holman (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Plenary 3

Understanding the genetics of diabetes: from the "geneticist's nightmare" to today's reality

Chair: O. Schnell (Germany)

Invited Speaker: *G. Hitman (United Kingdom)* 0520

15:30 - 16:30 Melbourne Room 2

Current management of diabetic nephropathy

Chair: S. Amiel (United Kingdom)

Invited Speaker: *H. Parving (Denmark)* 0521

In memory of Professor Harry Keen

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:30 - 16:30 Room 207

Fighting discrimination against people with diabetes

Chair: S. Langlois (Canada)

Major discrimination problems around the world 0522
Invited Speaker: W. Wientjens (The Netherlands)

Air flight pilots with diabetes 0523
Invited Speaker: D. Cairns (United Kingdom)

Barriers for people living with diabetes in low and middle-income countries 0524
Invited Speaker: S. Ajmal (Pakistan)

15:30 - 16:30 Room 208

Implementing diabetes care in vulnerable populations

Chair: T.S. Ty Willing (Philippines)

Prevention and control of diabetes and non-communicable diseases in Nigeria: challenges and strategic directions 0525

Invited Speaker: S. Chinenye (Nigeria)

Improving access and quality of diabetes care for Palestinian refugees 0526

Invited Speaker: A. Seita (Jordan)

PROGRAMME

FRIDAY 06 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:30 - 10:30 Plenary 2

Metabolic memory and epigenetics

Chair: P. Gluckman (New Zealand)
Chair: TBC

08:30 **The central role of RNA in environment-epigenome interactions** 0527
Invited Speaker: J. Mattick (Australia)

09:00 **Epigenetic regulation of alpha and beta cell fates** 0528
Invited Speaker: R. Humphrey (USA)

09:30 **Intrauterine programming of diabesity** 0529
Invited Speaker: C.S. Yajnik (India)

10:00 **Complications** 0530
Invited Speaker: A. El-Osta (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Plenary 1

Update: type 1 diabetes

Chair: T. Kay (Australia)
Chair: Z. Zhou (China)

08:30 **Immunological update: preclinical** 0531
Invited Speaker: M. von Herrath (USA)

09:00 **Low-dose IL-2 for treatment and prevention type 1 diabetes** 0532
Invited Speaker: D. Klatzmann (France)

09:30 **Clinical trials of immunotherapy for type 1 diabetes in the post GWAS era** 0533
Invited Speaker: F. Waldron-Lynch (United Kingdom)

10:00 **Update on DCCT - 30 years** 0534
Invited Speaker: B. Zinman (Canada)

08:30 - 09:30 Plenary 3

Nutrition and diabetes: from starvation to "healthy lifestyle"

Chair: S. Shera (Pakistan)

Invited Speaker: K. O'Dea (Australia) 0535

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Melbourne Room 1

Diabetes and the brain

Chair: Y. Fujita (Japan)
Chair: G. Lambert (Australia)

08:30 **Hypoglycaemia: physiology and pathophysiology** 0536
Invited Speaker: S. Amiel (United Kingdom)

09:00 **Hypoglycaemia: clinical trials** 0537
Invited Speaker: S. Heller (United Kingdom)

09:30 **Diabetic ketoacidosis: a disease of psyche and soma** 0538
Invited Speaker: F. Cameron (Australia)

10:00 **Diabetes and dementia** 0539
Invited Speaker: R.J. McCrimmon (United Kingdom)

08:30 - 10:30 Melbourne Room 2

Cross talk between cells, fat, muscle and liver

Chair: L. Bach (Australia)
Chair: TBC

08:30 **Pathways integrating vascular dysfunction, beta cell inflammation and insulin resistance in diabetes** 0540
Invited Speaker: J. Nadler (USA)

09:00 **Heart to fat** 0541
Invited Speaker: R. Bassel-Duby (USA)

09:30 **Crosstalk of fat cells to other critical metabolic organs** 0542
Invited Speaker: P. Scherer (USA)

10:00 **Liver to beta cell** 0543
Invited Speaker: B. Thorens (Switzerland)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 203/204

Can we regulate unhealthy food? What lessons from tobacco can be applied to the food industry

Chair: D. Chisholm (Australia)
Chair: S. Sadikot (India)

08:30 **What has worked in the control of tobacco that can be applied to the food industry?** 0544
Invited Speaker: M. Daube (Australia)

09:00 **Regulation of the food industry versus voluntary measures** 0545
Invited Speaker: P. James (United Kingdom)

09:30 **What role do governments have in reducing consumption of unhealthy foods? What can we learn from tobacco in doing this?** 0546
Invited Speaker: D. Yach (South Africa)

10:00 **Working the industry: friend or foe?** 0547
Invited Speaker: N. Unwin (Barbados)

08:30 - 09:30 Room 210/211

IDF award lecture - Education and integrated care

Chair: A. Forbes (United Kingdom)

Power and fragility in health, illness and disease: the role of healthcare providers and patients 0548
Invited Speaker: J. Assal (Switzerland)

Jean-Philippe Assal
Professor Jean-Philippe Assal, former chief, Division of Therapeutic Education for Chronic Diseases, University Hospital, Geneva, and Director of a WHO collaborating centre for research and development of new educational strategies for patients, currently helps various medical centres to develop therapeutic patient education programmes. He is an honorary member, International Committee of the Red Cross/Red Crescent, Geneva and the EASD.

Currently President of the Foundation for Research and Training in Patient Education he holds regular workshops for healthcare providers/patients where emphasis is put on coping with the burden of chronicity by creative approaches through theatre, painting and writing. He has over 300 peer-reviewed articles. Since 1989 over 6,000 participants from over 60 countries have participated in 1-week workshops. He has made 10 full-length films centred on medical psychology and therapeutic education. He created the Theatre of Lived Experience together with Marcos Malavia, a French-Bolivian stage-director, where 50 theatre performances were held in Switzerland, France, Italy, Guadeloupe, Bolivia and Madagascar.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 212/213

The diabetes cure: where are we?

Chair: P.J. Little (Australia)
Chair: L. Siminerio (USA)

08:30 **Encapsulated insulin-producing cells** 0549
Invited Speaker: B. Tuch (Australia)

09:00 **Re-establish functioning islet cells** 0550
Invited Speaker: J. Ludvigsson (Sweden)

09:30 **Funding the cure: how to raise money** 0551
Invited Speaker: S. Alberti (Australia)

10:00 **Funding the cure: how to lobby your politician** 0552
Invited Speaker: G. Barnett (Australia)

08:30 - 10:30 Room 219/220

Screening for type 2 diabetes

Chair: J. Tuomilehto (Finland)
Chair: S. Twigg (Australia)

08:30 **Screening tools: does one size fit all?** 0553
Invited Speaker: K. Khunti (United Kingdom)

09:00 **Should HbA1c have a role in screening?** 0554
Invited Speaker: E.S. Kilpatrick (United Kingdom)

09:30 **Does screening improve outcomes?** 0555
Invited Speaker: S. Griffin (United Kingdom)

10:00 **Cost-effectiveness of screening** 0556
Invited Speaker: W. Herman (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 09:30 Room 207

Diabetes and pregnancy

Chair: G. Crozier (Australia)

08:30 **Living with diabetes and pregnancy in China: difficulties and coping strategies** 0557
Invited Speaker: H. Yang (China)

09:00 **Living with diabetes and pregnancy in Africa: difficulties and coping strategies** 0558
Invited Speaker: E.J. Coetzee (South Africa)

08:30 - 10:30 Room 208

Twinning of diabetes programs between developed and developing nations

Chair: W. Jia (China)
Chair: K. Ramaiya (Tanzania)

08:30 **Rwanda and the University of Pittsburgh** 0559
Invited Speaker: T. Orchard (USA)

09:00 **Madagascar and Switzerland: foot care and TB** 0560
Invited Speaker: H.A. Ramamonjisoa (Madagascar)

09:30 **Diabetes in pregnancy: Israeli-Georgian twinning that resulted in a 17-year successful program** 0561
Invited Speaker: R. Kurashvili (Georgia)

10:00 **A model of diabetes eye care in developing countries** 0562
Invited Speaker: K. Murthy (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 - 10:30 Room 209

Innovative approaches to diabetes education

Chair: A. Belton (Canada)
Chair: Z. Sun (China)

08:30 **Diabetes education strategies in China** 0563
Invited Speaker: X. Guo (China)

09:00 **New developments from the DAFNE program** 0564
Invited Speaker: A. Beckwith (United Kingdom)

09:30 **The diabetes educator's role in preventing diabetes** 0565
Invited Speaker: M.Y. Tan (Malaysia)

10:00 **Health literacy: a challenge for diabetes education** 0566
Invited Speaker: M. Kennedy (Australia)

08:30 - 09:30 Room 106

Strategies to reduce the burden of diabetes and related conditions in Indigenous peoples

Chair: N. Brown (Australia)
Chair: A.W. Khan (Fiji)

Blank white sheet of copy paper approach to community engagement 0567
Invited Speaker: J. Henderson (USA)

Diabetes in the Pacific: what needs to be done? 0568
Invited Speaker: M. Okihiro (USA)

Genetic research: hope, hype and rights 0569
Invited Speaker: M. Hudson (New Zealand)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Plenary 3

Type 2 diabetes: past and future perspectives on therapy

Chair: S. Del Prato (Italy)

Invited Speaker: *H. Lebovitz (USA)* 0570

09:30 - 10:30 Room 210/211

Peer educators are more effective than health professionals

Chair: J. Grumitt (United Kingdom)

Health professional 0571
Invited Speaker: J. Davidson (USA)

Patient's peer 0572
Invited Speaker: I.A. Nwaturuocha (Nigeria)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

09:30 - 10:30 Room 207

Living with diabetes for more than 50 years

Chair: P. Madden (USA)

Invited Speaker: *R. Raab (Australia)* 0573

Invited Speaker: *W. Johnston (New Zealand)* 0574

09:30 - 10:30 Room 106

Diabetes education in disadvantaged and culturally diverse populations: making it work

Chair: M. McGill (Australia)

Invited Speaker: *C. Bushbreaker (USA)* 0575

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Plenary 2

Late-breaking clinical trials

Chair: T. Pieber (Austria)
Chair: TBC

SAVOR 0576
Invited Speaker: I. Raz (Israel)

EXAMINE 0577
Invited Speaker: S. Heller (USA)

Heart failure and DPP-IV inhibitors 0578
Invited Speaker: TBC

Panel Discussion

10:45 - 12:45 Plenary 1

Insulin resistance and metabolic syndrome

Chair: R. Eckel (USA)
Chair: A. Hanley (Canada)

10:45 **Distribution of glucose tolerance among women with previous history of gestational diabetes mellitus in urban India** OP-0579
N. Tandon, Y. Gupta, D. Kapoor, S. Doddamaneni, R. Rozati, N. Bhatla, N. Gupta, D. Praveen, R. Joshi, A. Desai, D. Prabhakaran, A. Patel, P. Reddy (India)

11:00 **Prevalence of gestational diabetes mellitus diagnosed by the IADPSG's criteria and the WHO s criteria in urban Tianjin, China** OP-0580
C. Zhang, Y. LI, L. Wang, S. Xin, M. Li, W. Li, J. Leng, Z. Yu, G. Hu, J. Chan, H. Tian, X. Yang (China)

11:15 **Vitamin D status in early pregnancy and development of gestational diabetes** OP-0581
L. Dodds, Y. Giguere, C. Woolcott, B.A. Armson, J.C. Forest, H. Weiler (Canada)

11:30 **Worldwide prevalence of gestational diabetes mellitus according to the IADPSG criteria: a systematic review** OP-0582
M. Falavigna, M. Sekerija, M.I. Schmidt, G. Roglic, S. Colagiuri, B.B. Duncan, H.J. Schunemann (Brazil)

11:45 **Are abdominal obesity and diabetes similarly distributed using different measures of socioeconomic status in urban South Asia?** OP-0583
M.K. Ali, B. Binukumar, R. Shivashankar, R. Pradeepa, M. Deepa, Z. Fatmi, M.M. Kadir, V. Mohan, N. Tandon, D. Prabhakaran, K.M. Narayan, F.O.R. CARRS Study Group (USA)

12:00 **The point of no return? Beta cell function and insulin resistance in prediabetes and normoglycemia** OP-0584
L. Staimez, M.B. Weber, H. Ranjani, M.K. Ali, R.M. Anjana, V. Mohan, K.M.V. Narayan (USA)

12:15 **A hospital based study in Bangladesh on the cost of diabetes care and its determinants** OP-0585
A. Afroz, M.A. Hafez, L. Ali (Bangladesh)

12:30 **Win, win outcomes: "Diabetes in the Community" Israeli program and its influence on health outcomes and cost containment** OP-0586
M. Goldfracht, M. Rotem, K. Zeiry, C. Key, M. Oren, N. Lieberman (Israel)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Plenary 3

Insulin action and inflammation

Chair: G. Lancaster (Australia)
Chair: S. Masters (Australia)

10:45 **Dimerisation and palmitoylation of the adiponectin receptors, AdipoR1 and AdipoR2, is required for efficient cell-surface expression** OP-0587
S. Keshvari, J. Whitehead (Australia)

11:00 **Glucose transporter 12 gene expression is upregulated with high glucose, feeding and obesity via CREB/CRTC activation** OP-0588
V. Hoang, A. Wilson-O'Brien, S. Galic, S. McGee, S. Rogers (Australia)

11:15 **Mapping the AMPK- and insulin-regulated signalling networks in skeletal muscle** OP-0589
N.J. Hoffman, S.J. Humphrey, P. Yang, D.J. Fazakerley, D.E. James (Australia)

11:30 **GLUT4 vesicle fusion regulator DOC2b is required for systemic glucose homeostasis** OP-0590
R. Nomiyama, M. Emoto, N. Fukuda, K. Matsui, A. Sakane, J. Miyoshi, T. Sasaki, Y. Tanizawa (Japan)

11:45 **IL-22 suppresses beta-cell endoplasmic reticulum stress and restores insulin production in type 2 diabetes** OP-0591
S.Z. Hasnain, B. Harcourt, D. Borg, H. Tong, I. Das, R. Wang, A.C.-H. Chen, J. Forbes, J. Whitehead, J. Prins, M.A. McGuckin (Australia)

12:00 **Inflamed adipose tissue promotes monocytosis via macrophage activation of the NLRP3 inflammasome and IL-1beta in obesity** OP-0592
A.J. Murphy, P.R. Nagareddy, I.J. Goldberg (Australia)

12:15 **Role of neutrophil associated lipocalin-2 (NGAL) in the increased MMP-9 activity in diabetic wound healing in rodents** OP-0593
M. Abdollahi, T. Ng, S. Aamidor, A. Rezaeizadeh, S. Twigg, D. Min, S. McLennan (Australia)

12:30 **Global 12/15-lipoxygenase deficiency leads to increased IL-23 in the pancreas of NOD-Alox15null mice** OP-0594
M.A. Morris, B. Haynes, S. Green-Mitchell, N.S. Kuhn, J.L. Nadler (USA)

10:45 - 12:30 Melbourne Room 1

Insulin resistance - experimental

Chair: Y. Seino (Japan)
Chair: J. Whitehead (Australia)

10:45 **HSP72 preserves insulin sensitivity and prevents peripheral tissue lipotoxicity by increasing oxidative metabolism in skeletal muscle** OP-0596
D.C. Henstridge, C.R. Bruce, K. Tory, A. Kolonics, B.G. Drew, N. Watson, E. Estevez, R.S. Lee-Young, M.J. Watt, S.L. McGee, A.L. Hevener, M.A. Febbraio (Australia)

11:00 **Heat shock protein 72 is a critical regulator of the E3-ligase parkin and subsequently modulates insulin sensitivity in skeletal muscle** OP-0597
B.G. Drew, J.A. Le, V. Ribas, D.C. Henstridge, L. Vergnes, K. Reue, M.A. Febbraio, A.L. Hevener (Australia)

11:15 **Fine particulates and ozone exposure induces inflammation in epicardial and perirenal adipose tissues in a rat model** OP-0598
Q. Sun, L. Sun, C. Liu, X. Xu, Z. Ying, S. Rajagopalan, J. Harkema, Z. Fan (USA)

11:30 **Overexpression of a mitochondrial deacetylase, SIRT3, in liver and its effects on metabolic parameters during excess lipid availability** OP-0599
B. Osborne, G.J. Cooney, N. Turner (Australia)

11:45 **Identification of the hepatoprotective drug matrine as a promising novel therapeutic for fatty liver and insulin resistance** OP-0600
X.Y. Zeng, H. Wang, F. Bai, X. Zhou, S.P. Li, L.P. Ren, H.L. Jiang, L.H. Hu, J.M. Ye (Australia)

12:00 **The impact of muscle specific deletion of glycogen synthase on glucose tolerance and insulin sensitivity in mice** OP-0601
C. Xirouchaki, A. Huang, Z. Ruan, A. Blair, J. Proietto, S. Andrikopoulos (Australia)

12:15 **Aspalathin-enriched green rooibos ameliorates peripheral insulin resistance in muscle cells: the role of major phenolic compounds** OP-0602
S.E. Mazibuko, C.J.F. Muller, E. Joubert, D. De Beer, R. Johnson, A.R. Opoku (South Africa)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Melbourne Room 2

Neuropathy, the foot and the brain

Chair: N. Efron (Australia)
Chair: R. Malik (United Kingdom)

10:45 **Awareness of foot health status in patients with type 2 diabetes: The Fremantle Diabetes Study Phase II** OP-0603
M. Baba, W.A. Davis, L. Foley, T.M.E. Davis (Australia)

11:00 **Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients?** OP-0604
J. Shen, F. Liu, H. Zeng, L.X. Li, F.D. Lu, Y.Q. Bao, W.P. Jia (China)

11:15 **Corneal nerve fibre length is reduced in diabetic individuals who develop 3-year incident diabetic neuropathy** OP-0605
N. Pritchard, K. Edwards, S. Srinivasan, C. Dehghani, D. Vagenas, A.W. Russell, R.A. Malik, N. Efron (Australia)

11:30 **Type 1 diabetic patients with neuropathy : prevalence and profile of sleep apnea syndrome** OP-0606
J.P. Courrèges, E. Ghanassia, A. Iosup, P. Fisher, H. Banciu, J.F. Thuan, H. Bonnaure, N. Vigier Simmore, N. Bastide (France)

11:45 **Longitudinal Assessment of Neuropathy in Diabetes using novel ophthalmic MARKers (LANDMark): baseline findings** OP-0607
N. Efron, N. Pritchard, K. Edwards, D. Vagenas, G.P. Sampson, A. Russell, I.N. Petropolous, A. Uazman, H. Fadavi, M. Tavakoli, R.A. Malik (Australia)

12:00 **Type 2 diabetes mellitus and cerebral atrophy – the role of advanced glycation end-products** OP-0608
C. Moran, G. Muench, R. Beare, L. Blizzard, A. Venn, T.G. Phan, J. Forbes, V. Srikanth (Australia)

12:15 **Hippocampal asymmetry is associated with poorer cognitive functioning in older adults with type 2 diabetes** OP-0609
N.T. Milne, R.S. Bucks, S.E. Starkstein, J. Mace, M. Nelson, W.A. Davis, D.G. Bruce (Australia)

10:45 - 11:45 Room 203/204

Diabetes and cancer

Chair: L. Campbell (Australia)

Invited Speaker: J. Johnson (Canada) 0610

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 11:45 Room 210/211

Developing effective diabetes support

Chair: C. Crosbie (Australia)

10:45 **Lowering postprandial glycaemia with a rice-mix in Asian people with type 2 diabetes** OP-0611
A. Liu, Z. Zhang, J. Kane, B. Venn (New Zealand)

11:00 **Using Weight Watchers approach to lifestyle modification to reduce risk for type 2 diabetes** OP-0612
D. Marrero, K. Palmer, S. Rost, A. Frederick, K. Miller-Kovach, C. Saha (USA)

11:15 **The application of mini nutritional assessment and geriatric nutritional risk index for foot outcome among hospitalized diabetic patients** OP-0613
B.R. Kao, H.Y. Chen, H.M. Yang, Y.Y. Huang (Taiwan)

11:30 **A randomized controlled trial to assess the effects of substituting brown rice for white rice on diabetes risk factors in India** OP-0614
V. Mohan, D. Spiegelman, M. Ramya Bai, P. Vijaylakshmi, N.M. Wedick, K. Krishnaswamy, R.M. Anjana, V. Malik, V. Sudha, B. Hong, F.B. Hu, W.C. Willett (India)

10:45 - 12:45 Room 212/213

Obesity and complications - experimental aspects

Chair: T. Allen (Australia)
Chair: M. Lean (United Kingdom)

10:45 **Nesfatin-1 knockdown in hypothalamic increases gluconeogenesis by mTOR/STAT3 pathway** OP-0615
L. Li, G. Yang (China)

11:00 **ER stress induces insulin and leptin resistance in striatum and amygdala of obese rats and its inhibition restores body weight** OP-0616
G. de Castro, L. Weissmann, P. Quaresma, C. Katashima, F. Condes, M. Saad, P. Prada (Brazil)

11:15 **Ginsenoside Rb1 reduces inflammation and central leptin resistance associated with high-fat diet-induced obesity** OP-0617
Y. Wu, X.F. Huang, A. Szabo, Y. Yu (Australia)

11:30 **DPP-4 inhibition in diabetic rats leads to activation of the cytoprotective transcription factor CREB in pancreatic beta cells and brain** OP-0618
S. Pugazhenthi, R. Bouchard, L. Qin (USA)

11:45 **Paternal high fat diet promotes sex specific metabolic defects in second generation rat offspring** OP-0619
V. Lecomte, C.A. Maloney, N.A. Youngson, M.J. Morris (Australia)

12:00 **The role of nox1 derived oxidative stress in diabetic associated atherosclerosis development** OP-0620
S. Gray, E. Di Marco, J. Okabe, C. Szyndralewiez, F. Heitz, M. Cooper, J. Chin-Dusting, R. Touzy, K. Wingler, H. Schmidt, K. Jandeleit-Dahm (Australia)

12:15 **Deletion of bone marrow or vascular derived receptor for advanced glycation end products attenuates diabetes-associated atherosclerosis** OP-0621
C. Koulis, P. Kanellakis, M.E. Cooper, K.A. Jandeleit-Dahm, T.J. Allen (Australia)

12:30 **Nox4 derived oxidative stress and its role in the development of diabetic nephropathy** OP-0622
J.C. Jha, S.P. Gray, J. Okabe, A. El-Osta, K. Wingler, C. Szyndralewiez, H. Freddy, M. Cooper, H. Schmidt, K. Jandeleit-Dahm (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 219/220

Type 1 diabetes epidemiology update

Chair: M. Craig (Australia)
Chair: N. Tajima (Japan)

10:45 **Incidence and early mortality: a global view** 0623
Invited Speaker: C. Patterson (United Kingdom)

11:15 **Environmental causes: prospective birth cohorts** 0624
Invited Speaker: M. Rewers (USA)

11:45 **Epidemiology of type 1 diabetes complications** 0625
Invited Speaker: K. Donaghue (Australia)

12:15 **Care delivery: the challenge of limited resources and increasing costs** 0626
Invited Speaker: M. Silink (Australia)

10:45 - 11:45 Room 207

Lipids

Chair: G. Muscat (Australia)

10:45 **A novel FXR regulated transcriptional repressor involved in the regulation of bile acid and glucose homeostasis** OP-0627
T. Vallim, L. Hagey, H. Ahn, P.A. Edwards (USA)

11:00 **IDOL-mediated degradation of lipoprotein receptors: in vitro and in vivo studies** OP-0628
A. Calkin, B.T. Goult, D. Weissglas-Volkov, L. Zhang, L. Fairall, C. Hong, P. Pajukanta, J.W.R. Schwabe, P. Tontonoz (Australia)

11:15 **Localized immune response to oxidized lipids in Abcg1–/– mice – a new model for lipid-driven autoimmunity** OP-0629
E.J. Aguiar Vallim, A. Gonen, X. Que, C. Diehl, J.L. Witztum, A. Baldan, P.A. Edwards (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 208

Contemporary issues in diabetes care in the developing world

Chair: B. Mankovsky (Ukraine)
Chair: J. Weng (China)

10:45 **Global use of HbA1c for diagnosis of diabetes and pre-diabetes: wise or unwise?** 0630
Invited Speaker: S. Dagogo-Jack (USA)

11:15 **Dental care and diabetes: a global perspective** 0631
Invited Speaker: M. Gillis (Canada)

11:45 **Bariatric surgery in developing nations: ethics and economics** 0632
Invited Speaker: G. Segal-Lieberman (Israel)

12:15 **Treating type 2 diabetes in LMICs** 0633
Invited Speaker: V. Fonseca (USA)

10:45 - 12:45 Room 209

Involving people in developing and using therapies

Chair: C. Bailey (United Kingdom)
Chair: L. Keuky (Cambodia)

10:45 **Quality use of medicines** 0634
Invited Speaker: J. Cramer (USA)

11:15 **Involving people with diabetes in developing medicines** 0635
Invited Speaker: J. Chan (China)

11:45 **Effective self-management and adherence interventions** 0636
Invited Speaker: E. Walker (USA)

12:15 **Access to medicines in developing and poorer countries** 0637
Invited Speaker: S. Bahendeka Karaireho (Uganda)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:45 - 12:45 Room 106

Determinants of diabetes in indigenous populations

Chair: J. Reading (Australia)
Chair: TBC

10:45 **What factors drive the gap in diabetes rates between Aboriginal and non-Aboriginal people in non-remote New South Wales?** OP-0638
R. Reeve, J. Church, M. Haas, W. Bradford, R. Viney (Australia)

11:00 **Does gender differences in the acculturation process explain the higher prevalence of diabetes in women among Brazilian Xavante Indians ?** OP-0639
L.J. Franco, A.L. Dal Fabbro, D.S. Sartorelli, L.P. Soares, A.S. Silva, L.F. Franco, P.C. Kuhn, R.S. Moisés, J.P.B. Vieira-Filho (Brazil)

11:15 **Lifetime risk of diabetes in Aboriginal people in a remote community** OP-0640
Z. Wang, W. Hoy (Australia)

11:30 **Sex differences in underweight, overweight, low protein intake and diabetes risk in Maasai following season-dependent food insecurity** OP-0641
D.L. Christensen, D.L. Mwaniki, M.K. Boit, D. Faurholt-Jepsen, H. Friis (Denmark)

11:45 **Diabetes and hypertension in a Santhal tribe in Bangladesh: a population based study** OP-0642
M.A. Sayeed, M.M. Rhaman, M.T. Hossain, P.A. Khanam, T. Begum, M.A.H.G. Morshed, S. Sayeed, A. Banu, H. Mahtab (Bangladesh)

12:00 **Prevalence and associates of depression in Aboriginal vs Anglo-Celt patients with type 2 diabetes: The Fremantle Diabetes Study Phase II** OP-0643
W.A. Davis, K. Hunt, T.C. Skinner, D.G. Bruce, S.E. Starkstein, D. McAullay, T.M.E. Davis (Australia)

12:15 **A study on prevalence of obesity and diabetes among a indigenous Vedda population of Sri Lanka** OP-0644
C.J. Kande Vidanalage, D.A. Adikariwattage, C. Sivagnanasooryar, C. Hettiarachchi, W. Mathangaweera (Sri Lanka)

12:30 **Vitamin D supplementation predicts improvement in insulin-resistance among Argentine Indian school children** OP-0645
V. Hirschler, G. Maccallini, C. Aranda, M. Hidalgo, C. Molinari, M. Sanchez (Argentina)

11:45 - 12:45 Room 203/204

Application of modern genetics to human disease: what we can learn from the past

Chair: M. McCarthy (United Kingdom)

Invited Speaker: *E. Willerslev (Denmark)* 0646

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:45 - 12:45 Room 210/211

Supportive care systems

Chair: A. Belton (Canada)

11:45 **Treatment pathways and target achievement in patients with co-morbid type-2 diabetes and hypertension – the DIALOGUE registry** OP-0647
D. Tschöpe, R.E. Schmieder, E. Duetting, P. Bramlage, S. Schneider, A.K. Gitt (Germany)

12:00 **My Diabetes My Way: an electronic personal health record for diabetes care** OP-0648
S.G. Cunningham, D.J. Wake, A.D. Morris, A. Waller, J. Walker (United Kingdom)

12:15 **Use of a traffic light system to aid the management of type 2 diabetes – insights from the Type2Care clinical audit** OP-0649
J. Barlow, G. Krassas, H. Palmer (Australia)

12:30 **Evaluating the management of type 2 diabetes in primary care setting through a novel multi-step needs assessment process** OP-0650
K. Bowering, S. Harris, L. Leiter, V. Woo, J.F. Yale (Canada)

11:45 - 12:45 Room 207

Late-breaking abstracts - Public Health and Epidemiology

Chair: N. Sulaiman (United Arab Emirates)

11:45 **Effect of population screening for type 2 diabetes and CVD risk factors on mortality: parallel cohort study of 1,946,061 Danish adults** OP-0651
R.K. Simmons, S.J. Griffin, D.R. Witte, K. Borch-Johnsen, T. Lauritzen, A. Sandbæk (United Kingdom)

12:00 **Severe hypoglycaemia and mortality post cardiovascular events in Swedish type 1 diabetes patients** OP-0652
T. Lung, D. Petrie, P. Clarke, A. Palmer, A. Svensson, B. Eliasson (Australia)

12:15 **IDF Diabetes Atlas: global estimates for hyperglycaemia in pregnancy in 2013** OP-0653
L. Guariguata, U. Linnenkamp, D. Whiting, N. Han Cho (Belgium)

12:30 **Making tracks towards closing the gap for Indigenous Australians in diabetes** OP-0654
A. Joseph, K. Hird, M. Nowak (Australia)

POSTER DISCUSSION
TUESDAY 03 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Experimental - metabolic

Chair: S. Twigg (Australia)

Regulation of glucose homeostasis by reversible lysine acetylation of GAPDH PD-0655
S. Bond, K. Walder, K. Howlett, S. McGee (Australia)

Sitagliptin and gliclazide protect against progressive non-alcoholic steatohepatitis in a model induced by high fat feeding and diabetes PD-0656
J. Ren, X. Wang, C. Yee, J. Bonner, A. Rezaeizadeh, S.V. McLennan, S.M. Twigg (Australia)

Development and validation of a high-sensitivity ELISA forspecific measurement of glucagon in rat and mouse samples PD-0657
M. Gäreskog, A. Carlsson, M. Schwanbeck, E. Karamihos, C. Gäredal, H. Ritzén, M. Simonsson, E. Ludvigsen, R. Gunnarsson (Sweden)

Anti-metabolic activity and its mechanism of fermented barley extract in stroke-prone spontaneously hypertensive rats PD-0658
A. Ardiansyah, H. Shirakawa, K. Ueda, K. Oguchi, P.E. Giriwono, S. Sato, H. Hokazono, K. Hiwatashi, S. Takahashi, M. Komai (Indonesia)

Metformin does not prevent the development of fatty liver in insulin resistance rats on a high fat diet PD-0659
S. Roux, S.C. Tshidino, S. Tilli, J. MacKenzie, T. Koekemoer, N. Smith, G. Dealtry (South Africa)

Investigation of inflammation intracellular signaling pathways in type 2 diabetes mellitus PD-0660
N.T. Pietrani, K.F. Rodrigues, A.A. Bosco, L.O. Perucci, L.P. Sousa, K.B. Gomes (Brazil)

Prevention of liver damages by targeting different physiological mechanisms in a new murine NASH model associated with metabolic syndrome PD-0661
T. Sulpice, F. Briand, B. Prunet-Marcassus, C. Dubuquoy (France)

Islet cell trajectories during development and after high fat programming in neonate, weanling and adolescent Wistar rats PD-0662
M.E. Cerf, C.S. Chapman, J. Louw (South Africa)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Maternal high fat diet alters skeletal muscle gene expression, insulin signalling and mitochondrial function in adult rat offspring PD-0663

C. Latouche, S.E. Heywood, S.L. Henry, M. Ziemann, R. Lazarus, A. El-Osta, J.A. Armitage, B.K. Kingwell (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Clinical - complications

Chair: L. Burrell (Australia)

The frequency and risk factors of diabetic foot ulcers in diabetic patients PD-0682
F. Sarac, S.E.F.A. Sarac, A. Tütüncüoglu, S. Savas, F. Akcicek (Turkey)

Urinary type IV collagen, a sensitive biomarker for vascular function in type 2 diabetes PD-0683
M. Morita, S. Yano, Y. Ishibashi, T. Sugimoto (Japan)

Disruption of components of VEGF angiogenic signaling system in metabolic syndrome: findings of a study in rural Bangladeshi women PD-0684
S. Jesmin, A. Al Mamun, N.A. Zahan, S. Akter, M. Rahman, M. Islam, T. Khatun, A. Rahman, F. Sohael, S.N. Sultana, T. Mizutani (Bangladesh)

The association between coronary artery calcium score and apolipoprotein A-1 PD-0685
H.A. Seo, Y.K. Choi, K.H. Bae, J.H. Jeon, J.Y. Jeong, K.G. Park, J.G. Kim, E.H. Kim, I.K. Lee (Korea)

QT prolongation during hypoglycaemia in an ambulatory setting: detection by simultaneous holter and continuous glucose monitoring PD-0686
A. Lee, B. Brooks, L. Simmons, M. Kilborn, J. Wong, S.M. Twigg, D. Yue (Australia)

ProBNP predicts future vascular events independently from the baseline coronary artery disease state in patients with and without diabetes PD-0687
P. Rein, C.H. Saely, A. Vonbank, H. Drexel (Austria)

Serum omentin significantly predicts cardiovascular events both in patients with and without the metabolic syndrome PD-0688
C.H. Saely, A. Muendlein, A. Leiherer, A. Vonbank, D. Zanolin, K. Geiger, P. Rein, H. Drexel (Austria)

Altered cardiovascular risk markers, cardiac structure and cardiac function in adolescents with type 1 diabetes PD-0689
L.S. Conwell, T. Baskerville, D. Duncan, R.M. Greer, J.S. Coombes, J. Cardinal, G.M. Leong, M. Harris, K. Kostner (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes PD-0690

S. Nicholls, K. Malmberg, M. Hanefeld, A.M. Lincoff, N. Mudie, M. Herz (Australia)

Restenosis after percutaneous transluminal coronary angioplasty in individuals with different categories of glucose tolerance PD-0691

L. Zhang, Y. Gu, Y. Dong, X. Zhang, D. Shang (China)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Human physiology

Chair: M. Horowitz (Australia)

Impaired GLP-1 response to intraduodenal glucose in type 2 diabetes is accounted for by BMI PD-0712
T. Wu, M.J. Bound, J. Ma, C.F. Deacon, K.L. Jones, M. Horowitz, C.K. Rayner (Australia)

Novel receptor-mediated bioassays accurately reflect bioactive levels of GIP and GLP-1 in human subjects PD-0713
Y. Fujita, T. Yanagimachi, J. Honjo, Y. Takiyama, A. Abiko, Y. Makino, M. Haneda (Japan)

The determinants of non-alcoholic fatty liver disease in South African females PD-0714
N. Naran, M. Haagensen, N.J. Crowther (South Africa)

Gender does not significantly modulate the association between inflammation and the metabolic syndrome among patients with stable CAD PD-0715
C.H. Saely, A. Vonbank, P. Rein, A. Leiherer, D. Zanolin, H. Drexel (Austria)

Serum vaspin and insulin resistance in Bangladeshi type 2 diabetic subjects PD-0716
L. Ali, F. Tasnim, M.O. Faruque (Bangladesh)

Chronic elevation of ?-glutamyltransferase may be a warning sign for diabetes and metabolic syndrome PD-0717
M. Macharia, T.E. Matsha, R.T. Erasmus, M.S. Hassan, A.P. Kengne (South Africa)

Insulin resistant obese subjects exhibit impaired glucagon suppression after glucose load PD-0718
G. Pacini, B. Ahren (Italy)

Effects of chronic HDL elevation with cholesteryl ester transfer protein inhibition on insulin secretion PD-0719
A.L. Siebel, A.K. Natoli, F.Y. Yap, A.L. Carey, M. Reddy-luthmoodoo, D. Sviridov, C. Kiu Weber, G. Meneses-Lorente, C. Maugeais, J.M. Forbes, B.A. Kingwell (Australia)

Lipoprotein (a), the metabolic syndrome and vascular risk in angiographied coronary patients PD-0720
A. Vonbank, C.H. Saely, P. Rein, H. Drexel (Liechtenstein)

13:00 - 14:00 Poster Area

Insulin

Chair: D. Simon (France)

The real world treatment outcome of T2DM patients switching from premixed to basal insulin plus OADs in China by Lantus registry study group PD-0740
W. Yang (China)

Short and long-term cost-effectiveness of switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes PD-0741
R. Baabbad, A.A. Shafie, E. Hammerby, A. Nikolajsen, M.F.B. Andersen, O. Henriksen, P. Home (Saudi Arabia)

Comparison of theoretical doses of insulin detemir and insulin glargin estimated from insulin action indices in Japanese diabetic patients PD-0742
A. Sakashita, C. Morisawa, Y. Abe, T. Morita, Y. Akiyama, N. Oshitani, M. Matsuda (Japan)

Use of an automated bolus advisor improves multiple outcomes in patients treated with MDI therapy: results from ABACUS PD-0743
I. Cranston, D.A. Cavan, R. Ziegler, K. Barnard, J. Ryder, C.G. Vogel, C.G. Parkin, W. Koehler, B. Petersen, I. Vesper, M.A. Schweitzer, R.S. Wagner (United Kingdom)

Insulin degludec improves long-term glycaemic control with less hypoglycaemia than insulin glargine in advanced type 2 diabetes PD-0744
A. Garber, A.B. King, S. Del Prato, S. Sreenan, M.K. Balci, M. Muñoz-Torres, J. Rosenstock, C.T. Hansen, M. Niemeyer, P. Hollander (USA)

Insulin degludec/insulin aspart has distinct prandial and basal glucose-lowering effects at steady state in subjects with type 1 diabetes PD-0745
T. Heise, L. Nosek, O. Klein, H. Hastrup, S. Chenji, H. Haahr (Germany)

The FullSTEP study: step-wise addition of insulin aspart to basal insulin therapy compared with basal bolus therapy PD-0746
H. Rodbard, V.E. Visco, H. Andersen, L. Conradsen Hiort, D.H.W. Shu (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Achieving FPG target without nocturnal hypoglycaemia: a pooled analysis of studies in T2D comparing insulin degludec vs insulin glargine PD-0747

B. Zinman, J. Vora, M. Niemeyer, M.A. Gall, C. Mathieu (Canada)

HbA1c and weight development one year after initiation of continuous subcutaneous insulin injection therapy in adult subject PD-0748

E. Hommel, H.U. Andersen, H.C. Andersen, J.N. Christensen, K. Rytter, A. Hougaard, A. Grynnerup, M. Riderstråle (Denmark)

Does continous subcutaneous insulin infusion increase or decrease psychological distress and depression in type 1 diabetes patients PD-0749

E. Hommel, A. Hougaard, H.-C. Andersen, J. Christensen (Denmark)

13:00 - 14:00 Poster Area

Experimental animal models

Chair: TBC

Diabetes mellitus type I protects from development of an allergic contact dermatitis in mice PD-0759
T. Schmidt, V. Raker, N. Lorenz, K. Steinbrink (Germany)

The effects of glycemia on pancreatic islet cell morphology in Nile grass rats PD-0760
K. Yang, M. Rajagopal, Y. Sauvé, C. Chan (Canada)

Partial deletion of the selenoprotein SEPS1 in ß-cells leads to impairment in insulin secretion. PD-0761
S. Weng, N. Wong, J. Proietto, S. Andrikopoulos (Australia)

Selenium-enriched milk casein causes hepatic insulin resistance in rats PD-0762
P. Stahel, S.R.L. Cieslar, J.M. Warrington, J.J. Kim, M. Corredig, C. Xiao, J.P. Cant (Canada)

Combination of the herbal medicine with voluntary running exercise improves in vivo insulin sensitivity in diabetic rats PD-0763
O. Khookhor, Y. Sato (Japan)

Alteration of sweet taste in high-fat diet induced obese rats after 4 weeks treatment of exenatide PD-0764
X.J. Zhang, Y.Q. Wang, Y. Long, L. Wang, Y. Li, F.B. Gao, H.M. Tian (China)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Clinical diabetes and genetics

Chair: TBC

Diabetes and smoking cessation are oppositely associated with liver cancer mortality in the middle-aged and elderly PD-0770
C.H. Chiang, K.C. Huang, S.H. Hung, W.Y. Lin, L.T. Lee, P.K. Sung (Taiwan)

High secretion and low hepatic extraction yield hyperinsulinemia in non-diabetic adrenal incidentaloma irrespective of Cushing status PD-0771
C.H. Anderwald, A. Tura, A. Gessl, A. Luger, G. Pacini, M. Krebs (Italy)

Extra- and intracranial blood flow in patients with type 2 diabetes mellitus PD-0772
Y. Saienko, A. Kovalenko, B. Mankovsky (Ukraine)

Association between Apolipoprotein B/ Apolipoprotein A-1 and arterial stiffness in metabolic syndrome PD-0773
J. Park, J. Nam, M. Kim, H. Baek, J. Ha, C. Kyung, S. Kim, S. Kang, K. Kim, C. Ahn (Korea)

Genome wide association study of glycemic related traits in Indians PD-0774
N. Tandon, N.M. Khan, O.P. Dwivedi, I. Kaur, A.K. Giri, D. Bharadwaj (India)

Impact of diabetes mellitus on spectrum of hepatic encephalopathy in patients with liver cirrhosis PD-0775
N.A. Jadoon, Z. Butt, K. Mushtaq, A. Shahzad, M. Hussain, F.U. Sulehri (Pakistan)

Replication of an association study between type 2 diabetes and IGF2BP2 in the Han Chinese population PD-0776
S.M. Zhang, J.Z. Xiao, Q. Ren, X.Y. Han, Y. Tang, W.Y. Yang, L. Ji (China)

Comparison of clinical usefulness between type 2 diabetes genetic risk score and family history in Japanese type 2 diabetic patients PD-0777
M. Iwata, S. Maeda, Y. Kamura, A. Takano, H. Kato, S. Murakami, K. Higuchi, R. Temaru, S. Asamizu, H. Oda, Y. Fukushima, K. Tobe (Japan)

13:00 - 14:00 Poster Area

Pregnancy and gestational diabetes

Chair: J. Gunton (Australia)

HbA1c in gestational diabetes mellitus (GDM): relationship to the OGTT and pregnancy outcomes PD-0793
L. Molyneaux, G. Ross, K. Tan, A. Harding, M. Constantino, D.K. Yue, J. Wong (Australia)

Benefits of medical nutrition intervention for impaired glucose tolerance in Taiwanese women PD-0794
P. Wang, Y.H. Yan, M.C. Lu (Taiwan)

A pilot study of hemodynamic parameters in Indian normal and diabetic pregnancies by noninvasive impedance cardiography PD-0795
S. Singh, N. Tandon, G. Kachhawa, A. Kumari, N. Shah, N. Gupta, A. Kriplani, A.C. Ammini, S.S. Malhotra (USA)

Predictors and post pregnancy sequelae of gestational diabetes mellitus in 102 urban healthy South Asian women with risk factors for T2DM PD-0796
M. Wijesuriya, L. Vasantharajah, M. Gulliford, G.C. Viberti, L. Gnudi, J. Karalliedde (Sri Lanka)

Predictibility of foetal gestational age by transcerebeller diameter measurements in diabetic pregnancies PD-0797
S.N. Masood, T. Zubairi (Pakistan)

An evaluation of adipokines for predicting macrosomia in gestational diabetes mellitus PD-0798
B. Crinall, P. Venkat, J. Burgess (Australia)

Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus PD-0799
M. Oncul, A. Tuten, H. Cicekci, R. Gelisgen, A. Benian, H. Uzun (Turkey)

To compare capillary blood glucose and venous plasma glucose for diagnosis of gestational diabetes mellitus: the IDF WINGS project PD-0800
V. Mohan, B. Bhavadharini, M.M. Mahalakshmi, K. Maheswari, G. Kalaiyarasi, R.M. Anjana, M. Priya, M. Belma, A. Belton, A. Kayal (India)

13:00 - 14:00 Poster Area

Placental FGF21 expression is increased in gestational diabetes mellitus (GDM) PD-0801

M. Dekker Nitert, H.L. Barrett, H.D. McIntyre, L.K. Callaway (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Comorbidities and complications of type 2 diabetes

Chair: W. Hoy (Australia)

Body-mass index, waist-size, waist-hip ratio and cardiovascular risk factors in North Indian Punjabi diabetic population PD-0817
R. Kapoor, R. Duggal, S. Kapoor, R. Kapoor (India)

Filtration markers as predictors of end-stage renal disease and mortality in type 2 diabetes: CKD Biomarkers Consortium PD-0818
M.C. Foster, L.A. Inker, C.Y. Hsu, J.H. Eckfeldt, A.S. Levey, M.E. Pavkov, B.D. Myers, P.H. Bennett, P.L. Kimmel, R.S. Vasan, J. Coresh, R.G. Nelson (USA)

Real-life observation of the effectiveness and tolerability of vildagliptin in Hispanic Native American T2DM patients PD-0819
P.M. Paldánius, G. Bader (Switzerland)

Does hyperfiltration exist in Indigenous Australians with and without diabetes? PD-0820
E.I. Ekinci, J.T. Hughes, M. Chatfield, P.D. Lawton, G.D. Jones, A. Ellis, A. Cass, W. Hoy, R.J. MacIsaac, K. O'Dea, G. Jerums, L.J. Maple-Brown (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Patient perspectives

Chair: R. Scibilia (Australia)

Education on native language at diabetes school as possibility for fighting discrimination PD-0837
I. Vlasenko, V. Ocheretenko (Ukraine)

Culturally competent, distance accessible advanced management of diabetes (CCDA-AMD) PD-0838
M. Hess, M. Talley, D. Mompoint-Williams, R. Saul, P. McKie (USA)

Between ideals and realities: realistic evaluation as a means of grasping the reality of patient education PD-0839
N. Schwennesen, V. Stenov, U. Møller Hansen, I. Willaing (Denmark)

Challenges met by diabetes educators when adapting to a new patient-centred, participatory concept of teaching PD-0840
T. Helms Andersen, N.F. Hempler, I. Willaing, U.M. Hansen (Denmark)

Gaps between Japanese patients and physicians in GAPP Survey data PD-0841
S. Harashima, N. Inagaki (Japan)

The experiences and needs of family members/carers of people with diabetes at the end of life PD-0842
S. Savage, T. Dunning, N. Duggan, P. Martin (Australia)

How can we deliver diabetes care to ethnic minority populations - a single city case survey study PD-0843
P. Zeh, H.K. Sandhu, P. Zeh, A.M. Cannaby, J.A. Sturt (United Kingdom)

Correlates of patient perception of access to support PD-0844
M.C. Rossi, B. Pintaudi, G. Lucisano, S. Gentile, G. Marra, F. Pellegrini, S.E. Skovlund, G. Vespasiani, A. Nicolucci, on Behalf of BENCH-D Study (Italy)

Education and support: the call for more training of healthcare professionals in the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study PD-0845
I. Willaing, M. Comaschi, M. Peyrot, A. Forbes, S. Kalra, A. Mayorov, E. Menendez Torre, N. Piana, H. Stuckey, M. Vallis, J. Wens, M. Peyrot, DAWN2 Study Group (Denmark)

13:00 - 14:00 Poster Area

Wishes for improvement in self-management: narratives from the second Diabetes Attitudes, Wishes and Needs (DAWN2) Study PD-0846

H. Stuckey, A. Greene, K. Kovacs Burns, N. Munro, J. Wens, M. Peyrot, DAWN2 Study Group (USA)

13:00 - 14:00 Poster Area

Psychology

Chair: A. Forbes (United Kingdom)

Health-related quality of life in Chinese patients with poor glycemic control in the Joint Asia Diabetes Evaluation Program PD-0864
J. Yin, R. Yeung, A. Luk, Y. Zhang, N. Brown, A. Kong, R. Ozaki, C. Ma, P. Tong, C. Chow, W.Y. So, J. Chan (China)

Screening tools for disordered eating in adolescents with diabetes PD-0865
H. Demden, L. Holden, B. McDermott, M. Harris, K. Gibbons, A. Cotterill, A. Gledhill (Australia)

Influencing factors on self-care behaviors and quality of life among Taiwanese patients with type 2 diabetes PD-0866
C.M. Ouyang, J. Dwyer, P.F. Jacques, K. Weinger (Taiwan)

Non-compliance to diabetes management among subjects attending selected health care facilities in Dhaka PD-0867
F. Ara, F. Saleh, S.J. Mumu, M.A. Hafez, L. Ali (Bangladesh)

A qualitative assessment of patients beliefs about adherence to oral anti-diabetes drug treatment PD-0868
L. Guénette, S. Lauzier, J. Moisan, G. Giguère, J.P. Grégoire, L. Guillaumie (Canada)

Systematic use of tools can facilitate dialogue on psychological problems in diabetes consultations PD-0869
C. Johansen, R. Torenholt, E. Hommel, M. Wittrup, I. Willaing (Denmark)

Setting up of a diabetes empowerment nurse clinic in an acute hospital: does it work? PD-0870
M.S.W. LAU, C.C. Tsang, Y.L. Cheng (Hong Kong China)

The impact of memory problems on diabetes treatment, patient functioning and well-being: a 5 country survey PD-0871
M. Brod, J. Kongso, K. Pfeiffer (USA)

13:00 - 14:00 Poster Area

Peer support improved diabetes knowledge and self-management activities among patients with type 2 diabetes mellitus in China PD-0872
Y.N. Wang, W.H. Xiao (China)

The role of mindfulness for patients with type 1 diabetes: a patient group's perspective PD-0873
A. Stride (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Diabetes care and therapies

Chair: A. Misra (India)

Nine-years post-partum follow-up of women with type 1 diabetes mellitus with micro- and macroalbuminuria in the 1st trimester of pregnancy PD-0891
M. Dundua, N. Asatiani, R. Kurashvili, E. Shelestova, L. Tsurskiridze, M. Ramazashvili, M. Hod (Georgia)

Does breastfeeding duration have a protective role on the development of type-2 diabetes mellitus? PD-0892
Y. Altuntas, B. Inal, F. Yener Ozturk, M.T. Egici (Turkey)

Successful implementation of insulin pump therapy in Kazakhstan PD-0893
N. Toktarova, A. Tulegalieva, G. Kulkaeva, A. Sagyndykova, A. Muratalina, G. Oroszlan, J.B. Welsh, L. Yedigarova, F.R. Kaufman (Kazakhstan)

The effect of vitamin D supplementation on maternal and neonatal outcomes PD-0894
S. Soheilikhah, M. Mojibia, M. Janati Moghadam (Iran)

Prevalence of chronic use of metformin-related vitamin B12 deficiency is lower in Asian population PD-0895
S.H. Ko, Y.B. Ahn, S.H. Ko (Korea)

The role of skeletal muscle mass in development of metabolic syndrome PD-0896
H. Yoon, J. Moon, J. Yoon, K. Won, H. Lee, H.W. Lee (Korea)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Lifestyle, education and behavioural interventions

Chair: S. Koski (Finland)

Development of video-based behavioural intervention to optimize self-management in children with poorly-controlled type 1 diabetes PD-0910
C. Webster, A.C. Greene, S.A. Greene (United Kingdom)

Adherence to dietary measures in type 2 diabetics of the National Obesity Centre of the Central Hospital of Yaoundé, Cameroon PD-0911
F. TCHEUTCHOUA NOULE, E. Sobngwi, L. Kleinebreil, C. Mesenge (Egypt)

Outcomes of type 2 diabetic patient during the holy month of Ramadan PD-0912
F. Khan, F. Amin, R. Sultana (Bangladesh)

Glycemic control and hypoglycemia during Ramadan in diabetes type 2 patients PD-0913
H. Shahbazian, M. Zakerkish, M. Karandish, P. Payami, H. Rashidi (Iran)

Patients perceptions of type 2 diabetes and health education needs in Nakhonsawan, Thailand PD-0914
N. Suparee (United Kingdom)

A new technology platform to improve the self-management of type 2 diabetes: the TLC diabetes program PD-0915
B. Oldenburg, D. Bird, A. Russell, M. Varnfield, R. Friedman, P. Scuffham, L. Gordon, E. Williams (Australia)

Psychological and educational intervention for working with adolescents with DSM 1 PD-0916
T. Lopez Radrigan, X.F. fantuzzi, M. Onetto, J. Pinto, K. Schuffeneger (Chile)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Type 1 diabetes and diabetes in youth

Chair: K. Donaghue (Australia)

IDF Life for a Child Index of diabetes care for children and youth PD-0929
G.D. Ogle, A.C. Middlehurst, M. Silink (Australia)

Cyclical variation in the national incidence of childhood type 1 diabetes in Australia (1999 - 2009) PD-0930
A. Haynes, M.K. Bulsara, C. Bower, T.W. Jones, E.A. Davis (Australia)

Estimation of compensation and prevalence of chronic complications of type 1 DM in children and teenagers according to the screening data PD-0931
S. Ismailov, A. Alieva, G. Rakhimova, N. Alimova, A. Akbarov, A. Tashmanova, N. Alikhanova, S. Bahadirov, M. Nigmatov (Uzbekistan)

50 yrs of childhood type 1 diabetes: genetic characteristics of survivors from the Pittsburgh Epidemiology of Diabetes Complications Study PD-0932
T.J. Orchard, R.G. Miller, T. Costacou (USA)

Costs of core standard outpatient package of care of persons with type 1 diabetes mellitus in Beijing and Shantou, China PD-0933
K. Kissimova-Skarbek, L. Ji, H. McGuire, D. Whiting, P. Zhang, J. Wu, T. Seuring, F. Aguirre, Y. Wu, S. Lin, J. Weng (Poland)

Young people with type 1 diabetes: prevalence and associated factors for vascular complications in Hunter New England PD-0934
L. Perry, S. James, J.S. Dunbabin, R. Gallagher, J. Lowe, K.S. Steinbeck, S. Acharya (Australia)

Obesity in adults with type 1 diabetes PD-0935
M. Ruiz, E. Lopez Gonzalez, A.B. Garcia, A. Luongo, S. Milrad, S. Houssay, M.C. Varela, C. Gonzalez, G. Fradyc DM1 (Argentina)

Diabetes in the young: a population based study of south asian, chinese and white patients PD-0936
C. Ke, P. Sohal, N.A. Khan (Canada)

13:00 - 14:00 Poster Area

Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB Prospective Complications Study PD-0937

D.A.J.M. Schoenaker, D. Simon, N. Chaturvedi, J.H. Fuller, S.S. Soedamah-Muthu (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Management and outcomes of type 2 diabetes

Chair: R. Gabbay (USA)

A U-shaped association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: The Fukuoka Diabetes Registry PD-0956
T. Ohkuma, M. Iwase, H. Fujii, U. Nakamura, T. Kitazono (Japan)

Effect of indoor air pollution on glycemic control – a case control study in a outreach clinic in South India PD-0957
P. Adhikari, R. Arpitha, B. Unnikrishnana, M.S. Kotian, R. Satish, A. Basavaprabhau (India)

Results of the mobile diabetes center in the remote areas of Western Siberia PD-0958
I. Bondar, O. Shabelnikova (Russia)

Behavioral changes and psychological impact of symptomatic hypoglycemia: HYPOS-1 study PD-0959
S. Gentile, A. Chiambretti, D. Cucinotta, F.M. Gentile, C.B. Giorda, G. Lucisano, A. Nicolucci, F. Pellegrini, B. Pintaudi, M.C. Rossi, on behalf of the HYPOS-1 Study Group (Italy)

Short and long-term cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes PD-0960
P. Home, G. Gonzalez-Galvez, R. Malek, E. Hammerby, A. Nikolajsen, M.F.B. Andersen, O. Henriksen (United Kingdom)

25-hydroxy vitamin D levels among 36728 adult patients in the United Arab Emirates: association with age and BMI and diabetes status PD-0961
N. Lessan, Z. Hannoun, M.T. Barakat (United Arab Emirates)

The changing trend in the management of diabetes patients at the primary care level: a case study in Malaysia PD-0962
F.I. Mustapha, O. Zainal-Ariffin, I. Fatanah (Malaysia)

Glycaemic control is associated with quality of life among patients with diabetes PD-0963
H. Kim, L. Gurrin, D. Magliano, J. Shaw, D. Liew (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Effects of the wireless IT-based self-management program for type II diabetes mellitus patients: six-month follow-up PD-0964
S. Kim, K. Park, J. Han, S. Lee (Korea)

Estimated vs actual medical cost of chronic diabetes care: the unbearable economic burden in low-income countries such as Mali PD-0965
H. Delisle, N. Baldé, S. Besançon, J. Drabo, K. Alouki (Canada)

Inter- and Intra-ethnic differences in HbA1c and other parameters in an ethnically diverse New Zealand community PD-0966
M. Choe, R. Cutfield, S. Morton, K. Pickering (New Zealand)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Risk factors for type 2 diabetes

Chair: J. Lindström (Finland)

C-reactive protein levels predicting change in body mass index during childhood: a prospective study in Brazilian Amazon PD-0984
B. Hatzlhoffer Lourenco, M.A. Cardoso (Brazil)

Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome PD-0985
A. Joham, S. Ranasinha, S. Zoungas, L. Moran, H. Teede (Australia)

Work-related risk factors for diabetes among municipal bus drivers PD-0986
B. Cleal, K. Poulsen, R. Persson, L.L. Andersen (Denmark)

Women with early severe, but not late severe, vasomotor menopausal symptoms have a higher risk of diabetes PD-0987
G. Herber, G. Mishra (Australia)

Associations of the PTEN 9C>G polymorphism with insulin sensitivity and central obesity in Chinese PD-0988
N.W.T. Tong, Q.Y. Yang, H.Y.C. Cao, S.G.X. Xie, Y.Z.T. Tong, Q.B.Z. Zhu, F.Z. Zhang, Q.G.L. Lü, Y.Y. Yang, D.G.L. Li, C.Y.Y. Yu, W.J. Jin (China)

Understanding diabetes risk perceptions and their links with health motivations and behaviors among at-risk Malaysians PD-0989
C.K.Y. Chan, L.D. Cameron, S. Yasin, B. Oldenburg (Malaysia)

Association of elevated serum ferritin levels with incident type 2 diabetes in Chinese: a prospective cohort study PD-0990
Z. Zhao, X. Zhang, Y. Ren, Y. Gao, T. Zheng, H. Tian (China)

Evening chronotype is associated with sarcopenia, metabolic syndrome and type 2 diabetes in middle-aged Korean men and women PD-0991
J. Yu, J. Ahn, K. Kim, Y. Kim, N. Kim, H. Yoo, S. Kim, K. Choi, S. Baik, D. Choi, C. Shin, N. Kim (Korea)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Relationship between moderate/high intensity physical activity and HbA1c levels in Japanese men and women PD-0992

J. Yasukata, Y. Higaki, N. Taguchi, M. Hara, Y. Nishida, T. Imaizumi, H. Nanri, K. Nakamura, T. Sakamoto, M. Horita, K. Shinchi, K. Tanaka (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Diabetes and special populations

Chair: G. Roglic (Switzerland)

Development of a risk assessment tool for undiagnosed diabetes for rural people in Bangladesh PD-1010
F.M.A. Islam, M.T. Islam, M.I. Khalil, M.F. Hossain, M. Wahab, R. Chakrabarti (Australia)

Prevalence of diabetes in a rural population of Bangladesh PD-1011
A. Banu, M.M. Rhaman, T. Begum, P.A. Khanam, H. Mahtab, S. Jahan, M.A. Sayeed (Bangladesh)

Undiagnosed diabetes in a rural community in Bangladesh: the diabetes risk in a rural community (DRIRC) study PD-1012
R. Chakrabarti, M. Islam, R. Finger, R. Parvez, M. Wahab, F. Islam (Australia)

Cost-effectiveness of preventing excess weight gain in pregnant overweight women at high-risk of gestational diabetes PD-1013
H. Teede, C. Harrison, C. Lombard, M. Boyle, M. Moodie, C. Keating (Australia)

Blood glucose concentration and hypertension among pregnant women in Tanzania PD-1014
A.W. Mwanri, J. Kinabo, K. Ramaiya, E.J.M. Feskens (Tanzania)

Is the care for diabetic patients worsening after new national guidelines for gestational diabetes mellitus? PD-1015
M. Zavrsnik, S. Zavrsnik (Slovenia)

Breaking the intergenerational cycle of diabetes in pregnancy PD-1016
S. Begum (Canada)

POSTER DISCUSSION
WEDNESDAY 04 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

13:00 - 14:00 Poster Area

Eye, nerve and foot complications

Chair: R. Malik (United Kingdom)

Anaemia and diabetic foot ulceration PD-0664
J. Wright, D.L. Becker, T. Richards (United Kingdom)

Role of calcaneal ultrasonometry for assessment of risk of Charcot foot in high risk populations PD-0665
R. Bem, A. Jirkovska, J. Brunova, M. Dubsky, V. Fejfarova, M. Schubertova, V. Woskova, S. Kratochvilova (Czech Republic)

Retrospective analysis of treatment with recombinant human epidermal growth factor (rhEGF) vs. standard therapy in diabetic foot ulcers PD-0666
M. Calvagno, M. Carrio, G. Garelli, P. Marinelli, A. Halabi, M. Pennazi, G. Jurczuk, J.L. Rizzardi, G. Tomasini, P. Caminos, M.I. Penna, R.E. Gómez (Argentina)

Retinal tissue thickness is reduced in diabetic peripheral neuropathy PD-0667
S. Srinivasan, N. Pritchard, K. Edwards, A.W. Russell, N. Efron (Australia)

Non-invasive techniques for imaging in-vivo human corneal sub basal nerve mapping and migration rate in diabetic neuropathy PD-0668
K. Edwards, N. Pritchard, C. Poole, D. Vagenas, C. Dehghani, S. Srinivasan, A.W. Russell, R.A. Malik, N. Efron (Australia)

Low intensity far-red light therapy reverses diabetes-induced retinal abnormalities in pigmented mice in vivo PD-0669
A. Saliba, T. Kern (USA)

An inexpensive handheld quantitative sensory testing device, which accurately diagnoses small and large fibre neuropathy PD-0670
G. Ponirakis, J.V. Vidal, R. Gomis, M. Odriozola, S. Odriozola, R. Malik, A. Odriozola (United Kingdom)

Characterisation of retinal neuropathy in Ins2Akita mice PD-0671
M. Chen, J. Hombrebueno, H. Xu (United Kingdom)

13:00 - 14:00 Poster Area

Therapeutic potential of the sodium-glucose cotransporter-2 inhibitoron the peripheral nerves in experimental diabetes PD-0672

K.A. Lee, H.Y. Jin, S.H. Kim, C.O. Baek, H.S. Baek, T.S. Park (Korea)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

DPP-IV

Chair: R. Holman (United Kingdom)

Linagliptin vs placebo followed by glimepiride in Japanese type 2 diabetes patients with moderate to severe renal impairment PD-0692
N. Hayashi, K. Shiki, T. Kagimura, U. Hehnke, I. Tamminen, S. Patel, M.V. Eynatten, H. Woerle (Japan)

Efficacy and safety of linagliptin and glimepiride in elderly T2DM patients insufficiently controlled with metformin PD-0693
B. Gallwitz, J. Rosenstock, T. Rauch, U. Hehnke, S. Patel, Y. Gong, M. von Eynatten, H.J. Woerle (Germany)

Effect of dipeptidyl peptidase-4 inhibitor, Sitagliptin, on beta-cell function in Japanese patients with type 2 diabetes: a 2-year study PD-0694
H. Hamamoto, K. Sakaguchi (Japan)

Significant improvement of lipid parameters by sitagliptin with comparable glycemic control to nateglinide PD-0695
Y. Kojima, A. Aida, H. Kaga, K. Takaya, M. Yoshitsugu, M. Noji, S. Ito, M. Fujiwara, T. Hiyoshi (Japan)

Safety and tolerability of linagliptin in 7400 patients with type 2 diabetes with or without renal impairment: a comprehensive analysis PD-0696
M. Lehrke, N. Marx, S. Patel, T. Seck, S. Crowe, M. von Eynatten, O.E. Johansen (Germany)

Linagliptin improves glycaemic control in patients with type 2 diabetes inadequately controlled on basal insulin and metformin PD-0697
S. Durán-Garcia, H. Yki-Järvinen, J. Rosenstock, J. Lee, U. Hehnke, S. Thiemann, S. Patel, H.-J. Woerle (Germany)

Linagliptin in elderly patients with type 2 diabetes: safety and efficacy analysis from a Phase III clinical trial programme PD-0698
S. Patel, G. Schernthaner, A.H. Barnett, S. Crowe, M. von Eynatten, H.J. Woerle (Austria)

A meta-analysis of the efficacy and safety of alogliptin in Indian patients with type 2 diabetes mellitus PD-0699
T. Araki, P. Fleck, C. Wilson (Singapore)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) PD-0700

M.A. Bethel, J.B. Green, A. Tajar, S.S. Engel, R.M. Califf, R.R. Holman (United Kingdom)

The efficacy and safety of teneligliptin in Japanese patients with type2 diabetes and chronic renal failure PD-0701

H. Tatsuoka, Y. Hamamoto, S. Honjo, Y. Kawasaki, K. Fujimoto, A. Matsuoka, Y. Wada, H. Ikeda, H. Koshiyama (Japan)

13:00 - 14:00 Poster Area

Insulin action

Chair: D.E. James (Australia)

Calmodulin dependent protein Kinase II activation by exercise results increased mitochondrial biogenesis in Wistar rats PD-0721
J. Joseph, E. Mukwevho (South Africa)

Circulating free fatty acids abolish down-regulation of skeletal muscle adiponectin receptor 1 expression caused by insulin infusion PD-0722
M. Straczkowski, M. Karczewska-Kupczewska, A. Adamska, M. Stefanowicz, N. Matulewicz, I. Kowalska, A. Nikolajuk (Poland)

Effect of EPA on cardiac muscle cell of infants of diabetic mother rats PD-0723
R. Kawaharada, H. Masuda, A. Nakamura (Japan)

Combination of Momordica charantia and Cinnamomum cassia owes synergistic activity in modulating pre-diabetes in rat model PD-0724
R. Hafizur, S. Shaukat, S.A. Raza (Pakistan)

Relationship between skeletal muscle and adipose tissue glycoprotein 130 expression and insulin resistance in humans PD-0725
M. Karczewska-Kupczewska, A. Nikolajuk, A. Adamska, N. Matulewicz, M. Stefanowicz, I. Kowalska, M. Straczkowski (Poland)

Demonstration of the additive effect of insulin degludec and insulin aspart in adipocytes PD-0726
E. Nishimura, A.R. Sørensen, A. Vølund (Denmark)

Progesterone ameliorates ER stress-induced insulin resistance in liver cells PD-0727
J.C. Molero, I. Ziko, I. Kanaan, M. Valamios, A. Alhadhwan, J.M. Ye (Australia)

Insulin-independent glucose uptake in skeletal muscle mediated by beta2-adrenoceptors, mTORC2 and GLUT4 PD-0728
D. Hutchinson, M. Sato, N. Dehvari, A. Oberg, O. Dallner, A. Sandstrom, J. Olsen, R. Csikasz, R. Summers, T. Bengtsson (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Toona sinensis leaf extract promotes the transformation of unilocular to multilocular lipid droplets in white adipocytes PD-0729

T.J. Hsieh, M.R. Kang, P.H. Hung, S.J. Shin (Taiwan)

Effect of the ethanolic leaf extract of moringa oleifera on insulin resistance in streptozotocin induced diabetic rats PD-0730

A. Anyanwu, O. Salako, O. Adeyemi (Nigeria)

13:00 - 14:00 Poster Area

Management

Chair: T. Davis (Australia)

Breakfast and lunch are better than six meals a day for patients with type 2 diabetes PD-0750
H. Kahleova, L. Belinova, H. Malinska, O. Oliyarnyk, L. Kazdova, M. Dezortova, M. Hajek, A. Tura, M. Hill, T. Pelikanova (Czech Republic)

Feasibility of individualised glycaemic targets in elderly T2DM patients and the factors impacting target-setting: the INTERVAL study PD-0751
P.M. Paldánius, W. David Strain (United Kingdom)

Effect of iron deficiency anaemia on HbA1c levels PD-0752
S.V. Madhu, A. Raj, S. Giri, U. Rusia, S. Rathi (India)

Discrepancies between the HbA1c-based criteria and glucose-based criteria for diagnosis of diabetes and pre-diabetes PD-0753
R. Shrestha, P. Gyawali, L. Shrestha, S.B. Rana Magar, B. Jha, S.S. Malla (Nepal)

Efficacy of two insulin protocols in hospitalized subjects with T2DM receiving medium/high dose of corticosteroids: preliminary results PD-0754
N. Colomo, S. Valdés, F. García-Torres, M.I. Fontalba, F. Linares, C. Maldonado, R. Fernández, C. Bautista, J.D. Fernández, I. Rubio, G. Olveira, M.S. Ruiz de Adana (Spain)

A feasibility assessment of PaQ®, a simple 3-day basal/bolus insulin delivery device, in patients with type 2 diabetes PD-0755
J.K. Mader, L.C. Lilly, F. Aberer, H. Kojzar, S. Korsatko, E. Strock, R. Mazze, P. Damsbo, T.R. Pieber (Austria)

The outcome of beta cell function after early insulin therapy in the recently diagnosed type 2 diabetes (in Egyptian population) PD-0756
M. Kamel, Y. mosa, A. mohamed, S. Heni, A. Osman (Egypt)

Comparison of the effect on raising HDL-C between statins in high risk hypercholesterolemia with DM TOHO-LIP sub-analysis for 96 wks PD-0757
T. Shiba, K. Sakamoto, S. Okahata, T. Ikeda, J. Yamazaki, T. Hirose, Y. Iwasaki, S. Yamamura, K. Sugi, T. Fujioka, H. Noike, I. Tatsuno (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Readiness of GlucoTrack - a truly non-invasive glucose monitor for home use PD-0758

A. Gal, I. Harman-Boehm, E. Naidis, Y. Mayzel, N. Goldstein, K. Horman (Israel)

13:00 - 14:00 Poster Area

Experimental complications

Chair: J. Forbes (Australia)

Morphological changes in diabetic kidney are associated with increased O-GlcNAc modification of cytoskeletal proteins PD-0778
Y. Akimoto, Y. Miura, T. Toda, T. Fukutomi, D. Sugahara, M.A. Wolfert, L. Wells, G.J. Boons, G.W. Hart, T. Endo, H. Kawakami (Japan)

Dh404, a novel bardoxolone methyl derivative, attenuates diabetes-associated atherosclerosis in ApoE knockout mice PD-0779
A. Sharma, S.M. Tan, N. Stefanovic, K. Ward, C. Meyer, M. Cooper, J.B. de Haan (Australia)

The role of NADPH oxidase- derived ROS on regional immunmodulation in diabetes-accelerated atherosclerosis PD-0780
E. Di Marco, S.P. Gray, P. Chew, C. Szyndralewiez, F. Heitz, K. Wingler, H.H.H.W. Schmidt, M.E. Cooper, K.A. Jandeleit-Dahm (Australia)

The incretin mimetic liraglutide attenuates pro-fibrotic but not prof-inflammatory changes in a murine model of diabetic cardiomyopathy PD-0781
X. Wang, S.V. McLennan, C. Yee, J. Bonner, C. Semsarian, S.M. Twigg (Australia)

Cooperative repression of SMAD7 and PTEN by miR-21 mediate pathological gene expression changes in renal fibrogenesis PD-0783
A. McClelland, M. Herman-Edelstein, R. Komers, J. Jha, M. Cooper, P. Kantharidis (Australia)

Interactions between glucagon-like peptide-1 (GLP-1) and the receptor for AGEs (RAGE) in diabetic nephropathy PD-0784
K.C. Sourris, S.A. Penfold, B.E. Harcourt, J.M. Forbes, M.E. Cooper, M.T. Coughlan (Australia)

Estrogens from adipose tissues modulate RAGE in the kidney via ER-beta PD-0785
B.E. Harcourt, A.K. Fotheringham, A. Zhuang, M.T. Coughlan, M.C. Thomas, M.E. Cooper, P.P. Nawroth, A. Bierhaus, P. Kantharidis, J.M. Forbes (Australia)

13:00 - 14:00 Poster Area

Developing models of care for Indigenous peoples

Chair: S. Harris (Canada)

Indigenous women explain what it takes to manage high-risk diabetes in pregnancy with outstanding maternal and infant health outcomes PD-0802
C. Porter, I. Ellis, J. Coffin, T. Skinner (Australia)

Using point-of-care HbA1c to simplify diabetes screening protocols in remote Australian Aboriginal communities PD-0803
J.V. Marley, K. Isaacs, M. Sian Oh, N. Hadgraft, D. Atkinson (Australia)

International translation of an Indigenous Australian point-of-care testing model for diabetes management PD-0804
M.D.S. Shephard, L.A. Motta, A.K. Shephard (Australia)

Closing the gap in practice for rural Indigenous Australians: realising diabetes outcomes through a shared care health model PD-0805
M. McGill, A. Waterman, T. Bolton, S. Grillett, C. Kennedy, M. Tchan, A. Cass, L. Molyneaux, H. Burke, S. Twigg (Australia)

Linking diabetes care and Indigenous eye health PD-0806
A.I. Boudville, M.D. Anjou, H.R. Taylor (Australia)

Using telehealth to improve diabetic foot management in remote indigenous communities PD-0807
S. O'Rourke, C. Steffen, D. Charles, D. Dean (Australia)

Clearly defined team based diabetes management in ACCHSs: improved service delivery and intermediate patient outcomes PD-0808
A. Stoneman, D. Atkinson, M. Davey, J. Marley (Australia)

Treatment of chronic disease and diabetes: comparison of PBS medications in two remote Australian Aboriginal communities PD-0809
C.E. Swanson, W.E. Hoy, R.W. Manning, P. Ball (Australia)

13:00 - 14:00 Poster Area

Lifestyle

Chair: R. Dave (India)

Effects of lifestyle modification on metabolic parameters and risk factors in subjects with type 2 diabetes mellitus in Bangladesh PD-0821
A. Ali, H. Rahman (Bangladesh)

Correlates of patient's attitude to follow a healthful eating plan PD-0822
B. Pintaudi, M.C. Rossi, G. Lucisano, S. Gentile, G. Marra, F. Pellegrini, S.E. Skovlund, G. Vespasiani, A. Nicolucci, on behalf of the BENCH-D Study Group (Italy)

Improvement of insulin secretion and sensitivity with moderate weight loss in Korean obese women PD-0823
J.E. Yim, H.O. Lee, Y.S. Kim, R.W. Choue (Korea)

The effects of vegan diet and american diabetes association diet among patients with type 2 diabetes on metabolic parameters PD-0824
J. Jeong, I. Lee, K. Park, J. Kim, Y. Lee, D. Lee (Korea)

The Glycemic Index Symbol Program: making healthy food choices easy choices for people with diabetes and those at risk PD-0825
A. Barclay (Australia)

Self-management of type 2 diabetes among mainland Chinese immigrants in Canada: a qualitative study PD-0826
Y. Huang, J. Sheeshka, P. Brauer (Australia)

The yellow brick road or the garden path? Assessing the quality of guidelines for the nutritional management of adults with type 2 diabetes PD-0827
K. Hale, J. Bauer, S. Capra (Australia)

13:00 - 14:00 Poster Area

Innovative approaches to diabetic foot care and other diabetes complications

Chair: K. Van Acker (Belgium)

Barriers and facilitators to diabetic foot care in Barbados: a qualitative interview study on Step by Step PD-0847
C. Guell, N. Unwin (Barbados)

Reduction in hospital acquired foot lesions using the Ipswich Touch Test and Foot of the Bed form to identify inpatients at risk PD-0848
G. Rayman, A. Scott, S. Mitchelle (United Kingdom)

Individualized intervention to improve knowledge and foot-care in patients with type 2 diabetes PD-0849
P. Bañuelos-Barrera, E.D. Arias-Merino, M.V. Gómez-Meza, Y. Bañuelos Barrera, O.V. Campos-Moreno (Mexico)

The Precaution Adoption Process Model (PAPM) to prevent foot ulcer in patient with type 2 diabetes PD-0850
P. Bañuelos-Barrera, Y. Bañuelos-Barrera, M.J. Garvalena-Vázquez, E. Ruiz-Sánchez, J.J. Gallegos-Sánchez, M.A. Villarreal-Ángeles, R. Castillo-Díaz (Mexico)

Arrangement of specialized help to patients with diabetic foot syndrome (DFS) in Uzbekistan at support from WDF PD-0851
K.H. Shakirov, I. Ibragimova, B. Babakhanov, L. Kokareva, I. Sattarov, O. Platonova (Uzbekistan)

Increased nocturnal hypoglycaemia in hospitalised people with diabetes PD-0852
G. Rayman, C. Kerry, S. Mitchell, R. Rajendran, S. Sharma, A. Scott (United Kingdom)

Increased risk of fracture and post-fracture adverse events in patients with diabetes: a nationwide cohort study PD-0853
Y.C. Chou, C.C. Liao, T.L. Chen (Taiwan)

Does use of standard IV insulin infusion orders during labour and delivery increase the risk maternal or infant hypoglycaemia? PD-0854
J. Lowe, C. Jebakumar (Canada)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Global experiences

Chair: T. Dunning (Australia)

Diabetes clinic in remote area with limited resources PD-0874
M. Kamel (Egypt)

Integrating diabetes care into an established HIV care program in rural Kenya PD-0875
J. Kamano, S. Pastakia, C. Wambui, D. Tulienge, L. Misoi (Kenya)

Effect of structured diabetes education program on glycaemic control in children with diabetes PD-0876
B. Zabeen, B. Banerjee, S. Tayyeb, F. Naz, M. Khanam, F. Ahmed, N. Nahar, K. Azad (Bangladesh)

Traditional medicine for type 2 diabetes in Burkina Faso: level of use and outcomes PD-0877
M. Sawadogo, Y. Sagna, H. Tiéno, O. Guira, M. Ouédraogo, Y.J. Drabo (Burkina Faso)

Improving access to diabetes care and education in the Maldives project 200 islands PD-0878
N. Abul Majeed, A. Shiruhana (Maldives)

Perceptions about insulin therapy amongst people with type 2 diabetes in a developing country. a study from Karachi, Pakistan PD-0879
S.I. Ali, F. Jawad, S.M. Abbas (Pakistan)

A prospective assessment of healthcare professional requirements for the care of diabetes patients managed with insulin pumps in Australia PD-0880
S. Xu, The Australian National Adult Insulin Pump Therapy Working Group (Australia)

The National Inpatient Diabetes Audit (NaDIA) demonstrates improvements in inpatient care in the UK PD-0881
G. Rayman, On behalf of the NaDIA steering group (United Kingdom)

Increasing postpartum follow-up visits for women with gestational diabetes PD-0882
C. Rasmussen, D. Winmill, L. Baksh, J. Ware, B. Ralls (USA)

13:00 - 14:00 Poster Area

Diabetes practice

Chair: S. Soderberg (Sweden)

Diabetes mellitus and lower body disability among Bangladeshi adults PD-0897
M.S.A.M. Ahmed, M.A. Sharker, M. Moniruzzaman, S. Chowdhury (Bangladesh)

Awareness, knowledge and attitude of diabetes in a semi-urban community in South West Nigeria PD-0898
T. Akinlabi, O. Onajole, O. Ademowo, O. Adejumo, O. Arubuolawe, J. Macfadden-Laja, O. Odunneye (Nigeria)

Burden of diabetes mellitus involvement in peripheral vascular disease in a Kenyan African population PD-0899
M. Obimbo, J. Ogeng'o (Kenya)

Retrospective study of prevalence of co-morbidities icluding type 2 DM in children weighing more than normal PD-0900
P. Phatale, H. Phatale (India)

Socio-cultural aspects of diabetes in Nigeria PD-0901
S. Chinenye, N. Ani, A.O. Ogbera, E.E. Young, C.N. Unachukwu (Nigeria)

Switching from insulin glargine to biphasic insulin aspart 30 therapy in patients with type 2 diabetes in the Gulf region PD-0902
B. Bin Abbas, H. Pennicks, K. Khudadah, S. Mehanna, W. Hussein (Saudi Arabia)

Treatment profile and insulin dose as a factor impacting glycaemic control among premix insulin users with T2DM in China PD-0903
L. Liu, Y. Chen, L. Gu, B. Curtis, S. Babineaux (China)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Physical activity and psychological aspects

Chair: M. Skjødt Sørensen (Denmark)

Effect of exercise intensity on carbohydrate intake to prevent hypoglycaemia during and after exercise in type 1 diabetic individuals PD-0917
V. Shetty, P.A. Fournier, R.J. Davey, A.J. Retterath, N. Paramalingam, H.C. Roby, M.N. Cooper, E.A. Davis, T.W. Jones (Australia)

Eccentric endurance exercise significantly improves both fasting and postchallenge metabolism in overweight and obese individuals PD-0918
P. Rein, C.H. Saely, A. Vonbank, H. Drexel (Austria)

Inspiratory loading or aerobic exercise session, but not aerobic plus resistance exercise reduces glucose variability in type 2 diabetes PD-0919
A.P.S. Corrêa, F.R. Figueira, D. Umpierre, K.R. Casali, B.D. Schaan (Bra)

Most hypoglycaemic events occurring in people with type 1 diabetes are exercise-related PD-0920
A. Piotrowicz, M. McGill, J.E. Overland, L. Sorensen, S.M. Twigg (Australia)

Diabetes treatment: a psychological impact analysis PD-0921
M. Carreira Soler, M.T. Anarte, N. Colomo, M. Domínguez-López, I. Esteva, S. Valdés, M.C. Almaraz, G. Olveira, M.S. Ruiz de Adana (Spain)

View of hypoglycaemia by people with diabetes and family members: 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study PD-0922
H. Stuckey, S. Kalra, B. Kulzer, R. Malek, N. Munro, M. Peyrot, DAWN2 Study Group (USA)

Clinical experience with GLP1 analogs in 268 patients with diabesity: differences between liraglutide and exenatide PD-0923
C. Morales Portillo, I. Serrano Olmedo, C. Garcia Garcia, C. Perez Rodriguez, V. Hernando Herrero (Spain)

Psychosocial impacts of diabetes on people with diabetes and family members in the 2nd Diabetes, Attitudes, Wishes and Needs (DAWN2) study PD-0924
K. Kovacs Burns, M. Escalante, N. Hermanns, B. Kulzer, R. Malek, M. Vallis, M. Peyrot, DAWN2 Study Group (Canada)

13:00 - 14:00 Poster Area

Prevention of type 2 diabetes

Chair: A. Nanditha (India)

A systematic review of screening and recruitment strategies into lifestyle programs that prevent or delay type 2 diabetes PD-0938
P. Vita, A. Gibson, S. Colagiuri (Australia)

Do community diabetes prevention programs work? Three year follow up of participants in the Sydney Diabetes Prevention Program PD-0939
P. Vita, A. Gibson, S. Partridge, S. Colagiuri (Australia)

The impact of a workplace diabetes prevention screening and follow-up program on productivity PD-0940
A. Peeters, K. Pasupathi, M. Sim (Australia)

Changes in lifestyle modestly reduce the estimated cardiovascular risk in one-year follow-up of the Finnish diabetes prevention program PD-0941
N. Rautio, J. Jokelainen, A. Pölönen, H. Oksa, M. Peltonen, M. Vanhala, H. Puolijoki, L. Moilanen, J. Tuomilehto, M. Uusitupa, S. Keinänen-Kiukaanniemi, T. Saaristo (Finland)

Three years experience with DE-PLAN diabetes mellitus type 2 DM2 prevention in Serbia: successful primary prevention in Europe is feasible PD-0942
P. Djordjevic, V. Dimitrijevic-Sreckovic, D. Gostiljac, F. Canovic, N. Raketic, R. Velickovic, R. Petkovic, P. Djuric, M. Ilic, A. Anic, D. Nikolic, S. Popovic (Serbia)

Changes in anthropometric measurements in Asian Indians enrolled in a lifestyle intervention program: one year results of the D-CLIP trial PD-0943
M.B. Weber, H. Ranjani, M.K. Ali, R.M. Anjana, L.R. Staimez, K.M.V. Narayan, V. Mohan (USA)

Transient improvements in HOMA-IR and HOMA-B during a lifestyle intervention: the Greater Green Triangle Diabetes Prevention Program PD-0944
N. Davis-Lameloise, E.D. Janus, J.D. Best, A. Januszewski, A. Jenkins, V.L. Versace, J.A. Dunbar (Australia)

A compliance evaluation model of lifestyle intervention in pre-diabetes PD-0945
W. Duan, H. Wang, Y. Luo, X. Zhou, L. Ji (China)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Intensive lifestyle modification as a strategy for the primary prevention of T2DM in a young urban population: Diabrisk-Sri Lanka Trial PD-0946

J. Karalliedde, M. Wijesuriya, L. Vasantharajah, M. Gulliford, L. Gnudi, G.C. Viberti (Sri Lanka)

Food intake and physical activity in a rural agricultural town in the Philippines: preliminary phase of a diabetes prevention program PD-0947

M.A.S. Sandoval, E. Canete, P. Patal, A.H. Aguilar, F.L. Lantion-Ang, N. Juban, E.R. Paterno, C.A. Jimeno, E. Paz-Pacheco (Philippines)

13:00 - 14:00 Poster Area

Complications

Chair: W. Herman (USA)

Incidence and predictors of first hospitalisation for end-stage kidney disease in type 2 diabetes: The Fremantle Diabetes Study PD-0967
W. Davis, T.M.E. Davis (Australia)

Prevalence of renal insufficiency according to different formulas to estimate glomerular filtration rate in patients with type 2 diabetes PD-0968
E. Jódar, J.L. Górriz, A. Pérez, F. Álvarez-Guisasola, F.J. Tinahones, L. Ávila, S. Artola, R. Gomis, J. Franch, F.X. Cos-Claramunt, E. Fuster (Spain)

The cost of chronic kidney disease by diabetes status in Australia PD-0969
C.M.Y. Lee, M. Wyld, S. Chadban, S. Colagiuri (Australia)

Insulin resistance in type 1 diabetes a risk factor for chronic complications PD-0970
N.M. Panduru, D. Clenciu, B. Cimpoca, S. Radu, M. Anghel, I. Duta, G. Pop, A. Pop, M. Robu, C. Serafinceanu, E. Mota, M. Mota (Romania)

Prevalence and factors associated with lens opacities in a Korean adult population with and without diabetes PD-0971
D.J. Kim, Y.J. Lee, J.H. Noh, K.S. Ko, B.D. Rhee (Korea)

Retinal vascular tortuosity interacts with gender and glycated hemoglobin to predict incident retinopathy in type 2 diabetes PD-0972
Y. Guo, B. Zee, J. Lee, Q. Li, R. Ozaki, A. Luk, A. Lam, C. Yu, P. Li, W. So, J.C. Chan (China)

Increase in rate of short duration hospital stays for diabetic ketoacidosis in young Australians, 2000-01 to 2010-11 PD-0973
C. Blumer, V. Prescott, M. Abouzeid, S. Senes, J. Shaw (Australia)

The prevalence of diabetes complications and associated risk factors in Pacific Islands Countries (PICs) PD-0974
S. Win Tin, G. Kenilorea, E.V.A. Gadabu, J.O.H.N. Tasserei, R.U.T.H. Colagiuri (Australia)

13:00 - 14:00 Poster Area

Prevalence and incidence

Chair: C. Patterson (United Kingdom)

Prevalence of diabetes and impaired glucose regulation in Faroe Islands PD-0993
J. Andreassen, J. Halling, H. Steinhólm, M. Hansen, P. Weihe (Faroe Islands)

Epidemiology of childhood type 1 diabetes in Taiwan during year 2003 to 2008: a population-based study PD-0994
C.L. Lu, H.N. Shen, C.Y. Li (Taiwan)

New estimates of diabetes prevalence in the Netherlands, based on information from 5 million subjects (DUDE-1) PD-0995
H. Bilo, N. Kleefstra, M. Meulepas, A. Romeijnders, M. Klomp, S.T. Houweling (The Netherlands)

A population-based survey of prevalence of diabetes and correlates in an urban slum community in Nairobi, Kenya PD-0996
R. ayah, M.J. Joshi, R. Wanjiru, E. Njau, C.F. Otieno, E. Njeru, K.K. Mutai (Kenya)

Implementation of a national registry of children and adolescents with type 1 diabetes epidemiological data PD-0997
J.M. Boavida, L. Gardete-Correia, R.T. Ribeiro, J.F. Raposo (Portugal)

The prevalence of diabetes mellitus and impaired glucose tolerance among Kyrgyz and Russian population of Kyrgyzstan PD-0998
R. Sultanalieva, V. Kniazeva (Kyrgyz Republic)

The prevalences of diabetic retinopathy and nephropathy are lower in type 2 diabetes with non-alcoholic fatty liver disease PD-0999
B.Y. Kim, C.H. Kim, J.O. Mok, C.H. Jung, K.J. Kim, S.K. Kang (Korea)

Prevalence of metabolic syndrome in India: sociodemographic and lifestyle risk factors: nationwide population based study PD-1000
A. Maheshwari, N. Maheshwari, K.K. Sharma, P.C. Deedwania, A. Bhansali, B. Saboo, A. Gupta, R. Gupta (India)

13:00 - 14:00 Poster Area

Risk factors for type 2 diabetes

Chair: K. Khunti (United Kingdom)

Behaviour patterns of exercisers and non-exercisers screened for a diabetes prevention trial in southern India PD-1017
A. Ranjit Mohan, H. Ranjani, M.B. Weber, L.R. Staimez, V. Mohan, K.M.V. Narayan (India)

Circulating levels of perflourinated compounds and prevalent diabetes in the elderly PD-1018
L. Lind, B. Zethelius, S. Salihovic, B. van Bavel, P.M. Lind (Sweden)

Circulating PCBs are related to markers of both a defect insulin secretion and insulin resistance PD-1019
M. Lind, S. Salihovic, B. van Bavel, B. Zethelius, L. Lind (Sweden)

Increasing prevalence of diabetes associated with organochlorine pesticide exposure in the northern Benin Republic PD-1020
C. Azandjeme, H. Delisle, M. Bouchard, F. Djrolo, D. Houinato (Canada)

Anthropometric centiles for measuring obesity in children and adolescents in urban South Indians PD-1021
M. Priya, J. Sonya, R. Harish, R.M. Anjana, V. Mohan (India)

Increased seated height is associated with cardio-metabolic risk factors in healthy young adult urban South Asians PD-1022
L. Vasantharajah, M. Wijesuriya, M. Gulliford, G.C. Viberti, L. Gnudi, J. Karalliedde (Sri Lanka)

Association between anthropometric measures and newly diagnosed dysglycemia among urban South Asians - the CARRS Surveillance study PD-1023
N. Tandon, B. Binukumar, R. Shivashankar, M. Deepa, V.S. Ajay, M.H. Kadir, Z.A. Fatmi, V. Mohan, D. Prabhakaran, K.M. Narayan, M.K. Ali, F.O.R. CARRS Study Group (India)

Metabolic health is more important for development of non-alcoholic fatty liver disease than simply being obese PD-1024
M.K. lee, J.D. Kim, W.S. Jeon, S.E. Park, C.Y. Park, W.Y. Lee, K.W. Oh, S.W. Park, E.J. Rhee (Korea)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Vitamin D deficit and metabolic syndrome PD-1025

I. Gonzalez-Molero, G. Rojo, M. Domínguez-López, S. Morcillo, C. Gutierrez, E. Rubio, M.S. Ruiz de Adana, I. Esteva, V. Perez Valero, F. Soriguer (Spain)

POSTER DISCUSSION
THURSDAY 05 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

13:00 - 14:00 Poster Area

Liraglutide

Chair: TBC

Addition of liraglutide to insulin degludec plus metformin vs addition of a single dose of insulin aspart in patients with type 2 diabetes PD-0673
C. Mathieu, H.W. Rodbard, B. Cariou, Y. Handelsman, A. Philis-Tsimikas, A.M. Ocampo Francisco, A. Rana, B. Zinman (Belgium)

Treat 4 Ramadan: randomised controlled trial comparing liraglutide with a sulphonylurea added to metformin in established type 2 diabetes PD-0674
M.J. Davies, E.M. Brady, L.J. Gray, M.A. Saeed, W. Hanif, K. Khunti (United Kingdom)

Liraglutide in combination with metformin provides greater PPG control vs metformin monotherapy across all 3 main meals PD-0675
G. Fulcher, D.R. Matthews, M. Nauck, C.B. Svendsen, M. Donsmark, A. Garber (Australia)

Liraglutide adjunct to insulin in type 1 diabetes: short-term effects on glycaemic control in a randomised trial PD-0676
S. Heller, S. Korsatko, J. Gurban, L. Jensen, E. Christiansen, F. Kiyomi, T. Pieber (United Kingdom)

Baseline BMI does not influence the HbA1c-lowering efficacy of liraglutide in patients with type 2 diabetes PD-0677
S. Colagiuri, L. Blonde, E. Montanya, V. Fonseca, F.M.M. Baeres, C.B. Svendsen, M.A. Nauck (Australia)

Efficacy and tolerability of exenatide once weekly in Asian vs White patients with type 2 diabetes mellitus PD-0678
W.H.H. Sheu, W. Huang, S.C. Brunell, E. Blase, M. Horng (Taiwan)

Influence of liraglutide treatment in obstructive sleep apnea(OSA) in patients with obesity and diabetes mellitus type 2 PD-0679
F. Gomez-Peralta, C. Abreu, J.C. Castro, E. Alcarria, M. Cruz-Bravo, M.J. Llorente, C. Albornos, C. Moreno, M. Cepeda, F. Almodovar (Spain)

13:00 - 14:00 Poster Area

Analysis of the influence of baseline diabetes duration on blood pressure responses to liraglutide PD-0680

V. Fonseca, J. Plutzky, J.H. DeVries, E. Bergan, M. Donsmark, R.R. Henry (USA)

Effect of liraglutide on glucocorticoid-induced diabetes PD-0681

M. Yamauchi, M. Oida, K. Taguchi, I. Mori, K. Kajita, H. Morita, T. Ishizuka (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Renal - clinical

Chair: G. Jerums (Australia)

Intensity of leisure-time physical activity predicts the development and progression of diabetic nephropathy PD-0702
H. Tikkanen, J. Waden, C. Forsblom, L.M. Thron, M. Saraheimo, N. Tolonen, M. Rosengård-Bärlund, D. Gordin, H. Tikkanen, P.H. Groop (Finland)

Cholesterol transport proteins and diabetic nephropathy PD-0703
K.C.B. Tan, J.G.S. Tsun, S.S.Y. Yung, M.K.M. Chau, S.W.M. Shiu, T.M. Chan (Hong Kong China)

Albuminuria predicts cardiovascular events in patients with type 2 diabetes independently from the coronary artery state PD-0704
P. Rein, C.H. Saely, A. Vonbank, D. Zanolin, H. Drexel (Austria)

Relationship of VWF, D-Dimer and ADAMTS13 with hypercoagulability in type 1 diabetic patients with and without nephropathy PD-0705
C.P. Domingueti, R.B. Fóscolo, J.S. Reis, L.M.S. Dusse, M.G. Carvalho, K.B. Gomes, A.P. Fernandes (Brazil)

Urinary excretion of site-specific tubular markers in patients with type 1 diabetes PD-0706
V.V. Klimontov, I.A. Bondar, E.M. Parfentjeva, V.V. Romanov, N.P. Bgatova (Russia)

Unequal impact of glycemic control on the development of microalbuminuria in normoalbuminuria patients with type 2 diabetes in Taiwan PD-0707
W.Z. Chen, C.C. Hung, Y.W. Wen, H.C. Ning, B.R. Gau, Y.Y. Huang (Taiwan)

Dapagliflozin as monotherapy in a Chinese population of drug-naïve patients with type 2 diabetes PD-0708
L. Ji, H. Li, T. Mansfield, N. Iqbal, A. Ptaszynska, J.F. List (China)

Short-term dietary salt supplementation is not associated with reduced renal function in hypertensive subjects with type 2 diabetes PD-0709
A.X. Chen, G. Jerums, S. Baqar, G. Thomas, R.J. MacIssac, C. O'Callaghan, E.I. Ekinci (Australia)

Rates of estimated glomerular filtration rate (eGFR) decline in patients with type 2 diabetes PD-0710
R.J. MacIsaac, E.I. Ekinci, S. Verma, E. Premaratne, S. Panagiotopoulos, S. Baker, S. Finch, G. Jerums (Australia)

13:00 - 14:00 Poster Area

Kidney injury molecule - 1 is linked to the loss of kidney function in diabetic nephropathy, in patients with type 1 diabetes PD-0711

N.M. Panduru, N. Sandholm, C. Forsblom, V. Harjutsalo, A. Bierhaus, M. Saraheimo, P.M. Humpert, P.H. Groop on behalf of the FinnDiane Study Group (Finland)

13:00 - 14:00 Poster Area

Islets

Chair: T. Mandrup-Poulsen (Denmark)

RNA-based analysis for prediction of islet death: the RAPID study group PD-0731
A.A. Hardikar (Australia)

Testosterone protects pancreatic beta cell apoptosis in glucotoxicity PD-0732
W. Hanchang, N. Semprasert, T. Limjindaporn, P. Yenchitsomanus, S. Kooptiwut (Thailand)

Mechanism of estrogen protects pancreatic ß cell apoptosis in glucotoxicity PD-0733
S. Kooptiwut, P. Mahawong, W. Hanchang, N. Semprasert, T. Limjindaporn, P.T. Yenchitsomanus (Thailand)

Effect of DPP-4 Inhibitor MK0626 and exercise on the protection of islet function in early pre-diabetic kkay mice PD-0734
Y. Li, H.U.I. Tian, Y.U. Pei, J.I.N.G. Xiao, X. Han, B. Sun, F. Fang, H.U.A. Shu (China)

The zebrafish as a model to study beta-cell regeneration in vivo PD-0735
L.L.F. Abreu, K. Walder, A.C. Ward, Y. Gibert (Australia)

Improved siRNA delivery to pancreatic islets using R3V6 peptide carrier PD-0736
S.H. Ihm, M.G. Choi, H.J. Yoo, M. Lee, J. Ihm (Korea)

Interleukin-17 producing Th17 cells induce the expression of Regenerating (Reg) family genes in pancreatic islets cells PD-0737
B. Singh, A. Qian, O. Krougly, T. Hill, S. Bellemore, E. Lee-Chan, E. Nikoopour, D.J. Hill (Canada)

Angiotensin-(1-7) promotes glucose-stimulated insulin secretion in mouse islets by a neprilysin dependent pathway PD-0738
R. Griesbach, B. Barrow, S. Zraika (USA)

Impact of urate on pancreatic beta cell function and the development of diabetes mellitus PD-0739
R. Johnstone, E. Rodrigues, A. Bahn (New Zealand)

13:00 - 14:00 Poster Area

Obesity - clinical/experimental

Chair: G. Wittert (Australia)

Branched-chain amino acids and tyrosine, methionine, modulate the energy-intake-suppressant and insulintropic effects of whey protein PD-0765
N.D. Luscombe-Marsh, A. Ryan, S. Soenen, R.E. Steinert, P. Clifton, M. Horowitz, C. Feinle-Bisset (Australia)

Body weight reduction with the alpha-glucosidase inhibitor Acarbose is independent of baseline levels of postprandial glucose excursions PD-0766
O. Schnell, J. Weng, W.H.H. Sheu, H. Watada, S. Kalra, S. Soegondo, N. Yamamoto, W. Grzeszczak (Germany)

Effects of L-tryptophan on energy intake, antropyloroduodenal motility, glycemia, insulinemia and GLP-1 in healthy men PD-0767
R.E. Steinert, N.D. Luscombe-Marsh, T.J. Little, T. Fatehi, S. Standfield, M. Horowitz, C. Feinle-Bisset (Australia)

Central administration of palmitic acid and arachidonic aciddecreases central leptin sensitivity and induces an inflammatory response PD-0768
L. Cheng, A. Szabo, Y. Wu, X. Huang, Y. Yu (Australia)

Relationship of adipokines, proinflammatory cytokines with obesity and youth onset type 2 diabetes among Asian Indians PD-0769
K. Gokulakrishnan, A. Amutha, Y.S. Bibin, H. Ranjani, M. Balakumar, R.M. Anjana, P. Gauthamkumar, M.K. Ali, K.M. Narayan, V. Mohan (India)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Hypoglycaemia

Chair: S. Heller (United Kingdom)

To evaluate the effectiveness of in-house hypoglycemia management protocol PD-0786
Z.L. Kek, Y.H. Kwan, J.M. Ng, J. Khoo, J.Y. Chang (Singapore)

Weight-based treatment is more effective for resolving hypoglycaemia in adults: a randomised trial PD-0787
L. McTavish, E. Wiltshire, J. Krebs (New Zealand)

Recurrent hypoglycemia as risk factor on the outcomes after ischaemic stroke in type 2 diabetes PD-0788
G. maldonado, V. Arosa Carril, M. Sánchez Goitia (Spain)

Lower rates of hypoglycaemia with insulin degludec/insulin aspart versus biphasic insulin aspart 30 in patients with T2DM: a meta-analysis PD-0789
G. Fulcher, A. Vaag, J. Christiansen, T. Johansen, S. Rasmussen, L. Niskanen (Australia)

Insulin degludec: its stability and flatness observed in continuous glucose monitoring data PD-0790
H. Fujii, Y. Watanabe, M. Hasegawa, M. Nogawa, T. Miyakawa, Y. Yoshida, H. Kondo, M. Kato, N. Kato, H. Takamura, M. Kitaoka, A. Ueki (Japan)

Similar risk of exercise-related hypoglycaemia for insulin degludec compared to insulin glargine in patients with type 1 diabetes PD-0791
T. Heise, E. Zijlstra, L. Nosek, R. Bracken, H.L. Haahr, C. Roepstorff, R. Rabøl, E. Rowe, S.C. Bain (Germany)

Diabetes management and glycaemic control in Russian children, adolescents and young adults with type 1 diabetes in the TEENS study PD-0792
V. Peterkova, E. Andrianova, O. Malievsky, L. Laffel, M. Phillip, V. Pilorget, M.P. Dain, C. Domenger, C. Candelas (Russia)

13:00 - 14:00 Poster Area

Approaches to prevention of type 2 diabetes

Chair: S. Manson (USA)

Storytelling for diabetes prevention among Aboriginal children and their families PD-0810
E. Nardi, H. Mitchell, J. Owen, J. Hurd, A. Singh (Australia)

Health benefits of traditional crop foods to manage type 2 diabetes in indigenous communities PD-0811
K. Shetty, D. Warne, D. Sarkar (USA)

Developing a pathway for Aboriginal health workers into the graduate certificate of diabetes education PD-0812
J. Browne, S. Thorpe, J. Hogarth (Australia)

Got Suga: empowering Indigenous Australians to tackle diabetes through culturally appropriate education PD-0813
M. Adams, L. Chalmers, T. Black, M. Trute (Australia)

Strong Culture: A Road to Good Health - a diabetes prevention project PD-0814
A. Singh, H. Mitchell, J. Owen, D. Schofield, J. Hurd, C. Hawkins, E. Nardi, A. Wagstaff (Australia)

Whakawhanaungatanga - Indentity, family bonds and building relationships PD-0815
T. Courtney (New Zealand)

How lifestyle became the dominant explanation for diabetes in marginalised communities: a historical analysis PD-0816
S. O'Donnnell (Ireland)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Education

Chair: M. Mack (Australia)

Diabetes education program based on physical exercises promotes acute reduction in blood glucose in people with type 2 diabetes PD-0828
T. Lins, G. Mendes, J. Dullius (Brazil)

The effects of structure education use Conversation Map on behavior and metabolic control for T2DM patients in a primary care clinic setting PD-0829
Y. Wu, Y. Yang, Y. Lu, E. Kornelius, Y. Chen, C. Huang (Taiwan)

Participatory group-based diabetes education: the art of transforming education practice PD-0830
U. Møller Hansen, M. Glindorf, J.R. Voigt, I. Willaing (Denmark)

Patient support program designed to improve adherence and maximize health outcomes for Chinese T2DM patients taking exenatide PD-0831
J. Newman, H. Wu, B. Zhang, C. Tsai (Australia)

Social marketing and diabetes prevention PD-0832
V. McArthur (New Zealand)

Impact of an open online educational workshop for carb counting on a spanish speaking virtual community PD-0833
M. Sáinz de la Maza Viadero (Mexico)

Diabetes Attitudes Wishes and Needs 2 (DAWN2): Results of Education, Information and Support in Spain PD-0834
M. Jansa Morato, M. Galindo, M. Aguilar, M.A. Galindo, D. Orozco, I. Lorente, M. Maderuelo, E. Menendez (Spain)

Cost-effectiveness of pharmacist managed Medication Therapy Adherence Clinic (MTAC) on type 2 diabetes patients in a Malaysian hospital PD-0835
N. Loganadan, K.Y. Lim, N. Mohd Nur (Malaysia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Effectiveness of a peer support program in disease management regarding improvement of metabolic control PD-0836

T. Johansson, S. Keller, H. Winkler, R. Weitgasser, A.C. Sönnichsen (Austria)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Young people

Chair: M.L. Ruiz (Argentina)

An analysis on the differences of self-care behaviors between type 1 diabetic children and adolescents PD-0855
H.F. Wang, S.H. Shieh, Y.M. Wang (Taiwan)

Brazilian Young Leaders in Diabetes' glycemic control PD-0856
M.T.U. Barone, R.J. Pineda Wieselberg, D. Wey, L.L. Galastri, C.G. Labate, J. Baptista (Brazil)

Efficacy of Conversation Map tool as training tool in children with type1 diabetes PD-0857
E. Ghafoor, M. Riaz, A. Basit, A. Fawwad, M.Y. Ahmedani (Pakistan)

The Brazilian Young Leaders in Diabetes training PD-0858
M.T.U. Barone, R.J. Pineda Wieselberg, L.L. Galastri, C.G. Labate, J. Baptista, D.R. Franco, M.A. Vivolo (Brazil)

Diabetes in children and adolescents in Guinea PD-0859
N. Balde, J.S. Bangoura, M. Kouyate, M.A. Diallo, M.M. Diallo, M.A. Diallo, A. Bah, T.O. Barry, K. Kaba-Dieng, S. Bah, D. Kasse, M. Sangare-Bah (Guinea)

Transition care of adolescents and young adults with diabetes from a stand-alone children's hospital in Singapore PD-0860
J. Lim, F. Yap (Singapore)

Emotional outlet play use in group sessions at an educative summer camp for children with diabetes: an experience report PD-0861
C. de Souza Costa, T.R. Burlina, A.K. Pereira, M.G.S. Cavicchioli, R.I.H. Borba, R.O. La Banca (Brazil)

Burdens related to diabetes management in Russian children, adolescents and young adults with Type 1 Diabetes (T1D) in the TEENS Study PD-0862
V. Peterkova, E. Andrianova, O. Malievsky, L. Laffel, M. Phillip, V. Pilorget, M.P. Dain, C. Domenger, C. Candelas (Russia)

The American Diabetes Association's HbA1c goals for young children are not realistic PD-0863
R. Hanas, K. Lundqvist, L. Windell (Sweden)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Clinical care and complications

Chair: D. Young (Australia)

Diabetic autonomic neuropathy predicts severe hypoglycemia in patients with type 2 diabetes mellitus: a ten-year follow up study PD-0883
S.H. Ko, J.S. Yun, K.H. Song, Y.B. Ahn, K.D. Yoo, Y.M. Park, S.H. Ko (Korea)

Prospective comparative study to estimate the prevalence of depression in type 2 diabetes patients in a tertiary care centre PD-0884
S. Jha, S. Siddiqui, S. Waghdhare, K. Singh (India)

Dental health in Pakistani diabetics presenting in a voluntary sector health facility PD-0885
M. Asif Mahmood, M. Aqeel, M.A.Z. Abu Zafar (Pakistan)

Glycaemic control in patients taking oral antihyperglycaemic medication only or insulin only regimens for patients with T2DM in China PD-0886
L. Liu, Y. Chen, B. Curtis, L. Gu, S. Babineaux (China)

Half century of type 1 (insulin dependent) childhood diabetes in India: change, progress and future? (1970s-2010s) PD-0887
V. Krishnaswamy, U. Rangaraj, G. Rao, K.N. Ashwini, S. Srikanta, M. Cavale, T. Kamala, S. Murugan, V. Rao, T. Deepak, A. Sharda, Diabetes Collaborative Study Group(1) (India)

Clinical audit on diabetes care for Palestinian refugees in UNRWA health centers PD-0888
Y. Shahin, A. Seita, A.N.I.L. Kapur, W. Zeidan (Jordan)

Endothelium dependent hemostatic factors and subclinical inflammation in women with previous gestational diabetes mellitus PD-0889
T. Demir, S. Eraslan, S. Yener, B. Akinci, M.A. öZcan, A. Cömlekci (Turkey)

To investigate the effectiveness of body weight management by telehealth platform PD-0890
Y. Chen, C. Liu, C. Chen, T. Huang, S. Tu, M. Hsieh (Taiwan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Diabetes complications

Chair: M. Saraheimo (Finland)

Corneal confocal microscopy detects neuropathy before retinopathy and nephropathy in children with type 1 diabetes: a preliminary study PD-0904
M. Tavakoli, R.A. Malik (United Kingdom)

Comparison of screening modalities for peripheral neuropathy in persons with diabetes, Dar es Salaam, Tanzania PD-0905
Z. Abbas, J. Lutale, L. Archibald (Tanzania)

Intravenous antimicrobial therapy of diabetic foot ulcers: an effective outpatient program in Tanzania PD-0906
Z. Abbas, J. Lutale, L. Archibald (Tanzania)

Screening for diabetic retinopathy in primary care in Portugal: an observational study PD-0907
R. Rangel, J.F. Raposo, J.M. Boavida, L. Gardete-Correia (Portugal)

Health related quality of life among patients with diabetic comorbidity in India: findings from SAGE survey PD-0908
S. Pati, M.A. Hussain, S. Swain, C. Millett (India)

Are changes in glycaemic control associated with quality of life and health status? Four year follow-up of screen-detected patients PD-0909
R.K. Simmons, L. Kuznetsov, G.H. Long, S.J. Griffin (United Kingdom)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Diabetes association activities

Chair: J. Raposo (Portugal)

Role of associations in inspiring people with diabetes, case of PLAVI Krug PD-0925
D. Damnjanovic (Serbia)

Camps are about having a great time and lots of fun!: evaluation of Diabetes Australia Vic's Diabetes Camps Program PD-0926
A. Scovelle, C. Hendrieckx, J. Cheney, R. Scibilia, J. Speight (Australia)

A telephone peer support for diabetes self-management intervention in Vietnamese adults with type 2 diabetes PD-0927
T. Dang, W. Deoisres, P. Keeratiyutawong, L. Baumann (Vietnam)

Annual cycle of care practices of people with diabetes in NSW PD-0928
A. Blair, K. Hazelwood, F. Gardner, M. Norman (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Type 2 diabetes screening and associated factors

Chair: D. Levitt (South Africa)

Validation of the FINDRISC score for prediction of type-2 diabetes in the Spanish population: the VIVA (Variability of Insulin with Visceral Adiposity) cohort study PD-0948
R. Gabriel, M. Serrano-Rios, C. Brotons, J.M. Fernández-Carreira, C. Gisbert, J. Parra, G. Rojo, A. Segura, S. Vega, R. Madero, J. Tuomilehto (Spain)

Detecting diabetes using the EZSCAN test PD-0949
S.K. Tanamas, J.P. Deslypere, P. Zimmet, J.E. Shaw (Australia)

Application of self-assessment risk score for diabetes to predict non-alcoholic fatty liver disease PD-0950
Y. Lee, Y.M. Park, E.S. Kang, B.W. Lee, B.S. Cha, H.C. Lee, D.J. Kim (Korea)

Does awareness of diabetes and hypertension vary across socioeconomic groups in urban South Asia? PD-0951
M.K. Ali, B. Binukumar, R. Shivashankar, M. Deepa, R. Pradeepa, Z. Fatmi, M.H. Kadir, V. Mohan, N. Tandon, K.M. Narayan, D. Prabhakaran, F.O.R. CARRS Study Group (USA)

Increased risk of vaginal infection among women with diabetes: a population-based retrospective cohort study PD-0952
C.C. Liao, T.L. Chen (Taiwan)

Risks of accidental injuries in diabetes with and without history of hypoglycemia: A population-based cohort study PD-0953
C.L. Lu, P.C. Hsu, Y.H. Chang, C.Y. Li (Taiwan)

Study on the support of compatibility between work and medical care and of return to work in diabetic patients in Japan PD-0954
A. Watarai, E. Nakashima, T. Sano, T. Kawamura, M. Omura, M. Nomura, Y. Yamamoto, K. Yaga, K. Kaneko, Y. Kobayashi, H. Yatsuya, N. Hotta (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Cytokeratin-18 fragment levels as a biomarker for nonalcoholic fatty liver disease in type 2 diabetes PD-0955

M. Miyasato, Y. Murase-Mishiba, M. Bessho, M. Miyawaki, H. Imbe, C. Tsutsumi, K. Tanimoto, A. Imagawa, J. Terasaki, T. Hanafusa (Japan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Risk factors for type 2 diabetes: nutrition

Chair: K.S. Chia (Singapore)

The Baltic Sea diet associated with lower hs-CRP concentrations in two independent study populations PD-0975
N. Kanerva, J.G. Eriksson, B.M. Loo, S. Männistö (Finland)

Dietary fiber intake and risk of type 2 diabetes mellitus: a dose-response meta-analysis of prospective cohort studies PD-0976
S. Rong, Y.X. Yang, W. Bao (China)

Tree nuts improve insulin resistance: a systematic review and meta-analysis of randomized controlled dietary trials PD-0977
C.W.C. Kendall, E. Viguiliouk, R.J. de Souza, S. Blanco Mejia, A.I. Cozma, V. Ha, A. Mirrahimi, D.J.A. Jenkins, J.L. Sievenpiper (Canada)

Fruits and vegetables for health: a macro-level analysis of global supply and demand PD-0978
K. Siegel, R.A. Nugent, K.M. Venkat Narayan (USA)

Wine consumption throughout life and risk of type 2 diabetes in the French E3N cohort PD-0979
G. Fagherazzi, A. Vilier, M. Lajous, J.L. Harding, D.J. Magliano, B. Balkau, F. Clavel-Chapelon (France)

Fruit and vegetable consumption and risk of type 2 diabetes mellitus PD-0980
S. Vasudevan, R.M. Anjana, K. Manobala, R. Pradeepa, M. Deepa, A. Bhansali, S.R. Joshi, P.P. Joshi, V.K. Dhandhania, A.K. Das, T. Kaur, V. Mohan (India)

Regional cooking oil preferences of Asian Indians and their influence on the risk of type 2 diabetes PD-0981
S. Vasudevan, R.M. Anjana, N. Lakshmi Priya, R. Pradeepa, M. Deepa, A. Bhansali, S.R. Joshi, P.P. Joshi, V.K. Dhandhania, A.K. Das, T. Kaur, V. Mohan (India)

Health behaviour changes in response to a gestational diabetes mellitus diagnosis in Ethnic women versus Caucasian women PD-0982
A. Banerjee, S. McTavish, E. Gucciardi, J. Lowe, D. Feig, J. Ray, L. Lipscombe (Canada)

13:00 - 14:00 Poster Area

Complications - cognitive, psychosocial and cardiovascular

Chair: S. Griffin (United Kingdom)

Diabetes status, fasting glucose, and HbA1c as a predictors of cognitive function after 12 years follow-up: Findings from the AusDiab study PD-1001
K.J. Anstey, D. Magliano, J. Shaw (Australia)

Depression prevalence in people with diabetes and foot ulcers attending podiatry outpatient clinics PD-1002
S. Pearson, T. Nash, V. Ireland (Australia)

The impact of educational level on vascular events and mortality in patients with type 2 diabetes mellitus PD-1003
J.I. Blomster, C.K. Chow, S. Zoungas, M. Woodward, J. Chalmers, G.S. Hillis (Australia)

Trends in the cardiovascular risk profile of U.S. adults with prediabetes from 1988 to 2010 PD-1004
M.K. Ali, K.M. Bullard, S.H. Saydah, G. Imperatore, A. Albright, E.W. Gregg (USA)

Prevalence of metabolic syndrome and its association with coronary artery disease among an urban elderly south Indian population PD-1005
R. Pradeepa, M. Deepa, R.M. Anjana, V. Mohan (India)

Trends in prevalence of cardiovascular and kidney diseases among U.S. adults with and without prediabetes, 1988-2010 PD-1006
M.K. Ali, K.M. Bullard, S.H. Saydah, G. Imperatore, A. Albright, E.W. Gregg (USA)

Associations between diabetes and mild cognitive impairment differ between men and women - results of the Heinz Nixdorf Recall Cohort Study PD-1007
A. Winkler, M. Dlugaj, N. Pundt, R. Erbel, K.H. Jöckel, D. Führer, N. Dragano, C. Weimar, S. Moebus (Germany)

Association between duration of diabetes and incident cancer in Australian adults PD-1008
Z. Shi, G.A. Wittert, E. Dal Grande, A.W. Taylor (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Prevalence of diagnosed cancer among patients with type 2 diabetes seen at a tertiary care diabetes centre in South India PD-1009

U. Ranjit, C. Ambrish, R. Pradeepa, R.M. Anjana, S. Jebarani, V. Mohan (India)

13:00 - 14:00 Poster Area

Diabetes management: diabetes in the elderly

Chair: D. Owens (United Kingdom)

Therapy changes and glycated haemoglobin levels in type 2 diabetes: clinical inertia is still a major problem. data from AMD annals PD-1026
C.B. Giorda, A. Cimino, S. Genovese, A. Nicolucci, F. Pellegrini, B. Pintaudi, M. Ragonese, M.C. Rossi (Italy)

Mapping diabetes, risk factors, and self-management education access: geographic clusters of need in the United States PD-1027
A. Curtis, C. Brooks, R. Paul, K. Baker, R. Chowdhary, C. Kothari (USA)

The association between patient-reported adherence to treatment and mortality in patients with type 2 diabetes: The KORA-A study PD-1028
M. Laxy, A. Mielck, M. Hunger, M. Schunk, C. Meisinger, I. Rückert, W. Rathmann, R. Holle (Germany)

Process- and intermediate outcome indicator results in the 2011 LOK survey (DUDE-2) PD-1029
H. Bilo, M. Meulepas, A. Romeijnders, M. Klomp, S.T. Houweling, N. Kleefstra (The Netherlands)

Diabetes education and physical exercise, who look for: the profile of people in 19000 attendances in Doce Desafio program PD-1030
J. Dullius, G.F. Mendes, C.G. Reis, T.C. Lins, W. Araujo (Brazil)

Ameliorative effects of "fire flame bush" on metabolic & anthropometric indices in diabetic patient:double blind placebo controlled study PD-1031
A. Chopra, R.P. Agrawal, S. Chopra, V. Agarwal, R. Chopra, N. Sharma (India)

The effect on HbA1c of regular exercise in patient with type 2-diabetes in Chinese - a propensity score approach PD-1032
E. Nørtoft, L. Wilkinson, P. Jain (Denmark)

Doubling of diabetes inpatients and greater hospital length of stay: Royal Melbourne Hospital inpatient study 2001-2011 PD-1033
S. Fourlanos, N. Nanayakarra, P.G. Colman (Australia)

Inpatient diabetes audit identifies frequent diabetes medication errors PD-1034
S. Elkassaby, N. Nanayakarra, N. Marijanovic, A. Nankervis, S. Fourlanos, P.G. Colman (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

13:00 - 14:00 Poster Area

Prevalence of diabetes and prediabetes among the elderly in urban South India - the Chennai Urban Rural Epidemiology Study PD-1035

R. Pradeepa, M. Deepa, R.M. Anjana, V. Mohan (India)

POSTER

TUESDAY 03 - FRIDAY 06 DECEMBER 2013

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

Late-breaking abstracts

Association between diabetic autonomic neuropathy and other microvascular complications P-1037
K.J. Ahn, Y.C. Hwang, I.C. Jeong, H.Y. Chung (Korea)

Does zinc supplementation affects changes in tissue factor activity and glycoprotein components in diabetic rat tissues? P-1038
O. Sacan, I.B. Turkyilmaz, B.B. Bayrak, O. Mutlu, R. Yanardag, N. Akev (Turkey)

Comprehensive genetic screening of maturity onset diabetes of the young in India using next generation sequencing P-1039
N. Thomas, A. Chapla, D.M. Mahesh, D. Varghese, S.V. Nadig, H.S. Asha, R.T. Varghese, M. Inbakumari, F. Christina, S. Mathai, T.V. Paul (India)

The role of clinical signs and procalsitonin in determining the existance of infection in the treated diabetic foot ulcer P-1040
A. Aswar, E. Yunir, A. Karuniawati, K. Harimurti (Indonesia)

Intestinal fermentation of wholegrain barley beta-glucan does not improve glucose tolerance P-1041
D.P. Belobrajdic, S.A. Jobling, M.K. Morell, S. Taheta, A.R. Bird (Australia)

Glycation of opticin possible role to diabetic retinopathy P-1042
A. Benjama, N. Ahmed, M. Slevin (United Kingdom)

An audit of bedside capillary glucose monitoring for diabetic patients in emergency care P-1043
D. Bohan Shaw, C. Thach, J. Kant (New Zealand)

Just how important is it when patients question whether or not they took their last insulin dose? Findings from a 5 country survey P-1044
M. Brod, K.M. Pfeiffer, J. Kongso (USA)

Type 2 diabetic with high normal BP had high urinary AER compared with normal BP diabetics and controls: a primary care cross-sectional study P-1045
D. Carvalho, J. Nazaré, L. Martins, P. Marques-da-Silva, C. Aguiar, M.C. Manso, T. Carqueja, J. Polónia, on behalf of RACE study group (Portugal)

Efficacy and safety of linagliptin in 2681 Asian patients: results of a pooled analysis of randomised, placebo-controlled trials P-1046
G. Ning, T. Bandgar, J.C.N. Chan, J. Lee, U. Hehnke, H.-J. Woerle (China)

Antithymocyte globulin does not preserve C-peptide in younger T1D subjects and is associated with faster T cell reconstitution P-1047
M. Ehlers, P.A. Gottlieb, M.R. Rigby, E.I. Felner, S.M. Willi, A. Pinckney, M. Howell, D. Phippard, L. Ding, J.A. Bluestone, S.E. Gitelman (USA)

Long-term intraindividual variability in albumin excretion rate in patients with type II diabetes P-1048
A. Leong, E.I. Ekinci, C. Nguyen, M. Milne, M. Dobson, R.J. Mac Isaac, G. Jerums (Australia)

BenecarbTM, a sugar cane molasses extract syrup, reduces postprandial glucose and insulin responses to a standardized mixed meal P-1049
T.P. Ellis, A.G. Wright, L.L. Ilag (Australia)

Lessons from early experience with insulin degludec in routine clinical practice P-1050
M. Evans, A.M. Ming, R. Robinson (United Kingdom)

Integrated systems analysis reveals cholesterol homeostasis to be a key determinant of insulin sensitivity in adipocytes P-1051
D. Fazakerley, R. Chauduri, P. Yang, S.J. Humphrey, N.J. Hoffman, X. Ma, C.C. Meoli, J.J. Junutula, G. Kolumam, Z. Modrusan, K.L. Hoehn, D.E. James (Australia)

A 24 hour high fat diet impairs glucose tolerance in C57BL/6J and C57BL/6N mice P-1052
K. Fisher-Wellman, L. Gilliam, C. Lin, L. Reese, B. Cathey, D. Lark, C. Smith, P.D. Neufer (USA)

Aloe vera juice as adjuvant in the healing of toe amputee: a case report P-1053
M. Flores-Trujillo, D. Rebollo (Mexico)

A prospective, claims-based study of the risk of acute pancreatitis and pancreatic cancer with liraglutide versus other antidiabetic drugs P-1054
D. Funch, H. Gydesen, K. Tornøe, A. Major-Pedersen, K.A. Chan (Denmark)

Recommendations for individualised medical treatment of hyperglycaemia in type 2 diabetes:a systematic analysis of expert opinion P-1055
B. Gallwitz, P.Y. Benhamou, G. Charpentier, A. Consoli, M. Diamant, K. Khunti, C. Mathieu, M. Ridderstråle, J. Seufert, C. Tack, T. Vilsbøll, F. Javier Ampudia-Blasco (Germany)

Diabetic foot: risk factors for multidrug-resistant bacteria infection P-1056
M. García Zafra, E. García Vazquez, A. Hernández Torres, T. Soria Cogollos, F.J. Tébar Massó, F. García Zafra, J. Ruíz Gómez, J. Barberán, J. Gómez Gómez (Spain)

The effects of switching glargine administration from evening to morning hours in type 1 diabetic patients P-1057
M. Gradiser, I. Bilic, M. Berkovic (Croatia)

No relation between serum undercarboxylated osteocalcin levels and microvascular complications in patients with type 2 diabetes mellitus P-1058
F. Kucukler, S. Bardak, T. Celik, Y. Tutuncu, G. Akbaba, S. Isik, S. Karaahmetoglu, E. Eskioglu, D. Berker, S. Guler (Turkey)

Prevalence and characteristics of diabetic foot ulcers in western Sydney P-1059
N. Haji Zaine, K. Hitos, J. Fletcher, M. Vicaretti, L. Begg, J. Burns (Australia)

Real life evidence of Liraglutide effects supports efficacy shown in RCTs P-1060
A. Heymann, Y. Maor, I. Goldstein, L. Todorava, P. Schertz-Sternberg, A. Karasik (Israel)

The role of mitochondrial turnover in diabetic nephropathy P-1061
G.C. Higgins, S.A. Penfold, J.M. Forbes, M.T. Coughlan (Australia)

The significant influence of risk factor on skin AF value through retrospective study in Japanese patients with type 2 diabetes P-1062
S. Hoshina, J. Miura, S. Kikuchi, K. Shimura, H. Kobayashi, M. Osawa, Y. Uchigata (Japan)

Successful transition to glyburide therapy in two patients with neonatal diabetes with novel mutations in genes encoding the K-ATP channel P-1063
J.A. Indyk, L.B. Rauch, W.B. Zipf (USA)

Post-delivery screening in women with gestational diabetes mellitus: prediction of abnormal glucose tolerance using antenatal factors P-1064
E. Ingram, I. Roberston, K. Ogden, A. Dennis, J. Campbell, A. Corbould (Australia)

The effect of exercise on the peripheral nerve in the STZ induced diabetic rats P-1065
H.Y. Jin, T.S. Park, H.S. Baek, K.A. Lee, S.H. Kim, C.O. Baek (Korea)

Pharmacodynamic profiles of lixisenatide vs. liraglutide in patients with type 2 diabetes mellitus on metformin P-1066
C. Kapitza, H.V. Coester, R. Berria, E. Nikonova, A. Hincelin-Mèry, T. Forst (Germany)

Healthy rice options for Asian diabetic patients: using the metabolic approach to evaluate crossbred and commercial rice varieties P-1067
T. Karupaiah, C.H. Se, K.A. Chuah, Z.W. Yeak, S. Sahathevan, W. Ratnam (Malaysia)

Sitagliptin improved glycemic control with less hypoglycemia and a lower insulin dose in patients who intensify basal insulin therapy P-1068
H.L. Katzeff, R.R. Shankar, C. Matheiu, D. Lorber, G. Umpierrez, F. Wu, L. Xu, G.T. Golm, M. Latham, S.S. Engel (USA)

Clinical, metabolic aspects of subclinical Cushing's syndrome in patients with adrenal incidentaloma P-1069
B.Y. Kim, C.H. Kim, J.O. Mok, S.K. Kang, C.H. Jung, K.J. Kim (Korea)

Lysosomal disruption in monocyte development to macrophages: a potential contributory factor in diabetes-associated atherosclerosis P-1070
C. Kim, D. van Reyk, M. Davies (Australia)

TEMPOL prevents obesity, hyperlipidaemia and inflammatory cytokines, but does not modulate atherosclerosis in obese mice P-1071
C. Kim, J. Mitchell, D. van Reyk, M. Davies (Australia)

Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic mice P-1072
C. Kim, B. Brown, F. Torpy, C. Bursill, L. McRobb, A. Heather, M. Davies, D. van Reyk (Australia)

Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes P-1073
S.H. Kim, C.O. Baek, K.A. Lee, H.Y. Jin, T.S. Park, H.S. Baek (Korea)

Glucose variability is associated with spot urine albumin/creatinine ratio in type 2 diabetes patients P-1074
T.H. Kim, S.M. Jin, J.H. Bae, S.H. Suh, K.Y. Hur, M.S. Lee, M.K. Lee, J.H. Kim (Korea)

Clinical factors associated with measures of glycemic variability as determined by CGM in type 1 and insuin-treated type 2 diabetes P-1075
T.H. Kim, S.M. Jin, J.H. Bae, S.H. Suh, K.Y. Hur, M.S. Lee, M.K. Lee, J.H. Kim (Korea)

Rescue for failure of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: the REGULATE study P-1076
Y. Kondo, S. Satoh, Y. Inoue, Y. Miyazaki, S. Hosokawa, U. Nezu, Y. Terauchi (Japan)

Ketoacidosis with lactic acidosis in patients with type 1 diabetes P-1077
J. Krzymien, W. Karnafel (Poland)

Clinical and genetic characteristics of slowly progressive type 1 diabetes patients with low titer of autoantibodies to GAD P-1078
S. Kudo, J. Miura, S. Hoshina, K. Shimura, S. Kikuchi, H. Kobayashi, Y. Uchigata (Japan)
Presenting Author: F. Kutluturk (Turkey)

Significance of CGRP and VIP in the diagnosis of diabetic autonomic neuropathy P-1080
O. Erbas, T. Tasliyurt, F. Kutluturk, V. Solmaz, S. Sahin, D. Taskiran (Turkey)

Metformin elevates secretion of GLP-1 but not GIP and improves postprandial glucose excursion in Japanese patients with type 2 diabetes P-1081
H. kuwata, D. Yabe, R. Usui, K. Watanabe, T. Hyo, T. Kurose, Y. Seino (Japan)

Pooled treatment outcomes with glargine and NPH from 3 treat-to-target trials in type 2 diabetes according to concomitant OAD therapy P-1082
R.G. Bretzel, L. Traylor, W. Landgraf (Germany)

Inpatient admission rates of antidiabetic initiators and non-initiators among newly diagnosed patients with type 2 Diabetes P-1083
J. Lian, P. Sun (USA)

Antidiabetic treatment pathways among newly diagnosed patients with type 2 diabetes: a three-year longitudinal study P-1084
P. Sun, J. Lian (USA)

Association of gender, age and payer types with antidiabetic treatment adherence among newly diagnosed patients with type 2 diabetes P-1085
J. Lian, P. Sun (USA)

Is better antidiabetic treatment adherence associated with lower use of inpatient care? A retrospective three-year study P-1086
J. Lian, P. Sun (USA)

Single administration of bethanechol + N-acetyl¬-cysteine reverses sucrose induced insulin resistance in virgin and pregnant rats P-1087
N. Lovat, D.J. Legare, W.W. Lautt (Canada)

Robust metabolic improvement observed with the endoscopic, duodenal-jejunal bypass liner: 12 month data in obese type 2 diabetes P-1088
D. Maggs, E. Moura, K. Malomo, A. Liao, J. Tetreault, J. Teare, R. Cohen (USA)

Assessing the real-world cost-effectiveness of switching patients with type 1 diabetes to insulin degludec in routine clinical practice P-1089
P. McEwan, V. Foos, M. Evans (United Kingdom)

New insights into statin action on the dyslipidemia of type 2 diabetes: normalisation of the plasma lipid profile P-1090
P. Meikle, G. Wong, R. Tan, B. Kingwell, A. Orsoni, N. Hounslow, P. Giral, M. Chapman (Australia)

Brite adipocytes show enhanced beta-adrenoceptor expression and function in vitro P-1091
J. Merlin, R. Fahey, T. Bengtsson, R.J. Summers, B.A. Evans, D.S. Hutchinson (Australia)

Effect of pistachio nuts on inflammatory and oxidative stress parameters in Asian Indians with metabolic syndrome P-1092
A. Misra, S. Gulati, R.M. Pandey, S.P. Bhatt, S. Saluja (India)

52-week effects of canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), added to insulin therapy in type 2 diabetes (T2D) P-1093
B. Neal, D. Matthews, G. Fulcher, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, G. Capuano, M. Alba, M. Desai, W. Shaw, E. Morales, F. Vercruysse (Australia)

Anti-beta2GPI antibodies in type 1 diabetes mellitus: an evaluation for Turkish population P-1094
F. Bakar, U. Unluturk, N. Baskal, S. Nebioglu (Turkey)

Validation of NerveCheck, a new quantitative sensory testing device to asses large and small fiber dysfunction P-1095
A. Odriozola, R. Malik, G. Ponirakis, R. Gomis, J. Vidal, M. Odriozola, B. Odriozola, A. Miro, S. Odriozola (Spain)

The screening impact on neuropathy using a new quantitative sensory testing nervecheck, in relationship to the time of diabetic evolution P-1096
A. Odriozola, G. Fuente, N. Weisse, P. Iglesias, C. Dominguez, J. Braver, V. Fusaro, S. Odriozola, M.B. Odriozola, R. Gomis, M. Odriozola, L. Collia (Spain)

Nervececk: a new diagnostic tool to asses diabetic polyneuropathy P-1097
A. Odriozola, G. Fuente, N. Weisse, P. Iglesias, C. Dominguez, J. Braver, V. Fusaro, S. Odriozola, M.B. Odriozola, J. Vidal, M.N. Odriozola, L. Collia (Spain)

Insulin presents proinflammatory and prooxidant effects in a model of experimental diabetes P-1098
A.A.F. Oliveira, L.L. Bobadilla, A.P.M. Loureiro (Brazil)

The fetal origins hypothesis of diabetes in animal research: A systematic review and meta-analysis of the evidence P-1099
M. Veenendaal, S. Thangaratinam, D. Yates, R.C. Painter, S.R. De Rooij, J.A. van der Post, P.M. Bossuyt, G. Saade, B.W. Mol, K. Khan, T.J. Roseboom (The Netherlands)

Angiotensin converting enzyme 2 (ACE2) is a novel marker of pre-clinical diastolic dysfunction in type 2 diabetes P-1100
S.K. Patel, B. Wai, T.F. Lancefield, E. Velkoska, P.M. Srivastava, L.M. Burrell (Australia)

Comparison of irbesartan and its combination with n-acetyl cysteine in experimental diabetic nephropathy P-1101
H. Peynirci, S. Sen, M. Kanter, S. Ustündag, C. Aktas (Turkey)

Clinical reversal of type 2 diabetes mellitus in two obese children P-1102
H. Phatale, P. Phatale (India)

Associations between regional body fat distribution and homocysteine levels in type 2 diabetes with coronary atherosclerosis patients P-1103
W. Ren, J. Guo, J. Liu, W. Jia (China)

A randomised controlled trial of linagliptin monotherapy vs initial combination with metformin in newly diagnosed type 2 diabetes patients P-1104
S.A. Ross, A.E. Caballero, S. Del Prato, B. Gallwitz, D. Lewis-D'Agostino, Z. Bailes, S. Thiemann, S. Patel, H.-J. Woerle, M. von Eynatten (Canada)

Combination regimen of statin/ezetimibe and reduction of sd-LDL-c among Japanese type2 diabetes, RESEARCH, a multicenter RCT. P-1105
K. Sakamoto, Y. Mori, T. Inazawa, T. Kohro, M. Omura, T. Watanabe, T. Hirano, M. Tagami, A. Tanaka, M. Kawamura, T. Yamazaki, T. Shiba (Japan)

Early vs late intervention in peripheral neuropathic pain P-1106
T. Siciliano, V.V.P. Van Paassen (United Kingdom)

Short term continuous subcutaneous insulin infusion - highly cost effective therapy in severe t2d patients with recovering or early sepsis P-1107
K. Singh, P. Rai, R. Behl, M. Galhotra (India)

The association between insulin dose and cardiovascular mortality in the ACCORD trial P-1108
E.S. Siraj, D.J. Rubin, M.E. Miller, F.C. Hsu, F. Ismail-Beigi, A. Thomas, S.H. Chen, W.T. Ambrosius, M.C. Riddle, For the ACCORD Investigators (USA)

Impaired cortisol and growth hormone responses during hypoglycemia in type 2 diabetes P-1109
K. Song, J.H. An, D.L. Kim, S.K. Kim (Korea)

Effect of Physalis angulata L. extracts on pancreas histologyof sprague dawley male rats hyperglycaemia P-1110
Y. Sulistyowati, I. Setyobroto, S. Sojarullah, S. Laila (Indonesia)

Prediabetes and peripheral inflammatory markers are associated with reduced fluid intelligence P-1111
F. Lombado, B. Fabre, M. Pandolfo, V. Ortiz, C. Carbia, M. Lardo, F. Reissig, E. Cagnacci, V. Quiroga, M.j. Perone, F.m. Puchulu, M.j. Taverna (Argentina)

Using of CGM and insulin pump therapy in management of nocturnal hypoglycemia in hospital settings in children and adolescents with T1DM P-1112
D.N. Laptev, N.N. Volevodz, A.O. Emelyanov, T.L. Kuraeva, V.A. Peterkova (Russia)

The TRPV1 receptor regulates glucose metabolism in mice P-1113
G. Wittert, G. Hatzinikolas, S. Kentish, T. O Donnell, C.L. Frisby, P. Cavuoto, A. McAinch, A. Page (Australia)

Safety and efficacy of insulin-to-liraglutide switch: a caution against inappropriate use in patients with reduced ß-cell function P-1114
D. Yabe, R. Usui, H. Kuwata, K. Watanabe, T. Hyo, T. Kurose, Y. Seino (Japan)

Glucagon secretion in normal, impaired and diabetic glucose tolerance: is dysregulated glucagon response a cause or effect of diabetes? P-1115
D. Yabe, M. Iwasaki, H. Kuwata, R. Usui, K. Watanabe, T. Hyo, N. Kitatani, T. Kurose, Y. Seino (Japan)

Pre-pregnancy BMI and LDL-C contribute to gestational weight gain among the normal pre-pregnancy BMI mothers with gestational diabetes P-1116
Y. Yang, P. Wang, W.Q. Xia, Y. Zhou, Y. Huang, Q. Wei, Y. Yuan, S.H. Wang (China)

Subject-driven titration of biphasic insulin aspart 30 is non-inferior to investigator-driven titration in Chinese subjects with T2DM P-1117
S. Ye, H. MIAO, Z. WANG, X. LV, G. YANG, J. YANG, J. LIU, W. ZHAO (China)

Oligosaccharyltransferase-48 membrane translocation can influence diabetic kidney disease P-1118
A. Zhuang, B.E. Harcourt, K.C. Sourris, S.A. Penfold, A.K. Fotheringham, D. McCarthy, P. Thorn, B. Schulz, J.M. Forbes (Australia)

Role of thrombophilia in re-stenosis after percutaneous transluminal angioplasty of ischemic limbs in diabetic patients P-1119
M. Dubsky, A. Jirkovska, L. Pagacova, R. Bem, V. Fejfarova, M. Schubertova, J. Skibova, (Czech Republic)

Oligosaccharyltransferase-48 as a novel mediator of chronic kidney disease in diabetes P-1120
A. Zhuang, B.E. Harcourt, K.C. Sourris, S.A. Penfold, M.S. Ward, A.K. Fotheringham, P. Thorn, J.M. Forbes (Australia)

Access to drugs and technologies

Protective effect of pioglitazone on hypercholesterolemic artery P-1121
H. Honda, H. Honda, J. Taniguchi, Y. Notoya (Japan)

Beneficial effects of the mulberry twig alkaloids in normal and diabetic animals as a potential alpha-glucosidase inhibitor P-1122
Q. Liu, M.Z. Xie, Y. Shen, Z.F. Shen (China)

Outcomes of pregnancy and childbirth in women with type 1 diabetes on insulin pump therapy P-1123
T. Skryplionak, T. Mokhort, O. Pancratova, V. Rimashevski (Belarus)

Assessing efficacy of Intra vitreal Bevacizumab in treatment of diabetic macular edema in Nepal P-1124
A. Shrestha, S. Vyas (Nepal)

8-Hexadecanolide, a medium-ring lactone, inhibits key enzymeslinked to diabetes mellitus P-1125
A. Yusufoglu, O. Sacan, H. Yasa, R. Yanardag (Turkey)

Animal models of type 1 diabetes

Protective effect of zinc sulfate on brain and lens antioxidant systems in STZ-induced diabetic rats P-1126
A. Can, O. Mutlu, R. Yanardag (Turkey)

Potential effects of flaxseed on metabolic and oxidative stress parameters in diabetic rats P-1127
N. Tarhan, C. Tufan, Y. Fidan, A. Aydin, N. Ari, G. Ozansoy (Turkey)

Animal models of type 2 diabetes

The role of erythrocytes glucose uptake in tissue damage and complications at experimental obesity, hyperinsulinemia and diabetes in rats P-1128
A. Alieva, A. Tashmanova, N. Akhrarova, A. Tsoy, Z. Shamansurova, S. Ismailov (Uzbekistan)

Evaluation of chronic administration of Zingiber officinale on glycemic and lipidemic status in normal and STZ induced type 2 rats P-1129
A. Bhowmik, S.M. Shadli, M.A. Haque, A.K. Azad Khan, B. Rokeya, M. Mossihuzzaman (Bangladesh)

Small intestinal mucosa of diabetic rats treated with sitagliptin P-1130
S. Bolkent, A.B. Beydogan, S. Karabulut (Turkey)

Influence of exogenous ghrelin on the kidney of newborn STZ-diabetic rats P-1131
S. Bolkent, O. Sacan, S. Bolkent, A. Karatug, N. Turk, R. Yanardag (Turkey)

The effects of oral antidiabetic drugs such as metformin, rosiglitazone and repaglinide on diabetic angiopathy P-1132
F. Kilicli, I. Bagcivan, A. Altun, H. Dokmetas (Turkey)

Effects of Bisphenol A exposure on zebrafish pancreas development P-1133
K. Graham, Y. Gibert (Australia)

Chemical characterization of germinated Glycine max & its evaluation as antidiabetic agent in STZ induced diabetic rats P-1134
R. Gupta, S.B. Sharma (India)

A polyherbal formulation improves glucose utilization and reduces insulin resistance by up-regulating Glut4 mRNA in type 2 diabetic rats P-1135
R. Hafizur, S. Shaukat, N. Kabir (Pakistan)

Development of an alternative non-obese non-genetic rat model of type 2 diabetes P-1136
P. Naidoo, M.S. Islam (South Africa)

9-tetrahydrocannabinol treatment improved endothelium-dependent relaxation in diabetic rat aorta P-1137
S. Ozyazgan, Z.M. Coskun, A. Altinok, K. Karaoglu, S. Bolkent, A.G. Akkan (Turkey)

Diabetic wound ulcer therapy: comparison of adjunctive topical mono- or combination-therapies and Low Energy Laser Therapy (LELT) P-1138
H. Saleh, B.P. Koeleman, P. Hamar (Egypt)

Nicotinamide improves the pathophysiology of type 2 diabetes and hepatic steatosis by altering the NAD-sirtuin pathway P-1139
H.K. Won, K.Y. Park, D.M. Lim, S.J. Yang, J.M. Choi, L.S. Kim, S.E. Park, S.W. Park, C.Y. Park (Korea)

Bariatric surgery and type 2 diabetes

Metabolic and nutritional profile after bariatric surgery in obese diabetic patients P-1140
S.K. Abdul Shakoor, A. Koura, J. Rao, Y. Kon (Singapore)

Resolution of type 2 diabetes and prediabetes following laparoscopic sleeve gastrectomy P-1141
A.R. Romero Lluch, A.J. Martínez Ortega, I. Jiménez Varo, J.L. Pereira Cunill, P. Serrano Aguayo, M. Socas Macías, A. Barranco Moreno, S. Morales Conde, P.P. García Luna (Spain)

The excess body mass index loss is the best predictor of metabolic syndrome criteria remission after laparoscopic metabolic gastric bypass P-1142
M. Nora, M. Guimarães, R. Almeida, P. Martins, G. Gonçalves, M. Santos, T. Morais, C. Freitas, M.P. Monteiro (Portugal)

Laparoscopic greater curvature plication transiently restores postprandial incretin peak in obese type 2 diabetic patients P-1143
M. Mraz, P. Kavalkova, K. Dolezalova, M. Urbanova, P. Trachta, J. Drapalova, Z. Lacinova, M. Fried, S. Svacina, M. Haluzik (Czech Republic)

Optimal management of morbidly obese diabetic patients undergoing bariatric surgery P-1144
B. Orr-Walker, M. White, C. Barratt-Boyes, R. Babor (New Zealand)

Glycaemia, insulin resistance and adipokines levels in diabetic and nondiabetic subjects with morbid obesity after gastric banding P-1145
V. Urbanavicius, T. Abalik?ta, G. Brimas, A. Abraitiene, L. Gogeliene, K. Strupas (Lithuania)

Diabetic foot ulcer: impact of biofilms on the antimicrobial resistance and clinical outcome in North Indian tertiary care hospital P-1146
M. Zubair, M. Abida, A. Jamal (India)

Blood pressure

Change of total blood and erythrocytes membranes plasmalogenes level in patients with diabetes and arterial hypertension P-1147
N. Akhrarova, A. Alieva, Z. Shamansurova, A. Tashmanova, A. Tsoy, T. Saatov (Uzbekistan)

Baroreceptor stimulation enhanced NO-dependent vascular dilation and blood pressure buffering, a new treatment for metabolic syndrome P-1148
J. Gmitrov, J. Gmitrov (Japan)

Prevalence of hypertension and its association with metabolic risk factors in type 2 diabetic Punjabi population P-1149
R. Kapoor, R. Duggal, S. Kapoor, R. Kapoor (India)

The effect of low dose spironolactone therapy on resistant hypertension in a group of patients with type 2 diabetes P-1150
R. Djoumessi, J.L. Ngeuwa, J.C. Katte, B. Edinga, M. Dehayem, A. Menanga, F. Kaze, A.P. Kengne, E. Sobngwi, J.C. Mbanya (Cameroon)

CNS/Hypothalamic regulation of obesity and diabetes

Central administration of palmitic acid increases food intake and body temperature in male Sprague Dawley rats P-1151
C. Dinh, A. Szabo, H. Wang, Y. Yu, X. Huang (Australia)

Relationship of plasma copeptin with glucose metabolism P-1152
S. Rathi, V.V. Holla, A. Raizada, R.L. Tripathi, A. Raj, S.V. Madhu (India)

Comorbidities - liver

LOX-1siRNA inhibits HLSEC oxidative stress induced by ox-LDL via NF-kappaB pathway P-1153
Q. Zhang, J. Liu, J. Quan, X. Chen, H. Wang, Y. Wang, R. Niu (China)

High glucose and ox-LDL induced LOX-1 expression in hepatic sinusoidal endothelial cells and its mechanism P-1154
J. Liu, Y.F. Wang, Q. Zhang, R.L. Niu (China)

Complications

Carbohydrate dysfunction in patients with acromegaly: structure and mechanism P-1155
Y. Karachentsev, O. Khyzhnyak, M. Mykytyuk, T. Sulima (Ukraine)

Obese diabetes mellitus patients are at higher risk of cardiovascular and renal complications P-1156
J. Alwakeel (Saudi Arabia)

Effect of vildagliptin or sulphonylureas on clinical outcomes in Muslims with type 2 diabetes fasting during Ramadan: influence of age P-1157
M.S. Chawla, M. Al-Arouj, A. Hassoun, R. Medlej, M.F. Pathan, I. Shaltout, D. Knap, S. DiTommaso, M.Y. Kadwa, J.A. Vaz (India)

Efficacy of thrice-daily injections of insulin Lispro Mix 50/50 in perioperative patients with type 2 diabetes P-1158
K.Y. Cho, H. Miyoshi, O. Nakagaki, K. Akikawa, T. Atsumi (Japan)

Incidence and causes of pancreatitis complicating diabetes: The Fremantle Diabetes Study P-1159
T.M.E. Davis, J. Drinkwater, W.A. Davis (Australia)

Association of TGF-beta 1 Codon 25 (G915C) polymorphism with type 2 diabetes mellitus complications P-1160
K.F. Rodrigues, N.T. Pietrani, P.H.C. Franco, A.A. Bosco, K.B. Gomes (Brazil)

L-arginine supplementation and wound healing: a systematic review and meta-analysis P-1161
A. Joseph, A.P. Anthikkat, S. Crook, J. Warnock (Australia)

Pulmonary function and high sensitive C-reactive protein in type 2 diabetic patients of Karachi P-1162
M.A. Kanpurwala, Z. Ayoob, M.A. Qureshi, Z. Shaikh, K. Afzal (Pakistan)

The significance of pancreatic enzyme elevations in patients with diabetic ketoacidosis P-1163
J.H. Park, S.M. Hong, C.B. Lee, Y.S. Park, W.H. Choi, Y.H. Ahn, D.S. Kim (Korea)

Diabetic ketoacidosis in China – a multicenter, clinic-based cross-sectional study P-1164
X. Wu, Y. Xu, L. Gao, J. Bai, X. Ma, China Initiative for Diabetes Excellence Collaborative Group (China)

Pioglitazone and lifestyle modification improve oxidative stress and carotid atherosclerosis in prediabetic and diabetic patients P-1165
J. Nam, J. Kim, S. Kang, J. Park, C. Ahn, B. Cha, K. Kim, H. Lee (Korea)

Diabetes related complications in Mongolia P-1166
S. Sonomtseren, S. Junai, A. Khasag (Mongolia)

Screening for metabolite excretion in type 2 diabetes patients by rapid and noninvasive magnetic resonance spectroscopy method P-1167
L.I. Stefan, A. Nicolescu, G. Mustafa, S.G. Popa, M. Mota, E. Kovacs, C. Deleanu (Romania)

Plasma 25-hydroxyvitamin D concentration is increased in patients with type 2 diabetes mellitus P-1168
M. Tanaka, S. Takeda, T. Kanda, H. Hirose, T. Kawai, S. Meguro, J. Irie, Y. Saisho, H. Kawabe, Y. Toyama, I. Saito, H. Itoh (Japan)

Incidence of GI side effects associated with the use of metformin xr for the treatment of type 2 diabetes is independent of weight P-1169
L. Guo, A. Huang, M. Ji, C. Tsai, L. Ji (China)

Methylation status of promoter region of endothelial-cell-function-related genes in macrovascular complications of type 2 diabetes P-1170
W.Y. Wang, L.L. Chen (China)

Complications - biomechanical mechanisms

Relationship between serum biochemical marker and osteoporosis in patients with type 2 diabetes mellitus P-1171
F. Hirano, Y. Takeda, H. Saito, K. Matsumoto, H. Nishimura (Japan)

Effect of high-density lipoprotein cholesterol on the proliferation and differentiation of osteoblastic MC3T3-E1 cells P-1172
T. Lei, K.Q. zhang, Y.J. Zhai (China)

Ranu's technology preventing high fore-foot pressures and amputations in diabetic patients P-1173
H. Ranu (Saudi Arabia)

Simulation of injury in ulcerated diabetic foot P-1174
H. Ranu (Saudi Arabia)

Intensive glycemic control improved the excretion of urine mineral ions in type 2 diabetes mellitus P-1175
Y. Tada, T. Yamaguchi, I. Kanazawa, M. Morita, N. Furuya, M. Yamamoto, M. Yamauchi, T. Sugimoto (Japan)

Complications - cardiovascular disease

Circulating apelin levels are associated with the markers of subclinical atherosclerosis in women with previous gestational diabetes P-1176
B. Akinci, A. Celtik, S. Tunali, S. Genc, F. Yuksel, M. Secil, M.A. Ozcan, F. Bayraktar (Turkey)

Alteration of cardiac VEGF signaling system in estrogen: estrogen receptor manipulated animal model with or without diabetes P-1177
A. Al Mamun, S. Jesmin, A. Rahman, N.A. Zahan, T. Mizutani (Bangladesh)

Predictors of cardiovascular disease in multi-ethnic Asian patients with type 2 diabetes mellitus P-1178
M.C. Tan, O.C. Ng, T.W. Wong, A. Joseph, A.R. Hejar, Y.M. Chan (Malaysia)

Eccentric endurance exercise significantly lowers liver enzymes in overweight and obese individuals P-1179
P. Rein, A. Vonbank, C.H. Saely, H. Drexel (Austria)

The metabolic syndrome significantly affects the association between resting heart rate and cardiovascular mortality in women P-1180
A. Vonbank, F. Schmid, C.H. Saely, P. Rein, H. Drexel (Liechtenstein)

Significant impact of gender on the association of HbA1c with angiographically diagnosed coronary atherosclerosis P-1181
C.H. Saely, A. Vonbank, P. Rein, D. Zanolin, H. Drexel (Austria)

HbA1c is a significantly stronger predictor of cardiovascular events in women than in men among patients undergoing coronary angiography P-1182
C.H. Saely, A. Vonbank, P. Rein, D. Zanolin, H. Drexel (Austria)

Correlation of diabetes duration with severity of coronary artery disease P-1183
S. Dsouza, B.C. Mahadeva swamy, K. Padmanabh kamath (India)

Hormonal and lipid profile in correlation with anthropometric measurements among offspring of diabetic mothers P-1184
N. Elbarbary, M. AboElAsrar, E. El-Hadidy, M. Maghrabi (Egypt)

Time to myocardial infarction is inversely related to age at diagnosis of type 2 diabetes P-1185
N. Nanayakarra, J. Lefkovits, A. Ajani, P.G. Colman, S. Fourlanos (Australia)

Anthropometric evaluation, trans fatty acids and Mediterranean diet in diabetes patients in cardiac rehabilitation program P-1186
J. Garcia-Almeida, J. Garcia-Aleman, J. Ruiz-Nava, M.M. Roca-Rodríguez, A. Gomez-Gonzalez, A. Montiel-Trujillo, J.L. Pinzon, B. Martinez-Alfaro, F.J. Tinahones-Madueño (Spain)

The effect of exercise on cardiac function in patients with type 2 diabetes and diastolic dysfunction P-1188
S.M. Hollekim, M.R. Bjorgaas, A.E. Tjonna, U. Wisloff, C. Bjork Ingul (Norway)

DA-9801 inhibits angiotensin II induced apoptosis via extracellular signal regulated kinase 1/2 in endothelial cells P-1189
O.K. Hong, J.W. Son, K.H. Song, S.J. Yoo, B.Y. Cha, H.S. Kwon (Korea)

Coronary artery disease is associated with peripheral artery disease and carotid artery atherosclerosis in type 2 diabetes mellitus P-1190
Y. Hu, F. Liu, J. Shen, H. Zeng, J. Zhao, J. Zhao, F. Lu, Y. Bao, W. Jia (China)

The role of PDK4 in developing vascular calcification P-1191
J. Jeong, S. Lee, K. Park, I. Lee (Korea)

Sirt3 deficiency aggravates myocardial ischemia/reperfusion injury in obesity-associated insulin resistance P-1192
L. Ji, W. Xing, H. Zhang, F. Gao (China)

Assesment of mechanical functions in prediabetics by using 3 dimensional echocardiography and relationship between NT-proANP levels P-1193
F. Eyupkoca, J. Yagmur, L. Keskin, S. Hidayet, A. Sertkaya, T. Tasci, R. Ozdemir (Turkey)

The association between serum total bilirubin and carotid artery intima-media thickness in Korean subjects with type 2 diabetes P-1194
S. Kim, Y. Choi, B. Huh, S. Kim, S. Park, Y. Cho, K. Hur (Korea)

Ivabradine in type 2 diabetes patients with silent myocardial ischemia P-1195
T. Akhobadze, R. Kurashvili, A. Kopaleishvili (Georgia)

Assessment of ventricular repolarization in patients with polycystic ovarian syndrome P-1196
C. Lengyel, É. Csajbók, A. Orosz, S. Magony, Z. Valkusz, R. Takács, I. Baczkó, A. Nemes, T. Várkonyi, P. Kempler, T. Wittmann, A. Varró (Hungary)

comparison of coronary plaque characteristics among DM and non-DM patients using integrated backscatter intravascular ultrasound P-1197
T. Miyazaki, H. Ishikawa, Y. Okusu, Y. Hiroe, M. Nakamura, T. Mochizuki, Y. Miyazaki, Y. Kondo, S. Sato, A. Wada (Japan)

Evaluation of serum OPG levels as an early atherosclerosis marker in type I and II diabetic patients P-1198
E. Altunoglu, C. Alkac, F. Erdenen, C. Muderrisoglu, M. Boz, Y. Karagoz, H. Aral, B. Alkac (Turkey)

The association between Fetuin-A and arterial stiffness P-1199
H.Y. Ou, F.H. Lu, H.T. Wu, H.C. Hung, J.S. Wu, Y.C. Yang, C.J. Chang (Taiwan)

Novel role of protease-activated receptor-4 in diabetic vascular remodeling P-1200
G. Pavic, J.W. Fischer, A. Fender (Germany)

High protein weight loss diets in type 2 diabetes participants with renal disease P-1201
E. Pedersen, D.R. Jesudason, P.M. Clifton (Australia)

Associations between Na and K excretion and carotid IMT, central blood pressure, augmentation index and PWV in people with diabetes P-1202
K.S. Petersen, P.M. Clifton, J.B. Keogh (Australia)

The influence of adiponectin gene polymorphism on omega-3 fatty acid effect in type 2 diabetic patients P-1203
M. Gorshunska, N. Kravchun, Y. Karachentsev, E. Jansen, L. Atramentova, T. Tyzhnenko, A. Gladkih, Z. Leshchenko, N. Krasova, A. Pochernyaev, Y. Opaleiko, V. Poltorak (Ukraine)

Metabolic syndrome, inflammatory markers and cardiovascular risk in patients with type 2 diabetes and chronic hepatitis C P-1204
R. Dragut, E. Rusu, C. Parpala, R. Nan, F. Rusu, G. Enache, M. Jinga, G. Tocaci, G. Radulian (Romania)

RDW: is it a risk marker for cardiac failure in diabetic patients? A cross-sectional study P-1205
A.R. Subhashree, B. Shanthi, P.J. Parameaswari, P. Subashini, B.O. Parijatham, G. Hemalatha (India)

Red cell distribution width: is it a risk marker for cardiac failure in diabetic patients? A cross-sectional study P-1206
A.R. Subhashree, S. B., P. P.J., P. B.O., H. Ganapathy (India)

Flow mediated dilatation does not correlate with depression scores in patients with type 2 diabetes – a cross sectional analysis P-1207
T.P. Wycherley, M.D. Riley, C.J. Wilson, N.D. Luscombe-Marsh, C.H. Thompson, J.D. Buckley, M. Noakes, G.A. Wittert, G.D. Brinkworth (Australia)

The effect of rutin on the proliferation of rat aortic vascular smooth muscle cells with glucose fluctuations P-1208
H. Yoo, S.H. Yu, J.M. Yoo, D.M. Kim (Korea)

Complications - eye

Co-existing hypertension as independent risk factor in diabetic retinopathy in type-2 diabetes P-1209
K.R. Ahmed, M.S. Bukht, M.N. Karim, A. Hussain (Bangladesh)

Associations between diabetic retinopathy and diagnosed age, C-peptide level and macrovascular disease in Chinese type 2 diabetes P-1210
X.L. Cai, T. Tao, X.Y. Han, J. Liu, L.N. Ji (China)

Antihypertensive therapy improve diabetic retinopathy progression: a meta-analysis P-1211
Y. Chen, Z. Chen, Y. Ni, X. Li, B. Feng (China)

High cystatin C level hints severe retinopathy in type 2 diabetic patients P-1212
R. He, J. Shen, F. Liu, H. Zeng, L. Li, W. Jia (Shanghai Diabetes Institute Shanghai Key Laboratory)

Mechanism of activation of hypoxia-inducible factor 1 alpha by insulin-like growth factor 1 in cultured human retinal pigment epithelium P-1213
P.C. Kothary, P. Lee, M.A. Del Monte (Usa)

Novel proteomic biomarkers in diabetic retinopathy P-1214
A.K. McAuley, J.J. Wang, P.P. Connell, M. Dirani, H. Liang, E. Lamoureux, A.W. Hewitt (Australia)

Indices of antioxidant system in patients with prediabetes and type 2 diabetes and concomitant diabetic retinopathy P-1215
O. Shyshko, T. Mokhort, I. Buko, E. Konstantinova, N. Tsapaeva (Belarus)

Complications - foot

Prospective, randomised trial of vacuum assisted closure in patients with chronic non healing leg ulcers in type-2 diabetes mellitus P-1216
R. Agrawal, R.P. Agrawal, B. Sihag, S. Gothwal, P. Sirohi, J.K. Meel (India)

Use of the biofeedback pressure sensor to promote healing of diabetic foot ulcers: beginnings of an answer P-1217
M.L. Chateau-Degat, J. Patry, C. Morin, R. Belley, M. Côté (Canada)

Neutrophil to lymphocyte ratio as a predictor of amputation in diabetic foot infection P-1218
A. Gedik, T. Demir, E. Celik, E. Gokdag, F.Y. Coban, A. Eroglu, M. Yilmaz, H. Havitcioglu, F. Bayraktar (Turkey)

Peripheral artery disease and diabetes: An eastern India perspective P-1219
A. Majumdar, D. Deep, S. Ghosh (India)

Cost effectiveness and acceptance of pressure offloading modalities in treatment of planter surface diabetic foot ulcers (DFU'S) P-1220
G. Goyal, K. Chaki, R. Srivastava, S. Kapoor, S. Mitra (India)

Major adverse cardiac events and nosocomial infection are two leading causes endanger patients treated for diabetic foot diseases P-1221
S.Y. Hung, Y.Y. Huang, H.M. Yang (Taiwan)

Magnesium deficiency can exacerbate diabetes and lead to diabetic foot ulcers P-1222
S. Keskek, S. Kirim, A. Karaca, G. Ortoglu, N. Golge, A. Atabay, T. Saler (Turkey)

Surgical treatment of neuropathic form of diabetic foot P-1223
M. Prystupiuk, L. Naumova, O. Prystupiuk, M. Naumova, L. Prystupiuk (Ukraine)

Association of grading and staging of diabetic foot ulcer with diabetic retinopathy and impaired kidney function P-1224
Z. Sabahi, N. Valizadeh, A. Mehdizadeh, R. Ghareaghaji (Iran)

The peculiarities of autodermoplasty using vacuum therapy at neuroischemic form of the diabetic foot P-1225
D.V. Seliverstov, I.V. Kondrus, V.A. Yudin, V.G. Kutskir, I.A. Podyablonskaya, V.V. Masevnin, L.A. Novikov, I.N. Kogarko, B.S. Kogarko (Russia)

The experience of "Varolast" use in diabetics with varicose ulcers at the regeneration stage P-1226
D.V. Seliverstov, I.V. Kondrus, V.A. Yudin, V.V. Masevnin, V.G. Kutskir, I.A. Podyablonskaya, L.A. Novikov, I.D. Savkin (Russia)

Antistax in the complex treatment of patients with diabetic foot syndrome and disturbance of lymph circulation P-1227
D.V. Seliverstov, I.D. Savkin, V.A. Yudin, V.G. Kutskir, I.V. Kondrus, V.V. Masevnin, L.A. Novikov (Russia)

Bacteriology of diabetic foot infections and susceptibility to antimicrobial agents in Cameroon P-1228
Y. Dehayem, E. Ngassam, F. Mendane, V. Mballa, J. Saji, E. Sobngwi, J.C. Mbanya (Cameroon)

Impact of aging on patients with diabetic foot diseases P-1229
C. Tsai, H. Yang, Y. Huang (Taiwan)

The high-risk diabetic foot - a two-year prospective study of the multidisciplinary team workload & interventions to save legs P-1230
J. Wright, S. Hurel, M. Brown, S. Morris-Jones, D.C. Patel, J.A.S. Brookes, M.J. Oddy, T. Richards (United Kingdom)

Risk assessment of diabetic patients for foot ulcers according to risk classification consensus of IWGDF P-1231
L. Yazdanpanah, H.b. Shahbazian, S.m. Latifi (Iran)

Complications - kidney

Nigella sativa ameliorates oxidative stress in kidneys of streptozotocin induced diabetic rats P-1232
R. Chaudhari, G. Somani, S. Sathaye (India)

Glyoxalase-1 inhibition leads to diabetic kidney disease associated with podocyte insulin resistance P-1233
L.A. Gallo, B.E. Harcourt, A.K. Fotheringham, D. McCarthy, S.A. Penfold, J.M. Forbes (Australia)

Genome wide association study of uric acid identify novel loci in Indians P-1234
A.K. Giri, O.P. Dwivedi, I. Kaur, N.M. Khan, N. Tandon, D. Bharadwaj (India)

Microalbuminuria and total antioxidant status in type 2 diabetics attending GMC Hospital Ajman, United Arab Emirates P-1235
H.S. Al Ameri, K.G. Gomathi, N. Khan, M.K. Jallo (United Arab Emirates)

Aegle marmelos prevent advanced glycation end-products formation by improving beta cell function and antioxidant status in diabetic rats P-1236
R. Hafizur, N. Fatima, M. Shahrukh, N. Kabir, M.I. Choudhary (Pakistan)

Arg72Pro polymorphism in TP53 is associated with all-cause mortality in type 2 diabetics P-1237
K. Kuricová, V. Tanhäuserová, L. Pácal, K. Kanková (Czech Republic)

Relationship of Urinary Albumin Excretion Rate and MMP-9 on vascular endothelial function in diabetic patients P-1238
S. LI (China)

Cystatin C was superior to other tested markers in predicting renal function in type 2 diabetes P-1239
S. Ljubic, A. Jazbec, M. Vucic Lovrencic, J. Knezevic-Cuca, N. Car (Croatia)

The role of renal dysfunction in development and progression of cardiac disease in patients with type 1 diabetes and chronic kidney disease P-1240
M. Biragova, S. Gracheva, A. Glazynova, I. Klephortova, O. Manchenko, I. Ulyanova, A. Ilin, M. Shamkhalova, A. Mayorov (Russia)

Relationships between high sensitive CRP (hs-CRP) and chronic kidney disease among type 2 diabetic patients P-1241
N. Milani, S. Bonakdaran (Iran)

Assessment of serum pregnancy – associated plasma protein – A (PAPP-A) levels in type 2 diabetes mellitus patients P-1242
A. Mohammadi Karakani (Iran)

Plasma macrophage inhibitory cytokine-1 (MIC -1) is associated with diabetic nephropathy P-1243
H. Tokunaga, Y. Hara, K. Akesaka, M. Tamaki, O. Ebisui, T. Ueda (Japan)

Association between nephropathy and left ventricular mass index in diabetic patients P-1244
V. Vasilkova, T. Mokhort (Belarus)

The relationship between renalase and dopamine in type 2 diabetic patients with and without diabetic nephropathy P-1245
E. Wagdy, H. El-Attar (Egypt)

Association of interleukin-6-174G/C promoter polymorphism and new onset diabetes after renal transplantation P-1246
E. Zakaria, M. Aziz, T. Fayad, N. Elsayed, M. Ishaak, B. Habashy (Egypt)

The hypertriglyceridemic-waist phenotype is associated with microalbuminuria in Chinese patients with type 2 diabetes P-1247
L. Zhang, Y. Dong, J. Li, N. Wang, X. Wang, Y. Zhu (China)

Complications - nerve

Sudomotor function assessment as a screening tool for microvascular complications in type 2 diabetes P-1248
V. Eranki, J.H. Calvet (France)

Evaluation of central neuropathy by blink reflex in diabetics P-1249
S. Chaudhary, S. Patel (Nepal)

Prevalence and clinical characteristics of insulin dependent patients suffering from sleep apnea syndrome P-1250
J.P. Courrèges, A. Iosup, H. Banciu, J.F. Thuan, N. Vigier Simmore, N. Bastide (France)

Determination of the possible effect of insulin pump treatment on autonomic function in young type 1 diabetic patients P-1251
T. Várkonyi, K. Fehértemplomi, A. Orosz, R. Takács, M.S. Kempler, M. Szabó, O. Vági, C. Lengyel, T. Wittmann, P. Kempler (Hungary)

Exendin-4 protected Aß(1-42) oligomers-induced PC12 cells apoptosis via activating neuron survival pathway P-1252
L. Liu (China)

Diabetes and infections

Melioidosis - an infection strongly associated with diabetes P-1253
R. Chandni, N.K. Thulaseedharan, V. Udayabhaskaran, P.K. Sasidharan, S. Remadevi (India)

A clinical study of fungal sinusitis in diabetic patients presenting with ophthalmologic complications P-1254
R. Suma, R. Chandni, K. Ramachandran (India)

Diabetes associations

Association of tuberculosis with diabetes mellitus: A hospital based study in southern India P-1255
M. Chowta, N. Chowta (India)

Diabetes in childhood and adolescence

Association between diabetes auto-antibodies and C-peptide secretion in children and young adults with diabetes in Saudi Arabia P-1256
A. Alzaid, S. Qahtani, M. Zitouni, S. Sobki, A. Alabdulaaly (Saudi Arabia)

Diabetes management

Effect of diets of varying food insulin index (FII) on day-long glucose and insulin profiles in adults with type 2 diabetes P-1257
K. Bell, S. Colagiuri, J.C. Brand-Miller (Australia)

Comparisons of alpha glucosidase inhibitors treatment between Asian and Caucasian type 2 diabetic patients P-1258
X. Cai, Y.Y. Luo, X.Y. Han, L.N. Ji (China)

Safety and effectiveness of intensifying biphasic insulin aspart 30 in insulin-naïve patients with type 2 diabetes P-1259
A. Palacio, I. Hajjaji, P. Soewondo, J.W. Chen, Z. Hussein (Switzerland)

Short-term changes in contemporary diabetes management: The Fremantle Diabetes Study Phase II P-1260
W.A. Davis, V. Cetrullo, S.A.P. Chubb, T.M.E. Davis (Australia)

Outcomes of switching from a glargine-based basal plus mealtime insulin regimen to biphasic insulin aspart 30 in people with type 2 diabetes P-1261
N. ElNaggar, S. Shah, M. Imtiaz Hasan, M. Ebrahim Khamseh, V. Prusty, S.Y. Goh (Saudi Arabia)

Switching from a glargine + mealtime multiple injection regimen to a mealtime + basal regimen with insulin detemir and insulin aspart in T2D P-1262
N. ElNaggar, J. Haddad, R. Malek, Z. Hussein, J.W. Chen, W. Yang (Saudi Arabia)

The SimpleMix study: subject-driven vs. investigator-driven titration with biphasic insulin aspart 30 P-1263
Y. Gao, C. Luquez, J. Råstam, H. Andersen, B. Saboo (China)

Relationship between ALDH2 polymorphism, drinking habits, and cardiovascular risk factors in Japanese type 2 diabetic patients P-1264
M. Kawai, E. Nakashima, A. Watarai, Y. Kouchi, M. Kusama, M. Minatoguchi, C. Tanaka, A. Kanai, T. Kawamura, T. Sano, N. Hotta, R. Imamine (Japan)

Postprandial C-peptide-to-glucose ratio for staged management of Korean type 2 diabetes P-1265
E. Lee, S. Hwang, Y.H. Lee, B.W. Lee, E.S. Kang, C.W. Ahn, B.S. Cha, H.C. Lee (Korea)

Adverse outcomes after non-cardiac surgery for patients with diabetes: a nationwide retrospective cohort study P-1266
C.C. Liao, T.L. Chen, C.C. Yeh (Taiwan)

A combination of insulin degludec and liraglutide improves postprandial glycaemic control in T2D: results from a meal test P-1267
S. Linjawi, J.B. Buse, S.C.L. Gough, J.J. Holst, H.W. Rodbard, V.C. Woo, P. Poulsen, L.H. Damgaard, B.W. Bode (Australia)

Within-subject variability in mean blood glucose concentration is lower with insulin degludec vs insulin glargine: a meta-analysis in T2D P-1268
L. Meneghini, S. Harris, M. Evans, S. Rasmussen, T. Johansen, T.R. Pieber (USA)

Analysis of fasting glycemia variability in patients with type 1 diabetes mellitus undergoing glargine vs. nph basal insulin therapy P-1269
M. Mashkova, T. Mokhort (Belarus)

Efficacy and safety of physician- vs. patient-led insulin glargine titration in type 2 diabetic patients in China P-1270
C.Y. Pan, H. Tian, Q.F. Li, W.Y. Yang, Y.D. Peng, B. Feng, T.P. Hong, J. Kuang, J.L. Du, L.L. Chen, H.M. Tian (China)

Patient experience in physician- and patient-led insulin glargine titration in Chinese type 2 diabetic patients P-1271
C.Y. Pan, Q.F. Li, H. Tian, Y.D. Peng, W.Y. Yang, B. Feng, T.P. Hong, J. Kuang, J.L. Du, L.L. Chen, H.M. Tian (China)

Factors affecting response to DiaPep277 in recent onset type 1 diabetes P-1272
P. Pozzilli, I. Raz, T. Linn, F. Bonnici, D. Elias, A. Avron, M. Tamir, R. Eren, S. Degan (Italy)

Effect of an insulin bolus calculator on glycemic control in subjects with type 1 diabetes on insulin pump treatment: preliminary results P-1273
N. Colomo, M. Domínguez, M. Guerrero, S. González, M. Carreira, M.I. Fontalba, F. Linares, A. Omiste, D.J. Palao, I. Sánchez, M.T. Anarte, M.S. Ruiz de Adana (Spain)

Randomized clinical trial to analyse effectiveness of telemedicine in patients with T1DM on insulin-pump treatment. Preliminary results P-1274
N. Colomo, M. Domínguez-López, M. Guerrero, M. Carreria, M.I. Fontalba, F. Linares, J.D. Fernández-Arias, I. Sánchez, M.T. Anarte, M.S. Ruiz de Adana (Spain)

Vitamin D deficiency is common in hospitalized patients with type 1 and type 2 diabetes P-1275
N. Gül, Ü. Korkmaz, A. Kubat Üzüm, G. Yenidünya Yalin, N. Dinççag, I. Satman (Turkey)

Wrist circumference as a simple and costly effective marker for type 2 diabetes P-1276
R. Buzzetti, A. Soare, A. Mitrea, Y.M. Khazrai, R. Del Toro, V. Formisano, F. Capata, E. Roncella, M.E. Diaz Sanchez, C. Porrata, P. Pozzilli (Italy)

Preliminary evidence that Ma-Pi 2 diet is more effective than standard recommended medical nutrition in subjects with type 2 diabetes P-1277
A. Soare, R. Del Toro, C. Porrata, Y.M. Khazrai, E. Roncella, L. Fontana, V. Formisano, F. Capata, V. Ruiz Alvarez, F. Fallucca, M. Pianesi, P. Pozzilli (Italy)

Performance of two glomerular filtration rate estimation equations in patients with type 2 diabetes P-1278

D. Agoons, E. Sobngwi, F. Kaze, M. Azabji, M. Djonou, B. Bate, A. Mawo, Y. Munang, M. Dehayem, J.C. Mbanya (Cameroon)

Optimization of liraglutide treatment in obese patients with type 2 diabetes resistant to conventional treatment P-1279

M.A. Núñez Sánchez, R. Soriano Sánchez, C. del Peso, M.T. Gallego García, N.V. García-Talavera Espín, M.B. Gómez Sánchez, T. Monedero Saiz, A.I. Meoro Avilés, J. Soriano Palao (Spain)

Qualitative study to explore the barriers faced by primary care health professionals in the management of type 2 diabetes mellitus (T2DM) P-1280

A. Zafar, M. Stone, M. Davies, K. Khunti (United Kingdom)

Results from a 2-year vildagliptin treatment observational study in eldery group of T2 DM patients in Russia P-1281

A. Zilov, M. Shestakova, A. Emirova (Russia)

Epigenetics and early foetal development

Improved insulin sensitivity in offspring of EGCG supplemented high fat diet fed dams: a hypothalamus-adipose connection P-1282

E.T.S. Li, S. Li, L.O.Y. Yeung (Hong Kong China)

Genetics of type 1 diabetes

The association of glutamic acid decarboxylase antibody titer (GADA) and therapies before insulin use with beta cell function in Japanese slow progressive insulin dependent diabetes P-1283

T. Horiuchi, Y. Sasaki, M. Murakami, S. Takekawa, F. Iwashima, T. Andou, T. Ohashi (Japan)

Genetics of type 2 diabetes

Variants in AOX1, CYP11B1, GSTM5, SLCO1B1, SULT1E1 are associated with efficacy of glibenclamide in Chinese type 2 diabetic patients P-1284

X.L. Cai, X.Y. Han, Q. Ren, S.M. Zhang, Y. Tang, L.L. Zhou, Y.L. Chen, L.N. Ji (China)

Of Mice and Men: A model-based integrated approach to identify biomarkers of T2D and obesity progression P-1285
R. Chaudhuri, P. Khoo, J. Yang, D. James (Australia)

Genetic and familial factors associated with younger age at diagnosis of type 2 diabetes P-1286
I.M. Gosadi, M.D. Teare, E.C. Goyder (United Kingdom)

Interaction between genetic susceptibility to T2DM and obesity on measures of autonomic nervous system function P-1287
A.B. Jenkins, A. Suker, D. Samocha-Bonet, A. Viardot, L. Purtell, J. Greenfield, K. Tonks, L.V. Campbell (Australia)

The contribution of WFS1 gene to the susceptibility of type 2 diabetes in Chinese population P-1288
Y. Luo, X. Sun, X. Han, S. Zhang, X. Zhang, X. Zhou, L. Ji (China)

Replication of the association between a common variant near ATM and metformin treatment response in type 2 diabetes of Chinese Han P-1289
S.M. Zhang, X.Y. Han, L.N. Ji (China)

DNA from diabetic subjects is a preferred antigen for anti-DNA antibodies in diabetic serum P-1290
S. Bansal, R. Ali, A. Kuvalekar (India)

Glycated haemoglobin and its role in diabetes

Study of glycated hemoglobin by ion exchange chromatography and affinity binding nycocard reader in diabetes mellitus P-1291
N. Gautam, J. Archana, Y. Neupane, R.K. Dubey, P. Padma vathi, S. Jha, S. Chaudhary, A.K. Sinha (Nepal)

The impact of chronic untreated hyperglycaemia on the long-term stability of paraoxonase 1 (PON1) and antioxidant status in human sera P-1292
M.S. Hassan, M. Muiriri, A.P. Kengne, D.M. Blackhurst, R.T. Erasmus, T.E. Matsha (South Africa)

Hypoglycaemia

Correlation between self-monitoring blood glucose and glycated albumin in pregnant women with diabetes P-1293b
K. Lee, S. Kim, J. Mok, J. Kim (Korea)

Lack of response to pharmacological treatment in family with hypoglycaemia due to the activating glucokinase gene mutation P-1036
S. Azriel, C. Vázquez Puertas, A. Siguero Sánchez, M.A. García Gimeno, P. Rodriguez Bada, D. Narankiewicz, P. Sanz, J. Parra Barona, R. Gómez Huelgas, A.L. Cuesta Muñoz (Spain)

Impact of nocturnal and daytime non-severe hypoglycaemic events on people with diabetes in Argentina P-1294
C. Buso, M. Yuma, N. Pugnaloni Rodriguez, L. Maffei (Argentina)

Hypoglycemia unawareness among patients with poorly controlled type 2 diabetes as assessed by continuous glucose monitoring P-1295
Y.C. Chen, Y.Y. Huang, J.H. Sun, C.H. Huang, Y.T. Ye, Y.H. Wu, C.H. Lin (Taiwan)

An assessment of the impact of nocturnal and daytime non-severe hypoglycaemic events on people with diabetes in Australia P-1296
G. Fulcher (Australia)

Recurrent confirmed hypoglycaemia – a meta-analysis in patients with type 2 diabetes receiving insulin degludec or insulin glargine P-1297
A. Garber, M. Evans, L. Bardtrum, T. Johansen, S. Heller (USA)

Self-reported exercise-related hypoglycaemia: a comparison of occurrence frequency between insulin degludec and insulin glargine P-1298
S.C.L. Gough, D. Oyer, S. Heller, K. Jensen, O. Kinduryte, A. Philis-Tsimikas (United Kingdom)

Lower rates of overall and nocturnal hypoglycaemia with insulin degludec vs. glargine are not due to differences in HbA1c or insulin dose P-1299
S. Heller, J.H. DeVries, A. Garber, A. Ceriello, T. Johansen, S. Rasmussen, P. Zimmet (United Kingdom)

Severe hypoglycaemia in diabetes (types 1 and 2) risk factors: second Diabetes Attitudes, Wishes and Needs (DAWN2) study P-1300
N. Hermanns, A. Nicolucci, M. Escalante, H. Ishii, S. Kalra, A. Kokoszka, A. Mayorov, E. Menendez Torre, N. Munro, J.E. Salles, I. Tarkun, M. Peyrot, DAWN2 Study Group (Germany)

Insulin degludec reduces the risk of hypoglycaemia vs. insulin glargine in type 2 diabetes patients with a BMI >30 kg/m2: a meta-analysis P-1301
A. Philis-Tsimikas, H.W. Rodbard, L.F. Meneghini, R. Kapur, L. Endahl, D.L. Russell-Jones (USA)

A reduced risk of nocturnal hypoglycaemia in patients with T1D requiring high dose basal insulin: insulin degludec vs. insulin glargine P-1302
H.W. Rodbard, W. Lane, Y. Handelsman, T.M. Hobbs, L. Korsholm, S.C.L. Gough (USA)

Impact and duration of hypoglycaemic events – a meta-analysis of 3 randomised studies of insulin degludec and insulin glargine P-1303
J. Vora, S. Harris, T. Christensen, R. Kapur, M. Brod (United Kingdom)

Insulin degludec has lower risk of hypoglycaemia than insulin glargine: meta-analysis in type 2 diabetes with >10 years disease duration P-1304
J. Vora, H.W. Rodbard, H. Mersebach, R. Kapur, S. Harris (United Kingdom)

Incretin physiology and pathophysiology

Association of glucose-dependent insulinotropic polypeptide (GIP) with insulin secretory defect in Bangladeshi type 2 diabetic subjects P-1305
M. Akhter, S. Akter, F. Zebunnesa, J. Ferdous, L. Ali (Bangladesh)

Different effect of DPP-4 inhibitor and GLP-1 mimetic on autonomic nervous system in type 2 diabetes mellitus P-1306
D. Kobayashi, H. Murai, J. Inomata, T. Hamaoka, O. Inoue, S. Usui, M. Okajima, H. Frusho, T. OTa, T. Takamura, S. Kaneko, M. Takamura (Japan)

Effect of acarbose compared with metformin on incretins of gip, pyy, ghrelin in patients of newly diagnosed type 2 diabetes mellitus P-1307
Y. Ren, H.O.N.G. Ma, S.O.N.G. Liu, H.A.O. Tian (China)

Incretin therapies

Liraglutide experience in clinical practice: results during the first year of monitoring P-1308
A. Arranz, S. Campos, M. Sampedro, R. Costa, I. Sánchez, R. Carraro, A. Gómez (Spain)

Treatment outcomes in patients with type 2 diabetes on combination therapy with metformin and DPP-4 (vidalgliptin) P-1309
A. Kopaleishvili, N. Asatiani, R. Kurashvili, M. Dundua, E. Shelestova, E. Inashvili (Georgia)

Improvements in HbA1c and body weight with liraglutide are largely independent of diabetes duration P-1310
J. Seufert, T. Bailey, M. Donsmark, E. Bergan, M. Nauck (USA)

Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1 and preproinsulin in the pancreas of diabetic rats P-1311
G. Barakat, M.E. Moustafa, I. Khalifeh, A.B. Bikhazi, S. Rizk (Lebanon)

Comparison of DPP-IV inhibitors treatment between Asian and Caucasian type 2 diabetic patients P-1312
X.L. Cai, X.Y. Han, Y.Y. Luo, L.N. Ji (China)

Fibroblast activation protein deficiency improves glucose tolerance, insulin sensitivity and lipid metabolism in DIO mouse model P-1313
S. Chowdhury, S. Song, M.G. Gall, X.M. Wang, D.M.T. Yu, L. Lo, N. Turner, G. Cooney, G.W. McCaughan, S.V. McLennan, S.M. Twigg, M.D. Gorrell (Australia)

Tolerability and glycemic profiles of vildagliptin add-on to 2000mg metformin therapy in Korean type 2 diabetic patients P-1314
S. Chun, S.J. Kim, Y.J. Kim, J.M. Lee, I.S. Lee, S.I. Mo, B.J. Ku, H.J. Kim, K.S. Park, J.M. Lee, K.Y. Park, D.M. Lim (Korea)

Changes in clinical and analytical parameters in a group of patients treated with liraglutide during 6 months P-1315
R. Darias, B.F. García, B. Gómez, B. Rivero, J. Rodríguez, A. Mora, J.G. Oliva, I. Llorente (Spain)

Liraglutide reduces the need of frequent self blood glucose monitoring in both insulin and oral agents treated patients with type 2 Diabetes P-1316
J. Doupis, A. Kokkinos, C. Kallinikou, V. Papandreopoulou, N. Tentolouris (Greece)

Vildagliptin added to metformin and sulfonylurea effectively improves glycemic control in Asian patients with T2DM P-1317
V. Lukashevich, G. Fulcher, Q. Shao, W. Kothny (Australia)

Liraglutide monotherapy provides superior PPG control after all three daily meals vs. sulphonylurea monotherapy P-1318
A. Garber, T. Bailey, E. Bergan, M. Donsmark, B. Bode (USA)

Linagliptin monotherapy in Asian patients with uncontrolled type 2 diabetes mellitus: further analyses from a Phase III trial P-1319
Y. Chen, G. Ning, C. Wang, Y. Gong, S. Patel, C. Zhang, T. Izumoto, H.J. Woerle, W. Wang (Germany)

Effects of triple combination of anagliptin, metformin and miglitol on the incretin and metabolic changes in patients with type 2 diabetes P-1320
T. Osonoi, M. Saito, N. Hariya, M. Goto, K. Mochizuki (Japan)

Saxagliptin and metformin XR combination increases time within euglycemic range in patients not controlled with metformin alone P-1321
B. Hirshberg, E. Allen, B. Bryzinski, W. Cook (USA)

Pharmacokinetic properties of liraglutide when used as adjunct to insulin treatment in subjects with type 1 diabetes P-1322
S. Ingwersen, S. Klim, L. Jensen, F. Kiyomi, J. Mader, S. Heller, T. Pieber (Denmark)

Discovery of dipeptidyl peptidase-4 gene variants and the associations with efficacy of vildagliptin in type 2 diabetes P-1323
E. Choe, Y. Choi, Y. Yun, H. Kim, O. Kwon, H. Kim, H. Wang, C. Ahn, B. Cha, H. Lee, E. Kang (Korea)

The efficacy of alogliptin in patients with type 2 diabetes mellitus: examination of new, concomitant, and switched administrations P-1324
T. Kudo (Japan)

Anti-diabetes properties of dairy proteins – allies in the management of diabetes P-1325
I. Lacroix, E. Li-Chan (Canada)

Improvement of lipid profile in patients with type 2 diabetes treated with liraglutide P-1326
A. López-Guzman, G. Prieto de Lamo, A.L. Fraile, L.V. Campos, S. Azriel, J.J. Cornejo (Spain)

One-year data from EVIDENCE®: effectiveness and tolerability of liraglutide in routine clinical practice P-1327
P. Gourdy, A. Penfornis, G. Charpentier, S. Madani, L. Martinez, E. Eschwege, J.P. Gautier (France)

One-year data from EVIDENCE®: sub-analysis of effectiveness of liraglutide in patients switched from a DPP-4 inhibitor P-1328
G. Charpentier, L. Martinez, E. Eschwège, S. Madani, A. Penfornis, P. Gourdy, J.P. Gautier (France)

Effect of type 2 diabetes disease stage on liraglutide response in clinical practice: data from the EVIDENCE® study P-1329
A. Penfornis, P. Gourdy, L. Martinez, S. Madani, G. Charpentier, E. Eschwège, J.F. Gautier (France)

Efficacy and safety of replacing a dpp4-inhibitor by liraglutide in obese patients with type 2 diabetes mellitus and poor glycemic control P-1330
A. Merchante, A. Fabra, M. Tolosa, J.C. Ferrer, C. Sanchez (Spain)

Liraglutide in patients with DM2 and obesity previously treated with oral antidiabetic agents: eDM Spain SEEN Study P-1331
P. Mezquita-Raya, M. López de la Torre Casares, O. Moreno Pérez, D.M. Diabetes WorkGroup (Spain)

Evolution of clinics and biochemists parameters in patients treated with liraglutide P-1332
M. Monreal, D. Alvarez, J. Acha, P. De Castro, M.L. Gracia, A. Sanz, P. Trincado, R. Albero (Spain)

Challenging in predicting response to liraglutide in real clinical practice P-1333
F.M. Morales Pérez, C. Tejera Pérez, A. López Navia, V. Hernandez Cordero, L.M. Luengo Pérez, I. Rasero Hernandez, R. Hernandez Lavado, M. Cabanillas Lopez, L.J. Fernández-Martín, P. Beato Víbora, J. Diaz Pérez de Madrid, J. Acedo Hidalgo (Spain)

Treatment persistence with liraglutide in patients with type 2 diabetes followed in an endocrinology unit P-1334
M. Muñoz-Torres, A. San Juan-McNulty, A. Muñoz-Martín, M. Cobo-Fernández, D. Carrillo-Mendigaño, M.D. Avilés- Perez (Spain)

Fasting serum C-peptide and age is a useful predictor of successful liraglutide monotherapy in Japanese type 2 diabetes patients P-1335
K. Nakamura, A. Yoshida, K. Nakata (Japan)

Retrospective evaluation of HbA1c & body weight in patients converted from pioglitazone to DPP-4 inhibitor in a primary care setting P-1336
P. Newman, B. Barrett, P. Bassett (United Kingdom)

Elucidating mechanism of action of a DPP4 inhibitor, alogliptin, on Japanese diabetes patients from the aspect of proinslin and insulin P-1337
S. Okahata, K. Sakamoto, T. Mitsumatsu, T. Shiba (Japan)

The effects of dipeptidyl peptidase 4 inhibition in colon cancer development and progression P-1338
F.B. Ozturk Ceyhan, S. Cetinkalp, H.S. Vatansever, F. Saygili, A.G. Ozgen, C. Yilmaz (Turkey)

Evolution of adrenal steroids in men with type 2 diabetes with liraglutide - relationship with insulin sensitivity P-1339
G. Piedrola, D. Cepero, C. Gil Anguita (Spain)

Islet regulatory mechanisms of exenatide and glucose stabilization effects of its tid administration P-1340
K. Sakamoto, S. Okahata, T. Mitsumatsu, T. Shiba, K. Shirai (Japan)

Clinical effects of additional use of sitagliptin in diabetic patients receiving insulin treatment at our outpatient clinic P-1341
T. Seguchi, K. Nakamaru, Y. Kaikou (Japan)

Effect of liraglutide on metabolic and renal outcomes over 12 months in community diabetic nephropathy clinic P-1342
P.A. Senior, J. Vretenar, K.K. Jindal (Canada)

Research of glucagon-like peptide-1 receptor agonist on the differentiation and function of brown adipocytes in mice P-1343
S. Shen, H. Shi, Y. Bi, W. Feng, W. Wang, X. Jin, X. Han, M. Hu, D. Zhu (China)

Switching to liraglutide from insulin improves glycaemic control with a reduction of body weight: association with pre-switching BMI P-1344
H. Shimizu, H. Kakishita, H. Akiyama, K. Uehara, K. Kashima, K. Kawada, T. Onai (Japan)

Greater PPG control across all 3 main meals with liraglutide vs placebo, when added on to metformin and rosiglitazone P-1345
M. Shomali, L. Blonde, B. Bode, C. Svendsen, H. Thomsen, B. Zinman (USA)

Saxagliptin improves glycemic control by modulating postprandial glucagon and c-peptide levels in Chinese patients with type 2 diabetes P-1346
M. Sjöstrand, N. Iqbal, J. Lu, B. Hirshberg (Sweden)

The liraglutide leads to not only improve glycemic control, but also cause liver inflammation of nonalcoholic fatty liver disease patients P-1347
A.S.G. Soto Gonzalez, D.B.G. Bellido Guerrero, M.B.S. Buño Soto, M.L.C. Lopez De La Torre Casares (Spain)

Efficacy of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes: results from subgroup analyses P-1348
M. Odawara, I. Hamada, M. Suzuki, LMF237A1301 Study Group (Japan)

The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits P-1349
K.Y. Thong, P. Sen Gupta, R.E.J. Ryder (United Kingdom)

Do agonist of GLP1 increase the need for thyroïd hormones ? P-1350
A. Trebea, G. Seng, G. Kazmierczak (France)

Residual C-peptide secretion predicts effective treatment with GLP-1 agonists in insulin-treated patients with type 2 diabetes P-1351
M. Vrtovec (Slovenia)

Addition of sitagliptin to various types of insulin regimens in Japanese type 2 diabetes patients: a 12-month follow-up P-1352
Y. Watanabe, H. Fujii, T. Miyakawa (Japan)

Linagliptin in Asian patients with type 2 diabetes mellitus uncontrolled on metformin: additional analyses of a Phase III trial P-1353
W. Wang, J. Yang, G. Yang, Y. Gong, S. Patel, C. Zhang, T. Izumoto, H.J. Woerle, G. Ning (Germany)

Vildagliptin added to glimepiride improves glycemic control without hypoglycemia and weight gain in Chinese patients with T2DM P-1354
W. Yang, X. Xing, X. Lv, Y. Li, J. Ma, on behalf of all investigators G. Yuan(6), F. Sun, W. Wang, M. Woloschak, V. Lukashevich, P. Kozlovski, W. Kothny (China)

Inflammation

Interferon gamma +874 T/A polymorphism is associated with depression in type 2 diabetes mellitus P-1355
K.F. Rodrigues, N.T. Pietrani, P.H.C. Franco, A.A. Bosco, K.B. Gomes (Brazil)

Polymorphism IFN+874T/A and levels of interferon gamma in women with polycystic ovary syndrome P-1356
M.O. Soter-França, M.F. Sales, C.N. Ferreira, A.L. Candido, K.D.S. Milagres, C. Ronda, I.F.O. Silva, M.O. Sousa, K.B.G. Borges (Brazil)

Plasma antioxidant capacity of type 2 diabetes patients and healthy controls P-1357
H. Gunawardena, K.D.R.R. Silva, R. Sivakanesan, P. Katulanda (Sri Lanka)

Lactoferrin via anti-inflammatory effects to improves insulin resistance and hepatic steatosis in high fructose-fed mice P-1358
C.C. Hsieh, Y.J. Li (Taiwan)

High sensitive C-reactive protein is a bio-marker of type 2 diabetes and cardiovascular disease risk in young urban South Asian subjects P-1359
J. Karalliedde, L. Vasantharajah, G.C. Viberti, M. Gulliford, L. Gnudi, M. Wijesuriya (United Kingdom)

Protective effect of endomorphins on HUVEC induced by high glucose / ox-LDL and its mechanisms of action P-1360
J. Liu, J. Zhao, L.M. Tian, J.X. Quan, S.H. Wei, J. Liu (China)

Anemia in uncomplicated (non nephropathy) diabetes P-1361
A.R. Subhashree, B. Shanthi, P. Subashini, P.J. Parameaswari, B.O. Parijatham, G. Hemalatha (India)

Insulin action - glucose transport, receptor, signal transduction, cellular mechanisms

Glucose deprivation stimulates expression of the endocannabinoid signalling system P-1362
C. Li (China)

Nr4a1 expression is regulated by lipid accumulation in rat liver cells P-1363
K. Sakurai, T. Ishibashi, K. Tachibana, K. Ishikawa (Japan)

Insulin action - physiology, carbohydrate, lipid and protein metabolism

Correlation of circulating acid-labile subunit levels with insulin sensitivity and serum LDL cholesterol in patients with type 2 diabetes P-1364
Y.C. Lai, H.Y. Li, T.J. Wu, C.Y. Jeng, L.M. Chuang (Taiwan)

The beneficial effects of medium-chain fatty acids in regulating metabolism and oxidative stress P-1365
M.K. Montgomery, B. Osborne, L. Small, G.J. Cooney, N. Turner (Australia)

Insulin resistance and the metabolic syndrome

A novel gp130 ligand improves obesity induced glucose intolerance P-1366
T.L. Allen, G. Krippner, T. Adams, L. Sparrow, J. Scoble, C. Yang, E. Estevez, M. Kraakman, L. O'Reilly, T. Biden, S. Rose-John, M.A. Febbraio (Australia)

The triterpene derivative bardoxolone methyl prevents the development of obesity and type 2 diabetes in mice P-1367
D. Camer, Y. Yu, C. Dinh, A. Szabo, X.F. Huang (Australia)

Decrease of insulin sensitivity, from obesity through pre-diabetes: importance of matsuda index P-1368
V. Dimitrijevic-Sreckovic, B. Sreckovic, I. Soldatovic, S. Popovic, H. Janeski, D. Gostiljac, M. Ilic, M. Dodevska, Z. Lazarevic, P. Djordjevic (Serbia)

Relationship between adiponectin level, insulin sensitivity and metabolic syndrome in type 1 diabetic patients P-1369
K. Blaslov, T. Bulum, K. Zibar, L. Duvnjak (Croatia)

Positive association between serum TGF-ß and metabolic parameters in women with polycystic ovary syndrome P-1370
M.O. Sousa, M.O. Sóter, L.M.S. Dusse, L.C. Gomes, C.N. Ferreira, A.P. Fernandes, A.L. Candido, M.F. Sales, K.B.G. Borges (Brazil)

Anti-inflammatory cytokines and metabolic parameters in women with polycystic ovary syndrome P-1371
M.O. Sousa, K.B.G. Borges, C.N. Ferreira, M.F. Sales, I.F.O. Silva, A.L. Candido, K.D.S. Milagres, C. Ronda, M.O. Sóter (Brazil)

Plasminogen Activator Inhibitor-1 (PAI-1) correlates with insulin resistance in polycystic ovary syndrome P-1372
K. Gomes, M. Sóter, A. Cândido, A. Fernandes, A. Ferreira, F. Oliveira, M. Sousa, C. Ferreira, M. Sales (Brazil)

Comparison of insulin resistance among non-obese secondary hypogonadal and eugonadal patients with prolactinoma P-1373
B. Aycicek Dogan, D. Berker, A.Y.S.E. Arduc, M. Tuna, N. Nasiroglu, E. Karakiliç, M. Basaran, S. Isik, Y. Tutuncu, M. Unal, S. Guler (Turkey)

The correlation between body fat distribution and insulin resistance in elderly type 2 diabetes P-1374
E.J. Jeon, H.S. Shon, E.D. Jung, J.H. Lee (Korea)

Psychological insulin resistance in indian type 2 diabetics P-1375
S. Jha, M. Panda, S. Kumar, R. Gupta, A. Neeani, J. Jacob, N. Thomas, A. James, S. Waghdhare, G. Agarwal (India)

Association between fasting serum insulin levels and waist circumference P-1376
S. Keskek, S. Kirim, G. Ortoglu, H. Capar, N. Keskek Sahinoglu, T. Saler (Turkey)

Polymethoxyflavone compounds suppress hepatic glucose production in H4IIE hepatoma cells P-1377
Z.G. Cui, M.J. Gu, E.J. Kwon, Y.K. Lee, D.B. Park (Korea)

Effect of herbal medicine "Diabeto-Cure" on clinical and biochemical parameters of metabolic syndrome P-1378
N. Sharma, M.S. Rathore, P. Arora, B.S. Morjand (India)

Fenofibrate eliminates hepatic insulin resistance in high fat feeding while activating unfolded protein response pathways P-1379
R.Q. Sun, S.M.H. Chan, X.Y. Zeng, H. Wang, X. Zhou, S.P. Li, J.M. Ye (Australia)

Correlation of HOMA-IR, beta cell function, insulin sensitivity and oxidative stress with serum apoptotic markers in newly diagnosed T2DM P-1380
K. Tripathi, H. Kumar, M. Mishra (India)

The relationship between hyperinsulinemia and hypokalemic periodic paralysis in overweight/obese Chinese subjects P-1381
Y. Yu, D. Chen (China)

Association of insulin sensitivity with serum adiponectin in Bangladeshi type 2 diabetic subjects P-1382
R. Zinnat, S.N. Eva, Z. Zeba, L. Ali (Bangladesh)

Insulin secretion, dysfunction, and the islet beta cell (in vivo)

Relationship of insulin secretory capacity and serum Vaspin levels in Bangladeshi type 2 diabetic subjects P-1383
M.O. Faruque, F. Tasnim, Z. Hassan, L. Ali (Bangladesh)

(Pro)renin receptor conditional knockout causes beta-cell loss and hyperglycemia by inducing pathological autophagy P-1384
K. Binger, A. Birkenfeld, S. Wurmsee, F. Qadri, S. Tattikota, D. Willmes, M. Poy, D. Mueller (Germany)

Dual effects of Cinnamomum cassia on pancreatic beta-cells in neonatally streptozotocin-induced non-obese type 2 diabetic rats P-1385
R. Hafizur, N. Fatima, A. Hameed, S. Chishti, N. Kabir, I. Mahmud (Pakistan)

Mechanistic study and target identification of an anti-diabetic compound, cytopiloyne P-1386
S. Huang, T. Kuo, C. Chang, W. Yang (Taiwan)

Glucose toxicity causes a defect in insulin secretion via the K+ATP channel P-1387
C.N. Joannides, B.J. Lamont, M. Stathopoulos, S.P. Mangiafico, B.C. Fam, J. Proietto, S. Andrikopoulos (Australia)

Insulin secretary defect and insulin resistance among Bangladeshi type 2 diabetic subjects P-1388
A. Khan, M. Akhter, F. Zebunnesa, J. Ferdous, L. Ali (Bangladesh)

The analyses of insulin secretion and insulin sensitivity in subjects with monophasic and biphasic plasma glucose pattern during OGTT P-1389
K. Sakaguchi, H. Komada, Y. Hirota, N. Hashimoto, M. Noguchi, W. Ogawa (Japan)

The relationship between clamp-based disposition index and the area under the curve for plasma glucose during 75g OGTT P-1390
H. Komada, K. Sakaguchi, Y. Hirota, N. Hashimoto, T. Nakamura, Y. Okuno, A. Tamagawa, W. Ogawa (Japan)

The relationship between glycated albumin level and pancreatic ßcell function in Chinese newly diagnosed type 2 diabetic patients P-1391
Q. Li, W.P. Jia, Y.Q. Bao, J.M. Pan, J.L. Tang (China)

Empirical indices are valuable for assessing B-cell function in subjects that underwent renal transplantation P-1392
A. Tura, M. Hecking, M. Wolzt, M.D. Saemann, G. Pacini (Italy)

Insulin therapy and devices

Safety and efficacy of insulin detemir in Indian patients switched from insulin glargine: a sub-analysis of the A1chieve study P-1393
S. Tripathi, A.J. Asirvatham, S. Singhal, R. Shetty, S. Bajaj (India)

Evaluating safety and efficacy of glucose-insulin-potassium infusions versus sliding scale insulin in managing inpatient hyperglycemia P-1394
S.M.V. Teo, Y.H. Kwan, J.M. Ng, T.L. Tay, J.Y. Chang (Singapore)

Insulin degludec/insulin aspart achieves superior FPG and less nocturnal hypoglycaemia vs biphasic insulin aspart 30 in Asians with T2DM P-1395
J. Christiansen, S. Kaneko, F.C.C. Chow, D.S. Choi, S. Taneda, K. Hirao, T.H. Andersen, M.A. Gall, Y. Park (Denmark)

Automated bolus advisor use impacts insulin parameter changes and glycemic outcomes in MDI-treated diabetes: results from ABACUS P-1396
I. Cranston, R. Ziegler, D.A. Cavan, K. Barnard, C.G. Parkin, W. Koehler, I. Vesper, M.A. Schweitzer, R.S. Wagner (United Kingdom)

Effect of switching to basal insulin (once daily) + bolus insulin (twice daily) in type 2 diabetic patients uncontrolled with pre-mix insulin P-1397
H. Daikuhara (Japan)

Two prandial insulin approaches for achieving glycemic control in patients on basal insulin therapy and oral agents alone: AUTONOMY study P-1398
S. Edelman, J. Johnson, R. Liu, L.C. Glass (USA)

Insulin degludec/insulin aspart achieves superior FPG and less hypoglycaemia vs biphasic insulin aspart 30 in poorly controlled T2DM P-1399
G. Fulcher, G. Bantwal, E. Poplawska, J. Christiansen, T.H. Andersen, H. Mersebach, L. Niskanen (Australia)

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes P-1400
T. Heise, L. Nosek, H.V. Coester, O. Klein, C. Roepstorff, A.L. Svendsen, H. Haahr (Germany)

Switching from insulin glargine to biphasic insulin aspart 30 therapy in ASEAN type 2 diabetics: a sub-analysis of the A1chieve study P-1401
Z. Hussein, A. Jain, M.A. Lim-Abrahan, G. Su-Yen, P. Soewondo (Malaysia)

Safety and effectiveness of biphasic insulin aspart 30 in ASEAN type 2 diabetes patients switched from neutral protamine Hagedorn insulin P-1402
M.A. Lim-Abrahan, A. Jain, M. Mohamed, K.C. Meng, P. Soewondo (Malaysia)

A prospective study to observe pattern and prescribing of insulin in non critically ill hospitalised patients with diabetes mellitus P-1403
S. Jha, N. Malik, A. Mazumder, D. Majumdar, R. Rishi (India)

A study to compare the efficacy and safety of glimepiride/metformin 1/500mg b.i.d over Glimepiride 4mg qd with insulin glargine P-1404
J. Lee, K. Park, S. Kim, K. Park, D. Lim (Korea)

Evaluation of the new ACCU-CHEK® DIAPORT, a port system for continuous intraperitoneal insulin infusion: final 12-month results P-1405
A. Liebl, B. Gehr, C. Kiehling, C. Rieger, C. Patte, T. Frei (Germany)

Short and long-term cost-effectiveness of switching therapy from NPH insulin to insulin detemir in people with type 2 diabetes P-1406
R. Malek, G. Gonzalez-Galvez, E. Hammerby, A. Nikolajsen, M.F.B. Andersen, O. Henriksen, P. Home (Algeria)

The distinct prandial and basal pharmacodynamics of insulin degludec/insulin aspart in younger adults are preserved in elderly with T1DM P-1407
T. Pieber, S. Korsatko, S. Deller, H. Kojzar, C. Roepstorff, A.L. Svendsen, H. Haahr (Austria)

A 24-week, open label, uncontrolled, observational study using insulin analogues for the treatment of type 2 diabetes in the Czech Republic P-1408
M. Prazny (Czech Republic)Basic and Clinical Science

Did people with baseline HbA1c <7.0% benefit from insulin analogue treatment in the A1chieve study? P-1409
L. Litwak, J. Haddad, Z. Latif, G. Gonzalez-Galvez, V. Prusty, P. Home (Switzerland)

Insulin lispro versus insulin aspart in type 2 diabetes subjects using continuous subcutaneous insulin infusion P-1410
T. Rees, A. Bhargava, C. Guzman, T. Wang, H.L. Murphy, L.C. Glass (USA)

Glycemic control with initiation of single shot of analog Premix 30/70 before lunch in uncontrolled type 2 diabetic patients P-1411
B.D. Saboo, P.A. Talaviya, S.R. Joshi, H.K. Chandarana, J.N. Padhiyar, S.J. Shah, A.N. Shah, C.K. Vyash (India)

Switching to biphasic insulin aspart 30 therapy from biphasic human insulin in an Indian subgroup with type 2 diabetes in the A1chieve® study P-1412
P. Shamanna, N. Gera, S. Akhtar, R. Shetty, S. Jindal (India)

Switching to biphasic insulin aspart 30 from insulin glargine in Indian patients with type 2 diabetes: a sub-analysis of the A1chieve study P-1413
S. Nallaperumal, M. Abubaker, S.H. Zargar, R. Shetty, R. Kovil (India)

The native protein fold of human insulin is retained in insulin degludec multi-hexamers in subcutaneous depot P-1414
D.B. Steensgaard, M. Norrman, J.M. Bearham, C.B. Andersen, E. Nishimura, A.V. Friderichsen, H.M. Strauss, G. Schluckebier, I. Jonassen (Denmark)

Effect of once-daily insulin detemir on oral anti-diabetic drug (OAD) use in patients with type 2 diabetes P-1415
J. Vora, S. Caputo, T. Damci, D. Orozco-Beltran, C. Pan, A.L. Svendsen, K.S. Søjle, K. Khunti (United Kingdom)

Positive Australian continuous subcutaneous insulin infusion outcomes: a rural audit P-1416
G. Kilmartin, J. Wilkinson, J. Kilmartin, S. Bohra, P. Eastaugh, A. Jenkins (Australia)

4-Year evolution of insulin regimens, HbA1c, hypoglycaemia and weight after starting insulin therapy in type 2 diabetes across 3 continents P-1417
P. Home, M.P. Dain, N. Freemantle, R. Kawamori, M. Pfohl, V. Pilorget, W.A. Scherbaum, G. Vespasiani, M. Vincent, B. Balkau (United Kingdom)

Pilot study on the influence of short-acting insulin analogs on biomarkers of chronic systemic inflammation P-1418
A. Pfützner, A.H. Pfützner, A. Löffler, I. Hermanns, J. Heise, T. Forst (Germany)

Islets - beta cell death and survival

Inhibition of synthesis of diabetogenic metabolits of tryptophan by 4 months prolonged treatment by pyridoxine P-1419
G. Meyramov, A.A. Kikimbaeva, F.A. Mindubaeva, L.G. Turgunova, A.M. Aitkulov, A.R. Alina, G.O. Shuzbaeva, O.L. Kovalenko, E.A. Aksartova, A.G. Meyramova, A.M. Tulieva, S.A. Mamatkan (Kazakhstan)

The transcription factor NRF2 protects against pancreatic beta cell apoptosis P-1420
B. Elango, T. Sekar, F. Kira, P. Rajaguru, R. Paulmurugan, K. Ramkumar (India)

SUMOylation protects beta-cells from apoptosis by reducing stimulus-induced nuclear translocation of NFkappaB P-1421
C. Hajmrle, G. Plummer, K. Lai, J.E. Manning Fox, P.E. MacDonald (Canada)

A glucagon-like peptide-1 analogue prevents clozapine-induced reduction of pancreatic islet beta cell mass in a rodent model P-1422
B.R. Hsu, S.H. Fu, C.H. Huang, P.J. Chen, W.J. Cheng, S.T. Chen, Y.Y. Huang (Taiwan)

Comparative ultra-structural analysis of isolated monkey and rat pancreatic islet prior to transplantation P-1423
D. Mohanasundaram, G. Akila, S. Gunasekaran Vaz (India)

Islets - insulin secretion, dysfunction (in vitro)

The beneficial effect of Ezetimibe in INS-1 cells from glucotoxicity via Cluster Determinant 36 (CD36) P-1424
J. Moon, J. Yoon, Y. Kim, H. Lee, K. Won, H.W. Lee (Korea)

Dysfunction and proliferation of pancreatic beta cells by intermittent hypoxia P-1425
H. Ota, A. Itaya-Hironaka, A. Yamauchi, S. Sakuramoto-Tsuchida, M. Takeda, T. Fujimura, H. Tsujinaka, C. Tsuchida, S. Tamaki, S. Takasawa, H. Kimura (Japan)

Lipids and lipoproteins

Insulin resistance and liver steatosis: reversal using Sutherlandia frutescens, a traditional plant extract P-1426
G. Dealtry, S. Clarke, H. Davids (South Africa)

Lipid parameters in acute coronary syndromes versus stable coronary artery disease in patients with and without the metabolic syndrome P-1427
A. Vonbank, C.H. Saely, P. Rein, H. Drexel (Liechtenstein)

Dyslipidemia and type-2 diabetes- disease burden, pattern and therapeutic outcomes: an eastern India perspective P-1428
S. Ghosh, A. Majumdar, S. Mukherjee, D. Dutta (India)

Effects of HMG-CoA reductase inhibitor (pitavastatin) on postprandial dyslipidemia in type 2 diabetes patients. - test meal tolerance - P-1429
T. Hiyoshi, A. Aida, H. Kaga, Y. Kojima, K. Takaya, M. Yoshitsugu, M. Noji, S. Ito, M. Fujiwara (Japan)

Differential effect of HDL cholesterol and apolipoprotein A-I on the development of type 2 diabetes P-1430
Y. Hwang, I. Jeong, K. Ahn, H. Chung, C. Park (Korea)

New insights into the pathogenesis of hypercholesterolemia using a mouse model with liver-specific ablation of Mig-6 gene P-1431
J.C. Lee, B.K. Park, Y. Lee, K.S. Kim, S.D. Lee, B.J. Ku (Korea)

Small dense LDL is closely related to diabetic nephropathy in women with type 2 diabetes P-1432
H.S. Kwon, T.S. Son, E.H. Jang, H.J. Chun, M.K. Kim, K.H. Baek, K.H. Song, B.Y. Cha (Korea)

Effects of pitavastatin versus pravastatin on glucose metabolism in patients with type 2 diabetes: a randomized controlled study P-1433
T. Ota, T. Takamura, S. Kaneko (Japan)

Living with diabetes

Treatment with liraglutide reduces the daily insulin requirements in patients with type 2 diabetes on insulin therapy P-1434
S. Irakleianou, S. Bakoyanni, A. Papazafeiropoulou, S. Bousmpoulas, N. Vrachnos (Greece)

Microbial flora

Antibiogram of lactose fermenting bacterial isolates in patients with diabetes P-1435
M.Q. Khan, R. Sabir, A. Fawwad (Pakistan)

Frequency of Methicillin-resistant Staphylococcus aureus in diabetic infections; a local hospital study from Pakistan P-1436
R. Sabir, S. Mustaqeem, A. Fawwad (Pakistan)

Human gut microbiota changes reveal the progression of glucose intolerance P-1437
X. zhang, D. Shen, Z. Fang, Z. Jie, X. Qiu, C. Zhang, Y. Chen, L. Ji (China)

Monitoring of diabetes control

Glucometrics - an approach to analysing hospital wide diabetes care P-1438
S. Neoh, D. Liew, J. Bowden, P. Colman (Australia)

Assessment of two point of care analysers for determination of HbA1c P-1439
G. Dunseath, R. Churm, S.D. Luzio (United Kingdom)

Glycemic control and its sociodemographic and clinical determinants in type 2 diabetes patients of Bangladesh P-1440
A.S. Mollah, M.I.H. Khan (Bangladesh)

Portable breath acetone analysis toward self-monitoring of diabetic control P-1441
T. Toyooka, S. Hiyama, Y. Yamada, T. Kondo (Japan)

Total antioxidant status and oxidative stress parameters in subjects with normal, impaired, and diabetic glucose tolerance P-1442
G.G. Korkmaz, D. Konukoglu, E.M. Kurtulus, M. Bolayirli, H. Uzun (Turkey)

Monogenic forms of diabetes

Young adult onset diabetes: the importance of establishing an exact genetic diagnosis P-1443
D.S.L. Gardner, S. Mughal, K.R. Owen (United Kingdom)

Spectrum of glucokinase (GCK) gene mutations and prevalence of monogenic diabetes type GCK-MODY in Slovakia P-1444
D. Gasperikova, J. Stanik, L. Valentinova, M. Huckova, M. Balogova, M.S.G. Slovak MODY Collaborative Study Group, I. Klimes (Slovakia)

Clinical homogeneity and genetic heterogeneity of patients with familial young-onset diabetes: the Slovak national data P-1445
J. Stanik, D. Gasperikova, M. Huckova, L. Valentinova, D. Stanikova, J. Michalek, L. Barak, S.M.G. Slovak MODY Collaborative Study Group, I. Klimes (Slovakia)

Obesity - physiology and pathophysiology of weight regulation

Comparison of two different methods to define sarcopenia: computed tomography and dual-energy x-ray absorptiometry P-1446
J.Y. Ryu, H.C. Hong, H.Y. Choi, H.J. Yoo, J.A. Seo, N.H. Kim, S.G. Kim, D.S. Choi, K.M. Choi, T.N. Kim, S.H. Baik (Korea)

Leptin signalling in the dorsal vagal complex and ventrolateral medulla with age and high-fat diet induced obesity P-1447
C. Bell, Y.H. Yu, A. Szabo, X.F. Huang (Australia)

Impact of the Pro12Ala polymorphism of the PPAR2 gene on diabetes and obesity in a highly consanguineous population P-1448
A. Bener, M. Zirie, A. Al-Hamaq, Z. Nawaz, M. Abdul-Ghani, R. Mohammad (Qatar)

Renal Doppler sonography in children and adolescents with obesity P-1449
F. Valeeva, L.R. Gaysina, A.I. Safina (Russia)

Dyslipidemia and proximal renal tubules function in children and adolescents with obesity P-1450
L. Gaysina, F.V. Valeeva, A.I. Safina (Russia)

Serum levels and gene expression of angiopoetin-like factors in obese type 2 diabetic patients: the influence of very-low-calorie diet P-1451
P. Trachta, J. Drapalova, P. Kavalkova, Z. Lacinova, M. Urbanova, M. Mraz, S. Svacina, M. Haluzik (Czech Republic)

Low vitamin D levels and changes in weight status: a prospective study of a group of adolescents P-1452
V. Hirschler, G. Maccallini, M. Sanchez, M. Hidalgo, P. Evangelista, C. Molinari (Argentina)

MC4R gene polymorphisms are associated with BMI in South Africans with type 2 diabetes of Indian origin but not in those of African origin P-1453
F.J. Pirie, A.A. Motala, I.M. Paruk, S. Maharaj (South Africa)

Expression of circulating CD4+CD25+Foxp3+ regulatory T cells in obese patients P-1454
Y. Ren, T.I.N.G. Che, S.O.N.G. Liu (China)

Obesity - prevention and management

Equivalent weight loss but different diabetes benefits with metabolic syndrome in non-morbid obesity T2DM patients after gastric bypass P-1455
H. Gao, L.I. Jia (China)

Body weight reduction effect of an alpha-glucosidase inhibitor, acarbose - comparison within South Asian countries P-1456
S. Kalra, W. Grzeszczak, J. Weng, W.H.H. Sheu, H. Watada, S. Soegondo, N. Yamamoto, O. Schnell (India)

Distribution of obesity phenotypes and their correlation with subclinical CVD in a mixed ancestry population from South Africa P-1457
A.P. Kengne, T.E. Matsha, Y.Y. Yako, R.T. Erasmus (South Africa)

The Protective effects of Rosiglitazone on kidney in diet-induced obese rats P-1458
X. Sun, Y. Yu (China)

Oral glucose-lowering therapies

Comparative effects of low-dose metformin and pioglitazone on blood lactate and lipid levels in type 2 diabetic patients P-1459
Y. Aoki (Japan)

Factors predicting therapeutic efficacy of treatment with Avandamet in Chinese type 2 diabetic patients P-1460
X.L. Cai, Y.L. Chen, X.Y. Han, L.L. Zhou, Q. Ren, L.N. Ji (China)

Sustained efficacy of dapagliflozin for treatment of type 2 diabetes P-1461
J.F. List, K. Lim, M.J. Gandy, S. Parikh (Australia)

Initial combination of miglitol and mitiglinide blunted postprandial blood glucose excursion in type 2 diabetes mellitus P-1462
M. Hashiramoto, F. Tatsumi, K. Kaku (Japan)

Potential anti-diabetic effects of xylitol investigated in a type 2 diabetes model of rats P-1463
M.S. Islam, M. Indrajit, C. Chukwuma (South Africa)

Canagliflozin in Asian subjects with type 2 diabetes on metformin (MET) alone or in combination with sulphonylurea (SU) P-1464
L. Ji, P. Han, Y. Liu, G. Yang, U. Vijapurkar, R. Qiu, G. Meininger (China)

Does gender influence response to alpha-glucosidase inhibitor [acarbose] therapy? - Analysis of real life 62,905 patient data pool P-1465
S. Kalra, H. Watada, J. Weng, O. Schnell, W. Grzeszczak, S. Soegondo, N. Yamamoto, W.H.H. Sheu (India)

Efficacy and safety of canagliflozin versus glimepiride in Korean subjects with type 2 diabetes on background metformin P-1466
M.-K. Lee, K.W. Min, J. Xie, R. Qiu, G. Meininger (Korea)

Dapagliflozin shows similar glycaemic efficacy plus added weight loss in head to head comparisons with metformin or glipizide P-1467
S. Parikh, K. Lim, M.J. Gandy, J.F. List (Australia)

AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and post-prandial glycemia in subjects with type 2 diabetes P-1468
L. Katz, N. Manamley, W. Snyder, M. Dodds, N. Einhorn, J. Sierra-Johnson, M. Cruz, P. Kaur, S. Mudaliar, P. Raskin, A. Pellacani (USA)

Effect of acarbose and metformin on inflammatory factor IL-6, TNF-a, IL-1ß, IL-2 in newly diagnosed type 2 diabetic patients P-1469
Y. Ren, S.O.N.G. Liu, H.O.N.G. Ma, H.A.O. Tian (China)

Antidiabetic and antioxidant effects of different fractions of Bougainvillea spectabilis leaves on STZ induced type 2 diabetic rats P-1470
B. Rokeya, U. Mondal, M. Mosihuzzaman, S.M.A. Rahman (Bangladesh)

Consistent efficacy of add-on combination of luseogliflozin with conventional oral antidiabetic drugs in Japanese patients with T2DM P-1471
T. Sasaki, Y. Seino, A. Fukatsu, M. Ubukata, H. Umeuchi, Y. Sato, S. Sakai, Y. Samukawa (Japan)

Luseogliflozin, a selective SGLT2 inhibitor, improves glycemic control as monotherapy in Japanese patients with T2DM P-1472
Y. Seino, T. Sasaki, A. Fukatsu, M. Ubukata, T. Sasaki, Y. Kasai, S. Sakai, Y. Samukawa (Japan)

Effects of metformin on the glycaemic, incretin hormone and glucagon responses to intraduodenal glucose infusion in type 2 diabetes P-1473
T. Wu, M.J. Bound, J. Ma, C.F. Deacon, K.L. Jones, M. Horowitz, C.K. Rayner (Australia)

Phenotypes versus genotypes

Wolfram syndrome in the Japanese population: genotype-phenotype correlation P-1474
K. Matsunaga, K. Tanabe, A. Taguchi, Y. Ohta, Y. Yamada, Y. Wada, S. Amemiya, K. Sugihara, Y. Nakao, H. Katagiri, Y. Oka, Y. Tanizawa (Japan)

Physical activity

Motivational interviewing-based counselling promotes maintenance of exercise in people with type 2 diabetes P-1475
M.J. Armstrong, T.S. Campbell, A.M. Lewin, F. Khandwala, S.N. Culos-Reed, R.J. Sigal (Canada)

Sprint interval training better than continuous moderate exercise in metabolic syndrome: a randomized controlled trial P-1476
K.M. Badaam, U.S. Zingade, S.T. Khan, A. Munibuddin (India)

The impact of aerobic or resistance exercise on continuous glucose response in individuals with insulin requiring type 2 diabetes P-1477
B.A. Gordon, S.R. Bird, R.J. MacIsaac, A.C. Benson (Australia)

Usefulness of using electrical stimulation sensation on physical inactivity-related blood vessel function test for T2DM P-1478
A. Kimura (Japan)

Exercise-based diabetes education program promotes chronic reduction in blood glucose, A1c, triglycerides in people with type 2 diabetes P-1479
G. Mendes, J. Dullius, T. Lins (Brazil)

Change in leg muscle volume in Japanese older adults with T2DM after 1-year fitness center-based resistance training P-1480
S. Okada, M. Furukawa, M. Ikejiri, H. Takahashi, Y. Sato (Japan)

Effects of short-term detraining on insulin-independent pathways of GLUT4 translocation in spontaneously hypertensive rats P-1481
A.M. Lehnen, G. Pinto, J. Borges, M. Markoski, B. Schaan (Brazil)

Pregnancy and gestational diabetes

Effects on maternal and fetal outcomes of gestational diabetes mellitus: case-control study in a tertiary care hospital in Bangladesh P-1482
R. Begum, S. Jahan (Bangladesh)

Correlation of lipid profile changes with pregnancy outcomes in patients with type 1 diabetes mellitus P-1483
S. Ismailov, L. Nugmanova, M. Atadjanova, S. Muratova (Uzbekistan)

The degree of glucose intolerance assessed in the mid-trimester of pregnancy is predictive of early postpartum glucose abnormality P-1484
K. Kankova, V. Bartakova, D. Maluskova, J. Muzik, J. Belobradkova (Czech Republic)

Effect of lipid parameters on fetal growth in type 2 diabetes mellitus and gestational diabetes mellitus pregnancies P-1485
B. Krstevska, V. Velkoska Nakova, S. Jovanovska Misevska, B. Jovanovska, I. Bitoska, I. Ahmeti, S. Simeonova, V. Livrinova (Macedonia)

Factors associated with early cessation of breastfeeding in Australian women with gestational diabetes mellitus P-1486
M. Morrison, C. Collins, J. Lowe (Australia)

Plasma thiamine levels are decreased in gestational diabetes mellitus P-1487
L. Pacal, V. Bartakova, A. Pleskacova, R. Kudlac, K. Kuricova, V. Tanhauserova, J. Belobradkova, J. Tomandl, K. Kankova (Czech Republic)

Result of ambulatory training and treatment of diabetic pregnant in Tehran P-1488
A. Rajab, A. Rajab, S. Shoeibi, G.R. Garmaroudi (Iran)

Insulin secretion in addition to insulin resistance predicts gestational diabetes mellitus P-1489
E.C.H. Krzizek, J.M. Brix, G.-H. Schernthaner, G. Schernthaner (Austria)

Clinical and metabolic factors associated with plasmaadipocytokines in gestational diabetes mellitus P-1490
S. Soares, E.B. Figueiredo, A.M. Ferreira (Brazil)

Food intake was a modifying factor on the association of weight gain with diagnosis for gestational diabetes mellitus P-1491
M.C. Lu, Y.H. Yan, C.W. Yu, P. Wang (Taiwan)

Quality assurance in diabetes care

Evaluation for diabetic retinopathy by clinic based physician Vs hospital based physician referring to a ophthalmologist P-1492
S. Dsouza, S. Dsouza, P. Adhikari, N. Dsouza, L. Dudeja, M. Nayak (India)

Autoantibodies to GAD and IA-2 in newly diagnosed diabetes subjects presenting with DKA at Auckland Hospital: 6-yr study P-1493
B. Secret, M. Khanolkhar, G. Braatvedt, S. Chan, M. Naidu (New Zealand)

Care delivery, care providers, coordinators and supporters

Challenges in establishment of community based diabetic retinopathy services: lessons learned from Bangladesh P-1494
A. Awal, A. Raihan (Bangladesh)

Diabetic care in Pakistan P-1495
S. Haque, A. Sheikh (Pakistan)

Empowering patients with diabetes to adhere to management plans in a southern African country P-1496
I.N.C. Kingsley, M.C. Bondo, L. Nkombua (South Africa)

Comorbidities

'Your Heart, Your Bloodline, Your Choice' – developing a successful resource through community engagement P-1497
J. Owen, H. Mitchell, J. Hurd, D. Schofield, C. Hawkins, A. Singh, E. Nardi, A. Wagstaff (Australia)

Complications

Higher Maori representation in subjects with readmissions for diabetic ketoacidosis when compared to those without a readmission P-1498
A. Tekiteki, A. Selvakumar, H. Britton, B. Secret, G. Braatvedt, M. Khanolkar (New Zealand)

Diabetes in Indigenous groups

Periodontal status of two indigenous population in relation to diabetes and life style P-1499
A. Haider, A. Ahmed, M. Naser, F. Ahmed, K. Zaman (Bangladesh)

The Desert Feet Tour sings about diabetes prevention P-1500
H. Mitchell, A. Sighn, J. Owen, D. Schofield, C. Hawkins, E. Nardi, A. Wagstaff, D. Thornbur (Australia)

Diabetes in rural areas

Issues in the provision of diabetes health care in a rural health settings P-1501
R. Munt, L. King, M. King, E. Willis (Australia)

Indigenous communities and ethnicity issues

Improvement in hdl-c levels in Argentine Indian school children after vitamin D supplementation: a pilot study P-1502
V. Hirschler, G. Maccallini, M. Sanchez, M. Hidalgo, C. Aranda, L.U.I.S. Castano, C. Molinari (Argentina)

Models of care, multi-disciplinary care and family-centred care

Eye care pathways: access and completion patterns for people with diabetes in Aboriginal community controlled health services (NT/NSW) P-1503
A. Burnett, A. Morse, H. Brown, C. Waddell, T. John (Australia)

Obesity - prevention and management

HOPE = "Healthy Options = Positive Eating": reducing inequalities and prevention of diabetes in Indigenous and migrant communities P-1504
R. Davy (New Zealand)

Pregnancy and gestational diabetes

Pregnancy outcomes at various periods of the Israeli-Georgian program diabetes in pregnancy (1997-2013) P-1505
N. Asatiani, R. Kurashvili, M. Dundua, E. Shelestova, M. Hod (Georgia)

Primary and secondary prevention

Better practice Aboriginal health promotion principles: a reflection on the implementation of the Aboriginal Life! prevention program P-1506
R. Alexander, J. Shill, L. Day, A. Timoshanko (Australia)

Traditional botanopharmacotherapy

Regulation of gene expression in insulin resistance and its reversal by the South African medicinal plant Sutherlandia frutescens P-1507

M. Fortuin, J. Mackenzie, S. Williams, S. Roux, M. van de Venter, D. Lang, G. Dealtry (South Africa)

Late-breaking abstracts

Patient experiences of type 2 diabetes mellitus care delivered by general practice nurses in a West Australian urban general practice P-1508
E.M. Boyle, R. Saunders, V. Drury (Australia)

How important is it when patients are unsure if they took their basal insulin as perscribed? iIpacts of questioning insulin behavior in China P-1509
M. Brod, J. Kongso, D. Bushnell, C. Yu, Z. Xu, L. Yang (USA)

Interactive computerized "Seven-Diabetic-Behavior Scoreboard" as a promising assessment to key diabetic behavior P-1510
H.C. Hsu, Y.H. Chang, Y.J. Lee, R.H. Wang (Taiwan)

Arogya World's mDiabetes Program – effectiveness results P-1511
F. Kaufman, S. Ramalingam, L. Blais, M. Arora, H. Ranjani, K. Kahol, R. Dave, A. Gowda, N. Saligram (USA)

Mentoring and motivation: perspectives of Australian diabetes educators on professional development: a phenomenological study P-1512
M. Kingston-Ray, T. Holland, K. Collier (Australia)

Self-monitoring of blood glucose data analysis technology with an electronic medical recording system P-1513
H. Kitaoka, M. Oh, Y. Inaba, H. Nakamura, M. Date (Japan)

Physician learning intervention to improve blood pressure in adults with and without diabetes: a randomized trial P-1514
P.J. O'Connor, D.J. Magid, K.L. Margolis, D.W. Price, S. Asche, W.A. Rush, H.L. Ekstrom, D.W. Brand, J.M. Sperl-Hillen (USA)

Health-related Quality of Life (QoL) in Russian children, adolescents and young adults with type 1 diabetes (T1D) in the TEENS Study P-1515
V. Peterkova, E. Andrianova, O. Malievsky, L. Laffel, M. Phillip, R. Hanas, V. Pilorget, M.P. Dain, C. Domenger, C. Candelas (Russia)

Facebook as a tool to improve glucose control in adolescents with type 1 diabetes P-1516
G. Petrovski, T. Milenkovic, B. Jovanovska, I. Bitovska, I. Ahmeti, M. Zivkovic (Macedonia)

Expert-designed, smartphone application significantly improved diabetes self-care activities with high user satisfaction P-1517
S.Y. Rhee, J.Y. Kim, J.K. Hwang, J.I. Son, S.O. Chin, S. Chon, S. Oh, J.T. Woo, S.W. Kim, Y.S. Kim (Korea)

Motivations for insulin misuse among women with disordered eating and type 1 diabetes P-1518
R. Tyo, J. Sheeshka, J. Madill, M. Preyde (Australia)

The effect of cognitive load manipulation on episodic memory in type 2 diabetes P-1519
N. Jones, L.M. Riby, M.A. Smith (United Kingdom)

A qualitative study exploring Japan's occupational care workers' perceptions and experiences of working with elderly diabetics P-1520
A. Wakui, M. Kondo, M. Agawa, T. Sugiyama, S. Clayton (Japan)

Adults under age 45 with insufficient diabetes knowledge have worse glycemic control among patients with type 2 diabetes mellitus in China P-1521
Y.N. Wang, W.H. Xiao (China)

Joint approach of diabete dialogue map and pictorial representation of illness and self P-1522
K. Yamada, J. Assal, T. Assal, S. Buchi, I. Yamada (Japan)

Age, gender, ethnicity and culture

Measured approach for diabetes and Ramadan fasting (MADAR):a structured education program in Egypt and Gulf countries P-1523
M. Hassanein, L. Kleinebreil, S. Ibrahim, A. El-Sayed, M. Kamel, I. Shaltout, A. Madani, M. Al-Arouj, A. Ben-Nakhi, M. Zeiri, K. Tayeb, E. Ba-Essa (United Kingdom)

Gendered barriers to services, self-care and wellness among adult diabetic women in Bangladesh P-1524
E. Khetran, L. Ali (Bangladesh)

Care delivery, care providers, coordinators and supporters

Collaborative diabetes care services in nigeria – the talabi diabetes centre experience in primary care P-1525
O. Adesina, T. Johnson, J. Talabi, O. Ade (Nigeria)

Integrated and comprehensive management of patients with type 1 diabetes in a low resource society; "Insulin my life" project P-1526
A. Fawwad, M.Y. Ahmedani, S.F.D. Alvi, B. Tahir, S. Naz, A. Basit (Pakistan)

Profile and performance of diabetes educators - physicians assistants in a community diabetes clinic network in India [1994 – 2013] P-1527
K.N. Ashwini, G. Rao, T. Kamala, S. Srikanta, M. Cavale, V. Rao, V. Shivaraj, H.K. Vasanthalakshmi, V. Krishnaswamy, S. Murugan, U. Rangaraj, Diabetes Collaborative Study Group(1) (India)

Improvement in care for people with diabetes during their stay in a busy general hospital in south Auckland, New Zealand P-1528
G. Aspin, H. Cattaway, B. Orr-Walker, N. Van der Merwe (New Zealand)

Outcomes of twin pregnancy complicated by gestational diabetes: a comparison with singleton pregnancies P-1529
M. Hussain, V. Wong (Australia)

A survey on nursing practices from a tertiary care hospital at India with a case for the role of diabetes nurse educator P-1530
S. Jha, N. Thomas, A. James, S. Waghdhare, M. Sahu (India)

Cardiometabolic risk management in an Australian Mental Health Service: it's all about the H.E.A.R.T P-1531
F. Millar (Australia)

Diabetes drug prescription pattern and awareness among health care providers in sub-Himalayan region of India: a population based study P-1532
J. Mokta, K. Mokta, P. panda (India)

Care facilitation for people with diabetes related foot complications: understanding the bigger picture to improve patient outcomes P-1533
R. Barber, R. Ogrin (Australia)

Improving service access for people with diabetes in the south east bayside area of Melbourne P-1534
M. Ryan, S. Wyatt (Australia)

Promoting partnerships in diabetes care: specialised inpatient service as a precursor to the introduction of a diabetes nurse practitioner P-1535
M. Schlaeppi, W. Kelly, P.G. Fegan (Australia)

New Zealand managed roll out of diabetes nurse specialist prescribing P-1536
P. Drury, H.J. Snell, T. Cundy, C. Budge (New Zealand)

Cognition, psychology and behaviour

Diabetes knowledge among Croatian non-medical high school and university students P-1537
A. Buklijas Skeledzija, K. Blaslov MD, N. Brcina MD (Croatia)

Validity and reliability of the Lithuanian version of the Audit of Diabetes Depended Quality of Life (ADDQoL) P-1538
Z. Visockiene, E. Muchlyte, R. Puronaite, J. Beisyte, Z. Bukelskiene, K. Lyskoit, I. Lucun (Lithuania)

Complementary medicine

The utilization of traditional Chinese medicine among patients with diabetes in Taiwan P-1539
C.C. Liao, T.L. Chen, C.C. Shih (Taiwan)

How often are complimentary herbal products used among diabetic patients? P-1540
I. Sahin, E. Timocin, L. Keskin (Turkey)

Diabetes and gender dynamics

The glycemic response in both genders and eating habit in age-stratified type 2 diabetes mellitus – based on the DCMP 2001, Taiwan P-1541
M. Fuh, C.-Y. Yang, P.-C. Chen, C.-I. Li (Taiwan)

Diabetes education across the ages

Development and validation of an insulin proficiency assessment tool for insulin self management in adults with type 2 diabetes mellitus P-1542
D. Fornasier, A. Dr Andrew Bonney (Australia)

Diabetes awareness in type 2 diabetics: where do we stand? A tertiary care clinic based data from central India P-1543
K. Gupta, S. Gupta, V. Mehta, S. Ugemuge, A. Ambade (India)

Medications associated with anti-diabetic drugs induced severe hypoglycemia in type 2 diabetes mellitus P-1544
S.H. Hsiao, Y.L. Liang, M.C. Lee, M.Y. Tsai, S.C. Hu, T.J. Wu (Taiwan)

Aspects of diabetes among selected community members in central Kenya P-1545
S. Irungu, C. Karekezi, E. Njenga (Kenya)

Diabetes education and technology

Health information-seeking and its impact on the key outcomes of a web-delivered dietary intervention among patients with diabetes P-1546
A. Ramadas, K.F. Quek, B. Oldenburg, C.K.Y. Chan, Z. Hussein (Malaysia)

SMS messaging to reduce emergency department visits for people with diabetes: human factors analysis P-1547
J. Cohen, A. Alameer, J. Pines (USA)

Electronically calculate insulin bolouses improve control in patient with type 1 diabetes treated with basal-bolus insulin therapy P-1548
I. Gonzalo, L. Prieto, C. Beltran, A. Martín, A. García- Manzanares, K. Manrique, A. Rovira (Spain)

Telehealth remote monitoring: structured self-monitoring of blood glucose and impact on A1C P-1549
D.A. Greenwood, H.M. Young, C.C. Quinn (USA)

The Copenhagen rehabilitation trial part 2: Telemedicine as a means to achieving good diabetes control among patients with type 2 Diabetes P-1550
C.R. Hansen, H. Perrild, B.G. Koefoed, D. Høst, P. Faurschou, M. Zander (Denmark)

Paediatric and adolescent diabetes electronic care plan and data base: MyPlan P-1551
A. Keid (Australia)

Continuous customized education via telemedicine: outcome data of events over 8 years P-1552
J. Kesavadev, A. Shankar, G. Sanal, J. Lally, G. Krishnan, S. Jothydev (India)

Evaluation and comparison of the diabetes conversation maps and the central gippsland health service 5-week diabetes group program P-1553
S. Kewming, E.K.L. Mitchell, A. D'Amore (Australia)

Evaluation of the insulin self-titration education program on glycemic control in type 2 diabetes mellitus patients. P-1554
H.Y. Lee, C.H. Lu (Taiwan)

Sensor-augmented pump therapy with automated low glucose insulin suspension: the patients' perspective P-1555
J.A. Nicholas, E.A. Davis, T.W. Jones, T.T. Ly (Australia)

High prevalence of depressive symptoms in hospitalized diabetic patients and the effect of "Accu-Chek Assist" education programme P-1556
S. Tkach, T. Milutina (Ukraine)

Motivating people with type 2 diabetes to increase their daily physical activity, for better metabolic control and weight reduction. P-1557
F. Toti, A. Shehu, G. Bejtja, B. Resulaj, V. Leka (Albania)

Fun and games technology with a dash of diabetes, not diabetes with a dash of fun and games P-1558
G. Tremayne (Spain)

A web-based self-management site for patients with type 2 diabetes may improve self-efficacy, self-care and diabetes distress P-1559
C. Yu, J. Parsons, M. Mamdani, G. Lebovic, S. Hall, B. Shah, O. Bhattacharyya, A. Laupacis, S.E. Straus (Canada)

Online diabetes self-management: why does – and doesn't – it work? P-1560
C. Yu, J. Parsons, S. Hall, S. Straus (Canada)

Diabetes education delivery

Dose Adjustment For Normal Eating (DAFNE), Singapore: 6-month interim results P-1561
K. Adaikan, H.B. Lim, S.L. Gardner, S.Y. Goh (Singapore)

The diabetes educator role in Canada: A national perspective P-1562
P. Agema, D. Sherifali, A. Belton (Canada)

Diabetes health promotion program to Bahraini school children using games and conversation maps P-1563
N. Al Amri (Bahrain)

Latin American diabetes camps, an update - Diabetes Camps and Convivencias IDF-SACA Task Force P-1564
M.T.U. Barone, C. Solari, C.G. Labate, M. Vera-Gonzalez (Brazil)

Exploring a model of diabetes self-management education from the patient perspective P-1565
S. Burke (USA)

diabetes care and education at a primary care setup in patients with type 2 diabetes mellitus P-1566
M.I. Khowaja, M.A. Ebrahim (Pakistan)

Effect of a client-centred diabetes group education program on attendees' knowledge, psychosocial and clinical outcomes P-1567
C. Eigenmann, L. Brown, G. Frydman, L. Kaoutarani, A. Lockie, M. Norman (Australia)

Effectiveness of 24 hours stationed base telephonic helpline service in resource constraint society P-1568
M. Ahmedani, F. Ahmed, M.Z. Awaz, E. Ghafoor, M. Riaz, A. Basit (Pakistan)

Getting the most from education factsheets: what is best practice? P-1569
J. Giles, K. Visentin (Australia)

Problems and complications of insulin application techniques in diabetic patients P-1570
M. Kulaksizoglu, A. Kaya, G. Gonulalan, F. Ozdamar (Turkey)

Working towards improvement in paediatric services in an australian public hospital P-1571
A. McLeod, V. Stevenson, L. Roberts, S. Baqar (Australia)

Conversation maps workshops as tool to improve glycemic control in type 2 diabetes patients P-1572
A. Merom, Y. Fried Isaac, R. Ben-david, Y. Nissim, S. Kaplan, M. Michaelie, N. Katshanski, R. Shamalov, P. Richter (Israel)

Out comes after 7 years of initiation of a community based pharmaceutical care for people with diabetes in the north west region of Cameroon P-1573
A. Nkwenti (Cameroon)

Knowledge and awareness of diabetic retinopathy among urban diabetes and non diabetes out-patients in the national eye hospital, Sri Lanka P-1574
K.Y.S. Perera, K. Sothilingam, P. Katulanda, S. Jayasinghe (Sri Lanka)

Effectiveness of information education and communication materials on diabetes knowledge: a comparative study (Kenya) P-1575
S. Pilleron, A. Brus, E. Bonareri, D. Olchini (France)

Keeping blood glucose under control, a card game P-1576
R.J. Pineda Wieselberg, M.T.U. Barone, J. Baptista, L.L. Galastri (Brazil)

Diabetes knowledge evaluation in type 2 diabetic patients P-1577
I. Gonzalez-Molero, M. Domínguez-López, M. García, J.A. García Arnes, M.S. Ruiz de Adana, F. Soriguer (Spain)

Does "hospitalization for diabetes education" improve blood glucose level and health-related quality of life? P-1578
E. Sakanaya, T. Sugiyama, A. Wakui, T. Tsujimoto, M. Kishimoto, K. Imai (Japan)

Education and awareness of diabetes among the public in western Fiji P-1579
A. Sewram (Fiji)

Medicine compliance T2DM patients P-1580
R. Shukla, S. Mishra, A. Bajpai (India)

Enhancing diabetes awareness and prevention: the second Diabetes Attitudes, Wishes and Needs (DAWN2) Study P-1581
H. Stuckey, M. Massi-Benedetti, K. Kovacs Burns, B. Kulzer, J. Wens, M. Peyrot, DAWN2 Study Group (USA)

Using community theatre to promote diabetes education and prevention in Fiji P-1582
P. Szmedra, A. Chand, C. Rozmus (USA)

The diabetes education in Lautoka Diabetic Hub Centre P-1583
M. Tikoimakogai, R. Koroi, A. Khasag (Fiji)

Targeted health education in care of vulnerable people with diabetes - development and testing of health care education methods and tools P-1584
M. Bagger, I. Willaing, K. Aebeloe, H. Nedergaard, S. Vestergaard (Denmark)

Diabetes in the elderly, in-patients and other special groups

Evaluating the impact of a diabetes monitoring chart and metric feedback on the management of hospitalised patients with diabetes P-1585
C. Holmes, P.H. Dyer (United Kingdom)

Education needs identified following an in-hospital hypoglycaemia management audit P-1586
Z. Huang, P. Hill (Australia)

Diabetes care for resource limited settings [D4RLS]: paradigm of adult type 2 diabetes in India [1994-2013] P-1587
V. Krishnaswamy, U. Rangaraj, G. Rao, S. Srikanta, T. Kamala, M. Cavale, K.N. Ashwini, S. Muragan, V. Shivaraj, T. Deepak, A. Sharda, S. DIABETES COLLABORATIVE STUDY GROUP (India)

Need of elderly patients with diabetes who live alone P-1588
Y. Miyawaki, Y. Shimizu (Japan)

Evaluation of the utility of diabetes day hospital (HDD) after a cardiovascular event P-1589
C. Morales Portillo, J.L. Jimenez Gallardo, R. Cortes Pelaez, E. Garcia Sanchez (Spain)

Adherence to an insulin protocol since its introduction five years ago in Virgen Macarena Hospital P-1590
C. Morales Portillo, M. Baquero Jimenez, A. Blanco Becerra, A. Sendon Perez (Spain)

Diabetes management

Comparison of treatment outcomes in type 2 diabetes patients treated either with acute dietary energy restriction or conventionally P-1591
E. Inashvili, N. Asatiani, R. Kurashvili, M. Dundua, E. Shelestova, A. Kopaleishvili (Georgia)

Diabetes management at primary care level is an illusion in a small district of Pakistan P-1592
M. Asif Mahmood, A. Saleem, O. Ishtiaq (Pakistan)

Algorithms in type 2 diabetes management do not reflect knowledge of physicians about the benefits of early treatment P-1593
M. Blüher, P. M. Paldánius, W. David Strain (Germany)

Impact of recognition and treatment of admission hyperglycaemia in diabetic patients: a paradoxical outcome? P-1594
T.Y. Chai, K.T. Tonks, L.V. Campbell (Australia)

Effects of diabetes care delivered in the primary care health center on metabolic control in patients with diabetes P-1595
L. Chen, L. Xu, L. Shen, Y. Zhang, H. Zhu, Q. Sun, Y. Bao, W. Jia (China)

A survey on the difference between diabetic hypoglycemic education and patient self-management and improvement plan P-1596
F. Chiu, T. Lee, C. Lo, C. Chang, W. Lee, Y. Jen (Taiwan)

Self-care behavior in patients diagnosed with type 2 diabetes mellitus in the outpatient department of the Philippine General Hospital P-1597
R. De Roxas (Philippines)

Racing through the Atlantic with Young Diabetics Type 1 "Quebec – St Malo's Project" P-1598
T. Froment, V.N. Vyncke (Belgium)

Strategies to initiate insulin therapy on time in patients with T2D - conclusions of a Delphi study in Spain P-1599
F. Gómez-Peralta, J. Escalada, D. Orozco, C. Morillas, F. Alvarez Guisasola, M. Mata, R. Palomares, R. Iglesias (Spain)

Enhancing the diabetes consultation within primary care settings: use of the MyQuest Consultation Tool – a pilot study P-1600
G.A. Hood, S. Shea, A. Worthington (United Kingdom)

Evaluation of lifestyle pattern and practices in type 2 diabetes patients, hospitalized with minor & major complications P-1601
S. James, R. Shetty, R. Gupta, A. Dunga, V. Shethna (India)

Empowering nurses in managing hypoglycemia by a structured action pathway, training, generating awareness and persistent monitoring P-1602
S. Jha, N. Thomas, A. James, M. Sahu, S. Waghdhare (India)

Effect of insulin glargine (Lantus®) on glycemic status and body weight in Bangladeshi type 2 diabetes P-1603
F. Pathan, F. Khan (Bangladesh)

Prevention of wound on the feet of diabetic patients in Cote d'Ivoire P-1604
D. Koffi, J. Abodo, F. Kouassi, A. Koné, A. Hué, F. Fagnidi, A. Lokrou (Côte D'ivoire)

Comparison of treatment outcomes in type 2 diabetes patients treated either with acute dietary energy restriction or conventionally P-1605
E. Inashvili, N. Asatiani, R. Kurashvili, M. Dundua, E. Shelestova, A. Kopaleishvili (Georgia)

DAFNE improves glycaemic control and reduces insulin needs in young adults with type 1 diabetes within Auckland Diabetes Centre, New Zealand P-1606
A. Liu, D. Howarth, A. Dean, M. Khanolkhar, B. Abrams (New Zealand)

HbA1c correlates more with post-prandial than post-exercise blood glucose in active individuals with type 2 diabetes mellitus P-1607
J. Dullius, G.F. Mendes, T.C. Lins (Brazil)

Weight loss among adults with prediabetes: A pooled analysis of two clinical trials using Weight Watchers P-1608
A.S. Juarascio, K. Miller-Kovach, L. Barraj, D.G. Marrero, P.M. O'Neil (USA)

Development of Insulin Knowledge Test Questionnaire (IKTQ) to assess knowledge of insulin therapy in insulin user type 2 diabetes patient P-1609
A.S. Mollah, M.I.H. Khan (Bangladesh)

Use of GLP-1 analogue (liraglutide) in 231 patients with diabesity: Andalucian multicenter study P-1610
C. Morales Portillo, M. Lainez Lopez, M. Rivas Fernandez (Spain)

Evaluation of the agreement on recommended dose of insulin from the software "insulinator" and an endocrinologist P-1611
C. Morales Portillo, J. Perez Rodriguez, V. Hernando Herrero, C. Garcia Garcia, M. Malagon Cobos, A. Sendon Perez (Spain)

Beginning insulin therapy: our experience in 448 type 1 and type 2 diabetic patients P-1612
C. Morales Portillo, M. Romero Correa, L. Martinez Martinez, I. Serrano Olmedo, A. Sendon Perez (Spain)

The prevalence and risk factors of secondary failure to oral hypoglycaemic agents among type two diabetes patients P-1613
S. Muazu, F. Anumah (Nigeria)

Starting a hospital-based diabetes management program in a semi-urban setting: from community action to implementation P-1614
J.C. Katte, C. Kouam, G. Tama, N. Dongmo, B. Orr Walker, M. Dehayem, E. Sobngwi, J.C. Mbanya (Cameroon)

Type 1 diabetes mellitus summer camps and their impact on glycemic control P-1615
M. Onetto Flores, B. López Radrigán, X. Fantuzzi Selle, F. Giraudo Abarca, P. Pinto Muñoz, T. López Radrigán, J. Pinto Muñoz (Chile)

Are we always successful with insulin pump treatment? P-1616
G. Oruk, N. Goren Atalay, M. Bahceci, S. Isli, A. Gorgel, D. Dolek Cetinkaya, F. Salgur, M.M. Demirpence (Turkey)

Treatment patterns of type 2 diabetes mellitus patients on metformin monotherapy with suboptimal glycemic control: a U.S. database study P-1617
S. Yu, P. Schwab, B. Bian, D. Nero, L. Radican, K. Tunceli, Y. Qui (USA)

To assess the intake of Vitamin D in diabetic peripheral neuropathy P-1618
T. Rashid, S. Jaffri, N. Fatima, M. Riaz, A. Basit (Pakistan)

The outcome of 5 years folllow-up of diabetic nephropathy at diabetic center, Paolo Memorial Hospital, Pholyothin, Bangkok P-1619
W. Sangdee, S. Surassanant, S. Ratanachaiyavong, A. Thongphiew (Thailand)

Effectiveness of cardiovascular risk reduction education in Turkish people with type 2 diabetes P-1620
A. Bayindir Cevik, S. Ozcan, I. Satman (Turkey)

Treating to target in type 2 diabetes - how close are we? Experience in a Nigerian tertiary hospital P-1621
D. Soyoye, B.A. Kolawole, R.T. Ikem, O.J. Adebayo, A.C. Enikuomehin, G.O.D. Ajani (Nigeria)

Association of diabetic autonomic neuropathy with RBC aldose reductase activity P-1622
N.S. Verma, P. Gupta, S. Bhattacharya, A.A. Mahdi, K. Usman, S. Tiwari (India)

Adherence to self-care, metabolic control and quality of life perception one year after onsel of type 1 diabetes P-1623
M. Vidal, M. Jansà, A. Amor, I. Conget, M. Giménez, P. Ara, G. Yago, D. Roca, E. Esmatjes (Spain)

Nurse practitioner Role; initiation, monitoring and facilitation GLP-1 analogue and insulin combination therapy P-1624
M. Woods (Australia)

Guidelines, clinical care

Validation of a toolkit to implement the transcultural diabetes nutrition algorithm (tDNA): a multinational survey P-1625
J.I. Mechanick, A. Marchetti, R. Hegazi, O. Hamdy (USA)

Injection technique: how to select the appropriate needle for insulin injection? P-1626
B. Hansen, G. Ehlers, G. Kirketerp (Denmark)

Clinical care keeping up with the evidence – diabetes educators leading the way using clinical leadership groups P-1627
S. Conway, B. Davies, A. Heard, J. Morley, R. Norman, K. Tapley, C. Vasjuta, R. Ogrin (Australia)

The University of Michigan health system diabetes research registry enhances patient recruitment for clinical trials P-1628
M. Tan, S. Bernstein, S. Gendler, N. Kessler, W. Herman (USA)

Hypoglycaemia management: achieving best practice and consistency in rural hospitals P-1629
K. Visentin, J. Giles (Australia)

Disseminating the Canadian Diabetes Association 2013 Clinical Practice Guidelines: a step-by-step approach P-1630
C.H. Yu, S. Jin, P.J. Lin, M. Clement, N. Ivers, C. Gall-Casey (Canada)

Health professional education and development

Knowledge attitude and practices of primary health care physicians towards type 2 diabetes mellitus in North Karnataka, India P-1631
J. Appajigol, M. Somannavar (India)

Diabetes care among older people with diabetes in primary care settings in Norway P-1632
M. Graue, T.D. Dunning, M.F. Hausken, B.R. Rokne (Norway)

The flourishing approach: A treatment approach based on what's already working P-1633
R. Greenberg, H.B. Bertsch (USA)

European workshops to promote knowledge of diabetic eye disease and its management to nurses working in diabetes care P-1634
M.S. Hall, A. Felton, S. Karadeniz (United Kingdom)

Training courses for multidisciplinary health care professionals – assessing impact and the role of action plans P-1635
K. Kapur, S. McAleer, F. Persson, U. Bjerre-Christensen (Denmark)

Beliefs of Australian diabetes educators in the care of people with diabetes and intellectual disability P-1636
J. Lehmann, V. Stevenson, R. Lehmann (Australia)

Rural and remote registered nurses' and Aboriginal health workers'experience having undertaken a specialist diabetes course P-1637
R. Munt, L. King, M. King, E. Willis (Australia)

A diabetic education lecture for nurses to understand the components of self-care agency P-1638
T. Nakahama, Y. Shimizu (Japan)

Evaluation of a novel educational program for healthcare professionals: diabetes theater, a workshop including drama and discussion P-1639
K. Okazaki, H. Okada, K. Ohashi, T. Yamamoto, T. Ashina (Japan)

Integrating of holistic approach to diabetes care; perspectives of young adults with diabetes and health professionals P-1640
N. Parsian, T. Dunning (Australia)

Training of healthcare workers and educators and empowerment of people with diabetes - crucial building blocks for effective health system P-1641
E. Shelestova, L. Tsutskiridze, R. Kurashvili, N. Asatiani, M. Gordeladze, M. Dundua, L. Petrenko, N. Vlasenko (Georgia)

How nurses grasp blood glucose variation in pattern management: a nurse's view point P-1642
Y. Shimizu, M. Mizuno, K. Uchiumi, N. Seto, H. Masaki (Japan)

Oral health information for diabetes educators P-1643
S. Sofronoff, A. Priede (Australia)

Operative groups in basic healthcare units: user perception regarding educational activities and treatment of type-2 diabetes P-1644
H. Torres (Brazil)

Diabetic retinopathy special interest group: optimising practitioner and patient education P-1645
M. Travis, N. Jaross (Australia)

Diabetes education programme for pharmacists in postgraduate education in Ukraine P-1646
I. Vlasenko (Ukraine)

The ABC's of DKA: computer-based simulation to improve the management of diabetic emergencies P-1647
C. Yu, R. Brydges, S. Straus (Canada)

Health services research

An exploratory analysis of clinical data and self-management behaviours of patients to develop an intensive insulin service. P-1648
S. Ozcan, S. Amiel, H. Roberts, P. Choudhary, A. Cox, N. de Zoysa, D. Hopkins, A. Forbes (United Kingdom)

Increase in daily steps after a 6-month lifestyle intervention for adults with type 2 diabetes in primary care: a controlled trial P-1649
S.T. Johnson, C. Mundt, A. Soprovich, L. Wozniak, W. Qui, R. Plotnikoff, J.A. Johnson (Canada)

Organisational and health professional factors impacting on insulin initiation: A mixed methods study P-1650
J. Manski-Nankervis, J. Furler, I. Blackberry, D. Young (Australia)

Health workforce

Evaluation of FINDRISK as an instrument for the detection of type2 diabetes in a population from the city of São Paulo P-1651
D. Beheregaray Kaplan, D. Franco, L.i. Indiani, G. Bechara, V. Giampaoli, G. Tunes, E. Silva, W. Amorim, C. Almeida, P. Rombolli, R. Rezende, F. Castelo Branco (Brazil)

Bitter and sweet outcomes of caring: compassion satisfaction and fatigue among diabetes nurse educators P-1652
M. Puno, F.I. Pasaporte (Philippines)

Living with diabetes

Gender disparities in psychosocial outcomes in the second Diabetes Attitudes, Wishes and Needs (DAWN2) study P-1653
R. Holt, A. Nicolucci, S. Kalra, R. Malek, N. Piana, J. Wens, I. Willaing, M. Peyrot, DAWN2 Study Group (Italy)

Words and behavior concerning self-evaluation by a diabetic patient in relation to using a self-evaluation scale for self-care ability P-1654
S. Waki, Y. Shimizu, N. Seto (Japan)

Models of care, multi-disciplinary care and family-centred care

Telehealth model of care - an unexpected journey P-1655
D. Dean, A. McLean (Australia)

All's well that ends better: Diabetes Transition Services in Auckland, 2006-2013 P-1656
R. Hornung, P. Reed, F. Mouat, R. Cutfield, B. Orr-Walker, P. Drury, C. Jefferies (New Zealand)

Influence of a diabetes nurse practitioner as part of the health care team – is it complementary or competitive? P-1657
K. Porter (Australia)

You2 Connect – a novel support program for gestational diabetes P-1658
M. Trute, U. Abeypala, K. MacDougall, L. Chalmers (Australia)

Defining the attributes of good pharmacy practice in providing pharmaceutical care for patients with diabetes mellitus P-1659
I. Vlasenko, L. Davtyan, I. Zhogov (Ukraine)

Metabolic outcomes for diabetes after 42-months intervention using community-hospital integrated care system in Beijing communities P-1660
M. Yuan, S. Yuan, G. Wan, H. Fu, L. Zhu, G. Yang, S. Pan, R. Xie, Y. Lv, N. Zhuang, Y. Li, X. Du (China)

Nutrition and diet

Meal pattern analysis of type 2 diabetes patients hospitalized with major and minor complications P-1661
S. James, R. Shetty, R. Gupta, V. Shethna, A. Dunga (India)

Carb counting test as a tool used as a tool in the planning of a dietary guidance course for children and adolescent P-1662
M. Nielsen (Denmark)

Carbohydrates prescription in children with type 1 diabetes mellitus and their relation with nutritional recommendation P-1663
M. Onetto Flores, M. Cabezón Arriagada, R. Jiménez Lira (Chile)

Food and nutritional intake of Portuguese adolescents with and without type 1 diabetes P-1664
M.J. Afonso, P. Moreira, I. Carmo, J.F. Raposo (Portugal)

Diet quality and macronutrient intake of type 2 diabetes mellitus patients in the cardiovascular program of Davao City, Philippines P-1665
M. Silva, W. Satheannoppakao, S. Pongpanich (Philippines)

Patient engagement and self-management - adult

Impact of continuous sub-management education on bio-chemical markers in the management of diabetes P-1666
R. Abdul Rehman, E. Ghafoor, B. Tahir, M. Riaz, A. Basit (Pakistan)

Getting back on track – ongoing education for those with type 2 of greater than three years duration P-1667
T. Cleary (New Zealand)

Therapeutic education for newly-arrived persons to a diabetes clinic P-1668
A.C. Paiva, M.J. Afonso, L. Serrabulho, J. Susano, J.F. Raposo ()

Improving diabetes management and cardiovascular risk factors through diabetes self-management support groups in Kenya P-1669
P. Park, C.K. Wambui, S. Atieno, S.D. Pastakia, G.S. Bloomfield, J.H. Kamano, J.S. Nyabundi (Kenya)

Diabetes self-management improvements: multi-stakeholder perspectives in the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study P-1670
K. Kovacs Burns, A. Nicolucci, N. Hermanns, S. Kalra, A. Forbes, A. Kokoszka, A. Mayorov, I. Tarkun, M. Peyrot, DAWN2 Study Group (Canada)

To assess the impact of diabetes education on self-management of people with diabetes P-1671
S. Mateen, E. Ghafoor, B. Tahir, M. Riaz, A. Basit (Pakistan)

Relative effectiveness of diabetes and chronic disease self-management programs P-1672
P. McGowan, S.L. Lynch (Canada)

Assessment of diabetes self-care activity in Beijing and Shantou, China using the summary of diabetes self-care activities measure P-1673
H.C. McGuire, K. Kissimova-Skarbek, F. Aguirre, D. Whiting, J. Yi, P. Zhang, Y. Wu, S. Lin, J. Weng, L. Ji (Belgium)

Non-predictive behavior of glycemic fluctuations in participants of an exercise program with type 1 and type 2 diabetes mellitus P-1674
G. Mendes, D. Dullius, T. Lins (Brazil)

Be absent in diabetes education program and physical exercise deteriorate glycemic control in type 2 diabetes mellitus on insulin therapy P-1675
J. Dullius, G.F. Mendes, T.C. Lins (Brazil)

DESMOND Down Under: the benefits of quality improvement for structured diabetes self management programs in Western Australia P-1676
H. Mitchell, D. Schofield, B. Stribling, M.J. Davies, K. Khunti, T.C. Skinner (Australia)

Color record in self-monitoring of blood glucose improves glycemic control for insulin-treated type 2 diabetes patients P-1677
A. Nishimura, I. Honda, S. Harashima, Y. Shimizu, K. Hosoda, N. Inagaki (Japan)

Oral health knowledge and behaviours of adults with diabetes: a literature review P-1678
A. Priede, J. Furler (Australia)

Effects of a self-management educational programme on glycemic control in type 2 diabetes P-1679
H. Sadeghian, K. Agrawal, S.V. Madhu, A.T. Kannan (India)

Peer education

Diabetes Conversation Map™ promotes understanding of diabetes and nutrition planning in dietetics students P-1680
N. Mizuno, S. Harashima, H. Higashiyama, K. Shide, N. Inagaki (Japan)

Effectiveness of a community-based diabetes self-management education (DSME) program in a rural agricultural setting in the Philippines P-1681
E. Paz-Pacheco, M.A.S. Sandoval, G.J.R. Ardena, P. Patal, J. Bongon, E. Paterno, N. Juban, C. Jimeno, F.L. Lantion-Ang (Philippines)

Psychosocial/behavioural interventions

Factor associated with non-adherence to insulin in patients with type 1 diabetes P-1682
M. Riaz, A. Basit, A. Fawwad, M.Y. Ahmedani, Z.A. Rizvi (Pakistan)

Diabetologists experience substantial barriers to addressing psychological problems in consultations P-1683
C. Johansen, R. Torenholt, E. Hommel, M. Wittrup, I. Willaing (Denmark)

Family stress reduction and coping response training among Filipino patients with Type 2 diabetes mellitus P-1684
M.T.P. Que, G. Lopez, Z.M. Briones (Philippines)

Influences of sympathetic psychological stress in glycemic control during short-term admission for education in type 2 diabetic patients. P-1685
A. Takizawa, N. Manpo, E. Fujimura, Y. Takeda, F. Hirano (Japan)

Quality assurance in diabetes care

Busting myths of gestational diabetes mellitus screening and diagnosis in the Australian capital region P-1686
J. Gallagher, L. Boisseau, J. Langridge, M. Ingle, J. Herron, L. Bancroft (Australia)

Audit of diabetes care at the Family Medicine Centre of Vilnius University Hospital Santariskiu Klinikos, Lithuania 2011-2012 P-1687
Z. Visockiene, J. Biesyte, Z. Bukelskiene, K. Lyskoit, I. Lucun, R. Puronaite, L. Venceviciene, V. Kasiulevicius (Lithuania)

Telecommunication, internet and social media

Investigating a pervasive INET mobile phone solution to support diabetes self-care P-1688
N. Wickramasinghe, P. Brooks, S. Cole, S. Fourlanos, S. Kirn, L. Kliman (Australia)

Traditional healing/therapies

Prevention of type 2 diabetes mellitus by yoga therapy among subjects with impaired glucose tolerance P-1689

N. Sharma, D. Jagwani, S. Sharma, S. Mathur (India)

Late-breaking abstracts

Evaluation of sexual functions in type 2 diabetic women P-1690
E. Tuncel, O. Durgun, H. Peynirci, C. Ersoy (Turkey)

Care delivery, care providers, coordinators and supporters

Food for Thought: advocating nutritional change for vulnerable victorians living in Supported Residential Services (SRS) P-1691
E. Farnbach (Australia)

Therapeutic compliance of type2 diabetic patients treated with oral antidiabetic agents at Gabriel Touré hospital in Bamako, Mali P-1692
S. Sanogo, M. Diallo, A.M. Diallo, A. Niantao (Côte d'Ivoire)

Glycemic status of the hospitalized uncontrolled type 2 diabetic patients treated with single anti diabetic agent before admission P-1693
S.M. Shefin, M.F. Pathan, M.O. Faruque (Bangladesh)

Complications

Diabetes mellitus and urinary tract infection: a study on their association to help prioritize protocols for management P-1694
D. Acharya, B. Bogati, J.B. Sherchan, S.K. Madhup, P. Karkee, N.R. Tuladhar (Nepal)

Temporal trends of nephropathy in patients with type 2 diabetes mellitus: a retrospective cohort study P-1695
T. Begum, P.A. Khanam, H.O. Rashid, M. Rahman, M.M.H. Chowdhury, H. Mahtab, M.A. Sayeed (Bangladesh)

Association between glycosylated hemoglobin and acute coronary syndrome in type 2 diabetes mellitus P-1696
N. Chowta, N. Kosuru, M. Prabhu, M. Chowta (India)

The frequency of neuropathic pain and its correlates in Turkish patient with diabetes mellitus P-1697
S. Celik, A. Kubat Uzum, E. Temel, S. Purisa, N. Gul, G. Yenidunya, G. Cinkil, N. Dinccag, I. Satman (Turkey)

Bilateral renal abscess in a case of diabetes mellitus with glycemic poor controlled P-1698
J.Y. Jiang, C.Y. Liu, W.K. Cheung (Taiwan)

Peripheral artery disease in elderly patients with type 2 diabetes mellitus P-1699
F. Sarac, S. Savas, S. Sarac, F. Akcicek (Turkey)

A novel complication : reduced quality of life from painful diabetic peripheral neuropathy in the nose? P-1700
S. Saxena (Australia)

Diabetes advocacy

Diabetes advocacy and education: experience from the first World Diabetes Day celebrations in Bafoussam, Cameroon P-1701
J.C. Njabou Katte, J.L. Ngeuwa, F. Tamghe, P. Fokapu, A. Okondoua, A. Djuitchou, G. Tama, D. Nkwenti (Cameroon)

Diabetes associations

Destination UnityA Diabetes New Zealand Auckland branch perspective P-1702
R. Ah Chee (New Zealand)

A good example of Association's work P-1703
N. Cuk Roland (Croatia)

GUDEAS - 20 Years with IDF, 2011 – 2013 Activities P-1704
R. Kurashvili, E. Shelestova, L. Tsutskiridze, M. Dundua, N. Asatiani, G. Kurashvili (Georgia)

Realization of the program "Monitoring the Situation in the Field of Diabetes in various Regions of Kazakhstan" P-1705
L. Zhubandykova (Kazakhstan)

Diabetes in childhood and adolescence

Diabetes camp as education tool in the follow-up of the diabetic children P-1706
J.S. Bangoura, N.M. Balde, M. Kouyate, M.A. Barry, T.O. Barry, M.M. Diallo, M.A. Diallo, M.A. Diallo, O.B. Diallo, S. Bah, M. Sangare-Bah (Guinea)

Glycaemic control and socio-economic impact of type 1 diabetes in Pointe-Noire P-1707
C. Elenga Bongo, Monabeka H.G.(2), Bouenizabila E.(2) (Republic of Congo)

Diabetes in India: European young leaders supporting Life for a child program P-1708
M. Hillinger, K. Schudmann (Austria)

Diabetes knowledge among selected children with type 1 diabetes in Kenya P-1709
C. Karekezi, J. Ndungu, E. Njenga, N.N. Ngugi (Kenya)

Children's perception of living with diabetes (CPLD) P-1710
C. Labate, V. Giampaoli, G. Bechara, M. Lopes, M. Barone (Brazil)

The use of the Psychosocial Assessment Tool (PAT2.0): can it predict outcomes in youth with newly diagnosed type 1 diabetes mellitus P-1711
J. Norfolk, K.A.R. McNamara, K. Browne-Cooper, E.A. Davis, J.H. Mace (Australia)

Taking type 1 diabetes care for the "have not" children of India to the next level: DISHA + CDiC and beyond? P-1712
V. Shivaraj, V. Rao, K.N. Ashwini, V. Krishnaswamy, S.G. Rao, U. Rangaraj, S. Srikanta, M. Cavale, T. Kamala, S. Muragan, R. Sriharsha, J. DIABETES COLLABORATIVE STUDY GROUP (India)

Supporting pupils who have diabetes type 1 - a qualative interview study about Swedish school nurse´s experiences P-1713
A. Wennick, N. Aranda Gani (Sweden)

Insulin therapy and devices

Glycaemic control, insulin pump use and diabetes-related emotional distress – what do we know? P-1714
H.C. Andersen, E. Hommel, V. Zoffmann (Denmark)

Confidence in carbohydrate counting for insulin pump users P-1715
L. Chan (Australia)

Glycemic improvement in using 5 mm pen needle - a case report P-1716
F. Chiu, T. Lee, C. Lo, C. Chang, W. Lee, Y. Jen (Taiwan)

Metabolic evolution of type 2 diabetes failing patients: study of an insulin multi-injections pattern followed by insulin pump P-1717
J.P. Courrèges, A. Iosup, N. Vigier Simmore, H. Bonnaure, J.F. Thuan, N. Bastide (France)

New glargine formulation: glucose control and hypoglycaemia in type 2 diabetes using a meal-time+basal insulin regimen (EDITION I) P-1718
P.D. Home, G.B. Bolli, M. Ziemen, I. Muehlen-Bartmer, F. Bizet, M.C. Riddle (United Kingdom)

Does insulin analogue improve treatment outcomes in our type 2 insulin treated patients state insulin program in Georgia P-1719
M. Nishnianidze, T. Ghvaladze, E. Skhiladze, R. Kurashvili, L. Tsutskiridze, E. Shelestova (Georgia)

To assess the use, handling and disposal of insulin injection equipment by diabetic patients in Pakistan P-1720
S. Mahar (Pakistan)

Do older patients with diabetes benefit from insulin pump therapy? P-1721
A. Rizvi, K. Smith (USA)

Evaluation of treatment satisfaction and diabetes related distress in very well controlled patients using the InsuPad device P-1722
A. Pfützner, N. Hermanns, B. Kulzer, K. Funke, T. Haak (Germany)

Living with diabetes

The impact of socio-economic factors on incidence of diabetes in Mongolia P-1723
A. Altaisaikhan, J. Suvd, S. Sainbileg (Mongolia)

Using technology in real-time to self-manage type 1 diabetes and enhance quality of life P-1724
G. Tremayne, F. Arechaga (Spain)

Communicating with older people with diabetes: listening and learning P-1725
N. Duggan, T. Dunning, S. Savage (Australia)

Diabetes Attitudes, Wishes and Needs 2 (DAWN2): depression and quality of life in type 1 vs. type 2 diabetes P-1726
R.I.G. Holt, I. Willaing, N. Folmann Hempler, N. Hermanns, A. Kokoszka, A. Mayorov, H. Stuckey, M. Peyrot, DAWN2 Study Group (United Kingdom)

Hypoglycemia and fear of hypoglycemia affect quality of life and daily activities in Spanish subjects with type 2 diabetes: HIPOQoL-II Study P-1727
E. Jódar, F. Alvarez, L. Avila, R. Palomares, B. Font, C. Roldán (Spain)

Quality of life in insulin-treated diabetics: preliminary results of a Tunisian prospective study of 100 cases P-1728
I. Khochtali, S. Graja, Y. Hasni, M. Jmal, H.E.L.A. Marmouch, H. Sayadi, S. Mahjoub (Tunisia)

Diabetes healthcare: a multi-stakeholder perspective in the second Diabetes Attitudes, Wishes and Needs (DAWN2) study P-1729
K. Kovacs Burns, M. Comaschi, S. Kalra, B. Kulzer, M. Massi-Benedetti, E. Menéndez Torre, N. Munro, M. Vallis, M. Peyrot, DAWN2 Study Group (Canada)

Non-adherence to lifestyle modification and Health related quality of life among type 2 diabetic patients P-1730
S.J. Mumu, F. Ara, F. Saleh, M.A. Hafez, L. Ali (Bangladesh)

Why do diabetic people get involved in support groups' activities? Example of Nindiri municipality (Nicaragua) P-1731
M. Narvaez, B. Tapia, F. Falla, M. Flores, A. Martinez, D. Olchini (Nicaragua)

An experience: living the life of a patient with type 1 diabetes for 3 consecutive days P-1732
A. Nkwenti (Cameroon)

Mental health of adults with type I diabetes P-1733
C.L. O'Brien, C. Silberberg, S.G. Mancuso, A.J. Jenkins, D.N. O'Neal, M. Loh, M. Salzberg, G. Ward, J.D. Best, D. Castle (Australia)

Is increased epicardial adipose tissue is a sign of cardivascular disease in women with gestasyonel diabetes mellitus? P-1734
F.B. Ozturk Ceyhan, H. Yilmaz Yasar, C. Ceyhan (Turkey)

Sexuality of 26-36-year-aged type 1 diabetics and age-matched control men: differences between various diabetes duration and control men P-1735
L. Radzeviciene, V. Matulevicius, R. Ostrauskas, N. Jurgeviciene, B. Urbonaite, I. Matuleviciute, I. Banisauskaite, J. Jureviciute, R. Verkauskiene (Lithuania)

Living with type 1 diabetes in India: a study on factors associated with uncontrolled blood sugar in children with type 1 diabetes P-1736
L. Simon (India)

A cognitive and emotional journey: measuring the experiences of a Diabetes Queensland member P-1737
M. Skinner, H. Bushell (Australia)

Promotion of safe sharp disposal in NSW P-1738
M. Taylor (Australia)

Quality of life in patients with diabetic nephropathy P-1739
O. Vasilkova, T. Mokhort (Belarus)

Living alone impairs psychosocial health and self-management: the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study P-1740
I. Willaing, U. Møller Hansen, L.E. Joensen, R.I.G. Holt, J. Wens, M. Peyrot, DAWN2 Study Group (Denmark)

Impact of InsuPad on insulin requirements and glycemic control: results from a randomized controlled real-world study P-1741
A. Pfützner, I. Raz, N. Hermanns, T. Behnke, T. Forst, G. Bitton, R. Nagar, T. Haak (Germany)

Patient engagement and self-management - adult

Incidence and risk factors of fatty liver disease in Bangladeshi type 2 diabetic subjects P-1742
M. Akand, Q. Nahar, O. Faruque (Bangladesh)

Diabetic education is effective for lowering HbA1c, irrespective of literacy state P-1743
S. Ashrafuzzaman, L. Zafar, I. Monami (Bangladesh)

Expectations and aspirations of patients and physicians at the diagnosis of type 2 diabetes P-1744
P. Paldánius, W. David Strain, M. Blüher (Germany)

Employment and economic hardship are barriers to self-management in people with type 2 diabetes: results from Diabetes MILES - Australia P-1745
J.L. Browne, A. O'Neil, E.D. Williams, R. Horne, F. Pouwer, J. Speight (Australia)

Perceived barriers to self-monitoring of blood glucose (SMBG) for patients with diabetes in Singapore - a mixed method study P-1746
X.L. Lin, S. Rahayu, N. Hassan, P.L. Lee, M.L. Lim, N.S. Hamid, A. Manikam, J. Chua, M.C.W. Chan, N. Khaw (Singapore)

Sweet and incredible days - how I manage my diabetes so I can live happily ever after P-1747
J. Machado (Brazil)

Autonomous use of the exercise game Wii Fit Plus improves glucometabolic control and quality of life: a randomized controlled trial P-1748
K. Kempf, S. Martin (Germany)

Ramadan fasting related experiences of Pakistani diabetics P-1749
Y. Masood, A. Shera, S. Masood (Pakistan)

Type 1 diabetes mellitus management in hospital: the person's experience P-1750
R. Munt (Australia)

Social barriers and enablers to type 2 diabetes self-management: the role of capital P-1751
R. Munt, J. Henderson, C. Wilson, M. Crotty, L. Roberts (Australia)

Life transitions management: an Australian-Danish qualitative study among young people with type 2 diabetes in the age between 20-40 years P-1752
B. Rasmussen, H. Terkildsen Maindal, T. Dunning, P. Livingston, V. Lorentzen (Australia)

Gestational diabetes: women's stories about their journey P-1753
K. Smallman, K. Pickering, D. Bermingham, J. Baker (New Zealand)

Buddhist values and self-management behaviors among Thais with type 2 diabetes: a path analysis P-1754
B. Wattanakul, C. Fritschi, L. Finnegan, J. Zerwic, C. Ferrans, L. Ruggiero, L. Quinn (Thailand)

Patient engagement and self-management - youth

Glycemic control and self-monitoring of blood glucose; a six month prospective study in subjects with type 1 diabetes P-1755
S. Naz, A. Fawwad, M.Y. Ahmedani, S.F.D. Alvi, B. Tahir, A. Basit (Pakistan)

To assess the common dietary practices among people with Type 1 diabetes P-1756
S. Jaffri, T. Rashid, M. Riaz, A. Basit (Pakistan)

Creating supportive environments for type 1 children and their families P-1757
C. Sumpton (New Zealand)

Physical activity

Step to the edge: Influencing diabetes self-management through outdoor adventure and physical activity pursuits P-1758
C. Vance, J. Hanson (Canada)

How I become a first person with diabetes type1 in the world who finished triple Ironman race (11,4km swim, 540km cycling and running 126,6km)? P-1759
N. Simunko (Croatia)

Telecommunication, internet and social media

Blue Power: putting young people together for World Diabetes Day activities P-1760
C. Labate, J. Baptista, G. Moreira, M. Barone (Brazil)

Raising awareness of diabetes globally using amateur radio communications: 60 years of Zagreb Diabetic Society P-1761
A. Paulin (Croatia)

Normasugar.ru — the first m-health system for online observation and treatment of diabetes mellitus in Russia P-1762
A. Podgrebelny, M. Zuev, A. Tiselko, N. Arbatskaya, I. Rybkina, E. Pronina (Russia)

Late-breaking abstracts

The Singapore Diabetes Risk Score (SINDRISC): A practical tool to predict undiagnosed diabetes in a multi-ethnic urban Asian population P-1763
D.J. Alperet, Y. Wu, W.Y. Lim, J.M.J. Lee, E.S. Tai, R.M. van Dam (Singapore)

Tuberculosis among diabetic patients: a lesson from double diseases burden in East Indonesia P-1764
F.A. Nugroho, M.D. Manurung, J.H. Untario, T.A. Pakasi, I.S. Widyahening, A. Aswar (Indonesia)

Metabolic surgery for type 2 Diabetes Mellitus (T2DM) in patients with BMI=30kg/m*: A metaanalysis P-1765
A. Baskota, S.Y. Li, N. Dhakal (China)

Diabetes mellitus and war stress P-1766
R. Bek (Croatia)

Insulin regimens and glycaemic control at initiation and 4 years in people with type 2 diabetes across Europe: the CREDIT observational study P-1767
L. Blonde, M. Marre, M.P. Dain, M. Vincent, N. Danchin, G. Vespasiani (USA)

The association between parental tobacco use and BMI in children and adolescents P-1768
I. Braithwaite, A.W. Stewart, R.J. Hancox, R. Beasley, R. Murphy, E.A. Mitchell, ISAAC Phase Three Study Group (New Zealand)

Continuous measures of cardiometabolic risk constructed from clinical factors: validation and comparison with Framingham Risk Scores P-1769
S.J. Carroll, C. Paquet, N.J. Howard, A.W. Taylor, R. Adams, M. Daniel (Australia)

The brown dog and his memorial in South London (1903-1911) P-1770
M. Cheng (Australia)

An international collaboration to compare glycaemic control among people with type 1 diabetes P-1771
M.N. Cooper (Australia)

Insufficient physical activity related to diabetes and obesity on 1ª and 2ª Nipo-Brazilians generations living a Brazilian inner city P-1772
C. de Souza Costa, E. Viana, S.R.G.F. Vívolo, S.G.A. Gimeno, L.K. Matsumura, H. Harima, A.T. Hirai, S. Andreoni (Brazil)

Relationship between 24h urinary sodium to potassium ratio with blood pressure in people with diabetes P-1773
R.J. Libianto, G. Jerums, S. Baker, R.J. MacIsaac, E.I. Ekinci (Australia)

Establishment of the Brunei Diabetic Foot Registry P-1774
N. Haji Zaine, K. Hitos, J. Fletcher, M. Vicaretti, L. Begg, J. Burns (Australia)

Hypoglycaemia among insulin-treated patients with diabetes: an international retrospective and prospective study of 3832 patients P-1775
K. Khunti, C. Enters-Weijnen, P. Geelhoed-Duijvestijn, T. Forsén, U. Pedersen-Bjergaard, E. Moberg, R. Kapur, H. Gydesen, B. Ludvik (United Kingdom)

Prevalance of pathological urine findings in spontaneous office-based samples of type 2 diabetes patients with and without CKD P-1776
J. Lee, L.F. Merker, B. Gallwitz, B. Waldeck, K. Schoene (Germany)

Doubling of service burden with proposed new Australian treatment targets for gestational diabetes P-1777
A. McLean, D. Kevat, S. Caddaye (Australia)

Association of maternal 25-hydroxyvitamin D concentration and criteria for diagnose gestational diabetes mellitus by 75 gram OGTT P-1778
S. Pengyos, N. Napartivaumnuay, S. Niramitmahapanya (Thailand)

HbA1c anthropometry and knowledge in households with and without a member with T2D P-1779
J. Nielsen, S.K. Bahendeka, S.R. Whyte, I.C. Bygbjerg, D.W. Meyrowitsch (Denmark)

Experiences and challenges in establishing a collaborative endocrinology & diabetes fellowship training program in Ethiopia P-1780
E. Siraj, A. Reja, T. Kebede (USA)

Expert-designed, smartphone application significantly improved diabetes self-care activities with high user satisfaction P-1781
J.I. Son, S.Y. Rhee, J.K. Hwang, S.O. Chin, S. Chon, S. Oh, J.T. Woo, S.W. Kim, Y.S. Kim, J.Y. Kim (Korea)

JNK expression in human monocytes are associated with prediabetes and insulin resistance P-1782
F. Lombardo, M. Pandolfo, C. Carbia, M. Lardo, B. Fabre, V. Ortiz, F. Reissig, E. Cagnacci, V. Quiroga, F.m. Puchulu, M.j. Perone, M.j. Taverna (Argentina)

Association between smoking status and obesity in a nationwide survey of Japanese adults P-1783
T. Watanabe, I. Tsujino, S. Konno, Y. Ito, T. Sato, A. Yamada, A. Isada, Y. Ohtsuka, M. Taniguchi, K. Akiyama, A. Akasawa, M. Nishimura (Japan)

Reference intervals and factors contributing to serum glycated albumin levels in West China P-1784
H. He, Z. An, S. Li, T. Zhang, L. Liang, H. Huang, (China)

Age, gender, ethnicity and culture

Birthweight standards for babies of northern Kerala, India P-1785
R. Chandni (India)

Body mass index (BMI) related to ethinicity and lifestyle in adolescent boys at an international high school in Riyadh, Saudi Arabia P-1786
Y. Kharal, H. Kharal, A. Al-Sayyari (Saudi Arabia)

A study of lifestyle to find out prevalence of cardio metabolic risk factors in a cohort of north Indian urban population P-1787
A. Maheshwari, B. Saboo, R. Gupta, K.K. Sharma, N. Maheshwari (India)

Anthropometric indexes of Cambodian type II diabetes mellitus patients P-1788
S. Sea, K. Touch (Cambodia)

Bariatric surgery and type 2 diabetes

The diagnostic dilemma for diabetes in patients with morbid obesity P-1789
J. Brix, H.P.K. Kopp, G.H.S. Schernthaner, G. Schernthaner (Austria)

High remission rate of prediabetes in patients after bariatric surgery P-1790
J.M. Brix, H.P. Kopp, G.H. Schernthaner, G. Schernthaner (Austria)

Care delivery, care providers, coordinators and supporters

The primary care extension service: improve diabetes quality in primary care across the United States P-1791
R. Gabbay, D. DeWalt, A. Kaufman, J. Mold (USA)

Transforming primary care delivery to improve diabetes care: the patient-centered medical home in Pennsylvania P-1792
R. Gabbay, M. Wolf, M. Meyers (USA)

Comparing diabetes outcomes in specialist and general practitioner settings: should more patients be managed in primary care? P-1793
E. Ho, W. Tee, H.M. Goh, K. Loy, H.S.H. Ng (Singapore)

China Initiative for Diabetes Excellence (CIDE): clinical status of 2143 individuals from 27 provinces with type 2 diabetes mellitus P-1794
R. Mazze, B. Hayes, E. Strock, D. Parker, M. Murphy, L. Ji, A. Cide Study Group (USA)

Coaching women to prevent diabetes P-1795
C. Rasmussen, B. Ralls, K. Digre, S. Simonsen, P. Eisenman, L. Johnston, H. Aiono, F. Tavake-Pasi, F. Davis, S. Rickard, E. Napia, V. Munkundente, I. Nash (USA)

COMPASS project: community pharmacists for diabetes patients intervention study in Japan P-1796
H. Okada, Y. Nakagawa, M. Onda, M. Shoji, N. Sakane (Japan)

Building capacity and access to diabetes care in Madagascar P-1797
H.A.J.A. Ramamonjisoa, C. Rakotonirina, F. Rakotoarisoa, M. Rakotoarimanana, A. Ravonison, R.I.V.O. Rakotonirina, B.O.D.O. Razafindrakoto, M. Razafimanatrika, J.O.S.É. Ratsitratrinihafa, J. Ramarolahy, T. Rajaonarison, G. Ramahandridona (Madagascar)

Implementation of programs for community healthcare providers and patients in China: The China Initiative for Diabetes Excellence (CIDE) P-1798
J. Dong, D. Parker, E. Strock, Y. Jiang, B. Hayes, J. Norstrom, F. Mao, L. Wang (USA)

China Initiative for Diabetes Excellence (CIDE): clinical status of individuals with type 1 diabetes P-1799
R. Mazze, B. Hayes, E. Strock, D. Parker, M. Murphy, L. Ji, A. Cide Study Group (USA)

Cognition, psychology and behaviour

The effect of yoga and peer support interventions on the quality of life of women with diabetes: results of an RCT P-1800
A. Sreedevi, U. Ambika Gopalakrishnan, S. Karimassery Ramaiyer (India)

Your risk versus my risk: the differentiation of perceived personal risk versus community diabetes risk P-1801
M. Skinner, H. Bushell (Australia)

Functional living in type 2 diabetes: executive functioning, dual task performance and the impact on postural stability and motor control P-1802
M.A. Smith, J.E. Else, L. Paul, J.K. Foster, K. Wesnes, L.M. Riby (United Kingdom)

Comorbidities

Prevalence of hypogonadotropic hypogonadism in type 2 diabetic males P-1803
R. Chawla, D. Garg, H. Punyani, G. Ramachandran (India)

Association between carotid artery stiffness and plaque burden in patients with type 2 diabetes mellitus P-1804
B.H. Kim, K.Y. Cho, Y.K. Jeon, S.S. Kim, I.J. Kim (Korea)

Clinical validation of a Korean version of the Peripheral Artery Questionnaire for peripheral artery disease P-1805
B.H. Kim, K.Y. Cho, J. Spertus, Y.H. Park, H. Je, M.S. Shin, J.S. Jang, J.R. Kim (Korea)

Depression among Nepalese type 2 diabetes mellitus patients and their quality of life P-1806
K. Niraula, M. Sabrina Flora, S. Jahan Mumu, N. Thapa, B.A. Kohrt, B. Pederson (Bangladesh)

Bioavailable testosterone levels are associated with nonalcoholic fatty liver disease in postmenopausal women with type 2 diabetes P-1807
J.Y. Shin, J.S. Lim, M.Y. Lee, C.H. Chung (Korea)

Relationship of plasma osmolality with obesity, glucose intolerance and insulin resistance P-1808
A. Raj, V.V. Holla, S. Rathi, G.S. Ranga, S.V. Madhu (India)

Fatty liver disease and loss of glycemic control on a 5-years follow-up population study P-1809
J.F. Raposo, M.P. Macedo, L. Gardete-Correia, R. Duarte, J.M. Boavida, I. Correia, Z. Peerally, F. Martins, R.T. Ribeiro (Portugal)

Complications

Association of vitamin D3 with painful diabetic neuropathy P-1810
K. Abdul Basit, A. Basit, A. Fawwad, N. Fatima, S.F.D. Alvi, R. Malik (Pakistan)

Differences in survival among multiple ethnic groups of type 2 diabetes in Australia P-1811
T. Alharbi, M. Constantino, L. Molyneaux, T. Wu, S. Twigg, D. Yue, J. Wong (Australia)

Cardiovascular risk prediction in newly diagnosed type- 2 diabetes mellitus patients: Framingham vs. UKPDS algorithms P-1812
D. Bansal, V.R. Vyamusani, A. Bhansali (India)

Anthropometric determinants of myocardial infarction: a case-control study in rural Bangladesh P-1813
K. Fatema, B. Rahman, N. Zwar, A.H. Milton, L. Ali (Australia)

Income level and HbA1c in adults living with diabetes in an urban primary care facility in Accra, Ghana P-1814
R. Lamptey, H.J.O. Lawson, G. Wontumi, A. Dodoo, M. Kissenger, D. Nortey, N. Tetteh, B. Nkum (Ghana)

Semen analysis among diabetic and non-diabetic male of subfertile couples: case study of a tertiary care hospital P-1815
N. Mahtab, N. Mahmud, H. Mahtab (Bangladesh)

Comparison of clinical profile and microvascular complications of younger and older onset type 2 diabetes in south India P-1816
U. Ranjit, R.M. Anjana, A. Amutha, V. Mohan (India)

Diabetic autonomic neuropathy: frequency and association with clinical and socio-economic variables P-1817
B. Pedro, H. Vieira Dias, F. Roque (Portugal)

Diabetes and risk of physical disability in old age: a systematic review and meta-analysis P-1818
E. Wong, K. Backholer, E. Gearon, J. Harding, R. Freak-Poli, C. Stevenson, A. Peeters (Australia)

Prevalence and associations of microvascular complications in Indian patients with newly diagnosed type 2 diabetes mellitus P-1819
S. Yadav, H. Gill, R. Agarwal, V. Kanaujia, K. Sharma, V. Ramesh, E. Bhatia (India)

Complications - cardiovascular disease

Angiographic finding and assessment of metabolic syndrome in subjects undergoing coronary angiogram P-1820
F. Afsana, Z. Ahmed Latif, M.M. Haq (Bangladesh)

Relationship between serum osteocalcin levels and carotid intima-media thickness in Chinese postmenopausal women P-1821
Y. Bao, R. Yang, X. Ma, J. Dou, F. Wang, Y. Luo, D. Li, J. Zhu, W. Jia (China)

Diet and endothelial function: effects of increased potassium intake P-1822
N. Blanch, P.M. Clifton, J.B. Keogh (Australia)

Trends in cardiovascular disease risk factors among individuals with type 1 diabetes P-1823
T. Costacou, T.J. Orchard (USA)

Independent correlation between serum pigment epithelium-derived factor levels and coronary artery disease P-1824
X. Ma, F. Wang, M. Zhou, X. Pan, J. Ni, M. Gao, Z. Lu, J. Hang, Y. Bao, W. Jia (China)

Emergency department patients with diabetes and chest pain demonstrate risk of coronary disease comparable to geriatric patients P-1825
T. Madsen, M. Fuller, J. Holly, D. Hamilton, C. Bossart, D. Eshenroeder, K. Vlasic, L. Oates, T. Rayner (USA)

Assessment of cardiovascular disease risk in Turkish people with type 2 diabetes by means of different risk calculation methods P-1826
A. Bayindir Cevik, S. Ozcan, I. Satman (Turkey)

Screening of asymptomatic patients with type 2 diabetes and high CVD-risks for silent CHD: benefit of coronary artery calcium scoring P-1827
M. Karlinskaya, I. Glinkina, A. Zilov, G. Melnichenko (Russia)

Complications - eye

The screening test for diabetic retinopathy in type 1 and 2 diabetes patients based on fundus colour photos in Poland P-1828
J. Rutkowska, E.B.-S. Bandurska-Stankiewicz, D.W.-B. Wiatr-Bykowska, W.M. Matuszewski, J.P. Pieczynski (Poland)

Development of guidelines for the management of diabetic retinopathy for low-resource settings P-1829
R. Chakrabarti, C.A. Harper, J.E. Keeffe (Australia)

Prevalence, patterns and correlates of diabetes retinopathy among Sri Lankan adults P-1830
R. Jayawardena, P. Ranasinghe, R. Sheriff, D.R. Matthews, P. Katulanda (Sri Lanka)

Prevalence of diabetic retinopathy in Mexico and its relation to inflammatory markers P-1831
A. Rebolledo, M. Hernández, J.L. Bojórquez, J.C. Bravo, A. Méndez, R. de Jesús, M. Cruz, J. Escobedo (Mexico)

Complications - foot

Prevalence of diabetic foot syndrome amongst population with type 2 diabetes in Pakistan, The Diabetic Foot Study Group P-1832
N. Junaid, A. Khan (Pakistan)

A case control study on determinants of diabetic foot ulcers among patients with type 2 diabetes mellitus, Nyeri, Kenya, 2012 P-1833
J. Kibachio, Z. Ng'ang'a, R. Juma, Z. Muriuki, L. Karugu, E. Muchemi, W. Maina (Kenya)

Wound healing and recurrence of lesions in patients with diabetic foot ulcers in a tertiary center P-1834
J.K. Mader, A. Dolic, G. Treiber, W. Haas, K. Horvath, T.R. Pieber (Austria)

The foot-health of people with diabetes in regional and rural Australia P-1835
B. Perrin, P. Allen, I. Ellis, J. Parsons, M. Gardner, A. Chappell, B. Phillips, C. Massey, T. Skinner (Australia)

Diabetic foot ulcer: plasmid mediated ESBL infections and its correlation in a tertiary care hospital in North India P-1836
M. Zubair, M. Abida, A. Jamal (India)

HbA1c status in subjects with diabetic foot and its correlation with clinical variables in a North Indian tertiary care hospital P-1837
M. Zubair, M. Abida, A. Jamal (India)

Complications - kidney

High blood sugar even below diabetic level affects e-GFR in Japanese women: an observational study in 5185 cases P-1838
H. Chishaki, N. Mandai, M. Inoue, N. Hara, Y. Ide, A. Chishaki (Japan)

The unrecognized prevalence of kidney disease in type 2 diabetes mellitus patients admitted at BIRDEM P-1839
P.A. Khanam, M.A. Sayeed, T. Begum, A. Banu, M.M. Rhaman, S. Choudhury, N. Nahar (Bangladesh)

e-GFR should be understood with caution in relationship with fasting blood sugar among healthy Japanese men P-1840
N. Mandai, M. Inoue, N. Hara, Y. Ide, A. Chishaki, H. Chishaki (Japan)

Diabetes and cancer

Type 2 diabetes and cancer P-1841
V. Kostadinova, I. Daskalova (Bulgaria)

The association between type 2 diabetes and risk of cancer: a study conducted in Indian population P-1842
K. Gudala, D. Bansal, A. Bhansali (India)

Diabetes and infections

Burden of endocrine diseases in the emergency unit in an urban hospital in Nigeria P-1843
A.C. Anyanwu, O. Adegoke, J. Adewunmi, I.A. Odeniyi, O.A. Fasanmade, A.E. Ohwovoriole (Nigeria)

Safety of pneumococcal and influenza vaccination in diabetes patients in South India P-1844
J. Kesavadev, A. Shankar, G. Krishnan, S. Jothydev (India)

Prevalance of hepatitis B and C in patients with diabetes mellitus in Turkey P-1845
O. Tabak, U.B. Demircioglu, F. Cenik, A. Temel, I. Sak, G.Y. Dumanli (Turkey)

Diabetes associations

Prevalence of peripheral arterial disease (PAD) in asymptomatic t2dm North Indians and its correlation with cardiovascular risk markers P-1846
R. Kapoor, R. Duggal, S. Kapoor, R. Kapoor (India)

Prevalence of sleep disorders among ambulant patients with type 2 diabetes at kenyatta National Hospital, Nairobi, Kenya P-1847
S. Sokwalla, E. Amayo, M. Joshi, J. Mecha, K. Acharya (Kenya)

Frequency of depression and effect of anti-depressant treatment in patients with diabetic foot ulcers P-1848
M.S. Ulhaque, M.Y. Ahmedani, A. Fawwad, S.F.D. Alvi, B. Tahir (Pakistan)

Diabetes in childhood and adolescence

Prevalence of cardio-metabolic risk factors among children and adolescents in Chennai, South India P-1849
R. Harish, J. Sonya, R.M. Anjana, V. Mohan (India)

Diabetes in Indigenous groups

Impact of physical activity in glycaemic control of type 2 diabetic adults amongst the Maltese population P-1850
C.J. Nwaokoro, H. Agius Muscat, A. Ellul (Nigeria)

Diabetes in rural areas

Knowledge related to diabetes mellitus in a rural community in Bangladesh: the diabetes risk in a rural community (DRIRC) study P-1851
F. Islam, M. Islam, G. Ormsby, R. Chakrabarti, R. Parvez, R. Finger, M. Wahab (Australia)

Factors influencing glycemic control in patients with diabetes in rural Kenya P-1852
C. Wambui, P.H. Park, J. Kamano (Kenya)

Awareness and knowledge of diabetic retinopathy among the known diabetic population in a rural South India P-1853
R. Pradeepa, M. Deepa, R.M. Anjana, R. Unnikrishnan, V. Mohan (India)

Surveillance, control, and prevention system of diabetes and hypertension in Thailand: from policy to action P-1854
V. Tienthavorn (Thailand)

Diabetes in the elderly, in-patients and other special groups

Growing burden of diabetes in older adults: an analysis of the IDF Diabetes Atlas P-1855
H. Florez, L. Oropesa, W. Valencia, F. Andrade, C. Guanipa, M. Gutt, S. Florez (USA)

High frequency of hypoglycaemia and hyperglycaemia in diabetes inpatients is associated with increased length of stay P-1856
S. Fourlanos, N. Nanayakarra, S. Elkassaby, N. Marijanovic, A. Nankervis, P.G. Colman (Australia)

Diabetes incidence and prevalence

The Reggio Emilia (Italy) diabetes register: an algorithm to ascertain case, define type of diabetes and model of care P-1857
S. Chiatamone Ranieri, P. Ballotari, M. Vicentini, S. Caroli, M. Greci, P. Giorgi Rossi, V. Manicardi (Italy)

Temporal changes in the prevalence of type 2 diabetes in a rural Bangladeshi population: a population based study at 0, 5 and 10 years P-1858
A. Hussain, B. Bhowmik, A.K.A. Khan (Norway)

Frequency of overt diabetes in patients with metabolic syndrome P-1859
S. Keskek, S. Kirim, H. Capar, G. Ortoglu, N. Sahinoglu Keskek, T. Saler (Turkey)

Does sickle cell disease protect against diabetes mellitus?: an exploratory cross-sectional study P-1860
A.A. Mohamed, D.L. Whitford, F. Al Qurashi (Bahrain)

Ambulance utilisation for diabetic emergencies in Victoria, Australia P-1861
C.Y. Tan, N. Nanayakkara, S. Ranasinha, K. Smith, A. Morgans, G. Soldatos, H.J. Teede, S. Zoungas (Australia)

Prevalence of diagnosed and undiagnosed diabetes mellitus and it's risk factors associated with diabetes in Ahmedabadi population P-1862
B.D. Saboo, P.A. Talaviya, S.R. Joshi, J.N. Padhiyar, H.K. Chandarana, S.J. Shah, D.J. Hasnani, C.K. Vyas, A.N. Shah (India)

Diabetes screening and awareness in the rural public in Fiji P-1863
A. Sewram (Fiji)

A novel sampling approach for expatriates in the United Arab Emirates: utilizing Preventive Medicine Departments (PMDs) P-1864
N. Sulaiman, S. El Badawi, S. Abusnana, M. Fikri, H. Hamdy, J. Shaw, P.A.U.L. Zimmet, M. Mairghani, A. Shendge (United Arab Emirates)

Prevalence of rheumatological manifestations in diabetic population from Northwest India P-1865
P. Tantia, R.P. Agrawal, S. Gothwal, S. Jain, R. Agrawal, P. Sirohi, J.K. Meel, D. Sharma (India)

Diabetes management

Effectiveness of the Happy Life ClubTM: A cluster randomised controlled trial of a type 2 diabetes health coach intervention P-1866
A. Chapman, C. Browning, S.A. Thomas, H. Yang, S. Liu, T. Zhang (Australia)

Enhancing the diabetes screening & management ecosystem in Singapore P-1867
H.S. Loh, G. Khoo, W.Y. Phoon, S. Thilagaratnam, S. Wadia, C. Fock (Singapore)

Quality and factors associated with glycemic control, among patients with type II Diabetes,in Kenyan Hospitals P-1868
Mwaniga Mwavua, S.(1); Ndungu Kiogora, E.(2)

Functional insulin therapy P-1869
F. Neves, C. Neves, C. Esteves, C. Dias, Z. Sousa, D. Carvalho (Portugal)

A culture sensitive lay diabetes education programme for adults with type 2 diabetes in six english-speaking Caribbean countries P-1870
N. Younger-Coleman, C. Riley, E. Morrison, S. McFarlane (Jamaica)

Diagnosis and classification

HbA1c as a diagnostic tool for diabetes in Bangladesh: Chandra Rural Study P-1871
B. Bhowmik, A. Hussain, A.K.A. Khan (Norway)

Racial differences in the prevalence of impaired glucose tolerance P-1872
L. Jaber, F. Salinitri, N. Pinelli, E. Martin (USA)

Concurrent HbA1c, OGTT & admission plasma glucoses in acute medical admissions with DM risk factors but no prior diagnosis of hyperglycaemia P-1873
K.T. O'Brien, F.M. Ali, I.M. Stratton, S.E. Manley, G.A. Roberts (United Kingdom)

Environment and lifestyles

An ecological framework for the prevention of type 2 diabetes mellitus P-1874
J. Varghese, M.K. Ali, D. Prabhakaran (India)

Relationship between cigarrette smoking and metabolic syndrome components and atherogenic index P-1875
L. Yazdanpanah, H.b. Shahbazian, S.m. Latifi (Iran)

Ethics, quality, standard and practice in diabetes

Insulin related knowledge amongst healthcare professionals from health facilities in Tangerang District, Indonesia P-1876
I. Wijaya, T.A. Yanto, V. Sungono (Indonesia)

Glycated haemoglobin and its role in diabetes

Demographic, clinical and technical aspects of HbA1c measurement in an ethnically diverse region of the UK P-1877
S. Manley, C. Mason, K. Morris, R. Round, P. Nightingale, I. Stratton, R. Cramb, S. Gough, J. Webber (United Kingdom)

Guidelines, clinical care

Comparative efficacy and safety of antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis P-1878
K. Gudala, N. Rudroju, D. Bansal (India)

Admission blood glucose predicts mortality at 90 days in patients admitted to an Australian teaching hospital P-1879
W. Martin, J. Galligan, T. Geenaway, J. Burgess (Australia)

Healthcare professionals' perception on the implementation of the practical guide to insulin therapy in type 2 diabetes mellitus P-1880
F.I. Mustapha, N.J. Nik Mahir (Malaysia)

Healthcare financing

Socioeconomic evaluation of lifestyle intervention in people with Type 2 diabetes Mellitus in Mumbai, India P-1881
B. Bafna, R. Dave, N. Rais (India)

Medical cost and health outcome of frequent operations in diabetic patients in a general hospital in Korea P-1882
I.B. Park, S. Kim, Y.S. Eom (Korea)

Transforming cohort-based results into population-based estimates P-1883
O. Henriksen, L. Wilkinson, P. Jain, E. Nørtoft (Denmark)

Cost of self-monitoring of blood glucose in Chinese patients with type 2 diabetes receiving insulin treatment P-1884
L. Zhang, Y. Dong, J. Li, N. Wang, Y. Sun (China)

Hypoglycaemia

Access to an emergency room for hypoglycemia in diabetic patients: Pisa survey P-1885
E. Salutini, C. Bianchi, M. Santini, R. Miccoli, S. Del Prato (Italy)

The social impact of severe hypoglycemia in elderly patients with type 2 diabetes P-1886
A. Nicolucci, B. Pintaudi, M.C. Rossi, R. Messina, F. Dotta, G. Sesti, S. Caputo, R. Lauro (Italy)

Incretin therapies

Correlation between baseline characteristics and clinical outcomes in a type 2 diabetic population treated with liraglutide in Italy P-1887
A. Lapolla, G. Bax, F. Piarulli, G. Sartore, B. Bonsembiante, A. Gallo, M. Masin, M. Dalfrà, V. Frison, N. Simioni, M. Strazzabosco, C.A. Mesturino (Italy)

Insulin resistance and the metabolic syndrome

Programming of metabolic syndrome: role of insulin resistance associated with restricted fetal growth P-1888
P. Bhasin, S. Kapoor (India)

Utility of assessing metabolic syndrome scores in youth for predicting adult type 2 diabetes and carotid atherosclerosis P-1889
S. Cheriyan, M. Juonala, J. Koskinen, M.A. Sabin, J.S.A. Viikari, O.T. Raitakari, C.G. Magnussen (Australia)

Association of gamma glutamyltransferase with insulin resistance and cardio-metabolic risk in a middle aged African population P-1890
R. Erasmus, M. Macharia, Y. Yako, T. Matsha, S. Hassan, A. Kengne (South Africa)

Metabolically healthy vs metabolically unhealthy overweight/obesity in the population of South-Western Romania: the PREDATORR study P-1891
S. Popa, M. Mota, E. Mota, C. Guja, R. Lichiardopol, B. Mihai, G. Roman, C. Serafinceanu, R. Timar, I.A. Veresiu, A. Vlad, N. Hancu (Romania)

The impact of overweight on beta-cell function and insulin resistance in a healthy young population P-1892
H. Seok, H.M. Kim, J.H. Huh, E.Y. Choe, B.W. Lee, E.S. Kang, H.C. Lee, B.S. Cha (Korea)

The major determinant for metabolic abnormalities in women with polycystic ovary syndrome P-1893
Y.S. Sung, J.Y. Oh, H.J. Lee (Korea)

Epicardial adipose tissue - as a surrogate marker for metabolic syndrome P-1894
M. Tonse, S. Vidyasagar, R. Shetty (India)

Insulin therapy and devices

Skin changes induced by subcutaneous insulin injection in diabetes patients in Lagos university teaching hospital P-1895
A.C. Anyanwu, F.A. Adelekan, S. Iwuala, A.E. Ohwovoriole (Nigeria)

Injection practices of the insulin using diabetics of Pakistan P-1896
M. Asif Mahmood, O. Ishtiaq, S. Mehar, G.M. Gondal, T. Iqbal, M. Rehman, S. Ali, N.Z. Janjua (Pakistan)

Hypoglycaemia detected with continuous glucose monitoring retrospective system in diabetic patients with intensive insulin therapy P-1897
S. Azriel, S. Pita, T. Seoane, F. Pita, F. Cordido, T. Martínez (Spain)

Short and long-term cost-effectiveness of switching from insulin glargine to biphasic insulin aspart 30 in people with type 2 diabetes P-1898
R. Baabbad, A.A. Shafie, E. Hammerby, A. Nikolajsen, M.F.B. Andersen, O. Henriksen, P. Home (Saudi Arabia)

Cardiovascular outcomes and their relationship to glycaemic control over 4 years when starting insulin in type 2 diabetes P-1899
N. Freemantle, B. Balkau, L. Blonde, F. Calvi-Gries, N. Danchin, M.P. Dain, M. Marre, V. Pilorget, M. Vincent, P. Home (United Kingdom)

Results from OPENING study: the effect of insulin treatment in combination with glucosidase inhibitor or metformin on glycemic control P-1900
X. Guo, L. Ji (China)

Results from OPENING study: insulin treatment in newly diagnosed T2DM patients on HbA1c levels and glycemic control P-1901
X. Guo (China)

Short and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with type 2 diabetes P-1902
P. Home, R. Baabbad, A.A. Shafie, E. Hammerby, A. Nikolajsen, M.F.B. Andersen, O. Henriksen (United Kingdom)

The clinical characteristics of type 2 diabetes whose both fasting and postprandial glucose were controlled by basal insulin therapy only P-1903
Y.J. Kim, E.J. Lee, T.N. Kim, T.G. Kim, M.J. Kwon, S.H. Lee, J.H. Park, B.D. Rhee, M.G. Kim (Korea)

The omission ratios of different insulin injection strategies P-1904
C.C. Liao, S.F. Chen, S.J. Sheu (Taiwan)

Safety and efficacy of insulin detemir in patients with type 2 diabetes switched from neutral protamine Hagedorn insulin in the Gulf region P-1905
A. Mahfouz, A. Gunaid, W. Abdelfattah, M. Milad (Saudi Arabia)

Lipids and lipoproteins

Sleep duration and the risk of future lipid profile abnormalities in middle-aged men: the Kansai Healthcare Study P-1906
S. Kinuhata, T. Hayashi, K.K. Sato, S. Uehara, H. Koh, I. Maeda, Y. Onishi, K. Oue, G. Endo, H. Kambe, K. Fukuda (Japan)

Living with diabetes

Affect of traditional cooking methods on glycemic index of Vietnames rices P-1907
C. Tran Quoc, D. Do Thi Ngoc, L. Ta Thi, V. Nguyen Thi Anh, V. Tran Thi Bich (Vietnam)

Monitoring of diabetes control

A validated platform for global diabetes monitoring: design and use of the BIRO system across 19 European countries P-1908
F. Carinci, M. Massi Benedetti, E.U. Eubirod (Italy)

Utilization rate and cost of test strips for self-monitoring blood glucose in the social security system of Argentina P-1909
J.F. Elgart, L. Gonzalez, E. Rucci, J.J. Gagliardino (Argentina)

Evaluation of minimally invasive glucose monitoring during OGTT for glucose intolerance screening and drug efficacy monitoring P-1910
K. Kosugi, I. Nakashotani, K. Sakamoto, K. Yoshiuchi, A. Ono, T. Sato, S. Okada, Y. Ohnishi, H. Koga, K. Tokunaga, H. Nakajima (Japan)

Accuracy of blood glucose meters in accordance with the new ISO guidelines P-1911
A.H. Pfützner, C. Hengesbach, F. Demircik, S. Ramljak, I. Hermanns, A. Pfützner (Germany)

Nutrition and diet

A prospective analysis of diet quality and type 2 diabetes risk P-1912
A. Alhazmi, E. Stojanovski, M. McEovy, M. Garg (Australia)

Relationship of diet quality and body mass index of husbands and wives in Bandar Baru Bangi, Malaysia P-1913
A. Ali, M.T. Mohd Nasir, M.Y. Rokiah, A.G. Nawalyah (United Kingdom)

Regional dietary profile of Asian Indians in the context of diabetes epidemiology P-1914
A. Ranjit Mohan, V. Sudha, P. Vijayalakshmi, R. Pradeepa, M. Deepa, A. Bhansali, S.R. Joshi, P.P. Joshi, V.K. Dhandhania, A.K. Das, T. Kaur, V. Mohan (India)

Dietary compliance, supplementation and traditional remedy usage in type 2 diabetics with and without cardiovascular disease: An update P-1915
M.C. Tan, O.C. Ng, A.R. Hejar, T.W. Wong, A. Joseph, Y.M. Chan (Malaysia)

Validation of a telephone administered 24-hr dietary recall in adults with T1DM in China: 3C nutrition ancillary study preliminary results P-1916
L.M. Jaacks, W. Liu, L. Ji, S. Du, J. Crandell, M. Mendez, W. Rosamond, B. Popkin, E.J. Mayer-Davis (USA)

Tree nuts improve features of the metabolic syndrome: A systematic review and meta-analysis of randomized controlled dietary trials P-1917
C.W.C. Kendall, S. Blanco Mejia, R.J. de Souza, L.S. Augustin, E. Viguiliouk, V. Ha, A. Maroleanu, A. Mirrahimi, L. Chiavaroli, A.I. Cozma, D.J.A. Jenkins, J.L. Sievenpiper (Canada)

Effect of nuts on coronary heart disease risk factors in type 2 diabetes P-1918
C.W.C. Kendall, S. Nishi, L.S. Augustin, B. Bashyam, J.L. Sievenpiper, D.J.A. Jenkins (Canada)

Dietary sodium intake among Korean adults with diabetes P-1919
C.H. Kim, S.R. Kim, J.O. Mok, C.H. Jung, K.Y. Lee, D.H. Cho, S.W. Jeon, K.H. Song, T.S. Park (Korea)

Dietary pattern analysis of pre-diabetes population living in Beijing P-1920
Y. Luo, H. Wang, X. Zhou, L. Ji (China)

Study into state guidelines compliance rate of school canteens P-1921
A. Mallon (Australia)

Is dietary diversity score associated with blood glucose levels and hypertension among pregnant women in Tanzania? P-1922
A.W. Mwanri, J. Kinabo, K. Ramaiya, E.J.M. Feskens (Tanzania)

Dietary quality in people with type 1 and type 2 diabetes compared to people without diabetes P-1923
K.S. Petersen, N. Blanch, P.M. Clifton, J.B. Keogh (Australia)

Coffee consumption is associated with lower risk of type 2 diabetes: a cross-sectional studies review P-1924
C.E.G. Reis, T.H.M. da Costa (Brazil)

Maternal dietary intake and anthropometric measurements of newborn at birth P-1925
F. Shaikh, F. Zeeshan, R. Hakeem, A. Basit, A. Hussain (Pakistan)

Fructose-containing sugars and risk of type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies P-1926
J.L. Sievenpiper, C.S. Tsilas, R.J. de Souza, R. Tawfik, S. Blanco Mejia, A.I. Cozma, A. Mirrahimi, V.H. Jayalath, V. Ha, J. Beyene, C.W.C. Kendall, D.J.A. Jenkins (Canada)

Estimation of resistant starch in commonly consumed Indian foods P-1927
V. Ruchi, R.M. Anjana RM, V. Mohan, K.K. Balasubramaniyam, S. Shobana, R. Gayathri, D. Asha, K. Krishnaswamy, S. Vasudevan (India)

Obesity - prevention and management

Metabolic syndrome, diabetes, and cardiovascular disease P-1928
J. Bae, S. Jin, J. Kim, T. Kim, K. Hur, S. Park, M. Lee (Korea)

Cohort trends in BMI in Australia: largest increase for highest BMI P-1929
B. Carstensen, E. Gearon, K. Backholer, A. Peeters (Denmark)

Does it matter what people think? Public support for obesity prevention food policies in Australia P-1930
J. Martin, B. Morley, P. Niven, M. Wakefield (Australia)

Boehringer Ingelheim employee study I: role of overweight and obesity on cardiometabolic risk P-1931
K. Kempf, S. Martin, C. Döhring, K. Dugi, C. Wolfram von Wolmar, B. Haastert, M. Schneider (Germany)

Genetic and environmental correlations between body mass index and waist circumference in China: Qingdao Adolescent Twin Study P-1932
F. Ning, K. Silventoinen, Z.C. Pang, J. Kaprio, S.J. Wang, D. Zhang, H.P. Duan, W.F. Wu, Q. Qiao (Finland)

Oral glucose-lowering therapies

Changes in prescription of oral hypoglycemic agents after introduction of DPP-4 inhibitors in a diabetes clinic in Japan P-1933
Y. Akiyama, T. Morita, Y. Abe, C. Morisawa, A. Sakashita, S. Kawazu, E. Omura, S. Wada, M. Tokunaga, S. Minagawa, M. Yazawa, M. Koike (Japan)

Effect of dipeptidyl peptidase-4 inhiditor added to sulfonylurea/metformin combination on treatment outcomes in type 2 diabetes patients P-1934
E. Skhiladze, T. Ghvaladze, M. Nishnianidze, R. Kurashvili, L. Tsutskiridze (Georgia)

Meta-analysis of studies examining medication adherence to oral antihyperglycemic agents in type 2 diabetes P-1935
K. Tunceli, S.E. Cartier, V.M. Rosen, V. Zarotsky, K. Iglay, S.N. Rajpathak, L. Radican, Y. Qio (USA)

Phenotypes versus genotypes

Type 2 diabetes and healthy obesity: ancestral and derived phenotypes P-1936
S. Corbett (Australia)

Physical activity

Perceptions of enablers and barriers to physical activity among Sri Lankan women with a recent history of gestational diabetes mellitus P-1937
M.J. Pinidiyapathirage, R. Jayasuriya, V. Rose (Australia)

The Alberta Diabetes and Physical Activity Trial: a RCT evaluating theory-based interventions to increase physical activity in T2D adults P-1938
R.C. Plotnikoff, N. Karunamuni, K.S. Courneya, R. Sigal, J.A. Johnson, S.T. Johnson (Australia)

Health promotion approach to improve physical activities among women who are in low socioeconomic group, Sri Lanka P-1939
C.P. Senevirathne, P. Katulanda, M. Fernando (Sri Lanka)

Pregnancy and gestational diabetes

Gestational diabetes mellitus: a neglected health issue in Bangladesh P-1940
A. Al Mamun, S. Jesmin, M. Islam, T. Khatun, F. Sohael, S.N. Sultana, M. Rahman, T. Mizutani (Bangladesh)

Association of gestational diabetes mellitus with vitamin D levels and insulin resistance P-1941
E. Bandurska-Stankiewicz, J. Rutkowska, D. Wiatr-Bykowska, E. Kuglarz, K. Myszka-Podgórska, R. Jalali (Poland)

Results of a departmental campaign to improve the detection of dysglycemia after GDM - the IMPACT study P-1942
H. Bihan, E. Cosson, L. Vittaz, C. Khiter, F. Faghfouri, D. Le Boeuf, L. Carbillon, H. Dauphin, A. Lepagnol, G. Reach, P. Valensi (France)

Association of foetomaternal prognosis with psychosocial insecurity in 994 women with gestational diabetes mellitus. The IMPACT study P-1943
H.B. Bihan, P.V. Valensi, G.R. Reach, L.C. Carbillon, E.C. Cosson (France)

The MAGDA study - advanced data linkage technologies to overcome legislative restrictions in research P-1944
D. Boyle, D. Asproloupos, H. Gasko, S.T.F. Shih, L. Kelsall, J. Dunbar (Australia)

Diabetes antenatal care in Pakistan P-1945
S. Haque (Pakistan)

Social cognitive predictors of exercise intentions and behaviour among women with a recent history of gestational diabetes mellitus P-1946
M.J. Pinidiyapathirage, R. Jayasuriya, N.W. Cheung, V. Rose (Australia)

Gestational diabetes mellitus: search for an optimal predictive marker before the 20th week of gestation P-1947
B.R. Sharma, A. Joshi, P.K. Varthakavi, M. Chadha, N. Bhagwat, A. Pawar, T. Lathia, S. Mittal, P. Pawal, P. Dalwadi, A.R. Dalal, S. Rahate (India)

Screening, prevalence and management of gestational diabetes mellitus in a Bahraini population P-1948
D. Whitford, R.J. Khalaf, A.H. Al Khalfan, A.S. Almedfa, L.A. Elreish, Y.H. Al Khalfan, F.H.A. Al Khalfan, H.E.S. Al-Thawadi (Bahrain)

Primary and secondary prevention

The impact of religion & culture on diabetes prevention & care in Nigeria P-1949
O. Odusan, H. Adejumo, O. Sogbein, N. Laiteerapong, M. Dauda (Nigeria)

Changes in barriers and enablers to involvement in the Life! program between 2009 and 2013: from the health service organisation perspective P-1950
J. Shill, L. Day, A. Timoshanko (Australia)

Peer-lead & telehealth interventions for diabetes prevention/management in older adults: effects on weight & glycemia P-1951
H. Florez, M. Gutt, F. Andrade, L. Oropesa, W. Valencia, C. Guanipa, A. Sorial, L. Salgueiro, G. Howard, B. Roos, M. Byrne, S. Dang (USA)

Prevention of type 2 diabetes in the real world - swap your iPOD for an X-POD! P-1952
A.M.R. Jesson, C.J. Duncan, S. Seed (United Kingdom)

Awareness regarding risk factors of type 2 diabetes and its determinants among individuals attending tertiary-care hospital in Bangladesh P-1953
S.J. Mumu, F. Ara, F. Saleh, L. Ali (Bangladesh)

Diabetes help network project in Moldova P-1954
N. Palarie, T. Pasenco, E. Bernaz, V. Palarie (Moldova)

Family doctors go for prevention of type 2 diabetes: the North German experience P-1955
C. Petersen, R. Joohs (Germany)

International Diabetes Association of Ukraine: Ukraine-Poland social action: active detection of diabetes mellitus type 2 by HbA1c method P-1956
L. Prystupiuk, L. Petrenko, M. Naumova, L. Naumova, O. Prystupiuk, N. Vlasenko, R. Vlasenko (Ukraine)

Moving knowledge spiral toward a community-based lifestyle intervention program for people with prediabetes P-1957
V. Tantayotai, S. Numsangkul, Y. Tinnaluck, W. Aekplakorn (Thailand)

Risk assessment for type 2 diabetes: application of diabetes risk assessment tool in community pharmacy in Australia P-1958
T. Thoopputra, S.C. Li, D. Newby, J. Schneider (Australia)

Rationale and design of a trial for the use of testosterone for the prevention of type 2 diabetes in men: The T4DM Trial P-1959
G. Wittert, B.B. Yeap, M. Grossmann, C. Allan, R. McLachlan, A. Conway, D. Handelsman, B. Stuckey, D. Jesudason, K. Bracken, M. Daniel, E. Atlantis (Australia)

Association of retinopathy with chronic kidney disease (stage III to V) in diabetes mellitus P-1960
H.S. Ferdous, R.S. Rouf, Z.A. Latif, S.M. Ashrafuzzaman, H. Rahman (Bangladesh)

Quality assurance in diabetes care

Improvement of quality of care in outpatient diabetes clinic in Tanzania: a cycle of clinical audit P-1961
S. Pilleron, A. Brus, Z. Ngoma, D. Olchini (France)

Experiences in programs and health care models to patients with diabetes mellitus in Colombia: systematic review P-1962
D.C. Tamayo, T.M. Tono (Colombia)

Measuring the quality of care for diabetes mellitus in the National Healthcare Group, Singapore, 2007-2011 P-1963
M.P.H.S. Toh (Singapore)

Risk factors for developing diabetes

Family history of diabetes as an influence on its knowledge attitude and practice in Sagamu, Ogun State, Nigeria P-1964
O. Arubuolawe, O. Ademowo, T. Akinlabi, O. Salako, A. Oduneye (Nigeria)

Prevalence and risk factors of metabolic syndrome in highly endogamous population P-1965
A. Bener, S. Darwish, A. Al-Hamaq (Qatar)

Health Check Ubon Ratchathani (HCUR): cardiometabolic risk profiles and diabetes in 663,284 Thai adults P-1966
P. Chamnan, W. Pimpakan, H. Cheonchoopol, J. Saereeratanakorn, S. Rojanasaksothorn, W. Muangmai (Thailand)

Raised urine albumin to creatinine ratio is associated with dysglycaemia (IFG and IGT) in at risk South Asian subjects P-1967
J. Karalliedde, L. Vasantharaja, M. Gulliford, L. Gnudi, G.C. Viberti, M. Wijesuriya (United Kingdom)

Prevalence of vitamin D deficiency in type 2 diabetes mellitus and its correlation with HbA1c in Saudi population P-1968
S. Safdar, S. Samman, B. Aljalsi (Saudi Arabia)

Variation in prevalence of cardiovascular risk factors by BMI status in South Asia - the CARRS Surveillance study P-1969
R. Shivashankar, M. Deepa, V.S. Ajay, B. Binukumar, M.K. Ali, M.H. Kadir, Z. Fatmi, V. Mohan, D. Prabhakaran, K.M. Narayan, N. Tandon, F.O.R. CARRS Study Group (India)

Association of serum uric acid with 2-hour postload glucose in prediabetic Chinese P-1970
T. Yang (China)

Screening and risk stratification

GDF15 as a novel biomarker for impaired fasting glucose P-1971
J.H. Hong, K.S. Kim, H.Y. Chung, J.C. Lee, J.H. Lee, H.J. Kim, M. Shong, B.J. Ku (Korea)

Project "Diabetes Prevention and Care Improvement" - an attempt to implement political declaration on NCDs P-1972
A. Meltzer, R. Kurashvili, S. Gabrichidze, E. Shelestova, L. Tsutskiridze, N. Asatiani, M. Gordeladze, M. Dundua (Georgia)

Optimal waist circumference cut off values to assess cardio-metabolic risk in a mixed ancestry population from South Africa P-1973
T. Matsha, A.P. Kengne, M.S. Hassan, G.M. Hon, D.J. Soita, R.T. Erasmus (South Africa)

Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and pre-diabetes in eastern Uganda P-1974
R. Mayega, D. Guwatudde, F. Makumbi, F.N. Nakwagala, P. Stefan, T. Göran, C.-G. Östenson, C.G. Östenson (Uganda)

Glycaemic profile and risk factors in a semi-urban Sub-Saharan population P-1975
N. Dongmo, J.C. Njabou Katte, C. Kouam, A.P. Kengne, E. Sobngwi (Cameroon)

A high prevalence of the metabolic syndrome in the urban black population of Cape Town P-1976
N. Peer, K. Steyn, C. Lombard, N. Levitt (South Africa)

Prevalence of obesity, diabetes and prediabetes in Tirana, the capital of Albania 2010-2011 P-1977
L. Cakerri, F. Toti, S. Budo, L. Bruka, M. Dollenga, G. Bejtja (Albania)

Early insulin response to glucose challenge: a marker for evaluating the diabetogenic potential of Olanzapine P-1978
P. Varthakavi, A. Chillar, P. Pandit, H. Dhavale, R. Sengupta, J. Dholye (India)

Prevalence and risk factors of diabetes among Vietnamese adults living in HCMC, Vietnam P-1979
D. Do Thi Ngoc, C. Tran Quoc, B.I.N.H. Phan N T (Vietnam)

Social and cultural determinants of health

Development, validation and translation of a new Asian diabetes quality of life (AD-QOL) questionnaire for type 2 diabetics in English, Malay language and Chinese (Mandarin) P-1980
S. Goh, R. Nordin, K. A.Kadir (Malaysia)

Early retirement in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil P-1981
M. Gomes, C.A. Negrato (Brazil)

Health related quality of life in patients with type 2 diabetes mellitus in the Middle East: a case study of Iran P-1982
M. Javanbakht, A. Mashayekhi, H. Baradaran, H. Rezaei (Iran)

Type 2 diabetes in children

Prevalence of raised fasting plasma glucose and IFG in 805 healthy children aged between 8 to 12 years old with risk factors for T2DM P-1983
M. Wijesuriya, L. Vasantharajah, M. Gulliford, L. Gnudi, G.C. Viberti, J. Karalliedde (Sri Lanka)

Awareness, attitudes and knowledge of type 2 diabetes prevention in young people P-1984
A. Timoshanko, J. Shill, D. Rankins (Australia)

ABSTRACTS ACCEPTED BY TITLE

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

The effects of a oxovanadium (IV) complex based on thiosemicarbazone on skin injury of streptozotocin-induced diabetic rats AbT-1985
R. Yanardag, S. Tunali, S. Bolkent, E. Kaptan, T. Bal Demirci, B. Ulkuseven (Turkey)

The changes of G protein-coupled cannabinoid receptors in type-2 diabetes AbT-1986
Z.M. Coskun, S. Bolkent (Turkey)

The modulated effects of high-fructose induced insulin resistance murine model in microbes fermented Anoectochilus formosanus AbT-1987
C.C. Hsieh, Y.L. Huang, Y.C. Tsai, C.C. Huang (Taiwan)

Patterns of persistence with antihypertensive medications among newly treated type 2 diabetic patients AbT-1988
M. Chowta, Y. Belagali, S. Rai, N. Chowta (India)

Verapamil buffering effect on the abrupt elevation in blood pressure, implications for metabolic syndrome and insulin resistance AbT-1989
J. Gmitrov, J. Gmitrov (Japan)

Hypertension in T2DM: are sulfonylureas also responsible? AbT-1990
D. Sehra (India)

Insulin resistance control blood pressure levels independently from the influence of anthropometrics AbT-1991
J. Silva-Nunes, L. Duarte, M. Brito, L. Veiga (Portugal)

Although adiponectin and HDL are closely related to fatty liver, cystatin C is more important in the prediction of diabetic nephropathy AbT-1992
S. Ljubic, A. Jazbec, D. Rogulj, B. Novak, N. Car (Croatia)

Prevalence of elevated alanine aminotransferase (ALT) in monotherapy treated T2DM patients in observational, real-life setting (EDGE) AbT-1993
G. Bader, P.M. Paldánius (Switzerland)

Gastrointestinal symptoms among people with diabetes AbT-1994
S. Bosseri, A. salem, S. Bouras, A. Gurnazi (Libya)

Deficiency of folic acid in patients with diabetes mellitus type 1 with anemia AbT-1995
F. Valeeva, T.U. Kufelkina, L. Gaysina (Russia)

The interaction between myostatin and extracellular matrix components in three-dimensional cell culture systems AbT-1996
O.K. Hong, J.W. Son, H.S. Kwon, K.H. Song, B.Y. Cha, S.J. Yoo (Korea)

A revised statistical model to predict expected pulmonary function indices in diabetic individuals of Karachi AbT-1997
M.A. Kanpurwala, Z. Ayoob, M.A. Qureshi, Z. Shaikh, K. Afzal (Pakistan)

The relationship between atrial natriuretic peptide and microvascular complications of diabetes AbT-1998
P. Karakaya, Ö. Soyluk, M. Mert, Y. Okuturlar, Y. Aral, Ö.H. Kaptanogullari (Turkey)

Effects of serum active ghrelin on glycemic control in obese patients with type 2 diabetes mellitus AbT-1999
M. Mert, M. Temizel, Y. Faki, Y. Arman (Turkey)

Age features of skin lesions in patients with diabetes mellitus AbT-2000
L. Naumova, O. Prystupiuk, M. Prystupiuk, M. Naumova, L. Prystupiuk (Ukraine)

Receiver operating characteristic analysis of a novel index for coronary heart disease risk prediction AbT-2001
N. Abdella, O.A. Mojiminiyi (Kuwait)

Echocardiographic changes in left ventricular function in prediabetes: a cross-sectional pilot study AbT-2002
M. Pathan, U.S. Zingade, K.M. Badaam, M.M. Ahmed (India)

Territorial location of cerebral infarcts on imaging in patients with first ever stroke with diabetes AbT-2003
N. Bhowmik, S. Mohammad, Z. Hassan, A. Rahman, R. Habib, R. Bhadra, M. Mannan (Bangladesh)

Implication of advanced glycation end products in the cardiac fibrosis progression in an animal model of Diabetes Mellitus type 2 AbT-2004
A.M. Guadrón-Llanos, A.I. Leal-Anguiano, A.O. Vázquez-Álvarez, S.G. Huerta-Olvera, A. Sobrevilla-Navarro, A.M. Salazar-Montes, J.S. Armendáriz-Borunda, A.G. Miranda-Díaz, E.G. Cardona-Muñoz, A.R. Rincón-Sánchez, M.C. Islas-Carbajal (Mexico)

The state of antioxidant system in patients with prediabetes and type 2 diabetes and concomitant coronary heart disease AbT-2005
O. Shyshko, T. Mokhort, I. Buko, E. Konstantinova, N. Tsapaeva (Belarus)

Silent ischemia is patient with type 2 diabetes mellitus AbT-2006
S. Samiullah, D. Bikha Ram, B. Ghulam Hussain, S. Syed Zulfiquar Ali, S. Shaikh (Pakistan)

The impacts of sulfonylureas in the outcome of T2DM patientswith ischemic stroke AbT-2007
D. Chen, Y. Yu (China)

Prevalence of asymptomatic peripheral arterial disease in Libyan patients with diabetes AbT-2008
S. Bosseri, R. Eryan Alrass, Z. Younes, S. Alzalet, K. Debri (Libya)

Diabete foot: alternative approach AbT-2009
N. Boudjenah (Algeria)

The association between the microvascular complications and minor amputation risk in patients with diabetic foot ulcerations AbT-2010
S. Akcay, H. Cabuk, A. Tütüncüoglu, C. Kazimoglu, I. Sahin (Turkey)

Factors affecting albuminuria in diabetic patients at King Fahad hospital in Almadinah Almunawwarah AbT-2011
D. Alshehri, M. Noorelahi, M. Shaheen, A. Ahmed, A. Soubhanneyaz, O. Bakkari, M. AlBeladi, S. Amer, K. Kasim, M. Alhammady, M. Mojaddidi (Saudi Arabia)

Assessment and follow-up of small fiber neuropathy through a quick, simple and non invasive method in a diabetes outpatient clinic AbT-2012
H. Winiecki, J.H. Calvet (France)

Subclinical diabetic neuropathy: an overlooked iceberg AbT-2013
H. Chuang, C.H. Lu, H.Y. Chiu, H.Y. Hsu, H.I. Yu, S.C. Hua, T.S. Tai (Taiwan)

Poor responders to the duloxetine for the control of diabetic neuropathic pain in Korea AbT-2014
S. Chun, S.I. Mo, Y.J. Kim, S.J. Kim, K.W. Kim (Korea)

Comparison of bacteremia's profile of in-hospital mortal cases with and without diabetes mellitus AbT-2015
S. Dagdelen, K. Agbaht, Y. Cetinkaya-Sardan, M. Bayraktar (Turkey)

A study of outcome and complications in patients with and without diabetes having Pyelonephritis in a medical unit in Sri Lanka AbT-2016
C.J. Kande Vidanalage, L. Vijeyakumar, R. Fernando, E.M.P.R. Ekanayeke, M.H.M. Nawshad (Sri Lanka)

Glycaemic profile of HIV+ patients on HAART in Kigali University Teaching Hospital AbT-2017
J. Nkurikiyimfura, J.B. Kakoma (Rwanda)

Monoballism associated with newly onset ketotic hyperglycemia AbT-2018
D. Ersil Soysal, A. Tütüncüoglu, S. Hizar, M.E.T.E. Pekdemir, E.B.R.U. Tekesin, B. Gelen, Y. Beckmann (Turkey)

Relationships between indicators of emotional problems and glycaemic control in 235 adults with type 1 diabetes AbT-2019
R. Bjarkøy, M. Graue, T. Wentzel-Larsen, B. Rokne (Norway)

Association of adiponectin concentrations with dietary intake and physical activity in multiethnic Malaysian with type 2 diabetes AbT-2020
H.C. Koo, H.J. Jan Mohamed, D. Robert (Malaysia)

Decreased neutrophil count in elderly witth type 2 diabetes mellitus AbT-2021
F. Sarac, S. Savas, F. Akcicek (Turkey)

Comparative assessment of efficiency of various schemes of insulin therapy in type 1 diabetes AbT-2022
A. Alieva, N. Alimova, S. Ismailov, G. Rakhimova, S. Bahadirov (Uzbekistan)

A case control study of VitaminD and VitaminB12 deficiency in newly detected diabetics in an urban Indian population AbT-2023
S. Krishnan, P. Sundar (India)

The effectiveness of combination therapy of metformin and hyperbaric oxygen in accelerating wound healing AbT-2024
B. Novita, I. Theodora, W. Tamayanti (Indonesia)

Effects of n-3 polyunsaturated fatty acids in treatment of hypertriglyceridemia in subjects with diabetes mellitus AbT-2025
C.E.G. Reis, K.C. Landim, A.C.S. Nunes, J. Dullius (Brazil)

Intensifying biphasic insulin aspart 30 in a jordanian cohort of the a1chieve study AbT-2026
J. Haddad, L. Sandalci, F.A. Annabi, A. Al-Shudifat, M. Al-Kilani, R. Nasser, F.H. Haddad (Turkey)

Vitamin D levels in the patients with diabetes mellitus in Turkey AbT-2027
O. Tabak, U.B. Demircioglu, F. Cenik, A. Temel, I. Sak, G.Y. Dumanli (Turkey)

Two years assessment of vildagliptin safety and efficacy in type 2 diabetes patients (T2DM) in Russian real clinical setting AbT-2028
M. Shestakova, A. Emirova, A. Zilov (Russia)

SLC22A1, SLC47A1 and HNF4A gene mutations have no relationship with metformin induced severe hypoglycemia AbT-2029
W. Liu, X. Han, L. Ji (China)

The impact of daytime and nocturnal non-severe hypoglycaemic events on people with diabetes in Israel AbT-2030
J. Singer, A. Tirosh (Israel)

Effectiveness of of liraglutide on metabolic control and weight reduction in patients with type 2 diabetes mellitus and obesity AbT-2031
L. Escobar Jimenez, L. Escobar Curbelo, M. Aguilar Diosdado (Spain)

Usefulness of liraglutide, a new R-GLP1 agonist, in the treatment of type 2 diabetes mellitus patients in clinical practice AbT-2032
F. del Cañizo-Gomez, N. Muñoz_Rivas, M. Méndez-Bailón (Spain)

Clinical use of GLP-1 analogue (Exenatide) in obese type 2 DM Taiwanese AbT-2033
K.Y. Lee (Taiwan)

Effects of GLP-1 analogues on N-terminal fraction of brain-natriuretic peptide and C-reactive protein levels: clinical experience AbT-2034
A.J. Martinez-Ortega, M.A. Mangas-Cruz, A.R. Romero-Lluch, A. Pumar-Lopez, F. Losada-Viñau, D. Acosta-Delgado, A. Aliaga-Verdugo, I. Jimenez-Varo, B. Gonzalez-Aguilera, N. Gros-Herguido, F. Morales-Garcia (Spain)

Interaction between gestational diabetes mellitus and gingival inflammation AbT-2035
F.B. Ozturk Ceyhan, O. Ozcaka, P. Gumus, A. Akcali, N. Buduneli (Turkey)

Evaluation of serum ferritin levels in non-acute inflammation patients with prediabetes AbT-2036
K. Sezer, V. Koksal, U. Cinkir, R. Gen, E. Akbay (Turkey)

Diabetes inactives Ca2+ depended - k+ channel of rough endoplasmic reticulum: cellular and molecular evidence AbT-2037
M. Ghasemi, A. Eliassi, F. Khodagholi, R. Saghiri (Iran)

Effects of insulin treatment on thermogenesis AbT-2038
I. Daskalova, T. Totomirova, D. Robbins, J. Light (Bulgaria)

Ferriman-Gallwey score correlates with obesity and insulin levels in polycystic ovary syndrome women AbT-2039
K. Gomes, M. Sóter, A. Cândido, A. Fernandes, M. Sousa, C. Ferreira, M. Sales (Brazil)

Serum visfatin levels in prediabetic patient AbT-2040
M. Yildiz, K. Gonderen, S. Oztekin, S. Yaman (Turkey)

Combination therapy with insulin plus sitagliptin in Japanese type 2 diabetic patients AbT-2041
H. Ishii, H. Asano (Japan)

Characteristics of patients treated with multiple-dose insulin injections versus insulin pump therapy in an academic diabetes unit AbT-2042
A. Rizvi, K. Smith (USA)

Extraction of fats from diet result decreasing of xanturenuria and blood glucose level in animals with diabetes caused by xanthurenic acid AbT-2043
G. Meyramov, A.A. Kikimbaeva, R.S. Mamatkan, A.M. Aitkulov, A.M. Tulieva, A.G. Shaybek, S.K. Turshanova, G.A. Katbaeva, A.G. Meyramova, B.B. Erniyasova, A.P. Andreewa, S.K. Eleupaeva (Kazakhstan)

Effect of lifestyle changes on hypertriglyceridemia in diabetic patients AbT-2044
I. Kammoun, E. Haouat, M. Antit, F. Hadj Kacem, Z. Turki, L. Ben Salem, C. Ben Slama (Tunisia)

Overall and abdominal adiposity and hypertriglyceridemia among North Indian Punjabi diabetic population AbT-2045
R. Kapoor, R. Duggal, S. Kapoor, R. Kapoor (India)

LDL-HDL ratio and total cholesterol-HDL ratio as potential indicator for dyslipidemia in type 2 diabetic mellitus patients AbT-2046
M.N. Karim, K.R. Ahmed, M.S. Bukht, J. Akter, H.A. Chowdhury, N. Anwar, S.U. Munshi, A. Silitonga, L. Ali (Australia)

Lipid profile in newly diagnosed people with type 2 diabetes in Albania AbT-2047
A. Shehu, F. Toti, L. Bruka, A. Doko, K. Hoti (Albania)

Outbreak of extremely drug-resistant acinetobacter baumannii in patients with diabetes AbT-2048
S. Ali Dina, R. Sabir, A. Fawwad (Pakistan)

Association analysis between body weight and management of glucose in Chinese type 2 diabetes patients AbT-2049
X.L. Cai, X. Jin, J. Wu, Y.L. Chen, X.Y. Han, L.N. Ji (China)

The impact of obesity indices on predictibility of metabolic syndrome AbT-2050
A. Bener, S. Darwish, A. Al-Hamaq, E.A. Nasralla (Qatar)

Bariatric surgery: prior history in parents does not mean future intention for children AbT-2051
R. Kalic, J.A. Curran, E.A. Davis (Australia)

Safety, tolerability and bioavailability of metformin glycinate in healthy Spanish volunteers AbT-2052
J. Iglesias, J. Gonzalez-Canudas, Y. Romero-Antonio, R.M. Antonijoan-Arbós (Mexico)

Metformin and lactic acidosis: coincidence rather than cause AbT-2053
E.Y. Lee, Y.H. Lee, B.W. Lee, E.S. Kang, C.W. Ahn, B.S. Cha, H.C. Lee (Korea)

Effects of mifepristone on glycolipid metabolism of type 2 diabetes mellitus in rats AbT-2054
X.H. Luo, R. Zhang, J. Zhou, C.Y. Wang, R.Y. Xu, X.Y. Ye (China)

Antidiabetic and antioxidant potential of Couroupita guianensis leaves in streptozotocin induced diabetic rats AbT-2055
G. Somani, R. Chaudhari, S. Sathaye (India)

Thrombin-activable fibrinolysis inhibitor levels and Thr325Ile polymorphism in women with polycystic ovary syndrome AbT-2056
J.C. Albuquerque, F.S. Silva, I.R. Santos, A.L. Cândido, F.R. Oliveira, M.O. Sóter, M.F. Sales, M.O. Sousa, K.B. Gomes, C.N. Ferreira (Brazil)

Dietary treatment in gestational diabetes mellitusand quality of habitual diet: relation with birth weight AbT-2057
F.F. Lauszus, A.S. Christensen, H.S. Jensen, J.H. Boris, L. Viggers (Denmark)

Ankle-brachial index in a sample of diabetic patients AbT-2058
E. Vazquez Seijas, M.C. Lopez silva, C. Pena Meilan, M.J. Cora Corral, C. Pardo Roibas, P. Gonzalez Gonzalez, M. Sanchez de Enciso Ruiz, C. Rodriguez Fernandez (Spain)

Feltman - evaluation of a culturally appropriate diabetes teaching tool for Aboriginal Australians AbT-2059

E. D'Amico, J. Browne, C. Mitchell, S. Thorpe (Australia)

International Diabetes Association of Ukraine: diabetes schools as a way for healthcare improvement AbT-2060
O. Prystupiuk, L. Petrenko, L. Naumova, M. Naumova, L. Prystupiuk, N. Vlasenko, R. Vlasenko (Ukraine)

Complimentary herbals can be harmful in the treatment of diabetes mellitus AbT-2061
I. Sahin, O. Celbis, H. Kapucu, B. Evren, M. Aladag, Z. Karaca, B. Ozdemir (Turkey)

A study of adherence and factors related and a1c of insulin injection in patients with type 2 diabetes mellitus AbT-2062
S. Liu (Taiwan)

Use of iPro 2 in real-life diabetes management of type 2 patients in India: if iPro 2 registry study design AbT-2063
V. Mohan, M. Chawla, S. Jain, J. Kesavadev, R. Kovil, A. Mutha, B. Saboo, S. Shaikh, V. Viswanathan (India)

Survey of knowledge on diabetes among the participants of the world diabetes day activities 2012 at Ampara, Sri Lanka AbT-2064
D.A. Adikariwattage, K.L.A.D. Dilrukshi (Sri Lanka)

Conversation maps: it's about the destination and the journey AbT-2065
G. Al Aali (Bahrain)

Conversational maps, effective enough? AbT-2066
L. Al-Muqla (Bahrain)

The implementation of group-based diabetes education program: an Indonesian story AbT-2067
H. Malini (Indonesia)

Building confidence in diabetes management: the 'Diabetes - What Now?' program AbT-2068
P. Roderick, F. Cross, A. Sanders (Australia)

An audit of exenatide use in an Australian public hospital AbT-2069
V. Stevenson, L. Roberts, A. McLeod (Australia)

Diabetes management paradigms in Kenya AbT-2070
K. Acharya (Kenya)

The relationship between total cholesterol levels and severity of diabetes among Mongolians with type 2 diabetes AbT-2071
A. Altaisaikhan, J. Suvd, S. Sainbileg (Mongolia)

Experience in a diabetes intensive care area after 4 years AbT-2072
I. Cornejo Pareja, A. Gómez-Pérez, J.L. Pinzon Martinez, A. Muñoz-Garach, S. Maraver-Selfa, F. Tinahones-Madueño (Spain)

Diabetes detection and education in Sao Paulo city and region, Brazil: lessons from the World Diabetes Day AbT-2073
P. De Luca, M.t.u. Barone, C.k. Tarasuk, D.b. Kaplan, V. Giampaoli, L. Indiani, M. Caliseo, P. Bernordi, C. Almeida, R. Rezende, D. Franco (Brazil)

Diabetes management: why understanding the role of community pharmacy will improve type-2 diabetes health outcomes AbT-2074
K. Gourlay (Australia)

Diabetes as community disease for patients and health care providres in distritcts of West Nile Region, Uganda AbT-2075
A. Joyo, A. Abaru Asia, P. Anguzu patrick, N. Jimmy Nebbi, C. Awanchanwage Carolyn, L. Acan lilian, C. Abiria C, S. James, B. Batia Samuel, E. Benard, C. Joyce, V. opia vicky (Uganda)

Effect of diabetes education on treatment succsess AbT-2076
A. Kaya, M. Kulaksizoglu, E. Turan, F. Ozdamar (Turkey)

Rapid acceptance of a basal bolus insulin regimen in a general teaching hospital by means of a computer-assisted tool AbT-2077
J. Manzanares Errazu, A. Gómez, N. Sardà, A. Rabassa, M.J. Rojas, A. Castro (Spain)

Prevention and management of diabetes in all ages AbT-2078
S. Mwangi (Kenya)

Managing diabetes in base of economic pyramid setting - recommendations based on the biopsychosocial model AbT-2079
M. Kanakatte Prasanna Kumar, A. Kumar Ajay, S. Kalra Sanjay, B. RamaBhat, A.G. Unni Krishnan (India)

Predication of hyperglycaemic excursions during Ramadan fasting in patients with diabetes mellitus AbT-2080
Z. Hannoun, N. Lessan, M.T. Barakat (United Arab Emirates)

Australia - Sri Lanka medical aide team: a partnership in developing diabetes care AbT-2081
C. Cross, D. Adikariwattage (Australia)

The difficulty of insulin therapy in elderly patients AbT-2082
M. Jemel, Y. Hasni, H. Marmouch, S. Graja, H. Sayadi, I. Khochtali (Tunisia)

Integration of diabetes care with a sustainable general health care model: an experience from Bangladesh AbT-2083
K. Begum, D. Ara, M.S. Uddin, A.K.A. Khan, L. Ali (Bangladesh)

Integrated approach to identify and treat diabetic retinopathy in rural population-ORBIS experience in Bangladesh AbT-2084
A. Raihan, F. Islam, N. Awal (Bangladesh)

Improving the Medical Nutrition Therapy(MNT) service for diabetes by newly appointed dietitian in primary care, an audit AbT-2085
V. Michael, F.I. Mustapha, S. Abdul Aziz, S. Razali, A. Mohd. Amir, N. Rais (Malaysia)

Importance of continued education: delivery of an advanced self management education program at Rockingham General Hospital AbT-2086
M. Schlaeppi, M. Aghabozorgi, P.G. Fegan (Australia)

Online interactions on oral health among the internet users AbT-2087
Z. Ahmed, S. Sarbadhikari (Bangladesh)

An educational case study: innovative culture-sensitive patient outreach in France via sports, art, travel, technology, and nutrition AbT-2088
K.J. Rose, S. Picard (France)

Early experience measuring diabetes-related distress in people attending the Integrated Diabetes Education and Assessment Service AbT-2089
E. Bongetti, C. Gilfillan, J. Scott (Australia)

Psychological barriers to insulin therapy AbT-2090
S. Bosseri, A. Salem, S. Bouras, A. Bezweek (Libya)

Research on nursing for objective self-awareness for patients with diabetes (results of the 2nd round) AbT-2091
M.O. Okura, C.U. Uetani, C.K. Kameishi, N.s. Seto, Y.S. Shimizu (Japan)

Social media and diabetes care in Nigeria..the Nigeria diabetes online community AbT-2092
H. Adejumo, O. Sogbein, M. Dauda, K. Rosiji, O. Ajose (Nigeria)

Design and application development for mobile devices for preventing diabetic foot AbT-2093
S. Soares, G.C.S. Graziela da Costa Santos, R.A.C.F. Renato Antonio Celso Ferreira, G.M. Guilherme Mattar (Brazil)

Telephone-based monitoring: an educational strategy for diabetes self-care at the primary health care level AbT-2094
H. Torres (Brazil)

Sutherlandia frutescens: a traditional South African medicine with anti-diabetic activity AbT-2095
G. Dealtry, J. Affun, V. Oosthuisen (South Africa)

Effect of standardized local injection site warming on post-meal glucose excursions AbT-2096
A. Pfützner, I. Raz, A.H. Pfützner, D. Feldmann, T. Alon, G. Bitton, R. Nagar (Germany)

Insulin or immunosuppression - a patient perspective AbT-2097
J.L. Colquhoun (Australia)

Assessment of knowledge, attitude and practices of diabetics in El-Mahsama Primary Health Care Centre, Ismailia, 2012 AbT-2098
S. Darwish, K. Elsabahy, M. Kamal, M. Ezz ElDin, N. El Garhy, M. Shata, A. Abd El Baset, L. Asran, A. ELeleedy, O. Mansy (Egypt)

Collaboration to provide support and care to vulnerable and people with NCDs AbT-2099
L. Tsutskiridze, M. Dundua, D. Khorava, K. Kvaratskhelia, M. Kvezereli, R. Khaburzania, K. Gabarashvili, R. Kukhalashvili, R. Kurashvili (Georgia)

Clinical investigation of the impact of interfering substances on the performance of blood glucose meters for self-monitoring AbT-2100
A.H. Pfützner, C. Hengesbach, M. Mitri, M. Borchert, I. Hermanns, T. Forst, A. Pfützner (Germany)

An examination of outdoor experiential diabetes education philosophy: Five years of community building AbT-2101
J. Hanson, C. Vance (Canada)

Patient-led initiatives: being the change we want to see AbT-2102
C. Vance, J. Hanson (Canada)

Doing well to do good - a challenge based approach to motivation in type 1 diabetes therapy AbT-2103
F. Debong, K.J. Rose, M. König, S. Besancon (France)

State insulin program - 20 years people with diabetes regularly receive this lifesaving drug AbT-2104
M. Jashi, R. Kurashvili, E. Shelestova (Georgia)

Hormonal disorders caused by metabolic syndrome in conjunction with the impaired fertility in women of different ethnic groups AbT-2105
A. Nakysh, A.S. Idrisov (Kazakhstan)

Comparison of demographic, and biochemical characteristics among younger and older patients with metabolic syndrome AbT-2106
A. Tütüncüoglu, F. Sarac, S. Savas, S. Sarac (Turkey)

High prevalence of undetected elevated blood pressure in Kerala population: Diabscreen Kerala 22 AbT-2107
J. Kesavadev, A. Shankar, G. Sanal, J. Lally, G. Krishnan, S. Jothydev (India)

Benefits of NGO participation in health care delivery for non communicable diseases (DM) - a primary health care model AbT-2108
B. Shanthi, A.R. Subhashree, B.J. Parameaswari, A.J. Manjuladevi, S.V. Mythili, S. A.R. (India)

Survey of patients in primary care for diabetes health centres in Kinshasa, DR Congo AbT-2109
J. Kalobu, E. Bewa, J. Van Olmen, B. Criel, G. Kegels, C. Darras (Democratic Republic of Congo)

Diabetes admissions to a University Hospital in Brussels, Belgium, over a 6 month period AbT-2110
F. Baleanu, H. Bodur, S. Bruno, R. Karmali, M.-F. Kong (Belgium)

Characteristics of diabetic patients seen during mobile clinics in Haiti AbT-2111
P. Larco, N. Charles-Larco, J. Pierre, R. Charles, E. Jean-Baptiste (Haiti)

The China Initiative for Diabetes Excellence (CIDE): a 5 year educational program to improve care and promote translation research AbT-2112
L. Ji, R. Mazze, B. Hayes, E. Strock, D. Parker, M. Murphy, J. Norstrom, J. Dong, A. Cide Study Group (USA)

Integrated assessment of the substantiation for medical care technologies in type 2 diabetes patients with late-onset hypogonadism AbT-2113
O. Vasilkova, T. Mokhort (Belarus)

The Israel Diabetes and Cognitive Decline (IDCD) study: functional assessment,cognition and long term metabolic control AbT-2114
A. Heymann, R. Ravona-Springer, M. Schnaider-Beeri (Israel)

Apathy in type 2 diabetes: a longitudinal study AbT-2115
M.E. Nelson, J.L. Mace, S.E. Starkstein, W.A. Davis, D.G. Bruce (Australia)

Various risk factors and their correlation with carotid intima media thickness among Egyptian subjects with & without metabolic syndrome AbT-2116
I. El Ebrashy, M. Khattab, A. Omara, M. Ibrahim (Egypt)

Hemorrheological approach for early detection of diabetic angiopathy AbT-2117
J. Ha, S. Shin, C. Kyung, S. Kim, M. Kim, H. Baek, S. Kang, J. Park, B. Lee, C. Ahn, K. Kim (Korea)

Prevalence and associated factors of erectile dysfunction in diabetic patients in Ouagadougou, Burkina Faso AbT-2118
Y. Sagna, H. Tiéno, O. Guira, R. Bognounou, A.R.D. Yanogo, A. Seghda, P.R. Kaboré, Y.J. Drabo (Burkina Faso)

Diabetic foot screening for ulcer risk in a cohort attending a secondary care diabetic clinic AbT-2119
N. Yousmi, S. Bruno, I. Goorden, G. Bruers, M. Kong, I. Dumont (Belgium)

Effect of lifestyle factors in diabetic nephropathy AbT-2120
H.C. Lin, C.N. Huang (Taiwan)

Changes in age, body mass index and clinical features for the first time detected diabetes mellitus type 1 in Belarus in 2003-2013 AbT-2121
A. Solntsava, O. Zagrebaeva, H. Mikhno, A. Semenovich, J. Semenovich, E. Kislaya, O. Kniazkina (Belarus)

Assessing overweight, obesity and hypertension risk in selected Sri Lankan employees and normal community people AbT-2122
C.P. Senevirathne, T.M.S.N. Thennakoon, P. Katulanda, M. Fernando (Sri Lanka)

Comparison of the use of fasting plasma glucose tests and HbA1c results in population level studies AbT-2123
L. Gates, J. Pettit (Australia)

Variability of diabetes prevalence and incidence in Georgia and comparative analysis of the data achieved with those for Europe and CIS AbT-2124
R. Kvanchakhadze, K. Kekelashvili, R. Kurashvili, E. Shelestova (Georgia)

Pilot testing a Global Registry and Surveillance System for Diabetes (GRAND) in Colombia AbT-2125
S. Mequanint, S. Harris, P. Aschner, N. Aamand, P. Jain (Canada)

Who does control better the diabetes, men or women? AbT-2126
M. Sanchez de Enciso, C. Rodriguez Fernandez, P. Gonzalez Gonzalez, C. Pardo Roibas, M.J. Cora Corral, C. Pena Meilan, E. Vazquez Seijas, M.C. Lopez Silva (Spain)

High prevalence of unknown diabetes in Ahvaz (Southwest of Iran) AbT-2127
H. Shahbazian, S.M. Latifi, M.T. Jalali, H. Shahbazian, R. Amani, A. Nikhoo, A. Jahanshahi, A.M. Aleali (Iran)

Evaluation of fasting glucose cutoff of 140 mg/dl to identify diabetic patients AbT-2128
H. Garcia-Alcala (Mexico)

Characteristics of patients with latent autoimmune diabetes of adults in a Spanish tertiary hospital AbT-2129
L. Prieto, I. Gonzalo, M. Ortega, A. Martin, C. Beltran, A. Estrella, M.J. De la Cruz, A. Rovira (Spain)

The utility Of glycated Hemoglobin and OGTT in diagnosis of pre-diabetes in Pakistani population AbT-2130
M.S. Sameed, D.T.M. Mahmood (Pakistan)

Lifestyle study in diabetic and non diabetic patients in Haiti (LIFDIAH) AbT-2131
E. Jean-Baptiste, P. Larco, N. Charles-Larco, R. Charles, B. Lubin, O. Noel (Haiti)

Micronutrient deficiencies in early pregnancy among urban Pakistani mothers AbT-2132
F. Shaikh, A. Basit, A. Hussain (Pakistan)

Role of social movements in active detection of patients with diabetes mellitus AbT-2133
L. Prystupiuk, O. Prystupiuk, M. Naumova, L. Naumova, M. Prystupiuk (Ukraine)

Poor glycaemic control in diabetic inpatients is associated with increased 90 day mortality AbT-2134
W. Martin, J. Galligan, T. Greenaway, J. Burgess (Australia)

Liraglutide effects on metabolic control of obese patients with type 2 diabetes AbT-2135
S. Maraver Selfa, M.E. Selfa Cabrera, A. Muñoz Garach, I. González Molero, M.M. Roca Rodríguez, J. García Arnés, F. Tinahones Madueño (Spain)

Prevalence of metabolic syndrome amongst jail inmates in central India AbT-2136
S. Gupta, J. Mulani, K. Gupta, N. Jaiswal (India)

Prevalence of metabolic syndrome in the rural area of Baluchistan province of Pakistan AbT-2137
B. Tahir, S.F.D. Alvi, A. Fawwad, M.Y. Ahmedani, R. Hakeem, A. Basit (Pakistan)

Trends in glycaemic control over a 4-year period in outpatients with diabetes in Qingdao, China AbT-2138
L. Zhang, J. Li, Y. Dong, N. Wang, X. Wang, Y. Zhu, W. Qian, W. Zhong (China)

Association between obesity and metabolic syndrome among Iranian children and adolescents: CASPIAN III Study AbT-2139
A. Ataie-Jafari, R. Heshmat, R. Kelishadi, M. Qorbani, M. Esmaeil Motlagh, M. Taslimi, M. Mahmoudarabi, G. Ardalan, H. Asayesh, B. Larijani (Iran)

The evaluation of the prevalence of obesity in Belarusian population AbT-2140
A. Shepelkevich, E. Kholodova, O. Salko, I. Bilodid, L. Pedchenets, L. Kovshil, A. Grigorovich, O. Zalesskaya, V. Selivanov, V. Lobashova (Belarus)

Impact of a managed care obesity intervention program on clinical outcomes and costs: a prospective observational study AbT-2141
A.E. Rothberg, L.N. McEwen, T. Fraser, C.F. Burant, W.H. Herman (USA)

Associations between baseline and change in physical activity and future visceral adiposity in Japanese Americans AbT-2142
K.K. Sato, T. Hayashi, Y. Onishi, D.L. Leonetti, M.J. McNeely, S.E. Kahn, W.Y. Fujimoto, E.J. Boyko (Japan)

Effect of fructose-containing beverages on body weight: a systematic review and meta-analysis of controlled dietary trials AbT-2143
J.L. Sievenpiper, V. Choo, R.J. de Souza, S. Kim, S. Blanco Mejia, A. Mirrahimi, A.I. Cozma, V. Ha, V.H. Jayalath, J. Beyene, C.W.C. Kendall, D.J.A. Jenkins (Canada)

Oral anti-diabetic drugs in Australia over ten years (2003 - 2012) AbT-2144
H. Kim, L. Gurrin, D. Liew (Australia)

Profiles of patients who were treated with acarbose - difference between regional and ethnicity groups - real life data of 62,905 patients AbT-2145
S. Soegondo, S. Kalra, O. Schnell, W.H.H. Sheu, W. Grzeszczak, H. Watada, N. Yamamoto, J. Weng (Indonesia)

Go Red for Women campaigns - what is happening globally and a personal perspective AbT-2146
D. Hilton (Australia)

Profile and adherence of participants with type 2 diabetes mellitus of a diabetes education program with emphasis on supervised exercise AbT-2147
J. Dullius, G.F. Mendes, T.C. Lins (Brazil)

Participants of a diabetes education program with type 2 diabetes have good lipid and glycemic control, but not anthropometric profile AbT-2148
T. Lins, G. Mendes, F. Teixeira, J. Dullius (Brazil)

Correlation between 25(OH)D and antropometric, metabolic parametres and blood pressure in women with GDM AbT-2149
J. Rutkowska, E. Bandurska-Stankiewicz, D. Wiatr-Bykowska, E. Kuglarz, K. Myszka-Podgórska, R. Jalali (Poland)

Glomerular filtration rate in patients with type 1 diabetes, depending on the gestational age and the severity of nephropathy AbT-2150
F. Valeeva, Z.R. Alimetova, L. Gaysina (Russia)

Renal function in pregnant women with DM 1 with normoalbuminuria depending on the carbohydrate metabolism compensation AbT-2151
F. Valeeva, Z.R. Alimetova, L. Gaysina (Russia)

Diabetes in pregnancy: a population based study in Bangladesh AbT-2152
M. Rhaman, H. Mahtab, P.A. Khanam, T. Begum, A. Banu, M.A. Sayeed (Bangladesh)

Rapid non-fasting screening test for gestational diabetes for low resource settings AbT-2153
B.H. Weigl, G. Zwisler, E. Abu-Haydar, R. Barney, H. McGuire (USA)

WHO CVD risk management package adaptation to cvd project in Davao City (Philippines): lessons learned AbT-2154
R. Caballero, I. Nolasco, S. Mishra, D. Olchini (Philippines)

Research training program for prevention and control of diabetes and other non-communicable diseases in South Asia AbT-2155
B. Oldenburg, P. Mithra, K. Singh, C.P. Senavirathne, T. Sathish, N. Pasricha (Australia)

Public audit of the state program "Diabetes. 2009-2013" in Ukraine AbT-2156
I. Krulko, V. Ocheretenko (Ukraine)

Diabetes Observatory of Colombia: a pioneering initiative AbT-2157
D.C. Tamayo, T.M. Tono (Colombia)

The influence of family history on glycaemic control and complications among adults with diabetes mellitus from Sri Lanka AbT-2158
P. Ranasinghe, R. Jayawardena, M.H.R. Sheriff, D.R. Matthews, P. Katulanda (Sri Lanka)

Characteristics of men evaluated as at high risk of type 2 diabetes based on the Australian diabetes risk assessment tool AbT-2159
E.J. Aguiar, P.J. Morgan, C.E. Collins, R.C. Plotnikoff, R. Callister (Australia)

Micro & macro-circulatory changes among Egyptian prediabetic subjects AbT-2160
M. Khattab, M. El Ghobary, I. El Ebrashy, Y. El Hadidy (Egypt)

Determination of waist circumference cutoff values predictive of obesity in apparently healthy Nigerians: a multi-centre study AbT-2161
C.I. Okafor, I. Gezawa, S. Anas, T. Raimi, O.A. Fasanmade, B.M. Mubi, O. Odusan, F. Puepet, E.N. Ofoegbu, A.E. Ohwovoriole (Nigeria)

Prevalence and associated risk factors of diabetes in a burkina faso urban population: a screening campaign report AbT-2162
Y. Sagna, H. Tiéno, O. Guira, A.R.D. Yanogo, R. Bognounou, L. Benon, S. Zida, P. Nikiéma, A. Tondé, P.R. Kaboré, Y.J. Drabo (Burkina Faso)

Prevalence of diabetes and cardiovascular risk factors in Ouagadougou (Burkina-Faso) AbT-2163
D. Yanogo, Y. Sagna, S. Zida, P. Nikiema, H. Tieno, O. Guira, J. Drabo (Burkina Faso)

Attendance at postpartum glucose tolerance test following gestational diabetes among South Asian women in Australia AbT-2164
M. Bandyopadhyay, M. Carolan, R. Small, M.A. Davey, H. Teede (Australia)

Obesity, impaired fasting glucose, metabolic syndrome in Romanian, Hungarian and Roma children in Transilvania, Romania AbT-2165
M. Szabo, E. Török, M. Germán Salló (Romania)

MEMBER ASSOCIATION PROGRAMME
TUESDAY 03 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:00 - 11:00 Diabetes Café

AFR Region - Diabetic foot: prevention and management

10:00 **Diabetic peripheral neuropathy – forerunner to diabetic foot ulcer: diagnosis and treatment**
Invited Speaker: S. Chinenye (Nigeria)

10:15 **The Diabetes Africa Foot Initiative (DAFI)**
Invited Speaker: M. Mbaye, E. Bouenzabila and S. Bahendeka (MENA)

10:30 **Diabetic foot prevention and management : the Togolese experience**
Invited Speaker: K.P. Tossou (Togo)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 - 12:00 Diabetes Café

SACA Region - Diabetic foot: centres to early attention

11:00 **Diabetes foot program**

Invited Speaker: *A. Ibrahim (Dominican Republic)*

12:00 - 13:00 Diabetes Café

EUR Region - How to put diabetes on the political agenda

12:00 **European Leadership Forum**
Invited Speaker: *H. Nedergaard (Denmark)*

12:15 **ExPAND**
Invited Speaker: *A. Sanders (United Kingdom)*

12:30 **Turkish experience - "Diabetes Parliaments" and "Diabetes 2020: vision and targets for Turkey"**
Invited Speaker: *S. Karadeniz (Turkey)*

14:00 - 15:30 Diabetes Café

EUR Region - Prevention of blindness in people with diabetes

14:00 **Roundtables against diabetes blindness**
Invited Speaker: *M. Hall (United Kingdom)*

14:20 **Prevention of blindness in people with diabetes - best practices**
Invited Speaker: *S. Ismailov (Uzbekistan)*

14:40 **European Forum Against Blindness (EFAB)**
Invited Speaker: *S. Karadeniz (Turkey)*

15:30 - 16:30 Diabetes Café

WP Region - Targets and indicators for treatment, prevention and management of diabetes

15:30 **Targets and indicators for treatment, prevention and management of diabetes in Taiwan**
Invited Speaker: S.T. Tsai (Taiwan)

15:50 **Hong Kong experience**
Invited Speaker: V. Hung (Hong Kong, China)

16:00 **Every number tells a story**
Invited Speaker: B.B.K. Lim (Singapore)

16:15 **Experience with a large scale type 2 diabetes prevention programme in Australia**
Invited Speaker: A. Timoshanko (Australia)

16:30 - 17:00 Diabetes Café

SEA Region - Diabetes prevention

16:30 **Prevention of diabetes based on nutrition**
Invited Speaker: *A.S. Bhoraskar (India)*

16:37 **Prevention of diabetes**
Invited Speaker: *P. Manil and B.B. Karki*

16:44 **Prevention**
Invited Speaker: *S. Uddin and A. Khan*

16:51 **Translation of LSM from Diabrisk-SL into the community**
Invited Speaker: *M. Wijesuriya (Sri Lanka)*

MEMBER ASSOCIATION PROGRAMME
WEDNESDAY 04 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:00 - 12:00 Diabetes Café

NAC Region - Youth

10:00 **MODiYouth activities**
Invited Speaker: O. Bernard (Jamaica)

10:08 **Diabetes education among youths**
Invited Speaker: R. Alexis (Grenada)

10:16 **Diabetes Association of Barbados**
Invited Speaker: N. Merritt (Barbados)

10:24 **Young leaders in the Caribbean**
Invited Speaker: K. Boyea (Barbados)

10:32 **Diabetes is sweet**
Invited Speaker: A. Alexis (Grenada)

10:40 **Diabetes association of Trinidad and Tobago**
Invited Speaker: Z. Ragbirsingh (Trinidad and Tobago)

10:48 **FHADIMAC**
Invited Speaker: N. Charles Larco (Haiti)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

12:00 - 13:00 Diabetes Café

MENA Region - Diabetes and youth

12:00 **YLD impact in the MENA region**
Invited Speaker: S. Ajmal (Pakistan)

12:05 **YLD impact in the MENA region**
Invited Speaker: M. Al-Ostad (Kuwait)

12:10 **YLD impact in the MENA region**
Invited Speaker: K.S. Al-Aryedh (Bahrain)

12:15 **Youth camps**
Invited Speaker: A.O. Al Hamaq (Qatar)

12:30 **Childhood obesity in the region: steps taken to address the gravity of the situation**
Invited Speaker: A. El-Sayed (Egypt)

12:45 **Insulin my life**
Invited Speaker: M.Y. Ahmedani (Pakistan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:00 - 15:00 Diabetes Café

AFR Region - Empowerment of diabetes associations: how to share success stories

14:00 **Corporate diabetes awareness programs**
Invited Speaker: *K.P. Tossou (Togo)*

14:15 **Empowerment of diabetes associations through the eyes of Diabetes Association of Zambia**
Invited Speaker: *S. Zimba-Tembo (Zambia)*

14:30 **Diabetes education: paradigm shift from lectures to dialogue**
Invited Speaker: *A. Jalango, E. Bouenzabila and S. Bahendeka (AFR)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

15:00 - 16:00 Diabetes Café

SACA Region - Living with diabetes: differenct experiences in the region

15:00 **Team approach to experiences in the region**
Invited Speaker: E. Jimenez Sancho (Costa Rica)

15:20 **Team approach to experiences in the region**
Invited Speaker: A. L. Gonzalez (Costa Rica)

15:40 **Team approach to experiences in the region**
Invited Speaker: M. Falabela (Argentina)

16:00 - 16:45 Diabetes Café

WP Region - Experience sharing

16:00 **Team approach to diabetes foot care in Taiwan**
Invited Speaker: Y. Huang (Taiwan)

16:20 **Diabetes Patient Congress 2013 of Diabetes Hong Kong: a platform for exchange, sharing and empowerment**
Invited Speaker: J. Leung (Hong Kong, China)

16:35 **Promotion of peers support activiities**
Invited Speaker: I. Wang (Taiwan)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

16:45 - 17:00 Diabetes Café

SEA Region - Experience sharing

16:45 **Footcare as a daily routine**

Invited Speaker: K. Basant Rai (Mauritius)

MEMBER ASSOCIATION PROGRAMME
THURSDAY 05 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:00 - 11:00 Diabetes Café

AFR Region - Diabetes education: innovative approaches

10:00 **Use of sketchs for diabetes education: the Togolese experience**
Invited Speaker: A. Djadou (Togo)

10:15 **Diabetes health centre committees**
Invited Speaker: J. Mangwiro (Zimbabwe)

10:30 **Art as a tool to promote diabetes education and self management in Madagascar**
Invited Speaker: T. Rajaonarison (Madagascar)

10:45 **Diabetes educators**
Invited Speaker: R. Kuni (South Africa)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 - 12:00 Diabetes Café

SACA Region - Educator programmes

11:00 **Presentation of the books "The Friends of Pipe" and "Living Better"**
Invited Speaker: B. Tshiedel and G. Lijteroff

11:15 **Workshops for newly diagnosed people and their families**
Invited Speaker: N. Flageat and E.J. Medina

11:30 **High School Team" to explain to teachers the treatments and cares of diabetic students**
Invited Speaker: T. Espinoza and C. Velasco

11:45 **Workshops for grand parents of newly diagnosed people**
Invited Speaker: F. Fialle and M. Vera

12:00 - 13:00 Diabetes Café

Life for a Child: education symposium

12:00 **Launch of new Pocketbook Guidelines for childhood diabetes care in less-resourced countries**
Invited Speaker: *G. Ogle (Australia)*

12:15 **LFAC's multilingual diabetes education resources website**
Invited Speaker: *A. Middlehurst (Australia)*

12:25 **Poster campaign to reduce deaths from diabetic ketoacidosis**
Invited Speaker: *A. Middlehurst (Australia)*

12:40 **Further diabetes education needs in developing countries: how you could help**
Invited Speaker: *G. Ogle (Australia)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:00 - 15:30 Diabetes Café

EUR Region - The IDF Europe leadership camp and related activities

14:00 **Youth: the IDF Europe leadership camp and related activities**
Invited Speaker: *L. Garcia Cañibano (Spain)*

14:20 **Youth: the IDF Europe leadership camp and related activities**
Invited Speaker: *R. Vlasenko (Ukraine)*

14:40 **Youth: the IDF Europe leadership camp and related activities**
Invited Speaker: *M. Skjødt Sørensen (Denmark)*

15:30 - 15:45 Diabetes Café

SEA Region - Youth camps

15:30 **Youth camp video**
Invited Speaker: *Zabben, B. and Kishwar, A. (Bangladesh)*

15:37 **Diabetes youth camp December 2012**
Invited Speaker: *Aishath, S. and Naila, A. (Maldives)*

15:45 - 16:00 Diabetes Café

WP Region - Youth camps

15:45 **Transition care of diabetes from youth to adult**

Invited Speaker: *C. Lin (Taiwan)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

16:00 - 17:00 Diabetes Café

Young Leaders in Diabetes: symposium

16:00 **Awareness and advocacy**
Invited Speaker: M. Hillinger and K. Schudmann

16:15 **Diabetes youth camps and education**
Invited Speaker: A. Abdul Rahman and S. Tembo

16:30 **Youth support groups**
Invited Speaker: J. Markovic and T. Froment

16:45 **Involvement of technology and media**
Invited Speaker: M. Al-Ostad (Kuwait)

MEMBER ASSOCIATION PROGRAMME

FRIDAY 06 DECEMBER

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:00 - 11:00 Diabetes Café

MENA Region - Regional and national activities

10:00 **Diabetic foot: are we saving legs in the MENA region?**
Invited Speaker: *H. Gawish (Egypt)*

10:20 **Primary prevention strategies: time of need to save millions**
Invited Speaker: *K. Salamah (Saudi Arabia)*

10:40 **Managing diabetes: challenges faced in the region and strategies developed**
Invited Speaker: *N. Al Bache (Syria)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 - 12:00 Diabetes Café

EUR Region - Sharing experiences

11:00 **Advocacy campaign**
Invited Speaker: *S. Gerlach (Germany)*

11:10 **Social network and diabetes**
Invited Speaker: *G. Petrovski (Macedonia)*

11:20 **DiaEuro**
Invited Speaker: *I. Vlasenko (Ukraine)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

12:00 - 12:15 Diabetes Café

NAC Region - Prevention and management

12:00 **What's new in 2013? Five pearls from the Canadian Diabetes Association clinical practice guidelines**
Invited Speaker: *C. Yu (Canada)*

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

12:15 - 13:00 Diabetes Café

EUR Region - Grand tour: engaging with the mHealth industry and access publishing

12:15 **Grand Tour: engaging wih the mHelath industry and access publishing**

Invited Speaker: *P. Buchanan (United Kingdom)*

SATELLITE SYMPOSIA

MONDAY 02 - THURSDAY 05 DECEMBER 2013

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

14:00 – 16:00 210/211

Abbott

Flash glucose monitoring and ambulatory glucose profile (AGP): expanding the glucose story beyond A1c

Chair: Richard Bergenstal, M.D. Executive Director, International Diabetes Center (USA)

14:00 – 14:05 **Welcome & introduction**
Richard Bergenstal, M.D. (USA)

14:05 – 14:25 **AGP: an evidence-based system for sensor data interpretation**
Roger S. Mazze, Ph.D. International Diabetes Center (USA)

14:25 – 14:45 **Using sensor data in clinical practice, the value of AGP**
Richard Bergenstal, M.D. (USA)

14:45 – 15:05 **Value of AGP in clinical decision-making and therapy management of diabetes**
Howard Wolpert, M.D. Joslin Diabetes Center (USA)

15:05 – 15:25 **AGP: Real-world experience**
Oliver Schubert, M.D. Diabetes Care Centre, Buxtehude (Germany)

15:25 – 15:45 **Flash glucose monitoring: next generation sensor-based system for diabetes management**
Steven Scott, Division Vice President R&D, Abbott Diabetes Care (USA)

15:45 – 16:00 **Panel discussion and closing**
Richard Bergenstal, M.D. (USA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 – 13:00 219/220

Boehringer Ingelheim/Lilly

Type 2 diabetes: Exploring innovative treatment options to improve patient outcomes

Co-chairs: Mark Cooper (Australia) and Juliana Chan (Hong Kong)

11:00 – 11:05 **Welcome and introduction**
Mark Cooper (Australia)

Session 1 - Modern management of type 2 diabetes: experts' perspectives

Chair: Mark Cooper (Australia)

11:05 – 11:15 **DPP4 inhibitors: an inclusive treatment option**
Juliana Chan (Hong Kong)

11:15 – 11:25 **The value of fixed-dose combinations**
Merlin Thomas (Australia)

11:25 – 11:55 **The role of SGLT2 inhibitors**
Vlado Perkovic (Australia)

11:55 – 12:05 **Panel discussion**

11:00 – 13:00 219/220

Boehringer Ingelheim/Lilly

Session 2 - Improving cardiovascular outcome: an essential aim of type 2 diabetes management

Chair: Juliana Chan (Hong Kong)

12:05 – 12:20 **Establishing the effect of type 2 diabetes treatment on cardiovascular outcomes**
Karin Jandeleit-Dahm (Australia)

12:20 – 12:35 **Cardiovascular risk factors in type 2 diabetes and the effects of glucose-lowering therapies**
Michael Lehrke (Germany)

12:35 – 12:50 **Optimising outcomes: the kidney and the heart in type 2 diabetes**
Mark Cooper (Australia)

12:50 – 12:55 **Q&A**

12:55 – 13:00 **Summary and close**
Mark Cooper (Australia)
Juliana Chan (Hong Kong)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 – 13:00 203/204

The Victorian Department of Health

Perspectives on tackling obesity in three countries: insights into the design and implementation of complex community level interventions

11.00 – 11.10 **Welcome and aim of the symposium**
Chair: Professor Elizabeth Waters, Jack Brockhoff Chair of Child Public Health, Melbourne School of Population and Global Health, The University of Melbourne, Australia

11.10 – 11.40 **The New York experience – a national community based initiative applied in one city**
Gretchen Van Wye, PhD, MA, Director – Operations & Planning, Bureau of Chronic Disease Prevention and Tobacco Control, New York City Department of Health and Mental Hygiene, USA (via satellite)
Discussion: Gretchen Van Wye and Professor Elizabeth Waters (via satellite)

11.40 – 12.10 **EPODE - a large multi-village community-based intervention**
Dr Jean-Michel Borys MD, Co-founder and Co-director of the EPODE programme and the EPODE European Network, France
Discussion: Dr Jean-Michel Borys and Professor Elizabeth Waters

12.10 – 12.40 **Implementation of Healthy Together Victoria: how policy plays out in the real world in prevention**
Dr Shelley Bowen, Senior Public Health Advisor, Victorian Department of Health, Melbourne, Australia
Discussion: Dr Shelley Bowen and Professor Elizabeth Waters

12.40 – 13.00 **How prevention efforts are tracking internationally and insights that we can take from this symposium**
Discussion: Professor Boyd Swinburn, Alfred Deakin Professor; CoDirector, WHO Collaborating Centre for Obesity Prevention (CO-OPS), Deakin University, Australia and Professor of Population Nutrition and Global Health, University of Auckland, New Zealand

13:00 **Symposium concludes and a light lunch is served**

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

11:00 – 13:00 210/211

GSMA

Working together to deliver diabetes care through mobile health

Chair: Michael Morgan-Curran, Director of mHealth and Diabetes Campaign Director, GSMA

11.00 – 11.15 **Introductory remarks: mHealth role in comprehensive diabetes care**
Panel introduction: Michael Morgan-Curran, Director of mHealth and Diabetes Campaign Director, GSMA

11.15 – 11.30 **Putting mobile health on the agenda: the benefits for people with diabetes**
John Grumitt, Vice-President, Finance, International Diabetes Federation

11.30 – 11.50 **Monitoring health on the move: Findings of GSMA mHealth Grand Tour**
Michael Trenell, Newcastle University

11.50 – 12.10 **Reaching people with diabetes: the impact of innovative mobile technology on health systems**
Tanya Felton: General Manager, mHealth, Telstra Australia

12.10 – 12.50 **Interactive Q&A and discussion between panel and audience**

12.50 – 13.00 **Conclusion**

14:00 – 16:00 203/204

The Global Partnership for Effective Diabetes Management

Setting and achieving individualised glycaemic goals in type 2 diabetes

A CME accredited symposium

Chair: Stefano Del Prato
Faculty: Members of the Global Partnership for Effective Diabetes Management*

14:00 – 14:05	**Introduction/Welcome: Overview and learning objectives**
14:05 – 14:20	**Defining glycaemic targets and the 10 steps to achieve goals: an update**
14:20 – 15:10	**Case-study series 1 and 2: strategies for managing newly-diagnosed individuals with type 2 diabetes**
15:10 – 15:35	**Case-study series 3: minimising disease progression and managing complications in patients with existing type 2 diabetes**
15:35 – 15:55	**Panel discussion: Reviewing the evidence – are we closer to optimising type 2 diabetes management?**
15:55 – 16:00	**Concluding remarks/close**

**Global Partnership for Effective Diabetes Management Members: Pablo Aschner, Clifford Bailey, Lawrence Blonde, Stefano Del Prato, Anne-Marie Felton, Ramon Gomis, Edward Horton, Linong Ji, James LaSalle, Lawrence A. Leiter, Stephan Matthaei, Margaret McGill, Neil Munro, Richard Nesto, Jay Skyler, Paul Zimmet.*
The Global Partnership for Effective Diabetes Management is supported by Bristol-Myers Squibb, AstraZeneca LP, and Novartis Pharma AG.

14:00 – 16:00 219/220

Lilly

Modern day management of type 2 diabetes mellitus in an aging population

14:00 – 14:05 **Welcome and Introduction**
Brian Frier (UK)

14:05 – 14:30 **Older adults with diabetes mellitus: clinical characteristics and practical assessment**
Brian Frier (UK)

14:30 – 15:20 **Managing patients with diabetes mellitus: traditional approaches vs. new therapies (Debate)**
- *Traditional approaches: Leszek Czupryniak (Poland)*
- *New therapies: Ted Wu (Australia)*

15:20 – 15:25 **Introduction to education for older patients with diabetes mellitus**
Brian Frier (UK)

15:25 – 16:00 **Integration of patient education with management of diabetes mellitus**
Barbara Eichorst (USA)
Michelle Robins (Australia)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:00 – 16:00 Plenary 1-3

Novo Nordisk

Advancing diabetes treatment and future perspectives

Morning session - Basal insulin therapy: combining to target

Chair: Jiten Vora (UK)
Host: Gregory Fulcher (AU)

09.00 – 09.10 **Welcome to the Novo Nordisk symposium at the World Diabetes Congress**
Gregory Fulcher (AU)

09.10 – 09.20 **Introduction and update on basal insulin therapy**
Jiten Vora (UK)

09.20 – 09.40 **Opportunities from designer proteins**
Peter Kurtzhals (DK)

09.40 – 09.55 **Clinical profiles of new long-acting insulins and insulin combination products**
Thomas Pieber (AT)

09.55 – 10.10 **Improving efficacy without compromising the risk of hypoglycaemia**
Athena Philis-Tsimikas (US)

10.10 – 10.25 **Flexibility in dose timing matching patient needs**
Luigi Meneghini (US)

10.25 – 10.55 **Coffee break**

10.55 – 11.10 **Harvesting the benefits of complementary drugs**
Chantal Mathieu (BE)

11.10 – 11.35 **Synergies of basal insulin and GLP-1 treatment**
Bernard Zinman (CA)

11.35 – 11.55 **Advancements in novel insulin combination therapy**
Gregory Fulcher (AU)

11.55 – 12.30 **Panel discussion**
All

12.30 – 13.30 **Lunch break**

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:00 – 16:00 Plenary 1-3

Afternoon session - Cardiovascular disease and special populations: is there a role for GLP-1?

Chair: Eduard Montanya (ES)

13.30 – 13.40 **Opening and welcome**
Eduard Montanya (ES)

13.40 – 14.05 **The history of cardiovascular disease trials in diabetes and overview of ongoing trials**
Steven Nissen (US)

14.05 – 14.30 **Cardiovascular effects of GLP-1: endothelial function, lipids and anti-inflammatory mechanisms**
Martin Haluzík (CZ)

14.30 – 14.55 **A role for GLP-1 in cardioprotection? Effects on cardiovascular remodelling and acute myocardial infarction**
Thomas Engstrøm (DK)

14.55 – 15.20 **Use of GLP-1 receptor agonists in special populations**
Richard Pratley (US)

15.20 – 15.45 **Panel discussion**
All

15.45 – 15.55 **Closure**
Eduard Montanya (ES

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

17:15 – 19:15 203/204

AstraZeneca/Bristol-Myers Squibb Diabetes Alliance

The evolving landscape in T2D

17.15 – 17.20 **Welcome address**
Stephen Colagiuri, University of Sydney, Sydney, Australia

17.20 – 17.35 **A snapshot of the type 2 diabetes treatment landscape in the Asia-Pacific region**
Stephen Colagiuri, University of Sydney, Sydney, Australia

17.35 – 18.00 **The role of DPP-4 inhibitors in type 2 diabetes and the New 2D study**
Linong Ji, Peking University People's Hospital, Beijing, China

18.00 – 18.25 **Beyond glycaemic control: Introducing the GLP-1 agonists**
Jianping Weng, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

18.25 – 18.50 **Weighing the role of SGLT-2 inhibitors in the treatment of type 2 diabetes**
Ted Wu, Royal Prince Alfred Hospital, Sydney, Australia

18.50 – 19.10 **Real World Discussion**
Panel

19.10 – 19.15 **Closing remarks**
Stephen Colagiuri, University of Sydney, Sydney, Australia

17:15 – 19:15 219/220

Merck Sharp & Dohme

The evolution of diabetes management in the 21st century: the role of sitagliptin

Chairman: John Prins, Australia

17:15 – 17:25 **Welcome and opening remarks**
John Prins, Australia

17:25 – 17:50 **DPP-4 inhibitors: incretin-based therapy differentiation**
Carolyn Deacon, Denmark

17:50 – 17:55 **Q&A**

17:55 – 18:20 **Determining the preferred partner to Metformin: sulfonylureas or DPP-4 inhibitors?**
John Prins, Australia

18:20 – 18:25 **Q&A**

18:25 – 18:50 **Sitagliptin in the treatment of type 2 diabetes: what do we know 7 years later?**
Michael Nauck, Germany

18:50 – 18:55 **Q&A**

18:55 – 19:20 **Focus on the type 2 diabetes patient with renal insufficiency: use of DPP-4 inhibitors**
Juliana Chan, Hong Kong

19:20 – 19:25 **Q&A**

19:25 – 19:50 **Potential cardiovascular effects of DPP-4 inhibitors and implications of long term outcomes trials for patients with type 2 diabetes**
Richard Gilbert, Canada

19:50 – 19:55 **Q&A**

19:55 – 20:10 **Panel discussion**

20:10 – 20:15 **Final comments and summary**
John Prins, Australia

17:15 – 19:15 Plenary 3

Novo Nordisk

Orchestrating success in diabetes management with premix insulins

Chair: Mark Evans, United Kingdom

17.15 –17.25 **Introduction**
Mark Evans, United Kingdom

17.25 – 17.45 **Putting the IDF guidelines into practice**
Naoko Tajima, Japan

17.45 – 18.40 **New clinical trial evidence with premix insulin**

- **Patient or physician insulin titration**
  Jancia Wong, Australia
- **Combining premix insulin and incretins**
  Mark Evans, United Kingdom
- **Basal plus mealtime insulin vs. premix insulin: what is the evidence?**
  Ajay Kumar, India

18.40 – 18.55 **A_1cheive: setting trial data into a clinical context**
Philip Home, United Kingdom

18.55 – 19.15 **Panel discussion and close**
All

17:15 – 19:15 210/211

Novo Nordisk

Breaking the barriers to sustainable access to care
Let's share experiences

Moderator: Jeffrey L. Sturchio, Ph.D., Senior Partner at Rabin Martin. Jeff is a thought leader in global health and former President & CEO of the Global Health Council

17.15 – 17.20 **Welcome and introduction to panel consisting of NCD experts and project partners**

17.20 – 17.40 **A word from the panel: barriers to sustainable access to diabetes care**

17.40 – 17.55 **Novo Nordisk contribution to improving global access to care**
Charlotte Ersbøll, Corporate Vice President, Novo Nordisk

Health for the next generation

18.00 – 18.10 **Changing Diabetes® in Children – towards a sustainable future**
Partner presentation by Dr. Ahmed Reja, President of Ethiopian Diabetes Association

Product distribution at the base of the pyramid

18.10 – 18.20 **Towards sustainable care and access to affordable insulin in Kenya**
Partner presentation by Zachary Ndegwa, Project Manager for the National Diabetes Control Program, Ministry of Health, Kenya

Building healthcare capacity

18.20 – 18.30 **Healthcare professional training programmes**
Partner presentation, speaker to be confirmed

18.30 – 19.10 **Panel discussion on the challenges of sustainability in access to diabetes care**

19.10 – 19-15 **Final remarks**

17:15 – 19:15 207

Qiagen

TB and diabetes: the rising tide

Chair: Anil Kapur, World Diabetes Foundation, India
Co-Chair: Kerri Viney, Secretariat of the Pacific Community (SPC), Noumea

17.15 –17.20 **Welcome & Introduction**
Anil Kapur, India
Kerri Viney, Noumea

17.20 – 18.10 **Overview of TB-DM syndemic: epidemiology and bidirectional impact**
Anil Kapur, India
Kerri Viney, Noumea

18.10 – 18.35 **Mechanism of TB disease in diabetics**
Blanca Restrepo, USA

18.35 – 19.00 **Practical approaches to TB screening and prevention among diabetics**
Richard Brostrom, USA

19.10 – 19.10 **Question and answer**

19.10 – 19.15 **Closing and evaluation**
Anil Kapur, India
Kerri Viney, Noumea

17:15 – 19:15 Plenary 1

Takeda Pharmaceuticals International

Recent developments in the treatment of type 2 diabetes

Chairs: Simon Heller, United Kingdom

17:15 – 17:20 **Welcome and introduction**
Simon Heller, United Kingdom

17:20 – 17:30 **Type 2 diabetes: an increasing global burden with significant unmet needs**
Simon Heller, United Kingdom

17:30 – 18:10 **What can we learn from long-term outcomes studies of type 2 diabetes treatments?**
Simon Heller, United Kingdom and Robert Chilton, USA

18:10 – 18:40 **Type 2 diabetes: from pathophysiology to management**
Richard Pratley, USA

18:40 – 19:00 **Novel and emerging therapies: looking into the future**
Charles Burant, USA

19:00 – 19:15 **Panel discussion**

17:15 – 19:15 212/213

CM Education Resources

New frontiers and emerging treatment paradigms for optimising cardiovascular outcomes in type 2 diabetes

Focus mechanisms of action, cardiometabolic risk profiles, and pathobiology of macrovascular heart disease in T2D: the evolving role of multimodal, therapeutic interventions for mitigating atherosclerosis in the diabetic patient

17.15 – 17.45 **Co-Chair's introduction and overview**
The burden, epidemiology and challenges of CVD risk reduction in T2D: critical interfaces among diabetes, macrovascular disease, and treatment strategies for multimodal CV risk reduction - the diabetes specialist's perspective
Vivian Fonseca, MD, FRCP - Program Co-Chair, Professor of Medicine and Pharmacology, Tullis Tulane Alumni, Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA

17.45 – 18.15 **From incretin-based mechanisms to cardiovascular outcomes: emerging data and evolving clinical investigations focusing on the role of GLP-1 agonists and DPP-4 inhibitors**
Mark Cooper, MD, Deputy Director (Research), Director, JDRF Centre for Diabetes Complications, Baker IDI Heart and Diabetes Institute, Professor of Medicine, Monash University, University of Melbourne, Melbourne, Australia

18.15 – 18.45 **New therapeutic strategies for CV risk reduction based on SGLT2 inhibition: mechanisms, evidence and rationale for achieving HA1c target goals and optimising cardiometabolic status**
Ralph DeFronzo, MD, Professor of Medicine, Chief, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX

18.45 – 19.00 **Chairman's summary and vision statement: emerging strategies for cardiovascular disease reduction in the setting of T2D - A year 2013 science-to-practice update**
Vivian Fonseca, MD, FRCP - Program Co-Chair, Professor of Medicine and Pharmacology, Tullis Tulane Alumni, Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, LA

19.00 -19.15 **Interactive question and answer session**

17:15 – 19:15 207

Becton Dickinson

Lipohypertrophy: overlooked bumps in the road to successful insulin therapy - Let's talk about I.T.*

**Injection Technique*

17.35 **What is lipohypertrophy and why do we care about it?**
Chair: Laurence Hirsch, MD Worldwide Vice President, Medical Affairs - BD Medical - Diabetes Care

18.15 **Future studies on lipohypertrophy**
Ji Linong, MD Professor of Medicine and Chair, Department of Endocrinology and Metabolism, Peking University People's Hospital, Vice President, International Diabetes Federation (IDF);Former President of the Chinese Diabetes Society; President of the Endocrine and Metabolic Physician Society under the Chinese Physician Association.

18.40 **Education on lipohypertrophy – Practical screening and treatment interventions**
Jan Alford - Credentialled Diabetes Educator, Registered Nurse and Registered Midwife
Nurse Unit Manager at the Diabetes Centre, St Vincent's Hospital, Darlinghurst, Sydney, Australia.
Michelle Robins - Credentialled Diabetes Educator, Northern Hospital, Nurse Practitioner and Chair of the ADEA Clinical Practice Committee, Australia.

19.00 **Q&A to presentation panel**

19.00 **Close**

17:15 – 19:15 219/220

Janssen

SGLT2 inhibition: new strategies in the era of individualised therapy

17:15 – 17:20 **Welcome and introduction**
Gregory Fulcher

17:20 – 17:35 **Type 2 diabetes - a pathophysiological approach to management**
Gregory Fulcher

17:35 – 17:45 **Q&A**

17:45 – 18:00 **Role of the kidney in type 2 diabetes**
John Wilding

18:00 – 18:10 **Q&A**

18:10 – 18:35 **SGLT2 as a target for type 2 diabetes**
Guntram Schernthaner

18:35 – 18:45 **Q&A Session**

18:45 – 19:10 **Panel discussion - individualising treatment targets in type 2 diabetes**
Gregory Fulcher
John Wilding
Guntram Schernthaner

19:10 – 19:15 **Closing remarks**
Gregory Fulcher

17:15 – 19:15 Plenary 3

Novartis

Contemporary therapeutic strategies in the management of type 2 diabetes: optimising patient care

Chair: Michael Horowitz

17.15 – 17.30 **Chairman's welcome: challenges and opportunities in type 2 diabetes**
Michael Horowitz - University of Adelaide, Australia

17.30 – 17.55 **Individualising patient care – early intervention strategies for the effective management of type 2 diabetes**
Stefano Del Prato - University of Pisa, Italy

17.55 – 18.20 **Addressing the pathophysiology of type 2 diabetes: mechanistic insights and perspectives**
Bo Ahrén - Lund University, Sweden

18.20 – 18.45 **Modern approaches to the management of type 2 diabetes: assessing the clinical evidence**
Marc Evans - University Hospital of Wales, UK

18.45 – 19.10 **Panel discussion**
All

19.10 – 19.15 **Summary and close**
Michael Horowitz - University of Adelaide, Australia

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

17:15 – 19:15 110

Novo Nordisk

Scientific update meeting

Chair: Jiten Vora

Welcome

TREAT 4 Ramadan
Melanie Davies

Liraglutide in type 1 diabetes
Thomas Pieber

The significance of a soluble basal-bolus combination: from PK/PD to phase 3 clinical data
Tim Heise

The insulin degludec poster tour
Jiten Vora and Bernard Zinman

Class combination beyond basal insulin: BEGIN: LIRAGLUTIDE ADD-ON
Chantal Mathieu

Combining two modes of action - the IDegLira DUAL I and DUAL II trials
Stephen Gough and Tina Vilsbøll

Panel discussion and close
All

17:15 – 19:15 210/211

Novo Nordisk

Getting straight to the point

Exposing the misconceptions around injections, and tackling the barriers they create

Chair: Professor Luc Martinez (France)

Panel Members: Dr Andreas Liebl (Germany), Dr Natalia Piana (Italy), Dr Moshe Mishali (Israel)

17:15 – 17:20 **Official opening of world premiere: getting straight to the point**
Luc Martinez (Chair)

17:20 – 17:45 **Act one: The injection barrier**
Live drama and discussion around injection fear myths

17:45 – 18:10 **Act two: The trial of Mrs Annabel Jenkins**
Live drama and discussion around fears of hypoglycaemia and weight gain

18:10 – 18:35 **Act three: It's complicated**
Live drama and discussion around treatment complexity barriers

18:35 – 18:45 **Questions and close**

17:15 – 20:30 Plenary 1

Sanofi Diabetes

Translating clinical experience and innovation into improved patient outcomes

17.15 **Welcome and introduction**
Neale Cohen

Session 1 - A comprehensive approach to type 2 diabetes: combining clinical experience with technological advances

Chair: J. Rosenstock

17.20 **Basal insulin therapy in type 2 diabetes: hypoglycemia, cardiovascular risk and other key efficacy and safety outcomes**
L. Ryden

17.45 **New investigative basal insulins: glycemic control and nocturnal hypoglycaemia**
R. Bergenstal

18.10 **The contribution of technology to the management of diabetes**
S. Garg

18.35 **Panel discussion**
R. Bergenstal

17:15 – 20:30 Plenary 1

Sanofi Diabetes

Session 2 - Effective control of dysglycemia in T2D: the complementary role of GLP-1 receptor agonists

Chair: J. Rosenstock

18.50 **The glycemic burden of PPG in type 2 diabetes: an unmet clinical need**
C. J. Bailey

19.10 **The evolving clinical evidence of PPG targeted GLP-1 receptor agonists**
L. Leiter

19.35 **Intensifying glycemic control: GLP-1 receptor agonists in combination with basal insulin**
R. Henry

19.55 **What are we learning from the incretin cardiovascular outcomes trials?**
H. Gerstein

20.15 **Panel discussion & conclusions**
Chair: J. Rosenstock

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

17:15 – 19:15 203/204

Servier

Optimising glycemic control to improve renal and cardiovascular outcomes

Chairs: J.P. Chalmers (Australia)
S. Colagiuri (Australia)

Introduction
John Philip Chalmers (Australia)

Optimal management of type 2 diabetes: new guidance
Stephen Colagiuri (Australia)

Glycemic control: what matters?
Siew Pheng Chan (Malaysia)

Impact of glycemic control on renal outcomes
Pavel Hamet (Canada)

Cardiovascular protection: what can we expect next?
John Philip Chalmers (Australia)

Conclusion
Stephen Colagiuri (Australia)

17:15 – 19:15 212/213

Joint IDF Diabetes Atlas/BRIDGES

International Diabetes Federation joint Diabetes Atlas and BRIDGES symposium: translating the evidence into real solutions

17.15 – 17.20 **Welcome**
Sir Michael Hirst (President, IDF)

17.20 – 17.30 **Aim of the symposium**
Juan Jose Gagliardino (BRIDGES Executive Committee)

17.30 – 17.40 **Presentation of the Diabetes Atlas**
Jonathan Shaw (IDF Diabetes Atlas Committee)

17.40 – 17.50 **Presentation of BRIDGES**
Linda Siminerio (Chair, BRIDGES Executive Committee)

17.50 – 18.05 **Diabetes in South and Central America**
Pablo Aschner Montoya (IDF Diabetes Atlas Committee)

18.05 – 18.20 **Demonstration area for primary prevention of type 2 diabetes, JUAN Mina and Soledad, Barranquilla, Colombia**
Jaakko Tuomilehto

18.20 – 18.35 **The burden of hyperglycaemia in pregnancy**
Nam Han Cho (Chair, IDF Diabetes Atlas)

18.35 – 18.50 **A randomised trial of effects of translation of intervention of gestational diabetes into the three level-prenatal care network in Tianjin, China**
Xilin Yang

18.50 – 19.15 **Q&A**

BRIDGES is an International Diabetes Federation program supported by an educational grant from Lilly Diabetes. The 6th edition of the IDF Diabetes Atlas was supported by the following sponsors: Lilly Diabetes, Merck and Co, Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi Diabetes.

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

17:15 – 19:15 207

Diabetes Research Group

Joint Symposium: Diabetes & Cardiovascular Disease, EASD Study Group and Forschergruppe Diabetes e.V. at the Helmholtz Center Munich including presentation of the Hellmut Mehnert Award 2013

Session1 - Hellmut Mehnert Award

Chairs: Antonio Ceriello, Paul Zimmet

17:15 – 17:20 **Introduction to the Award including commemoration of the late Prof. Harry Keen**
Paul Zimmet

17:20 – 17:25 **Video message by Hellmut Mehnert**

17:25 – 17:30 **Laudation and presentation of Awardee**
Antonio Ceriello/Paul Zimmet

17:30 – 17:50 **Lecture of Awardee: CVD impacts on individual glycemic targets and therapy – knowns and unknowns**
Eberhard Standl

17:15 – 19:15 207

Session 2 - The heart & diabetes: unravelling some missing links

Chairs: Linong Ji, Oliver Schnell

17:50 – 17:55 **Introduction**
Oliver Schnell

17:55 – 18:15 **The updated ESC/EASD Guidelines on "Diabetes and Cardiovascular Disease": what is new?**
Lars Rydén

18:15 – 18:20 **Discussion**

18:20 – 18:40 **Postprandial hyperglycemia & glucose variability as a CVD risk factor – what do we know and what is still missing?**
Antonio Ceriello

18:40 – 18:45 **Discussion**

18:45 – 19:05 **Lessons from applying CGMS to tackle postprandial hyperglycemia & glucose variability**
Oliver Schnell

19:05 – 19:10 **Discussion**

19:10 – 19:15 **Summary and close**
Linong Ji

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

17:15 – 19:15 203/204

Nestlé

Nutritional management of obesity in diabetes - an outlook into the future

Substantial weight loss reverses the metabolic syndrome: why is it not used more as a therapeutic strategy?
Joseph Proietto, University of Melbourne, Australia

Low and very low calorie diets as treatment options for managing and preventing diabetes
Mike Lean, University of Glasgow, Scotland

Ketogenic diets for weight loss - Effect of ketosis on appetite hormones
Priya Sumithran, University of Melbourne, Australia

Incorporating behaviour modification strategies in weight management programs
David Sarwer, University of Pennsylvania, USA

AUTHOR INDEX

KEYWORD INDEX

Please find the latest programme information using the congress application or online:

Congress application - eventmobi/wdc2013

Website - http://www.idf.org/worlddiabetescongress/programme

A

A.Kadir, K. P-1980
A.R., S. AbT-2108
Aamand, N. AbT-2125
Aamidor, S. OP-0593
Abalik?ta, T. P-1145
Abaru Asia, A. AbT-2075
Abbas, S.M. PD-0879
Abbas, Z. 0378, PD-0905, PD-0906
Abcouwer, S. 0505
Abd El Baset, A. AbT-2098
Abdelfattah, W. P-1905
Abdella, N. AbT-2001
Abdoli, S. OP-0456
Abdollahi, M. OP-0593
Abdul Aziz, S. AbT-2085
Abdul Basit, K. P-1810
Abdul Rehman, R. P-1666
Abdul Shakoor, S.K. P-1140
Abdul-Ghani, M. OP-0067, OP-0420, P-1448
Abe, Y. P-1933, PD-0742
Aberer, F. PD-0755
Abeypala, U. P-1658
Abida, M. P-1146, P-1836, P-1837
Abiko, A. OP-0450, PD-0713
Abiria C, C. AbT-2075
Ables, E. 0138
Abodo, J. P-1604
AboElAsrar, M. P-1184
Abouzeid, M. PD-0973
Abraitiene, A. P-1145
Abrams, B. P-1606
Abreu, C. PD-0679
Abreu, L.L.F. PD-0735
Abu Zafar, M.A.Z. PD-0885
Abu-Haydar, E. AbT-2153
Abubaker, M. P-1413
Abul Majeed, N. PD-0878
Abusnana, S. P-1864
Acan lilian, L. AbT-2075
Accili, D. 0189
Acedo Hidalgo, J. P-1333
Acha, J. P-1332
Acharya, D. P-1694
Acharya, K. AbT-2070, P-1847
Acharya, S. PD-0934
Achu, B. OP-0469
Ackley, T. 0393
Acosta, T. OP-0405
Acosta-Delgado, D. AbT-2034
Adaikan, K. P-1561
Adams, J. OP-0420
Adams, M. PD-0813
Adams, R. P-1769
Adams, T. P-1366
Adamska, A. PD-0722, PD-0725
Ade, O. P-1525
Adebayo, O.J. P-1621
Adegoke, O. P-1843
Adejumo, H. AbT-2092, P-1949
Adejumo, O. PD-0898
Adelekan, F.A. P-1895
Ademowo, O. P-1964, PD-0898
Adesina, O. P-1525
Adewunmi, J. P-1843
Adeyemi, O. PD-0730
Adhikari, P. P-1492, PD-0957
Adikariwattage, D. AbT-2081
Adikariwattage, D.A. AbT-2064, OP-0644
Adly, A. OP-0431
Aebeloe, K. P-1584
Aekplakorn, W. P-1957
Affun, J. AbT-2095
Afonso, M.J. P-1664, P-1668
Afroz, A. OP-0585
Afsana, F. P-1820
Afzal, K. AbT-1997, P-1162
Agarwal, G. P-1375
Agarwal, R. P-1819
Agarwal, V. PD-1031
Agawa, M. P-1520
Agbaht, K. AbT-2015
Agema, P. P-1562
Aghabozorgi, M. AbT-2086
Agius Muscat, H. P-1850
Agoons, D. P-1278
Agrawal, K. P-1679
Agrawal, R. P-1216, P-1865
Agrawal, R.P. P-1216, P-1865, PD-1031
Aguiar Vallim, E.J. OP-0629
Aguiar, C. P-1045
Aguiar, E.J. AbT-2159
Aguilar Diosdado, M. AbT-2031
Aguilar, A.H. PD-0947
Aguilar, M. PD-0834
Aguirre, F. P-1673, PD-0933
Ah Chee, R. P-1702
Ahmed Latif, Z. P-1820
Ahmed, A. AbT-2011, P-1499
Ahmed, F. P-1499, P-1568, PD-0876
Ahmed, K.R. AbT-2046, P-1209
Ahmed, M.M. AbT-2002
Ahmed, M.S.A.M. PD-0897
Ahmed, N. P-1042
Ahmed, Z. AbT-2087
Ahmedani, M. P-1568
Ahmedani, M.Y. AbT-2137, P-1526, P-1682, P-1755, P-1848, PD-0857
Ahmeti, I. P-1485, P-1516
Ahn, C. AbT-2117, P-1165, P-1323, PD-0773
Ahn, C.W. AbT-2053, P-1265
Ahn, H. OP-0627
Ahn, J. PD-0991
Ahn, K. P-1430
Ahn, K.J. P-1037
Ahn, Y.B. PD-0883, PD-0895
Ahn, Y.H. P-1163
Ahren, B. OP-0454, PD-0718
Aida, A. P-1429, PD-0695
Aiono, H. P-1795
Aitkulov, A.M. AbT-2043, P-1419
Ajani, A. P-1185
Ajani, G.O.D. P-1621
Ajay, V.S. P-1969, PD-1023
Ajmal, S. 0524
Ajose, O. AbT-2092
Akand, M. P-1742
Akasawa, A. P-1783
Akbaba, G. P-1058
Akbarov, A. PD-0931
Akbay, E. AbT-2036
Akcali, A. AbT-2035
Akcay, S. AbT-2010
Akcicek, F. AbT-2021, P-1699, PD-0682
Akesaka, K. OP-0419, P-1243
Akev, N. P-1038
Akhobadze, T. P-1195
Akhrarova, N. P-1128, P-1147
Akhtar, S. P-1412
Akhter, M. P-1305, P-1388
Akikawa, K. P-1158
Akila, G. P-1423
Akimoto, Y. PD-0778
Akinci, B. P-1176, PD-0889
Akinlabi, T. P-1964, PD-0898
Akiyama, H. P-1344
Akiyama, K. P-1783
Akiyama, Y. P-1933, PD-0742
Akkan, A.G. P-1137
Aksartova, E.A. P-1419
Aktas, C. P-1101
Akter, J. AbT-2046
Akter, S. P-1305, PD-0684
Akyol, Y. OP-0462
Al Aali, G. AbT-2065
Al Ameri, H.S. P-1235
Al Amri, N. P-1563
Al Arouj, M. 0222
Al Hamaq, A. 0507
Al Khalfan, A.H. P-1948
Al Khalfan, F.H.A. P-1948
Al Khalfan, Y.H. P-1948
Al Mamun, A. P-1177, P-1940, PD-0684
Al Qurashi, F. P-1860
Al Sayah, F. OP-0116
Al-Arouj, M. P-1157, P-1523
Al-Daher, S. 0181
Al-Hamaq, A. AbT-2050, P-1448, P-1965
Al-Jundi Matthis, S. 0349
Al-Kilani, M. AbT-2026
Al-Muqla, L. AbT-2066
Al-Natour, A. 0526
Al-Ostad, M. 0110
Al-Sayyari, A. P-1786
Al-Shudifat, A. AbT-2026
Al-Thawadi, H.E.S. P-1948
Alabdulaaly, A. P-1256
Aladag, M. AbT-2061
Alameer, A. P-1547
Alba, M. P-1093
AlBeladi, M. AbT-2011
Albero, R. P-1332
Alberti, S. 0551
Albornos, C. PD-0679
Albright, A. OP-0237, PD-1004, PD-1006
Albuquerque, J.C. AbT-2056
Alcarria, E. PD-0679
Aldington, S.J. OP-0446
Aleali, A.M. AbT-2127
Alexander, R. P-1506
Alhadhwan, A. PD-0727
Alhammady, M. AbT-2011
Alharbi, T. OP-0101, P-1811
Alhazmi, A. P-1912
Ali Dina, S. AbT-2048
Ali, A. P-1913, PD-0821
Ali, F.M. P-1873

AUTHOR INDEX

Ali, L. AbT-2046, AbT-2083, OP-0585, P-1305, P-1382, P-1383, P-1388, P-1524, P-1730, P-1813, P-1953, PD-0716, PD-0867
Ali, M.K. OP-0237, OP-0239, OP-0444, OP-0583, OP-0584, P-1874, P-1969, PD-0769, PD-0943, PD-0951, PD-1004, PD-1006, PD-1023
Ali, R. P-1290
Ali, S. P-1896
Ali, S.I. PD-0879
Aliaga-Verdugo, A. AbT-2034
Alieva, A. AbT-2022, P-1128, P-1147, PD-0931
Alikhanova, N. PD-0931
Alimetova, Z.R. AbT-2150, AbT-2151
Alimova, N. AbT-2022, PD-0931
Alina, A.R. P-1419
Aljalsi, B. P-1968
Alkac, B. P-1198
Alkac, C. P-1198
Allan, C. P-1959
Allen, E. P-1321
Allen, P. P-1835
Allen, T.J. OP-0621, PD-0782
Allen, T.L. P-1366
Almaraz, M.C. PD-0921
Almedfa, A.S. P-1948
Almeida, C. AbT-2073, P-1651
Almeida, R. P-1142
Almodovar, F. PD-0679
Alon, T. AbT-2096
Alouki, K. PD-0965
Alperet, D.J. P-1763
Alshehri, D. AbT-2011
Altaisaikhan, A. AbT-2071, P-1723
Altinok, A. P-1137
Altshuler, D. OP-0253
Altun, A. P-1132
Altunoglu, E. P-1198
Altuntas, Y. PD-0892
Alvarez Guisasola, F. P-1599
Alvarez, D. P-1332
Alvarez, F. P-1727
Álvarez-Guisasola, F. PD-0968
Alvi, S.F.D. AbT-2137, P-1526, P-1755, P-1810, P-1848
Alwakeel, J. P-1156
Alwis, I. 0181
Alzaid, A. P-1256
Alzalet, S. AbT-2008
Amani, R. AbT-2127
Amarchand, R. OP-0411
Amayo, E. P-1847
Ambade, A. P-1543
Ambika Gopalakrishnan, U. P-1800
Ambrish, C. PD-1009
Ambrosius, W.T. P-1108
Amemiya, S. P-1474
Amer, S. AbT-2011
Ametov, A. 0187
Amiel, S. P-1648
Amin, F. PD-0912
Amini, M. OP-0456
Ammini, A.C. PD-0795
Amor, A. P-1623
Amorim, W. P-1651
Amutha, A. P-1816, PD-0769
An, J.H. P-1109
An, Z. P-1784
Anand, S. OP-0430
Anarte, M.T. P-1273, P-1274, PD-0921
Anas, S. AbT-2161
Andersen, C.B. P-1414
Andersen, H. P-1263, PD-0746
Andersen, H.-C. PD-0749
Andersen, H.C. P-1714, PD-0748
Andersen, H.U. PD-0748
Andersen, L.L. PD-0986
Andersen, M.F.B. P-1406, P-1898, P-1902, PD-0741, PD-0960
Andersen, T.H. P-1395, P-1399
Anderwald, C.H. PD-0771
Ando, R. 0132
Andou, T. P-1283
Andrade, F. P-1855, P-1951
Andrade, S. OP-0452
Andreassen, J. PD-0993
Andreewa, A.P. AbT-2043
Andreoni, S. P-1772
Andrews, R. 0512
Andrianova, E. P-1515, PD-0792, PD-0862
Andrikopoulos, S. 0192, OP-0601, P-1387, PD-0761
Anghel, M. PD-0970
Anguzu patrick, P. AbT-2075
Ani, N. PD-0901
Anic, A. PD-0942
Anjana RM, R.M. P-1927
Anjana, R. 0400
Anjana, R.M. OP-0584, OP-0614, P-1816, P-1849, P-1853, PD-0769, PD-0800, PD-0943, PD-0980, PD-0981, PD-1005, PD-1009, PD-1021, PD-1035
Anjou, M.D. PD-0806
Annabi, F.A. AbT-2026
Anstey, K.J. PD-1001
Anthikkat, A.P. P-1161
Anthony, D. OP-0404
Antit, M. AbT-2044
Antonijoan-Arbós, R.M. AbT-2052
Antsiferov, M. 0187
Anumah, F. P-1613
Anwar, N. AbT-2046
Anyangwe, F. OP-0469
Anyanwu, A. PD-0730
Anyanwu, A.C. P-1843, P-1895
Aoki, Y. P-1459
Apecechea, M. OP-0272
Appajigol, J. P-1631
Aqeel, M. PD-0885
Ara, D. AbT-2083
Ara, F. P-1730, P-1953, PD-0867
Ara, P. P-1623
Araki, T. PD-0699
Aral, H. P-1198
Aral, Y. AbT-1998
Aranda Gani, N. P-1713
Aranda, C. OP-0645, P-1502
Araujo, W. PD-1030
Aravind, S.R. OP-0265
Arbatskaya, N. P-1762
Archana, J. P-1291
Archibald, L. PD-0905, PD-0906
Ardalan, G. AbT-2139
Ardena, G.J.R. P-1681
Ardiansyah, A. PD-0658
Arduc, A.Y.S.E. P-1373
Arechaga, F. P-1724
Ari, N. P-1127
Arias-Merino, E.D. PD-0849
Arman, Y. AbT-1999
Armendáriz-Borunda, J.S. AbT-2004
Armitage, J.A. PD-0663
Armson, B.A. OP-0581
Armstrong, M.J. P-1475
Aronson, R. OP-0454
Arora, M. P-1511
Arora, P. P-1378
Arosa Carril, V. PD-0788
Arpitha, R. PD-0957
Arranz, A. P-1308
Arslanian, S. 0321
Arthur, I. OP-0476
Artola, S. PD-0968
Arubuolawe, O. P-1964, PD-0898
Arundell, L. 0324
Asamizu, S. PD-0777
Asano, H. AbT-2041
Asatiani, N. 0561, P-1309, P-1505, P-1591, P-1605, P-1641, P-1704, P-1972, PD-0891
Asayesh, H. AbT-2139
Asche, S. P-1514
Aschner, P. 0313, AbT-2125
Asha, D. P-1927
Asha, H.S. P-1039
Asher, G. 0317
Ashina, T. P-1639
Ashrafuzzaman, S. P-1743
Ashrafuzzaman, S.M. P-1960
Ashwini, K.N. P-1527, P-1587, P-1712, PD-0887
Ashworth, K. 0181
Asif Mahmood, M. P-1592, P-1896, PD-0885
Asiki, G. OP-0238
Asimit, J. OP-0252
Asirvatham, A.J. P-1393
Aspin, G. P-1528
Asproloupos, D. P-1944
Asran, L. AbT-2098
Assah, F. 0385
Assal, J. P-1522
Assal, J.P. 0548, 0560
Assal, M. 0560
Assal, T. 0125, P-1522
Aston-Mourney, K. 0338
Aswar, A. P-1040, P-1764
Atabay, A. P-1222
Atadjanova, M. P-1483

Ataie-Jafari, A. AbT-2139, OP-0429
Atieno, S. P-1669
Atkinson, D. PD-0803, PD-0808
Atkinson-Briggs, S. 0264
Atlantis, E. P-1959
Atmaca, A. OP-0462
Atramentova, L. P-1203
Atsumi, T. P-1158
Audehm, R. OP-0273
Augustin, L.S. P-1917, P-1918
Avila, L. P-1727, PD-0968
Avilés- Perez, M.D. P-1334
Avril, C. OP-0284
Avron, A. P-1272
Awal, A. P-1494
Awal, N. AbT-2084
Awanchanwage Carolyn, C. AbT-2075
Awaz, M.Z. P-1568
ayah, R. PD-0996
Aycicek Dogan, B. P-1373
Aydin, A. P-1127
Ayoob, Z. AbT-1997, P-1162
Aytug, H. P-1079
Azabji, M. P-1278
Azad Khan, A.K. P-1129
Azad, K. PD-0876
Azandjeme, C. PD-1020
Aziz, M. P-1246
Azriel, S. P-1293b, P-1326, P-1897

B

B., S. P-1206
B.O., P. P-1206
Ba-Essa, E. P-1523
Baabbad, R. P-1898, P-1902, PD-0741
Baan, C. 0347
Baba, M. OP-0603
Babakhanov, B. PD-0851
Babineaux, S. PD-0886, PD-0903
Babor, R. P-1144
Backholer, K. P-1818, P-1929
Baczkó, I. P-1196
Badaam, K.M. AbT-2002, P-1476
Bader, G. AbT-1993, PD-0819
Bae, J. P-1928
Bae, J.H. P-1074, P-1075
Bae, K.H. PD-0685
Baek, C.O. P-1065, P-1073, PD-0672
Baek, H. AbT-2117, PD-0773
Baek, H.S. P-1065, P-1073, PD-0672
Baek, K.H. OP-0056, P-1432
Baeres, F.M.M. PD-0677
Bafna, B. P-1881
Bagcivan, I. P-1132
Bagger, M. P-1584
Bah, A. PD-0859
Bah, S. P-1706, PD-0859
Bahadir, C.T. OP-0462
Bahadirov, S. AbT-2022, PD-0931
Bahceci, M. P-1616
Bahendeka Karaireho, S. 0637
Bahendeka, S.K. P-1779
Bahn, A. PD-0739
Bai, F. OP-0600
Bai, J. P-1164
Baik, S. PD-0991
Baik, S.H. P-1446
Bailes, Z. P-1104
Bailey, T. P-1310, P-1318
Bain, S.C. PD-0791
Bajaj, S. P-1393
Bajpai, A. P-1580
Bajurny, V. OP-0280
Bakar, F. P-1094
Baker, J. P-1753
Baker, K. PD-1027
Baker, S. P-1773, PD-0710
Bakkari, O. AbT-2011
Bakker, K. 0220
Bakoyanni, S. P-1434
Baksh, L. PD-0882
Bal Demirci, T. AbT-1985
Balakumar, M. PD-0769
Balasubramaniyam, K.K. P-1927
Balci, M.K. PD-0744
Balcou-Debussche, M. OP-0477
Baldan, A. OP-0629
Balde, N. PD-0859, PD-0965
Balde, N.M. P-1706
Baleanu, F. AbT-2110
Balkau, B. OP-0268, OP-0406, OP-0408, P-1417, P-1899, PD-0979
Ball, K. 0324
Ball, P. PD-0809
Ballotari, P. P-1857
Ballout, G. 0526
Balogova, M. P-1444
Banciu, H. OP-0606, P-1250
Bancroft, L. P-1686
Bandgar, T. P-1046
Bandurska-Stankiewicz, E. AbT-2149, P-1941
Bandurska-Stankiewicz, E.B.-S. P-1828
Bandyopadhyay, M. AbT-2164
Banerjee, A. PD-0982
Banerjee, B. PD-0876
Bangoura, J.S. P-1706, PD-0859
Banisauskaite, I. P-1735
Bansal, D. P-1812, P-1842, P-1878
Bansal, S. P-1290
Bantwal, G. P-1399
Banu, A. AbT-2152, OP-0642, P-1839, PD-1011
Bañuelos Barrera, Y. PD-0849
Bañuelos-Barrera, P. PD-0849, PD-0850
Bañuelos-Barrera, Y. PD-0850
Bao, W. PD-0976
Bao, Y. OP-0060, P-1190, P-1595, P-1821, P-1824
Bao, Y.Q. OP-0604, P-1391
Baptista, J. P-1576, P-1760, PD-0856, PD-0858
Baqar, S. P-1571, PD-0709
Baquero Jimenez, M. P-1590
Baradaran, H. P-1982
Barak, L. P-1445
Barakat, G. P-1311
Barakat, M.T. AbT-2080, PD-0961
Barba-Martín, R. OP-0267
Barber, R. P-1533
Barberán, J. P-1056
Barclay, A. PD-0825
Bardak, S. P-1058
Bardtrum, L. P-1297
Barlow, J. OP-0476, OP-0649
Barnard, K. P-1396, PD-0743
Barnett, A.H. PD-0698
Barnett, G. 0552
Barney, R. AbT-2153
Barone, M. P-1710, P-1760
Barone, M.T.U. P-1564, P-1576, PD-0856, PD-0858, AbT-2073
Barr, E.L. OP-0240
Barraj, L. P-1608
Barranco Moreno, A. P-1141
Barratt-Boyes, C. P-1144
Barrett, B. P-1336
Barrett, H.L. PD-0801
Barrio, F. OP-0236
Barrow, B. PD-0738
Barry, M.A. P-1706
Barry, T.O. P-1706, PD-0859
Bartakova, V. P-1484, P-1487
Bartlett, B. OP-0425
Barzalai, N. 0159
Basaran, M. P-1373
Basavaprabhau, A. PD-0957
Bashyam, B. P-1918
Basit, A. AbT-2132, AbT-2137, P-1526, P-1568, P-1618, P-1666, P-1671, P-1682, P-1755, P-1756, P-1810, P-1925, PD-0857
Baskal, N. P-1094
Baskerville, T. PD-0689
Baskin, K. 0541
Baskota, A. P-1765
Bassel-Duby, R. 0541
Bassett, P. P-1336
Bassil, M. OP-0063
Bastide, N. OP-0606, P-1250, P-1717
Batchuluun, B. OP-0427
Bate, B. P-1278
Batia Samuel, B. AbT-2075
Battelino, T. 0373
Battin, M. 0481
Bauer, J. PD-0827
Baumann, L. PD-0927
Bautista, C. PD-0754
Bax, G. P-1887
Bayindir Cevik, A. P-1620, P-1826
Bayrak, B.B. P-1038
Bayraktar, F. P-1176, P-1218
Bayraktar, M. AbT-2015
Beals, C.R. OP-0426
Beare, R. OP-0608
Bearham, J.M. P-1414
Beasley, R. P-1768
Beato Víbora, P. P-1333
Beaton, A. 0569
Bechara, G. P-1651, P-1710
Becker, D.L. PD-0664
Beckmann, Y. AbT-2018
Begg, L. P-1059, P-1774
Begum, K. AbT-2083
Begum, R. P-1482
Begum, S. PD-1016

AUTHOR INDEX

Begum, T. AbT-2152, OP-0642, P-1695, P-1839, PD-1011
Beheregaray Kaplan, D. P-1651
Behl, R. P-1107
Behnke, T. P-1741
Beisyte, J. P-1538
Bejtja, G. P-1557, P-1977
Bek, R. P-1766
Belagali, Y. AbT-1988
Belinova, L. PD-0750
Bell, C. P-1447
Bell, K. P-1257
Bellemore, S. PD-0737
Belley, R. P-1217
Bellido Guerrero, D.B.G. P-1347
Belma, M. PD-0800
Belobradkova, J. P-1484, P-1487
Belobrajdic, D.P. P-1041
Belton, A. P-1562, PD-0800
Beltran, C. AbT-2129, P-1548
Bem, R. P-1119, PD-0665
Ben Salem, L. AbT-2044
Ben Slama, C. AbT-2044
Ben-david, R. P-1572
Ben-Nakhi, A. P-1523
Benard, E. AbT-2075
Bener, A. AbT-2050, P-1448, P-1965
Bengtsson, T. P-1091, PD-0728
Benhamou, P.Y. P-1055
Benian, A. PD-0799
Benjama, A. P-1042
Bennett, P. 0085
Bennett, P.H. PD-0818
Benon, L. AbT-2162
Benson, A.C. P-1477
Bergan, E. P-1310, P-1318, PD-0680
Bergenstal, R.M. OP-0075
Berger, M. 0335
Berker, D. P-1058, P-1373
Berkovic, M. P-1057
Bermingham, D. P-1753
Bernal-López, R. OP-0267
Bernaz, E. P-1954
Bernier, M. OP-0229
Bernordi, P. AbT-2073
Bernstein, S. P-1628
Berria, R. P-1066
Bertsch, H.B. P-1633
Besancon, S. AbT-2103, OP-0477, PD-0965
Besarab, A. OP-0076
Bessho, M. PD-0955
Best, J. OP-0273
Best, J.D. P-1733, PD-0944
Bethel, M.A. PD-0700
Bewa, E. AbT-2109
Beydogan, A.B. P-1130
Beyene, J. AbT-2143, P-1926
Bezweek, A. AbT-2090
Bgatova, N.P. PD-0706
Bhadada, S.K. OP-0430
Bhadra, R. AbT-2003
Bhagwat, N. P-1947
Bhansali, A. P-1812, P-1842, P-1914, PD-0980, PD-0981, PD-1000
Bharadwaj, D. OP-0230, OP-0255, P-1234, PD-0774
Bhargava, A. P-1410
Bhasin, P. P-1888
Bhat, D. OP-0067b
Bhatia, E. P-1819
Bhatla, N. OP-0579
Bhatt, S.P. P-1092
Bhattacharya, S. P-1622
Bhattacharyya, O. P-1559
Bhavadharini, B. PD-0800
Bhowmik, A. P-1129
Bhowmik, B. P-1858, P-1871
Bhowmik, N. AbT-2003
Bi, Y. P-1343
Bian, B. P-1617
Bian, R. OP-0265
Bianchi, C. P-1885
Bibin, Y.S. PD-0769
Bich Nga, V. OP-0064
Biden, T. P-1366
Biden, T.J. 0136
Bierhaus, A. PD-0711, PD-0785
Biessels, G. 0204
Biesyte, J. P-1687
Bihan, H. P-1942
Bihan, H.B. P-1943
Bikha Ram, D. AbT-2006
Bikhazi, A.B. P-1311
Bilic, I. P-1057
Bilo, H. PD-0995, PD-1029
Bilodid, I. AbT-2140
Bin Abbas, B. PD-0902
Binger, K. P-1384
Binukumar, B. OP-0583, P-1969, PD-0951, PD-1023
Biragova, M. P-1240
Bird, A.R. P-1041
Bird, D. PD-0915
Bird, S.R. P-1477
Birkenfeld, A. P-1384
Birkenfeld, A.L. OP-0229
Birnbaum, M.J. 0012
Bitoska, I. P-1485
Bitovska, I. P-1516
Bitton, G. AbT-2096, P-1741
Bizet, F. P-1718
Bjarkøy, R. AbT-2019
Bjerre-Christensen, U. P-1635
Bjorgaas, M.R. P-1188
Bjork Ingul, C. P-1188
Black, T. PD-0813
Blackberry, I. OP-0273, P-1650
Blackhurst, D.M. P-1292
Blair, A. OP-0601, PD-0928
Blais, L. P-1511
Blanch, N. P-1822, P-1923
Blanco Becerra, A. P-1590
Blanco Mejia, S. AbT-2143, P-1917, P-1926, PD-0977
Blase, E. PD-0678
Blaslov MD, K. P-1537
Blaslov, K. P-1369
Blevins, T. OP-0082
Blickem, C. OP-0468
Blizzard, L. OP-0608
Blomster, J.I. PD-1003
Blonde, L. P-1345, P-1767, P-1899, PD-0677
Bloomfield, G.S. P-1669
Bluestone, J.A. P-1047
Blüher, M. OP-0461, P-1593, P-1744
Blumer, C. PD-0973
Boavida, J.M. P-1809, PD-0907, PD-0997
Bobadilla, L.L. P-1098
Bode, B. OP-0068, P-1318, P-1345
Bode, B.W. OP-0421, OP-0422, P-1267
Bodur, H. AbT-2110
Boehnke, M. OP-0253
Boelle, E. OP-0075
Bogati, B. P-1694
Bognounou, R. AbT-2118, AbT-2162
Bohan Shaw, D. P-1043
Bohra, S. P-1416
Boisseau, L. P-1686
Boit, M.K. OP-0641
Bojórquez, J.L. P-1831
Bolayirli, M. P-1442
Bolkent, S. AbT-1985, AbT-1986, P-1130, P-1131, P-1131, P-1137
Bolli, G.B. P-1718
Bolton, T. PD-0805
Bonakdaran, S. P-1241
Bonareri, E. P-1575
Bond, S. PD-0655
Bondar, I. PD-0958
Bondar, I.A. PD-0706
Bondo, M.C. P-1496
Bongetti, E. AbT-2089
Bongon, J. P-1681
Boni-Schnetzler, M. 0120
Bonnaure, H. OP-0606, P-1717
Bonner, J. PD-0656, PD-0781
Bonnici, F. P-1272
Bonsembiante, B. P-1887
Boons, G.J. PD-0778
Borba, R.I.H. PD-0861
Borch-Johnsen, K. OP-0651
Borchert, M. AbT-2100
Borg, D. OP-0591
Borg, D.J. OP-0090
Borges, J. P-1481
Borges, K.B.G. P-1356, P-1370, P-1371
Boris, J.H. AbT-2057
Bornfeldt, K. OP-0453
Bornfeldt, K.E. 0099
Boschem, E. OP-0276
Bosco, A.A. P-1160, P-1355, PD-0660
Bossart, C. P-1825
Bosseri, S. AbT-1994, AbT-2008, AbT-2090
Bossuyt, P.M. P-1099
Bouchard, M. PD-1020
Bouchard, R. OP-0618
Boudjenah, N. AbT-2009
Boudville, A.I. PD-0806
Bouenizabila E. P-1707
Boulton, A.J.M. 0035
Bound, M.J. OP-0424, P-1473, PD-0712
Bouras, S. AbT-1994, AbT-2090
Bousmpoulas, S. P-1434
Bowden, J. P-1438
Bowen, S. 0247
Bower, C. PD-0930
Bowering, K. OP-0650
Boyea, K. 0053
Boyko, E.J. 0332, AbT-2142
Boyle, D. P-1944

Boyle, E.M. P-1508
Boyle, J. OP-0103
Boyle, M. PD-1013
Boz, M. P-1198
Braatvedt, G. P-1493, P-1498
Bracken, K. P-1959
Bracken, R. PD-0791
Bradford, W. OP-0638
Bradley, C. OP-0069
Brady, E.M. PD-0674
Braithwaite, I. P-1768
Bramlage, P. OP-0647
Brand, D.W. P-1514
Brand-Miller, J.C. P-1257
Brauer, P. PD-0826
Braver, J. P-1096, P-1097
Bravo, J.C. P-1831
Brazionis, L. 0264
Brcina MD, N. P-1537
Bretzel, R.G. P-1082
Briand, F. PD-0661
Bridgman, H. OP-0279b
Briers, N. OP-0271
Brimas, G. P-1145
Brinkworth, G. OP-0058
Brinkworth, G.D. P-1207
Briones, Z.M. P-1684
Brito, M. AbT-1991
Britton, H. P-1498
Brix, J. P-1789
Brix, J.M. P-1489, P-1790
Brod, M. P-1044, P-1303, P-1509, PD-0871
Broedl, U.C. OP-0081
Brookes, J.A.S. P-1230
Brooks, B. OP-0061, PD-0686
Brooks, C. PD-1027
Brooks, P. P-1688
Brooks-Worrell, B. 0246
Brotons, C. PD-0948
Brown, A. 0214, 0264
Brown, B. P-1072
Brown, H. 0324, P-1503
Brown, L. P-1567
Brown, M. P-1230
Brown, N. OP-0265, PD-0864
Browne, J. AbT-2059, OP-0242, PD-0812
Browne, J.L. OP-0457, P-1745
Browne-Cooper, K. P-1711
Browning, C. P-1866
Brownlee, M. 0134
Bruce, C.R. OP-0596
Bruce, D. 0017
Bruce, D.G. AbT-2115, OP-0117, OP-0609, OP-0643
Bruers, G. AbT-2119
Bruka, L. AbT-2047, P-1977
Brunell, S.C. PD-0678
Brüning, J.C. 0354
Brunner, M. OP-0073
Bruno, S. AbT-2110, AbT-2119
Brunoldi, S. OP-0470
Brunova, J. PD-0665
Brus, A. P-1575, P-1961
Brushbreaker, C. OP-0104
Brydges, R. P-1647
Bryzinski, B. P-1321
Buchi, S. P-1522
Buckley, J.D. OP-0058, P-1207
Bucks, R.S. OP-0609
Budge, C. P-1536
Budo, S. P-1977
Buduneli, N. AbT-2035
Bukelskiene, Z. P-1538, P-1687
Bukht, M.S. AbT-2046, P-1209
Buklijas Skeledzija, A. P-1537
Buko, I. AbT-2005, P-1215
Bullard, K.M. OP-0237, PD-1004, PD-1006
Bulsara, M.K. PD-0930
Bulum, T. P-1369
Buño Soto, M.B.S. P-1347
Burant, C.F. AbT-2141
Burcelin, R. 0007
Burgess, J. AbT-2134, P-1879, PD-0798
Burgos, S.A. OP-0063, OP-0233
Burke, H. PD-0805
Burke, S. P-1565
Burlina, T.R. PD-0861
Burnett, A. P-1503
Burns, J. P-1059, P-1774
Burrell, L. 0182
Burrell, L.M. P-1100
Burrows, N.R. OP-0444
Bursell, S. 0264
Bursill, C. P-1072
Burtt, N. OP-0254
Buschard, K. OP-0089
Buse, J. OP-0082
Buse, J.B. OP-0421, OP-0422, P-1267
Bushbreaker, C. 0575
Bushell, H. P-1737, P-1801
Bushnell, D. P-1509
Buso, C. P-1294
Buss, K. OP-0275
Butt, Z. PD-0775
Buzzetti, R. P-1276
Bygbjerg, I.C. P-1779
Byrne, M. P-1951

C

Caballero, A.E. P-1104
Caballero, R. AbT-2154
Cabanillas Lopez, M. P-1333
Cabezón Arriagada, M. P-1663
Cabré, J.J. OP-0236
Cabuk, H. AbT-2010
Caddaye, S. P-1777
Cagnacci, E. P-1111, P-1782
Cai, X. P-1258
Cai, X.L. AbT-2049, P-1210, P-1284, P-1312, P-1460
Cairns, D. 0523
Cakerri, L. P-1977
Calcutt, N.A. 0032
Califf, R.M. PD-0700
Caliseo, M. AbT-2073
Calkin, A. OP-0628
Callaway, L.K. PD-0801
Callister, R. AbT-2159
Calvagno, M. PD-0666
Calvet, J.H. AbT-2012, P-1248
Calvi-Gries, F. OP-0268, P-1899
Camer, D. P-1367
Cameron, F. OP-0433
Cameron, F.J. 0538
Cameron, L.D. PD-0989
Caminos, P. PD-0666
Campbell, J. P-1064
Campbell, L.V. OP-0057, P-1287, P-1594
Campbell, T.S. P-1475
Campos, L.V. P-1326
Campos, S. P-1308
Campos-Moreno, O.V. PD-0849
Can, A. P-1126
Candelas, C. P-1515, PD-0792, PD-0862
Cândido, A. AbT-2039, P-1372
Candido, A.L. P-1356, P-1370, P-1371, AbT-2056
Canete, E. PD-0947
Cannaby, A.M. PD-0843
Canovic, F. PD-0942
Cant, J.P. PD-0762
Cao, C. OP-0079
Cao, H.Y.C. PD-0988
Capar, H. P-1376, P-1859
Capata, F. P-1276, P-1277
Capra, S. PD-0827
Capuano, G. P-1093
Caputo, S. P-1415, P-1886
Car, N. AbT-1992, P-1239
Carbia, C. P-1111, P-1782
Carbillon, L. P-1942
Carbillon, L.C. P-1943
Cardinal, J. PD-0689
Cardona-Muñoz, E.G. AbT-2004
Cardoso, M.A. PD-0984
Carey, A.L. PD-0719
Carinci, F. OP-0266, P-1908
Cariou, B. PD-0673
Carlsson Ekander, L. OP-0055
Carlsson, A. PD-0657
Carlsson, L.M.S. OP-0054
Carmo, I. P-1664
Carolan, M. AbT-2164
Caroli, S. P-1857
Carqueja, T. P-1045
Carraro, R. P-1308
Carreira Soler, M. PD-0921
Carreira, M. P-1273
Carreria, M. P-1274
Carrillo-Mendigaño, D. P-1334
Carrio, M. PD-0666
Carroll, S.J. P-1769
CARRS Study Group, F.O.R. OP-0583, P-1969, PD-0951, PD-1023
Carson, V. 0324
Carstensen, B. P-1929
Cartier, S.E. P-1935
Carvalho, D. P-1045, P-1869
Carvalho, M.G. PD-0705
Cary, M. OP-0118
Casali, K.R. PD-0919
Cass, A. PD-0805, PD-0820
Castano, L.U.I.S. P-1502
Castelo Branco, F. P-1651
Castillo-Díaz, R. PD-0850
Castle, D. P-1733
Castro, A. AbT-2077
Castro, J.C. PD-0679
Catalano, P.M. 0480
Cathey, B. P-1052
Cattaway, H. P-1528
Cavale, M. P-1527, P-1587, P-1712, PD-0887
Cavan, D.A. P-1396, PD-0743
Cavanagh, E. OP-0061
Cavanaugh, K. 0465
Cavicchioli, M.G.S. PD-0861
Cavuoto, P. P-1113
Celbis, O. AbT-2061

AUTHOR INDEX

Celik, E. P-1218
Celik, S. P-1697
Celik, T. P-1058
Celtik, A. P-1176
Cenik, F. AbT-2027, P-1845
Cepeda, M. PD-0679
Cepero, D. P-1339
Cerf, M.E. PD-0662
Ceriello, A. 0098, P-1299
Cerin, E. 0324
Cersosimo, E. OP-0420
Cetinkalp, S. P-1338
Cetinkaya-Sardan, Y. AbT-2015
Cetrullo, V. P-1260
Ceyhan, C. P-1734
Cha, B. P-1165, P-1323
Cha, B.S. AbT-2053, P-1265, P-1892, PD-0950
Cha, B.Y. AbT-1996, OP-0056, P-1189, P-1432
Chadban, S. PD-0969
Chadha, M. P-1947
Chai, T.Y. P-1594
Chait, A. 0140
Chaki, K. P-1220
Chakrabarti, R. P-1829, P-1851, PD-1010, PD-1012
Chalmers, J. OP-0257, OP-0412, PD-1003
Chalmers, L. P-1658, PD-0813
Chamberlain, C. OP-0107
Chamnan, P. OP-0440, P-1966
Champagne, B. OP-0404
Chan, C. PD-0760
Chan, C.K.Y. P-1546, PD-0989
Chan, D. OP-0445
Chan, J. OP-0115, OP-0414, OP-0415, OP-0580, PD-0864
Chan, J.C. OP-0418, PD-0972
Chan, J.C.N. 0403, 0635, OP-0265, OP-0445, P-1046
Chan, K.A. P-1054
Chan, L. P-1715
Chan, M.C.W. P-1746
Chan, S. P-1493
Chan, S.M.H. P-1379
Chan, T.M. PD-0703
Chan, Y.M. P-1178, P-1915
Chand, A. P-1582
Chandarana, H.K. P-1411, P-1862
Chandni, R. P-1253, P-1254, P-1785
Chandra, R. OP-0071
Chang, C. P-1386, P-1596, P-1716
Chang, C.J. OP-0091, P-1199
Chang, H.Y. OP-0088
Chang, J.Y. P-1394, PD-0786
Chang, Y.H. P-1510, PD-0953
Chapla, A. P-1039
Chapman, A. P-1866
Chapman, C.S. PD-0662
Chapman, M. P-1090
Chappell, A. P-1835
Charles, D. PD-0807
Charles, R. AbT-2111, AbT-2131
Charles-Larco, N. AbT-2111, AbT-2131
Charpentier, G. P-1055, P-1327, P-1328, P-1329
Chateau-Degat, M.L. P-1217
Chatfield, M. PD-0820
Chaturvedi, N. OP-0443, PD-0937
Chau, M.K.M. PD-0703
Chaudhari, R. AbT-2055, P-1232
Chaudhary, S. P-1249, P-1291
Chaudhuri, R. 0467, P-1285
Chauduri, R. P-1051
Chave, S. 0146
Chawla, A. 0198
Chawla, M. AbT-2063
Chawla, M.S. P-1157
Chawla, R. P-1803
Che, T.I.N.G. P-1454
Chen, A.C.-H. OP-0591
Chen, A.X. PD-0709
Chen, C. PD-0890
Chen, D. AbT-2007, OP-0231, P-1381
Chen, H.Y. OP-0613
Chen, J.W. P-1259, P-1262
Chen, L. P-1595
Chen, L.L. P-1170, P-1270, P-1271
Chen, M. PD-0671
Chen, P.-C. P-1541
Chen, P.J. P-1422
Chen, S.F. P-1904
Chen, S.H. P-1108
Chen, S.T. P-1422
Chen, T. OP-0451
Chen, T.L. P-1266, P-1539, PD-0853, PD-0952
Chen, W.Z. PD-0707
Chen, X. P-1153
Chen, Y. P-1211, P-1319, P-1437, PD-0829, PD-0886, PD-0890, PD-0903
Chen, Y.C. P-1295
Chen, Y.L. AbT-2049, P-1284, P-1460
Chen, Z. P-1211
Chen, Z.-P. OP-0235
Cheney, J. PD-0926
Cheng, L. PD-0768
Cheng, M. P-1770
Cheng, W.J. P-1422
Cheng, Y.L. PD-0870
Chenji, S. PD-0745
Cheonchoopol, H. P-1966
Cheriyan, S. P-1889
Cherney, D.Z. OP-0081
Cheung, B.M.Y. OP-0062
Cheung, K. OP-0445
Cheung, N.W. P-1946
Cheung, W.K. P-1698
Chevalier, S. OP-0063, OP-0233
Chew, P. PD-0780
Chew-Graham, C.A. OP-0468
Chia, K.S. 0010
Chiambretti, A. PD-0959
Chiang, C.H. PD-0770
Chiatamone Ranieri, S. P-1857
Chiavaroli, L. P-1917
Chik, C.L. OP-0116
Chillar, A. P-1978
Chin, S.O. P-1517, P-1781
Chin-Dusting, J. OP-0620
Chinapaw, M. 0324
Chinenye, S. 0525, PD-0901
Chishaki, A. P-1838, P-1840
Chishaki, H. P-1838, P-1840
Chisholm, D. OP-0231
Chishti, S. P-1385
Chiu, F. P-1596, P-1716
Chiu, H.Y. AbT-2013
Cho, D.H. P-1919
Cho, K.Y. P-1158, P-1804, P-1805
Cho, N. 0437
Cho, P. OP-0441
Cho, Y. P-1194
Choe, E. P-1323
Choe, E.Y. P-1892
Choe, M. PD-0966
Choi, D. PD-0991
Choi, D.S. P-1395, P-1446
Choi, H.Y. P-1446
Choi, J.M. P-1139
Choi, K. PD-0991
Choi, K.M. P-1446
Choi, M.G. PD-0736
Choi, W.H. P-1163
Choi, Y. P-1194, P-1323
Choi, Y.K. PD-0685
Chon, S. P-1517, P-1781
Chondros, P. OP-0273
Choo, V. AbT-2143
Chopra, A. PD-1031
Chopra, R. PD-1031
Chopra, S. PD-1031
Chou, Y.C. PD-0853
Choudhary, M.I. P-1236
Choudhary, P. P-1648
Choudhury, S. P-1839
Choue, R.W. PD-0823
Chow, C. OP-0414, PD-0864
Chow, C.C. OP-0415, OP-0418
Chow, C.K. PD-1003
Chow, F.C.C. P-1395
Chow, W.S. OP-0062
Chowdhary, R. PD-1027
Chowdhury, H.A. AbT-2046
Chowdhury, M.M.H. P-1695
Chowdhury, S. P-1313, PD-0897
Chowta, M. AbT-1988, P-1255, P-1696
Chowta, N. AbT-1988, P-1255, P-1696
Christensen, A.S. AbT-2057
Christensen, D.L. OP-0641
Christensen, J. PD-0749
Christensen, J.N. PD-0748
Christensen, T. P-1303
Christiansen, E. OP-0073, PD-0676
Christiansen, J. P-1395, P-1399, PD-0789
Christina, F. P-1039
Christodoulides, C. 0014
Chua, J. P-1746
Chuah, K.A. P-1067
Chuang, H. AbT-2013
Chuang, L.M. P-1364
Chubb, S.A.P. P-1260
Chue, P. OP-0116
Chukwuma, C. P-1463
Chun, H.J. P-1432
Chun, S. AbT-2014, P-1314
Chung, C.H. P-1807
Chung, H. OP-0445, P-1430
Chung, H.Y. P-1037, P-1971
Church, J. OP-0638
Churm, R. P-1439

Cicekci, H. PD-0799
Cide Study Group, A. AbT-2112, P-1794, P-1799
Cieslar, S.R.L. PD-0762
Cimino, A. PD-1026
Cimpoca, B. PD-0970
Cinkil, G. P-1697
Cinkir, U. AbT-2036
Clarke, P. OP-0652
Clarke, S. P-1426
Clavel-Chapelon, F. OP-0408, PD-0979
Clayton, S. P-1520
Cleal, B. PD-0986
Cleary, T. P-1667
Clement, M. P-1630
Clenciu, D. PD-0970
Clifton, P. PD-0765
Clifton, P.M. P-1201, P-1202, P-1822, P-1923
Close, K. 0214
Coban, F.Y. P-1218
Cobo-Fernández, M. P-1334
Coester, H.V. P-1066, P-1400
Coetzee, E. 0558
Coffin, J. PD-0802
Cohen, J. P-1547
Cohen, N. 0040
Cohen, R. 0399, OP-0083, P-1088
Colagiuri, R.U.T.H. PD-0974
Colagiuri, S. 0389, OP-0582, P-1257, PD-0677, PD-0938, PD-0939, PD-0969
Colak, E. OP-0066
Cole, S. P-1688
Collia, L. P-1096, P-1097
Collier, K. P-1512
Collins, C. P-1486
Collins, C.E. AbT-2159
Collombat, P. 0367
Colman, P. OP-0433, P-1438
Colman, P.G. P-1185, P-1856, PD-1033, PD-1034
Colomo, N. P-1273, P-1274, PD-0754, PD-0921
Colquhoun, J.L. AbT-2097, OP-0471
Comaschi, M. OP-0475, P-1729, PD-0845
Cömlekci, A. PD-0889
Condes, F. OP-0616
Conget, I. P-1623
Connell, P.P. P-1214
Connor, T. OP-0092
Conradsen Hiort, L. PD-0746
Consoli, A. P-1055
Constantino, M. OP-0101, P-1811, PD-0793
Conway, A. P-1959
Conway, S. P-1627
Conwell, L.S. PD-0689
Cook, W. P-1321
Coombes, J.S. PD-0689
Cooney, G. 0318, P-1313
Cooney, G.J. OP-0599, P-1365
Cooper, A.R. 0322
Cooper, M. 0181, OP-0620, OP-0622, PD-0779, PD-0783
Cooper, M.E. OP-0412, OP-0621, PD-0780, PD-0782, PD-0784, PD-0785
Cooper, M.N. OP-0119, P-1771, PD-0917
Cora Corral, M.J. AbT-2058, AbT-2126
Corbett, S. P-1936
Corbould, A. P-1064
Cordido, F. P-1897
Coresh, J. PD-0818
Cornejo Pareja, I. AbT-2072
Cornejo, J.J. P-1326
Corrêa, A.P.S. PD-0919
Corredig, M. PD-0762
Correia, I. P-1809
Cortes Pelaez, R. P-1589
Cos, X. OP-0405
Cos-Claramunt, F.X. PD-0968
Coskun, Z.M. AbT-1986, P-1137
Cosson, E. P-1942
Cosson, E.C. P-1943
Costa, A. 0045
Costa, B. OP-0236
Costa, M. OP-0452
Costa, R. P-1308
Costacou, T. P-1823, PD-0932
Côté, M. P-1217
Cotterill, A. PD-0865
Coughlan, M. OP-0095
Coughlan, M.T. 0497, OP-0090, P-1061, PD-0784, PD-0785
Courneya, K.S. P-1938
Courrèges, J.P. OP-0606, P-1250, P-1717
Courtney, T. PD-0815
Coustan, D. 0435
Cox, A. P-1648
Cozma, A.I. AbT-2143, P-1917, P-1926, PD-0977
Cramb, R. P-1877
Cramer, J.A. 0634
Crandell, J. P-1916
Cranston, I. P-1396, PD-0743
Criel, B. AbT-2109
Crinall, B. PD-0798
Crook, S. P-1161
Cross, C. AbT-2081
Cross, F. AbT-2068
Crotty, M. P-1751
Crowe, S. PD-0696, PD-0698
Crowther, N.J. PD-0714
Cruz, M. P-1468, P-1831
Cruz-Bravo, M. PD-0679
Csajbók, É. P-1196
Csikasz, R. PD-0728
Cucinotta, D. PD-0959
Cuesta Muñoz, A.L. P-1293b
Cui, Z.G. P-1377
Cuk Roland, N. P-1703
Culos-Reed, S.N. P-1475
Cundy, T. P-1536
Cunningham, J. OP-0103
Cunningham, S.G. OP-0648
Curran, J.A. AbT-2051, OP-0432
Curtis, A. PD-1027
Curtis, B. PD-0886, PD-0903
Cutfield, R. P-1656, PD-0966
Czeczor, J.K. OP-0092

D

D'Amico, E. AbT-2059
D'Amore, A. P-1553
da Costa, T.H.M. P-1924
Dabelea, D. 0459
Dagdelen, S. AbT-2015
Dagogo-Jack, S. 0630
Dahlquist, G. 0623
Daikuhara, H. P-1397
Dain, M.P. P-1417, P-1515, P-1767, P-1899, PD-0792, PD-0862
Dal Fabbro, A.L. OP-0106, OP-0639
Dal Grande, E. PD-1008
Dalal, A.R. P-1947
Dalfrà, M. P-1887
Dallner, O. PD-0728
Dalwadi, P. P-1947
Daly, R.M. 0324
Damato, E. OP-0105
Damci, T. P-1415
Damgaard, L.H. OP-0082, OP-0421, OP-0422, P-1267
Damlund, D.M. OP-0089
Damnjanovic, D. PD-0925
Damsbo, P. PD-0755
Danchin, N. P-1767, P-1899
Dang, S. P-1951
Dang, T. PD-0927
Daniel, M. P-1769, P-1959
Dapice, A. 0129
Darias, R. P-1315
Darras, C. AbT-2109
Darwish, S. AbT-2050, AbT-2098, P-1965
Das, A.K. P-1914, PD-0980, PD-0981
Das, I. OP-0591
Daskalova, I. AbT-2038, P-1841
Date, M. P-1513
Daud Khan, M. 0395
Dauda, M. AbT-2092, P-1949
Dauphin, H. P-1942
Dave, R. P-1511, P-1881
Davey, J. OP-0095
Davey, M. PD-0808
Davey, M.A. AbT-2164
Davey, R.J. OP-0070, PD-0917
David Strain, W. OP-0461, P-1593, P-1744, PD-0751
Davids, H. P-1426
Davidson, J.A. 0571
Davies, B. P-1627
Davies, M. OP-0475, P-1070, P-1071, P-1072, P-1280
Davies, M.J. P-1676, PD-0674
Davis, B. OP-0107
Davis, E.A. AbT-2051, OP-0070, OP-0119, OP-0432, P-1555, P-1711, PD-0917, PD-0930
Davis, F. P-1795
Davis, T.M. OP-0117

AUTHOR INDEX

Davis, T.M.E. OP-0603, OP-0643, P-1159, P-1260, PD-0967
Davis, W. PD-0967
Davis, W.A. AbT-2115, OP-0117, OP-0603, OP-0609, OP-0643, P-1159, P-1260
Davis-Lameloise, N. PD-0944
Davtyan, L. P-1659
Davy, R. P-1504
DAWN2 Study Group OP-0455, P-1300, P-1581, P-1653, P-1670, P-1726, P-1729, P-1740, PD-0845, PD-0846, PD-0922, PD-0924
Day, L. P-1506, P-1950
Dayal, D. OP-0430
De Beer, D. OP-0602
de Cabo, R. OP-0229
de Castro, G. OP-0616
De Castro, P. P-1332
de Courten, B. OP-0065
de Courten, M. OP-0065
de Haan, J.B. PD-0779
de Jesús, R. P-1831
de Klerk, N.H. OP-0119
De la Cruz, M.J. AbT-2129
De Luca, P. AbT-2073
de Pablos-Velasco, P. OP-0069
De Rooij, S.R. 0156, P-1099
De Roxas, R. P-1597
de Souza Costa, C. P-1772, PD-0861
de Souza, R.J. AbT-2143, P-1917, P-1926, PD-0977
de Zeeuw, D. 0501, P-1093
de Zoysa, N. P-1648
Deacon, C.F. OP-0424, P-1473, PD-0712
Dealtry, G. AbT-2095, P-1426, P-1507, PD-0659
Dean, A. P-1606
Dean, D. P-1655, PD-0807
Debong, F. AbT-2103
Debri, K. AbT-2008
Debussche, X. OP-0477
Dedov, I. 0187
Deed, G. OP-0476
Deedwania, P.C. PD-1000
Deep, D. P-1219
Deepa, M. OP-0583, P-1853, P-1914, P-1969, PD-0951, PD-0980, PD-0981, PD-1005, PD-1023, PD-1035
Deepak, T. P-1587, PD-0887
Deerochanawong, C. 0186
DeFronzo, R. 0363
DeFronzo, R.A. OP-0067, OP-0420
Degan, S. P-1272
DeHaan, J. 0181
Dehayem, M. P-1150, P-1278, P-1614
Dehayem, Y. P-1228
Dehghani, C. OP-0605, PD-0668
Dehn, C.A. OP-0413
Dehvari, N. PD-0728
Dekker Nitert, M. PD-0801
del Cañizo-Gomez, F. AbT-2032
Del Monte, M.A. P-1213
del Peso, C. P-1279
Del Prato, S. OP-0416, OP-0443, P-1104, P-1885, PD-0744
Del Toro, R. P-1276, P-1277
Deleanu, C. P-1167
Deliard, S. OP-0251
Delisle, H. PD-0965, PD-1020
Deller, S. OP-0073, P-1407
Delormier, T. 0325
Demden, H. PD-0865
Demessinov, A. OP-0296
Demil, N. OP-0454
Demir, T. P-1218, PD-0889
Demircik, F. P-1911
Demircioglu, U.B. AbT-2027, P-1845
Demirpence, M.M. P-1616
Dennis, A. P-1064
Deoisres, W. PD-0927
Derave, W. OP-0065
Desai, A. OP-0579
Desai, M. P-1093
Deslypere, J.P. PD-0949
DeVries, J.H. P-1299, PD-0680
DeWalt, D. P-1791
Dezortova, M. PD-0750
Dhakal, N. P-1765
Dhandhania, V.K. P-1914, PD-0980, PD-0981
Dhavale, H. P-1978
Dhingra, M. OP-0074
Dholye, J. P-1978
Di Marco, E. OP-0620, PD-0780
Diallo, A.M. P-1692
Diallo, M. P-1692
Diallo, M.A. P-1706, P-1706, PD-0859, PD-0859
Diallo, M.M. P-1706, PD-0859
Diallo, O.B. P-1706
Diamant, M. P-1055
Dias, C. P-1869
Diaz Pérez de Madrid, J. P-1333
Diaz Sanchez, M.E. P-1276
Diehl, C. OP-0629
Digre, K. P-1795
Dilrukshi, K.L.A.D. AbT-2064
DiMeglio, L.A. OP-0080
Dimitrijevic-Sreckovic, V. OP-0066, P-1368, PD-0942
Dinccag, N. P-1697, P-1275
Ding, L. P-1047
Dinh, C. P-1151, P-1367
Dinh, P. OP-0064
DiPilato, L.M. 0012
Dirani, M. P-1214
DiTommaso, S. P-1157
Djonou, M. P-1278
Djordjevic, P. OP-0066, P-1368, PD-0942
Djoumessi, R. P-1150
Djrolo, F. PD-1020
Djuitchou, A. P-1701
Djuric, P. PD-0942
Dlugaj, M. PD-1007
Do Thi Ngoc, D. P-1907, P-1979
Do, D. OP-0064
Dobrian, A.D. 0540
Dobson, M. P-1048
Doddamaneni, S. OP-0579
Dodds, L. OP-0581
Dodds, M. P-1468
Dodevska, M. P-1368
Dodoo, A. P-1814
Döhring, C. P-1931
Dokmetas, H. P-1132
Doko, A. AbT-2047
Dolek Cetinkaya, D. P-1616
Dolezalova, K. P-1143
Dolic, A. P-1834
Dollenga, M. P-1977
Domenger, C. P-1515, PD-0792, PD-0862
Domingueti, C.P. PD-0705
Dominguez, C. P-1096, P-1097
Domínguez, M. P-1273
Domínguez-López, M. P-1274, P-1577, PD-0921, PD-1025
Donaghue, K.C. 0625
Dong, J. AbT-2112, P-1798
Dong, K. OP-0060
Dong, Y. AbT-2138, P-1247, P-1884, PD-0691
Dongmo, N. P-1614, P-1975
Donsmark, M. P-1310, P-1318, PD-0675, PD-0680
Doosti Irani, M. OP-0456
Dorairaj, P. OP-0411
Dotta, F. P-1886
Dou, J. P-1821
Double, J. 0379
Doupis, J. P-1316
Dowey, C. OP-0107
Dr Andrew Bonney, A. P-1542
Drabo, J. AbT-2163, PD-0965
Drabo, Y.J. AbT-2118, AbT-2162, PD-0877
Dragano, N. PD-1007
Dragut, R. P-1204
Drapalova, J. P-1143, P-1451
Drew, B.G. 0492, OP-0596, OP-0597
Drexel, H. P-1179, P-1180, P-1181, P-1182, P-1427, PD-0687, PD-0688, PD-0704, PD-0715, PD-0720, PD-0918
Drinkwater, J. P-1159
Drucker, D. 0009
Drury, P. P-1536, P-1656
Drury, V. P-1508
Dsouza, N. P-1492
Dsouza, S. P-1183, P-1492, P-1492
Du, J.L. P-1270, P-1271
Du, S. P-1916

Du, X. P-1660
Duan, H.P. P-1932
Duan, W. PD-0945
Duarte, L. AbT-1991
Duarte, R. P-1809
Dubey, R.K. P-1291
Dubsky, M. P-1119, PD-0665
Dubuquoy, C. PD-0661
Dudeja, L. P-1492
Duetting, E. OP-0647
Duggal, R. AbT-2045, P-1149, P-1846, PD-0817
Duggan, N. OP-0464, P-1725, PD-0842
Dugi, K. P-1931
Dullius, D. P-1674
Dullius, J. AbT-2025, AbT-2147, AbT-2148, P-1479, P-1607, P-1675, PD-0828, PD-1030
Dumanli, G.Y. AbT-2027, P-1845
Dumont, I. AbT-2119
Dunbabin, J.S. PD-0934
Dunbar, J. OP-0273, P-1944
Dunbar, J.A. PD-0944
Duncan, B.B. OP-0582
Duncan, C.J. P-1952
Duncan, D. PD-0689
Dundua, M. AbT-2099, P-1309, P-1505, P-1591, P-1605, P-1641, P-1704, P-1972, PD-0891
Dunga, A. P-1601, P-1661
Dunning, T. 0513, OP-0273, OP-0281, OP-0464, P-1640, P-1725, P-1752, PD-0842
Dunning, T.D. P-1632
Dunseath, G. P-1439
Dunstan, D.W. 0324, 0386
Duprat-Lomon, I. OP-0069
Durán-Garcia, S. PD-0697
Durgun, O. P-1690
Dusse, L.M.S. P-1370, PD-0705
Duta, I. PD-0970
Dutta, D. P-1428
Duvnjak, L. P-1369
Dwivedi, O.P. OP-0230, OP-0255, P-1234, PD-0774
Dwyer, J. PD-0866
Dyer, P.H. P-1585
Dyson, P.A. OP-0404

E

Eades, S. OP-0107
Eastaugh, P. P-1416
Ebenibo, S. 0630
Ebisui, O. OP-0419, P-1243
Ebrahim Khamseh, M. P-1261
Ebrahim, M.A. P-1566
Ecemis, G.C. OP-0462
Eckel, R. 0141
Eckfeldt, J.H. PD-0818
Edelman, S. 0128, P-1398
Edeoga, C. 0630
Edidin, D.V. 0559
Edinga, B. P-1150
Edwards, H. OP-0277, OP-0279b
Edwards, K. OP-0605, OP-0607, PD-0667, PD-0668
Edwards, P.A. OP-0627, OP-0629
Efron, N. OP-0605, OP-0607, PD-0667, PD-0668
Eggers, P.W. OP-0441
Egi, M. 0489
Egici, M.T. PD-0892
Ehau, T. 0024
Ehlers, G. P-1626
Ehlers, M. P-1047
Ehlers, M.R. OP-0080
Ehrmann, D.A. 0201
Ehses, J. 0244
Eigenmann, C. P-1567
Einhorn, N. P-1468
Eisenman, P. P-1795
Ekanayeke, E.M.P.R. AbT-2016
Ekinci, E.I. P-1048, P-1773, PD-0709, PD-0710, PD-0820
Ekoru, K. OP-0238
Ekstrom, H.L. P-1514
El Badawi, S. P-1864
El Ebrashy, I. AbT-2116, AbT-2160
El Garhy, N. AbT-2098
El Ghobary, M. AbT-2160
El Hadidy, Y. AbT-2160
El-Attar, H. P-1245
El-Hadidy, E. P-1184
El-Osta, A. 0530, OP-0622, PD-0663
El-Sayed, A. P-1523
Elango, B. P-1420
Elbarbary, N. OP-0431, P-1184
Elchalal, U. 0438
Eldor, R. OP-0067
ELeleedy, A. AbT-2098
Elenga Bongo, C. P-1707
Eleupaeva, S.K. AbT-2043
Elgart, J.F. P-1909
Elias, D. P-1272
Eliassi, A. AbT-2037
Eliasson, B. OP-0652
Elkassaby, S. P-1856, PD-1034
Ellis, A. PD-0820
Ellis, I. P-1835, PD-0802
Ellis, T.P. P-1049
Ellul, A. P-1850
ElNaggar, N. P-1261, P-1262
Elreish, L.A. P-1948
Elsabahy, K. AbT-2098
Elsaid, N. P-1187
Elsayed, N. P-1246
Else, J.E. P-1802
Emelyanov, A.O. P-1112
Emirova, A. AbT-2028, P-1281
Emma, S. OP-0105
Emoto, M. OP-0590
Enache, G. P-1204
Endahl, L. P-1301
Endo, G. P-1906
Endo, T. PD-0778
Engel, S.S. OP-0272, P-1068, PD-0700
Enikuomehin, A.C. P-1621
Enters-Weijnen, C. P-1775
Eom, Y.S. P-1882
Eranki, V. P-1248
Eraslan, S. PD-0889
Erasmus, R. P-1890
Erasmus, R.T. P-1292, P-1457, P-1973, PD-0717
Erbas, O. P-1079, P-1080
Erbel, R. PD-1007
Erdenen, F. P-1198
Eren, R. P-1272
Eriksson, J.G. PD-0975
Eriksson, N. 0491
Erniyasova, B.B. AbT-2043
Eroglu, A. P-1218
Ersil Soysal, D. AbT-2018
Ersoy, C. P-1690
Eryan Alrass, R. AbT-2008
Escalada, J. P-1599
Escalante, M. P-1300, PD-0924
Escalona, A. OP-0083
Eschwege, E. P-1327, OP-0069, P-1328, P-1329
Escobar Curbelo, L. AbT-2031
Escobar Jimenez, L. AbT-2031
Escobedo, J. P-1831
Eshenroeder, D. P-1825
Eskioglu, E. P-1058
Esmaeil Motlagh, M. AbT-2139
Esmatjes, E. P-1623
Espehaug, B. OP-0270
Esteva, I. PD-0921, PD-1025
Esteves, C. P-1869
Estevez, E. OP-0095, OP-0596, P-1366
Estrella, A. AbT-2129
Eubirod, E.U. OP-0266, P-1908
Eva, S.N. P-1382
Evangelista, P. P-1452
Evans, B.A. P-1091
Evans, M. P-1050, P-1089, P-1268, P-1297
Evans, M.D.M. 0549
Everaert, I. OP-0065
Evren, B. AbT-2061
Eynatten, M.V. PD-0692
Eyupkoca, F. P-1193
Ezz ElDin, M. AbT-2098

F

Fabra, A. P-1330
Fabre, B. P-1111, P-1782
Fadavi, H. OP-0607
Fagan, N. OP-0081
Fagherazzi, G. OP-0408, PD-0979
Faghfouri, F. P-1942
Fagnidi, F. P-1604
Fahey, R. P-1091
Fairall, L. OP-0628
Faki, Y. AbT-1999
Falabella, M. OP-0470
Falavigna, M. OP-0582
Fall, C. OP-0067b
Falla, F. P-1731
Fallucca, F. P-1277
Fam, B.C. P-1387
Fan, C.P.S. OP-0272
Fan, Z. OP-0598
Fang, F. PD-0734
Fang, Q. OP-0060
Fang, Z. P-1437
Fantuzzi Selle, X. P-1615
fantuzzi, X.F. PD-0916

Farnbach, E. P-1691
Faruque, M.O. P-1383, P-1693, PD-0716
Faruque, O. P-1742
Fasanmade, O.A. AbT-2161, P-1843
Fatanah, I. PD-0962
Fatehi, T. PD-0767
Fatema, K. P-1813
Fatima, N. P-1236, P-1385, P-1618, P-1810
Fatmi, Z. OP-0583, P-1969, PD-0951
Fatmi, Z.A. PD-1023
Faurholt-Jepsen, D. OP-0641
Faurschou, P. P-1550
Fawwad, A. AbT-2048, AbT-2137, P-1435, P-1436, P-1526, P-1682, P-1755, P-1810, P-1848, PD-0857
Fawzy, M. P-1187
Fayad, T. P-1246
Fazakerley, D. P-1051
Fazakerley, D.J. 0467, OP-0589
Febbraio, M. 0351, OP-0095
Febbraio, M.A. OP-0596, OP-0597, P-1366
Fegan, P.G. AbT-2086, P-1535
Fehértemplomi, K. P-1251
Feig, D. PD-0982
Feijoo, J. 0028
Feinle-Bisset, C. OP-0425, PD-0765, PD-0767
Fejfarova, V. P-1119, PD-0665
Feldmann, D. AbT-2096
Felner, E.I. P-1047
Felton, A. P-1634
Fender, A. P-1200
Feng, B. P-1211, P-1270, P-1271
Feng, W. P-1343
Fenton, B. OP-0404
Ferdous, H.S. P-1960
Ferdous, J. P-1305, P-1388
Fernandes, A. AbT-2039, P-1372
Fernandes, A.P. P-1370, PD-0705
Fernández, J.D. PD-0754
Fernández, R. PD-0754
Fernández-Arias, J.D. P-1274
Fernández-Carreira, J.M. PD-0948
Fernández-Martín, L.J. P-1333
Fernando, M. AbT-2122, P-1939
Fernando, R. AbT-2016
Ferrans, C. P-1754
Ferrante Jr, A.W. 0138
Ferreira, A. P-1372
Ferreira, A.M. P-1490
Ferreira, C. AbT-2039, P-1372
Ferreira, C.N. AbT-2056, P-1356, P-1370, P-1371
Ferreira, T. OP-0253
Ferrer, J.C. P-1330
Feskens, E.J.M. P-1922, PD-1014
Feste, C. 0179
Fhärm, E. OP-0407
Fidan, Y. P-1127
Figueira, F.R. PD-0919
Figueiredo, E.B. P-1490
Fikri, M. P-1864
Finch, S. PD-0710
Finger, R. P-1851, PD-1012
Finnegan, L. P-1754
Finney, K.M. 0538
Firas, M. 0131
Fischer, E. OP-0071
Fischer, G. OP-0276
Fischer, J.W. P-1200
Fisher, E. OP-0478
Fisher, L. 0165
Fisher, P. OP-0606
Fisher-Wellman, K. P-1052
Fitzsimmons, R. 0491
Flacke, F. OP-0074
Flannick, J. OP-0250, OP-0254
Fleck, P. PD-0699
Fletcher, J. P-1059, P-1774
Florence, P. OP-0116
Flores, M. P-1731
Flores-Trujillo, M. P-1053
Florez, H. P-1855, P-1951
Florez, S. P-1855
Fock, C. P-1867
Fokapu, P. P-1701
Foley, L. OP-0603
Folmann Hempler, N. P-1726
Fong, C.H.Y. OP-0062
Fonseca, V. 0633, PD-0677, PD-0680
Font, B. P-1727
Fontalba, M.I. P-1273, P-1274, PD-0754
Fontana, L. P-1277
Foos, V. P-1089
For the ACCORD Investigators, . P-1108
Forbes, A. P-1648, P-1670, PD-0845
Forbes, J. OP-0591, OP-0608
Forbes, J.M. OP-0090, P-1061, P-1118, P-1120, P-1233, PD-0719, PD-0784, PD-0785
Ford, R.J. OP-0235
Forest, J.C. OP-0581
Formisano, V. P-1276, P-1277
Fornasier, D. 0046, P-1542
Forsblom, C. PD-0702, PD-0711
Forsén, T. P-1775
Forst, T. AbT-2100, P-1066, P-1418, P-1741
Fort, P. 0505
Fortuin, M. P-1507
Fóscolo, R.B. PD-0705
Foster, J.K. P-1802
Foster, M.C. PD-0818
Fotheringham, A.K. OP-0090, P-1118, P-1120, P-1233, PD-0785
Fountaine, T. 0037
Fourlanos, S. 0243, P-1185, P-1688, P-1856, PD-1033, PD-1034
Fournier, P.A. OP-0070, PD-0917
Fradyc DM1, G. PD-0935
Fraile, A.L. P-1326
Franch, J. PD-0968
Franco, D. AbT-2073, P-1651
Franco, D.R. PD-0858
Franco, L.F. OP-0106, OP-0639
Franco, L.J. OP-0106, OP-0639
Franco, M. OP-0076
Franco, P.H.C. P-1160, P-1355
Franks, P.W. OP-0407
Franquet, M. OP-0470
Fraser, T. AbT-2141
Freak-Poli, R. P-1818
Freddy, H. OP-0622
Frederick, A. OP-0612
Fredericks, B. OP-0107
Freemantle, N. OP-0268, P-1417, P-1899
Frei, T. P-1405
Freitas, C. P-1142
Friderichsen, A.V. P-1414
Fried Isaac, Y. P-1572
Fried, M. P-1143
Friedman, A. 0249
Friedman, R. PD-0915
Friis, H. OP-0641
Frisby, C.L. P-1113
Frison, V. P-1887
Fritschi, C. P-1754
Frøkiær, H. OP-0089
Froment, T. P-1598
Frusho, H. P-1306
Frydman, G. P-1567
Fu, H. P-1660
Fu, S.H. P-1422
Fuchsberger, C. OP-0254
Fuente, G. P-1096, P-1097
Fuh, M. P-1541
Führer, D. PD-1007
Fujii, H. P-1352, PD-0790, PD-0956
Fujimoto, K. OP-0423, PD-0701
Fujimoto, W.Y. AbT-2142
Fujimura, E. P-1685
Fujimura, T. P-1425
Fujimura, Y. OP-0427
Fujioka, T. PD-0757
Fujita, Y. OP-0450, PD-0713
Fujiwara, M. P-1429, PD-0695
Fukatsu, A. P-1471, P-1472
Fukuda, K. P-1906
Fukuda, N. OP-0590
Fukushima, Y. PD-0777
Fukutomi, T. PD-0778
Fulcher, G. P-1093, P-1296, P-1317, P-1399, PD-0675, PD-0789
Fuller, J.H. OP-0443, PD-0937
Fuller, M. P-1825
Fullerton, M.D. OP-0235
Funch, D. P-1054
Funke, K. P-1722
Funnell, M. 0127
Furler, J. OP-0273, P-1650, P-1678
Furukawa, M. P-1480
Furuya, N. P-1175
Fusaro, V. P-1096, P-1097
Fuster, E. PD-0968

G

Gabarashvili, K. AbT-2099

Gabbay, R. 0144, P-1791, P-1792
Gabrichidze, S. P-1972
Gabriel, R. OP-0405, PD-0948
Gadabu, E.V.A. PD-0974
Gagliardino, J.J. 0195, P-1909
Gal, A. PD-0758
Galastri, L.L. P-1576, PD-0856, PD-0858
Galhotra, M. P-1107
Galic, S. OP-0235, OP-0588
Galindo, M. PD-0834
Galindo, M.A. PD-0834
Galkina, E.V. 0540
Gall, M.A. P-1395, PD-0747
Gall, M.G. P-1313
Gall-Casey, C. P-1630
Gallagher, J. P-1686
Gallagher, R. PD-0934
Gallego García, M.T. P-1279
Gallegos-Sánchez, J.J. PD-0850
Galligan, J. AbT-2134, P-1879
Gallo, A. P-1887
Gallo, L.A. P-1233
Gallwitz, B. P-1055, P-1104, P-1776, PD-0693
Galstyan, G. 0187
Ganapathy, H. P-1206
Gandy, M.J. P-1461, P-1467
Gao, F. OP-0094, P-1192
Gao, F.B. PD-0764
Gao, H. P-1455
Gao, L. P-1164
Gao, M. P-1824
Gao, Y. P-1263, PD-0990
Garber, A. OP-0072, P-1297, P-1299, P-1318, PD-0675, PD-0744
García Arnés, J. AbT-2135
García Arnes, J.A. P-1577
Garcia Garcia, C. P-1611, PD-0923
García Gimeno, M.A. P-1293b
García Luna, P.P. P-1141
Garcia Sanchez, E. P-1589
García Vazquez, E. P-1056
García Zafra, F. P-1056
García Zafra, M. P-1056
Garcia, A.B. PD-0935
García, B.F. P-1315
García, M. P-1577
García- Manzanares, A. P-1548
Garcia-Alcala, H. AbT-2128
Garcia-Aleman, J. P-1186
Garcia-Almeida, J. P-1186
García-Talavera Espín, N.V. P-1279
García-Torres, F. PD-0754
Gardete-Correia, L. P-1809, PD-0907, PD-0997
Gardner, D.S.L. P-1443
Gardner, F. PD-0928
Gardner, M. P-1835
Gardner, S.L. P-1561
Gardner, T. 0505
Gäredal, C. PD-0657
Garelli, G. PD-0666
Gäreskog, M. PD-0657
Garg, D. P-1803
Garg, M. P-1912
Garg, S. OP-0074
Garmaroudi, G.R. P-1488
Garofolo, M. OP-0416, OP-0443
Garvalena-Vázquez, M.J. PD-0850
Gasko, H. P-1944
Gasperikova, D. P-1444, P-1445
Gates, L. AbT-2123
Gau, B.R. PD-0707
Gaughran, F. 0164
Gautam, N. P-1291
Gauthamkumar, P. PD-0769
Gautier, J.F. P-1329
Gautier, J.P. P-1327, P-1328
Gavin III, J.R. 0248
Gayathri, R. P-1927
Gaysina, L. AbT-1995, AbT-2150, AbT-2151, P-1450
Gaysina, L.R. P-1449
Gearon, E. P-1818, P-1929
Gedik, A. P-1218
Geelhoed-Duijvestijn, P. P-1775
Geenaway, T. P-1879
Geh, E. OP-0469
Gehr, B. P-1405
Geiger, K. PD-0688
Geiss, L. OP-0444
Geiss, L.S. OP-0237
Gelen, B. AbT-2018
Gelisgen, R. PD-0799
Gen, R. AbT-2036
Genc, S. P-1176
Genders, A.J. OP-0092
Gendler, S. P-1628
Genovese, S. PD-1026
Gentile, F.M. PD-0959
Gentile, S. PD-0822, PD-0844, PD-0959
George, J. 0016
Georgeff, M. 0109
Gera, N. P-1412
Germán Salló, M. AbT-2165
German, M. 0335
Gerst, F. OP-0449
Gerstein, H. 0487
Gessl, A. PD-0771
Gezawa, I. AbT-2161
Ghafoor, E. P-1568, P-1666, P-1671, PD-0857
Ghanassia, E. OP-0606
Ghareaghaji, R. P-1224
Ghasemi, M. AbT-2037
Ghosh, S. P-1219, P-1428
Ghulam Hussain, B. AbT-2006
Ghvaladze, T. P-1719, P-1934
Giampaoli, V. AbT-2073, P-1651, P-1710
Gibbons, K. PD-0865
Gibert, Y. P-1133, PD-0735
Gibson, A. PD-0938, PD-0939
Giguère, G. PD-0868
Giguere, Y. OP-0581
Gil Anguita, C. P-1339
Gilboa, A.Y.A. 0334
Giles, J. P-1569, P-1629
Gilfillan, C. AbT-2089
Gill, H. P-1819
Gilliam, L. P-1052
Gillis, M.R. 0631
Giménez, M. P-1623
Gimeno, S.G.A. P-1772
Giorda, C.B. PD-0959, PD-1026
Giorgi Rossi, P. P-1857
Giral, P. P-1090
Giraudo Abarca, F. P-1615
Giri, A.K. OP-0230, P-1234, PD-0774
Giri, S. PD-0752
Giriwono, P.E. PD-0658
Gisbert, C. PD-0948
Gitelman, S.E. OP-0080, P-1047
Gitonga, E. OP-0279
Gitt, A.K. OP-0647
Giuseppe, D. OP-0067
Giusti, L. OP-0416, OP-0443
Gladkih, A. P-1203
Glass, L.C. P-1398, P-1410
Glazynova, A. P-1240
Gledhill, A. PD-0865
Glindorf, M. PD-0830
Glinkina, I. P-1827
Gloyn, A. OP-0250
Gluckman, P.D. 0479
Gmitrov, J. AbT-1989, AbT-1989, P-1148, P-1148
Gnudi, L. P-1359, P-1967, P-1983, PD-0796, PD-0946, PD-1022
Gogeliene, L. P-1145
Goh, H.M. P-1793
Goh, S. P-1980
Goh, S.Y. OP-0265, P-1261, P-1561
Gokdag, E. P-1218
Gokulakrishnan, K. PD-0769
Goldberg, I.J. OP-0592
Goldfracht, M. OP-0586
Goldstein, I. P-1060
Goldstein, N. PD-0758
Golge, N. P-1222
Golm, G.T. P-1068
Gomathi, K.G. P-1235
Gomes, K. AbT-2039, P-1372
Gomes, K.B. AbT-2056, P-1160, P-1355, PD-0660, PD-0705
Gomes, L.C. P-1370
Gomes, M. P-1981
Gómez Gómez, J. P-1056
Gómez Huelgas, R. P-1293b
Gómez Sánchez, M.B. P-1279
Gómez, A. AbT-2077, P-1308
Gómez, B. P-1315
Gómez, R.E. PD-0666
Gomez-Gonzalez, A. P-1186
Gómez-Huelgas, R. OP-0267
Gómez-Meza, M.V. PD-0849
Gomez-Peralta, F. PD-0679, P-1599
Gómez-Pérez, A. AbT-2072
Gomis, R. P-1095, P-1096, PD-0670, PD-0968
Gonçalves, G. P-1142
Gondal, G.M. P-1896
Gönder-Frederick, L. OP-0069
Gonderen, K. AbT-2040
Gonen, A. OP-0629
Gong, Y. P-1319, P-1353, PD-0693
Gonuguntla, S. 0528
Gonulalan, G. P-1570
Gonzalez Gonzalez, P. AbT-2058, AbT-2126
González Molero, I. AbT-2135
Gonzalez, C. PD-0935
Gonzalez, L. P-1909
González, S. P-1273
Gonzalez-Aguilera, B. AbT-2034

Gonzalez-Canudas, J. AbT-2052
Gonzalez-Galvez, G. P-1406, P-1409, PD-0960, OP-0295
Gonzalez-Molero, I. P-1577, PD-1025
Gonzalo, I. AbT-2129, P-1548
Goode, J. 0491
Goorden, I. AbT-2119
Göran, T. P-1974
Gordeladze, M. P-1641, P-1972
Gordin, D. PD-0702
Gordon, B.A. P-1477
Gordon, L. PD-0915
Goren Atalay, N. P-1616
Gorgel, A. P-1616
Gorrell, M.D. OP-0061, P-1313
Górriz, J.L. PD-0968
Gorshunska, M. P-1203
Gosadi, I.M. P-1286
Gostiljac, D. P-1368, PD-0942
GoT2D Consortium, . OP-0250
Gothwal, S. P-1216, P-1865
Goto, M. P-1320
Gottlieb, P.A. P-1047
Gougeon, R. OP-0063, OP-0233
Gough, S. 0303, P-1877
Gough, S.C.L. OP-0421, OP-0422, P-1267, P-1298, P-1302
Goult, B.T. OP-0628
Gourdy, P. P-1327, P-1328, P-1329
Gourlay, K. AbT-2074
Gowda, A. P-1511
Goyal, G. P-1220
Goyder, E.C. P-1286
Gracheva, S. P-1240
Gracia, M.L. P-1332
Gradiser, M. P-1057
Graham, K. P-1133
Graja, S. AbT-2082, P-1728
Grant, P.J. 0320
Grant, S.F.A. OP-0251
Grarup, N. OP-0254
Graue, M. AbT-2019, OP-0270, P-1632
Gray, L.J. PD-0674
Gray, S. OP-0620
Gray, S.P. OP-0622, PD-0780
Graziela da Costa Santos, G.C.S. AbT-2093
Greci, M. P-1857
Green, J.B. PD-0700
Green-Mitchell, S. OP-0594
Greenaway, T. AbT-2134
Greenbaum, C. 0171
Greenbaum, C.J. OP-0080
Greenberg, R. P-1633
Greene, A. PD-0846
Greene, A.C. PD-0910
Greene, S. 0298
Greene, S.A. PD-0910
Greenfield, J. OP-0231, P-1287
Greenfield, J.R. OP-0057
Greenwood, D. OP-0275
Greenwood, D.A. P-1549
Greer, R.M. PD-0689
Gregg, E.W. OP-0237, OP-0444, PD-1004, PD-1006
Grégoire, J.P. PD-0868
Gregorevic, P. OP-0095
Griesbach, R. PD-0738
Griffin, S.J. OP-0059, OP-0440, OP-0651, PD-0909
Grigorovich, A. AbT-2140
Grillett, S. PD-0805
Groop on behalf of the FinnDiane Study Group , P.H.
Groop, L. 0302
Groop, P. 0361
Groop, P.H. PD-0702
Gros-Herguido, N. AbT-2034
Grossmann, M. P-1959
Grueter, C. 0541
Grumitt, J. 0178
Grynnerup, A. PD-0748
Grzeszczak, W. AbT-2145, P-1456, P-1465, PD-0766
Gu, L. PD-0886, PD-0903
Gu, M.J. P-1377
Gu, Y. PD-0691
Guadrón-Llanos, A.M. AbT-2004
Guanipa, C. P-1855, P-1951
Guariguata, L. 0084, OP-0653
Gucciardi, E. PD-0982
Gudala, K. P-1842, P-1878
Guelfi, K.J. OP-0070
Guell, C. PD-0847
Guénette, L. PD-0868
Guerrero, M. P-1273, P-1274
Guijarro-Merino, R. OP-0267
Guilherme Mattar, G.M. AbT-2093
Guillaumie, L. PD-0868
Guimarães, M. P-1142
Guira, O. AbT-2118, AbT-2162, AbT-2163, PD-0877
Guiver, T. OP-0114
Guja, C. P-1891
Gul, N. P-1697, P-1275
Gulati, S. P-1092
Guler, S. P-1058, P-1373
Gulliford, M. P-1359, P-1967, P-1983, PD-0796, PD-0946, PD-1022
Gulmira Abduakhassova, M.S. OP-0296
Gumus, P. AbT-2035
Gunaid, A. P-1905
Gunasekaran Vaz, S. P-1423
Gunawardena, H. P-1357
Gunnarsson, R. PD-0657
Guo, J. P-1103
Guo, L. P-1169
Guo, X. OP-0115, P-1900, P-1901
Guo, Y. PD-0972
Gupta, A. PD-1000
Gupta, K. AbT-2136, P-1543
Gupta, N. OP-0579, PD-0795
Gupta, P. P-1622
Gupta, R. OP-0411, P-1134, P-1375, P-1601, P-1661, P-1787, PD-1000
Gupta, S. AbT-2136, P-1543
Gupta, Y. OP-0579
Gurban, J. PD-0676
Gurdasani, D. OP-0238
Gurnazi, A. AbT-1994
Gurrin, L. AbT-2144, PD-0963
Gutierrez, C. PD-1025
Gutt, M. P-1855, P-1951
Guwatudde, D. P-1974
Guzman, C. P-1410
Gyawali, P. PD-0753
Gydesen, H. P-1054, P-1775

H

Ha, J. AbT-2117, PD-0773
Ha, V. AbT-2143, P-1917, P-1926, PD-0977
Haagensen, M. PD-0714
Haahr, H. P-1400, P-1407, PD-0745
Haahr, H.L. PD-0791
Haak, T. P-1722, P-1741
Haas, M. OP-0638
Haas, W. P-1834
Haastert, B. P-1931
Hababeh, M. 0526
Habashy, B. P-1246
Habib, R. AbT-2003
Hackney, D. OP-0453
Haddad, F.H. AbT-2026
Haddad, J. AbT-2026, OP-0295, P-1262, P-1409
Hadgraft, N. PD-0803
Hadj Kacem, F. AbT-2044
Hafez, M.A. OP-0585, P-1730, PD-0867
Hafizur, R. P-1135, P-1236, P-1385, PD-0724
Hagey, L. OP-0627
Hague, W. 0481
Haider, A. P-1499
Hajek, M. PD-0750
Haji Zaine, N. P-1059, P-1774
Hajjaji, I. P-1259
Hajmrle, C. P-1421
Hakeem, R. AbT-2137, P-1925
Hakkarainen, A. OP-0232
Halabi, A. PD-0666
Halberg, P.B. OP-0279
Hale, K. PD-0827
Halimi, S. OP-0477
Hall, K.R. 0052
Hall, M.S. P-1634
Hall, S. P-1559, P-1560
Halliday, J.A. OP-0242
Halling, J. PD-0993
Haluzik, M. P-1143, P-1451
Hamada, I. P-1348
Hamaguchi, T. OP-0417
Hamamoto, H. PD-0694
Hamamoto, Y. OP-0423, PD-0701
Hamaoka, T. P-1306
Hamar, P. P-1138
Hamdy, H. P-1864
Hamdy, O. P-1625
Hameed, A. P-1385
Hamet, P. OP-0257
Hamid, N.S. P-1746
Hamilton, D. P-1825
Hammer, G.L. OP-0070
Hammerby, E. P-1406, P-1898, P-1902, PD-0741, PD-0960
Hammes, H. 0504
Han Cho, N. OP-0653
Han, J. PD-0964
Han, P. P-1464

Han, X. AbT-2029, P-1288, P-1343, PD-0734
Han, X.Y. AbT-2049, P-1210, P-1258, P-1284, P-1289, P-1312, P-1460, PD-0776
Hanafusa, T. PD-0955
Hanas, R. P-1515, PD-0863
Hanchang, W. PD-0732, PD-0733
Hancox, R.J. P-1768
Hancu, N. P-1891
Handelsman, D. P-1959
Handelsman, Y. P-1302, PD-0673
Haneda, M. OP-0450, PD-0713
Hanefeld, M. PD-0690
Hang, J. P-1824
Hanif, W. PD-0674
Hankins, A. OP-0275
Hanley, A. 0025
Hannoun, Z. AbT-2080, PD-0961
Hansen, A.K. OP-0089
Hansen, B. P-1626
Hansen, C.R. P-1550
Hansen, C.T. PD-0744
Hansen, M. PD-0993
Hansen, U.M. PD-0840
Hanson, J. AbT-2101, AbT-2102, OP-0282, P-1758
Haouat, E. AbT-2044
Haq, M.M. P-1820
Haque, M.A. P-1129
Haque, S. P-1495, P-1945
Hara, M. PD-0992
Hara, N. P-1838, P-1840
Hara, Y. OP-0419, P-1243
Harashima, S. P-1677, P-1680, PD-0841
Harcourt, B. OP-0591
Harcourt, B.E. OP-0090, P-1118, P-1120, P-1233, PD-0784, PD-0785
Hardikar, A.A. PD-0731
Harding, A. PD-0793
Harding, J. OP-0114, P-1818
Harding, J.L. OP-0408, PD-0979
Hare, M.J.L. OP-0059
Harima, H. P-1772
Harimurti, K. P-1040
Häring, H.U. OP-0449
Harish, R. P-1849, PD-1021
Hariya, N. P-1320
Harjutsalo, V. PD-0711
Harkema, J. OP-0598
Harman-Boehm, I. PD-0758
Harno, K. 0108
Harper, C.A. P-1829
Harrap, S. OP-0257
Harries, A. 0526
Harris, M. PD-0689, PD-0865
Harris, S. 0261, AbT-2125, OP-0650, P-1268, P-1303, P-1304
Harrison, C. PD-1013
Hart, G.W. PD-0778
Harvey, F. OP-0257
Harwood, M. 0327
Hasegawa, M. PD-0790
Hashimoto, N. P-1389, P-1390
Hashiramoto, M. P-1462
Hashmi, A. 0524
Hasnain, S.Z. OP-0591
Hasnani, D.J. P-1862
Hasni, Y. AbT-2082, P-1728
Hassan, M.S. P-1292, P-1973, PD-0717
Hassan, N. P-1746
Hassan, S. OP-0431, P-1890
Hassan, Z. AbT-2003, P-1383
Hassanein, M. P-1523
Hasselby, J.P. OP-0089
Hassoun, A. P-1157
Hastrup, H. PD-0745
Hatzinikolas, G. P-1113
Hatzlhoffer Lourenco, B. PD-0984
Hauck, B. 0029
Hauptman, J. 0350
Hausken, M.F. P-1632
Havitcioglu, H. P-1218
Hawkins, C. P-1497, P-1500, PD-0814
Hayashi, N. PD-0692
Hayashi, T. AbT-2142, P-1906
Hayek, A. 0528
Hayes, B. AbT-2112, P-1794, P-1798, P-1799
Hayman, N. 0174
Haynes, A. PD-0930
Haynes, B. OP-0594
Hazelwood, K. PD-0928
He, H. P-1784
He, R. P-1212
Heard, A. P-1627
Heather, A. P-1072
Hecking, M. P-1392
Hegar, R. OP-0272
Hegazi, R. P-1625
Hehnke, U. P-1046, PD-0692, PD-0693, PD-0697
Heinonen, S. OP-0232
Heise, J. P-1418
Heise, T. OP-0068, P-1400, PD-0745, PD-0791
Heitz, F. OP-0620, PD-0780
Hejar, A.R. P-1178, P-1915
Helfand, S.L. OP-0229
Heller, S. OP-0073, OP-0412, P-1297, P-1298, P-1299, P-1322, PD-0676
Heller, S.R. 0537
Helms Andersen, T. PD-0840
Hemalatha, G. P-1205, P-1361
Hempler, N.F. PD-0840
Henderson, J. P-1751
Henderson, J.A. 0567
Hendrieckx, C. OP-0242, OP-0281, PD-0926
Hengesbach, C. AbT-2100, P-1911
Heni, S. PD-0756
Henriksen, O. P-1406, P-1883, P-1898, P-1902, PD-0741, PD-0960
Henry, R.R. PD-0680
Henry, S.L. PD-0663
Henstridge, D.C. OP-0596, OP-0597
Herber, G. PD-0987
Herman, W. P-1628
Herman, W.H. 0556, AbT-2141
Herman-Edelstein, M. PD-0783
Hermanns, I. AbT-2100, P-1418, P-1911
Hermanns, N. OP-0475, P-1300, P-1670, P-1722, P-1726, P-1741, PD-0924
Hernandez Cordero, V. P-1333
Hernandez Lavado, R. P-1333
Hernández Torres, A. P-1056
Hernandez, J.R. OP-0404
Hernández, M. P-1831
Hernando Herrero, V. P-1611, PD-0923
Herron, J. P-1686
Heruc, G. OP-0425
Herz, M. PD-0690
Heshmat, R. AbT-2139
Hesketh, K. 0324
Hess, M. PD-0838
Hettiarachchi, C. OP-0644
Hevener, A. 0492
Hevener, A.L. OP-0596, OP-0597
Hewitt, A.W. P-1214
Heymann, A. AbT-2114, P-1060
Heywood, S.E. PD-0663
Hidalgo, M. OP-0645, P-1452, P-1502
Hidayet, S. P-1193
Higaki, Y. PD-0992
Higashiyama, H. P-1680
Higgins, G.C. 0497, P-1061
Higuchi, K. PD-0777
Hill, D.J. PD-0737
Hill, M. PD-0750
Hill, P. P-1586
Hill, S.R. 0194
Hill, T. PD-0737
Hillinger, M. P-1708
Hillis, G.S. PD-1003
Hilton, D. AbT-2146
Hincelin-Mèry, A. P-1066
Hinton, A. 0528
Hirai, A.T. P-1772
Hirano, F. P-1171, P-1685
Hirano, T. P-1105
Hirao, K. P-1395
Hird, K. OP-0654
Hiroe, Y. P-1197
Hirose, H. P-1168
Hirose, T. PD-0757
Hirota, Y. P-1389, P-1390
Hirschler, V. OP-0645, P-1452, P-1502
Hirshberg, B. P-1321, P-1346
Hirst, K. 0030
Hirst, M. 0133, 0345
Histed, M. OP-0446
Hitman, G.A. 0520
Hitos, K. P-1059, P-1774
Hiwatashi, K. PD-0658

Hiyama, S. P-1441
Hiyoshi, T. P-1429, PD-0695
Hizar, S. AbT-2018
Ho, E. P-1793
Hoang, V. OP-0588
Hobbs, T. OP-0072
Hobbs, T.M. P-1302
Hod, M. P-1505, PD-0891
Hodson, L. 0014
Hoehn, K.L. 0467, P-1051
Hoffman, N.J. 0467, OP-0589, P-1051
Hogarth, J. PD-0812
Hokazono, H. PD-0658
Holden, L. PD-0865
Holla, V.V. P-1152, P-1808
Holland, T. P-1512
Hollander, P. PD-0744
Holle, R. PD-1028
Hollekim, S.M. P-1188
Holly, J. P-1825
Holman, R.R. PD-0700
Holmes, C. P-1585
Holmes-Truscott, E. OP-0281
Holst, J.J. P-1267
Holt, R. P-1653
Holt, R.I.G. P-1726, P-1740
Hombrebueno, J. PD-0671
Home, P. 0147, OP-0268, OP-0295, P-1406, P-1409, P-1417, P-1898, P-1899, P-1902, PD-0741, PD-0960
Home, P.D. P-1718
Hommel, E. OP-0434, P-1683, P-1714, PD-0748, PD-0749, PD-0869
Hon, G.M. P-1973
Honda, H. P-1121, P-1121
Honda, I. P-1677
Hong, B. OP-0614
Hong, C. OP-0628
Hong, H.C. P-1446
Hong, J.H. P-1971
Hong, O.K. AbT-1996, OP-0056, P-1189
Hong, S.M. P-1163
Hong, T.P. P-1270, P-1271
Honjo, J. OP-0450, PD-0713
Honjo, S. OP-0423, PD-0701
Hood, G.A. P-1600
Hopkins, D. P-1648
Horikoshi, M. OP-0252
Horita, M. PD-0992
Horiuchi, T. P-1283
Horman, K. PD-0758
Horne, R. P-1745
Horng, M. PD-0678
Hornung, R. P-1656
Horowitz, M. 0162, OP-0424, OP-0425, P-1473, PD-0712, PD-0765, PD-0767
Horton, M. 0264
Horvath, K. P-1834
Hoshina, S. P-1062, P-1078
Hosoda, K. P-1677
Hosokawa, S. P-1076
Hossain, M.F. PD-1010
Hossain, M.T. OP-0642
Høst, D. P-1550
Hoti, K. AbT-2047
Hotta, N. 0161, P-1264, PD-0954
Hou, X. OP-0060
Hougaard, A. PD-0748, PD-0749
Houinato, D. PD-1020
Hounslow, N. P-1090
Houssay, S. PD-0935
Houweling, S.T. PD-0995, PD-1029
Hovorka, R. 0375
Howard, G. P-1951
Howard, N.J. P-1769
Howarth, D. P-1606
Howell, M. OP-0080, P-1047
Howlett, K. PD-0655
Hoy, W. OP-0102, OP-0640, PD-0820
Hoy, W.E. 0262, PD-0809
Hsiao, S.H. P-1544
Hsieh, C.C. AbT-1987, P-1358
Hsieh, M. PD-0890
Hsieh, T.J. PD-0729
Hsu, B.R. P-1422
Hsu, C.Y. PD-0818
Hsu, F.C. P-1108
Hsu, H.C. P-1510
Hsu, H.Y. AbT-2013
Hsu, P.C. OP-0113, PD-0953
Hu, F.B. OP-0614
Hu, G. OP-0580
Hu, L.H. OP-0600
Hu, M. P-1343
Hu, S.C. P-1544
Hu, Y. P-1190
Hua, S.C. AbT-2013
Huang, A. OP-0601, P-1169
Huang, C. PD-0829
Huang, C.C. AbT-1987
Huang, C.H. P-1295, P-1422
Huang, C.N. AbT-2120
Huang, H. P-1784
Huang, K.C. PD-0770
Huang, S. P-1386
Huang, T. PD-0890
Huang, W. PD-0678
Huang, X. P-1151, PD-0768
Huang, X.F. OP-0617, P-1367, P-1447
Huang, Y. P-1116, P-1229, PD-0826
Huang, Y.L. AbT-1987
Huang, Y.Y. OP-0613, P-1221, P-1295, P-1422, PD-0707
Huang, Z. P-1586
Huckova, M. P-1444, P-1445
Hudson, M. 0569
Hué, A. P-1604
Huerta-Olvera, S.G. AbT-2004
Hughes, J.T. PD-0820
Hughes, T.C. 0549
Huh, B. P-1194
Huh, J.H. P-1892
Humpert, P.M. PD-0711
Humphrey, R.K. 0528
Humphrey, S.J. OP-0589, P-1051
Hung, C.C. PD-0707
Hung, H.C. OP-0091, P-1199
Hung, P.H. PD-0729
Hung, S.H. PD-0770
Hung, S.Y. P-1221
Hung, T. OP-0439
Hunger, M. PD-1028
Hunt, K. OP-0643
Hur, K. P-1194, P-1928
Hur, K.Y. P-1074, P-1075
Hurd, J. P-1497, PD-0810, PD-0814
Hurel, S. P-1230
Hussain, A. AbT-2132, P-1209, P-1858, P-1871, P-1925
Hussain, M. P-1529, PD-0775
Hussain, M.A. PD-0908
Hussein, W. PD-0902
Hussein, W.I. 0111
Hussein, Z. OP-0295, P-1259, P-1262, P-1401, P-1546
Hutchinson, D. PD-0728
Hutchinson, D.S. P-1091
Huus, K. OP-0291
Huyghe, J.R. OP-0252
Hwang, J.K. P-1517, P-1781
Hwang, S. P-1265
Hwang, Y. P-1430
Hwang, Y.C. P-1037
Hyo, T. P-1081, P-1114, P-1115

I

Ibragimova, I. PD-0851
Ibrahim, M. AbT-2116
Ibrahim, S. P-1523
Ide, Y. P-1838, P-1840
Idrisov, A.S. AbT-2105
Iglay, K. P-1935
Iglesias, J. AbT-2052
Iglesias, P. P-1096, P-1097
Iglesias, R. P-1599
Ihm, J. PD-0736
Ihm, S.H. PD-0736
Ikawa, T. OP-0417
Ikeda, H. OP-0423, PD-0701
Ikeda, T. PD-0757
Ikeda, Y. P-1404b
Ikejiri, M. P-1480
Ikem, R.T. P-1621
Ilag, L.L. P-1049
Ilic, M. P-1368, PD-0942
Ilin, A. P-1240
Imagawa, A. PD-0955
Imai, K. P-1578
Imai, S. 0137
Imai, Y. 0540
Imaizumi, T. PD-0992
Imamine, R. P-1264
Imbe, H. PD-0955
Imperatore, G. OP-0237, PD-1004, PD-1006
Imtiaz Hasan, M. P-1261
Inaba, Y. P-1513
Inagaki, N. P-1677, P-1680, PD-0841
Inal, B. PD-0892
Inashvili, E. P-1309, P-1591, P-1605
Inazawa, T. P-1105
Inbakumari, M. P-1039
Indiani, L. AbT-2073
Indiani, L.i. P-1651
Indrajit, M. P-1463
Indyk, J.A. P-1063

Ingle, M. P-1686
Ingram, E. P-1064
Ingwersen, S. P-1322
Inker, L.A. PD-0818
Inoguchi, T. OP-0427
Inomata, J. P-1306
Inoue, M. P-1838, P-1840
Inoue, O. P-1306
Inoue, T. OP-0427
Inoue, Y. P-1076
Iosup, A. OP-0606, P-1250, P-1717
Iqbal, N. P-1346, PD-0708
Iqbal, T. P-1896
Iraj, B. OP-0456
Irakleianou, S. P-1434
Ireland, V. PD-1002
Irie, J. P-1168
Irungu, S. P-1545
ISAAC Phase Three Study Group P-1768
Isaacs, K. PD-0803
Isada, A. P-1783
Ishaak, M. P-1246
Ishibashi, T. P-1363
Ishibashi, Y. PD-0683
Ishigaki, Y. 0132
Ishii, H. AbT-2041, P-1300
Ishikawa, H. P-1197
Ishikawa, K. P-1363
Ishizuka, T. PD-0681
Ishtiaq, O. P-1592, P-1896
Isik, S. P-1058, P-1373
Islam, F. AbT-2084, P-1851, PD-1012
Islam, F.M.A. PD-1010
Islam, M. P-1851, P-1940, PD-0684, PD-1012
Islam, M.S. P-1136, P-1463
Islam, M.T. PD-1010
Islas-Carbajal, M.C. AbT-2004
Isli, S. P-1616
Ismail, E. OP-0431
Ismail-Beigi, F. P-1108
Ismailov, S. AbT-2022, P-1128, P-1483, PD-0931
Itaya-Hironaka, A. P-1425
Ito, S. P-1429, PD-0695
Ito, Y. P-1783
Itoh, H. P-1168
Ivanga, M. OP-0257
Ivers, N. P-1630
Iversen, M.M. OP-0270
Iwabu, M. 0300
Iwabu-Okada, M. 0300
Iwasaki, M. P-1115
Iwasaki, Y. PD-0757
Iwase, M. PD-0956
Iwashima, F. P-1283
Iwata, M. PD-0777
Iwuala, S. P-1895
Izumoto, T. P-1319, P-1353

J

Jaacks, L. OP-0112
Jaacks, L.M. P-1916
Jaber, L. P-1872
Jackson, G. 0505
Jackson, S. 0181
Jacob, J. P-1375
Jacobs, M. 0168
Jacques, P.F. PD-0866
Jacquier, J. OP-0116
Jadoon, N.A. PD-0775
Jaffri, S. P-1618, P-1756
Jagwani, D. P-1689
Jahan Mumu, S. P-1806
Jahan, S. P-1482, PD-1011
Jahanshahi, A. AbT-2127
Jain, A. P-1401, P-1402
Jain, P. AbT-2125, P-1883, PD-1032
Jain, S. AbT-2063, P-1865
Jaiswal, N. AbT-2136
Jalali, M.T. AbT-2127
Jalali, R. AbT-2149, P-1941
Jalang'O, G.A. 0224
Jallo, M.K. P-1235
Jamal, A. P-1146, P-1836, P-1837
James, A. P-1375, P-1530, P-1602
James, D. P-1285
James, D.E. 0467, OP-0589, P-1051
James, P. 0545
James, S. AbT-2075, P-1601, P-1661, PD-0934
Jan Mohamed, H.J. AbT-2020
Janati Moghadam, M. PD-0894
Jandeleit-Dahm, K. 0181, OP-0620, OP-0622
Jandeleit-Dahm, K.A. OP-0621, PD-0780, PD-0782
Janeski, H. OP-0066, P-1368
Jang, E.H. P-1432
Jang, J.S. P-1805
Janjua, N.Z. P-1896
Jansa Morato, M. PD-0834
Jansà, M. P-1623
Jansen, E. P-1203
Janus, E.D. PD-0944
Januszewska, A. OP-0405
Januszewski, A. PD-0944
Jaross, N. P-1645
Jashi, M. AbT-2104
Javanbakht, M. P-1982
Javier Ampudia-Blasco, F. P-1055
Jawad, F. PD-0879
Jayalath, V.H. AbT-2143, P-1926
Jayasinghe, S. P-1574
Jayasuriya, R. P-1937, P-1946
Jayawardena, R. AbT-2158, OP-0410, P-1830
Jazbec, A. AbT-1992, P-1239
Je, H. P-1805
Jean-Baptiste, E. AbT-2111, AbT-2131
Jebakumar, C. PD-0854
Jebarani, S. PD-1009
Jefferies, C. P-1656
Jemel, M. AbT-2082
Jen, Y. P-1596, P-1716
Jeng, C.Y. P-1364
Jenkins, A. 0264, P-1416, PD-0944
Jenkins, A.B. P-1287
Jenkins, A.J. P-1733
Jenkins, D.J.A. AbT-2143, P-1917, P-1918, P-1926, PD-0977
Jennings, G. 0263
Jensen, H.S. AbT-2057
Jensen, K. P-1298
Jensen, L. OP-0073, P-1322, PD-0676
Jeon, E.J. P-1374
Jeon, J.H. PD-0685
Jeon, S.W. P-1919
Jeon, W.S. PD-1024
Jeon, Y.K. P-1804
Jeong, I. P-1430
Jeong, I.C. P-1037
Jeong, J. P-1191, PD-0824
Jeong, J.Y. PD-0685
Jerums, G. P-1048, P-1773, PD-0709, PD-0710, PD-0820
Jesmin, S. P-1177, P-1940, PD-0684
Jesson, A.M.R. P-1952
Jesudason, D. P-1959
Jesudason, D.R. P-1201
Jha, B. PD-0753
Jha, J. PD-0783
Jha, J.C. OP-0622
Jha, S. P-1291, P-1375, P-1403, P-1530, P-1602, PD-0884
Jhala, U.S. 0528
Jhingan, A. OP-0297, OP-0458
Ji, L. 0154, AbT-2029, AbT-2112, OP-0112, OP-0115, P-1169, P-1192, P-1288, P-1437, P-1464, P-1673, P-1794, P-1799, P-1900, P-1916, P-1920, PD-0708, PD-0776, PD-0933, PD-0945
Ji, L.N. AbT-2049, OP-0439, P-1210, P-1258, P-1284, P-1289, P-1312, P-1460
Ji, M. P-1169
Ji, Q.H. OP-0439
Jia, L.I. P-1455
Jia, W. OP-0060, OP-0115, P-1103, P-1190, P-1212, P-1595, P-1821, P-1824
Jia, W.P. OP-0604, P-1391
Jiang, H.L. OP-0600
Jiang, J.Y. P-1698
Jiang, Y. P-1798
Jie, Z. P-1437
Jimenez Gallardo, J.L. P-1589
Jiménez Lira, R. P-1663
Jiménez Varo, I. P-1141
Jimenez-Varo, I. AbT-2034
Jimeno, C. P-1681
Jimeno, C.A. PD-0947
Jimmy Nebbi, N. AbT-2075

Jin, H.Y. P-1065, P-1073, PD-0672
Jin, S. P-1630, P-1928
Jin, S.M. P-1074, P-1075
Jin, W.J. PD-0988
Jin, X. AbT-2049, P-1343
Jindal, K.K. P-1342
Jindal, S. P-1412
Jinga, M. P-1204
Jirkovska, A. P-1119, PD-0665
Jmal, M. P-1728
Joannides, C.N. P-1387
Jobling, S.A. P-1041
Jöckel, K.H. PD-1007
Jódar, E. P-1727, PD-0968
Joensen, L.E. P-1740
Joglekar, C. OP-0067b
Joham, A. PD-0985
Johansen, C. P-1683, PD-0869
Johansen, O.E. OP-0081, PD-0696
Johansen, T. OP-0068, P-1268, P-1297, P-1299, PD-0789
Johansson, T. PD-0836
John, T. P-1503
Johnson, J. 0610, OP-0116, P-1398
Johnson, J.A. P-1649, P-1938
Johnson, M.E. OP-0251
Johnson, R. OP-0602
Johnson, S.T. P-1649, P-1938
Johnson, T. P-1525
Johnston, L. P-1795
Johnstone, R. PD-0739
Jokelainen, J. PD-0941
Jonassen, I. P-1414
Jones, G.D. PD-0820
Jones, K.L. OP-0424, P-1473, PD-0712
Jones, N. P-1519
Jones, T.W. OP-0070, OP-0119, P-1555, PD-0917, PD-0930
Joohs, R. P-1955
Jordan, J. OP-0229
Joseph, A. OP-0654, P-1161, P-1178, P-1915
Joseph, J. PD-0721
Joshi, A. P-1947
Joshi, M. P-1847
Joshi, M.J. PD-0996
Joshi, P.P. P-1914, PD-0980, PD-0981
Joshi, R. OP-0579
Joshi, S.R. P-1411, P-1862, P-1914, PD-0980, PD-0981
Jothydev, K. OP-0265
Jothydev, S. AbT-2107, OP-0294, P-1552, P-1844
Joubert, E. OP-0602
Jovanovska Misevska, S. P-1485
Jovanovska, B. P-1485, P-1516
Joyce, C. AbT-2075
Joyo, A. AbT-2075
Juang, J.H. OP-0088
Juarascio, A.S. P-1608
Juban, N. P-1681, PD-0947
Jukarainen, J.S. OP-0232
Juma, R. P-1833
Junai, S. P-1166
Junaid, N. P-1832
Jung, C.H. P-1069, P-1919, PD-0999
Jung, E.D. P-1374
Juntula, J.J. 0467
Junutula, J.J. P-1051
Juonala, M. P-1889
Jurczuk, G. PD-0666
Jureviciute, J. P-1735
Jurgeviciene, N. P-1735
Justice, T.D. OP-0070

K

Kaba-Dieng, K. PD-0859
Kabir, N. P-1135, P-1236, P-1385
Kaboré, P.R. AbT-2118, AbT-2162
Kachhawa, G. PD-0795
Kadir, M.H. P-1969, PD-0951, PD-1023
Kadir, M.M. OP-0583
Kadowaki, T. 0300
Kadwa, M.Y. P-1157
Kaga, H. P-1429, PD-0695
Kagimura, T. PD-0692
Kahleova, H. PD-0750
Kahn, C.R. 0346
Kahn, S.E. 0301, 0338, AbT-2142
Kahol, K. P-1511
Kaikou, Y. P-1341
Kaiser, G. OP-0449
Kajita, K. PD-0681
Kakishita, H. P-1344
Kakoma, J.B. AbT-2017
Kaku, K. 0353, P-1462
Kalaiyarasi, G. PD-0800
Kalic, R. AbT-2051, OP-0432
Kallinikou, C. P-1316
Kalobu, J. AbT-2109
Kalra Sanjay, S. AbT-2079
Kalra, S. AbT-2145, OP-0455, P-1300, P-1456, P-1465, P-1653, P-1670, P-1729, PD-0766, PD-0845, PD-0922
Kalweit, K.L. OP-0271
Kamal, M. AbT-2098
Kamala, T. P-1527, P-1587, P-1712, PD-0887
Kamali, A. OP-0238
Kamano, J. P-1852, PD-0875
Kamano, J.H. P-1669
Kambe, H. P-1906
Kameishi, C.K. AbT-2091
Kamel, M. P-1523, PD-0756, PD-0874
Kamiya, H. 0033
Kammoun, I. AbT-2044
Kamura, Y. PD-0777
Kanaan, I. PD-0727
Kanai, A. P-1264
Kanakatte Prasanna Kumar, M. AbT-2079
Kanaujia, V. P-1819
Kanaya, A. 0210
Kanazawa, I. P-1175
Kanda, T. P-1168
Kande Vidanalage, C.J. AbT-2016, OP-0644
Kane, J. OP-0611
Kaneko, K. PD-0954
Kaneko, S. OP-0093, P-1306, P-1395, P-1433
Kanellakis, P. OP-0621
Kanerva, N. PD-0975
Kang, E. P-1323
Kang, E.S. AbT-2053, P-1265, P-1892, PD-0950
Kang, M.R. PD-0729
Kang, S. AbT-2117, P-1165, PD-0773
Kang, S.K. P-1069, PD-0999
Kankova, K. P-1484, P-1487, P-1237
Kannan, A.T. P-1679
Kanpurwala, M.A. AbT-1997, P-1162
Kant, J. P-1043
Kanter, M. P-1101
Kantharidis, P. 0022, OP-0090, PD-0783, PD-0785
Kao, B.R. OP-0613
Kaoutarani, L. P-1567
Kapitza, C. P-1066
Kaplan, D.b. AbT-2073
Kaplan, S. P-1572
Kapoor, D. OP-0579
Kapoor, R. AbT-2045, AbT-2045, P-1149, P-1149, P-1846, P-1846, PD-0817, PD-0817
Kapoor, S. AbT-2045, P-1149, P-1220, P-1846, P-1888, PD-0817
Kaprio, J. OP-0232, P-1932
Kaptan, E. AbT-1985
Kaptanogullari, Ö.H. AbT-1998
Kapucu, H. AbT-2061
Kapur, A. 0018, 0562
Kapur, A.N.I.L. PD-0888
Kapur, K. P-1635
Kapur, R. P-1301, P-1303, P-1304, P-1775
Karaahmetoglu, S. P-1058
Karabulut, S. P-1130
Karaca, A. P-1222
Karaca, Z. AbT-2061
Karachentsev, Y. P-1155, P-1203
Karadeniz, S. P-1634
Karagoz, Y. P-1198
Karakaya, P. AbT-1998
Karakiliç, E. P-1373
Karalliedde, J. P-1359, P-1967, P-1983, PD-0796, PD-0946, PD-1022
Karamihos, E. PD-0657
Karandish, M. PD-0913
Karaoglu, K. P-1137
Karasik, A. P-1060
Karatug, A. P-1131

Karczewska-Kupczewska, M. PD-0722, PD-0725
Karekezi, C. OP-0279, P-1545, P-1709
Karim, M.N. AbT-2046, P-1209
Karimassery Ramaiyer, S. P-1800
Karkee, P. P-1694
Karlinskaya, M. P-1827
Karmali, R. AbT-2110
Karnafel, W. P-1077
Karpe, F. 0014
Karter, A. 0087
Karugu, L. P-1833
Karunamuni, N. P-1938
Karuniawati, A. P-1040
Karupaiah, T. P-1067
Kasai, Y. P-1472
Kashima, K. P-1344
Kasim, K. AbT-2011
Kasiulevicius, V. P-1687
Kaspers, S. OP-0081
Kasse, D. PD-0859
Katagiri, H. 0132, P-1474
Katashima, C. OP-0616
Katbaeva, G.A. AbT-2043
Kato, H. PD-0777
Kato, M. PD-0790
Kato, N. OP-0252, PD-0790
Katon, W. OP-0116
Katshanski, N. P-1572
Katsuno, T. OP-0417
Katte, J.C. P-1150, P-1614
Katulanda, P. AbT-2122, AbT-2158, OP-0410, P-1357, P-1574, P-1830, P-1939
Katz, L. P-1468
Katzeff, H.L. P-1068
Kaufman, A. P-1791
Kaufman, F. 0227, P-1511
Kaufman, F.R. PD-0893
Kaur, I. OP-0230, OP-0255, P-1234, PD-0774
Kaur, N. OP-0430
Kaur, P. P-1468
Kaur, T. P-1914, PD-0980, PD-0981
Kavalkova, P. P-1143, P-1451
Kawabe, H. P-1168
Kawada, K. P-1344
Kawaharada, R. PD-0723
Kawai, M. P-1264
Kawai, T. P-1168
Kawakami, H. PD-0778
Kawamori, R. P-1417
Kawamura, M. P-1105
Kawamura, T. 0161, P-1264, PD-0954
Kawasaki, E. OP-0430
Kawasaki, Y. PD-0701
Kawasaki-Ogita, Y. OP-0423
Kawazu, S. P-1933
Kaya, A. AbT-2076, P-1570
Kayal, A. PD-0800
Kazdova, L. PD-0750
Kaze, F. P-1150, P-1278
Kazimoglu, C. AbT-2010
Kazmierczak, G. P-1350
Ke, C. PD-0936
Keane, F.M. OP-0061
Keating, C. PD-1013
Kebede, T. P-1780
Keeffe, J.E. P-1829
Keeratiyutawong, P. PD-0927
Kegels, G. AbT-2109
Keid, A. P-1551
Keinänen-Kiukaanniemi, S. PD-0941
Kek, Z.L. PD-0786
Kekelashvili, K. AbT-2124
Kelishadi, R. AbT-2139
Keller, S. PD-0836
Kelley, D.E. OP-0426
Kelly, W. P-1535
Kelsall, L. P-1944
Kemp, B.E. OP-0235
Kempf, K. OP-0276, P-1748, P-1931
Kempler, M.S. P-1251
Kempler, P. P-1196, P-1251
Kendall, C.W.C. AbT-2143, P-1917, P-1918, P-1926, PD-0977
Kengne, A. P-1890
Kengne, A.P. P-1150, P-1292, P-1457, P-1973, P-1975, PD-0717
Kenilorea, G. PD-0974
Kennedy, A.P. OP-0468
Kennedy, C. PD-0805
Kennedy, M. 0566, OP-0476
Kentish, S. P-1113
Keogh, J.B. P-1202, P-1822, P-1923
Kern, T. PD-0669
Kerry, C. PD-0852
Kesavadev, J. AbT-2063, AbT-2107, OP-0294, P-1552, P-1844
Keshvari, S. OP-0587
Keskek Sahinoglu, N. P-1376
Keskek, S. P-1222, P-1376, P-1859
Keskin, L. P-1193, P-1540
Kessler, N. P-1628
Keuky, L. 0155
Kevat, D. P-1777
Kewming, S. P-1553
Key, C. OP-0586
Key, T. OP-0448
Khaburzania, R. AbT-2099
Khader, A. 0526
Khalaf, R.J. P-1948
Khalifeh, I. P-1311
Khalil, M.I. PD-1010
Khan, A. P-1388, P-1832
Khan, A.K.A. AbT-2083, P-1858, P-1871
Khan, F. P-1603, PD-0912
Khan, K. P-1099
Khan, M.I.H. P-1440, P-1609
Khan, M.Q. P-1435
Khan, N. P-1235
Khan, N.A. PD-0936
Khan, N.M. P-1234, PD-0774
Khan, S.T. P-1476
Khanam, M. PD-0876
Khanam, P.A. AbT-2152, OP-0642, P-1695, P-1839, PD-1011
Khandwala, F. P-1475
Khanolkar, M. P-1498
Khanolkhar, M. P-1493, P-1606
Kharal, H. P-1786
Kharal, Y. P-1786
Khasag, A. P-1166, P-1583
Khattab, M. AbT-2116, AbT-2160
Khatun, T. P-1940, PD-0684
Khaw, K.T. OP-0440
Khaw, N. P-1746
Khazrai, Y.M. P-1276, P-1277
Khetran, E. P-1524
Khiter, C. P-1942
Khochtali, I. AbT-2082, P-1728
Khodagholi, F. AbT-2037
Kholodova, E. AbT-2140
Khoo, G. P-1867
Khoo, J. OP-0442, PD-0786
Khoo, P. P-1285
Khookhor, O. PD-0763
Khorava, D. AbT-2099
Khowaja, M.I. P-1566
Khudadah, K. PD-0902
Khunti, K. 0553, P-1055, P-1280, P-1415, P-1676, P-1775, PD-0674
Khyzhnyak, O. P-1155
Kibachio, J. P-1833
Kieffer, T.J. 0365
Kiehling, C. P-1405
Kikimbaeva, A.A. AbT-2043, P-1419
Kikuchi, S. P-1062, P-1078
Kilborn, M. PD-0686
Kilicli, F. P-1132
Kilmartin, G. P-1416
Kilmartin, J. P-1416
Kilov, G. OP-0476
Kilpatrick, E.S. 0554
Kim, B.H. P-1804, P-1805
Kim, B.Y. P-1069, PD-0999
Kim, C. P-1070, P-1071, P-1072
Kim, C.H. P-1069, P-1919, PD-0999
Kim, D.J. PD-0950, PD-0971
Kim, D.L. P-1109
Kim, D.M. P-1208
Kim, D.S. P-1163
Kim, E.H. PD-0685
Kim, E.K. OP-0056
Kim, H. 0335, AbT-2144, P-1323, P-1323, PD-0963
Kim, H.J. P-1314, P-1971
Kim, H.M. P-1892
Kim, I.J. P-1804
KIM, J. P-1293, P-1165, P-1928, PD-0824
Kim, J.D. PD-1024
Kim, J.G. PD-0685
Kim, J.H. P-1074, P-1075
Kim, J.J. PD-0762
Kim, J.R. P-1805
Kim, J.Y. P-1517, P-1781
Kim, K. AbT-2117, P-1165, PD-0773, PD-0991
Kim, K.J. P-1069, PD-0999
Kim, K.S. P-1431, P-1971
Kim, K.W. AbT-2014
Kim, L.S. P-1139
Kim, M. AbT-2117, PD-0773

Kim, M.G. P-1903
Kim, M.K. OP-0056, P-1432
Kim, N. PD-0991, PD-0991
Kim, N.H. P-1446
KIM, S. P-1293, AbT-2117, AbT-2143, P-1194, P-1194, P-1404, P-1882, PD-0773, PD-0964, PD-0991
Kim, S.G. P-1446
Kim, S.H. P-1065, P-1073, PD-0672
Kim, S.J. AbT-2014, P-1314
Kim, S.K. P-1109
Kim, S.R. P-1919
Kim, S.S. P-1804
Kim, S.W. P-1517, P-1781
Kim, T. P-1928
Kim, T.G. P-1903
Kim, T.H. P-1074, P-1075
Kim, T.N. P-1446, P-1903
Kim, W. OP-0056
Kim, Y. P-1424, PD-0991
Kim, Y.J. AbT-2014, P-1314, P-1903
Kim, Y.S. P-1517, P-1781, PD-0823
Kimmel, P.L. PD-0818
Kimura, A. P-1478
Kimura, H. P-1425
Kinabo, J. P-1922, PD-1014
Kinduryte, O. P-1298
King, A.B. PD-0744
King, L. P-1501, P-1637
King, M. P-1501, P-1637
Kingsley, I.N.C. P-1496
Kingston-Ray, M. P-1512
Kingwell, B. P-1090
Kingwell, B.A. PD-0719
Kingwell, B.K. PD-0663
Kinuhata, S. P-1906
Kira, F. P-1420
Kirim, S. P-1222, P-1376, P-1859
Kirketerp, G. P-1626
Kirn, S. P-1688
Kishimoto, M. P-1578
Kislaya, E. AbT-2121
Kissenger, M. P-1814
Kissimova-Skarbek, K. OP-0112, P-1673, PD-0933
Kitaoka, H. P-1513
Kitaoka, M. PD-0790
Kitatani, N. P-1115
Kitazono, T. PD-0956
Kitsunai, H. OP-0450
Kiu Weber, C. PD-0719
Kiyomi, F. OP-0073, P-1322, PD-0676
Klatzmann, D. 0532
Kleefstra, N. PD-0995, PD-1029
Klein, O. P-1400, PD-0745
Kleinebreil, L. P-1523, PD-0911
Klephortova, I. P-1240
Kliewer, S. 0493
Klim, S. P-1322
Kliman, L. P-1688
Klimes, I. P-1444, P-1445
Klimontov, V.V. PD-0706
Klingensmith, G. OP-0428
Klomp, M. PD-0995, PD-1029
Knap, D. P-1157
Knezevic-Cuca, J. P-1239
Kniazeva, V. PD-0998
Kniazkina, O. AbT-2121
Knowler, W. 0207
Knowler, W.C. OP-0407
Ko, K.S. PD-0971
Ko, S.H. PD-0883, PD-0883, PD-0895, PD-0895
Kobayashi, D. P-1306
Kobayashi, H. P-1062, P-1078
Kobayashi, Y. PD-0954
Koefoed, B.G. P-1550
Koehler, W. P-1396, PD-0743
Koekemoer, T. PD-0659
Koeleman, B.P. P-1138
Koffi, D. P-1604
Koga, H. P-1910
Kogarko, B.S. P-1225
Kogarko, I.N. P-1225
Koh, H. P-1906
Kohro, T. P-1105
Kohrt, B.A. P-1806
Koike, M. P-1933
Kojima, Y. P-1429, PD-0695
Kojzar, H. P-1407, PD-0755
Kokareva, L. PD-0851
Kokkinos, A. P-1316
Kokoszka, A. OP-0455, P-1300, P-1670, P-1726
Koksal, V. AbT-2036
Kolawole, B.A. P-1621
Kolic, J. OP-0447
Kolonics, A. OP-0596
Kolumam, G. 0467, P-1051
Komada, H. P-1389, P-1390
Komai, M. PD-0658
Komers, R. PD-0783
Kon, Y. P-1140
Kondo, H. PD-0790
Kondo, M. P-1520
Kondo, T. P-1441
Kondo, Y. P-1076, P-1197
Kondrus, I.V. P-1225, P-1226, P-1227
Koné, A. P-1604
Kong, A. OP-0414, OP-0418, PD-0864
Kong, M. AbT-2119
Kong, M.-F. AbT-2110
Kongso, J. P-1044, P-1509, PD-0871
König, M. AbT-2103
Konkar, A. 0350
Könner, J. OP-0276
Konno, S. P-1783
Kono, S. 0219
Konstantinova, E. AbT-2005, P-1215
Konukoglu, D. P-1442
Konya, H. OP-0417
Koo, H.C. AbT-2020
Kooptiwut, S. PD-0732, PD-0733
Kopaleishvili, A. P-1195, P-1309, P-1591, P-1605
Kopp, H.P. P-1790
Kopp, H.P.K. P-1789
Korkmaz, G.G. P-1442
Korkmaz, Ü. P-1275
Kornelius, E. PD-0829
Koroi, R. P-1583
Korsatko, S. P-1407, PD-0676, PD-0755
Korsholm, L. P-1302
Koshiyama, H. OP-0423, PD-0701
Koski, S. 0167
Koskinen, J. P-1889
Kostadinova, V. P-1841
Kostner, K. PD-0689
Kosugi, K. P-1910
Kosuru, N. P-1696
Kothari, C. PD-1027
Kothary, P.C. P-1213
Kothny, W. P-1317, P-1354
Kotian, M.S. PD-0957
Kouam, C. P-1614, P-1975
Kouassi, F. P-1604
Kouchi, Y. P-1264
Koulis, C. OP-0621, PD-0782
Koura, A. P-1140
Kouyate, M. P-1706, PD-0859
Kovacs Burns, K. P-1581, P-1670, P-1729, PD-0846, PD-0924
Kovacs, E. P-1167
Kovacs-Burns, K. 0383
Kovalenko, A. PD-0772
Kovalenko, O.L. P-1419
Koves, T.R. 0310
Kovil, R. AbT-2063, P-1413
Kovshil, L. AbT-2140
Kowalska, I. PD-0722, PD-0725
Kowlessur, S. 0039
Koya, D. 0360
Kozlovski, P. P-1354
Kraakman, M. P-1366
Krasova, N. P-1203
Krassas, G. OP-0649
Kratochvilova, S. PD-0665
Kravchun, N. P-1203
Krebs, J. PD-0787
Krebs, M. PD-0771
Krieger, K. OP-0071
Kriplani, A. PD-0795
Krippner, G. P-1366
Krishnan, A. OP-0411
Krishnan, G. AbT-2107, OP-0294, P-1552, P-1844
Krishnan, S. AbT-2023
Krishnaswamy, K. OP-0614, P-1927
Krishnaswamy, P. PD-0782
Krishnaswamy, V. P-1527, P-1587, P-1712, PD-0887
Kristensen, M.B. OP-0089
Krougly, O. PD-0737
Krstevska, B. P-1485
Krulko, I. AbT-2156
Krzizek, E.C.H. P-1489
Krzymien, J. P-1077
KSDPP Community Advisory Board & Research Team, . 0325
Ku, B.J. P-1314, P-1431, P-1971
Kuang, J. P-1270, P-1271
Kubat Uzum, A. P-1697, P-1275
Kucukler, F. P-1058

Kudlac, R. P-1487
Kudo, S. P-1078
Kudo, T. P-1324
Kufelkina, T.U. AbT-1995
Kuglarz, E. AbT-2149, P-1941
Kuhn, N.S. OP-0594
Kuhn, P.C. OP-0106, OP-0639
Kukhalashvili, R. AbT-2099
Kulaksizoglu, M. AbT-2076, P-1570
Kulkaeva, G. PD-0893
Kulzer, B. OP-0475, P-1581, P-1722, P-1729, PD-0922, PD-0924
Kumar Ajay, A. AbT-2079
Kumar, H. P-1380
Kumar, S. P-1375
Kumaran, K. OP-0067b
Kumari, A. PD-0795
Kume, S. 0360
Kuo, C.H. OP-0088
Kuo, T. P-1386
Kuraeva, T.L. P-1112
Kurashvili, G. P-1704
Kurashvili, R. 0561, AbT-2099, AbT-2104, AbT-2124, P-1195, P-1309, P-1505, P-1591, P-1605, P-1641, P-1704, P-1719, P-1934, P-1972, PD-0891
Kuricova, K. P-1487, P-1237
Kurose, T. P-1081, P-1114, P-1115
Kurtulus, E.M. P-1442
Kuru, O. OP-0462
Kusama, M. P-1264
Kusunoki, Y. OP-0417
Kutluturk, F. P-1079, P-1080
Kutskir, V.G. P-1225, P-1226, P-1227
Kuvalekar, A. P-1290
Kuwata, H. P-1114, P-1115, P-1081
Kuznetsov, L. PD-0909
Kvanchakhadze, R. AbT-2124
Kvaratskhelia, K. AbT-2099
Kvezereli, M. AbT-2099
Kwadiba, O. OP-0118
Kwan, Y.H. P-1394, PD-0786
Kwon, E.J. P-1377
Kwon, H.S. AbT-1996, OP-0056, P-1189, P-1432
Kwon, M.J. P-1903
Kwon, O. P-1323
Kyung, C. AbT-2117, PD-0773

L

La Banca, R.O. PD-0861
Labate, C. 0110, P-1710, P-1760
Labate, C.G. P-1564, PD-0856, PD-0858
Lacinova, Z. P-1143, P-1451
Lacroix, I. P-1325
Laffel, L. P-1515, PD-0792, PD-0862
Lai, K. P-1421
Lai, Y.C. P-1364
Laila, S. P-1110
Lainez Lopez, M. P-1610
Laiteerapong, N. P-1949
Lajous, M. OP-0408, PD-0979
Lakshmi Priya, N. PD-0981
Lally, J. AbT-2107, OP-0294, P-1552
Lam, A. PD-0972
Lam, K.S.L. 0158, OP-0062
Lam, V. OP-0414
Lamarche, M. OP-0063, OP-0233
Lamont, B.J. P-1387
Lamoureux, E. P-1214
Lamptey, R. P-1814
Lancefield, T.F. P-1100
Landgraf, W. P-1082
Landim, K.C. AbT-2025
Lane, W. P-1302
Lang, D. P-1507
Langbakke, I.H. OP-0082
Langridge, J. P-1686
Lantion-Ang, F.L. P-1681, PD-0947
Lapolla, A. P-1887
Laptev, D.N. P-1112
Larco, P. AbT-2111, AbT-2131
Lardo, M. P-1111, P-1782
Larijani, B. AbT-2139, OP-0429
Lark, D. P-1052
Latham, M. P-1068
Lathia, T. P-1947
Latif, Z. OP-0295, P-1409
Latif, Z.A. P-1960
Latifi, S.M. AbT-2127, P-1231, P-1875
Latouche, C. PD-0663
Lau, E. OP-0415
LAU, M.S.W. PD-0870
Lau, W. OP-0445
Laupacis, A. P-1559
Lauritzen, T. OP-0651
Lauro, R. P-1886
Lauszus, F.F. AbT-2057, OP-0274
Lautt, W.W. P-1087
Lauzier, S. PD-0868
Lawson, H.J.O. P-1814
Lawton, P.D. PD-0820
Laxy, M. PD-1028
Lazarevic, Z. P-1368
Lazarus, R. PD-0663
Le Boeuf, D. P-1942
le Roux, C. 0308
Le, J.A. OP-0597
Leal-Anguiano, A.I. AbT-2004
Lebovic, G. P-1559
Lebovitz, H. 0570, OP-0078
Lecomte, V. OP-0619
Lee, A. PD-0686
Lee, B. AbT-2117
Lee, B.W. AbT-2053, P-1265, P-1892, PD-0950
Lee, C. 0350
Lee, C.B. P-1163
Lee, C.M.Y. PD-0969
Lee, D. PD-0824
Lee, E. P-1265
Lee, E.J. P-1903
Lee, E.Y. AbT-2053
Lee, H. OP-0414, P-1165, P-1323, P-1424, PD-0896
Lee, H.C. AbT-2053, P-1265, P-1892, PD-0950
Lee, H.J. P-1893
Lee, H.O. PD-0823
Lee, H.W. P-1424, PD-0896
Lee, H.Y. P-1554
Lee, I. P-1191, PD-0824
Lee, I.K. PD-0685
Lee, I.S. P-1314
Lee, J. P-1046, P-1404, P-1776, PD-0697, PD-0972
Lee, J.C. P-1431, P-1971
Lee, J.H. P-1374, P-1971
Lee, J.M. P-1314, P-1314
Lee, J.M.J. P-1763
Lee, K. P-1293
Lee, K.A. P-1065, P-1073, PD-0672
Lee, K.Y. AbT-2033, P-1919
Lee, L.T. PD-0770
Lee, M. P-1928, PD-0736
Lee, M.-K. P-1466
Lee, M.C. P-1544
Lee, M.K. P-1074, P-1075, PD-1024
Lee, M.S. P-1074, P-1075
Lee, M.Y. P-1807
Lee, P. P-1213
Lee, P.C.H. OP-0062
Lee, P.H. OP-0256
Lee, P.L. P-1746
Lee, S. P-1191, PD-0964
Lee, S.D. P-1431
Lee, S.H. P-1903
Lee, T. OP-0076, P-1596, P-1716
Lee, W. P-1596, P-1716
Lee, W.Y. PD-1024
Lee, Y. OP-0253, P-1431, PD-0824, PD-0950
Lee, Y.H. AbT-2053, P-1265
Lee, Y.J. P-1510, PD-0971
Lee, Y.K. P-1377
Lee-Chan, E. PD-0737
Lee-Young, R.S. OP-0596
Lefebvre, P. 0562, 0290
Lefkovits, J. P-1185
Legare, D.J. P-1087
Lehmann, J. P-1636
Lehmann, R. P-1636
Lehnen, A.M. P-1481
Lehrke, M. PD-0696
Lei, T. P-1172
Leiherer, A. PD-0688, PD-0715
Leila Zhubandykova, M.S. OP-0296
Leiter, L. OP-0650
Leka, V. P-1557
Leng, J. OP-0580
Lengyel, C. P-1196, P-1251
Leonetti, D.L. AbT-2142
Leong, A. P-1048
Leong, G.M. PD-0689
Leong, R. OP-0076
Leow, S. OP-0476
Lepagnol, A. P-1942

AUTHOR INDEX

Lernmark, A. 0139
Leshchenko, Z. P-1203
Lessan, N. AbT-2080, PD-0961
Levey, A.S. PD-0818
Levitt, N. P-1976
Levitt, N.S. 0208
Lewin, A.M. P-1475
Lewis-D'Agostino, D. P-1104
Li, C. P-1362
Li, C.-I. P-1541
Li, C.Y. OP-0113, PD-0953, PD-0994
Li, D. P-1821
Li, D.G.L. PD-0988
Li, E.T.S. P-1282
Li, G. 0401
Li, G.W. OP-0439
Li, H. OP-0060, PD-0708
Li, H.Y. OP-0113, P-1364
Li, J. AbT-2138, OP-0409, P-1247, P-1884
Li, L. OP-0404, OP-0595, OP-0615, P-1212
Li, L.X. OP-0604
Li, M. OP-0580
Li, P. PD-0972
Li, Q. OP-0272, OP-0412, P-1391, PD-0972
Li, Q.F. P-1270, P-1271
LI, S. P-1238, P-1282, P-1784
Li, S.C. P-1958
Li, S.P. OP-0600, P-1379
Li, S.Y. P-1765
Li, W. OP-0115, OP-0580
Li, X. P-1211
LI, Y. OP-0580, OP-0094, OP-0444, P-1354, P-1660, PD-0734, PD-0764
Li, Y.J. P-1358
Li, Z. OP-0272
Li-Chan, E. P-1325
Lian, J. P-1083, P-1084, P-1085, P-1086
Liang, H. P-1214
Liang, L. P-1784
Liang, Y.L. P-1544
Liao, A. OP-0083, P-1088
Liao, C.C. P-1266, P-1539, P-1904, PD-0853, PD-0952
Libianto, R.J. P-1773
Lichiardopol, R. P-1891
Lieberman, N. OP-0586
Liebl, A. P-1405
Lieske, S. OP-0229
Liess, C. OP-0231
Liew, D. AbT-2144, OP-0273, P-1438, PD-0963
Light, J. AbT-2038
Lilly, L.C. PD-0755
Lim, D. P-1404
Lim, D.M. P-1139, P-1314
Lim, H.B. P-1561
Lim, J. PD-0860
Lim, J.S. P-1807
Lim, K. P-1461, P-1467
Lim, K.Y. PD-0835
Lim, M.L. P-1746
Lim, W.Y. P-1763
Lim-Abrahan, M.A. P-1401, P-1402
Limjindaporn, T. PD-0732, PD-0733
Lin, C. P-1052
Lin, C.H. P-1295
Lin, C.L. OP-0256
Lin, H.C. AbT-2120
Lin, P.J. P-1630
Lin, S. OP-0112, P-1673, PD-0933
Lin, W.Y. PD-0770
Lin, X.L. P-1746
Linares, F. P-1273, P-1274, PD-0754
Lincoff, A.M. PD-0690
Lind, L. PD-1018, PD-1019
Lind, M. PD-1019
Lind, P.M. PD-1018
Lindstrom, J. OP-0405, 0151
Linjawi, S. OP-0421, OP-0422, P-1267
Linn, T. P-1272
Linnenkamp, U. OP-0653
Lins, T. AbT-2148, P-1479, P-1674, PD-0828
Lins, T.C. AbT-2147, P-1607, P-1675, PD-1030
Lipscombe, L. PD-0982
List, J.F. P-1461, P-1467, PD-0708
Little, T. OP-0425
Little, T.J. PD-0767
Litwak, L. P-1409
Liu, A. OP-0611, P-1606
Liu, C. OP-0598, PD-0890
Liu, C.Y. P-1698
Liu, F. OP-0604, P-1190, P-1212
LIU, J. P-1117, P-1103, P-1153, P-1154, P-1210, P-1360, P-1360
Liu, L. P-1252, PD-0886, PD-0903
Liu, Q. P-1122
Liu, R. P-1398
Liu, S. AbT-2062, P-1866
Liu, S.O.N.G. P-1307, P-1454, P-1469
Liu, W. AbT-2029, OP-0112, P-1916
Liu, Y. OP-0439, P-1464
Liu, Y.H. OP-0088
Livingston, P. P-1752
Livrinova, V. P-1485
Ljubic, S. AbT-1992, P-1239
Llorente, I. P-1315
Llorente, M.J. PD-0679
Lloyd, C.E. 0019
LMF237A1301 Study Group P-1348
Lo, C. P-1596, P-1716
Lo, L. P-1313
Lobashova, V. AbT-2140
Lockie, A. P-1567
Loeken, M. 0482
Löffelholz, C. OP-0229
Löffler, A. P-1418
Loganadan, N. PD-0835
Loh, H.S. P-1867
Loh, M. P-1733
Løkke, M. OP-0274
Lokrou, A. P-1604
Lombado, F. P-1111
Lombard, C. P-1976, PD-1013
Lombardo, F. P-1782
Long, G.H. OP-0059, PD-0909
Long, Y. OP-0451, PD-0764
Loo, B.M. PD-0975
Lopes, M. P-1710
López de la Torre Casares, M. P-1331
Lopez De La Torre Casares, M.L.C. P-1347
Lopez Gonzalez, E. PD-0935
López Navia, A. P-1333
López Radrigán, B. P-1615
Lopez Radrigan, T. PD-0916, P-1615
Lopez Silva, M.C. AbT-2126, AbT-2058
Lopez, A. 0528
Lopez, G. P-1684
López-Carmona, M.D. OP-0267
López-Guzman, A. P-1326
Lorber, D. P-1068
Lorente, I. PD-0834
Lorentzen, V. P-1752
Lorenz, N. PD-0759
Losada-Viñau, F. AbT-2034
Loudovaris, T. OP-0448
Loureiro, A.P.M. P-1098
Louw, J. PD-0662
Lovat, N. P-1087
Lowe, J. P-1486, PD-0854, PD-0934, PD-0982
Loy, K. P-1793
Lu, C.H. AbT-2013, P-1554
Lu, C.L. OP-0113, PD-0953, PD-0994
Lu, F. P-1190
Lu, F.D. OP-0604
Lu, F.H. OP-0091, P-1199
Lu, J. 0481, P-1346
Lu, J.M. OP-0439
Lu, M.C. P-1491, PD-0794
Lü, Q.G.L. PD-0988
Lu, Y. PD-0829
Lu, Z. P-1824
Luan, J. OP-0414
Lubin, B. AbT-2131
Lubree, H. OP-0067b
Lucchesi, D. OP-0416, OP-0443
Lucisano, G. PD-0822, PD-0844, PD-0959
Lucun, I. P-1538, P-1687
Ludvigsen, E. PD-0657
Ludvigsson, J. 0550
Ludvik, B. P-1775
Luengo Pérez, L.M. P-1333
Luger, A. PD-0771

Luk, A. OP-0414, OP-0415, OP-0418, OP-0445, PD-0864, PD-0972
Lukashevich, V. P-1317, P-1354
Lundbom, J. OP-0232
Lundqvist, K. PD-0863
Lung, T. OP-0652
Luo, X.H. AbT-2054
Luo, Y. P-1288, P-1821, P-1920, PD-0945
Luo, Y.Y. P-1258, P-1312
Luongo, A. PD-0935
Luquez, C. P-1263
Luscombe-Marsh, N. OP-0425
Luscombe-Marsh, N.D. OP-0058, P-1207, PD-0765, PD-0767
Lutale, J. PD-0905, PD-0906
Luzio, S.D. P-1439
Lv, J. OP-0404
LV, X. P-1117, P-1354
Lv, Y. P-1660
Ly, T.T. P-1555
Lynch, S.L. P-1672
Lysak, P. OP-0116
Lyskoit, K. P-1538, P-1687

M

M. Paldánius, P. P-1593
Ma, C. PD-0864
Ma, H.O.N.G. P-1307, P-1469
Ma, J. OP-0424, P-1354, P-1473, PD-0712
Ma, R. 0209, OP-0414, OP-0415, OP-0418
Ma, X. P-1051, P-1164, P-1821, P-1824
Mac Isaac, R.J. P-1048
Maccallini, G. OP-0645, P-1452, P-1502
MacDonald, P.E. OP-0447, P-1421
MacDougall, K. P-1658
Mace, J. OP-0609
Mace, J.H. P-1711
Mace, J.L. AbT-2115, OP-0117
Macedo, M.P. P-1809
Macfadden-Laja, J. PD-0898
Machado, J. P-1747
Macharia, M. P-1890, PD-0717
Macias, H. 0335
MacIsaac, R.J. P-1477, P-1773, PD-0710, PD-0820
MacIssac, R.J. PD-0709
MacKay, M. 0538
MacKenzie, J. PD-0659, P-1507
Mackie, A. OP-0285
Madani, A. P-1523
Madani, S. P-1327, P-1328, P-1329
Madden, P. 0394
Mader, J. P-1322
Mader, J.K. P-1834, PD-0755
Madero, R. PD-0948
Maderuelo, M. PD-0834
Madhu, S.V. P-1152, P-1679, P-1808, PD-0752
Madhup, S.K. P-1694
Madill, J. P-1518
Madsen, T. P-1825
Maeda, I. P-1906
Maeda, S. PD-0777
Maffei, L. P-1294
Maggs, D. OP-0083, P-1088
Maghrabi, M. P-1184
Magid, D.J. P-1514
Magliano, D. 0330, PD-0963, PD-1001
Magliano, D.J. OP-0114, OP-0240, OP-0269, OP-0406, OP-0408, PD-0979
Magnussen, C.G. P-1889
Magony, S. P-1196
Mahadeva swamy, B.C. P-1183
Mahaffey, K.W. P-1093
Mahajan, A. OP-0252, OP-0253, OP-0254
Mahalakshmi, M.M. PD-0800
Mahar, S. P-1720
Maharaj, S. P-1453
Mahawong, P. PD-0733
Mahdi, A.A. P-1622
Mahesh, D.M. P-1039
Maheshwari, A. P-1787, PD-1000
Maheshwari, N. P-1787, PD-1000
Maheswari, K. PD-0800
Mahfouz, A. P-1905
Mahjoub, S. P-1728
Mahmood, D.T.M. AbT-2130
Mahmoudarabi, M. AbT-2139
Mahmud, I. P-1385
Mahmud, N. P-1815
Mahtab, H. AbT-2152, OP-0642, P-1695, P-1815, PD-1011
Mahtab, N. P-1815
Maina, W. P-1833
Mairghani, M. P-1864
Majaliwa, E. OP-0292
Majithiaon, A. OP-0250
Major-Pedersen, A. P-1054
Majumdar, A. P-1219, P-1428
Majumdar, D. P-1403
Majumdar, S.R. OP-0116
Makino, Y. OP-0450, PD-0713
Makrilakis, K. OP-0405
Makumbi, F. P-1974
Malagon Cobos, M. P-1611
Maldonado, C. PD-0754
maldonado, G. PD-0788
Malek, R. OP-0475, P-1262, P-1406, P-1653, PD-0922, PD-0924, PD-0960
Malhotra, S.S. PD-0795
Malievsky, O. P-1515, PD-0792, PD-0862
Malik, N. P-1403
Malik, R. P-1095, P-1810, PD-0670
Malik, R.A. OP-0605, OP-0607, PD-0668, PD-0904
Malik, V. OP-0614
Malini, H. AbT-2067
Malinska, H. PD-0750
Malla, S.S. PD-0753
Mallon, A. P-1921
Malmberg, K. PD-0690
Malomo, K. OP-0083, P-1088
Maloney, C.A. OP-0619
Maluskova, D. P-1484
Mamatkan, R.S. AbT-2043
Mamatkan, S.A. P-1419
Mamdani, M. P-1559
Manamley, N. P-1468
Manchenko, O. P-1240
Mancuso, S.G. P-1733
Mandai, N. P-1838, P-1840
Mandrup-Poulsen, T. 0336
Mangas-Cruz, M.A. AbT-2034
Mangelsdorf, D. 0493
Mangiafico, S.P. P-1387
Manicardi, V. P-1857
Manikam, A. P-1746
Manjuladevi, A.J. AbT-2108
Mankovsky, B. PD-0772
Manley, S. P-1877
Manley, S.E. P-1873
Mannan, M. AbT-2003
Manning Fox, J.E. OP-0447, P-1421
Manning, R.W. PD-0809
Männistö, S. PD-0975
Manobala, K. PD-0980
Manpo, N. P-1685
Manrique, K. P-1548
Mansfield, T. PD-0708
Manski-Nankervis, J. P-1650
Manso, M.C. P-1045
Manson, S. 0175
Mansy, O. AbT-2098
Manurung, M.D. P-1764
Manzanares Errazu, J. AbT-2077
Mao, F. P-1798
Maor, Y. P-1060
Maple-Brown, L. 0371
Maple-Brown, L.J. PD-0820
Mapletoft, D. OP-0277
Maraver Selfa, S. AbT-2135
Maraver-Selfa, S. AbT-2072
Marchetti, A. P-1625
Marcinak, J. OP-0079
Marcinko, K. OP-0235
Margolis, K.L. P-1514
Mariea Bosco, D. OP-0448
Marijanovic, N. P-1856, PD-1034
Marinelli, P. PD-0666
Markoski, M. P-1481
Marley, J. PD-0808
Marley, J.V. PD-0803
Marliss, E.B. OP-0063, OP-0233
Marmouch, H. AbT-2082
Marmouch, H.E.L.A. P-1728
Maroleanu, A. P-1917
Marques-da-Silva, P. P-1045
Marra, G. PD-0822, PD-0844
Marre, M. OP-0257, P-1767, P-1899
Marrero, D. OP-0612
Marrero, D.G. P-1608
Marsh, K. OP-0277
Martin, A. AbT-2129, P-1548
Martin, E. P-1872
Martin, H. 0214
Martin, J. P-1930
Martin, P. OP-0464, PD-0842
Martin, S. OP-0276, P-1748, P-1931
Martin, W. AbT-2134, P-1879

AUTHOR INDEX

Martinez Martinez, L. P-1612
Martínez Ortega, A.J. P-1141
Martinez, A. P-1731
Martinez, L. P-1327, P-1328, P-1329
Martínez, T. P-1897
Martinez-Alfaro, B. P-1186
Martinez-Ortega, A.J. AbT-2034
Martins, F. P-1809
Martins, L. P-1045
Martins, P. P-1142
Marx, N. PD-0696
Masaki, H. P-1642
Masevnin, V.V. P-1225, P-1226, P-1227
Mashayekhi, A. P-1982
Mashkova, M. P-1269
Masin, M. P-1887
Mason, C. P-1877
Masood, S. P-1749
Masood, S.N. PD-0797
Masood, Y. P-1749
Massey, C. P-1835
Massi Benedetti, M. OP-0266, P-1908
Massi-Benedetti, M. OP-0455, P-1581, P-1729
Masuda, H. PD-0723
Mata Mouros, F. 0031
Mata, M. P-1599
Mateen, S. P-1671
Mathai, S. P-1039
Mathangaweera, W. OP-0644
Matheiu, C. P-1068
Mathenge, C. 0396
Mathieu, C. 0177, P-1055, PD-0673, PD-0747
Mathur, S. P-1689
Matsha, T. P-1890, P-1973
Matsha, T.E. P-1292, P-1457, PD-0717
Matsuda, M. PD-0742
Matsui, K. OP-0590
Matsumoto, K. P-1171
Matsumura, L.K. P-1772
Matsunaga, K. P-1474
Matsuo, T. OP-0417
Matsuoka, A. OP-0423, PD-0701
Matthews, D. P-1093
Matthews, D.R. AbT-2158, OP-0404, P-1830, PD-0675
Mattick, J.S. 0527
Mattocks, C. 0212
Matulevicius, V. P-1735
Matuleviciute, I. P-1735
Matulewicz, N. PD-0722, PD-0725
Matuszewski, W.M. P-1828
Maugeais, C. PD-0719
Maurice, B. 0560
Mawo, A. P-1278
Mayega, R. P-1974
Mayer-Davis, E.J. P-1916
Mayorov, A. 0187, OP-0475, P-1240, P-1300, P-1670, P-1726, PD-0845
Mayzel, Y. PD-0758
Mazibuko, S.E. OP-0602
Mazumder, A. P-1403
Mazze, R. AbT-2112, P-1794, P-1799, PD-0755
Mballa, V. P-1228
Mbanya, J.C. 0368, P-1150, P-1228, P-1278, P-1614
Mboi, J.M. OP-0293
Mburu, J.M. OP-0293
McAinch, A. P-1113
McAleer, S. P-1635
McArthur, V. PD-0832
McAuley, A.K. P-1214
McAullay, D. OP-0643
McCarthy, D. OP-0090, P-1118, P-1233
McCarthy, M. 0169
McCarthy, M.I. OP-0252, OP-0253
McCaughan, G.W. P-1313
McClelland, A. PD-0783
McCrimmon, R. 0539
McDermott, B. PD-0865
McEovy, M. P-1912
McEwan, P. P-1089
McEwen, L.N. AbT-2141
McFadyen, J. 0181
McFarlane, S. P-1870
McGee, S. OP-0092, OP-0588, PD-0655
McGee, S.L. OP-0596
McGhee, C.M. OP-0105
McGill, M. PD-0805, PD-0920
McGowan, P. P-1672
McGuckin, M.A. OP-0591
McGuire, H. AbT-2153, OP-0112, PD-0933
McGuire, H.C. P-1673
McIntyre, H.D. PD-0801
McKeever Bullard, K. OP-0441
McKie, P. PD-0838
McLachlan, R. P-1959
McLarty, D. OP-0292
McLean, A. OP-0107, P-1655, P-1777
McLennan, S. OP-0593
McLennan, S.V. OP-0061, P-1313, PD-0656, PD-0781
McLeod, A. AbT-2069, P-1571
McMichael, A.J. 0011
McNamara, J. OP-0080
McNamara, K.A.R. P-1711
McNeely, M.J. AbT-2142
McRobb, L. P-1072
McTavish, L. PD-0787
McTavish, S. PD-0982
Mecha, J. P-1847
Mechanick, J.I. P-1625
Medlej, R. P-1157
Meel, J.K. P-1216, P-1865
Meguro, S. P-1168
Mehanna, S. PD-0902
Mehar, S. P-1896
Mehdizadeh, A. P-1224
Mehta, V. P-1543
Mei, Q. OP-0453
Meier, D.T. 0338
Meier, M. 0350
Meikle, P. P-1090
Mein, J. OP-0107
Meininger, G. P-1464, P-1466
Meisinger, C. PD-1028
Melnichenko, G. P-1827
Meltzer, A. P-1972
Menanga, A. P-1150
Mendane, F. P-1228
Mendes, G. AbT-2148, P-1479, P-1674, PD-0828
Mendes, G.F. AbT-2147, P-1607, P-1675, PD-1030
Méndez, A. P-1831
Mendez, M. P-1916
Méndez-Bailón, M. AbT-2032
Meneghini, L. P-1268
Meneghini, L.F. P-1301
Menendez Torre, E. P-1300, PD-0845, P-1729
Menendez, E. PD-0834
Meneses-Lorente, G. PD-0719
Meng, K.C. P-1402
Meoli, C.C. 0467, P-1051
Meoro Avilés, A.I. P-1279
Mequanint, S. AbT-2125
Merchante, A. P-1330
Merker, L.F. P-1776
Merlin, J. P-1091
Merom, A. P-1572
Merovci, A. OP-0067
Mersebach, H. P-1304, P-1399
Mert, M. AbT-1998, AbT-1999
Mesenge, C. PD-0911
Messina, R. P-1886
Mesturino, C.A. P-1887
Metzdorff, S. OP-0089
Metzger, B.E. 0484
Meulepas, M. PD-0995, PD-1029
Meyer, C. PD-0779
Meyers, M. P-1792
Meyramov, G. AbT-2043, P-1419
Meyramova, A.G. AbT-2043, P-1419
Meyrowitsch, D.W. P-1779
Mezquita-Raya, P. P-1331
MIAO, H. P-1117
Miccoli, R. OP-0416, OP-0443, P-1885
Michael, V. AbT-2085
Michaelie, M. P-1572
Michalek, J. P-1445
Middlehurst, A.C. PD-0929
Midthjell, K. OP-0270, OP-0405
Mielck, A. PD-1028
Mihai, B. P-1891
Mikhno, H. AbT-2121
Milad, M. P-1905
Milagres, K.D.S. P-1356, P-1371
Milani, N. P-1241
Milenkovic, T. P-1516
Millar, F. P-1531
Miller, D. OP-0426
Miller, M.E. P-1108
Miller, R.G. PD-0932
Miller-Kovach, K. OP-0612, P-1608
Millett, C. PD-0908
Milne, M. 0569, P-1048
Milne, N.T. OP-0609
Milner, B. OP-0231
Milner, K.L. OP-0057
Milrad, S. PD-0935
Milton, A.H. P-1813
Milutina, T. P-1556
Min, D. OP-0593
Min, K.W. P-1466
Minagawa, S. P-1933
Minatoguchi, M. P-1264
Mindubaeva, F.A. P-1419
Ming, A.M. P-1050
Minz, R.W. OP-0430
Miranda-Díaz, A.G. AbT-2004
Mirmira, R. 0540
Miro, A. P-1095
Mirrahimi, A. AbT-2143, P-1917, P-1926, PD-0977
Mishra, G. PD-0987

Mishra, M. P-1380
Mishra, S. AbT-2154, P-1580
Misoi, L. PD-0875
Misra, A. 0342, P-1092
Mitchell, C. AbT-2059
Mitchell, E.A. P-1768
Mitchell, E.K.L. P-1553
Mitchell, H. P-1497, P-1500, P-1676, PD-0810, PD-0814
Mitchell, J. P-1071
Mitchell, S. PD-0852
Mitchelle, S. PD-0848
Mithra, P. AbT-2155
Mitra, S. P-1220
Mitrea, A. P-1276
Mitri, M. AbT-2100
Mitsumatsu, T. P-1337, P-1340
Mittal, S. P-1947
Miuchi, M. OP-0417
Miura, D. OP-0427
Miura, J. P-1062, P-1078
Miura, Y. PD-0778
Mixson, L. OP-0426
Miyagawa, J. OP-0417
Miyakawa, T. P-1352, PD-0790
Miyasato, M. PD-0955
Miyatsuka, T. 0335
Miyawaki, M. PD-0955
Miyawaki, Y. P-1588
Miyazaki, T. P-1197
Miyazaki, Y. P-1076, P-1197
Miyoshi, H. P-1158
Miyoshi, J. OP-0590
Mizuno, M. P-1642
Mizuno, N. P-1680
Mizutani, T. P-1177, P-1940, PD-0684
Mo, S.I. AbT-2014, P-1314
Moberg, E. P-1775
Mochizuki, K. P-1320
Mochizuki, T. P-1197
Modrusan, Z. 0467, P-1051
Moebus, S. PD-1007
mohamed, A. PD-0756
Mohamed, A.A. P-1860
Mohamed, M. P-1402
Mohamed, N. P-1187
Mohammad, R. P-1448
Mohammad, S. AbT-2003
Mohammadi Karakani, A. P-1242
Mohan, V. 0390, AbT-2063, OP-0583, OP-0584, OP-0614, P-1816, P-1849, P-1853, P-1914, P-1927, P-1969, PD-0769, PD-0800, PD-0943, PD-0951, PD-0980, PD-0981, PD-1005, PD-1009, PD-1017, PD-1021, PD-1023, PD-1035
Mohanasundaram, D. OP-0448, P-1423
Mohd Nasir, M.T. P-1913
Mohd Nur, N. PD-0835
Mohd. Amir, A. AbT-2085
Moilanen, L. PD-0941
Moisan, J. PD-0868
Moisés, R.S. OP-0106, OP-0639
Mojaddidi, M. AbT-2011
Mojibia, M. PD-0894
Mojiminiyi, O.A. AbT-2001
MOK, J. P-1293
Mok, J.O. P-1069, P-1919, PD-0999
Mokhort, T. AbT-2005, AbT-2113, P-1123, P-1215, P-1244, P-1269, P-1739
Mokta, J. P-1532
Mokta, K. P-1532
Mol, B.W. P-1099
Mold, J. P-1791
Molero, J.C. PD-0727
Molinari, C. OP-0645, P-1452, P-1502
Mollah, A.S. P-1440, P-1609
Møller Hansen, U. P-1740, PD-0830, PD-0839
Molyneaux, L. OP-0101, P-1811, PD-0793, PD-0805
Mompoint-Williams, D. PD-0838
Monabeka H.G. P-1707
Monami, I. P-1743
Mondal, U. P-1470
Monedero Saiz, T. P-1279
Moniruzzaman, M. PD-0897
Monreal, M. P-1332
Montanya, E. PD-0677
Monteiro, D. OP-0452
Monteiro, M.P. OP-0452, P-1142
Montgomery, M.K. P-1365
Montiel-Trujillo, A. P-1186
Moodie, M. PD-1013
Moon, J. P-1424, PD-0896
Mora, A. P-1315
Morais, J.A. OP-0063, OP-0233
Morais, T. OP-0452, P-1142
Morales Conde, S. P-1141
Morales Pérez, F.M. P-1333
Morales Portillo, C. P-1589, P-1590, P-1610, P-1611, P-1612, PD-0923
Morales, E. P-1093
Morales-Garcia, F. AbT-2034
Moran, C. OP-0608
Moran, L. PD-0985
Morcillo, S. PD-1025
Moreira, G. P-1760
Moreira, P. P-1664
Morell, M.K. P-1041
Moreno Pérez, O. P-1331
Moreno, C. PD-0679
Morgan, P.J. AbT-2159
Morgans, A. P-1861
Mori, I. PD-0681
Mori, K. OP-0423
Mori, Y. P-1105
Morillas, C. P-1599
Morin, C. P-1217
Morisawa, C. P-1933, PD-0742
Morita, H. PD-0681
Morita, M. P-1175, PD-0683
Morita, T. P-1933, PD-0742
Morjand, B.S. P-1378
Morley, B. P-1930
Morley, J. P-1627
Morris, A. OP-0254
Morris, A.D. OP-0648
Morris, A.P. OP-0252, OP-0253
Morris, K. P-1877
Morris, M.A. 0540, OP-0594
Morris, M.J. OP-0619
Morris-Jones, S. P-1230
Morrison, E. P-1870
Morrison, M. P-1486
Morse, A. P-1503
Morshed, M.A.H.G. OP-0642
Morton, G.J. 0357
Morton, S. PD-0966
mosa, Y. PD-0756
Mosely, K. OP-0457
Moser, E. OP-0074
Mosihuzzaman, M. P-1470
Mossaz, A. 0560
Mossihuzzaman, M. P-1129
Mota, E. P-1891, PD-0970
Mota, M. P-1167, P-1891, PD-0970
Motala, A.A. P-1453
Motta, L.A. PD-0804
Mouat, F. P-1656
Moura, E. OP-0083, P-1088
Moustafa, M.E. P-1311
Moylan, J. 0343
Moyo, D. OP-0118
Mraz, M. P-1143, P-1451
Mshunqane, N. OP-0286
Muangmai, W. P-1966
Muazu, S. P-1613
Mubi, B.M. AbT-2161
Muchemi, E. P-1833
Muchlyte, E. P-1538
Mudaliar, S. P-1468
Muderrisoglu, C. P-1198
Mudie, N. PD-0690
Muehlen-Bartmer, I. OP-0075, P-1718
Mueller, D. P-1384
Muench, G. OP-0608
Muendlein, A. PD-0688
Mughal, S. P-1443
Muiriri, M. P-1292
Mukherjee, S. OP-0278, P-1428
Mukwevho, E. PD-0721
Mulani, J. AbT-2136
Muller, C.J.F. OP-0602
Mumu, S.J. P-1730, P-1953, PD-0867
Munakata, M. OP-0409
Munang, Y. P-1278
Mundinger, T. OP-0453
Mundt, C. P-1649
Munibuddin, A. P-1476
Munisamy, M. OP-0442
Munkundente, V. P-1795
Muñoz Garach, A. AbT-2135
Muñoz-Garach, A. AbT-2072
Muñoz-Martín, A. P-1334
Muñoz-Torres, M. P-1334, PD-0744
Muñoz_Rivas, N. AbT-2032

Munro, N. OP-0455, OP-0475, P-1300, P-1729, PD-0846, PD-0922
Munshi, M. 0217
Munshi, S.U. AbT-2046
Munt, R. P-1501, P-1637, P-1750, P-1751
Muoio, D. 0310
Muragan, S. P-1587, P-1712
Murai, H. P-1306
Murai, K. OP-0417
Murakami, M. P-1283
Murakami, S. PD-0777
Murase-Mishiba, Y. PD-0955
Muratalina, A. PD-0893
Muratova, S. P-1483
Muriuki, Z. P-1833
Murphy, A.J. OP-0592
Murphy, G.A.V. OP-0238
Murphy, H.L. P-1410
Murphy, M. AbT-2112, P-1794, P-1799
Murphy, R. P-1768
Murray, N. OP-0105
Murthy, G. 0562
Murthy, K. 0562
Murthy, P. 0562
Murugan, S. P-1527, PD-0887
Muscat, G. 0491
Mushtaq, K. PD-0775
Mustafa, G. P-1167
Mustapha, F.I. AbT-2085, P-1880, PD-0962
Mustaqeem, S. P-1436
Mutai, K.K. PD-0996
Mutha, A. AbT-2063
Mutlu, O. P-1038, P-1126
Muzik, J. P-1484
Mwangi, S. AbT-2078
Mwaniga Mwavua, S. P-1868
Mwaniki, D.L. OP-0641
Mwanri, A.W. P-1922, PD-1014
Myers, B.D. PD-0818
Mykytyuk, M. P-1155
Myszka-Podgórska, K. AbT-2149, P-1941
Mythili, S.V. AbT-2108

N

Nadebaum, C. 0538
Nadig, S.V. P-1039
Nadler, J. 0540
Nadler, J.L. OP-0594
Nagar, R. AbT-2096, P-1741
Nagareddy, P.R. OP-0592
Nagashimada, M. OP-0093
Nagata, N. OP-0093
Nahar, N. P-1839, PD-0876
Nahar, Q. P-1742
Naidis, E. PD-0758
Naidoo, P. P-1136
Naidu, M. P-1493
Naila Tokhtarova, M.S. OP-0296
Nakagaki, O. P-1158
Nakagawa, Y. P-1796
Nakahama, T. P-1638
Nakajima, H. P-1910
Nakamaru, K. P-1341
Nakamura, A. PD-0723
Nakamura, H. P-1513
Nakamura, J. 0033
Nakamura, K. P-1335, PD-0992
Nakamura, M. P-1197
Nakamura, T. P-1390
Nakamura, U. PD-0956
Nakao, Y. P-1474
Nakashima, E. P-1264, PD-0954
Nakashotani, I. P-1910
Nakata, K. P-1335
Nakwagala, F.N. P-1974
Nakysh, A. AbT-2105
Nallaperumal, S. P-1413
Nam, J. P-1165, PD-0773
Namba, M. OP-0417
Namur, A. OP-0284
Nan, H. OP-0115
Nan, R. P-1204
Nanayakarra, N. P-1185, P-1856, PD-1033, PD-1034
Nanayakkara, N. P-1861
Nanditha, A. 0315
Nankervis, A. P-1856, PD-1034
Nanri, H. PD-0992
Napartivaumnuay, N. P-1778
Napia, E. P-1795
Naqshbandi Hayward, M. 0261
Naran, N. PD-0714
Narankiewicz, D. P-1293b
Narayan, K.M. OP-0583, P-1969, PD-0769, PD-0951, PD-1023
Narayan, K.M.V. OP-0584, PD-0943, PD-1017
Narayan, R. 0214
Nardi, E. P-1497, P-1500, PD-0810, PD-0814
Narva, A.S. OP-0441
Narvaez, M. P-1731
Naser, M. P-1499
Nash, I. P-1795
Nash, T. PD-1002
Nasiroglu, N. P-1373
Nasralla, E.A. AbT-2050
Nasser, R. AbT-2026
Natarajan, R. 0023
Natoli, A.K. PD-0719
Nauck, M. 0008, P-1310, PD-0675
Nauck, M.A. PD-0677
Naumova, L. AbT-2000, AbT-2060, AbT-2133, P-1223, P-1956
Naumova, M. AbT-2000, AbT-2060, AbT-2133, P-1223, P-1956
Nawalyah, A.G. P-1913
Nawaz, Z. P-1448
Nawroth, P.P. PD-0785
Nawshad, M.H.M. AbT-2016
Nayak, M. P-1492
Naz, F. PD-0876
Naz, S. P-1526, P-1755
Nazaré, J. P-1045
Ndungu Kiogora, E. P-1868
Ndungu, J. P-1709
Neal, B. P-1093
Nebioglu, S. P-1094
Nedergaard, H. P-1584
Neeani, A. P-1375
Neff, T. OP-0076
Nefs, G. OP-0242, OP-0270
Negrato, C.A. P-1981
Neil, J.J. 0538
Nekrep, N. 0335
Nelson, M. OP-0117, OP-0609
Nelson, M.E. AbT-2115
Nelson, R.G. 0206, 0499, PD-0818
Nemes, A. P-1196
Neoh, S. P-1438
Nepom, G.T. OP-0080
Nero, D. P-1617
Neufer, D. 0495
Neufer, P.D. P-1052
Neupane, Y. P-1291
Neuschafer-Rube, F. OP-0229
Neves, C. P-1869
Neves, F. P-1869
Neville, M.J. 0014
Newby, D. P-1958
Newman, J. PD-0831
Newman, P. P-1336
Nezu, U. P-1076
Ng'ang'a, Z. P-1833
Ng, H.S.H. P-1793
Ng, J.M. OP-0442, P-1394, PD-0786
Ng, O.C. P-1178, P-1915
Ng, T. OP-0593
Ngassam, E. P-1228
Ngeuwa, J.L. P-1150, P-1701
Ngoma, Z. P-1961
Ngugi, N.N. P-1709
Nguyen Thi Anh, V. P-1907
Nguyen, C. P-1048
Nguyen, T.K. OP-0265
Ni, J. P-1824
Ni, Y. OP-0093, P-1211
Niantao, A. P-1692
Nicholas, J.A. P-1555
Nicholls, S. PD-0690
Nichols, G. OP-0241
Nicola Tara Dunne, M.S. OP-0296
Nicolescu, A. P-1167
Nicolucci, A. 0382, P-1300, P-1653, P-1670, P-1886, PD-0822, PD-0844, PD-0959, PD-1026
Nielsen, J. P-1779
Nielsen, M. P-1662
Niemeyer, M. PD-0744, PD-0747
Nientao, I. OP-0477
Nightingale, P. P-1877
Nigmatov, M. PD-0931
Nijpels, G. 0347
Nik Mahir, N.J. P-1880
Nikhoo, A. AbT-2127
Nikiema, P. AbT-2163, AbT-2162
Nikolajsen, A. P-1406, P-1898, P-1902, PD-0741, PD-0960
Nikolajuk, A. PD-0722, PD-0725
Nikolic, D. PD-0942
Nikonova, E. P-1066
Nikoopour, E. PD-0737
Ning, F. P-1932
Ning, G. P-1046, P-1319, P-1353
Ning, H.C. PD-0707
Niramitmahapanya, S. P-1778
Niraula, K. P-1806
Nishi, S. P-1918
Nishida, Y. PD-0992

Nishimura, A. P-1677
Nishimura, E. P-1414, PD-0726
Nishimura, H. P-1171
Nishimura, M. P-1783
Nishnianidze, M. P-1719, P-1934
Niskanen, L. P-1399, PD-0789
Nissim, Y. P-1572
Niu, R. P-1153
Niu, R.L. P-1154
Niven, P. P-1930
Njabou Katte, J.C. P-1701, P-1975
Njau, E. PD-0996
Njenga, E. OP-0279, P-1545, P-1709
Njeru, E. PD-0996
Nkombua, L. P-1496
Nkum, B. P-1814
Nkurikiyimfura, J. AbT-2017
Nkwenti, A. P-1573, P-1732
Nkwenti, D. P-1701
Noakes, M. OP-0058, P-1207
Noel, O. AbT-2131
Nogawa, M. PD-0790
Noguchi, M. P-1389
Noh, H.L. 0138
Noh, J.H. PD-0971
Noike, H. PD-0757
Noji, M. P-1429, PD-0695
Nolasco, I. AbT-2154
Nomiyama, R. OP-0590
Nomura, M. PD-0954
Noorelahi, M. AbT-2011
Nora, M. P-1142
Norberg, M. OP-0407
Nordin, R. P-1980
Norfolk, J. P-1711
Norman, M. P-1567, PD-0928
Norman, R. OP-0103, P-1627
Norrman, M. P-1414
Norstrom, J. AbT-2112, P-1798
Nortey, D. P-1814
Northam, E.A. 0538
Nørtoft, E. P-1883, PD-1032
Nosek, L. P-1400, PD-0745, PD-0791
Notoya, Y. P-1121
Novak, B. AbT-1992
Novikov, L.A. P-1225, P-1226, P-1227
Novita, B. AbT-2024
Nowak, M. OP-0654
Nsubuga, R.N. OP-0238
Nugent, R.A. PD-0978
Nugmanova, L. P-1483
Nugroho, F.A. P-1764
Numsangkul, S. P-1957
Nunes, A.C.S. AbT-2025
Núñez Sánchez, M.A. P-1279
Nwaokoro, C.J. P-1850
Nwaokoro, J.C. 0525
Nwaturuocha, I.A. 0572
Nyabundi, J.S. P-1669
Nyström, L. OP-0407

O

O Donnell, T. P-1113
O'Brien, C.L. P-1733
O'Brien, K.T. P-1873
O'Brien, P.E. OP-0077, OP-0234
O'Callaghan, C. PD-0709
O'Connell, M. OP-0433
O'Connor, P.J. P-1514
O'Dea, K. 0326, 0535, OP-0103, PD-0820
O'Donnnell, S. PD-0816
O'Neal, D.N. P-1733
O'Neil, A. P-1745
O'Neil, P.M. P-1608
O'Neill, H.M. OP-0235
O'Rahilly, S. 0228
O'Reilly, L. 0136, P-1366
O'Rourke, S. PD-0807
Oates, L. P-1825
Oats, J. OP-0107
Oats, J.J.N. 0369
Oberg, A. PD-0728
Obimbo, M. PD-0899
Ocampo Francisco, A.M. PD-0673
Ocheretenko, V. AbT-2156, PD-0837
Ochi, F. OP-0417
Oda, H. PD-0777
Odawara, M. P-1348
Oddy, M.J. P-1230
Odeniyi, I.A. P-1843
Odriozola, A. P-1095, P-1096, P-1097, PD-0670
Odriozola, B. P-1095
Odriozola, M. P-1095, P-1096, PD-0670
Odriozola, M.B. P-1096, P-1097
Odriozola, M.N. P-1097
Odriozola, S. P-1095, P-1096, P-1097, PD-0670
Oduneye, A. P-1964
Odunneye, O. PD-0898
Odusan, O. AbT-2161, P-1949
Ofoegbu, E.N. AbT-2161
Ogawa, W. P-1389, P-1390
Ogbera, A.O. PD-0901
Ogden, K. P-1064
Ogeng'o, J. PD-0899
Ogle, G.D. 0130, 0626, PD-0929
Ogrin, R. P-1533, P-1627
Oguchi, K. PD-0658
Oh, J.Y. P-1893
Oh, K.W. PD-1024
Oh, M. P-1513
Oh, S. P-1517, P-1781
Ohashi, K. P-1639
Ohashi, T. P-1283
Ohkuma, T. PD-0956
Ohnishi, Y. P-1910
Ohta, Y. P-1474
Ohtsuka, Y. P-1783
Ohwovoriole, A.E. AbT-2161, P-1843, P-1895
Oida, M. PD-0681
Oka, Y. P-1474
Okabe, J. OP-0620, OP-0622
Okada, H. P-1639, P-1796
Okada, S. P-1480, P-1910
Okafor, C.I. AbT-2161
Okahata, S. P-1337, P-1340, PD-0757
Okajima, M. P-1306
Okawa, T. 0033
Okazaki, K. P-1639
Okihiro, M. 0568
Okondoua, A. P-1701
Oksa, H. PD-0941
Okuno, Y. P-1390
Okura, M.O. AbT-2091
Okusu, Y. P-1197
Okuturlar, Y. AbT-1998
Olchini, D. AbT-2154, P-1575, P-1731, P-1961
Oldenburg, B. AbT-2155, OP-0107, P-1546, PD-0915, PD-0989
Oliva, J.G. P-1315
Oliveira, A.A.F. P-1098
Oliveira, F. P-1372
Oliveira, F.R. AbT-2056
Oliyarnyk, O. PD-0750
Olorunju, S.A.S. OP-0271
Olsen, B. OP-0434
Olsen, J. PD-0728
Olson, E.N. 0541
Oltulu, F. P-1079
Olveda, J. OP-0275
Olveira, G. PD-0754, PD-0921
Omara, A. AbT-2116
Omiste, A. P-1273
Omura, E. P-1933
Omura, M. P-1105, PD-0954
on behalf of all investigators G. Yuan P-1354
on Behalf of BENCH-D Study, . PD-0844
on behalf of DE-PLAN Consortium OP-0405
on behalf of RACE study group, . P-1045
on behalf of the BENCH-D Study Group, . PD-0822
on behalf of the HYPOS-1 Study Group, . PD-0959
On behalf of the NaDIA steering group, . PD-0881
Onai, T. P-1344
Onajole, O. PD-0898
Oncul, M. PD-0799
Onda, M. P-1796
Onetto Flores, M. P-1615, P-1663
Onetto, M. PD-0916
Onishi, Y. AbT-2142, P-1906
Ono, A. P-1910
Oosthuisen, V. AbT-2095
Opaleiko, Y. P-1203
Opegenorth, A. OP-0116
opia vicky, V. AbT-2075
Opoku, A.R. OP-0602
Orchard, T. 0559
Orchard, T.J. P-1823, PD-0932
Oren, M. OP-0586
Ormsby, G. P-1851
Oropesa, L. P-1855, P-1951
Orosz, A. P-1196, P-1251
Oroszlan, G. PD-0893
Orozco, D. P-1599, PD-0834
Orozco-Beltran, D. P-1415
Orr Walker, B. P-1614
Orr-Walker, B. P-1144, P-1528, P-1656
Orsoni, A. P-1090
Ortega, M. AbT-2129
Ortiz, V. P-1111, P-1782
Ortoglu, G. P-1222, P-1376, P-1859
Oruk, G. P-1616
Osawa, M. P-1062
Osborne, B. OP-0599, P-1365
Oshitani, N. PD-0742
Osman, A. PD-0756
Osonoi, T. P-1320
Östenson, C.-G. P-1974
Östenson, C.G. P-1974
Ostrauskas, R. P-1735
Ota, H. P-1425
OTa, T. P-1306, OP-0093, P-1433
Otieno, C.F. PD-0996

Ou, H.Y. OP-0091, P-1199
Oue, K. P-1906
Ouédraogo, M. PD-0877
Ouyang, C.M. PD-0866
Overbeeke, A. 0213
Overland, J.E. PD-0920
Owen, J. P-1497, P-1500, PD-0810, PD-0814
Owen, K.R. P-1443
Owens, D. 0146
Oyer, D. P-1298
Ozaki, R. OP-0415, PD-0864, PD-0972
Ozansoy, G. P-1127
Ozcaka, O. AbT-2035
Ozcan, L. 0180
Ozcan, M.A. P-1176, PD-0889
Ozcan, S. P-1620, P-1648, P-1826
Ozdamar, F. AbT-2076, P-1570
Ozdemir, B. AbT-2061
Ozdemir, R. P-1193
Ozgen, A.G. P-1338
Oztekin, S. AbT-2040
Ozturk Ceyhan, F.B. AbT-2035, P-1338, P-1734
Ozyazgan, S. P-1137

P

P.J., P. P-1206
Pacal, L. P-1487, P-1237
Pacini, G. P-1392, PD-0718, PD-0771
Padhiyar, J.N. P-1411, P-1862
Padma vathi, P. P-1291
Padmanabh kamath, K. P-1183
Pagacova, L. P-1119
Page, A. 0322, P-1113
Painter, R.C. 0156, P-1099
Paiva, A.C. P-1668
Pajukanta, P. OP-0628
Pakasi, T.A. P-1764
Palacio, A. P-1259
Palanivel, R. OP-0235
Palao, D.J. P-1273
Palarie, N. P-1954
Palarie, V. P-1954
Paldánius, P. P-1744
Paldánius, P.M. AbT-1993, OP-0461, PD-0751, PD-0819
Pall, N. 0047
Palmer, A. OP-0652
Palmer, C.N.A. OP-0253
Palmer, H. OP-0649
Palmer, J. 0246
Palmer, K. OP-0612
Palomares, R. P-1599, P-1727
Pan, C. P-1415
Pan, C.Y. OP-0439, P-1270, P-1271
Pan, J.M. P-1391
Pan, S. P-1660
Pan, X. P-1824
Panagiotopoulos, S. PD-0710
Pancratova, O. P-1123
Panda, M. P-1375
panda, P. P-1532
Pandey, R.M. P-1092
Pandit, P. P-1978
Pandolfo, M. P-1111, P-1782
Panduru, N.M. PD-0711, PD-0970
Pang, Z.C. P-1932
Papa, F. 0337
Papandreopoulou, V. P-1316
Papazafeiropoulou, A. P-1434
Paquet, C. P-1769
Paramalingam, N. OP-0070, PD-0917
Parameaswari, B.J. AbT-2108
Parameaswari, P.J. P-1205, P-1361
Pardo Roibas, C. AbT-2058, AbT-2126
Parfentjeva, E.M. PD-0706
Parhofer, K.G. OP-0069
Parijatham, B.O. P-1205, P-1361
Parikh, S. P-1461, P-1467
Parise, C. OP-0275
Park, B.K. P-1431
Park, C. P-1430
Park, C.Y. P-1139, PD-1024
Park, D.B. P-1377
Park, I.B. P-1882
Park, J. AbT-2117, P-1165, PD-0773
Park, J.H. P-1163, P-1903
Park, K. P-1191, P-1404, P-1404, PD-0824, PD-0964
Park, K.G. PD-0685
Park, K.S. P-1314
Park, K.Y. P-1139, P-1314
Park, P. P-1669
Park, P.H. P-1852
Park, S. P-1194, P-1928
Park, S.E. P-1139, PD-1024
Park, S.W. P-1139, PD-1024
Park, T.S. P-1065, P-1073, P-1919, PD-0672
Park, Y. P-1395
Park, Y.H. P-1805
Park, Y.M. PD-0883, PD-0950
Park, Y.S. P-1163
Parker, D. AbT-2112, P-1794, P-1798
Parker, D.(. P-1799
Parkin, C.G. P-1396, PD-0743
Parpala, C. P-1204
Parra Barona, J. P-1293b
Parra, J. PD-0948
Parsian, N. P-1640
Parsons, J. P-1559, P-1560, P-1835
Partridge, H. OP-0081
Partridge, S. PD-0939
Paruk, I.M. P-1453
Parvez, R. P-1851, PD-1012
Parving, H.H. 0521, 0521
Parvizy, S. OP-0456
Pasaporte, F.I. P-1652
Pasenco, T. P-1954
Pasko, D. OP-0254
Pasricha, N. AbT-2155, OP-0430
Pastakia, S. PD-0875
Pastakia, S.D. P-1669
Pasupathi, K. PD-0940
Patal, P. P-1681, PD-0947
Patel, A. OP-0579
Patel, D.C. P-1230
Patel, N.R. OP-0468
Patel, S. P-1104, P-1249, P-1319, P-1353, PD-0692, PD-0693, PD-0696, PD-0697, PD-0698
Patel, S.K. P-1100
Paterno, E. P-1681
Paterno, E.R. PD-0947
Pathan, F. P-1603
Pathan, M. AbT-2002
Pathan, M.F. P-1157, P-1693
Pati, S. PD-0908
Patry, J. P-1217
Patte, C. P-1405
Patterson, C. 0623
Paul, L. P-1802
Paul, R. PD-1027
Paul, T.V. P-1039
Paulin, A. P-1761
Paulmurugan, R. P-1420
Pavic, G. P-1200
Pavkov, M.E. OP-0441, PD-0818
Pawal, P. P-1947
Pawar, A. P-1947
Payami, P. PD-0913
Paz-Pacheco, E. P-1681, PD-0947
Pearen, M. 0491
Pearson, J. OP-0104
Pearson, S. PD-1002
Pedchenets, L. AbT-2140
Pedersen, B.K. 0309
Pedersen, E. P-1201
Pedersen-Bjergaard, U. P-1775
Pederson, B. P-1806
Pedro, B. P-1817
Peer, N. P-1976
Peerally, Z. P-1809
Peeters, A. OP-0114, P-1818, P-1929, PD-0940
Pei, Y.U. PD-0734
Pekdemir, M.E.T.E. AbT-2018
Pelikanova, T. PD-0750
Pellacani, A. P-1468
Pellegrini, F. PD-0822, PD-0844, PD-0959, PD-1026
Peltonen, M. OP-0054, OP-0055, PD-0941
Pena Meilan, C. AbT-2058, AbT-2126
Penfold, S.A. P-1061, P-1118, P-1120, P-1233, PD-0784
Penfornis, A. P-1327, P-1328, P-1329
Peng, X. OP-0079
Peng, Y.D. P-1270, P-1271
Pengyos, S. P-1778
Penna, M.I. PD-0666
Pennazi, M. PD-0666
Pennicks, H. PD-0902
Penno, G. OP-0416, OP-0443
Pereira Cunill, J.L. P-1141
Pereira, A.K. PD-0861
Pereira, S.S. OP-0452
Perera, K.Y.S. P-1574
Perez Rodriguez, C. PD-0923
Perez Rodriguez, J. P-1611
Perez Valero, V. PD-1025
Pérez, A. PD-0968
Perkins, B. 0097
Perkins, B.A. OP-0081
Perkovic, V. P-1093

Perone, M.j. P-1111, P-1782
Perrild, H. P-1550
Perrin, B. P-1835
Perry, J. OP-0250
Perry, L. PD-0934
Persson, F. P-1635
Persson, R. PD-0986
Perucci, L.O. PD-0660
Pesala, K. OP-0411
Peter Zalewski, P. OP-0448
Peterkova, V. 0187, P-1515, PD-0792, PD-0862
Peterkova, V.A. P-1112
Petersen, B. PD-0743
Petersen, C. P-1955
Petersen, K.S. P-1202, P-1923
Petkovic, R. PD-0942
Petrenko, L. AbT-2060, P-1641, P-1956
Petrie, D. OP-0652
Petropolous, I.N. OP-0607
Petrovski, G. P-1516
Pettit, J. AbT-2123
Pettitt, D.J. 0370
Peynirci, H. P-1101, P-1690
Peyrot, M. 0382, 0384, OP-0455, OP-0475, OP-0475, P-1300, P-1581, P-1653, P-1670, P-1726, P-1729, P-1740, PD-0845, PD-0845, PD-0846, PD-0922, PD-0924
Peyrot, M.o.b.o.t.D.S.G. 0381
Pfeiffer, A.F. OP-0229
Pfeiffer, K. PD-0871
Pfeiffer, K.M. P-1044
Pfohl, M. P-1417
Pfützner, A. AbT-2096, AbT-2100, P-1418, P-1722, P-1741, P-1911
Pfützner, A.H. AbT-2096, AbT-2100, P-1418, P-1911
Phan N T, B.I.N.H. P-1979
Phan, T.G. OP-0608
Phatale, H. P-1102, PD-0900
Phatale, P. P-1102, PD-0900
Philis-Tsimikas, A. P-1298, P-1301, PD-0673
Phillip, M. 0374, P-1515, PD-0792, PD-0862
Phillips, B. P-1835
Phillips, P. OP-0476
Philp, K. OP-0277
Phippard, D. P-1047
Phoon, W.Y. P-1867
Piana, N. 0124, OP-0475, P-1653, PD-0845
Pianesi, M. P-1277
Piarulli, F. P-1887
Picard, S. AbT-2088
Pickering, K. P-1753, PD-0966
Pieber, T. OP-0073, P-1322, P-1407, PD-0676
Pieber, T.R. OP-0068, P-1268, P-1834, PD-0755
Pieczynski, J.P. P-1828
Piedrola, G. P-1339
Pierre, J. AbT-2111
Pietiläinen, K.H. OP-0232
Pietrani, N.T. P-1160, P-1355, PD-0660
Pilleron, S. P-1575, P-1961
Pillich, R. 0528
Pilorget, V. OP-0268, P-1417, P-1515, P-1899, PD-0792, PD-0862
Pimpakan, W. P-1966
Pinckney, A. OP-0080, P-1047
Pineda Wieselberg, R.J. P-1576, PD-0856, PD-0858
Pinelli, N. P-1872
Pines, J. P-1547
Pinidiyapathirage, M.J. P-1937, P-1946
Pinnick, K. 0014
Piñol, J.L. OP-0236
Pintaudi, B. P-1886, PD-0822, PD-0844, PD-0959, PD-1026
Pinto Muñoz, J. P-1615
Pinto Muñoz, P. P-1615
Pinto, G. P-1481
Pinto, J. PD-0916
Pinzon Martinez, J.L. AbT-2072
Pinzon, J.L. P-1186
Piotrowicz, A. PD-0920
Pirie, F.J. P-1453
Pita, F. P-1897
Pita, S. P-1897
Plank, L. 0481
Platonova, O. PD-0851
Pleskacova, A. P-1487
Plotnikoff, R. P-1649
Plotnikoff, R.C. AbT-2159, P-1938
Plummer, G. P-1421
Plutzky, J. PD-0680
Pochernyaev, A. P-1203
Podgrebelny, A. P-1762
Podyablonskaya, I.A. P-1225, P-1226
Poitout, V. 0352
Pölönen, A. PD-0941
Polónia, J. P-1045
Poltorak, V. P-1203
Pongpanich, S. P-1665
Ponirakis, G. P-1095, PD-0670
Poole, C. PD-0668
Pop, A. PD-0970
Pop, G. PD-0970
Popa, S. P-1891
Popa, S.G. P-1167
Popkin, B. P-1916
Poplawska, E. P-1399
Popovic, S. P-1368, PD-0942
Porrata, C. P-1276, P-1277
Porter, C. PD-0802
Porter, K. P-1657
Poulsen, K. PD-0986
Poulsen, P. OP-0421, OP-0422, P-1267
Pouwer, F. 0383, OP-0242, OP-0270, P-1745
Powers, A. 0376
Poy, M. P-1384
Pozzilli, P. P-1272, P-1276, P-1277
Prabhakaran, D. OP-0579, OP-0583, P-1874, P-1969, PD-0951, PD-1023
Prabhu, M. P-1696
Prada, P. OP-0616
Pradeep, P. OP-0411
Pradeepa, R. OP-0583, P-1853, P-1914, PD-0951, PD-0980, PD-0981, PD-1005, PD-1009, PD-1035
Prakoso, E. OP-0061
Pramanik, B. OP-0426
Praveen, D. OP-0579
Prazny, M. P-1408
Premaratne, E. PD-0710
Prescott, V. PD-0973
Preyde, M. P-1518
Price, D.W. P-1514
Priede, A. P-1643, P-1678
Prieto de Lamo, G. P-1326
Prieto, L. AbT-2129, P-1548
Prins, J. OP-0591
Pritchard, N. OP-0605, OP-0607, PD-0667, PD-0668
Priya, M. PD-0800, PD-1021
Proietto, J. OP-0601, P-1387, PD-0761
Pronina, E. P-1762
Prunet-Marcassus, B. PD-0661
Prusty, V. OP-0295, P-1261, P-1409
Prystupiuk, L. AbT-2000, AbT-2060, AbT-2133, P-1223, P-1956
Prystupiuk, M. AbT-2000, AbT-2133, P-1223
Prystupiuk, O. AbT-2000, AbT-2060, AbT-2133, P-1223, P-1956
Ptaszynska, A. PD-0708
Pucci, L. OP-0416, OP-0443
Puchulu, F.m. P-1111, P-1782
Puckett, C. OP-0420
Puepet, F. AbT-2161
Pugazhenthi, S. OP-0618
Pugnaloni Rodriguez, N. P-1294
Puhong, Z. OP-0112
Pulinikunnil, T. OP-0235
Pumar-Lopez, A. AbT-2034
Pundt, N. PD-1007
Puno, M. P-1652
Punyani, H. P-1803
Puolijoki, H. PD-0941
Purisa, S. P-1697
Puronaite, R. P-1538, P-1687

Purtell, L. P-1287
Püschel, G.P. OP-0229

Q

Qadri, F. P-1384
Qahtani, S. P-1256
Qian, A. PD-0737
Qian, H. OP-0095
Qian, W. AbT-2138
Qiao, Q. P-1932
Qin, L. OP-0618
Qio, Y. P-1935
Qiu, R. P-1464, P-1466
Qiu, W. OP-0116
Qiu, X. P-1437
Qiu, Y. OP-0272
Qorbani, M. AbT-2139
Quan, J. P-1153
Quan, J.X. P-1360
Quaresma, P. OP-0616
Que, M.T.P. P-1684
Que, X. OP-0629
Quek, K.F. P-1546
Qui, W. P-1649
Qui, Y. P-1617
Quinn, C.C. P-1549
Quinn, L. P-1754
Quiroga, V. P-1111, P-1782
Qureshi, M.A. AbT-1997, P-1162

R

Raab, R. 0573
Raanan, M. OP-0079
Rabassa, A. AbT-2077
Rabøl, R. PD-0791
Radican, L. P-1617, P-1935
Radu, S. PD-0970
Radulian, G. P-1204
Radzeviciene, L. P-1735
Raelson, J. OP-0257
Ragonese, M. PD-1026
Rahate, S. P-1947
Rahayu, S. P-1746
Rahman, A. AbT-2003, P-1177, PD-0684
Rahman, B. P-1813
Rahman, H. P-1960, PD-0821
Rahman, M. P-1695, P-1940, PD-0684
Rahman, S.M.A. P-1470
Rahmat, A. OP-0429
Rai, P. P-1107
Rai, S. AbT-1988
Raihan, A. AbT-2084, P-1494
Raimi, T. AbT-2161
Rais, N. AbT-2085, P-1881
Raitakari, O.T. P-1889
Raizada, A. P-1152
Raj, A. P-1152, P-1808, PD-0752
Raj, S. OP-0463
Rajab, A. P-1488, P-1488
Rajagopal, M. PD-0760
Rajagopalan, S. OP-0598
Rajaguru, P. P-1420
Rajaonarison, T. 0560, P-1797
Rajendran, R. PD-0852
Rajpathak, S.N. P-1935
Raker, V. PD-0759
Raketic, N. PD-0942
Rakhimova, G. AbT-2022, PD-0931
Rakotoarimanana, M. P-1797
Rakotoarisoa, F. P-1797
Rakotomizao, J. 0560
Rakotonirina, C. 0560, P-1797
Rakotonirina, R.I.V.O. P-1797
Raleigh, D.P. 0338
Raleigh, J. OP-0061
Ralls, B. P-1795, PD-0882
Ram Mohan Jhingan, D.R. OP-0297
Ram Mohan Jhingan, M.D. OP-0458
RamaBhat, B. AbT-2079
Ramachandran, A. 0473
Ramachandran, G. P-1803
Ramachandran, K. P-1254
Ramadas, A. P-1546
Ramadhinara, A. 0131
Ramahandridona, G. 0560, P-1797
Ramahandrisoa, E.L.I.E. 0560
Ramaiya, K. P-1922, PD-1014
Ramakrishnan, L. OP-0411
Ramalingam, S. P-1511
Ramamonjisoa, H.A.J.A. 0560, P-1797
Ramarolahy, J. 0560, P-1797
Ramayia, K. OP-0292
Ramazashvili, M. PD-0891
Ramesh, V. P-1819
Ramkumar, K. P-1420
Ramljak, S. P-1911
Ramya Bai, M. OP-0614
Ran, W. OP-0595
Rana Magar, S.B. PD-0753
Rana, A. PD-0673
Ranasinghe, P. AbT-2158, OP-0410, P-1830
Ranasinha, S. P-1861, PD-0985
Ranga, G.S. P-1808
Rangaraj, U. P-1527, P-1587, P-1712, PD-0887
Rangel, R. PD-0907
Ranjani, H. OP-0584, P-1511, PD-0769, PD-0943, PD-1017
Ranjit Mohan, A. P-1914, PD-1017
Ranjit, U. 0391, P-1816, PD-1009
Rankins, D. P-1984
Ranu, H. P-1173, P-1174
Rao, G. P-1527, P-1587, PD-0887
Rao, J. P-1140
Rao, S.G. P-1712
Rao, S.K. 0562
Rao, V. P-1527, P-1712, PD-0887
Raposo, J.F. 0348, P-1664, P-1668, P-1809, PD-0907, PD-0997
Rasero Hernandez, I. P-1333
Rashid, H.O. P-1695
Rashid, T. P-1618, P-1756
Rashidi, H. PD-0913
Raskin, P. P-1468
Rasmussen, B. 0216, 0216, P-1752
Rasmussen, C. P-1795, PD-0882
Rasmussen, O.W. OP-0274
Rasmussen, S. OP-0068, OP-0072, P-1268, P-1299, PD-0789
Råstam, J. P-1263
Ratanachaiyavong, S. P-1619
Rathi, S. P-1152, P-1808, PD-0752
Rathmann, W. PD-1028
Rathore, M.S. P-1378
Ratnam, W. P-1067
Ratner, R. 0398
Ratsitratrinihafa, J.O.S.É. P-1797
Rauch, L.B. P-1063
Rauch, T. PD-0693
Rautio, N. PD-0941
Ravona-Springer, R. AbT-2114
Ravonison, A. P-1797
Ravussin, E. 0199
Ray, J. PD-0982
Rayman, G. PD-0848, PD-0852, PD-0881
Raymond, G. OP-0284
Rayner, C.K. OP-0424, OP-0425, P-1473, PD-0712
Rayner, N.W. OP-0253
Rayner, T. P-1825
Raz, I. AbT-2096, P-1272, P-1741
Raza, S.A. PD-0724
Razafimanatrika, M. P-1797
Razafindrakoto, B.O.D.O. P-1797
Razali, S. AbT-2085
Reach, G. P-1942
Reach, G.R. P-1943
Reading, J. 0328
Rebolledo, A. P-1831
Rebollo, D. P-1053
Reddy, K.S. OP-0411
Reddy, P. OP-0579
Reddy-luthmoodoo, M. PD-0719
Reed, K. OP-0074
Reed, P. P-1656
Rees, S. OP-0116
Rees, T. P-1410
Reese, L. P-1052
Reeve, R. OP-0638
Reeves, D. OP-0468
Rehman, M. P-1896
Reid, M. OP-0118
Reilly, K. OP-0275
Rein, P. P-1179, P-1180, P-1181, P-1182, P-1427, PD-0687, PD-0688, PD-0704, PD-0715, PD-0720, PD-0918
Reis, C.E.G. AbT-2025, P-1924
Reis, C.G. PD-1030
Reis, J.S. PD-0705
Reissig, F. P-1111, P-1782
Reja, A. P-1780
Remadevi, S. P-1253
Ren, J. PD-0656
Ren, L.P. OP-0600
Ren, Q. P-1284, P-1460, PD-0776
Ren, W. P-1103
Ren, Y. P-1307, P-1454, P-1469, PD-0990
Renato Antonio Celso Ferreira, R.A.C.F. AbT-2093
Rendell, M.S. OP-0080
Research Group, D. OP-0236
Resulaj, B. P-1557

Rett, K. OP-0071
Retterath, A.J. PD-0917
Reue, K. OP-0597
Reutens, A.T. 0036
Rewers, A. OP-0428
Rewers, M. 0624, OP-0428
Rezaei, H. P-1982
Rezaeizadeh, A. OP-0593, PD-0656
Rezende, R. AbT-2073, P-1651
Rhaman, M. AbT-2152
Rhaman, M.M. OP-0642, P-1839, PD-1011
Rhee, B.D. P-1903, PD-0971
Rhee, E.J. PD-1024
Rhee, S.Y. P-1517, P-1781
Rhodes, C.J. 0096
Riaz, M. P-1568, P-1618, P-1666, P-1671, P-1682, P-1756, PD-0857
Ribas, V. 0492, OP-0597
Ribeiro, A.J.V. OP-0061
Ribeiro, R.T. P-1809, PD-0997
Riby, L.M. P-1519, P-1802
Richards, T. P-1230, PD-0664
Richter, P. P-1572
Rickard, S. P-1795
Ridderstråle, M. P-1055
Riddle, M. OP-0075
Riddle, M.C. P-1108, P-1718
Riderstråle, M. PD-0748
Ridgers, N. 0324
Rieger, C. P-1405
Rigby, M.R. OP-0080, P-1047
Riley, C. P-1870
Riley, M.D. P-1207
Rimashevski, V. P-1123
Rincón-Sánchez, A.R. AbT-2004
Rios-Burrows, N. OP-0441
Rishi, R. P-1403
Rissanen, A. OP-0232
Ritzén, H. PD-0657
Rivas Fernandez, M. P-1610
Rivero, B. P-1315
Rizk, S. P-1311
Rizvi, A. AbT-2042, OP-0287, P-1721
Rizvi, Z.A. P-1682
Rizzardi, J.L. PD-0666
Robbins, D. AbT-2038
Roberston, I. P-1064
Robert, D. AbT-2020
Roberts, B. OP-0076
Roberts, G.A. P-1873
Roberts, H. P-1648
Roberts, L. AbT-2069, P-1571, P-1751
Robertson, N. OP-0254
Robinson, R. P-1050
Robu, M. PD-0970
Roby, H.C. PD-0917
Roca Rodríguez, M.M. AbT-2135
Roca, D. P-1623
Roca-Rodríguez, M.M. P-1186
Rodbard, H. PD-0746
Rodbard, H.W. OP-0072, OP-0082, OP-0421, OP-0422, P-1267, P-1301, P-1302, P-1304, PD-0673
Roderick, P. AbT-2068
Rodgers, G. 0150
Rodrigues, E. PD-0739
Rodrigues, K.F. P-1160, P-1355, PD-0660
Rodriguez Bada, P. P-1293b
Rodriguez Fernandez, C. AbT-2058, AbT-2126
Rodríguez, J. P-1315
Roepstorff, C. P-1400, P-1407, PD-0791
Rogers, S. OP-0588
Roglic, G. 0148, OP-0582
Rogulj, D. AbT-1992
Rojanasaksothorn, S. P-1966
Rojas, M.J. AbT-2077
Rojo, G. PD-0948, PD-1025
Rokeya, B. P-1129, P-1470
Rokiah, M.Y. P-1913
Rokne, B. AbT-2019
Rokne, B.R. P-1632
Rolandsson, O. OP-0407
Roldán, C. P-1727
Roman, G. P-1891
Romanov, V.V. PD-0706
Rombolli, P. P-1651
Romeijnders, A. PD-0995, PD-1029
Romero Correa, M. P-1612
Romero Lluch, A.R. P-1141
Romero-Antonio, Y. AbT-2052
Romero-Lluch, A.R. AbT-2034
Roncella, E. P-1276, P-1277
Ronda, C. P-1356, P-1371
Rong, S. PD-0976
Roos, B. P-1951
Roque, F. P-1817
Rorsman, P. 0364
Rosamond, W. P-1916
Rose, K.J. AbT-2088, AbT-2103
Rose, V. P-1937, P-1946
Rose-John, S. P-1366
Roseboom, T.J. 0156, P-1099
Rosen, E. 0013
Rosen, V.M. P-1935
Rosengård-Bärlund, M. PD-0702
Rosenstock, J. PD-0693, PD-0697, PD-0744
Rosiji, K. AbT-2092
Ross, G. PD-0793
Ross, S.A. P-1104
Rossi, M.C. P-1886, PD-0822, PD-0844, PD-0959, PD-1026
Rossing, P. 0500
Rost, S. OP-0612
Rotem, M. OP-0586
Rothberg, A.E. AbT-2141
Rouf, R.S. P-1960
Round, R. P-1877
Roux, S. P-1507, PD-0659
Rovira, A. AbT-2129, P-1548
Rowan, J. 0481
Rowe, E. PD-0791
Rowley, K.G. 0264
Roy, A. OP-0411
Roy, D.M. OP-0442
Roy, T. 0019
Rozati, R. OP-0579
Rozmus, C. P-1582
Ruan, Z. OP-0601
Rubin, D.J. P-1108
Rubio, E. PD-1025
Rubio, I. PD-0754
Rucci, E. P-1909
Ruchi, V. P-1927
Rückert, I. PD-1028
Rudroju, N. P-1878
Ruggiero, L. P-1754
Ruiz Alvarez, V. P-1277
Ruiz de Adana, M.S. P-1273, P-1274, P-1577, PD-0754, PD-0921
Ruiz de Adana, M.S.p. PD-1025
Ruíz Gómez, J. P-1056
Ruiz Morosini, M. 0215
Ruiz, M. PD-0935
Ruiz-Nava, J. P-1186
Ruiz-Sánchez, E. PD-0850
Rush, E. 0481
Rush, W.A. P-1514
Rusia, U. PD-0752
Russell, A. OP-0607, PD-0915
Russell, A.W. OP-0605, PD-0667, PD-0668
Russell, K. 0569
Russell-Jones, D. OP-0068
Russell-Jones, D.L. P-1301
Russo, E. OP-0416, OP-0443
Russo, R. OP-0416, OP-0443
Rusu, E. P-1204
Rusu, F. P-1204
Rutkowska, J. AbT-2149, P-1828, P-1941
Ryan, A. PD-0765
Ryan, M. P-1534
Ryan, M.T. 0494
Rybkina, I. P-1762
Ryder, J. PD-0743
Ryder, R.E.J. P-1349
Rytter, K. PD-0748
Ryu, J.Y. P-1446

S

Saad, M. OP-0616
Saade, G. P-1099
Saade, R. 0526
Saaristo, T. PD-0941
Saatov, T. P-1147
Sabahi, Z. P-1224
Sabin, M.A. P-1889
Sabir, R. AbT-2048, P-1435, P-1436
Saboo, B. AbT-2063, P-1263, P-1787, PD-1000
Saboo, B.D. P-1411, P-1862
Sabrina Flora, M. P-1806
Sacan, O. P-1038, P-1125, P-1131
Sadeghian, H. P-1679
Saeed, M.A. PD-0674
Saely, C.H. P-1179, P-1180, P-1181, P-1182, P-1427, PD-0687, PD-0688, PD-0704, PD-0715, PD-0720, PD-0918
Saemann, M.D. P-1392
Saereeratanakorn, J. P-1966
Safdar, S. P-1968
Safina, A.I. P-1449, P-1450
Sagarra, R. OP-0236
Saghiri, R. AbT-2037

AUTHOR INDEX

Sagna, Y. AbT-2118, AbT-2162, AbT-2163, PD-0877
Sagyndykova, A. PD-0893
Saha, C. OP-0612
Sahathevan, S. P-1067
Sahin, I. AbT-2010, AbT-2061, P-1540
Sahin, S. P-1079, P-1080
Sahinoglu Keskek, N. P-1859
Sahu, M. P-1530, P-1602
Saienko, Y. PD-0772
Saikali, K. OP-0076
Saikia, B. OP-0430
Sainbileg, S. AbT-2071, P-1723
Sáinz de la Maza Viadero, M. PD-0833
Saisho, Y. P-1168
Saito, H. P-1171
Saito, I. P-1168
Saito, M. P-1320
Sajj, J. P-1228
Sak, I. AbT-2027, P-1845
Sakagami, H. OP-0450
Sakaguchi, K. P-1389, P-1390, PD-0694
Sakai, S. P-1471, P-1472
Sakamoto, K. P-1105, P-1337, P-1340, P-1910, PD-0757
Sakamoto, T. PD-0992
Sakanaya, E. P-1578
Sakane, A. OP-0590
Sakane, N. P-1796
Sakashita, A. P-1933, PD-0742
Sakurai, K. P-1363
Sakuramoto-Tsuchida, S. P-1425
Salako, O. P-1964, PD-0730
Salazar-Montes, A.M. AbT-2004
Saleem, A. P-1592
Saleh, F. P-1730, P-1953, PD-0867
Saleh, H. P-1138
Salem, A. AbT-2090, AbT-1994
Saler, T. P-1222, P-1376, P-1859
Sales, M. AbT-2039, P-1372
Sales, M.F. AbT-2056, P-1356, P-1370, P-1371
Salgueiro, L. P-1951
Salgur, F. P-1616
Saliba, A. PD-0669
Saligram, N. P-1511
Salihovic, S. PD-1018, PD-1019
Salinitri, F. P-1872
Salko, O. AbT-2140
Salles, J.E. P-1300
Salmon, J. 0324
Saluja, S. P-1092
Salutini, E. P-1885
Salzberg, M. P-1733
Sameed, M.S. AbT-2130
Samiullah, S. AbT-2006
Samman, S. P-1968
Samocha-Bonet, D. OP-0231, P-1287
Sampedro, M. P-1308
Sampson, G.P. OP-0607
Samukawa, Y. P-1471, P-1472
San Juan-McNulty, A. P-1334
Sanal, G. AbT-2107, OP-0294, P-1552
Sanchez de Enciso Ruiz, M. AbT-2058
Sanchez de Enciso, M. AbT-2126
Sánchez Goitia, M. PD-0788
Sanchez, C. P-1330
Sánchez, I. P-1273, P-1274, P-1308
Sanchez, M. OP-0645, P-1452, P-1502
Sancho Bornez, V. OP-0416, OP-0443
Sandalci, L. AbT-2026
Sandbæk, A. OP-0651
Sanders, A. 0344, AbT-2068
Sanders, T.A.B. 0511
Sandholm, N. PD-0711
Sandhu, H.K. PD-0843
Sandhu, M.S. OP-0238
Sandoval, M.A.S. P-1681, PD-0947
Sandstrom, A. PD-0728
Sangare-Bah, M. P-1706, PD-0859
Sangdee, W. P-1619
Sano, T. P-1264, PD-0954
Sanogo, S. P-1692
Santamaría-Fernández, S. OP-0267
Santini, M. P-1885
Santos, I.R. AbT-2056
Santos, M. P-1142
Sanz, A. P-1332
Sanz, P. P-1293b
Sarac, F. AbT-2021, AbT-2106, P-1699, PD-0682
Sarac, S. AbT-2106, P-1699
Sarac, S.E.F.A. PD-0682
Saraheimo, M. 0226, PD-0702, PD-0711
Sarbadhikari, S. AbT-2087
Sardà, N. AbT-2077
Sarink, D. OP-0240
Sarkar, D. PD-0811
Sartore, G. P-1887
Sartorelli, D.S. OP-0106, OP-0639
Sartorius, N. OP-0115
Sasaki, S. OP-0427
Sasaki, T. OP-0590, P-1471, P-1472, P-1472
Sasaki, Y. P-1283
Sasidharan, P.K. P-1253
Sathaye, S. AbT-2055, P-1232
Satheannoppakao, W. P-1665
Sathish, T. AbT-2155
Satish, R. PD-0957
Satman, I. P-1275, P-1620, P-1697
Satman, I.$. P-1826
Sato, K.K. AbT-2142, P-1906
Sato, M. PD-0728
Sato, S. P-1197, PD-0658
Sato, T. P-1783, P-1910
Sato, Y. P-1471, P-1480, PD-0763
Satoh, H. 0132
Satoh, J. 0132
Satoh, S. P-1076
Sattar, N. 0331
Sattarov, I. PD-0851
Sauer, I.M. OP-0229
Saul, R. PD-0838
Saunders, R. P-1508
Sauvé, Y. PD-0760
Savage, S. OP-0464, P-1725, PD-0842
Savas, S. AbT-2021, AbT-2106, P-1699, PD-0682
Savkin, I.D. P-1226, P-1227
Saw, A.M. OP-0442
Sawadogo, M. PD-0877
Saxena, S. P-1700
Sayadi, H. AbT-2082, P-1728
Saydah, S.H. OP-0237, PD-1004, PD-1006
Sayeed, M.A. AbT-2152, OP-0642, P-1695, P-1839, PD-1011
Sayeed, S. OP-0642
Saygili, F. P-1338
Scanlon, P.H. OP-0446
Schaan, B. P-1481
Schaan, B.D. PD-0919
Schatzman, B. OP-0275
Schellevis, F. 0347
Scherbaum, W.A. P-1417
Scherer, P.E. 0542
Schernthaner, G. P-1489, P-1789, P-1790, PD-0698
Schernthaner, G.-H. P-1489
Schernthaner, G.H. P-1790
Schernthaner, G.H.S. P-1789
Schertz-Sternberg, P. P-1060
Schertzer, J.D. OP-0235
Schlaeppi, M. AbT-2086, P-1535
Schlaich, M.P. 0143
Schluckebier, G. P-1414
Schmid, F. P-1180
Schmidt, H. OP-0620, OP-0622
Schmidt, H.H.H.W. PD-0780
Schmidt, M.I. 0372, OP-0582
Schmidt, T. PD-0759
Schmieder, R.E. OP-0647
Schnaider-Beeri, M. AbT-2114
Schneider, J. P-1958
Schneider, M. P-1931
Schneider, S. OP-0647
Schnell, O. AbT-2145, P-1456, P-1465, PD-0766
Schoenaker, D.A.J.M. PD-0937
Schoene, K. P-1776
Schofield, D. P-1497, P-1500, P-1676, PD-0814
Schubertova, M. P-1119, PD-0665
Schudmann, K. P-1708
Schuffeneger, K. PD-0916
Schulz, B. P-1118
Schunemann, H.J. OP-0582
Schunk, M. PD-1028
Schwab, P. P-1617
Schwabe, J.W.R. OP-0628
Schwanbeck, M. PD-0657
Schwarz, P. OP-0405
Schweitzer, M.A. P-1396, PD-0743
Schwennesen, N. PD-0839
Scibilia, R. PD-0926
Scoble, J. P-1366
Scott, A. PD-0848, PD-0852
Scott, J. AbT-2089
Scovelle, A. PD-0926

Scratch, S.E. 0538
Scuffham, P. PD-0915
Se, C.H. P-1067
Sea, S. P-1788
Secil, M. P-1176
Seck, T. PD-0696
Secret, B. P-1493, P-1498
Seed, S. P-1952
Seeley, J. OP-0238
Segal, L. OP-0273
Seghda, A. AbT-2118
Seguchi, T. P-1341
Segura, A. PD-0948
Sehra, D. AbT-1990
Seied Fatemi, N. OP-0456
Seiler, S. 0310
Seino, S. 0191
Seino, Y. 0006, P-1081, P-1114, P-1115, P-1471, P-1472
Seita, A. 0526, PD-0888
Sekar, T. P-1420
Sekerija, M. OP-0582
Selfa Cabrera, M.E. AbT-2135
Selivanov, V. AbT-2140
Seliverstov, D.V. P-1225, P-1226, P-1227
Selvakumar, A. P-1498
Semenovich, A. AbT-2121
Semenovich, J. AbT-2121
Semprasert, N. PD-0732, PD-0733
Semsarian, C. PD-0781
Sen Gupta, P. P-1349
Sen, S. P-1101
Senavirathne, C.P. AbT-2155
Sendon Perez, A. P-1590, P-1611, P-1612
Senes, S. PD-0973
Senevirathne, C.P. AbT-2122, P-1939
Seng, G. P-1350
Sengupta, R. P-1978
Senior, P.A. P-1342
Seo, H.A. PD-0685
Seo, J.A. P-1446
Seoane, T. P-1897
Seok, H. P-1892
Serafinceanu, C. P-1891, PD-0970
Serrabulho, L. P-1668
Serrano Aguayo, P. P-1141
Serrano Olmedo, I. P-1612, PD-0923
Serrano-Rios, M. PD-0948
Sertkaya, A. P-1193
Sesti, G. P-1886
Seto, N. P-1642, P-1654
Seto, N.s. AbT-2091
Setyobroto, I. P-1110
Seufert, J. P-1055, P-1310
Seuring, T. PD-0933
Seuring, T.I.L.L. OP-0112
Sewram, A. P-1579, P-1863
Sezer, K. AbT-2036
Shabelnikova, O. PD-0958
Shackel, N.A. OP-0061
Shadli, S.M. P-1129
Shafie, A.A. P-1898, P-1902, PD-0741
Shah, A.N. P-1411, P-1862
Shah, B. P-1559
Shah, M. OP-0432
Shah, N. PD-0795
Shah, S. P-1261
Shah, S.J. P-1411, P-1862
Shahbazian, H. AbT-2127, AbT-2127, PD-0913
Shahbazian, H.b. P-1231, P-1875
Shaheen, M. AbT-2011
Shahin, Y. 0526, PD-0888
Shahrukh, M. P-1236
Shahzad, A. PD-0775
Shaikh, F. AbT-2132, P-1925
Shaikh, I. 0526
Shaikh, S. AbT-2006, AbT-2063
Shaikh, Z. AbT-1997, P-1162
Shakirov, K.H. PD-0851
Shaltout, I. P-1157, P-1523
Shamalov, R. P-1572
Shamanna, P. P-1412
Shamansurova, Z. P-1128, P-1147
Shamkhalova, M. P-1240
Shang, D. PD-0691
Shankar, A. AbT-2107, OP-0294, P-1552, P-1844
Shankar, N.K. OP-0413
Shankar, R. OP-0272, OP-0426
Shankar, R.R. P-1068
Shankar, S. OP-0426
Shanthi, B. AbT-2108, P-1205, P-1361
Shao, Q. P-1317
Sharda, A. P-1587, PD-0887
Sharker, M.A. PD-0897
Sharma, A. OP-0476, PD-0779
Sharma, B.R. P-1947
Sharma, D. P-1865
Sharma, K. P-1819
Sharma, K.K. P-1787, PD-1000
Sharma, N. P-1378, P-1689, PD-1031
Sharma, S. P-1689, PD-0852
Sharma, S.B. P-1134
Shata, M. AbT-2098
Shaukat, S. P-1135, PD-0724
Shaw, J. P-1864, PD-0963, PD-0973, PD-1001
Shaw, J.E. OP-0114, OP-0234, OP-0240, OP-0269, OP-0406, PD-0949
Shaw, W. P-1093
Shaybek, A.G. AbT-2043
Shea, S. P-1600
Sheeshka, J. P-1518, PD-0826
Shefin, S.M. P-1693
Shehu, A. AbT-2047, P-1557
Sheikh, A. P-1495
Shelestova, E. 0561, AbT-2104, AbT-2124, P-1309, P-1505, P-1591, P-1605, P-1641, P-1704, P-1719, P-1972, PD-0891
Shen, D. P-1437
Shen, H.N. PD-0994
Shen, J. OP-0604, P-1190, P-1212
Shen, L. P-1595
Shen, S. P-1343
Shen, Y. P-1122
Shen, Z.F. P-1122
Shendge, A. P-1864
Shepelkevich, A. AbT-2140
Shephard, A.K. PD-0804
Shephard, M.D.S. PD-0804
Shera, A. P-1749
Sherchan, J.B. P-1694
Sherifali, D. P-1562
Sheriff, M.H.R. AbT-2158
Sheriff, R. P-1830
Shestakova, M. 0187, AbT-2028, P-1281
Shethna, V. P-1601, P-1661
Shetty, K. PD-0811
Shetty, R. P-1393, P-1412, P-1413, P-1601, P-1661, P-1894
Shetty, V. PD-0917
Sheu, S.J. P-1904
Sheu, W. 0185
Sheu, W.H.H. AbT-2145, P-1456, P-1465, PD-0678, PD-0766
Shi, H. P-1343
Shi, Z. PD-1008
Shiba, T. P-1105, P-1337, P-1340, PD-0757
Shibasaki, T. 0191
Shide, K. P-1680
Shieh, S.H. PD-0855
Shih, C.C. P-1539
Shih, S.T.F. P-1944
Shiki, K. PD-0692
Shill, J. P-1506, P-1950, P-1984
Shimizu, H. P-1344
Shimizu, Y. P-1588, P-1638, P-1642, P-1654, P-1677
Shimizu, Y.S. AbT-2091
Shimura, K. P-1062, P-1078
Shin, C. PD-0991
Shin, J.Y. P-1807
Shin, M.S. P-1805
Shin, S. AbT-2117
Shin, S.J. PD-0729
Shinchi, K. PD-0992
Shirai, K. P-1340
Shirakawa, H. PD-0658
Shiruhana, A. PD-0878
Shiu, S.W.M. PD-0703
Shivaraj, V. P-1527, P-1587, P-1712
Shivashankar, R. OP-0583, P-1969, PD-0951, PD-1023
Shobana, S. P-1927
Shoeibi, S. P-1488
Shoelson, S. 0135
Shoji, M. P-1796
Shomali, M. P-1345
Shon, H.S. P-1374
Shong, M. P-1971
Shrestha, A. P-1124
Shrestha, L. PD-0753
Shrestha, R. PD-0753
Shu, D.H.W. PD-0746
Shu, H.U.A. PD-0734
Shukla, R. P-1580
Shuto, Y. P-1404b
Shuzbaeva, G.O. P-1419
Shyshko, O. AbT-2005, P-1215
Sian Oh, M. PD-0803
Siciliano, T. P-1106

Siddiqui, S. PD-0884
Sidibe, A.T. OP-0477
Siebel, A.L. PD-0719
Siegel, K. OP-0239, PD-0978
Sierra-Johnson, J. P-1468
Sievenpiper, J.L. AbT-2143, P-1917, P-1918, P-1926, PD-0977
Sigal, R. P-1938
Sigal, R.J. P-1475
Sighn, A. P-1500
Siguero Sánchez, A. P-1293b
Sihag, B. P-1216
Sikivou, B. 0397
Sikivu, B. OP-0105
Silberberg, C. P-1733
Silink, M. 0188, 0623, 0626, PD-0929
Silitonga, A. AbT-2046
Silva, A.S. OP-0106, OP-0639
Silva, E. P-1651
Silva, F.S. AbT-2056
Silva, I.F.O. P-1356, P-1371
Silva, K.D.R.R. P-1357
Silva, M. P-1665
Silva-Nunes, J. AbT-1991
Silventoinen, K. P-1932
Silverstein, A. 0051
Sim, M. PD-0940
Sim, X. OP-0254
Simeonova, S. P-1485
Simioni, N. P-1887
Simmons, D. 0436
Simmons, L. PD-0686
Simmons, R.K. OP-0059, OP-0440, OP-0651, PD-0909
Simon, D. OP-0069, PD-0937
Simon, L. 0380, P-1736
Simons, M. 0260
Simonsen, S. P-1795
SImonson, G. OP-0104
Simonsson, M. PD-0657
Simunko, N. P-1759
Sinclair, A. 0333
Sinding-Olsen, A. OP-0434
Singer, J. AbT-2030
Singh, A. P-1497, PD-0810, PD-0814
Singh, B. PD-0737
Singh, K. AbT-2155, P-1107, PD-0884
Singh, S. PD-0795
Singhal, S. P-1393
Sinha, A. 0460, OP-0107
Sinha, A.K. P-1291
Sinha, S. OP-0100
Siraj, E. P-1780
Siraj, E.S. P-1108
Sirohi, P. P-1216, P-1865
Sissoko, D. OP-0477
Sivagnanasooryar, C. OP-0644
Sivakanesan, R. P-1357
Sjöstrand, M. P-1346
Sjostrom, L. OP-0055, OP-0054
Skhiladze, E. P-1719, P-1934
Skibova, J. P-1119
Skinner, M. P-1737, P-1801
Skinner, T. OP-0281, P-1835, PD-0802
Skinner, T.C. OP-0279b, OP-0643, P-1676
Skjødt Sørensen, M. OP-0292
Skovlund, S.E. PD-0822, PD-0844
Skryplionak, T. P-1123
Skyler, J.S. 0358
Slattery, R. OP-0090
Slevin, M. P-1042
Small, L. P-1365
Small, R. AbT-2164
Smallman, K. P-1753
Smith, A.M. OP-0447
Smith, B. 0569
Smith, C. OP-0107, P-1052
Smith, K. AbT-2042, P-1721, P-1861
Smith, M.A. P-1519, P-1802
Smith, N. PD-0659
Snell, H.J. P-1536
Snell-Bergeon, J. OP-0074
Snoek, F.J. 0163
Snyder, W. P-1468
So, W. OP-0414, PD-0972
So, W.Y. OP-0415, OP-0418, OP-0445, PD-0864
Soare, A. P-1276, P-1277
Soares, L.P. OP-0106, OP-0639
Soares, S. AbT-2093, P-1490
Sobki, S. P-1256
Sobngwi, E. P-1150, P-1228, P-1278, P-1614, P-1975, PD-0911
Sobrepena, L. OP-0265
Sobrevilla-Navarro, A. AbT-2004
Socas Macías, M. P-1141
Soedamah-Muthu, S.S. PD-0937
Soegondo, S. 0131, AbT-2145, P-1456, P-1465, PD-0766
Soenen, S. PD-0765
Soewondo, P. P-1259, P-1401, P-1402
Sofronoff, S. P-1643
Sogbein, O. AbT-2092, P-1949
Sohael, F. P-1940, PD-0684
Sohal, P. PD-0936
Soheilikhah, S. PD-0894
Soita, D.J. P-1973
Sojarullah, S. P-1110
Søjle, K.S. P-1415
Sokwalla, S. P-1847
Solari, C. P-1564
Soldatos, G. P-1861
Soldatovic, I. OP-0066, P-1368
Soleymanlou, N. OP-0081
Solis, C. OP-0067
Solmaz, V. P-1080
Solntsava, A. AbT-2121
Soltész, G. 0623
Somani, G. AbT-2055, P-1232
Somannavar, M. P-1631
Son, J.I. P-1517, P-1781
Son, J.W. AbT-1996, P-1189
Son, T.S. P-1432
Song, K. P-1109
Song, K.H. AbT-1996, OP-0056, P-1189, P-1432, P-1919, PD-0883
Song, Q. OP-0060
Song, S. P-1313
Sönnichsen, A.C. PD-0836
Sonoda, N. OP-0427
Sonomtseren, S. P-1166
Sonya, J. P-1849, PD-1021
Soprovich, A. P-1649
Sørensen, A.R. PD-0726
Sorensen, L. PD-0920
Soria Cogollos, T. P-1056
Sorial, A. P-1951
Soriano Palao, J. P-1279
Soriano Sánchez, R. P-1279
Soriguer, F. P-1577, PD-1025
Sóter, M. AbT-2039, P-1372
Sóter, M.O. AbT-2056, P-1370, P-1371
Soter-França, M.O. P-1356
Sothilingam, K. P-1574
Soto Gonzalez, A.S.G. P-1347
Soubhanneyaz, A. AbT-2011
Souhami, E. OP-0454
Sourris, K.C. P-1118, P-1120, PD-0784
Sousa, L.P. PD-0660
Sousa, M. AbT-2039, P-1372
Sousa, M.O. AbT-2056, P-1356, P-1370, P-1371
Sousa, Z. P-1869
Southey, K. 0569
Soyluk, Ö. AbT-1998
Soyoye, D. P-1621
Sparrow, L. P-1366
Speight, J. OP-0242, OP-0279b, OP-0281, OP-0457, P-1745, PD-0926
Sperl-Hillen, J.M. P-1514
Sperling, M.A. 0388
Spertus, J. P-1805
Spiegelman, D. OP-0614
Spier, V. OP-0275
Spigelman, A.F. OP-0447
Spirakis, R. OP-0275
Sreckovic, B. OP-0066, P-1368
Sreedevi, A. P-1800
Sreenan, S. PD-0744
Sriharsha, R. P-1712
Srikanta, S. P-1527, P-1587, P-1712, PD-0887
Srikanth, V. OP-0608
Srinivasan, S. OP-0605, PD-0667, PD-0668
Srivastava, P.M. P-1100
Srivastava, R. P-1220
STAELS, B. 0319
Stahel, P. PD-0762
Staimez, L. OP-0584
Staimez, L.R. PD-0943, PD-1017
Standfield, S. PD-0767
Standl, E. 0160
Stanik, J. P-1444, P-1445
Stanikova, D. P-1445
Starkstein, S.E. AbT-2115, OP-0117, OP-0609, OP-0643
Stathopoulos, M. P-1387
Steenhoff, A. OP-0118
Steensgaard, D.B. P-1414

Stefan, L.I. P-1167
Stefan, N. OP-0449
Stefan, P. P-1974
Stefanovic, N. PD-0779
Stefanowicz, M. PD-0722, PD-0725
Steffen, C. PD-0807
Steinbeck, K.S. PD-0934
Steinberg, G. OP-0235
Steinberg, H. OP-0413
Steinberg, H.O. OP-0426
Steinbrink, K. PD-0759
Steinert, R.E. PD-0765, PD-0767
Steinhólm, H. PD-0993
Stenlund, H. OP-0407
Stenov, V. PD-0839
Stevens, D.E. OP-0404
Stevenson, C. P-1818
Stevenson, V. AbT-2069, P-1571, P-1636
Stewart, A.V. OP-0286
Stewart, A.W. P-1768
Steyn, K. P-1976
Stichert, M. OP-0276
Stier, C. OP-0071
Stitt, A. 0503
Stoch, S.A. OP-0426
Stoeckli, J. 0467
Stoffel, M. 0020
Stojanovski, E. P-1912
Stone, M. P-1280
Stoneman, A. PD-0808
Stopher, J. 0288
Straczkowski, M. PD-0722, PD-0725
Stratton, I. P-1877
Stratton, I.M. OP-0446, P-1873
Straus, S. P-1560, P-1647
Straus, S.E. P-1559
Strauss, H.M. P-1414
Strazzabosco, M. P-1887
Stribling, B. P-1676
Stride, A. PD-0873
Strock, E. AbT-2112, P-1794, P-1798, P-1799, PD-0755
Strupas, K. P-1145
Stuckey, B. P-1959
Stuckey, H. OP-0475, P-1581, P-1726, PD-0845, PD-0846, PD-0922
Sturt, J.A. PD-0843
Su, B.L. OP-0439
Su, Y.C. OP-0091
Su-Yen, G. P-1401
Subashini, P. P-1205, P-1361
Subhashree, A.R. AbT-2108, P-1205, P-1206, P-1361
Sudha, V. OP-0614, P-1914
Sudhoff, S. OP-0279
Sugahara, D. PD-0778
Sugi, K. PD-0757
Sugihara, K. P-1474
Sugimoto, T. P-1175, PD-0683
Sugiyama, T. P-1520, P-1578
Suh, S.H. P-1074, P-1075
Suker, A. P-1287
Sulaiman, N. P-1864
Sulehri, F.U. PD-0775
Sulima, T. P-1155
Sulistyowati, Y. P-1110
Sulpice, T. PD-0661
Sultana, R. PD-0912
Sultana, S.N. P-1940, PD-0684
Sultanalieva, R. PD-0998
Suma, R. P-1254
Summers, R. PD-0728
Summers, R.J. P-1091
Summers, S.A. 0015
Sumpton, C. P-1757
Sun, B. PD-0734
Sun, F. P-1354
Sun, J.H. P-1295
Sun, L. OP-0598
Sun, P. P-1083, P-1084, P-1085, P-1086
Sun, Q. OP-0598, P-1595
Sun, R.Q. P-1379
Sun, X. P-1288, P-1458
Sun, Y. P-1884
Sundar, P. AbT-2023
Sung, P.K. PD-0770
Sung, Y.S. P-1893
Sungono, V. P-1876
Suntsov, Y. 0187
Suparee, N. PD-0914
Surassanant, S. P-1619
Susano, J. P-1668
Suvd, J. AbT-2071, P-1723
Suzuki, M. P-1348
Svacina, S. P-1143, P-1451
Svendsen, A.L. P-1400, P-1407, P-1415
Svendsen, C. P-1345
Svendsen, C.B. PD-0675, PD-0677
Svensson, A. OP-0652
Svensson, J. OP-0434
Sviridov, D. PD-0719
Swain, S. PD-0908
Swanson, C.E. PD-0809
Swinburn, B. 0026
Syed Zulfiquar Ali, S. AbT-2006
Szabo, A. OP-0617, P-1151, P-1367, P-1447, PD-0768
Szabo, M. AbT-2165, P-1251
Szetu, J. 0397, OP-0105
Szmedra, P. P-1582
Szyndralewiez, C. OP-0620, OP-0622, PD-0780

T

Ta Thi, L. P-1907
Tabak, O. AbT-2027, P-1845
Tabas, I. 0180
Taborsky, G. OP-0453
Tachibana, K. P-1363
Tack, C. P-1055
Tack, C.J. 0123
Tada, Y. P-1175
Tagami, M. P-1105
Taguchi, A. P-1474
Taguchi, K. PD-0681
Taguchi, N. PD-0992
Taheta, S. P-1041
Tahir, B. AbT-2137, P-1526, P-1666, P-1671, P-1755, P-1848
Tai, E.S. P-1763
Tai, T.S. AbT-2013
Tajar, A. PD-0700
Tajima, N. 0086
Takács, R. P-1196, P-1251
Takahashi, H. 0191, P-1480
Takahashi, K. 0132
Takahashi, S. PD-0658
Takahashi, T. 0191
Takamura, H. PD-0790
Takamura, M. P-1306
Takamura, T. P-1306, P-1433
Takano, A. PD-0777
Takasawa, S. P-1425
Takaya, K. P-1429, PD-0695
Takayanagi, R. OP-0427
Takeda, M. P-1425
Takeda, S. P-1168
Takeda, Y. P-1171, P-1685
Takekawa, S. P-1283
Takeuchi, F. OP-0252
Takiyama, Y. OP-0450, PD-0713
Takizawa, A. P-1685
Talabi, J. P-1525
Talaviya, P.A. P-1411, P-1862
Talley, M. PD-0838
Tam, C. OP-0414
Tama, G. P-1614, P-1701
Tamagawa, A. P-1390
Tamaki, M. P-1243
Tamaki, S. P-1425
Tamayanti, W. AbT-2024
Tamayo, D.C. AbT-2157, P-1962
Tamghe, F. P-1701
Tamir, M. P-1272
Tamminen, I. PD-0692
Tan, C.Y. P-1861
Tan, K. PD-0793
Tan, K.C.B. PD-0703
Tan, M. 0565, P-1628
Tan, M.C. P-1178, P-1915
Tan, R. P-1090
Tan, S.M. PD-0779
Tanabe, K. P-1474
Tanaka, A. P-1105
Tanaka, C. P-1264
Tanaka, K. PD-0992
Tanaka, M. P-1168
Tanamas, S.K. OP-0269, OP-0406, PD-0949
Tander, B. OP-0462
Tandon, N. OP-0230, OP-0255, OP-0411, OP-0579, OP-0583, P-1234, P-1969, PD-0774, PD-0795, PD-0951, PD-1023
Taneda, S. P-1395
Tang, A. OP-0057
Tang, J. OP-0272
Tang, J.L. P-1391
Tang, Y. P-1284, PD-0776
Tanhauserova, V. P-1487, P-1237
Taniguchi, J. P-1121
Taniguchi, M. P-1783
Tanimoto, K. PD-0955
Tanizawa, Y. OP-0590, P-1474
Tantayotai, V. P-1957
Tanthuma, G. OP-0118
Tantia, P. P-1865
Tao, T. P-1210
Tapia, B. P-1731
Tapley, K. P-1627
Tarasuk, C.k. AbT-2073
Tarhan, N. P-1127
Tarigan, T.J. 0131
Tarkun, I. P-1300, P-1670
Tasci, T. P-1193
Tashmanova, A. P-1128, P-1147, PD-0931

Taskiran, D. P-1079, P-1080
Taslimi, M. AbT-2139
Tasliyurt, T. P-1079, P-1080
Tasnim, F. P-1383, PD-0716
Tasserei, J.O.H.N. PD-0974
Tatsumi, F. P-1462
Tatsuno, I. PD-0757
Tatsuoka, H. OP-0423, PD-0701
Tattikota, S. P-1384
Tavake-Pasi, F. P-1795
Tavakoli, M. OP-0607, PD-0904
Taverna, M.j. P-1111, P-1782
Tawfik, R. P-1926
Tay, J. OP-0058
Tay, T.L. P-1394
Tayama, J. OP-0409
Tayeb, K. P-1523
Taylor, A.W. P-1769, PD-1008
Taylor, H.R. PD-0806
Taylor, M. P-1738
Taylor-Fishwick, D.A. 0540
Tayyeb, S. PD-0876
Tchan, M. PD-0805
TCHEUTCHOUA NOULE, F. PD-0911
Teare, J. OP-0083, P-1088
Teare, M.D. P-1286
Tébar Massó, F.J. P-1056
Tee, W. P-1793
Teede, H. AbT-2164, PD-0985, PD-1013
Teede, H.J. P-1861
Teixeira, F. AbT-2148
Tejera Pérez, C. P-1333
Tekesin, E.B.R.U. AbT-2018
Tekiteki, A. P-1498
Tell, G.S. OP-0270
Temaru, R. PD-0777
Temel, A. AbT-2027, P-1845
Temel, E. P-1697
Temizel, M. AbT-1999
Tentolouris, N. P-1316
Teo, S.M.V. P-1394
Teo, Y.Y. OP-0252
Terasaki, J. PD-0955
Terauchi, Y. P-1076
Terkildsen Maindal, H. P-1752
Teslovich, T.M. OP-0253
Tetreault, J. OP-0083, P-1088
Tetteh, N. P-1814
Thach, C. P-1043
Thangaratinam, S. P-1099
Thanh Ha, T. OP-0064
Thanh Lam, N. OP-0064
Thankappan, K.R. OP-0404
Thapa, N. P-1806
Thennakoon, T.M.S.N. AbT-2122
Theodora, I. AbT-2024
Thi Thu Trang, N. OP-0064
Thiemann, S. P-1104, PD-0697
Thilagaratnam, S. P-1867
Thomas, A. P-1108
Thomas, C. 0050
Thomas, G. PD-0709
Thomas, M. 0181
Thomas, M.C. PD-0785
Thomas, N. P-1039, P-1375, P-1530, P-1602
Thomas, R. 0146
Thomas, S. 0288
Thomas, S.A. P-1866
Thompson, C.H. OP-0058, P-1207
Thomsen, H. P-1345
Thomson, R. OP-0095
Thong, K.Y. P-1349
Thongphiew, A. P-1619
Thoopputra, T. P-1958
Thorens, B. 0543
Thorn, P. P-1118, P-1120
Thornbur, D. P-1500
Thorpe, S. AbT-2059, PD-0812
Thron, L.M. PD-0702
Thuan, J.F. OP-0606, P-1250, P-1717
Thulaseedharan, N.K. P-1253
Thurman, J. OP-0082
Tian, H. OP-0451, OP-0580, P-1270, P-1271, PD-0990
Tian, H.A.O. P-1307, P-1469
Tian, H.M. OP-0439, P-1270, P-1271, PD-0764
Tian, H.U.I. PD-0734
Tian, L.M. P-1360
Tieno, H. AbT-2163, AbT-2118, AbT-2162, PD-0877
Tienthavorn, V. P-1854
Tikkanen, H. PD-0702, PD-0702
Tikoimakogai, M. P-1583
Tilli, S. PD-0659
Timar, R. P-1891
Timocin, E. P-1540
Timoshanko, A. P-1506, P-1950, P-1984
Tinahones Madueño, F. AbT-2135
Tinahones, F.J. PD-0968
Tinahones-Madueño, F. AbT-2072
Tinahones-Madueño, F.J. P-1186
Ting, R. OP-0445
Tinnaluck, Y. P-1957
Tirosh, A. AbT-2030
Tiselko, A. P-1762
Tiwari, S. P-1622
Tjonna, A.E. P-1188
Tkach, S. P-1556
Tobe, K. PD-0777
Toby Coates, P.T.H. OP-0448
Tocaci, G. P-1204
Toda, T. PD-0778
Todorava, L. P-1060
Toh, M.P.H.S. P-1963
Toki, V. 0569
Toktarova, N. PD-0893
Tokuda, M. OP-0417
Tokunaga, H. OP-0419, P-1243
Tokunaga, K. P-1910
Tokunaga, M. P-1933
Tolonen, N. PD-0702
Tolosa, M. P-1330
Tomandl, J. P-1487
Tomasini, G. PD-0666
Tondé, A. AbT-2162
Tong, H. OP-0591
Tong, N.W.T. PD-0988
Tong, P. OP-0414, PD-0864
Tong, Y.Z.T. PD-0988
Tonks, K. P-1287
Tonks, K.T. P-1594
Tono, T.M. AbT-2157, P-1962
Tonse, M. P-1894
Tontonoz, P. 0490, OP-0628
Torenholt, R. P-1683, PD-0869
Tornøe, K. P-1054
Török, E. AbT-2165
Torpy, F. P-1072
Torres, H. AbT-2094, P-1644
Tory, K. OP-0596
Toti, F. AbT-2047, P-1557, P-1977
Totomirova, T. AbT-2038
Touch, K. P-1788
Touzy, R. OP-0620
Toyama, Y. P-1168
Toyooka, T. P-1441
Trachta, P. P-1143, P-1451
Tran Quoc, C. P-1907, P-1979
Tran Thi Bich, V. P-1907
Travis, M. P-1645
Traylor, L. P-1082
Trebea, A. P-1350
Treiber, G. P-1834
Tremayne, G. P-1558, P-1724
Tremblay, J. OP-0257
Trenell, M. OP-0231
Trincado, P. P-1332
Tripathi, K. P-1380
Tripathi, R.L. P-1152
Tripathi, S. P-1393
Tripathy, D. OP-0067
Triplitt, C. OP-0420
Trute, M. P-1658, PD-0813
Tsai, C. P-1169, P-1229, PD-0831
Tsai, M.Y. P-1544
Tsai, Y.C. AbT-1987
Tsang, C.C. PD-0870
Tsapaeva, N. AbT-2005, P-1215
Tschirhart, H. OP-0081
Tschöpe, D. OP-0647
Tshidino, S.C. PD-0659
Tsilas, C.S. P-1926
Tso, A.W.K. OP-0062
Tsoy, A. P-1128, P-1147
Tsuchida, C. P-1425
Tsuchiya, Y. 0132
Tsujimoto, T. P-1578
Tsujinaka, H. P-1425
Tsujino, I. P-1783
Tsukube, S. P-1404b
Tsun, J.G.S. PD-0703
Tsurskiridze, L. PD-0891
Tsutskiridze, L. AbT-2099, P-1641, P-1704, P-1719, P-1934, P-1972
Tsutsumi, C. PD-0955
Tu, S. PD-0890
Tuch, B.E. 0549
Tufan, C. P-1127
Tuladhar, N.R. P-1694
Tulegalieva, A. PD-0893
Tulienge, D. PD-0875
Tulieva, A.M. AbT-2043, P-1419
Tuna, M. P-1373
Tunali, S. AbT-1985, P-1176
Tuncel, E. P-1690
Tunceli, K. P-1617, P-1935
Tunes, G. P-1651
Tuomi, T. 0245
Tuomilehto, J. OP-0405, PD-0941, PD-0948
Tuong, Z. 0491
Tura, A. P-1392, PD-0750, PD-0771
Turan, E. AbT-2076
Turgunova, L.G. P-1419
Turk, N. P-1131
Turkey, Y. 0526
Turki, Z. AbT-2044
Turkyilmaz, I.B. P-1038

Turner, N. OP-0599, P-1313, P-1365
Turshanova, S.K. AbT-2043
Tuten, A. PD-0799
Tuttle, K.R. 0498
Tutuncu, Y. P-1058, P-1373
Tütüncüoglu, A. AbT-2010, AbT-2018, AbT-2106, PD-0682
Twigg, S. OP-0101, OP-0593, P-1811, PD-0805
Twigg, S.M. OP-0061, P-1313, PD-0656, PD-0686, PD-0781, PD-0920
Two Hawk, S. OP-0104
Tyo, R. P-1518
Tyzhnenko, T. P-1203

U

Uazman, A. OP-0607
Ubukata, M. P-1471, P-1472
Uchigata, Y. P-1062, P-1078
Uchiumi, K. P-1642
Udayabhaskaran, V. P-1253
Uddin, M.S. AbT-2083
Ueda, K. PD-0658
Ueda, T. OP-0419, P-1243
Uehara, K. P-1344
Uehara, S. P-1906
Ueki, A. PD-0790
Ueki, K. 0002
Uetani, C.U. AbT-2091
Ugemuge, S. P-1543
Ukropcova, B. OP-0065
Ukropec, J. OP-0065
Ulhaque, M.S. P-1848
Ulkuseven, B. AbT-1985
Ullrich, S. OP-0449
Ulus, Y. OP-0462
Ulyanova, I. P-1240
Umemura, T. 0161
Umeuchi, H. P-1471
Umpierre, D. PD-0919
Umpierrez, G. P-1068
Unachukwu, C.N. PD-0901
Unal, M. P-1373
Unluturk, U. P-1094
Unni Krishnan, A.G. AbT-2079
Unnikrishnan, R. P-1853
Unnikrishnana, B. PD-0957
Untario, J.H. P-1764
Unwin, N. 0547, PD-0847
Urano, F. 0122
Urbanavicius, V. P-1145
Urbanova, M. P-1143, P-1451
Urbonaite, B. P-1735
Usman, K. P-1622
Ustündag, S. P-1101
Usui, R. P-1081, P-1114, P-1115
Usui, S. P-1306
Uusitupa, M. PD-0941
Uzun, H. P-1442, PD-0799

V

Vaag, A. PD-0789
Vagenas, D. OP-0605, OP-0607, PD-0668
Vági, O. P-1251
Vaithilingam, V. 0549
Valamios, M. PD-0727
Valdés, S. PD-0754, PD-0921
Vale, M. OP-0273
Valeeva, F. AbT-1995, AbT-2150, AbT-2151, P-1449
Valeeva, F.V. P-1450
Valencia, W. P-1855, P-1951
Valensi, P. P-1942
Valensi, P.V. P-1943
Valentinova, L. P-1444, P-1445
Valizadeh, N. P-1224
Valkusz, Z. P-1196
Vallim, T. OP-0627
Vallis, M. P-1729, PD-0845, PD-0924
van Bavel, B. PD-1018, PD-1019
Van Binh, T. OP-0064
van Dam, R.M. P-1763
van de Goor, B. 0048
van de Venter, M. P-1507
van Denderen, B.J. OP-0235
Van der Merwe, N. P-1528
van der Post, J.A. P-1099
Van Dong, N. OP-0064
Van Olmen, J. AbT-2109
Van Paassen, V.V.P. P-1106
van Reyk, D. P-1070, P-1071, P-1072
Van Sam, M. OP-0064
Van, Y.H. OP-0088
Vance, C. AbT-2101, AbT-2102, OP-0282, P-1758
Vandenberghe, H. OP-0069
Vanhala, M. PD-0941
Vardi, P. 0334
Varela, M.C. PD-0935
Varghese, D. P-1039
Varghese, J. P-1874
Varghese, R.T. P-1039
Várkonyi, T. P-1196, P-1251
Varnfield, M. PD-0915
Varró, A. P-1196
Varthakavi, P. P-1978
Varthakavi, P.K. P-1947
Vasan, R.S. PD-0818
Vasanthalakshmi, H.K. P-1527
Vasantharaja, L. P-1967
Vasantharajah, L. P-1359, P-1983, PD-0796, PD-0946, PD-1022
Vasilkova, O. AbT-2113, P-1739
Vasilkova, V. P-1244
Vasjuta, C. P-1627
Vasudevan, S. P-1927, PD-0980, PD-0981
Vatansever, H.S. P-1338
Vaucher, J.E.A.N. 0560
Vaz, J.A. P-1157
Vázquez Puertas, C. P-1293b
Vazquez Seijas, E. AbT-2058, AbT-2126
Vázquez-Álvarez, A.O. AbT-2004
Veenendaal, M. P-1099
Vega, S. PD-0948
Veiga, L. AbT-1991
Velickovic, R. PD-0942
Velkoska Nakova, V. P-1485
Velkoska, E. P-1100
Venceviciene, L. P-1687
Venkat Narayan, K.M. OP-0239, PD-0978
Venkat, M. 0214
Venkat, P. PD-0798
Venn, A. OP-0608
Venn, B. OP-0611
Ventura, A. OP-0457
Vera-Gonzalez, M. P-1564
Vercruysse, F. P-1093
Veresiu, I.A. P-1891
Vergnes, L. OP-0597
Verkauskiene, R. P-1735
Verma, N.S. P-1622
Verma, S. PD-0710
Versace, V.L. PD-0944
Versnel, N. 0347
Vespasiani, G. P-1417, P-1767, PD-0822, PD-0844
Vesper, I. P-1396, PD-0743
Vestergaard, S. P-1584
Viana, E. P-1772
Viardot, A. P-1287
Viberti, G.C. P-1359, P-1967, P-1983, PD-0796, PD-0946, PD-1022
Vicaretti, M. P-1059, P-1774
Vicentini, M. P-1857
Vickers, K. OP-0107
Vidal, J. P-1095, P-1097
Vidal, J.V. PD-0670
Vidal, M. P-1623
Vidyasagar, S. P-1894
Vieira Dias, H. P-1817
Vieira-Filho, J.P. OP-0106
Vieira-Filho, J.P.B. OP-0639
Viggers, L. AbT-2057
Vigier Simmore, N. OP-0606, P-1250, P-1717
Viguiliouk, E. P-1917, PD-0977
Viikari, J.S.A. P-1889
Vijapurkar, U. P-1464
Vijayakumar, G. 0380
Vijayalakshmi, P. P-1914
Vijaylakshmi, P. OP-0614
Vijeyakumar, L. AbT-2016
Vikram Kalra, D.R. OP-0297
Vilier, A. OP-0408, PD-0979
Villarreal-Ángeles, M.A. PD-0850
Villarroel, D. 0218
Vilsbøll, T. OP-0082, P-1055
Vincent, M. OP-0268, P-1417, P-1767, P-1899
Viney, R. OP-0638
Visco, V.E. PD-0746
Visentin, K. P-1569, P-1629
Visockiene, Z. P-1538, P-1687
Viswanathan, P. OP-0079
Viswanathan, V. 0221, AbT-2063
Vita, P. PD-0938, PD-0939
Vittaz, L. P-1942
Vivolo, M.A. PD-0858
Vívolo, S.R.G.F. P-1772
Vlad, A. P-1891
Vlasenko, I. P-1646, P-1659, PD-0837
Vlasenko, N. AbT-2060, P-1641, P-1956
Vlasenko, R. AbT-2060, P-1956
Vlasic, K. P-1825
Vogel, C.G. PD-0743
Voigt, J.R. PD-0830
Volevodz, N.N. P-1112
Vølund, A. PD-0726

von Eynatten, M. P-1104, PD-0693, PD-0696, PD-0698
von Herrath, M. 0531
Vonbank, A. P-1179, P-1180, P-1181, P-1182, P-1427, PD-0687, PD-0688, PD-0704, PD-0715, PD-0720, PD-0918
Vora, J. P-1303, P-1304, P-1415, PD-0747
Vorokhobina, N. OP-0454
Vrachnos, N. P-1434
Vretenar, J. P-1342
Vrtovec, M. P-1351
Vucic Lovrencic, M. P-1239
Vyamusani, V.R. P-1812
Vyas, C.K. P-1862
Vyas, S. P-1124
Vyash, C.K. P-1411
Vyncke, V.N. P-1598

W

Wada, A. P-1197
Wada, S. P-1933
Wada, Y. OP-0423, P-1474, PD-0701
Waddell, C. P-1503
Waden, J. PD-0702
Wadia, S. P-1867
Wagdy, E. P-1245
Wagenknecht, D. OP-0071
Waghdhare, S. P-1375, P-1530, P-1602, PD-0884
Wagner, R.S. P-1396, PD-0743
Wagstaff, A. P-1497, P-1500, PD-0814
Wahab, M. P-1851, PD-1010, PD-1012
Wai, B. P-1100
Wake, D.J. OP-0648
Wakefield, M. P-1930
Waki, S. P-1654
Wakui, A. P-1578
Wakui, A.(. P-1520
Waldeck, B. P-1776
Walder, K. OP-0092, PD-0655, PD-0735
Waldron-Lynch, F. 0533
Walker, C. OP-0273
Walker, E. 0636
Walker, J. OP-0648
Waller, A. OP-0648
Wambui, C. P-1852, PD-0875
Wambui, C.K. P-1669
Wan, G. P-1660
Wang, C. P-1319
Wang, C.Y. AbT-2054
Wang, F. P-1821, P-1824
Wang, F.S. OP-0256
Wang, H. OP-0600, P-1151, P-1153, P-1323, P-1379, P-1920, PD-0945
Wang, H.F. PD-0855
Wang, J. OP-0444
Wang, J.J. P-1214
Wang, L. OP-0580, P-1798, PD-0764
Wang, N. AbT-2138, P-1247, P-1884
Wang, P. P-1116, P-1491, PD-0794
Wang, R. OP-0591
Wang, R.H. P-1510
Wang, S.-C. 0491
Wang, S.C. 0491
Wang, S.H. P-1116
Wang, S.J. P-1932
Wang, T. P-1410
Wang, W. P-1319, P-1343, P-1353, P-1354
Wang, W.Y. P-1170
Wang, X. AbT-2138, P-1247, PD-0656, PD-0781
Wang, X.M. P-1313
Wang, Y. OP-0414, P-1153
Wang, Y.F. P-1154
Wang, Y.M. PD-0855
Wang, Y.N. P-1521, PD-0872
Wang, Y.Q. PD-0764
WANG, Z. P-1117, OP-0102, OP-0640
Wanjiru, R. PD-0996
Ward, A.C. PD-0735
Ward, G. P-1733
Ward, K. PD-0779
Ward, M. OP-0090
Ward, M.S. P-1120
Wardecki, M. OP-0075
Ware, J. PD-0882
Wareham, N.J. OP-0059, OP-0440
Warne, D. OP-0104, PD-0811
Warnock, J. P-1161
Warrington, J.M. PD-0762
Watada, H. AbT-2145, P-1456, P-1465, PD-0766
Watanabe, K. P-1081, P-1114, P-1115
Watanabe, T. 0132, P-1105, P-1783
Watanabe, Y. P-1352, PD-0790
Watarai, A. P-1264, PD-0954
Waterman, A. PD-0805
Watson, N. OP-0596
Watt, M.J. OP-0596
Wattanakul, B. P-1754
Webber, J. P-1877
Weber, M.B. OP-0584, PD-0943, PD-1017
Webster, C. PD-0910
Wedick, N.M. OP-0614
Wei, Q. P-1116
Wei, S.H. P-1360
Weigl, B.H. AbT-2153
Weihe, P. PD-0993
Weiler, H. OP-0581
Weimar, C. PD-1007
Weiner, R. OP-0071
Weinger, K. PD-0866
Weisse, N. P-1096, P-1097
Weissglas-Volkov, D. OP-0628
Weissmann, L. OP-0616
Weitgasser, R. PD-0836
Weitz, E. OP-0071
Wellard, R.M. 0538
Wells, L. PD-0778
Welsh, J.B. PD-0893
Wen, Y.W. PD-0707
Weng, J. AbT-2145, OP-0112, OP-0115, P-1456, P-1465, P-1673, PD-0766, PD-0933
Weng, J.P. OP-0265, OP-0439
Weng, S. PD-0761
Wennick, A. OP-0291, P-1713
Wens, J. OP-0455, P-1581, P-1653, P-1740, PD-0845, PD-0846
Wentworth, J. OP-0077
Wentworth, J.M. OP-0234
Wentzel-Larsen, T. AbT-2019
Wesnes, K. P-1802
Wey, D. PD-0856
White, M. OP-0433, P-1144
Whitehead, J. OP-0587, OP-0591
Whitford, D. P-1948
Whitford, D.L. P-1860
Whiting, D. OP-0112, OP-0653, P-1673, PD-0933
Whitman, M. OP-0095
Whitworth, P.T. 0136
Whyte, S.R. P-1779
Wiatr-Bykowska, D. AbT-2149, P-1941
Wiatr-Bykowska, D.W.-B. P-1828
Wickramasinghe, N. P-1688
Widyahening, I.S. P-1764
Wientjens, W.H.J.M. 0522
Wijaya, I. P-1876
Wijesuriya, M. P-1359, P-1967, P-1983, PD-0796, PD-0946, PD-1022
Wilcox, P. 0569
Wilde, H. OP-0277
Wilding, J. 0488
Wilkin, T. 0323
Wilkinson, J. P-1416
Wilkinson, L. P-1883, PD-1032
Wilkinson-Berka, J. 0502
Willaing, I. 0384, OP-0475, P-1584, P-1653, P-1683, P-1726, P-1740, PD-0830, PD-0839, PD-0840, PD-0845, PD-0869
Willett, W.C. OP-0614
Willi, S.M. OP-0080, P-1047
Williams, D.E. OP-0444
Williams, E. PD-0915
Williams, E.D. P-1745
Williams, J. OP-0463

Williams, K.H. OP-0061
Williams, R. 0126
Williams, S. P-1507
Willis, E. P-1501, P-1637
Willmes, D. P-1384
Willmes, D.M. OP-0229
Wilson, C. P-1751, PD-0699
Wilson, C.J. P-1207
Wilson-O'Brien, A. OP-0588
Wiltshire, E. PD-0787
Win Tin, S. PD-0974
Windell, L. PD-0863
Wing, Y. OP-0115
Wingler, K. OP-0620, OP-0622, PD-0780
Winiecki, H. AbT-2012
Winkler, A. PD-1007
Winkler, H. PD-0836
Winmill, D. PD-0882
Wisloff, U. P-1188
Witte, D.R. OP-0651
Wittert, G. OP-0058, P-1113, P-1959
Wittert, G.A. P-1207, PD-1008
Wittmann, T. P-1196, P-1251
Wittrup, M. OP-0434, P-1683, PD-0869
Witztum, J.L. OP-0629
Woerle, H. PD-0692
Woerle, H.-J. P-1046, P-1104, PD-0697
Woerle, H.J. OP-0081, P-1319, P-1353, PD-0693, PD-0698
Wolf, M. P-1792
Wolfert, M.A. PD-0778
Wolfram von Wolmar, C. P-1931
Woloschak, M. P-1354
Wolzt, M. P-1392
Won, H.K. P-1139
Won, K. P-1424, PD-0896
Wong, E. P-1818
Wong, G. P-1090
Wong, J. OP-0101, P-1811, PD-0686, PD-0793
Wong, N. PD-0761
Wong, R. OP-0445
Wong, T.W. P-1178, P-1915
Wong, V. P-1529
Wontumi, G. P-1814
Woo, J.T. P-1517, P-1781
Woo, V. OP-0650
Woo, V.C. OP-0421, OP-0422, P-1267
Woo, Y.C. OP-0062
Woods, M. P-1624
Woodward, M. OP-0257, OP-0412, PD-1003
Woolcott, C. OP-0581
Worthington, A. P-1600
Woskova, V. PD-0665
Wozniak, L. P-1649
Wright, A.G. P-1049
Wright, J. P-1230, PD-0664
Wu, C.L. OP-0091
Wu, E. OP-0445
Wu, F. P-1068
Wu, H. PD-0831
Wu, H.T. OP-0091, P-1199
Wu, J. AbT-2049, PD-0933
Wu, J.S. OP-0091, P-1199
Wu, Q. OP-0451
Wu, T. OP-0101, OP-0424, P-1473, P-1811, PD-0712
Wu, T.J. P-1364, P-1544
Wu, W.F. P-1932
Wu, X. P-1164
Wu, Y. OP-0112, OP-0617, P-1673, P-1763, PD-0768, PD-0829, PD-0933
Wu, Y.H. P-1295
Wurmsee, S. P-1384
Wyatt, S. P-1534
Wycherley, T.P. P-1207
Wyld, M. PD-0969

X

Xia, Q. OP-0251
Xia, W.Q. P-1116
Xiang, K. OP-0060
Xiao, C. PD-0762
Xiao, J.I.N.G. PD-0734
Xiao, J.Z. PD-0776
Xiao, W.H. P-1521, PD-0872
Xie, J. P-1466
Xie, M.Z. P-1122
Xie, R. P-1660
Xie, S.G.X. PD-0988
Xin, S. OP-0580
Xing, W. OP-0094, P-1192
Xing, X. P-1354
Xirouchaki, C. OP-0601
Xu, A. OP-0060, OP-0062
Xu, H. PD-0671
Xu, L. P-1068, P-1595
Xu, R.Y. AbT-2054
Xu, S. PD-0880
Xu, X. 0138, OP-0598
Xu, Y. P-1164
Xu, Z. P-1509

Y

Yabe, D. 0006, P-1081, P-1114, P-1115
Yach, D. 0546
Yadav, S. P-1819
Yaga, K. PD-0954
Yagmur, J. P-1193
Yago, G. P-1623
Yahata, K. 0132
Yajnik, C.S. OP-0067b
Yajnik, C.S.(. 0529
Yajnik, P.C. OP-0067b
Yako, Y. P-1890
Yako, Y.Y. P-1457
Yale, J.F. OP-0650
Yamada, A. P-1783
Yamada, I. P-1522
Yamada, K. P-1522
Yamada, Y. P-1441, P-1474
Yamaguchi, T. P-1175
Yamamoto, M. P-1175
Yamamoto, N. AbT-2145, P-1456, P-1465, PD-0766
Yamamoto, T. P-1639
Yamamoto, Y. PD-0954
Yamamura, S. PD-0757
Yaman, S. AbT-2040
Yamauchi, A. P-1425
Yamauchi, M. P-1175, PD-0681
Yamauchi, T. 0300
Yamazaki, J. PD-0757
Yamazaki, T. P-1105
Yan, Y.H. P-1491, PD-0794
Yanagimachi, T. OP-0450, PD-0713
Yanardag, R. AbT-1985, P-1038, P-1125, P-1126, P-1131
Yang, C. P-1366
Yang, C.-Y. P-1541
YANG, G. P-1117, OP-0595, OP-0615, P-1353, P-1464, P-1660
Yang, H. P-1229, P-1866
Yang, H.M. OP-0613, P-1221
Yang, H.X. 0557
YANG, J. P-1117, P-1285, P-1353
Yang, J.Y. 0467
Yang, K. PD-0760
Yang, L. P-1509
Yang, P. 0467, OP-0589, P-1051
Yang, Q.Y. PD-0988
Yang, R. P-1821
Yang, S.J. P-1139
Yang, T. P-1970
Yang, W. OP-0115, P-1262, P-1354, P-1386, PD-0740
Yang, W.Y. P-1270, P-1271, PD-0776
Yang, X. OP-0418, OP-0580
Yang, Y. P-1116, PD-0829
Yang, Y.C. OP-0091, P-1199
Yang, Y.X. PD-0976
Yang, Y.Y. PD-0988
Yano, S. PD-0683
Yanogo, A.R.D. AbT-2118, AbT-2162
Yanogo, D. AbT-2163
Yanto, T.A. P-1876
Yap, F. PD-0860
Yap, F.Y. PD-0719
Yap, F.Y.T. OP-0090
Yasa, H. P-1125
Yasin, S. PD-0989
Yasukata, J. PD-0992
Yates, D. P-1099
Yatsuya, H. PD-0954
Yazawa, M. P-1933
Yazdanpanah, L. P-1231, P-1875
Ye, J. OP-0454
Ye, J.M. OP-0600, P-1379, PD-0727
Ye, S. P-1117
Ye, X.Y. AbT-2054
Ye, Y.T. P-1295
Yeak, Z.W. P-1067
Yeap, B.B. P-1959
Yedigarova, L. PD-0893
Yee, C. PD-0656, PD-0781
Yeh, C.C. P-1266
Yenchitsomanus, P. PD-0732
Yenchitsomanus, P.T. PD-0733
Yener Ozturk, F. PD-0892
Yener, S. PD-0889
Yenidünya Yalin, G. P-1275

Yenidunya, G. P-1697
Yeung, L.O.Y. P-1282
Yeung, R. OP-0115, PD-0864
Yeung, R.O. OP-0265, OP-0445
Yi, J. P-1673
Yildirim, M. 0324
Yildiz, M. AbT-2040
Yilmaz Yasar, H. P-1734
Yilmaz, C. P-1338
Yilmaz, M. P-1218
Yim, J.E. PD-0823
Yin, J. PD-0864
Ying, Z. OP-0598
Yki-Järvinen, H. 0004, OP-0075, PD-0697
Yokono, K. 0132, 0166
Yoo, H. P-1208, PD-0991
Yoo, H.J. P-1446, PD-0736
Yoo, J.M. P-1208
Yoo, K.D. PD-0883
Yoo, S.J. AbT-1996, OP-0056, P-1189
Yoon, H. PD-0896
Yoon, J. P-1424, PD-0896
Yoon, K.H. OP-0265
Yoshida, A. P-1335
Yoshida, Y. PD-0790
Yoshihito, A. 0225
Yoshitsugu, M. P-1429, PD-0695
Yoshiuchi, K. P-1910
Younes, Z. AbT-2008
Young, B. 0506
Young, D. OP-0273, P-1650
Young, E.E. 0525, PD-0901
Young, E.H. OP-0238
Young, H.M. P-1549
Younger-Coleman, N. P-1870
Youngson, N.A. OP-0619
Yousmi, N. AbT-2119
Yu, C. P-1509, P-1559, P-1560, P-1647, PD-0972
Yu, C.H. P-1630
Yu, C.W. P-1491
Yu, C.Y.Y. PD-0988
Yu, D.M.T. P-1313
Yu, H.I. AbT-2013
Yu, J. PD-0991
Yu, K. OP-0076
Yu, S. 0528, P-1617
Yu, S.H. P-1208
Yu, Y. AbT-2007, OP-0617, P-1151, P-1367, P-1381, P-1458, PD-0768
Yu, Y.H. P-1447
Yu, Z. OP-0580
Yuan, C.S. 0510
Yuan, C.X. OP-0251
Yuan, M. P-1660
Yuan, S. P-1660
Yuan, Y. 0181, P-1116
Yudin, V.A. P-1225, P-1226, P-1227
Yue, D. OP-0101, P-1811, PD-0686
Yue, D.K. PD-0793
Yuen, M.M.A. OP-0062
Yuksel, F. P-1176
Yuma, M. P-1294
Yun, J.S. PD-0883
Yun, Y. P-1323
Yung, S.S.Y. PD-0703
Yunir, E. P-1040
Yusufoglu, A. P-1125

Z

Zabeen, B. PD-0876
Zafar, A. P-1280
Zafar, L. P-1743
Zagrebaeva, O. AbT-2121
Zahan, N.A. P-1177, PD-0684
Zainal-Ariffin, O. PD-0962
Zakaria, E. P-1246
Zakerkish, M. PD-0913
Zalesskaya, O. AbT-2140
Zalewski, M. OP-0078
Zaman, K. P-1499
Zander, M. P-1550
Zanolin, D. P-1181, P-1182, PD-0688, PD-0704, PD-0715
Zapatero-Gaviria, A. OP-0267
Zargar, S.H. P-1413
Zarotsky, V. P-1935
Zavrsnik, M. PD-1015
Zavrsnik, S. PD-1015
Zeba, Z. P-1382
Zebunnesa, F. P-1305, P-1388
Zee, B. PD-0972
Zeeshan, F. P-1925
Zeggini, E. OP-0252
Zeh, P. PD-0843, PD-0843
Zeidan, W. 0526, PD-0888
Zeiri, M. P-1523
Zeiry, K. OP-0586
Zeitler, P. 0223
Zekry, A. OP-0061
Zeng, H. OP-0604, P-1190, P-1212
Zeng, X.Y. OP-0600, P-1379
Zerwic, J. P-1754
Zethelius, B. PD-1018, PD-1019
Zhai, Y.J. P-1172
Zhang, B. PD-0831
Zhang, C. OP-0580, P-1319, P-1353, P-1437
Zhang, D. P-1932
Zhang, D.Y. OP-0439
Zhang, F.Z. PD-0988
Zhang, H. OP-0094, P-1192
zhang, K.Q. P-1172
Zhang, L. AbT-2138, OP-0628, P-1247, P-1884, PD-0691
Zhang, P. P-1673, PD-0933
Zhang, Q. P-1153, P-1154
Zhang, R. AbT-2054
Zhang, S. P-1288
Zhang, S.M. P-1284, P-1289, PD-0776
Zhang, T. P-1784, P-1866
Zhang, X. P-1288, PD-0691, PD-0990, P-1437
Zhang, X.J. PD-0764
Zhang, Y. OP-0115, P-1595, PD-0864
Zhang, Y.Y. OP-0265, OP-0445
Zhang, Z. OP-0611
Zhao, J. P-1190, P-1190, P-1360
ZHAO, W. P-1117
Zhao, Z. OP-0451, PD-0990
Zheng, T. PD-0990
Zhogov, I. P-1659
Zhong, W. AbT-2138
Zhou, D.J. OP-0439
Zhou, J. AbT-2054
Zhou, L.L. P-1284, P-1460
Zhou, M. OP-0060, P-1824
Zhou, X. 0154, OP-0600, P-1288, P-1379, P-1920, PD-0945
Zhou, Y. P-1116
Zhou, Z. OP-0112
Zhu, D. P-1343
Zhu, H. P-1595
Zhu, J. P-1821
Zhu, L. P-1660
Zhu, Q.B.Z. PD-0988
Zhu, Y. AbT-2138, P-1247
Zhuang, A. P-1118, P-1120, PD-0785
Zhuang, N. P-1660
Zhubandykova, L. P-1705
Zhuge, F. OP-0093
Zibar, K. P-1369
Zida, S. AbT-2162, AbT-2163
Ziegler, R. P-1396, PD-0743
Ziemann, M. PD-0663
Ziemen, M. OP-0075, P-1718
Zierath, J.R. 0003
Zijlstra, E. PD-0791
Ziko, I. PD-0727
Zilov, A. AbT-2028, P-1281, P-1827
Zimmet, P. 0299, 0299, OP-0269, OP-0406, P-1299, PD-0949
Zimmet, P.A.U.L. P-1864
Zingade, U.S. AbT-2002, P-1476
Zinman, B. 0534, OP-0081, P-1345, PD-0673, PD-0747
Zinnat, R. P-1382
Zipf, W.B. P-1063
Zirie, M. P-1448
Zitouni, M. P-1256
Zivkovic, M. P-1516
Zoffmann, V. P-1714
Zoungas, S. 0203, OP-0412, P-1861, PD-0985, PD-1003
Zraika, S. 0338, PD-0738
Zubair, M. P-1146, P-1836, P-1837
Zubairi, T. PD-0797
Zuev, M. P-1762
Zwar, N. P-1813
Zwisler, G. AbT-2153

Access to drugs and technologies *AbT-2104, P-1121, P-1122, P-1123, P-1124, P-1125, 194, 195, 396, 558, 570, 637*
Age, gender, ethnicity and culture *AbT-2105, AbT-2106, P-1523, P-1524, P-1785, P-1786, P-1787, P-1788, 159, 212*
Animal models of type 1 diabetes *AbT-1985, P-1126, P-1127*
Animal models of type 2 diabetes *AbT-1986, AbT-1987, P-1128, P-1129, P-1130, P-1131, P-1132, P-1133, P-1134, P-1135, P-1136, P-1137, P-1138, P-1139, 346, 542*
Approaches to prevention of T2DM *PD-0810, PD-0811, PD-0812, PD-0813, PD-0814, PD-0815, PD-0816*
Bariatric surgery and type 2 diabetes *P-1140, P-1141, P-1142, P-1143, P-1144, P-1145, P-1789, P-1790, 308, 398, 399*
Basic and Clinical Science *P-1146*
Blood pressure *AbT-1988, AbT-1989, AbT-1990, AbT-1991, AbT-2107, P-1147, P-1148, P-1149, P-1150*
Care delivery, care providers, coordinators and supporters *AbT-2060, AbT-2108, AbT-2109, AbT-2110, AbT-2111, AbT-2112, AbT-2113, P-1494, P-1495, P-1496, P-1525, P-1526, P-1527, P-1528, P-1529, P-1530, P-1531, P-1532, P-1533, P-1534, P-1535, P-1536, P-1691, P-1692, P-1693, P-1791, P-1792, P-1793, P-1794, P-1795, P-1796, P-1797, P-1798, P-1799, PD-0854, PD-0880*
Care delivery, providers and coordinator *47, 397, 633*
Clinical - cardiorenal complications *OP-0412, OP-0413, OP-0414, OP-0415, OP-0416, OP-0417, OP-0418, OP-0419*
Clinical - Complications *PD-0682, PD-0683, PD-0684, PD-0685, PD-0686, PD-0687, PD-0688, PD-0689, PD-0690, PD-0691*
Clinical care and complications *PD-0883, PD-0884, PD-0885, PD-0886, PD-0887, PD-0888, PD-0889, PD-0890*
Clinical Diabetes and Genetics *PD-0770, PD-0771, PD-0772, PD-0773, PD-0774, PD-0775, PD-0776, PD-0777*
CNS/Hypothalamic regulation of obesity a *0493*
CNS/Hypothalamic regulation of obesity and diabetes *P-1151, P-1152*
Cognition, psychology and behaviour *AbT-2114, AbT-2115, P-1537, P-1538, P-1800, P-1801, P-1802, 165, 166, 204*
Comorbidities *P-1497, P-1803, P-1804, P-1805, P-1806*
Comorbidities *260, 333, 347*
Comorbidities - liver *AbT-1992, AbT-1993, P-1153, P-1154, P-1807*
Comorbidities - sleep disturbances *0201*
Comorbidities and complications of T2DM *PD-0817, PD-0818, PD-0819*
Comorbidities and emerging risk factors *AbT-2116, P-1808, P-1809, 19*
Complementary medicine *AbT-2061, P-1539, P-1540*
Complications *AbT-1994, AbT-1995, AbT-1996, AbT-1997, AbT-1998, AbT-1999, AbT-2000, AbT-2117, AbT-2118, P-1155, P-1156, P-1157, P-1158, P-1159, P-1160, P-1161, P-1162, P-1163, P-1164, P-1165, P-1166, P-1167, P-1168, P-1169, P-1170, P-1498, P-1694, P-1695, P-1696, P-1697, P-1698, P-1699, P-1700, P-1810, P-1811, P-1812, P-1813, P-1814, P-1815, P-1816, P-1817, P-1818, P-1819, PD-0967, PD-0968, PD-0969, PD-0970, PD-0971, PD-0972, PD-0973, PD-0974*
Complications *16, 18, 128, 188, 261, 497, 534, 625, 631*
Complications - biomechanical mechanisms *P-1171, P-1172, P-1173, P-1174, P-1175, 98, 134*
Complications - cardiovascular disease *AbT-2001, AbT-2002, AbT-2003, AbT-2004, AbT-2005, AbT-2006, AbT-2007, P-1176, P-1177, P-1178, P-1179, P-1180, P-1181, P-1182, P-1183, P-1184, P-1185, P-1186, P-1188, P-1189, P-1190, P-1191, P-1192, P-1193, P-1194, P-1195, P-1196, P-1197, P-1198, P-1199, P-1200, P-1201, P-1202, P-1203, P-1204, P-1205, P-1206, P-1207, P-1208, P-1820, P-1821, P-1822, P-1823, P-1824, P-1825, P-1826, P-1827, 99, 140, 141, 160, 181, 182*
Complications - eye *P-1209, P-1210, P-1211, P-1212, P-1213, P-1214, P-1215, P-1828, P-1829, P-1830, P-1831, 146, 502, 504, 505*
Complications - foot *AbT-2008, AbT-2009, AbT-2010, AbT-2119, P-1216, P-1217, P-1218, P-1219, P-1220, P-1221, P-1222, P-1223, P-1224, P-1225, P-1226, P-1227, P-1228, P-1229, P-1230, P-1231, P-1832, P-1833, P-1834, P-1835, P-1836, P-1837, 35, 219, 220, 221, 222, 378, 560*
Complications - kidney *AbT-2011, AbT-2120, P-1232, P-1233, P-1234, P-1235, P-1236, P-1237, P-1238, P-1239, P-1240, P-1241, P-1242, P-1243, P-1244, P-1245, P-1246, P-1247, P-1838, P-1839, P-1840, 22, 23, 97, 360, 361, 498, 499, 500, 501*
Complications - nerve *AbT-2012, AbT-2013, AbT-2014, P-1248, P-1249, P-1250, P-1251, P-1252, 32, 33*
Complications: cognitive, psychosocial and CV *PD-1001, PD-1002, PD-1003, PD-1004, PD-1005, PD-1006*
Complimentary Medicine *510, 532*
Defining diabetes *363, 494*
Determinants of diabetes in indigenous populations *OP-0638, OP-0639, OP-0640, OP-0641, OP-0642, OP-0643, OP-0644, OP-0645*
Developing effective diabetes support *OP-0611, OP-0612, OP-0613, OP-0614*
Developing models of care for Indigenous Peoples *PD-0802, PD-0803, PD-0804, PD-0805, PD-0806, PD-0807, PD-0808, PD-0809*
Diabetes advocacy *P-1701, 29, 39, 85, 133, 343, 344, 345, 368, 546, 551, 552*
Diabetes and cancer *OP-0114, P-1841, P-1842, PD-1008, PD-1009, 610*
Diabetes and gender dynamics *P-1541*
Diabetes and infections *AbT-2015, AbT-2016, AbT-2017, P-1253, P-1254, P-1843, P-1844, P-1845, 531*
Diabetes and special populations *PD-1010, PD-1011, PD-1012, PD-1013, PD-1014, PD-1015, PD-1016*
Diabetes and the brain *AbT-2018, 17, 357, 513, 538, 539*
Diabetes association activities *PD-0925, PD-0926, PD-0927*
Diabetes associations *AbT-2019, AbT-2020, AbT-2021, P-1255, P-1702, P-1703, P-1704, P-1705, P-1846, P-1847, P-1848, 348, 349*
Diabetes care and therapies *PD-0891, PD-0892, PD-0893, PD-0894, PD-0895, PD-0896*
Diabetes childhood and adolescence *OP-0428, OP-0429, OP-0430, OP-0431, OP-0432, OP-0433, OP-0434*
Diabetes complications *PD-0904, PD-0905, PD-0906, PD-0907, PD-0908, PD-0909*
Diabetes education across the ages *P-1542, P-1543, P-1544, P-1545, 334*
Diabetes education and technology *AbT-2062, AbT-2063, P-1546, P-1547, P-1548, P-1549, P-1550, P-1551, P-1552, P-1553, P-1554, P-1555, P-1556, P-1557, P-1558, P-1559, P-1560, 111, 373, 374*
Diabetes education delivery *AbT-2064, AbT-2065, AbT-2066, AbT-2067, AbT-2068, AbT-2069, P-1561, P-1562, P-1563, P-1564, P-1565, P-1566, P-1567, P-1568, P-1569, P-1570, P-1571, P-1572, P-1573, P-1574, P-1575, P-1576, P-1577, P-1578, P-1579, P-1580, P-1581, P-1582, P-1583, P-1584, PD-0834, PD-0860, PD-0870, PD-0879, PD-0882, 46, 127, 224, 225, 465, 565, 566*
Diabetes in childhood and adolescence *AbT-2022, AbT-2121, P-1256, P-1706, P-1707, P-1708, P-1709, P-1710, P-1711, P-1712, P-1713, P-1849, PD-0916, 223, 298, 379, 393, 394, 460, 559*
Diabetes in Indigenous groups *AbT-2070, P-1499, P-1500, P-1850, 25, 175, 206, 262, 264, 328, 535, 568*
Diabetes in rural areas *P-1501, P-1851, P-1852, P-1853, P-1854*
Diabetes in the elderly, in-patients and *0217*
Diabetes in the elderly, in-patients and other special groups *AbT-2122, P-1585, P-1586, P-1587, P-1588, P-1589, P-1590, P-1855, P-1856*
Diabetes incidence and prevalence *AbT-2123, AbT-2124, AbT-2125, AbT-2126, AbT-2127, P-1857, P-1858, P-1859, P-1860, P-1861, P-1862, P-1863, P-1864, P-1865, 84, 87, 158, 187, 400, 507, 623*
Diabetes management *AbT-2023, AbT-2024, AbT-2025, AbT-2026, AbT-2027, AbT-2028, AbT-2071, AbT-2072, AbT-2073, AbT-2074, AbT-2075, AbT-2076, AbT-2077, AbT-2078, OP-0265, OP-0266, OP-0267, OP-0268, OP-0269, OP-0270, OP-0271, OP-0272, P-1257, P-1258, P-1259, P-1260, P-1261, P-1262, P-1263, P-1264, P-1265, P-1266, P-1267, P-1268, P-1269, P-1270, P-1271, P-1272, P-1273, P-1274, P-1275, P-1276, P-1277, P-1278, P-1279, P-1280, P-1281, P-1591, P-1592, P-1593, P-1594, P-1595, P-1596, P-1597, P-1598, P-1599, P-1600, P-1601, P-1602, P-1603, P-1604, P-1605, P-1606, P-1607, P-1608, P-1609, P-1610, P-1611, P-1612, P-1613, P-1614, P-1615, P-1616, P-1617, P-1618, P-1619, P-1620, P-1621, P-1622, P-1623, P-1624, P-1866, P-1867, P-1868, P-1869, P-1870, PD-0853*
Diabetes management *40, 143, 150, 162, 174, 185, 186, 203, 388, 487, 488, 489, 521, 525, 526, 553, 556, 557, 563, PD-1032*
Diabetes management: DM in the elderly *PD-1026, PD-1027, PD-1028, PD-1029, PD-1030, PD-1031, PD-1033, PD-1034, PD-1035*
Diabetes practice *PD-0897, PD-0898, PD-0899, PD-0900, PD-0901, PD-0902, PD-0903*

KEYWORD INDEX

Diabetic complications in Indigenous peoples *OP-0100, OP-0101, OP-0102, OP-0103, OP-0104, OP-0105, OP-0106, OP-0107*
Diagnosis and classification *AbT-2128, AbT-2129, AbT-2130, P-1871, P-1872, P-1873, 171, 243, 245, 246, 302, 435, 484, 630*
Disasters and diabetes *130, 131, 132, 155*
Discrimination and diabetes *OP-0455, OP-0456, OP-0457, OP-0458, 522, 524*
DPP-IV *PD-0692, PD-0693, PD-0694, PD-0695, PD-0696, PD-0697, PD-0698, PD-0699, PD-0700, PD-0701*
Education *PD-0828, PD-0829, PD-0830, PD-0831, PD-0832, PD-0833*
Enhancing patient care and self-management with e-health *OP-0273, OP-0274, OP-0276, OP-0277, OP-0278, OP-0279*
Environment and lifestyles *AbT-2131, AbT-2132, P-1874, P-1875, 10, 11, 167, 168, 247, 249, 299, 330, 391*
Epigenetics and early foetal development *P-1282, 3, 530*
Ethics, quality, standard and practice in diabetes *P-1876*
Experimental - metabolic *PD-0655, PD-0656, PD-0657, PD-0658, PD-0659, PD-0660, PD-0661, PD-0662, PD-0663*
Experimental animal models *PD-0759, PD-0760, PD-0761, PD-0762, PD-0763, PD-0764*
Experimental complications *PD-0778, PD-0779, PD-0780, PD-0781, PD-0782, PD-0783, PD-0784, PD-0785*
Experimental models of type 1 and type 2 diabetes *OP-0088, OP-0089, OP-0090, OP-0091, OP-0092, OP-0093, OP-0094, OP-0095*
Eye, Nerve and Foot complications *PD-0664, PD-0665, PD-0666, PD-0667, PD-0668*
Food security *0326*
Foot *PD-0847, PD-0848, PD-0849, PD-0850, PD-0851*
Genetics and Epigenetics *OP-0250, OP-0251, OP-0252, OP-0253, OP-0254, OP-0255*
Genetics of type 1 diabetes *P-1283, 533*
Genetics of type 2 diabetes *P-1284, P-1285, P-1286, P-1287, P-1288, P-1289, 169, 520*
Global experiences *PD-0874, PD-0875, PD-0876, PD-0877, PD-0878*
Glucagon physiology and pathophysiology *180, 290, 364*
Glycated haemoglobin and its role in dia *0554*
Glycated haemoglobin and its role in diabetes *AbT-2133, P-1291, P-1292, P-1293, P-1877*
Guidelines, clinical care *AbT-2079, AbT-2080, AbT-2134, P-1625, P-1626, P-1627, P-1628, P-1629, P-1630, P-1878, P-1879, P-1880, PD-0852, PD-0881, 36, 147, 635*
Health professional education and development *AbT-2081, P-1631, P-1632, P-1633, P-1634, P-1635, P-1636, P-1637, P-1638, P-1639, P-1640, P-1641, P-1642, P-1643, P-1644, P-1645, P-1646, P-1647, PD-0845*
Health services research *P-1648, P-1649, P-1650*
Health workforce *P-1651, P-1652*
Healthcare financing *P-1881, P-1882, P-1883, P-1884, 626*
Healthcare professional education and de *0571*
Human Physiology *PD-0712, PD-0713, PD-0714, PD-0715, PD-0716, PD-0717, PD-0718, PD-0719, PD-0720*
Hypoglycaemia *AbT-2029, AbT-2030, OP-0068, OP-0069, OP-0070, OP-0071, OP-0072, OP-0073, P-1293b, P-1294, P-1295, P-1296, P-1297, P-1298, P-1299, P-1300, P-1301, P-1302, P-1303, P-1304, P-1885, P-1886, 537*
Hypoglycemia *PD-0786, PD-0787, PD-0788, PD-0789*
Incretin physiology and pathophysiology *P-1305, P-1306, P-1307, 6, 9, 300*
Incretin therapies *AbT-2031, AbT-2032, AbT-2033, AbT-2034, AbT-2135, P-1308, P-1309, P-1310, P-1311, P-1312, P-1313, P-1314, P-1315, P-1316, P-1317, P-1318, P-1319, P-1320, P-1321, P-1322, P-1323, P-1324, P-1325, P-1326, P-1327, P-1328, P-1329, P-1330, P-1331, P-1332, P-1333, P-1334, P-1335, P-1336, P-1337, P-1338, P-1339, P-1340, P-1341, P-1342, P-1343, P-1344, P-1345, P-1346, P-1347, P-1348, P-1349, P-1350, P-1351, P-1352, P-1353, P-1354, P-1887, 8, 350*
Indigenous communities and ethnicity iss *24, 263, 327, 569, 575*
Indigenous communities and ethnicity issues *AbT-2059, P-1502*
Inflammation *AbT-2035, AbT-2036, P-1355, P-1356, P-1357, P-1358, P-1359, P-1360, P-1361, 120, 244, 540*
Insulin *PD-0740, PD-0741, PD-0742, PD-0743, PD-0744, PD-0745, PD-0746, PD-0747, PD-0748, PD-0749*
Insulin Action *PD-0721, PD-0722, PD-0723, PD-0724, PD-0725, PD-0726, PD-0727, PD-0729, PD-0730*
Insulin action - glucose transport, rece *0012*
Insulin action - glucose transport, receptor, signal transduction, cellular mechanisms *AbT-2037, P-1362, P-1363*
Insulin action - physiology, carbohydrate, lipid and protein metabolism *AbT-2038, P-1364, P-1365*
Insulin action and inflammation *OP-0587, OP-0588, OP-0589, OP-0590, OP-0591, OP-0592, OP-0593, OP-0594*
Insulin resistance - Clinical *OP-0062, OP-0063, OP-0064, OP-0065, OP-0066, OP-0067*
Insulin Resistance - Experimental *OP-0595, OP-0596, OP-0597, OP-0598, OP-0599, OP-0600, OP-0601, OP-0602*
Insulin resistance and metabolic syndrome *OP-0579, OP-0580, OP-0581, OP-0582, OP-0583, OP-0584, OP-0585, OP-0586*
Insulin resistance and the metabolic syn *2, 4, 13, 15, 318, 319, 492, 495*
Insulin resistance and the metabolic syndrome *AbT-2039, AbT-2040, AbT-2136, AbT-2137, P-1366, P-1367, P-1368, P-1369, P-1370, P-1371, P-1372, P-1373, P-1374, P-1375, P-1376, P-1377, P-1378, P-1379, P-1380, P-1381, P-1382, P-1888, P-1889, P-1890, P-1891, P-1892, P-1893, P-1894*
Insulin secretion, dysfunction, and the *0192*
Insulin secretion, dysfunction, and the islet beta cell (in vivo) *P-1383, P-1384, P-1385, P-1386, P-1387, P-1388, P-1389, P-1390, P-1391, P-1392*
Insulin therapy *OP-0295, OP-0296, OP-0297*
Insulin therapy and devices *AbT-2041, AbT-2042, P-1393, P-1394, P-1395, P-1396, P-1397, P-1398, P-1399, P-1400, P-1401, P-1402, P-1403, P-1404, P-1404b, P-1405, P-1406, P-1407, P-1408, P-1409, P-1410, P-1411, P-1412, P-1413, P-1414, P-1415, P-1416, P-1714, P-1715, P-1716, P-1717, P-1718, P-1719, P-1720, P-1721, P-1895, P-1896, P-1897, P-1898, P-1899, P-1900, P-1901, P-1902, P-1903, P-1904, P-1905, 227, 303, 358, 375, AbT-2096, P-1417, P-1418, P-1722*
Internet, social media and community *OP-0279b, OP-0280, OP-0281, OP-0282*
Islets *PD-0731, PD-0732, PD-0733, PD-0734, PD-0735, PD-0736*
Islets - beta cell death and survival *AbT-2043, P-1419, P-1420, P-1421, P-1422, P-1423, 122, 189, 336, 338*
Islets - beta cell gene regulation *0528*
Islets - beta cell growth and regenerati *335, 367*
Islets - insulin secretion, dysfunction *136, 301, 376, 543*
Islets - insulin secretion, dysfunction (in vitro) *P-1424, P-1425*
Islets - other islet cells/hormones (IAP *365, 366*
Islets & Incretin biology *OP-0447, OP-0448, OP-0449, OP-0450, OP-0451, OP-0452*
Lifestyle *PD-0821, PD-0822, PD-0823, PD-0824, PD-0825*
Lifestyle, education and behavioural interventions *PD-0910, PD-0911, PD-0912, PD-0913, PD-0914, PD-0915*
Lipids *OP-0627, OP-0628, OP-0629*
Lipids and lipoproteins *AbT-2044, AbT-2045, AbT-2046, AbT-2047, P-1426, P-1427, P-1428, P-1429, P-1430, P-1431, P-1432, P-1433, P-1906, 317, 490*
Liraglutide *PD-0673, PD-0674, PD-0675, PD-0676, PD-0677, PD-0678, PD-0679, PD-0680, PD-0681*
Living with diabetes *AbT-2082, AbT-2097, AbT-2098, AbT-2099, OP-0468, OP-0469, OP-0470, OP-0471, P-1434, P-1653, P-1654, P-1723, P-1724, P-1725, P-1726, P-1727, P-1728, P-1729, P-1730, P-1731, P-1732, P-1733, P-1734, P-1735, P-1736, P-1737, P-1738, P-1739, P-1740, PD-0844, 28, 30, 31, 51, 52, 125, 129, 178, 216, 381, 383, 573, P-1741, P-1907*
Management *PD-0750, PD-0751, PD-0752, PD-0753, PD-0754, PD-0755, PD-0756, PD-0757, PD-0758*
Management and outcomes of type 2 DM *PD-0956, PD-0957, PD-0958, PD-0959, PD-0960, PD-0961, PD-0962, PD-0963, PD-0966*
Meeting the needs of older people *OP-0461, OP-0462, OP-0463, OP-0464*
Micro and macrovascular complications *OP-0439, OP-0440, OP-0441, OP-0442, OP-0443, OP-0444, OP-0445, OP-0446*
Microbial flora *AbT-2048, P-1435, P-1436, P-1437, 177*
Models of care, multi-disciplinary care *288, 506, 562*
Models of care, multi-disciplinary care and family-centred care *AbT-2083, AbT-2084, P-1503, P-1655, P-1656, P-1657, P-1658, P-1659, P-1660*
Monitoring of diabetes control *AbT-2138, P-1438, P-1439, P-1440, P-1441, P-1442, P-1908, P-1909, P-1910, AbT-2100, P-1911*
Monogenic forms of diabetes *P-1443, P-1444, P-1445*

Neuropathy,the Foot and the Brain *OP-0603, OP-0604, OP-0605, OP-0606, OP-0607, OP-0608, OP-0609*
Nutrition and diet *AbT-2085, P-1661, P-1662, P-1663, P-1664, P-1665, P-1912, P-1913, P-1914, P-1915, P-1916, P-1917, P-1918, P-1919, P-1920, P-1921, P-1922, P-1923, P-1924, P-1925, P-1926, P-1927, 137, 511, 547*
Obesity - Clinical/Experimental *PD-0765, PD-0766, PD-0767, PD-0768*
Obesity - physiology and pathophysiology *14, 138, 198, 199, 228, 323*
Obesity - physiology and pathophysiology of weight regulation *AbT-2049, P-1446, P-1447, P-1448, P-1449, P-1450, P-1451, P-1452, P-1453, P-1454*
Obesity - prevention and management *AbT-2050, AbT-2051, AbT-2139, AbT-2140, AbT-2141, AbT-2142, AbT-2143, P-1455, P-1456, P-1457, P-1458, P-1504, P-1928, P-1929, P-1930, P-1931, P-1932, 26, 248, 541*
Obesity and bariatric surgery *OP-0054, OP-0055, OP-0056, OP-0057, OP-0058, OP-0059, OP-0060, OP-0061*
Obesity and complications - experimental aspects *OP-0615, OP-0616, OP-0617, OP-0618, OP-0619, OP-0620, OP-0621, OP-0622*
Oral glucose-lowering therapies *AbT-2052, AbT-2053, AbT-2054, AbT-2055, AbT-2144, AbT-2145, P-1459, P-1460, P-1461, P-1462, P-1463, P-1464, P-1465, P-1466, P-1467, P-1468, P-1469, P-1470, P-1471, P-1472, P-1473, P-1933, P-1934, P-1935, 352, 353*
P-1290 *0000*
Patient engagement and self-management - *213, 214, 384, 636*
Patient engagement and self-management - adult *AbT-2086, AbT-2101, AbT-2102, AbT-2103, P-1666, P-1667, P-1668, P-1669, P-1670, P-1671, P-1672, P-1673, P-1674, P-1675, P-1676, P-1677, P-1678, P-1679, P-1742, P-1743, P-1744, P-1745, P-1746, P-1747, P-1748, P-1749, P-1750, P-1751, P-1752, P-1753, P-1754, PD-0846*
Patient engagement and self-management - youth *P-1755, P-1756, P-1757*
Patient Perspectives *PD-0837, PD-0838, PD-0839, PD-0840, PD-0841, PD-0842, PD-0843*
PD-0711 *0000*
Peer education *AbT-2087, AbT-2088, P-1680, P-1681*
Peer to peer *OP-0475, OP-0476, OP-0477, OP-0478*
Phenotypes versus genotypes *AbT-2056, P-1474, P-1936*
Physical activity *AbT-2146, AbT-2147, AbT-2148, P-1475, P-1476, P-1477, P-1478, P-1479, P-1480, P-1481, P-1758, P-1759, P-1937, P-1938, P-1939*
Physical activity *309, 310, 322, 385, 386, 512*
Physical activity and psychological aspects *PD-0917, PD-0918, PD-0919, PD-0920, PD-0921, PD-0922, PD-0923, PD-0924*
Physiology of Insulin Actions & Obesity *OP-0229, OP-0230, OP-0231, OP-0232, OP-0233*
Pregnancy and gestational diabetes *AbT-2057, AbT-2149, AbT-2150, AbT-2151, AbT-2152, AbT-2153, P-1482, P-1483, P-1484, P-1485, P-1486, P-1487, P-1488, P-1489, P-1490, P-1491, P-1505, P-1940, P-1941, P-1942, P-1943, P-1944, P-1945, P-1946, P-1947, P-1948, 354, 369, 370, 371, 372, 437, 438, 479, 480, 482*
Pregnancy and Gestational DM *PD-0793, PD-0794, PD-0795, PD-0796, PD-0797, PD-0798, PD-0799, PD-0801*
Prevalence and incidence *PD-0993, PD-0994, PD-0995, PD-0996, PD-0997, PD-0998, PD-1000*
Prevention of type 2 diabetes *PD-0938, PD-0939, PD-0940, PD-0941, PD-0942, PD-0943, PD-0944, PD-0945, PD-0947, PD-0989*
Primary and secondary prevention *AbT-2154, AbT-2155, P-1506, P-1949, P-1950, P-1951, P-1952, P-1953, P-1954, P-1955, P-1956, P-1957, P-1958, P-1959, 139, 148, 151, 207, 315, 380, 390, 401, 473, 545, OP-0405*
Psychological and other complications of DM *OP-0112, OP-0113, OP-0115, OP-0116, OP-0117, OP-0118, OP-0119, PD-1007*
Psychology *PD-0864, PD-0865, PD-0866, PD-0867, PD-0868, PD-0869*
Psychosocial/behavioural interventions *AbT-2089, AbT-2090, AbT-2091, P-1682, P-1683, P-1684, P-1685, 163, 215, 634*
Public Health and Epidemiology *P-1960*
Quality assurance in diabetes care *AbT-2058, AbT-2156, AbT-2157, P-1492, P-1493, P-1686, P-1687, P-1961, P-1962, P-1963, 144, 403*
Renal - Clinical *PD-0702, PD-0703, PD-0704, PD-0705, PD-0706, PD-0707, PD-0708*
Risk factors for developing diabetes *AbT-2158, P-1964, P-1965, P-1966, P-1967, P-1968, P-1969, P-1970, 154, 209, 320, 331, 624*
Risk factors for T2DM *PD-0984, PD-0985, PD-0986, PD-0987, PD-0988, PD-0990, PD-1017, PD-1018, PD-1019, PD-1020, PD-1021, PD-1022, PD-1023, PD-1024, PD-1025*
Risk factors for T2DM: nutrition *PD-0975, PD-0976, PD-0977, PD-0978, PD-0979, PD-0980, PD-0981*
Screening and risk stratification *AbT-2159, AbT-2160, AbT-2161, AbT-2162, AbT-2163, P-1971, P-1972, P-1973, P-1974, P-1975, P-1976, P-1977, P-1978*
Screening and risk stratification *389, P-1979, PD-0948*
Screening and risk stratification of T2DM *OP-0236, OP-0237, OP-0238, OP-0239, OP-0240, OP-0241, OP-0242*
Sedentary behaviour *0324*
Self-management *OP-0284, OP-0285, OP-0286, OP-0287*
Social and cultural determinants of heal *208, 210, 567*
Social and cultural determinants of health *AbT-2164, P-1980, P-1981, P-1982*
Stem cell therapy *0549*
Supportice care systems *OP-0647, OP-0648, OP-0649, OP-0650*
T1 diabetes & DM in youth *PD-0929, PD-0930, PD-0931, PD-0932, PD-0933, PD-0934*
T2 risk factors, prevention and prevelance *OP-0404, OP-0406, OP-0407, OP-0408, OP-0409, OP-0410, OP-0411*
T2DM Screening and associated factors *PD-0949, PD-0950, PD-0951, PD-0952, PD-0953, PD-0954*
Telecommunication, internet and social m *108, 109, 110, OP-0275*
Telecommunication, internet and social media *AbT-2092, AbT-2093, AbT-2094, P-1688, P-1760, P-1761, P-1762*
Traditional botanopharmacotherapy *P-1507*
Traditional healing/therapies *AbT-2095, P-1689*
Transplantation - islet and pancreas *0550*
Treatment T2DM *OP-0420, OP-0421, OP-0422, OP-0423, OP-0424, OP-0425, OP-0426, OP-0427*
Type 2 diabetes in children *AbT-2165, P-1983, P-1984, 321, 459*
Young people *PD-0855, PD-0856, PD-0857, PD-0858, PD-0859*
Youth living with diabetes *OP-0291, OP-0292, OP-0293, OP-0294*